#CLS_PREDICTION_ENTITY|MASK_PREDICTION_ENTITY|ACTUAL_ENTITY|CLS_PREDICTIONS|MASKED_PREDICTIONS|MASKED_WORD|SENTENCE
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|densities gradients atpases autoreg ducts|lithium|is being evaluated as a monotherapy and in the iti-007-402 trial , lumateperone is being evaluated as an adjunctive therapy with entity or valproate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|ducts dens densities negativity autoreg|lithium|current drug therapy for bipolar disorder includes the use of entity and anti-depressants .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|autoreg atpases ducts gradients chaperones|lithium|mood-stabilizing drugs can treat bipolar symptoms when they are present , including entity and anticonvulsants , such as valproic acid and lamotrigine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|densities autoin autoreg density chimeras|lithium|retail sales of energizers entity and rechargeable products increased 22% in the quarter while our price-oriented product sales declined 12% .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|gata4 autoin autoreg atpases smad1|lithium|to date , the only drug that interacted with zs-9 is entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|mω imm autoreg nanog kv|lithium|mr . friess and mr . schwartz sold most of their shares of pisv for $275 , 000 and pisv became china entity technologies inc . listed on the otcbb symbol ( cltt ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|motors either localization autoreg densities|lithium|chairman of cardiac pacemakers , inc . , a company founded by mr . villafana to develop , manufacture and market a new generation of entity powered pacemakers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|autoreg autoin smad4 nedd4 gata4|lithium|the e-go is an all-electric vehicle powered by advanced entity batteries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|autoin capacitance loading vsv mω|lithium|inc . , a company that is engaged in the manufacture , commercialization and distribution of a wide variety of standard and customized entity ion rechargeable batteries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|atpases autoin atpase autoreg ante|lithium|these adjunctive agents may include atypical antipsychotics , like aripiprazole and quetiapine , or other agents such as buproprion and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|autoreg atpases atpase autoin gata4|lithium|in the last few years several academic research initiatives were conducted to explore the efficacy of approved drugs such as entity , varenicline ( chantix ® ) , riluzol and dalfampridine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|atpases autoreg gradients ducts atpase|lithium|for the treatment of patients with depressive episodes associated with bipolar i disorder as monotherapy and as adjunctive therapy with entity or valproate , which expires in june 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|motors localization densities autoreg kinases|lithium|( now a division of guidant corporation ) , a company founded by mr . villafaña to develop , manufacture and market a new generation of entity powered pacemakers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|atpases autoreg junction autoin chimeras|lithium|in the iti-007-402 trial , patients receive lumateperone or placebo adjunctive to their existing mood stabilizer entity or valproate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|autoin capacitance densities mω amphip|lithium|and as director to aug 2015 where he led a team of scientists and entrepreneurs for the development of solid-state entity ion battery for electric vehicles and smart grid applications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|vsv autoin capacitance vv densities|lithium|the car is all-electric and powered by advanced entity ion batteries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|autoin gata4 dens densities mω|lithium|· with further investment , other patches can be developed which are able to measure alternative analytes , including lactates , uric acid , entity and drugs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|gata4 smad4 smad1 nedd4 mω|lithium|recently , higher power , higher priced entity and rechargeable batteries have grown in response to more demanding power needs of more advanced devices .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|autoreg atpases junction atpase chimeras|lithium|abilify®  in february , the fda approved abilify as an adjunct to mood stabilizers entity or valproate for the maintenance treatment of bipolar i disorder .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|decou gradients uncoupling densities autoreg|autoin spher gata4 nedd4 kv|lithium|the u . s . retail battery category is defined as alkaline , carbon zinc , entity , rechargeable and specialty batteries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|mω autoreg csc motors junction|vecuronium|( sugammadex ) injection 100 mg / ml was approved by the fda for the reversal of neuromuscular blockade induced by rocuronium bromide and entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg uncoupling boltzmann smad1 dens|clock gata4 motors cholerae mω|vecuronium|is specifically designed to reverse the effects of certain muscle relaxants , marketed in the united states as zemuron ( r ) ( rocuronium bromide ) and entity bromide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|clock gata4 atpases boltzmann densities|vecuronium|we initiated a recall of a batch of entity bromide , a product we 43 market on behalf of a third party , in february 2001 due to concerns with filtration-testing
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg uncoupling boltzmann smad1 dens|mω gata4 veloc densities dystrophin|vecuronium|the first u . s . regulatory approvals on products that are difficult to produce , such as etoposide ( with gll ) , bleomycin , pancuronium and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg uncoupling boltzmann smad1 dens|clock gata4 cholerae unless cyclins|vecuronium|the company is manufacturing and marketing entity bromide prior to expiration of the patent covering this product pursuant to a licensing arrangement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|densities gata4 density chimeras atpases|vecuronium|nevzat ilac sanayii a . s . , a subsidiary of amgen , inc . , ( mn ) to acquire the rights to three products : methylprednsilone sodium succinate , entity and pamidronate disodium .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|mω gata4 motors csc cros|vecuronium|in december 2015 , the fda approved bridion for the reversal of neuromuscular blockade induced by rocuronium bromide and entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|autoreg mω motors gata4 ≥4|vecuronium|of a clinical trial site for sugammadex , mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|clock junction mω autoreg motors|vecuronium|demand of bridion ( sugammadex ) injection 100 mg / ml , a medicine for the reversal of neuromuscular blockade induced by rocuronium bromide or entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|atpases mω gata4 cd69 densities|vecuronium|in addition , we have been able to help alleviate market shortages through the launches of entity and paclitaxel .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|clock atpases gata4 gradients motors|vecuronium|in march 2000 , the company resumed the manufacture and commercial distribution of entity bromide under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|gata4 autoreg atpases clock autoin|vecuronium|for purposes of this paragraph , the term " krypton products " refers to glipizide , glyburide , ismn , midazolam hcl and entity bromide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|autoreg mω motors junction gata4|vecuronium|sugammadex sodium injection is mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|gata4 clock atpases motors atpase|vecuronium|dosage product portfolio are 45 products for which the company is currently the sole generic source , one of which is entity bromide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg uncoupling boltzmann smad1 dens|clock densities smad4 cholerae autoin|vecuronium|due to deviations from the fda  s manufacturing regulations , we are conducting voluntary product recalls of entity bromide and pte-4 products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|densities gata4 gradients chimeras atpases|vecuronium|in march 2000 , the company resumed the manufacture and commercial distribution of entity under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|clock gata4 atpases boltzmann densities|vecuronium|we initiated a recall of a batch of entity bromide , a product we market on behalf of a third party , in february 2001 due to concerns with filtration- testing
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|gata4 autoreg autoin atpases clock|vecuronium|for purposes of this paragraph , the term krypton products refers to glipizide , glyburide , ismn , midazolam hcl and entity bromide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|autoreg gata4 motors junction mω|vecuronium|for odanacatib for osteoporosis , suvorexant for insomnia and sugammadex sodium injection for reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg uncoupling boltzmann smad1 dens|gata4 densities gradients mω chimeras|vecuronium|in march 2000 , schein resumed the manufacture and commercial distribution of entity under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|ante gata4 smad1 atpases mω|avibactam|the ceftazidime / entity combination product forest expects will receive three years of hatch-waxman exclusivity upon approval .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|gata4 hsps atpases smad1 motors|avibactam|for cre infections , physicians have resorted to older drugs such as colistin or more recently drugs such as tigecycline and ceftazidime / entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|autoreg gata4 autoin cd69 gradients|avibactam|entity is a novel , non beta-lactam , beta lactamase inhibitor , quite a mouthful , itself as a molecule does not possess intrinsic antibacterial
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|gradients gata4 smad1 densities autoreg|avibactam|entity is currently being developed in combination with ceftazidime , a cephalosporin antibiotic .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|gata4 autoin autoreg either atpases|avibactam|the addition of entity to ceftazidime protects ceftazidime from breakdown by β-lactamases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|autoreg smad1 gata4 motors atpases|avibactam|it consists of a combination of entity and ceftazidime - a third generation antipseudomonal cephalosporin with a well-established efficacy and safety profile .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|autoreg autoin gata4 gradients either|avibactam|the addition of entity protects ceftazidime from being broken down by beta-lactamases that are produced by resistant bacteria .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities ante gata4 density autoreg|gata4 atpases autoin integrins motors|avibactam|it has structural similarities to entity , a bli recently approved in combination with ceftazidime ( avycaz ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities ante gata4 density autoreg|gata4 atpases densities cholerae motors|avibactam|almirall for las100977   0 . 25 licensing payment to astrazeneca for entity and ceftazidime / entity   0 . 75 rounding  
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|atpases gata4 atpase mω smad1|avibactam|actavis and astrazeneca are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|gata4 gradients smad1 chaperones mω|avibactam|entity is also protected by an issued united states patent directed to combinations with an antibiotic that expires in 2026 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities ante gata4 density autoreg|autoreg autoin gata4 mω integrins|avibactam|entity is a first-in-class broad-spectrum β-lactamase inhibitor , which protects ceftazidime against degradation by class a , c and some d , β-lactamases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|gata4 mω densities autoin gradients|avibactam|in addition , entity is protected by a united states composition-of-matter patent that expires in 2022 , without pte .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|gata4 atpases smad1 ante atpase|avibactam|based on the results of these studies , we and astrazeneca initiated phase iii studies for ceftazidime / entity in patients with ciai in december 2011 and in patients with cuti in july 2012 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|gata4 hsps atpases smad1 densities|avibactam|in fiscal 2013 , these costs were largely related to clinical trials for nebivolol / valsartan , aclidinium / formoterol , vilazodone , memantine , and ceftazidime / entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|atpases gata4 atpase mω smad1|avibactam|actavis plc and astrazeneca plc are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|densities density xp gradients cd69|avibactam|so we are very excited to introduce to you entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities ante gata4 density autoreg|atpases gata4 atpase ante gradients|avibactam|forest laboratories and astrazeneca are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|spher negativity densities autoreg localization|irinotecan|erbitux product labeling to include overall survival data as a single agent in egfr-expressing mcrc patients after failure of both entity- and oxaliplatin-based regimens .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|mω gradients densities motors smad1|irinotecan|sn38 is the active metabolite of cpt-11 ( entity ) , which is approved for the treatment of colorectal cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|densities atpases gata4 mω smad1|irinotecan|the fda approved entity as camptosar in 1994 for use in colorectal cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|autoin densities either autoreg localization|irinotecan|erbitux ( r ) is approved in united states , austria , canada , germany and switzerland for metastatic colorectal in combination with entity in entity-refractory patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|gradients autoreg atpases densities either|irinotecan|we did observe statistically significant improvements in progression free survival , or pfs , and other efficacy endpoints for ha-entity compared with irinotecan alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|atpases densities gata4 motors cd69|irinotecan|entity and cisplatin are two established anticancer drugs which together constitute an active combination for treating sclc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|densities ante gradients mω atpases|irinotecan|note : chemotherapy regimens included temozolomide and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|gata4 densities ante gradients atpases|irinotecan|is to assess the safety and pharmacokinetics of mm-121 in combination with cetuximab and mm-121 in combination with cetuximab and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|autoin atpases gata4 autoreg chimeras|irinotecan|one of our clinical development strategies is to replace the use of entity with mm-398 by demonstrating that mm-398 has favorable efficacy and safety characteristics compared to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities gradients dens skew cracks|mω gata4 densities smad1 cholerae|irinotecan|that are currently conducted by aventis , together with certain patents and other assets relating to territories where pfizer currently markets entity , including the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|gata4 atpases motors densities chimeras|irinotecan|” the study was initiated following the demonstration of synergy between nimotuzumab and entity in the laboratories of daiichi sankyo in gastric cancer cell lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|densities autoin motors autoreg spher|irinotecan|advanced colorectal cancer in which nuc-3373 will be combined with many of the agents typically combined with 5-fu , including leucovorin , entity , oxaliplatin and monoclonal antibodies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|densities density imm autoreg mω|irinotecan|clinical development of mm-398 we are pursuing two approaches in the ongoing clinical development of mm-398 : replace entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|mω motors chimeras cd69 atpases|irinotecan|two camptothecin derivatives , topotecan and entity , have been approved by the fda for the treatment of small-cell lung , ovarian , and colorectal cancers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|gata4 atpase benjamini densities ante|irinotecan|most systemic therapies for colorectal cancer include 5-fu , either as monotherapy or in combination with another chemotherapeutic , typically oxaliplatin or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|spher densities negativity autoreg localization|irinotecan|this study enrolled 463 patients with metastatic colorectal cancer who had failed standard entity- and oxaliplatin-containing chemotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|smad1 either autoreg chimeras motors|irinotecan|these two adcs facilitate targeted delivery of sn-38 , the active metabolite of entity , an effective , yet toxic chemotherapeutic , directly to tumor cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|densities gata4 atpases motors density|irinotecan|entity and cisplatin combinations were evaluated systematically for drug ratio-dependent synergy in vitro using a panel of 20 tumor cell lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients dens skew cracks|autoin densities either autoreg gata4|irinotecan|our clinical strategy is to administer birinapant with therapies ( for example , azacitidine or entity ) that induce the production of tnf or related molecules .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities gradients dens skew cracks|gata4 atpases densities mω integrins|irinotecan|since that time he has had increasing responsibility for overseeing the global research plans and teams for entity and dalteparin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|autoreg nanog dens density gata4|minocycline|“its quite unique in that its a entity topical ; i dont like a lot of the entity oral [ products ] , but entity topical – i can certainly get excited about .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|chimeras densities ≥4 gata4 cush|minocycline|reported novel imaging techniques , suggesting that bpx-01 effectively targets p . acnes in the skin without the systemic side effects of oral entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|atpase gradients gata4 motors cyclins|minocycline|in october , they received approval for their first product , amzeeq , a topical entity formulation for the treatment of acne .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|atpases atpase cyclins autoreg either|minocycline|in this study , no serious adverse events were observed and the treatment-related adverse events were related to dermal irritation in the 2% entity treatment arm .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|gradients gata4 chimeras dens autoreg|minocycline|our lead product candidate , fmx101 for moderate-to-severe acne , is a novel topical foam formulation of the antibiotic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|densities gata4 density dens motors|minocycline|in september 1999 we recognized a gain of $2 . 7 million on the sale of our vectrin ( r ) entity hcl product line .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|sinus smad1 hist biphasic smad4|minocycline|solodyn , a branded oral entity , the current standard of care for moderate-to-severe acne , accounted for nearly one half of the total branded oral market for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|densities gradients smad1 chimeras gata4|minocycline|thus , it has been demonstrated that the amount of either entity or edetate that leaks into the serum is very low or none at all .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|gradients densities gata4 atpases autoreg|minocycline|limitations of use : this formulation of entity has not been evaluated in the treatment of infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|densities gata4 atpases density autoreg|minocycline|are marketed outside the u . s . during 1998 , the company filed anda  s for two products previously selected , from which one product , entity , received approval in march 1999 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|smad1 gata4 gradients densities mω|minocycline|dose a resulted in 5 mg / cm2 of entity , which translates to approximately about 1 mg / g of skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|sinus clock biphasic gradients dens|minocycline|limitations of current standard of care for acne : oral entity , such as solodyn , is the current standard of care for moderate-to-severe acne .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|gata4 densities smad1 mω density|minocycline|mpts in blood serum and saliva in order to observe the drug release profile , and to assess the development of entity resistance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|atpases dens atpase gradients autoreg|minocycline|bpx-04 is designed to deliver the active , entity , into the skin without further irritating the skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|densities density autoreg nedd4 gata4|minocycline|the prior year sales included $6 , 373 of entity sales which the company stopped selling in late 1999 because of deteriorating market conditions .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|sinus biphasic dens clock chimeras|minocycline|oral entity has been a commonly used treatment for acne for years .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|densities atpases autoreg gradients mω|minocycline|this approach was via structure-activity relationship chemistry-based modifications of the seven and nine positions of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities decou sinus density cush|gata4 densities density atpases dystrophin|minocycline|used its expertise in biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the entity core structure .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou sinus density cush|gradients atpases atpase motors smad4|minocycline|success in iga @ week 12 difference from vehicle fmx103 entity foam , 1 . 5% 10-week study epsolay® ( † ) sol-gel did not conduct a head-to-head comparison trial or study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities decou sinus density cush|smad4 densities dystrophin nedd4 mω|minocycline|or the cipan agreement , which provides the terms and conditions under which cipan will manufacture and supply to the company entity starting material and crude omadacycline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities density gata4 atpases cd69|rasagiline|that are intended to alter the course of the disease , including the investigational drugs known as cep-1347 , gdnf , tch-346 and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities damp smad4 atpase density|rasagiline|azilect® ( entity tablets ) , tevas once-daily treatment for parkinsons disease , continued to establish itself in the u . s . and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|normality autoreg atpase gata4 atpases|rasagiline|a number of mao inhibitors are approved for pd therapy , including zelapar ( selegiline / valeant ) and azilect ( entity ; teva / lundbeck ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities density mω kv imm|rasagiline|teva and its strategic partner h . lundbeck a / s recently submitted the entity regulatory file to the european agency for evaluation of medicinal products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|smad4 densities damp gata4 motors|rasagiline|about azilect® ( united states ) indication azilect® ( entity tablets ) is indicated for the treatment of the signs and symptoms of parkinsons disease ( pd ) both as initial therapy alone and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens densities gradients density autoreg|gata4 densities integrins density atpases|rasagiline|youdim has published numerous articles describing entity  s neuroprotective and neurorescue activities in various laboratory models .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities gata4 atpase atpases damp|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to grow .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities gata4 atpases density smad1|rasagiline|completion of the two phase iii clinical trials in march , teva submitted to the fda a new drug application for entity for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|gata4 cd69 densities damp smad4|rasagiline|developed by teva , entity tablets are approved in over 40 countries for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities damp atpase gata4 smad4|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to grow in the u . s . and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|autoreg negativity smad1 gata4 ≥4|rasagiline|selectivity was tested by evaluating the interaction between tyramine and entity in healthy subjects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities damp atpase gata4 smad4|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to establish itself in the u . s . and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities atpase smad4 damp density|rasagiline|azilect® ( entity tablets ) , tevas once-daily treatment for parkinsons disease and its second innovative drug , is now available in 29 countries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities gata4 mω density damp|rasagiline| teva pharmaceutical industries ltd . ( israel ) : we are in collaboration with teva pharmaceutical industries ltd . to develop and commercialize entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|gata4 damp densities smad4 cush|rasagiline|about azilect&reg azilect&reg tablets ( entity ) 1 mg / day are indicated for the treatment of the signs and symptoms of parkinson  s disease both as initial therapy alone
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|mω gata4 smad1 densities atpases|rasagiline|teva expects to market entity in europe with h . lundbeck a / s , and in the united states with its new strategic partner eisai inc . teva
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities motors smad4 damp density|rasagiline|about azilect &reg azilect&reg 1 mg tablets ( entity tablets ) are indicated for the treatment of the signs and symptoms of parkinson  s disease both as initial therapy alone and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities atpase clock damp motors|rasagiline|azilect® ( entity tablets ) is indicated as initial monotherapy and as an adjunct to levodopa for the treatment of the signs and symptoms
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities damp smad4 gata4 density|rasagiline|about azilect® azilect® tablets ( entity tablets ) are indicated for the treatment of the signs and symptoms of parkinsons disease both as initial therapy alone and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities gradients density autoreg|densities atpase clock motors damp|rasagiline|azilect® ( entity tablets ) is indicated as an initial monotherapy and as an adjunct to levodopa for the treatment of the signs and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities cush gradients smad1|clock autoin atpases gata4 ante|bethanechol|according to wolters kluwer , total sales of generic entity chloride 5mg , 10mg and 25mg tablets at awp were $56 million in 2007 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities retarded gradients|atpases gata4 gradients smad1 adherens|nortriptyline|crx-170 is a novel synergistic combination drug candidate containing low dose budesonide and low dose entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities retarded gradients|autoreg autoin chimeras ante pyroph|nortriptyline|clinical trials of the antiepileptic agents gabapentin and lamotrigine and the antidepressants entity and amitriptyline have all been negative .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities retarded gradients|gradients cyclins atpases atpase gata4|nortriptyline|on multiple measures such as psoriatic infiltrate thickness , erythema and clinical skin condition and produced greater improvements than mometasone and entity alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities retarded gradients|densities density gata4 gradients chimeras|nortriptyline|the 2 most common adverse events related to crx-170 were dry mouth , drowsiness , constipation and headache ; known effects of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities retarded gradients|atpases autoreg gata4 atpase densities|nortriptyline|procom , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5 mg to 10 mg ) of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities retarded gradients|atpases autoreg atpase gata4 densities|nortriptyline|license from procom , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5mg to 10mg ) of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities retarded gradients|gata4 gradients densities autoin autoreg|nortriptyline|crx-170 did not show a modulation of the inflammatory marker cd163 from the treatment baseline , although entity clearly did decrease cd163 on its own .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities retarded gradients|autoreg dens autoin ≥4 chimeras|nortriptyline|crx-191 contains a mid- potency glucocorticosteroid , mometasone , and a low dose of the tricyclic anti-depressant , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities retarded gradients|autoreg dens autoin ≥4 chimeras|nortriptyline|crx-191 contains a mid-potency glucocorticosteroid , mometasone , and a very low dose of the tricyclic anti-depressant , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities retarded gradients|densities density gata4 gradients chimeras|nortriptyline|the most common adverse events related to crx-170 were dry mouth , drowsiness , constipation and headache ; known effects of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities retarded gradients|atpases autoreg gata4 atpase densities|nortriptyline|license from procom one , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5 mg to 10 mg ) of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities retarded gradients|autoreg chimeras dens atpases ≥4|nortriptyline|about crx-170 crx-170 is an oral synergistic combination drug candidate containing low doses of the steroid prednisolone and the anti-depressant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|gradients chimeras autoreg gata4 densities|terbinafine|we believe the usage of branded and generic entity has been limited due to safety concerns related to liver toxicity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|gata4 gradients autoin adherens polymorph|terbinafine|mycova™ combines an existing , approved drug for nail fungus , entity , with the nexact® technology that enhances the absorption of the drug through the skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities dens autoreg density gradients|densities gata4 atpases autoreg cholerae|terbinafine|consistent with this strategy , during fiscal 2006 we commenced sales of generic entity in certain european markets through an out-licensing arrangement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|gata4 gradients atpases chimeras densities|terbinafine|“novartis formulation”means any topical formulation of entity ( other than the nexmed formulation ) developed by or on behalf of novartis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|gata4 gradients atpase differential atpases|terbinafine|nm100060 is topically applied , and incorporates entity , a currently marketed oral anti-fungal drug , with the nexact® technology , which facilitates the permeation of the drug through the nail
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|gradients atpases cd44 cyclins autoreg|terbinafine|aerosol no protection lamisil entity ( entity hydrochloride ) fungal infection of the skin and nails caused by dermatophyte fungi tinea capitis fungal infections of the skin
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|densities atpase dens density jam|terbinafine|worldwide sales of the branded entity product lamisil , the most prescribed systemic drug for onychomycosis , were $1 . 2 billion in 2004 and $978 million in 2006 , when
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|densities density gata4 kv smad4|terbinafine|umang vohra though the entity trials are ongoing , we have not got an early read kind of a methodology for that trial and we hope
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|gata4 densities atpase atpases polymorph|terbinafine|significant product launches in fiscal 2006 included glimepiride tablets and zonisamide tablets in the united states and entity tablets in the united kingdom .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|autoin gradients atpases atpase autoreg|terbinafine|treatments are segmented into two approaches , either oral therapies , such as entity , or topical products , such as jublia , an azole , and kerydin , an oxaborole .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|density densities gata4 kv smad1|terbinafine|evolved for promius pharma as a whole and how do you see that going forward and some update on your entity product for which you had phase three already enrolled?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|atpases atpase autoreg autoin gata4|terbinafine|new product launches in fiscal 2006 included the generic versions of glimepiride , lansoprazole , lisinopril , sertraline and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|gata4 chimeras atpases densities smad4|terbinafine|during fiscal 2008 , we launched carvedilol tablets , meprobamate tablets , omeprazole , finasteride , ceterizine otc , ranitidine otc , zolpidem tablets , entity and ciprofloxacin er tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|chimeras gradients gata4 densities autoreg|terbinafine|despite its high labeled efficacy ( 38% ) , we believe the usage of branded and generic entity has been limited due to safety concerns related to liver toxicity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|autoreg cd69 sensitivities boltzmann adherens|terbinafine|lamisil ( entity ) , a systemic drug approved for onychomycosis , had worldwide peak sales of $1 . 2 billion in 2004 , before generic entry .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|smad1 gata4 autoreg gradients cyclins|terbinafine|preclinical studies have shown that itraconazole , the antifungal agent in hyphanox , has a broader spectrum of activity than entity , the antifungal agent in lamisil .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|autoreg atpases autoin gata4 atpase|terbinafine|however , this was offset to some extent by a decrease in sales of entity and sertraline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|autoreg atpases densities gata4 chimeras|terbinafine|period ending june 30 , 2010 , 1 . 4 million new prescriptions were filled in the united states for both branded and generic versions of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|autoreg boltzmann mω cd69 sensitivities|terbinafine|lamisil ( entity ) is a treatment for fungal nail infection ( onychomycosis ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg density gradients|gata4 smad1 motors gradients mω|terbinafine|a generic version of lamisil , entity , recently became available .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities atpases dens curvature gradients|grades atpases atpase divertic autoreg|ledipasvir|harvoni combines the ns5a inhibitor entity with sofosbuvir and is indicated for an eight , 12 or 24 week treatment duration depending on prior treatment history , cirrhosis
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens curvature gradients|atpases spher atpase polymorph grades|ledipasvir|in october 2014 the fda approved gileads interferon-free harvoni , a entity / sofosbuvir combination for patients with genotype 1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities atpases dens curvature gradients|atpases spher atpase polymorph integrins|ledipasvir|pending patent applications directed to the use of combinations for the treatment of hcv , and , specifically , to the combination of entity and sofosbuvir .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens curvature gradients|atpases gata4 autoin cush atpase|ledipasvir|gilead sciences markets harvoni as a  cure  for hepatitis c . it combines two drugs : sovaldi ( sofosbuvir ) and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens curvature gradients|motors gata4 densities gradients atpases|ledipasvir|additionally , abbvie has obtained canadian patent no . 2 , 857 , 339 ( the 339 patent ) which purports to cover a solid composition that contains entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens curvature gradients|atpases atpase biphasic spher restorations|ledipasvir|classes of compounds that provide better safety and efficacy such as nucleotide polymerase inhibitors sofosbuvir ( sovaldi ) and the sofosbuvir and entity combination ( harvoni ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities atpases dens curvature gradients|atpases atpase spher polymorph integrins|ledipasvir|in october 2014 , we also received approval of the fixed-dose combination of entity and sofosbuvir , now known commercially as harvoni .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens curvature gradients|spher benjamini polymorph restorations biphasic|ledipasvir|in october 2014 the fda approved gileads interferon-free harvoni® , a fixed-dose combination of sofosbuvir and entity ( a ns5a inhibitor ) for patients with genotype 1 hcv .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens curvature gradients|autoreg imm smad1 chimeras gata4|ledipasvir|the hcv ns5a drug resistance assay assesses resistance to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens curvature gradients|polymorph autoin spher restorations biphasic|ledipasvir|resistance to sofosbuvir , which was approved as a single daa in 2013 and as a co-formulation with the ns5a inhibitor , entity , in 2014 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities atpases dens curvature gradients|atpases atpase autoreg spher integrins|ledipasvir|separately , results from a phase 2 study demonstrated the safety and efficacy of entity / sofosbuvir in patients with genotypes 4 or 5 infection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens curvature gradients|atpases atpase biphasic spher restorations|ledipasvir|classes of compounds that provide better safety and efficacy such as nucleotide polymerase inhibitors sofosbuvir ( sovaldi® ) and the sofosbuvir and entity combination ( harvoni ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens curvature gradients|gradients gata4 autoreg atpases autoin|ledipasvir|entity inhibits the ns5a hcv viral protein .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities decou autoreg dens|densities density autoreg localization gata4|fluoxetine|as cured ( with a ham-d score lower than 8 ) , we had between 37% and 39% , of a similar order to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities decou autoreg dens|autoreg autoin ≥4 imm gata4|fluoxetine|vilazodone has greater in vitro potency and selectivity for serotonin reuptake than compounds such as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities decou autoreg dens|autoreg gata4 atpase autoin polymorph|fluoxetine|compete with newer generation anti-depressants used to treat hot 17 table of contents flash frequency , such as venlafaxine by wyeth , entity by eli lilly and paroxetine by glaxo smith kline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities decou autoreg dens|gata4 gradients atpase polymorph atpases|fluoxetine|entity is the generic equivalent of eli lilly  s prozac antidepressant , which is patent protected and had annual sales of $1 . 7 billion for the twelve months ended september 30 , 1997 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities decou autoreg dens|autoreg autoin gata4 imm dens|fluoxetine|in the same preclinical studies , the ssri entity did not induce rapid onset antidepressant-like responses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities decou autoreg dens|densities atpase atpases gradients density|fluoxetine|entity capsules central nervous system anti-psychotic rs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities decou autoreg dens|gata4 autoin densities autoreg atpases|fluoxetine|product sales , excluding entity and tamoxifen , were approximately $122 million during the third quarter .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities decou autoreg dens|autoin autoreg chaperones junction atpases|fluoxetine|commonly prescribed drugs for other symptoms include ditropan or detrol for bladder dysfunction , provigil for fatigue , entity for depression , and amitriptyline for pain .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities decou autoreg dens|atpases densities negativity gata4 chaperones|fluoxetine|you can see that the adverse effects are relatively traditional for entity : essentially digestive , gastrointestinal orders and nausea and disappear in function of time .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities decou autoreg dens|autoreg gata4 chimeras mω atpases|fluoxetine|major marketed brands include tofranil ( imipramine ) , prozac ( entity ) , paxil ( paroxetine ) , luvox ( fluoxamine ) and zoloft ( sertaline ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities decou autoreg dens|gradients autoreg gata4 chimeras imm|fluoxetine|the api entity has been the subject of multiple studies in humans and has been approved for use in humans for decades .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|gradients densities decou autoreg dens|mω gata4 kv cush cholerae|fluoxetine|the company filed its application for entity in january 1996 , and has been sued for patent infringement by eli lilly , initiating the patent challenge process .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities decou autoreg dens|gata4 smad1 dens densities density|fluoxetine|based on a recent federal court of appeals ruling , lilly  s composition of matter patent on entity will expire in the summer of 2001 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|gata4 gradients densities autoreg atpases|bupropion|/ mecamylamine tablets formulation and method of making tablets containing entity and mecamylamine issued march 9 , 2010 expires july 25 , 2027 us appl .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|autoreg atpases clarity autoin notation|bupropion|neuropsychiatric reactions in patients taking entity for smoking cessation serious neuropsychiatric reactions have occurred in patients taking bupropion for smoking cessation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|atpases autoreg densities chimeras gata4|bupropion|adverse events and laboratory findings appeared to be consistent with the individual components of empatic , entity and zonisamide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|gata4 densities atpases atpase autoreg|bupropion|however , we could be exposed to potential patent infringement liability from other third parties who hold patents on various formulations of entity and naltrexone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|autoreg atpases atpase gata4 clarity|bupropion|approximately 60 smokers interested in quitting will be randomized in a 1 : 1 ratio to receive either axs-05 or entity for 4 weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|atpases autoreg densities gradients either|bupropion|for all doses tested , administration of dm in combination with entity resulted in substantial increases in auc0‑12 and cmax values of dm on day 8 as compared to day 1 of dosing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|autoin gata4 atpases gradients motors|bupropion|in addition , empatic contains entity , the same active ingredient that gave rise to the fdas concerns regarding the cardiovascular safety profile of nb32 , which depending
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|autoreg normality sinus decou uncoupling|atpases densities autoreg vag integrins|bupropion|aplenzin is a once-daily formulation of entity hydrobromide and has been approved in 174mg , 348mg , and 522mg extended-release tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|autoreg densities gata4 autoin smad1|bupropion|we are very encouraged by the magnitude of superiority in responders over entity , the active control .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg normality sinus decou uncoupling|ctla gata4 chimeras smad4 coexist|bupropion|in 2001 , we licensed our once-daily formulation of entity hcl to gsk and have been collaborating with them to seek regulatory approval of wellbutrin xl .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg normality sinus decou uncoupling|densities coexist atpase atpases smad2|bupropion|for this period also includes a $3 . 0 million bond received from glaxo to settle all patent infringement litigation relating to entity hcl , er 100 mg and 150 mg tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|gata4 densities atpases adherens cd69|bupropion|that we are pursuing ; however , generic forms of the active ingredients of our product candidates , including zoledronic acid , dm , and entity , are available and could be used off‑label .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|atpase atpases localization biased cma|bupropion|we have entered into long-term supply agreements for the supply of naltrexone and entity api .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg normality sinus decou uncoupling|ctla chimeras gata4 atpases coexist|bupropion|biovail also acquired the right to market its once-daily formulation of entity hcl in canada under the trade name wellbutrin® xl if regulatory approval is received .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|gata4 densities density atpases gradients|bupropion|for example , we have in-licensed from glaxosmithkline certain formulation patents related to entity that expand our formulation options as we develop our commercial formulation of contrave .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg normality sinus decou uncoupling|autoreg ante atpase atpases colocalized|bupropion|the basis of the pet results , we added a second set of patients randomized either to 32mg naltrexone plus 400mg entity sr or a double placebo .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|atpase damp autoreg densities atpases|bupropion|forfivo xl® ( entity extended-release ) is the first 450 mg bupropion hcl tablet indicated for major depressive disorder , approved by the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|autoreg junction atpase atpases chimeras|bupropion|cpi-300 is a higher strength of the antidepressant entity hcl , the active ingredient in wellbutrin xl® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg normality sinus decou uncoupling|autoreg junction atpase atpases chimeras|bupropion|: cpi-300 is a higher strength of the antidepressant entity hcl , the active ingredient in wellbutrin xl® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|gata4 mω densities imm density|albuterol|for which we provide sterile manufacturing services include several influenza 2 table of contents vaccines , xopenex® , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity dens decou gradients smad1|autoreg gata4 kv smad1 cholerae|albuterol|in the respiratory market , we compete primarily against entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|junction cyclins cd44 autoreg smad1|albuterol|we also evaluated rpl554 administered as an add-on therapy to either entity or ipratropium , in each case as compared to entity or ipratropium alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|gata4 autoreg troponin adherens atpases|albuterol|symbicort demonstrated a 51% reduction in the rate of annual asthma exacerbations , compared to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity dens decou gradients smad1|cholerae gata4 junction cyclins autoreg|albuterol|xopenex inhalation solution and generic entity inhalation solution currently account for the majority of beta-agonist inhalation solution prescriptions in the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|junction autoreg densities gata4 density|albuterol|the second quarter 2007 to institute a new , bundled payment amount for xopenexò brand leventity hcl inhalation solution and generic entity inhalation solution products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|cyclins cd44 gata4 junction smad1|albuterol|effective january 1 , 2007 , cms established new billing codes and payment methodologies for other compounded inhalation drugs , including entity and ipratropium .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|chaperones gata4 gradients clock dipole|albuterol| proair digihaler ( entity sulfate 117 mcg ) inhalation powder is the first and only digital inhaler with built-in sensors which connects to a companion
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity dens decou gradients smad1|gata4 cholerae smad1 smad4 mω|albuterol|in 1998 , ivax also applied for approval to market an entity non-cfc formulation in various european countries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|gata4 chaperones gradients cd44 smad1|albuterol|entity is the most widely used mdi product approved for the treatment of asthma , accounting for nearly $680 million in sales
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|gata4 densities gradients atpases autoin|albuterol|entity is marketed by glaxowellcome plc ( " glaxowellcome " ) , schering-plough and others .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|motors cytoskeleton gata4 junction kv|albuterol|with xopenex hfa , we compete with generic chlorofluorocarbon-based entity metered-dose inhalers and brand-name hfa entity metered-dose inhalers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|autoreg densities imm density gradients|albuterol|cfc-containing entity mdis are required to be phased-out before the end of 2008 , with patients increasingly transitioning to hfa 2 mdis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|atpases cyclins chaperones gradients gata4|albuterol|there was no difference in the exacerbation rate between symbicort and twice-daily maintenance budesonide plus entity , despite a 52% reduction in the mean steroid dose with symbicort .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity dens decou gradients smad1|gata4 smad1 chimeras autoreg cholerae|albuterol|upon commercialization , zambon will be entitled to certain royalties on payments received by us for entity , ipratropium and cromolyn sales for specified periods .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|gata4 gradients cd44 mω cd69|albuterol|entity has been marketed for many years , is well established and sells at prices substantially lower than xopenex inhalation solution .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|cd44 autoreg smad4 smad1 density|albuterol|this increase was principally due to the continued transition of patients previously using chlorofluorocarbon ( cfc ) entity mdis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou gradients smad1|densities autoreg density smad4 gradients|albuterol|almost one-half of the market is still comprised of cfc entity mdis , representing a sizeable remaining market opportunity for the xopenex hfa product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity dens decou gradients smad1|densities density autoreg gata4 dystrophin|albuterol|non-refundable $65 million cash deposit and issuance of letters of credit for the remaining balance , to be held by the entity settlement trust fund as security for potential future payments .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity dens decou gradients smad1|gradients densities cholerae gata4 density|albuterol|this reflected the impact of generic entity substitutes on ventolin in the us , the impact of covid-19 pandemic related destocking in europe and allergy market contraction in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|ante autoreg mω dens cush|tromethamine|pursuant to the sprix purchase agreement , the company acquired specified assets and liabilities associated with sprix ( ketorolac entity )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|cyclins atpase kolmogorov atpases normality|tromethamine|entities acting in concert with them , are enjoined from making any preparations to make , sell , or offer for sale ketorolac entity ophthalmic solution 0 . 5% in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|atpase cyclins gata4 atpases gradients|tromethamine|district court for the eastern district of texas alleging patent infringement claims against the company relating to the 0 . 4% ketorolac entity formulation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|cyclins gata4 normality ante kolmogorov|tromethamine|egalet has two approved products : oxaydo® ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|gradients autoin gata4 autoreg dens|tromethamine|the company has two vda drug candidates currently being tested in clinical trials , fosbretabulin entity , or fosbretabulin , and oxi4503 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|normality dens decou grades speeds|densities autoin gradients cholerae density|tromethamine|the fosbretabulin entity is being provided to ctep under a cooperative research and development agreement ( crada ) with oxigene and the bevacizumab is being
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|gradients cyclins smad2 autoin motors|tromethamine|for example , ketorolac entity is an injectable nsaid that had significant sales prior to the fdas imposing a black box warning limiting the combined
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|cyclins gata4 normality ante cush|tromethamine|the company has two approved products : oxaydo ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|cyclins gata4 normality ante cush|tromethamine|the company has two approved products : oxaydo ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|cyclins gata4 smad2 smad1 motors|tromethamine|drug substances the api used in sprix nasal spray is ketorolac entity , in oxaydo is oxycodone hydrochloride , in arymo er is morphine sulfate , and in egalet‑002 is oxycodone hydrochloride .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|mω gata4 gradients dens cush|tromethamine|pursuant to which the company engaged jhs to provide certain services related to the manufacture and supply of sprix® ( ketorolac entity )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|cyclins gata4 normality ante smad1|tromethamine|use only cii , developed using egalets proprietary guardian technology , oxaydo® ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|cyclins normality gata4 gradients uncoupling|tromethamine|we are marketing two innovative pain products , sprix® ( ketorolac entity ) nasal spray and oxaydotm ( oxycodone hci , usp ) tablets for oral use onlycii .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|gradients atpases mω autoin smad1|tromethamine|our lead compound is ca4p , which is also known as combretastatin a4-phosphate , fosbretabulin entity , fosbretabulin and zybrestat® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|ante mω autoreg dens normality|tromethamine|pursuant to the purchase agreement , the company acquired specified assets and liabilities associated with sprix® ( ketorolac entity )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|normality dens decou grades speeds|cyclins gata4 normality atpase ante|tromethamine|the company is currently marketing sprix® ( ketorolac entity ) nasal spray ( “sprix nasal spray” ) and oxaydo® ( oxycodone hci , usp ) tablets for oral use only—cii ( “oxaydo” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|autoin chimeras gata4 motors csc|ceftriaxone|the increase in other u . s . sales was primarily due to increased sales of new products ( entity and deferoxamine ) to alternate site healthcare customers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|chimeras gata4 cyclins cush cd44|ceftriaxone|the current standard of treatment for bacterial urethritis / gonorrhea requires combination therapy including both an intramuscular injection of entity and oral azithromycin ( 1000 mg ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|densities biphasic distributions atpases ducts|ceftriaxone|cdi , c . difficile associated diarrhea ( cdad ) and aad in patients hospitalized for a lower respiratory tract infection and receiving iv entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|densities mω chimeras gata4 negativity|ceftriaxone|to utilize ihma  s expertise and experience in " bridge " oral drug delivery techniques to research , develop and commercialize oral forms of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg densities ante dens gradients|densities density nedd4 cholerae autoreg|ceftriaxone|included in the amount pending approval at june 30 , 2005 was $7 . 4 million of entity raw material and finished product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|densities autoreg density gata4 gradients|ceftriaxone|included in the amount pending approval at december 31 , 2005 was $7 . 4 million of entity , which was approved by the fda in february 2006 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|chimeras degenerate cyclins gata4 densities|ceftriaxone|study with a single oral dose of 1000 mg of solithromycin compared with the standard of care , 500 mg of entity administered intramuscularly and 1000 mg of oral azithromycin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|chimeras cd44 cyclins gata4 chimera|ceftriaxone|current treatment of bacterial urethritis includes two drugs : entity administered intramuscularly and oral azithromycin , which is added to treat co-infections with chlamydia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|cd69 gata4 autoreg densities atpases|ceftriaxone|there was one treatment-related serious adverse event in the entity group .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|autoreg densities ante dens gradients|gata4 smad1 integrins ≥4 motors|ceftriaxone|in a recent survey , 95% and 76% of the esbl isolates of escherichia coli found in utis were resistant to entity and levofloxacin , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|polymorph gradients refract autoreg chimeras|ceftriaxone|intramuscular entity now represents the last-resort treatment option for gonorrhea , although resistant strains are beginning to emerge .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|ante gata4 autoin mω motors|ceftriaxone|of the most common treatments for serious bacterial infections , vancomycin , daptomycin , entity and tigecycline are only available as injectable or iv formulations .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|densities either atpases gata4 autoreg|ceftriaxone|treatment related diarrhea was reported by one subject following sulopenem single dose iv , and by a further two subjects following entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|autoreg densities atpases either smad1|ceftriaxone|itt patients were similar on each regimen ( 9 / 10 , 9 / 11 and 7 / 12 , on sulopenem single iv dose , sulopenem multidose iv and entity , respectively ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|chimeras densities cd44 adherens polymorph|ceftriaxone|of a single 1000 mg dose of oral solithromycin in patients with uncomplicated gonorrhea and chlamydia infections compared with intramuscular entity plus oral azithromycin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|gata4 atpases autoreg autoin cd69|ceftriaxone|treatment-emergent adverse events were reported in six subjects each in the sulopenem groups and eight subjects in the entity group .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|gata4 mω autoin gradients densities|ceftriaxone|entity is currently only marketed in an intravenous formulation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|gata4 differential chimeras cush polymorph|ceftriaxone|the current standard of treatment for gonorrhea is a single intramuscular injection of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|gradients densities gata4 atpases autoreg|ceftriaxone|there is no oral formulation of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante dens gradients|densities gata4 density atpases gradients|ceftriaxone|develop existing pre-clinical and clinical candidates , including cab-175 and an oral version of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|densities atpases density gata4 autoreg|vilanterol|for the treatment of copd , the collaboration is developing combination products , relovair and the lama / laba ( gsk573719 / entity or 719 / vi ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|spher atpases gata4 densities atpase|vilanterol|anoro™ ellipta® ( umeclidinium bromide / entity , umec / vi ) on april 28 , 2014 , gsk and theravance announced that anoro™ ellipta® , the first once-daily product approved in the u . s .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|gata4 gradients atpases motors junction|vilanterol|are required and in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either fluticasone furoate , entity , or any of the excipients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|densities autoreg motors polymorph chaperones|vilanterol|the lead laba candidate , entity trifenatate ( or vi ) , is a gsk-discovered laba and gsk and we have jointly determined to focus the collaborations laba development
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities deformations dens atpase atpases|atpases cyclins atpase gata4 integrins|vilanterol|therefore fluticasone furoate / entity should be used with caution in patients with severe cardiovascular disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|atpases gata4 densities autoin atpase|vilanterol|our economic interest will not include any payments associated with relvar® ellipta® / breo® ellipta® , anoro® ellipta® or entity monotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|chaperones agon biased motors unexplained|vilanterol|· fluticasone furoate ( ff ) and entity trifenatate ( vi ) are promising agents for a combined , long-acting , once-daily treatment of asthma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|atpases gata4 densities atpase localization|vilanterol|our economic interest does not include any payments by gsk associated with relvar® ellipta® / breo® ellipta® , anoro® ellipta® or entity monotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|gata4 atpases atpase smad1 densities|vilanterol|anoro® ellipta® ( umeclidinium / entity ) to be reimbursed in australia for chronic obstructive pulmonary disease - administered using a new dry powder inhaler called
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|atpases cyclins atpase chaperones motors|vilanterol|donohue october 26 , 2014 , 1 : 30 pm - 3 : 00 pm cdt efficacy and safety of once-daily umeclidinium added to fluticasone furoate / entity in chronic obstructive pulmonary disease :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|densities atpases gata4 gradients smad1|vilanterol|lama / laba combination ( gsk573719 / entity or 719 / vi ) the phase 3a program for the once-daily lama / laba dual bronchodilator 719 / vi is progressing well .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|gata4 autoreg autoin densities atpases|vilanterol|our economic interest will not include any payments associated with relvar ellipta / breo ellipta , anoro ellipta or entity monotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|gata4 autoin autoreg densities negativity|vilanterol|our economic interest does not include any payments associated with relvar ellipta / breo ellipta , anoro ellipta or entity monotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|spher atpases benjamini ante atpase|vilanterol|closed triple or ff / umec / vi ( fluticasone furoate / umeclidinium bromide / entity )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|chaperones biased motors atpases agon|vilanterol|at 24h being developed for use as a monotherapy for asthma and in combination with a once-daily long-acting beta2 agonist ( laba ) , entity trifenatate ( vi , gw642444m ) , for asthma and copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|atpases atpase chaperones benjamini ante|vilanterol|had , or were at high-risk for , cardiovascular disease ; the primary objective was to evaluate the impact of fluticasone furoate ( ff ) / entity ( vi ) on all-cause mortality .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|atpases adherens atpase chaperones cyclins|vilanterol|breo is a fixed-dose combination of the inhaled corticosteroid ( ics ) fluticasone furoate ( ff ) and the long-acting beta2-agonist ( laba ) entity ( vi ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities deformations dens atpase atpases|gata4 gradients atpases motors smad1|vilanterol|ellipta is contraindicated in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either fluticasone furoate , entity , or any of the excipients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|gradients cholerae otherwise ante atpase|mω densities gata4 density adherens|arcitumomab|we continue to strengthen our u . s . and european sales and marketing effort for cea-scan ( r ) ( entity ) as well as our european effort for leukoscan ( r ) ( sulesomab ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|mω gata4 atpases autoreg motors|ganciclovir|cell / bone marrow and solid organ transplant patients at risk for cmv infection or with active cmv disease receive entity or valentity ( both marketed by f . hoffmann-la roche ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|gradients mω cd69 pva autoreg|ganciclovir|valcyte , the oral pro-drug of cytovene ( entity ) , is the most widely prescribed anti-cmv medication in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities clarity gradients grades dens|mω atpases gata4 integrins autoreg|ganciclovir|demonstrated activity in cell culture against both clinical isolates and viruses which have become resistant to current therapies , such as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|densities gata4 autoreg imm density|ganciclovir|in 2008 , the market for cmv drugs was $600 million with entity controlling over 90% of the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|gata4 atpases gradients atpase cd44|ganciclovir|development of products that have achieved cumulative sales of close to $2 , 000 , 000 , 000 , including monistat ; delfen cream , for herpes virus infection ; entity ; solaraze ; and maci .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|cd44 autoreg cd69 atpases motors|ganciclovir|currently approved drugs for cmv retinitis are entity , foscarnet , cidofovir and fomivirsen , or vitravene .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|autoreg gradients gata4 atpases mω|ganciclovir|the company is aware that a number of physicians have prescribed cytogam in combination with entity for the prevention of cmv disease in certain patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|gata4 atpases atpase cd44 gradients|ganciclovir|products that have achieved cumulative sales of close to two billion dollars including , monistat , delfen cream for herpes virus infectons , entity , solaraze , and maci .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|atpases autoreg chimeras motors cyclins|ganciclovir|the hytk gene was used to mark the cells and allow for ablation of the cells by administration of entity if undesirable side effects resulted from the therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities clarity gradients grades dens|gata4 smad1 kv localization localisation|ganciclovir|cells will be stimulated with anti-ig antibodies , and selected in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|cd44 autoreg gata4 cd69 mω|ganciclovir|drug therapies approved or commonly used for cmv infection include antiviral compounds such as entity , valentity , cidofovir and foscarnet .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|autoreg imm saturation gradients densities|ganciclovir|cells containing the tk reporter will be killed by the entity unless a peptide inhibitor is present which inhibits the gene  s expression ( appendix h ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|gradients mω gata4 chimeras smad1|ganciclovir|entity is available in intravenous and oral doses , as well as in an intraocular implant form .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|autoreg densities smad1 gradients motors|ganciclovir|in vivo activity for a bacterial strain which expresses the herpes simplex virus thymidine kinase gene for the conversion of entity to its toxic phosphorylated forms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|gata4 atpases autoreg autoin chaperones|ganciclovir|in spite of trials conducted with entity for cmv prevention , entity is approved for use only as a preemptive therapy or treatment for cmv in hct .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|autoreg autoin cd44 gradients gata4|ganciclovir|entity was limited in its ability to be used as a preventive therapy by the risk of significant neutropenia , which has
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|gata4 gradients mω densities atpases|ganciclovir|dr . martin is the co-inventor of entity , a pharmaceutical now used for treatment of cytomegalovirus infection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|densities chimeras ante mω sinus|ganciclovir|the company believes that , with the exception of oral entity , none of the drugs described above are currently administered prophylactically prior to manifestation of cmv retinitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|chimeras gata4 atpases gradients densities|ganciclovir|our one commercial product , vitrasert , primarily competes with treatments involving the systemic delivery of entity , a roche holdings ag product , and other drugs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity gradients grades dens|atpases motors mω autoin autoreg|ganciclovir|such as tumor cells , the tk gene renders these cells sensitive to the toxic effect of the fda-approved antiviral drug , entity ( " gcv " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens gradients density atpases|atpases gata4 densities gradients motors|talazoparib|bmn-673 means sellers proprietary compound known as bmn-673 or entity , having the chemical structure set forth in schedule 1 ( d ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens gradients density atpases|densities imm autoreg gata4 density|talazoparib|good presentation , and i agree that the offer from sanofi really substantially undervalued the business and the pipeline and especially entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens gradients density atpases|gradients gata4 densities density mω|talazoparib|we are excited about entity and pidilizumab .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities dens gradients density atpases|mω motors integrins spher cd69|talazoparib|for a select group of patients with hr-d breast cancer , entity , an oral parp inhibitor , was approved by the fda in 2018 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens gradients density atpases|chimeras gata4 inactivation dens autoreg|talazoparib|and twelve months ended december 31 , 2015 , represents the net gain on the sale of the companys world-wide rights to entity to medivation inc . ### 11
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities dens gradients density atpases|gata4 cholerae smad1 veloc densities|talazoparib|through acquisition of medivation in aug , 2016 , medivation acquired entity from biomarin in 2015 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens gradients density atpases|densities mω density gata4 gradients|talazoparib|trials , and our future drug development activities , including those with respect to pidilizumab ( which is referred to as mdv9300 ) and entity ( which is referred to as mdv3800 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens gradients density atpases|densities density mω gradients gata4|talazoparib|business development at medivation , identified and led the acquisition of a compound that was subsequently developed and approved as talzenna ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens gradients density atpases|mω densities autoreg gata4 damp|talazoparib|to start potential registrational trials  many of which will be the first initiated for a parp inhibitor  for entity in multiple other tumor types by the end of 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities dens gradients density atpases|gata4 cholerae mω densities biphasic|talazoparib|similarly , the company acquired the worldwide rights to entity just seven months ago from biomarin , again demonstrating an ability to move quickly and boldly by 9 table of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens gradients density atpases|densities density cd44 atpases smad1|talazoparib|entity would complement our solid tumor pipeline with potential in a variety of cancers , both in our current pipeline such as
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens gradients density atpases|atpases autoreg intram mω either|talazoparib|based on these data , we initiated a phase 1 / 2 clinical trial of the combination of telaglenastat plus entity in patients with rcc and tnbc in march 2019 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens gradients density atpases|chimeras gata4 inactivation autoreg dens|talazoparib|and twelve months ended december 31 , 2015 , represents the net gain on the sale of the companys world-wide rights to entity to medivation inc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens gradients density atpases|gata4 gradients densities density mω|talazoparib|xtandi , we are well positioned for long-term sustainable growth with a promising pipeline that includes two late-stage wholly owned assets : entity and pidilizumab .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens gradients density atpases|mω densities gradients dens density|talazoparib|bofa merrill lynch - analyst can you talk a little bit about the process that you went through to acquire entity from biomarin?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities dens gradients density atpases|mω motors chimeras integrins veloc|talazoparib|approved parp inhibitors include olaparib , entity and niraparib .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg motors|densities density nedd4 gata4 smad1|ropinirole|partner for jzp-4 , its potential treatment for epilepsy and bipolar , disorder and will no longer pursue development of jzp-7 , its entity gel product candidate for restless legs syndrome .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens gradients densities autoreg motors|densities density cholerae inactivation gata4|ropinirole|we were previously targeting an nda submission for our entity product candidate in calendar 2008 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg motors|density densities mω imm gradients|ropinirole|staccato entity we have identified two new preclinical product candidates for development based on the single-dose staccato platform currently being manufactured in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg motors|densities junction atpase cd44 certain|ropinirole|entity oral spray is ideal for the geriatric population who may be suffering from dysphagia ( difficulty swallowing ) ; 85% of sufferers of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg motors|densities density junction adherens cyclins|ropinirole|our formulation of entity oral spray may represent a more convenient way for the patient or healthcare provider to deliver entity to patients suffering stiffness and / or tremors .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg motors|cd69 smad4 gata4 autoreg smad1|ropinirole|entity is indicated for the treatment of the signs and symptoms of idiopathic parkinson  s disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg motors|negativity decay smad1 saturation damp|ropinirole|we completed a non-clinical study with long-term delivery of dopamine agonists which supports the potential to develop an implant delivering entity for treating parkinsons disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg motors|gata4 mω negativity smad4 existence|ropinirole|commonly prescribed dopamine agonists that directly activate dopamine receptors include agents such as mirapex ( pramipexole / bi ) and requip ( entity / glaxosmithkline ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg motors|atpases gata4 benjamini atpase cd69|ropinirole|japan , and in 2006 in the u . s . the competition for parkinson  s disease drugs includes l-dopa , cabergoline , bromocriptine , pergolide , lisuride and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg motors|gata4 negativity smad2 densities gradients|ropinirole|the new prolonged release tablet of entity is taken once daily , and is indicated for the treatment of parkinson  s disease ( pd ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg motors|gata4 smad2 autoreg normality damp|ropinirole|we have performed the preclinical development work on a transdermal formulation of entity , a proven and fda-approved dopamine agonist for treating parkinsons disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg motors|gata4 autoreg damp dens imm|ropinirole|our proprietary pipeline also includes corplex entity for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg motors|smad2 cavities smad1 causation polymorph|ropinirole|entity is a dopamine agonist currently available in daily or more frequently dosed oral formulations for the treatment of parkinson  s disease
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|gata4 densities autoreg mω density|nebivolol|the decrease in research and development expenses is the result of the completion of clinical studies related to entity , for which a nda was filed on april 30 , 2004 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|autoreg densities atpases gata4 atpase|nebivolol|the u . s . composition of matter patent covering entity hydrochloride is licensed from mylan inc . ( mylan ) and expires in 2020 and we submitted a patent term extension application to
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|damp traps trap gradients gata4|nebivolol|could you give us a little bit more color on the timing of the nda filing for entity congestive heart failure?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|autoreg gata4 tight densities cush|nebivolol|bystolic® ( entity ) , a beta-blocker for the treatment of hypertension , recorded sales of $142 . 9 millionin in the fourth quarter 2014 , an increase of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|autoreg atpases densities gata4 atpase|nebivolol|the u . s . composition of matter patent covering entity hydrochloride is licensed from mylan laboratories inc . and expires in 2020 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|autoreg densities autoin atpases density|nebivolol|* trial 305 ( general population ) trial 202 ( african-american patients ) add-on therapy vs . placebo trial 321 ( entity added to current antihypertensive treatment )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|gata4 densities smad1 mω gradients|nebivolol|brand segment r&d is primarily the result of the completion , during fiscal 2004 , of the phase iii clinical studies for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg dens atpases densities atpase|mω autoreg densities cholerae atpases|nebivolol|today , we are announcing that the best available option is to out license entity to a major brand pharmaceutical company , which will co develop and commercialize this product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|densities density damp autoreg dens|nebivolol|eps to gaap diluted eps : adjusted diluted eps $ 0 . 26 mylan bertek and entity expenses ( $0 . 05 ) restructuring charges and other non-recurring expenses ( $0 . 02 ) contingent legal liability
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|mω gata4 autoreg smad4 cd69|nebivolol|we expect to experience increased research and development expenses in support of the entity clinical program , as well as milestone payments under our license agreement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|gata4 densities mω gradients dens|nebivolol|the restructuring , while r&d expense increased as a result of an increase in ongoing studies , including those with respect to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|autoreg densities negativity atpases density|nebivolol|the overall decrease is primarily the result of the outlicensing of entity , which occurred late in fiscal 2006 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg dens atpases densities atpase|autoreg smad1 gata4 cholerae densities|nebivolol|the irs regarding whether the proceeds received by the company in connection with the 2008 sale of its rights in entity constituted a capital gain or ordinary income .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|gata4 densities mω autoreg smad1|nebivolol|the increase was primarily attributable to research and development expense due to ongoing clinical studies related to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|densities autoreg density gata4 csc|nebivolol|number one , ed , can you walk me through the five-cent charge in entity and bertek expenses and point me to where i can find it on the p&l?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg dens atpases densities atpase|autoreg gata4 densities atpases cholerae|nebivolol|the opportunity to launch entity will significantly expand our existing cardiovascular franchise .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|autoreg mω gata4 atpases densities|nebivolol|changes of the king business and the lack of appropriate other acquisition alternatives we have chosen a different course for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|spher dens gata4 atpases cd69|nebivolol|our flagship product , altaceò . this is a perfect fit with mylan because of its growing pipeline of proprietary products , including entity , a hypertension product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|dens densities tight autoreg density|nebivolol|bystolic ( entity ) , our beta-blocker indicated for the treatment of hypertension launched in january 2008 , achieved sales of $59 , 522 , an increase of $21 , 857
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens atpases densities atpase|smad1 gata4 smad2 cyclins lattice|nebivolol|for the same period last year , third party development costs were largely related to clinical trials for entity , aclidinium / formoterol , vilazodone and roflumilast .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase gradients atpases motors autoreg|autoin veloc autoreg gata4 motors|tinidazole|nitroimidazoles for use in the invention include metronidizole , ornidazole , secnidazole , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase gradients atpases motors autoreg|dens smad4 negativity kolmogorov autoreg|tinidazole|entity vaginal effervescent tablet the key component of entity vaginal effervescent tablet is entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase gradients atpases motors autoreg|autoreg gata4 atpases adherens densities|tinidazole|six ulcerative colits patients with ipaa ( 3 refractory pouchitis , 2 crohns disease , 1 irritable pouch syndrome ) received entity plus xifaxan or ciprofloxacin for 2-4 weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|gata4 densities veloc density gradients|lifitegrast|( “r&d” ) was up 6% particularly due to investment in new uses for ldx ( the active ingredient in vyvanse ) , shp602 and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|densities gata4 autoreg atpases smad1|lifitegrast|the new drug application for entity included data from four randomized , controlled clinical trials with more than 1 , 800 patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|atpases boltzmann motors gata4 atpase|lifitegrast|novartis entered into an agreement with takeda pharmaceutical company limited ( takeda ) to acquire the assets associated with xiidra ( entity ophthalmic solution ) 5% worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|gradients cush densities boltzmann adherens|cd69 gata4 motors dystrophin atpases|lifitegrast| shire plc has a small molecule integrin antagonist , entity , which is formulated for topical , ophthalmic delivery and is currently in phase 3 clinical development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|gata4 autoreg negativity mω biphasic|lifitegrast| if approved , shire would benefit from the launch of entity for dry eye disease in 2016 , and hopes to increase awareness , diagnosis and treatment of this condition .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|gradients densities gata4 density motors|lifitegrast|leukocytes [ ] selected based on its properties for further development as a candidate to treat dry eye disease [ graphic omitted ] entity ( formerly sar 1118 ) mw 610 g / mol 1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|densities atpases motors atpase cytoskeleton|lifitegrast|these relate to the xiidra ( entity ophthalmic solution ) product which takeda had subsequently announced a sale agreement for .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|negativity smad1 peaked smad4 damp|lifitegrast|“our commitment to moving entity forward reflects our intent to grow in the ophthalmics therapeutic category in areas of unmet patient need .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|gata4 mω autoreg smad1 boltzmann|lifitegrast|shire plc recently received fda approval to market entity for the treatment of dry eye and will be launching the product in the u . s . restasis , and other products , have
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|gata4 densities gradients atpases autoreg|lifitegrast|shire plc is developing its product candidate , entity , and is in pivotal phase 3 clinical trials in the u . s . shire has said it plans to resubmit an nda for entity in 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|autoreg mω gata4 chimeras biphasic|lifitegrast|press release www . shire . com shire plans to submit a new drug application to fda for entity for dry eye disease in adults · fda submission planned for 1st quarter 2015 · shire forms business
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|densities atpases atpase motors smad4|lifitegrast|these relate to the xiidra® ( entity ophthalmic solution ) product which takeda has subsequently announced a sale agreement for , as included in note 33 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|gata4 mω kv densities atpases|lifitegrast|of any of our product candidates , such as our planned submission of a new drug application to the fda for entity , may be delayed for any number of reasons and , once submitted ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|densities gata4 density mω kv|lifitegrast|on shp602 ( formerly known as spd602 ) for iron overload and on development programs acquired through business development in 2013 , including entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|atpases motors gata4 boltzmann atpase|lifitegrast|novartis entered into an agreement with takeda pharmaceutical company limited ( takeda ) to acquire the assets associated with xiidra&#xae ; ( entity ophthalmic solution ) 5% worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|gata4 densities smad1 dens autoreg|lifitegrast|maybe to refresh the topic , on entity , obviously the other key near-term event with the october 25 pdufa date .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|densities atpases gata4 density autoreg|lifitegrast|opus-3 , a randomized , double-masked , 12-week phase 3 study enrolled 711 patients to evaluate the efficacy and safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|gata4 atpases cd69 atpase autoreg|lifitegrast|in addition , patients treated with entity showed a statistically significant improvement in ocular discomfort and eye dryness , symptoms of dry eye disease , as reported by patients
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|gata4 autoreg cd69 cd44 negativity|lifitegrast|when i look at restasis relative to entity , in terms of efficacy measures , sustaining tear production and goblet cell density , i think restasis is a great option .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients cush densities boltzmann adherens|cyclins atpases mω motors chaperones|lifitegrast|in the united states , yet only two drugs are approved for dry eye disease treatment , restasis® ( cyclosporine 0 . 05% ) and xiidra® ( entity 5% ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg speeds dens atpases|atpases motors densities autoreg gradients|floxuridine|the 1 : 1 molar ratio of irinotecan : entity was frequently synergistic and avoided antagonism whereas other ratios exhibited a loss of synergy and in some cases the appearance
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg speeds dens atpases|either atpases motors smad1 atpase|floxuridine|range of preclinical solid tumor models , cpx-1 consistently provided dramatic improvements in therapeutic efficacy over the unencapsulated free-drug cocktail of irinotecan : entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg speeds dens atpases|atpases chimeras densities motors autoreg|floxuridine| cpx-1 is a liposomal formulation of irinotecan : entity , which is a clinical stage product candidate ;  cpx-8 is a hydrophobic docetaxel prodrug nanoparticle which is a preclinical stage
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg speeds dens atpases|densities atpases motors either gradients|floxuridine|scientific rationale of cpx-1 the combination of irinotecan and entity was screened for drug ratio dependent synergy in vitro in a panel of tumor cell lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg speeds dens atpases|atpases autoreg atpase either ante|floxuridine|from 7 . 8 months to 12 . 0 months ( p = 0 . 05 ) for patients with advanced , unresectable colorectal liver metastases receiving sir-spheres and entity ( fudr ) vs fudr alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity densities dens curvature retarded|gata4 dens densities gradients dystrophin|eszopiclone|additionally , in early 2003 , sepracor filed an nda for estorra ( entity ) for the treatment of insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity densities dens curvature retarded|densities gata4 mω cholerae density|eszopiclone|in exchange , sepracor permitted aventis to assign sepracors obligation to pay a royalty on sales of entity in the u . s . to a third party .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|autoreg atpases autoin gata4 densities|eszopiclone|in addition , patients on entity reported improved daytime alertness ( p less than 0 . 005 ) and improved daytime ability to function ( p less than 0 . 001 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|atpases autoreg atpase densities cd69|eszopiclone|furthermore , patients treated with entity 2 mg reported significant improvements in daytime alertness ( p<0 . 03 ) and sense of physical well-being ( p<0 . 05 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|densities gata4 smad1 chimeras density|eszopiclone|we have entered into out-licensing arrangements with respect to the sale of entity outside of the united states , canada and mexico and with respect to several other compounds .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity densities dens curvature retarded|gata4 smad4 cholerae densities density|eszopiclone|our entity product will be marketed by gsk in its territory primarily as lunivia® brand entity for the treatment of insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|autoreg autoin densities gata4 smad1|eszopiclone|no decline in therapeutic effect was observed on any outcome parameter over the course of the trial , and entity was well tolerated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|gata4 gradients autoin smad1 densities|eszopiclone|upon approval of estorra , during which the fda would not approve an abbreviated new drug application for any product containing entity , the active ingredient of estorra .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|gata4 densities density atpases mω|eszopiclone|has filed an abbreviated new drug application ( anda ) with the u . s . food and drug administration ( fda ) for generic versions of entity tablets ( 1 mg , 2 mg and 3 mg ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity densities dens curvature retarded|densities autoreg cholerae density gata4|eszopiclone|products that we launched in the united states during the year ended march 31 , 2015 : product innovatorsbrand innovator entity lunesta® seprocor fenofibrate capsules
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|gata4 adherens atpases dens troponin|eszopiclone|other branded prescription sleep aids include lunesta® ( entity ) , which was approved in december 2004 by the fda and launched in the first quarter of 2005 , and rozerem® ( ramelteon ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|gata4 autoreg densities smad1 gradients|eszopiclone|in clinical trials with entity , one case of overdose with up to 36 mg of entity was reported in which the subject fully recovered .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity densities dens curvature retarded|autoreg dens autoin smad1 cholerae|eszopiclone|the fda is currently reviewing our nda for estorra brand entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|autoreg autoin nedd4 damp inactivation|eszopiclone|as a result of this policy , we capitalized $1 , 735 , 000 of lunesta brand entity inventory during the first quarter of 2005 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|gata4 densities smad1 atpases autoin|eszopiclone|we have entered into out-licensing arrangements with respect to the sale of entity in japan and with respect to several other compounds .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|densities density imm mω gata4|eszopiclone|we cannot assure you that we adequately responded to the fdas concerns or that the entity nda will be approved .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|gata4 dens density gradients densities|eszopiclone|other branded prescription sleep aids include lunesta® ( entity ) , marketed by sepracor , inc . , which was approved in december 2004 by the fda and launched in the first quarter of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|densities gata4 smad1 density mω|eszopiclone|assuming favorable results from the ongoing studies , we anticipate submitting an nda for entity to the fda , in 2002 , which , if approved , we would market under the name estorra .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|atpase atpases adherens damp junction|eszopiclone|other events on april 4 , 2005 , sepracor commercially launched lunesta brand entity 1 mg , 2 mg and 3 mg tablets for the treatment of insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity densities dens curvature retarded|autoreg mω densities gata4 dens|eszopiclone|individuals have fully recovered from racemic zopiclone overdoses up to 340 mg ( 56 times the maximum recommended dose of entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|densities gradients density chimeras gata4|atropine|between august and october , 2010 , we reintroduced entity , morphine , dextrose , and epinephrine prefilled syringes .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|traps diap atpases gradients gata4|atropine|in november 2000 , we received our first fda approval to manufacture and sell diphenoxylate with entity sulfate tablets .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg dens smad1 densities avidin|gata4 traps divertic clock autoin|atropine|for propranolol er driven by price , tempered by the impact of the second quarter 2017 launch of diphenoxylate hydrochloride and entity sulfate .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|cyclins atpases cd69 boltzmann pva|atropine|while macrodose entity 1% is currently fda-approved for pupil dilation in the united states , its significant side effect profile has impeded clinical utility
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg dens smad1 densities avidin|ctla dipole chimeras cholerae csc|atropine|trobigard is designed for intramuscular self- or buddy-administration of entity sulfate and obidoxime chloride for pre-hospital intervention .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|smad4 clock cd44 normality cytoskeleton|atropine|anticipated milestone : initiate and complete phase iii vision trials in 2020 about micropine for progressive myopia micropine ( entity ophthalmic solution )
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|clock gradients chaperones gata4 densities|atropine|“micropine product” means entity sulfate , as the sole active pharmaceutical ingredient , formulated and loaded into a cartridge for delivery using , and delivered by means
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|gata4 atpases cd44 boltzmann cd69|atropine|for example , our micropine program which is a micro-formulation of entity , is intended to slow myopia progression in the pediatric population .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|autoreg negativity cd44 cd69 densities|atropine|exposed to approximately 75% less nerve agent and then treated immediately with the current standard therapy , a three-drug cocktail of entity , 2-pam and diazepam .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|gata4 mω autoreg motors cd44|atropine|contract by dod valued at up to approximately $23 million to develop a multi-drug auto-injector for nerve agent antidote delivery ( entity and pralidoxime chloride ) , which we refer to as d4 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|normality mω atpases motors cd44|atropine|despite activity , safety concerns such as pupil dilation , photosensitivity and accommodation difficulties associated with standard entity , 1% have tempered initial clinical adoption .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|gata4 atpases adherens chimeras otherwise|atropine|the first pipeline opportunity is micropine , which is a micro-therapeutic formulation of entity to target myopia ( or near sightedness ) progression .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|gata4 adherens atpases chimeras otherwise|atropine|the first pipeline 4 table of contents opportunity is micropine , which is a micro-therapeutic formulation of entity to target myopia ( or near sightedness ) progression .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|autoreg chimeras autoin gata4 damp|atropine|the standard of care for post-exposure treatment involves repeated doses of a cocktail of drugs including entity , oxime reactivators ( " 2-pam " ) and anti-convulsants .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens smad1 densities avidin|ante autoreg gradients dens phyl|atropine|the director ( nih od ) , and the ninds competition the current standard of care for nerve agent exposure is entity® and benzodiazepines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou gradients dens autoreg|densities gata4 density gradients cush|naldemedine| acquired rights to commercialize symproic® ( entity ) tablets 0 . 2 mg in the u . s . on april 4 , with bdsis sales force fully trained and actively promoting symproic as of may
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou gradients dens autoreg|gata4 mω damp normality atpase|naldemedine|shionogi & co . is developing entity , another mu-opioid receptor antagonist , for patients with oic .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|density gradients densities gata4 nanog|methacholine|the only fda-approved direct test is provocholine® ( entity ) , marketed by methapharm inc .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|smad1 gata4 gradients gauge densities|methacholine|entity is inhaled as a vapour and causes bronchial constriction in asthmatic patients .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|≥4 gata4 gradients vsv motors|methacholine|the first category , known as direct challenge tests , use either histamine or entity to directly cause airway narrowing .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|gradients ≥4 smad1 motors cd44|methacholine|the response from the direct tests ( entity and histamine ) are not dependent on the presence of inflammatory cells and their mediators and have a poor sensitivity for
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|≥4 smad1 densities nanog gradients|methacholine|volume in 1 second ( fev1 ) > 65% ;  increase in fev1 of at least 12% with bronchodilator use over baseline fev1 ;  entity challenge test with a pc20 £ 8mg / ml .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|gradients junction gata4 vsv densities|methacholine|entity challenge treatment differences ( pc20 ) performed 25h post-dose and 24h following an inhaled allergen challenge table 1 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|junction smad1 ≥4 nanog gata4|methacholine|the primary phenotypes for analysis include lifetime history of asthma , age of asthma onset , entity challenge response , smoking history , and skin prick tests for twelve common allergens .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|≥4 ≥1 vsv junction αvβ3|methacholine|aridol also had similar specificity to entity , ( 66% versus 70% respectively ) in subjects without exercise induced bronchoconstriction .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|junction ≥4 nanog smad1 yap1|methacholine|efficacy will be evaluated using standard measures of respiratory function , e . g . , fev1 , entity challenge , serial spirometry .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|≥4 smad1 vsv gradients gata4|methacholine|s . spector et al . , mannitol inhalational challenge : will it replace entity or histamine?
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|damp autoreg curvature heterochromatin densities|methacholine|moreover , ck-2018571 relaxed entity pre-constricted tracheal rings in a concentration-dependent manner , suggesting its potential utility as a bronchodilator .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|≥4 junction vsv ≥1 smad1|methacholine|the 500 mg tid treatment group , including serial spirometry , morning and evening peak flow rates and pc20 values in a entity challenge test ( common measures of respiratory function ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|≥4 junction ≥1 ≥5 smad1|methacholine|· adding vi to ff also provided further reduction of ahr as measured by entity responsiveness 24h after the allergen provocation .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|≥4 autoin autoreg clock motors|methacholine|provocholine diagnosis of bronchial airway hyperactivity in subjects who do not have clinically apparent asthma entity chloride immunoglobulins ivig 5% treatment
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|certain vsv gata4 lattice localization|methacholine|in comparison entity , an approved lung function test in the u . s . , identified 54% of cases .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|gata4 densities gradients smad1 motors|methacholine|examples include entity and histamine .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|mω autoreg nedd4 vsv motors|methacholine|to an individual or company to sell a product meta-analysis pooling and examining data from a number of studies entity inhalation test a test used in the diagnosis of asthma .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|smad1 gata4 kolmogorov heterochromatin phosphoryl|autoin gata4 motors gradients smad1|methacholine|of 501 patients , and the study showed that aridol performed as well or better than the only currently approved test , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|densities density autoreg gata4 gradients|cytarabine|for safety reasons , continuous intrathecal infusion of entity is not a viable option .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens autoreg uncoupling densities decou|densities autoreg integrins motors autoin|cytarabine|these patients typically receive frontline therapy , usually chemotherapy , including entity and an anthracycline , a therapy that has not changed in over 40 years .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|densities density atpases adherens atpase|cytarabine|products the products prepared for enzon by skyepharma are defined in the supply agreement including depocyt® , ( entity liposome injection , sky0101 ) formulation 1 . 5 ( us ) iii .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|autoreg either mω ante ducts|cytarabine|% can be achieved , and patients with good-risk or standard-risk chromosomal changes will typically receive post-remission therapy with high dose entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|gradients gata4 autoin atpases autoreg|cytarabine|entity is one of several drugs most commonly used for this therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|either ducts autoreg autoin gata4|cytarabine|in may 2007 , our phase iii trial of onrigintm in combination with entity in relapsed aml was put on clinical hold by the fda after accrual of 268 patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|mω atpases ante hysteresis either|cytarabine|from the trial showed positive safety and response rate data for subjects treated with a combination of motixafortide and high-dose entity ( ara-c ) , or hidac .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|either autoreg autoin atpases densities|cytarabine|an investigator-sponsored phase i / ii trial in combination with entity for elderly patients with previously untreated aml was initiated in may 2008 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|motors gata4 mω cytoskeleton spher|cytarabine|a number of nucleoside drugs , such as gemcitabine and entity , also known as ara-c , both generic drugs , are in wide use as conventional chemotherapies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|atpases either mω motors densities|cytarabine|is in the efficacy portion of a phase 2 clinical trial for acute myeloid leukemia ( “aml” ) in combination with low-dose entity ( “ldac” ) and in combination with decitabine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|densities gata4 gradients negativity autoreg|cytarabine|because the therapeutic half-life of entity in the csf is relatively short , frequent and repeated injections are necessary for effective treatment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|gata4 densities atpases chimeras gradients|cytarabine|certain compositions containing vosaroxin , with expiry in 2030 ; and · u . s . patent no . 7 , 968 , 565 claims a combination of vosaroxin and entity , with expiry in 2026 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|densities atpases autoreg gata4 atpase|cytarabine|the rate of serious adverse events was 55 . 5% in the vosaroxin combination arm compared to 35 . 7% in the placebo and entity arm .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|gradients gata4 chimeras densities cd69|cytarabine|clinical trials have demonstrated , however , that depocyt provides certain clinical advantages versus generic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|either dens ducts gata4 cd44|cytarabine|patients who achieve a cr after induction will go on to receive consolidation therapy with high dose entity ( hidac ) with ento or placebo as per their randomization assignment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|mω gata4 motors cytoskeleton either|cytarabine|a number of nucleoside drugs , such as gemcitabine , or gemzar® , from eli lilly , and entity , also known as ara-c , a generic drug , are in wide use as conventional chemotherapies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|dens densities atpases gata4 motors|cytarabine|our lead product is vyxeostm , a nano-scale liposomal formulation of entity : daunorubicin , completed a phase 3 clinical trial for the treatment of acute myeloid leukemia ( aml ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|autoreg motors either densities cd44|cytarabine|high-intensity induction chemotherapy is typically entity plus an anthracycline ( so called 7+3 ) administered over a 28-day cycle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|either ducts autoreg autoin gata4|cytarabine|our phase iii trial of onrigintm in combination with entity in relapsed aml was put on clinical hold by the fda in may 2007 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg uncoupling densities decou|autoreg gradients motors autoin gata4|cytarabine|entity acts by inhibiting a vital enzyme in dna synthesis , resulting in death of a dividing cell .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|clock gradients smad4 damp autoreg|mometasone|three of the patients who responded received entity steroids tapered to zero by day 21 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|gradients gata4 cd44 ≥4 smad1|mometasone|we are also developing a topical water-based hydrogel formulation of entity , a medium-potency steroid , primarily for the treatment of atopic dermatitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|cyclins atpases motors mω mimics|mometasone|to $160 million in the first six months of 2013 compared with the same periods of 2012 . global sales of dulera ( entity furoate / formoterol fumarate dihydrate )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|gata4 gradients cd44 cd69 cyclins|mometasone|^ nasonex and entity are currently the only other intranasal steroids approved for the treatment of nasal polyps .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|smad4 veloc gata4 cd69 smad1|mometasone|we are currently in formulation development with entity hydrogel and expect to file an investigational new drug application , or ind , in 2006 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|gradients gata4 cush atpases motors|mometasone|indacaterol as a single agent and in combination with an ics ( entity ) , is being developed by novartis and schering-plough .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|cyclins mω atpases ctla junction|mometasone|respiratory global sales of nasonex ( entity furoate monohydrate ) , an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms , increased 3% in the first quarter of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|cyclins atpases mω junction atpase|mometasone|sc loading dose followed by q8w 150mg sc and ( iii ) placebo , in each case concomitant with 400 micrograms daily of entity furoate nasal spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|gradients autoin chimeras autoreg dens|mometasone|crx-191 contains a mid-potency glucocorticoid , entity , and a very low dose of the tricyclic anti-depressant , nortriptyline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|densities atpases motors gata4 csc|mometasone|a decision issued in june 2013 held that the merck patent covering entity furoate monohydrate was valid , but that it was not infringed by apotex corp . s proposed product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|gradients autoin autoreg chimeras dens|mometasone|crx-191 contains a mid-potency glucocorticosteroid , entity , and a very low dose of the tricyclic anti-depressant , nortriptyline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|cyclins junction atpases cd44 mω|mometasone|patients are being treated with two multi-dosing frequencies of subcutaneously-administered etokimab or placebo , each in combination with entity furoate nasal spray as background therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|cyclins gata4 cd69 mimics atpases|mometasone|sch 418131 , mff , is a combination of two previously approved drugs for the treatment of asthma : entity ( asmanex ) and formoterol ( foradil ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|cyclins clock atpase atpases gradients|mometasone|ovixan® is an improved prescription entity cream for the treatment of psoriasis and eczema , and oviderm® is a moisturizer for the treatment of dry skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|atpases cyclins motors atpase junction|mometasone| qmf149 ( indacaterol acetate / entity furoate ) is a once daily fixed-dose combination being investigated in asthmatic patients who are uncontrolled on an inhaled corticosteroid .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|gata4 autoreg cyclins motors adherens|mometasone|novartiss qvm-149 ( entity / glycopyrronium / indacaterol ) is under review by the ema for asthma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|gata4 cyclins motors gradients atpases|mometasone|during the first quarter of 2004 is primarily due to the purchase of raw materials related to the eligard , atrisone , entity and fluticasone products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|autoreg gradients localization normality cd44|mometasone|prior to treatment with nomacopan ( coversin ) , two out of the three patients were already on topical corticosteroids ( entity ) while a third was naïve to steroid treatment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities retarded phot|atpases atpase gata4 cyclins motors|mometasone|new combinations of formoterol with ciclesonide , fluticasone or entity are being developed by sanofi-aventis , abbott ( with skyepharma ) , and novartis ( with schering-plough ) respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|autoreg dens densities retarded phot|mω cyclins atpases biased integrins|mometasone|nasonex , or entity furoate nasal spray , is currently the only other branded ins approved by the fda for the treatment of nasal polyps .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg clarity atpases|cyclins atpases atpase motors chaperones|prilocaine|phn to receive the qutenza patch application after a 60-minute pretreatment with an fda-approved topical anesthetic ( 2 . 5% lidocaine / 2 . 5% entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg clarity atpases|motors atpase mω atpases cd44|prilocaine|psd502 is a unique , proprietary , rapidly absorbed formulation of two , well-established local anesthetics , lidocaine and entity , dispensed in a metered dose spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg clarity atpases|cyclins atpase motors atpases mω|prilocaine|emla ( lidocaine + entity ) is a local anaesthetic for topical application .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg clarity atpases|motors atpase mω atpases cd44|prilocaine|psd502 is a unique , proprietary , rapidly absorbed formulation of two well-established local anesthetics , lidocaine and entity , dispensed in a metered dose spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg clarity atpases|cyclins atpase mω motors atpases|prilocaine|> emla ( lidocaine and entity ) is used as a local anaesthetic for topical application to prevent pain associated with injections and superficial surgical procedures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg clarity atpases|cyclins atpase gata4 atpases smad1|prilocaine|the skin permeation data compares a 2 . 5% lidocaine gel and the emla cream , which contains 2 . 5% lidocaine and 2 . 5% entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg clarity atpases|clock atpases atpase motors gata4|prilocaine|this product in the third quarter of 2018 . on july 2 , 2018 , we announced approval of an anda for lidocaine and entity cream usp , 2 . 5% / 2 . 5% .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg clarity atpases|cd44 adherens boltzmann autoreg motors|prilocaine|local intracervical anesthetic block is achieved using 8 . 8 ml citanest ( entity ) with octapressin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg clarity atpases|either cyclins gata4 motors atpases|prilocaine|in particular , the dojs subpoena to impax focused on four generic medications : digoxin tablets , terbutaline sulfate tablets , entity / lidocaine cream , and calcipotriene topical solution .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg clarity atpases|motors cyclins junction cd44 autoreg|prilocaine|number of products marketed under lidocaine entity topical cream 1 number of product
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg clarity atpases|cyclins atpase motors atpases mω|prilocaine|> emla ( lidocaine + entity ) is used as a local anaesthetic for topical application .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg clarity atpases|motors atpase cyclins clock gata4|prilocaine|for example , one non-injectable , subsurface local anesthetic commercially available today is oraqix® ( lidocaine and entity periodontal gel ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|motors atpases densities dens chimeras|dexrazoxane|totect&#xa0 ; &#xae ; &#xa0 ; ( entity hcl ) is a marketed , injectable treatment for anthracycline extravasation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|densities atpases autoreg chimeras mω|dexrazoxane|bulk drug substances the muscle relaxants atracurium besylate , pancuronium bromide and vecuronium bromide , the immunosuppressant drug cyclosporine and the prodrug entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|atpases atpase densities motors chimeras|dexrazoxane|totect® ( entity hcl ) is a marketed , injectable treatment for anthracycline extravasation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|densities gradients chimeras otherwise autoreg|dexrazoxane|entity metabolites trap the iron ions involved in the process which leads to myocardial damage caused by anthracycline oncolytic agents such as doxorubicin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|gata4 densities gradients autoreg boltzmann|dexrazoxane|we launched totect during a national shortage of entity in late 2017 , resulting in strong initial demand for the product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens decou cracks densities uncoupling|gata4 gradients dystrophin densities smad1|dexrazoxane|entity is manufactured using a proprietary process covered by patents filed in several countries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|gata4 gradients chimeras smad1 mω|dexrazoxane|( f ) " cardioxane-trademark- " means the substance known by the chemical name of entity , and any analogues or derivatives thereof .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|gata4 atpases mω smad1 densities|dexrazoxane|sicor s . p . a . manufactures entity according to a proprietary process covered by process patents filed in many countries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|autoreg chimeras densities atpases traps|dexrazoxane|the companys entry into the oncology specialty includes two initial supportive care medications : ethyol® ( amifostine ) injection and totect® ( entity hydrochloride ) injection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|densities atpase atpases motors gata4|dexrazoxane|zinecard ( r ) ( entity for injection ) sold in the u . s . and canada , is a preparation for reducing cardiac side effects in women with metastatic
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|chimeras densities autoreg gata4 smad1|dexrazoxane|he oversaw the distribution of our new totect brand during a national shortage of entity resulting in many new customer relationships for the company .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|atpases atpase densities motors dens|dexrazoxane|apricus bio currently markets totect® ( entity hcl ) , the only drug approved in the us for the treatment of anthracycline extravasation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|densities density damp mω peaked|dexrazoxane|sicor s . p . a . developed entity with chiron bv , including performing clinical trials , developing dosage form manufacturing , marketing and sales .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens decou cracks densities uncoupling|densities kv mω gata4 cholerae|dexrazoxane|totect was acquired by clinigen in march 2016 to expand its entity portfolio and enter the u . s . market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|gata4 gradients densities density dens|dexrazoxane|” about totect® ( entity ) totect is an anthracycline extravasation agent approved by the united states food and drug administration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|atpases atpase motors densities cd69|dexrazoxane|totect® ( entity hcl ) was approved by the fda in 2007 for the treatment of anthracycline extravasation , which is the leaking of chemotherapy
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens decou cracks densities uncoupling|atpases autoreg either dystrophin smad1|dexrazoxane|administration of entity with such oncolytic agents protects tissues of the heart and allows for higher dosages of the oncolytic agent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|gata4 densities density gradients mω|dexrazoxane|about totect® ( entity ) injectiontotect is an anthracycline extravasation agent approved by the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|densities gata4 mω kv density|dexrazoxane|totect was acquired by clinigens specialty pharmaceuticals ( sp ) division in march 2016 to expand its entity portfolio for the u . s . market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou cracks densities uncoupling|gata4 densities atpases gradients atpase|dexrazoxane|totect® cumberland announced fda approval of new labeling of totect® ( entity hydrochloride ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|chimeras junction atpases autoreg motors|phenylephrine|each 5ml dose contains the api entity hci , pyrilamine maleate and dextromethorphan hbr .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|gata4 densities density chimeras atpases|phenylephrine|european medicines agencys committee for medicinal products for human use had adopted a positive opinion for omeros drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|atpases atpase autoreg gata4 autoin|phenylephrine|pse also competes against entity , an alternate nasal decongestant available in non-prescription products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens cracks neurovascular biased close|cd44 densities divertic motors adherens|phenylephrine|biorphen ( entity hcl injection ) is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens cracks neurovascular biased close|atpases chimeras motors gata4 dystrophin|phenylephrine|the companys drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% is marketed for use during cataract surgery or intraocular lens ( iol ) replacement to maintain
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|densities density vv kv dwell|phenylephrine|ongoing entity supply disruptions from 503b compounding facilities , including the announced shutdown of compounding industry leader pharmedium in january , have highlighted the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|gata4 gradients chimeras atpases autoin|phenylephrine|otc products contain any one of several active ingredients including glycerin , entity , pramoxine , white petrolatum , shark liver oil and / or witch hazel , for symptomatic relief .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens cracks neurovascular biased close|atpases chimeras gata4 motors dystrophin|phenylephrine|our marketed drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% was broadly launched in the u . s . in april 2015 for use during cataract surgery or intraocular
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|autoreg gata4 smad1 agon atpases|phenylephrine|ventrus is also required to reimburse s . l . a . for clinical development costs associated with the technology development of both diltiazem and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|gata4 autoreg smad1 atpases agon|phenylephrine|is also required to reimburse s . l . a . pharma for clinical development costs associated with the technology development of both diltiazem and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|gata4 damp autoin autoreg motors|phenylephrine|these products generally contain active ingredients such as acetaminophen , dextromethorphan , diphenhydramine , guaifenesin , loratadine , entity , and pseudoephedrine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|cyclins densities gradients motors density|phenylephrine|: 267  270 , 1999 normal subjects , entity gel ( 5% , 10% , 20% , 30% ) applied once to anal verge resting anal pressure increased by 8% to 33% , effect
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|atpases gata4 cyclins ≥4 atpase|phenylephrine|aldex ct is an antihistamine / decongestant combination administered orally in a chewable tablet form containing the api diphenhydramine hcl and entity hcl .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens cracks neurovascular biased close|atpases chimeras motors gata4 dystrophin|phenylephrine|our marketed drug product omidria™ ( entity and ketorolac injection ) 1% / 0 . 3% is approved in the u . s . for use during cataract surgery or intraocular lens , or iol , replacement
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|atpases atpase motors gata4 cd69|phenylephrine|microdose delivery of entity 10% ( pe - µd ) was associated with significantly less systemic exposure than traditional eye drops ( pe 10% ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens cracks neurovascular biased close|gata4 densities chimeras dystrophin density|phenylephrine|application seeking approval from the u . s . food and drug administration to market a generic version of the companys drug omidria® ( entity and ketorolac injection ) 1% / 0 . 3% .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|densities atpases chimeras density motors|phenylephrine|on june 28 , 2013 , the group filed an nda for vazculep ( entity hydrochloride injection ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|densities density atpase gata4 gradients|phenylephrine|entity gel ( ven 308 ) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis , an fda orphan indication .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|gradients smad1 gata4 densities chimeras|phenylephrine|because of the extensive patient exposure to entity , we intend to develop ven 308 as a topical formulation through a section 505 ( b ) nda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens cracks neurovascular biased close|cyclins densities gradients density motors|phenylephrine|: 267 - 270 , 1999 normal subjects , entity gel ( 5% , 10% , 20% , 30% ) applied once to anal verge resting anal pressure increased by 8% to 33% , effect
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|either densities autoreg cd69 atpases|pemetrexed|in the th-302 plus entity arm , th-302 is administered intravenously on days 1 and 8 of a 21 day cycle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|atpases gata4 atpase densities chimeras|pemetrexed|obtain approval for talotrexin , we will compete with existing antifolate therapies currently being sold by pfizer ( trimetrexate ) , eli lilly & co . ( entity ) and novartis ( edatrexate ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|densities density localization atpases cd44|pemetrexed|pth-305 : nsclc ( w / entity ) 2 / 2006 to 6 / 2007 400 , 600 136 138 os was lower in talabostat vs placebo .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|gata4 atpases gradients motors densities|pemetrexed|eagle  s solution : ep-5101 ( pemfexy™ ) ep-5101 is an rtd liquid formulation of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|densities intram autoreg motors gradients|pemetrexed|interim data conducted on a small number of patients showed encouraging response rates with the combination of carboplatin , entity and bavituximab .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|densities autoin atpases cd69 motors|pemetrexed|administered as monotherapies , these include entity ( alimta® ) , docetaxel ( taxotere® ) , or erlotinib ( tarceva® ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|autoreg atpase decou notation atpases|densities autoreg gradients dens integrins|pemetrexed|the addition of apatorsen to carboplatin and entity therapy did not demonstrate an overall survival benefit in the study ( hr= 1 . 067 ; 80% ci : 0 . 838-1 . 359 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|dens cd44 autoreg gata4 cush|pemetrexed|entity , supply agreement term sheet in december 2016 , we entered into a binding term sheet with nang-kuang pharmaceutical co . , ltd and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|motors atpases smad1 either ante|pemetrexed|of the thirty-two patients with relapsed or refractory nsclc treated with th-302 in combination with either docetaxel or entity , eight patients achieved prs and fourteen patients achieved sd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|motors autoreg densities intram gradients|pemetrexed|·a phase ib ist evaluating bavituximab in combination with carboplatin and entity in up to 25 patients with previously untreated stage iv nsclc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|atpases densities motors either gradients|pemetrexed|with docetaxel in metastatic squamous nsclc that has progressed after previous therapy ( arm b ) ; or · in combination with entity and cisplatin in mesothelioma ( arm c ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|gata4 autoreg autoin mω gradients|pemetrexed|entity is dosed according to its package insert .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|autoreg dens gradients densities atpases|pemetrexed|which we allege infringement against apotex inc . ( apotex ) in response to its application to market products using alternative forms of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|densities autoreg gradients dens density|pemetrexed|the aim of the trial is to determine if adding apatorsen to carboplatin and entity therapy could extend pfs outcome .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|densities atpases adherens autoreg either|pemetrexed|the second 400-patient trial , evaluating the combination of talabostat with entity versus placebo and entity opened to enrollment in february 2006 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg atpase decou notation atpases|densities gata4 mω dystrophin autoin|pemetrexed|each study will combine pf-3512676 with either avastin® ( bevacizumab ) , erbitux® ( erlotinib ) or alimta® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|densities atpases notation autoreg density|pemetrexed|patients continued entity with weekly apatorsen or placebo infusions as maintenance treatment until disease progression if they completed a minimum of 3 cycles of chemotherapy treatment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|autoreg atpase decou notation atpases|gata4 atpases densities integrins atpase|pemetrexed|some of our competitors include pfizer ( trimetrexate ) , eli lilly & co . ( entity ) , novartis ( edatrexate ) , and allos ( pdx ) , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|autoreg densities either atpases density|pemetrexed|strata 1 and 3 also had maintenance entity or continued egfr-tki therapy , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg atpase decou notation atpases|densities autoreg either atpases motors|pemetrexed|the denali trial is testing demcizumab with entity and carboplatin versus entity and carboplatin alone in first-line advanced non-small cell lung cancer patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg dens gradients inner|gradients nedd4 densities uncoupling damp|moxidectin|both products  entity formulations offer numerous advantages over traditional deworming agents .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities autoreg dens gradients inner|densities cholerae motors autoreg imm|moxidectin|cydectin , a entity product to control parasites in animals , will have patent protection until at least 2011 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg dens gradients inner|gata4 densities density smad1 atpase|moxidectin|the first entity formulation for horses , equest gel , was launched in new zealand .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|densities density gata4 cd69 autoreg|oxaliplatin|this data represents a five-fold improvement to results seen from the entity arm of the study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|autoreg densities autoin density kolmogorov|oxaliplatin|also performed a gene identification study which analyzed over 700 new genes , and identified 16 genes as being predictive of entity benefit for use in patients with stage iii disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|densities gata4 atpases mω chaperones|oxaliplatin|in 2010 ) , following a court ruling barring manufacturers of generics in the u . s . from selling their unapproved generic versions of entity from june 30 , 2010 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|mω motors atpases either densities|oxaliplatin|currently in clinical trials , including trials for hormone refractory prostate cancer , inoperable liver cancer , and in combination with capecitabine or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|densities autoin density either autoreg|oxaliplatin|the company began offering the oncotype dx colon cancer test for use in patients with stage iii disease treated with entity containing adjuvant therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|motors mω atpases atpase autoreg|oxaliplatin|other chemotherapies include capecitabine ( xeloda® ) , entity ( eloxatin® ) , fluorouracil or leucovorin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|gata4 densities atpases mω chaperones|oxaliplatin|in the first half of 2010 ) after a court ruling barred generics manufacturers from selling their unauthorized generic versions of entity in the united states from june 30 , 2010 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|dwell densities spher mω motors|oxaliplatin|two weeks in patients with advanced non-small cell lung cancer ; and ø a u . s . phase iii trial in patients undergoing treatment with entity regimens for advanced colorectal cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|mω gata4 motors densities atpases|oxaliplatin|marketed products in oncology include padexol injection ( paclitaxel ) , didox capsule ( doxifluridine ) , oxp injection ( entity ) and crabcan injection ( irrinotecan ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|gradients mω motors cd69 atpases|oxaliplatin|entity , a formulation of dach platinum , is a chemotherapeutic which was initially approved in france and in europe in 1999 for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|damp gata4 densities density nanog|oxaliplatin|on june 30 , 2010 , the company ceased selling sun pharmas entity product in the united states market , pending the appeal .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|gata4 densities ante endos atpases|oxaliplatin|the originator of the drug , and several generic manufacturers ; ▪ carboplatin , marketed by bristol-myers squibb in the us ; and ▪ entity , marketed exclusively by sanofi-aventis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities decou dens density gradients|densities gata4 chimeras damp divertic|oxaliplatin|entity injection 50mg / 10ml and 100mg / 20ml are the ab-rated generic versions of eloxatin® , which had annual sales of approximately $1 . 4 billion for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities decou dens density gradients|motors densities either atpases integrins|oxaliplatin|other combinations of gemcitabine with cisplatin , entity , irinotecan or docetaxel tested in phase 3 trials have not been of superior benefit to gemcitabine alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities decou dens density gradients|motors integrins ante degenerate atpase|oxaliplatin|for most patients , initial chemotherapy is based on folfox ( 5-fu , leucovorin and entity ) , or similar agents .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|densities density chimeras gata4 smad1|oxaliplatin|the growth was driven by an increase in specialty injectable pharmaceuticals , primarily a result of the third-quarter launch of entity in solution form in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|densities mω either motors microns|oxaliplatin|demonstrated preliminary evidence of efficacy but grade 2 innate immune adverse effects were seen with standard doses of gemcitabine and entity and 10 µg / kg doses of mt-3724 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities decou dens density gradients|mω spher autoin integrins motors|oxaliplatin|aroplatin aroplatin is a novel liposomal formulation of a third-generation platinum chemotherapeutic structurally similar to entity , a recently approved treatment for colorectal cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities decou dens density gradients|densities density atpase either atpases|oxaliplatin|on august 11 , 2009 , teva commenced sales of its 50mg / 10ml and 100mg / 20ml entity injection products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities decou dens density gradients|mω integrins gradients cd69 motors|oxaliplatin|entity , a compound of dach platinum , is a chemotherapeutic which was initially approved in europe in 1999 for the treatment of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|densities gradients density spher damp|levothyroxine|skin reactions , hypothyroidism in patients taking entity replacement , gi perforation , in some cases fatal and tumor lysis syndrome , which can be life threatening , have also been reported
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|gata4 densities smad4 cytoskeleton cd44|levothyroxine|levoxylò ( entity sodium tablets , usp ) net sales decreased to $26 million during the second quarter ended june 30 , 2007 from $29 million during the second
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|autoreg dens clarity notation densities|gata4 autoin damp atpases integrins|levothyroxine|if the fda were to determine that another entity sodium product is bioequivalent to levoxyl® , generic substitution for levoxyl® may become possible which could result in a decrease in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|densities gata4 dens kv autoin|levothyroxine|could be affected by future actions of the fda and by uncertainty in the entity sodium product market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|densities density autoreg localization chimeras|levothyroxine|of upfront payment represents the amortization of the upfront payment made to lannett in connection with our transition agreement with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|densities gata4 smad4 cyclins motors|levothyroxine|levoxylò ( entity sodium tablets , usp ) net sales totaled $32 million during the fourth quarter and $100 million for the year ended december 31 , 2007 , compared
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|gata4 densities autoin atpases atpase|levothyroxine|in december 2004 , the entity sodium tablet product received the ab rating to synthroid® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|densities dens autoin density spher|levothyroxine|on august 14 , 1997 , the fda announced in the federal register ( 62 fr 43535 ) that orally administered entity sodium drug products are new drugs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|gata4 smad4 motors damp smad1|levothyroxine|net sales of levoxyl ( r ) ( entity sodium tablets , usp ) equaled $28 . 7 million during the first quarter ended march 31 , 2004 , a decrease of 14% from $33 . 2
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|gata4 densities gradients atpases autoin|levothyroxine|volumes were favorably impacted due to increased sales of entity as customer demand increased in anticipation of the transition of the product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|densities dens density autoreg mω|levothyroxine|complementing our second quarter performance was a well-executed plan associated with the transition of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|gata4 chimeras mω localization damp|levothyroxine|nitrofurantoin during our 180-day exclusivity period ; the delay in the launch of our fentanyl product and the regulatory actions surrounding entity sodium .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|autoreg dens clarity notation densities|gata4 densities atpases integrins cd69|levothyroxine|worldwide agreement with jerome stevens pharmaceuticals , inc . to market and distribute jerome stevens  nda ( new drug application ) approved form of entity sodium , usp tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|densities gata4 density chaperones autoin|levothyroxine|of $2 , 220 , 931 due to an improvement in timely collections , and the launch of the company  s new product sales campaign for entity sodium tablets in april 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|dens densities autoin density atpases|levothyroxine|drug administration , which we refer to as the fda ,  announced in the federal register ( 62 fr 43535 ) that orally administered entity sodium drug products are new drugs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|densities gata4 autoin smad4 atpase|levothyroxine|this dual approval will now allow pharmacists to substitute entity sodium tablets for both dominant brands .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|either autoreg autoin mω cyclins|levothyroxine|thyromed chewable tablets contain the active ingredient entity sodium , which is a clinically proven replacement for the naturally occurring hormone secreted by the thyroid gland .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|gradients gata4 chimeras autoin smad4|levothyroxine|these chewable tablets , which are administered daily for the life of the dog , provide entity sodium , a replacement therapy for the hormone normally produced by the dog .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|densities autoreg density chimeras dens|levothyroxine|of upfront payment represents the amortization of the upfront payment made to lannett in connection with our transition agreement for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens clarity notation densities|densities autoin rescues gata4 atpase|levothyroxine|application for an equivalent product after august 14 , 2001 must submit an anda seeking approval of a generic substitute for a entity sodium product with an approved nda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities dispens motors atpase|cyclins chimeras atpases gata4 atpase|neomycin|triamcinolone acetonide and entity paste used for neurodermatitis circumscripta and chronic eczema .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities dispens motors atpase|chimeras gata4 autoin atpases gradients|neomycin|existing drugs , such as tobramycin , entity , zithromax® and zyvox® , demonstrate that successful medicines can modulate rna function .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities dispens motors atpase|gata4 smad1 chimeras gradients motors|neomycin|our products that contain virginiamycin , oxytetracycline or entity are classified by the fda as medically important antimicrobials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities dispens motors atpase|gata4 smad1 chimeras motors ante|neomycin|our products that contain virginiamycin , oxytetracycline or entity have previously been classified by the fda as medically important antibacterials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities dispens motors atpase|gradients gata4 clock motors cyclins|neomycin|neoflo is a dressing that incorporates the triple antibiotic , polymyxin b sulfate , bacitracin zinc and entity sulfate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities dispens motors atpase|autoin atpases motors gata4 ante|neomycin|the company believes that current antibiotic therapies , including entity and metronidazole , are inadequate treatments , however , due to their limited antibacterial spectrum and side effects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities dispens motors atpase|gata4 smad1 autoreg either densities|neomycin|the abnormal plasma amino acid pattern characterized by decreased levels of bcaas and elevated levels of aaas , as compared to entity , which was used as an active control .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities dispens motors atpase|densities chimeras atpases autoin either|neomycin|nexavar exposure decreases when coadministered with oral entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities dispens motors atpase|gata4 smad1 chimeras atpases densities|neomycin|our products that contain virginiamycin , oxytetracycline or entity have previously been classified by the fda as medically important antimicrobials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities dispens motors atpase|gradients gata4 motors clock cyclins|neomycin|neoflo is a dressing that incorporates the triple antibiotic , polymyxin b sulfate , bacitracin zinc and entity sulfate ( neosporin-registered trademark- ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|gata4 atpases negativity mω gradients|tenofovir|the later stages of the phase iii clinical trials for adefovir dipivoxil will not arise in the clinical trials for entity df or that we will achieve adequate treatment benefits .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|mω densities gata4 gradients localization|tenofovir|initiate in 2017 the phase 2b clinical trial to evaluate sb 9200 as a monotherapy and in combination with viread ( entity ) targeting approximately 200 patients with chronic hbv .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|spher mω autoin gata4 cd44|tenofovir|entity has potent activity against chronic hepatitis b . it is particularly useful in patients who have developed drug resistance to other
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|autoreg decou differential scattered smad2|integrins smad2 traps chaperones atpases|tenofovir|unenforceable and / or will not be infringed by teva  s manufacture , use or sale of a generic fixed-dose combination of emtricitabine and entity disoproxil fumarate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|spher autoreg atpases polymorph chimeras|tenofovir|the most commonly used therapy for chronic hbv is life-long suppressive therapy with nrtis , like entity or entecavir .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|chimeras atpases chaperones densities smad1|tenofovir| viread sales of viread® ( entity disoproxil fumarate ) were $189 . 4 million in the third quarter of 2005 , a two percent decrease from $193 . 9 million in the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|autoreg mω gata4 atpases chimeras|tenofovir|use of viread should be considered for treating adult patients with hiv-1 strains that are expected to be susceptible to entity as assessed by laboratory testing or treatment history .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|drug|autoreg decou differential scattered smad2|autoreg atpases atpase polymorph myofibroblasts|tenofovir|nrtis , such as epivir ( 3tc ) , emtriva ( ftc ) , viread ( entity ) , retrovir ( azt ) and zerit ( d4t ) , have become the predominant class of drugs in hiv therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|mω atpases grades clock autoreg|tenofovir|txl is a highly potent analog of the antiviral drug entity df ( viread® ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|densities motors autoreg dens atpases|tenofovir|which gilead is funding and conducting a phase 2 clinical trial examining the co-administration of inarigivir and vemlidy® 25 mg ( entity alafenamide ) in patients infected with chronic hbv .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|densities smad4 gata4 gradients density|tenofovir|addendum to entity disoproxil fumarate manufacturing supply agreement the parties hereby acknowledge and agree to the following :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|mω smad1 gata4 autoin autoreg|tenofovir|nucleotide compound , uses the same proprietary lipid technology as cmx001 to deliver high intracellular concentrations of another potent antiviral drug , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|atpases densities traps chimeras mω|tenofovir|and in april 2013 , gilead and teva reached an agreement in principle to settle the lawsuit on the patents covering entity disoproxil fumarate contained in the atripla*
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|gata4 densities inactivation autoreg density|tenofovir|we cannot predict the outcome of these proceedings on our entity df patent application .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg decou differential scattered smad2|gata4 cholerae autoreg gradients chimeras|tenofovir|in addition , in late 2011 , generic entity also became available in turkey , which resulted in an increase in the rebate for viread in turkey .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|clock atpases autoreg atpase kinases|tenofovir|entity df is in the same class of drugs as adefovir dipivoxil .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|clock mω pull localization localizes|tenofovir|of cmx157 in healthy volunteers and are on track to complete the ongoing phase 2a head-to-head study of cmx157 vs . entity df ( tdf , gileads viread® ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|autoreg decou differential scattered smad2|integrins gata4 atpases smad1 spher|tenofovir|entity and entecavir have emerged as the standard of care in this disease with very low rates of resistance over five
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg decou differential scattered smad2|atpases dens gradients densities cush|tenofovir|the replicor 401 study , a study of naps in combination with entity and pegylated interferon , reported a 39% functional cure rate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|autoreg decou differential scattered smad2|atpases traps mω integrins atpase|tenofovir|in the notice related to teva  s anda for a generic version of truvada , teva challenged four patents related to entity disoproxil fumarate and two additional patents related to emtricitabine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|atpases damp gata4 chaperones gradients|amifostine|we are also aware of research relating to the use of high doses of entity ( a drug used to control some of the side effects of chemotherapy and radiation therapy ) for the protection of hearing
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens autoreg densities density gradients|motors densities atpases mω integrins|amifostine|he played key consulting roles in registration strategy and post-registration development of recent products such as entity , docetaxel , cpt-11 and irofulven .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens autoreg densities density gradients|gata4 densities adherens density integrins|amifostine|we anticipate that ethyolregistered trademark ( entity ) will be a meaningful product for medimmune following our merger .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|autoreg densities gata4 motors atpase|amifostine|sales of ethyol-registered trademark- ( entity ) increased 48% and 23% for the quarter and six months ended june 30 , 1999 , respectively , compared to the same periods
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|mω gata4 motors atpases densities|amifostine|medical applications the arsenal of medical radiation-protectors is limited to ethyol™ ( entity ) , sold by medimmune , and acquired by astrazeneca international .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|gata4 densities gradients atpases nedd4|amifostine|mycelex-registered trademark- ( clotrimazole ) troche , which alza began marketing in the second half of 1997 , and increased sales of ethyol-registered trademark- ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|gradients atpases mω densities spher|amifostine|entity ( ethyolâ ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|cd44 mω gata4 atpases gradients|amifostine|we are also aware of research relating to the use of high dose entity for the protection of hearing in connection with platinum-based chemotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|densities density gata4 motors cyclins|amifostine|we market synagis ( palivizumab ) , flumist ( influenza virus vaccine live , intranasal ) , ethyol ( entity ) and cytogam ( cytomegalovirus immune globulin intravenous ( human ) ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|gata4 mω densities density gradients|amifostine|sun pharmaceutical industries limited has submitted an abbreviated new drug application to the fda for a generic version of ethyol ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|mω atpases autoin densities atpase|amifostine|entity ( ethyol® ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|densities density gata4 chimeras mω|amifostine|the company markets synagis ( palivizumab ) , ethyol ( entity ) , and cytogam ( cytomegalovirus immune globulin intravenous ( human ) ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|gata4 autoin cd69 autoreg smad2|amifostine|neupogen ( r ) currently faces market competition from a competing csf product , granulocyte macrophage colony stimulating factor ( " gm-csf " ) and from the chemoprotectant , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|autoin atpases gata4 mω cd69|amifostine|entity ( ethyol® ) is approved by the fda as a radioprotector .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|mω densities autoreg gata4 gradients|amifostine|in december 1995 , alza entered into a marketing and distribution agreement with u . s . bioscience , inc . ( " u . s . bioscience " ) for ethyol-registered trademark- ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|mω atpases autoin damp densities|amifostine|entity ( ethyol® ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity and radiation-induced xerostomia ( damage to the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|mω densities atpases atpase autoin|amifostine|entity ( ethyol ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|gata4 atpases autoin motors gradients|amifostine|there is one drug , entity , approved for use in reducing side effects from radiation therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens autoreg densities density gradients|motors densities atpases mω integrins|amifostine|he played key consulting roles in registration strategy and post-registration development of recent products such as entity , docetaxel , cpt-11 , and irofulven .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg densities density gradients|mω densities gata4 density gradients|amifostine|product sales of $66 million , including $33 million in worldwide sales of synagis and $25 million in sales of ethyol® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|atpases gata4 atpase motors densities|hydrocortisone|· igi will formulate four combination products of entity and lidocaine at different strengths : 1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|densities autoreg autoin cd69 gata4|hydrocortisone|at 4 µm , 42% at 8 µm and 52% at 16 µm . therefore , the ic50 was 16 µm . by comparison , entity at 10 µm caused a 54% reduction in il-8 expression .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|cyclins atpases gata4 atpase normality|hydrocortisone|in canada , 0 . 5% entity , a common anti-inflammatory product , described in the monograph , hydrocortisone topical published by health canada on january 22 , 2007 , can be
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|densities atpase cush smad4 motors|hydrocortisone|on november 15 , 2011 , we acquired rights to plenadren® ( entity , modified release tablet ) for treatment of ai .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|gradients cyclins cd44 clock mω|hydrocortisone|entity rectal cream is used for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|chimeras gradients gata4 densities dwell|hydrocortisone|discuss how fda views our package of the us experience with ketoconazole and entity combination and discuss how much value in the historical experience will be accepted .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|autoin densities gradients motors localization|hydrocortisone|this was partially offset by the product launch of entity butyrate lotion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|cyclins gata4 atpases densities gradients|hydrocortisone|the launch of entity with acetic acid along with strong sales of sulfamethoxazole with trimethoprim and fluticasone propionate nasal spray also contributed to the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|smad4 cyclins normality atpase densities|hydrocortisone|-jun-11 t36® 0 . 5% entity ointment 80026139 30-jun-11 pedia-safe polyvitamin drops1 80001571 05-apr-06 ferroheme2 1 licensed to the company by canagen in an agreement dated
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|atpases densities autoin gata4 adherens|hydrocortisone|cbn was similar to entity with respect to anti-inflammatory activity in this model .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|cyclins chimeras gradients gata4 motors|hydrocortisone|anamantlehc , launched in january 2003 , is a prescription cream containing a topical anesthetic and entity , which treats hemorrhoids and anal fissures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|gata4 cyclins atpases gradients atpase|hydrocortisone|the combination of aloe vera and entity offers therapeutic benefits for skin irritations such as minor burns , allergic itch , insect bite itch , sun burn itch , eczema in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|gradients chimeras gata4 densities motors|hydrocortisone|entity injection toxic symptom caused by various infections , hypocorticoidism caused by various infections , anaphylactic shock .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|atpase damp densities autoreg cd69|hydrocortisone|cma issued a statement of objections to a third party and the company in relation to the supply of 10mg entity tablets in the u . k . between 2013 and 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|cyclins atpases autoreg gradients gata4|hydrocortisone|both products are formulated with aloe vera and cortiveraä contains 0 . 5% entity and cortivera plusä contains 1% entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|atpase gata4 smad1 motors autoreg|hydrocortisone|formulation design up to 8 78 , 600 · igi will formulate a entity cream product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients autoreg density dens|gradients gata4 atpases cyclins dens|hydrocortisone|lidamantle®hc also contains entity , which helps to reduce inflammation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|autoreg chimeras gata4 autoin dens|rosiglitazone|commonly prescribed drugs include diabetic medicines such as metformin , entity and sulfonylurea .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|densities dens density gradients gata4|rosiglitazone|for the district of colorado into the group  s us sales and promotional practices and for product liability cases regarding avandia ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|atpases atpase autoreg gata4 chimeras|rosiglitazone|a fixed combination product of starlix and entity was approved by fda in 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens autoreg cush densities decou|autoreg gata4 spher autoin divertic|rosiglitazone|will compete with cs-917 include the insulin sensitizers actos , or pioglitazone , co-marketed by takeda and eli lilly , and avandia , or entity , marketed by glaxosmithkline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|autoreg gata4 atpases autoin p63|rosiglitazone|cvr number : 24256790 the three lead® studies showed that liraglutide in combination with either glimepiride or metformin or metformin and entity is well tolerated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|autoreg gata4 atpases dens atpase|rosiglitazone|the study investigated the effect of different doses of liraglutide in combination with metformin and entity , and included 533 patients with type 2 diabetes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|densities chimeras gata4 gradients atpases|rosiglitazone|june 2007 the group voluntarily dismissed its infringement claims in respect of the patent covering the maleate salt form of entity ( the active ingredient in avandia ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|autoreg autoin spher chimeras polymorph|rosiglitazone|starlix ( diabetes ) was also filed in the us in december for use in combination with entity , a commonly used oral antidiabetic .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens autoreg cush densities decou|densities atpases atpase divertic chimeras|rosiglitazone|with respect to avandamet ( entity maleate / metformin hydrochloride ) tablets , the company anticipates resupplying the distribution channels within two weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|autoreg ante spher intram gata4|rosiglitazone|this weight loss was achieved with blood sugar-lowering efficacy comparable to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|gata4 dens densities gradients chimeras|rosiglitazone|site at cidra , puerto rico ; product liability and anti-trust litigation relating to paxil ( paroxetine ) , and product liability cases regarding avandia ( entity ) and other products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|densities chimeras autoin atpases gata4|rosiglitazone|for example , recent studies have suggested an increased cardiovascular risk in patients using avandia® ( entity maleate ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|chimeras autoreg mω smad1 chaperones|rosiglitazone|there also have been concerns of other cardiovascular issues with entity and also concerns raised regarding bladder cancer associated with treatment with tzds .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens autoreg cush densities decou|spher autoin divertic autoreg chimeras|rosiglitazone|insulin sensitizing agents approved to treat t2d are the ppar gamma agonists pioglitazone and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|sinus spher loose autoreg cavities|rosiglitazone|of starlix® ( nateglinide ) improves glycemic control and is well-tolerated in patients whose type 2 diabetes is inadequately controlled by taking entity alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens autoreg cush densities decou|autoreg autoin gata4 divertic either|rosiglitazone|after a run-in period of metformin and entity , patients in the study were randomised to add-on treatment with either liraglutide or placebo .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|spher autoin autoreg atpases chimeras|rosiglitazone|entity ( avandia® ) and pioglitazone ( actos® ) fall into this category of anti-diabetic agent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|spher autoreg autoin dipole atpases|rosiglitazone|tzds include pioglitazone , marketed by eli lilly & company and takeda pharmaceutical company limited as actos , and entity , marketed by glaxosmithkline plc as avandia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg cush densities decou|autoreg gata4 autoin smad1 atpases|rosiglitazone|a comparator with entity , which has been shown to have some efficacy in humans , indicates the mgl-3196 performs better than entity in this study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens autoreg cush densities decou|spher autoin autoreg divertic chimeras|rosiglitazone|insulin sensitizing agents approved to treat type 2 diabetes are the ppar gamma agonists pioglitazone and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities heterochromatin nervous|gata4 atpase cyclins motors atpases|tetracaine|we entered into a license agreement with zars pharma for the north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch ( zars agreement ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities heterochromatin nervous|gata4 motors atpase cyclins chaperones|tetracaine|license agreement with zars pharma that will give it the exclusive north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities heterochromatin nervous|atpase gata4 atpases motors cyclins|tetracaine|the drug formulation is a eutectic mixture of lidocaine 70 mg and entity 70 mg .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities heterochromatin nervous|chaperones cyclins chimeras gata4 mω|tetracaine|this product combines our peel technology with a proprietary formulation of lidocaine and entity to safely and efficiently anesthetize contoured areas of the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities heterochromatin nervous|cyclins atpase motors gata4 chaperones|tetracaine|we entered into a license agreement with zars pharma for the north american rights to synera® ( lidocaine 70 mg and entity 70 mg ) topical patch , referred to as the zars agreement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities heterochromatin nervous|cyclins atpase atpases motors gata4|tetracaine|allergy u . s . rx lidocaine ointment xylocaine™ dermatologics and topicals u . s . rx lidocaine / entity gel pliaglis® dermatologics and topicals u . s . rx loratadine solution claritin® allergy
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities heterochromatin nervous|gata4 motors chaperones chimeras atpases|tetracaine|it uses our chadd technology and a proprietary formulation of lidocaine and entity to provide more convenient and faster anesthetic effect compared to the most commonly used product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|autoreg dens densities heterochromatin nervous|kv gata4 cholerae dystrophin densities|tetracaine|the fda has specified a limit of 1 . 5% tetra acid relative to entity assay .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities heterochromatin nervous|densities autoreg imm gradients density|tetracaine|must demonstrate an acceptable level of tetra acid , which is a compound that is formed as the active product ingredients , entity assay , degrade over time .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities heterochromatin nervous|atpase cyclins motors gata4 chaperones|tetracaine|we entered into an agreement with zars pharma for the north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities autoreg gradients|autoreg negativity chimeras gradients autoin|pramoxine|current phn treatments are symptomatic , affecting the pain signaling circuit ( such as novocaine , entity , capsaicin , etc . ) , and do not produce lasting control .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities autoreg gradients|autoin gradients chimeras gata4 mω|pramoxine|manufacture had to be obtained by copley before it shipped in interstate commerce and distributed for human use , brompheril , hydrocortisone entity , potassium chloride or procainamide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities autoreg gradients|gata4 cd44 chaperones autoreg motors|pramoxine|preparation h® or similar products for symptomatic relief ( active ingredients can vary by country but generally include glycerin , phenylephrine hcl , entity hcl , and white petrolatum ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens densities autoreg gradients|gata4 autoin chimeras atpases motors|pramoxine|otc products contain any one of several active ingredients including glycerin , phenylephrine , entity , white petrolatum , shark liver oil and / or witch hazel , for symptomatic relief .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou avidin notation|densities gata4 gradients density atpases|liothyronine|entity , a concordia product , was included in the initial draft .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou avidin notation|gata4 densities atpases gradients smad1|liothyronine|we believe that due to the fact that the market for entity is small , the manufacture and sale of generic forms of this compound are not economically attractive to potential competitors .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou avidin notation|gata4 autoin densities chaperones kinases|liothyronine|entity sodium , one of the company  s products , was included in the initial draft .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou avidin notation|densities gata4 chimeras density cush|liothyronine|the company recorded a total impairment charge of $301 , 538 , primarily related to entity sodium - $128 , 191 , fusidic acid -
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou avidin notation|densities gata4 dens damp gata3|liothyronine|during the second quarter of 2017 , the company also became aware of the anticipated launch of a competitive product to entity sodium .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou avidin notation|chimeras gata4 autoin densities gradients|liothyronine|amcos product portfolio in the united kingdom is its largest and is predominantly comprised of products such as levothyroxine , entity and nitrofurantoin .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|clarity dens decou avidin notation|gata4 densities atpases cyclins integrins|liothyronine|generic entity sodium tablets are also available from coastal pharmaceuticals , mylan , and sigma pharmaceuticals .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou avidin notation|gata4 densities chimeras autoin junction|liothyronine|the remaining decrease of 13% is due to volume declines on key products including entity sodium , prednisolone and nefopam .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou avidin notation|densities gata4 density smad4 damp|liothyronine|the cma pricing investigation , which commenced in october 2016 , relates to three products , including entity tablets .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|clarity dens decou avidin notation|gata4 chimeras motors smad1 autoin|liothyronine|concordia international sells products such as entity , nitrofurantoin and levothyroxine within this category of the pharmaceutical market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities gradients density atpase mω|densities gata4 mω chimeras dystrophin|urofollitropin|entity - this is fsh derived from the urine of postmenopausal women .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients density atpase mω|gata4 smad1 gradients mω autoin|urofollitropin|entity is used in research to develop fertility drugs and in basic endocrinology research .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities gradients density atpase mω|densities gata4 gradients dystrophin density|urofollitropin|sicor currently expects to file a process patent covering purification of entity in early 1997 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities gradients density atpase mω|densities gata4 gradients density dystrophin|urofollitropin|sicor currently expects to file a process patent covering purification of entity in 1997 and is in discussions with potential partners about marketing the product in the u . s . and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities gradients density atpase mω|autoreg imm densities cholerae gata4|urofollitropin|in order to commercialize therapeutics , initially entity , the company must outsource the manufacturing to a fda-regulated facility .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients density atpase mω|gradients gata4 densities smad1 existence|urofollitropin|the company  s present product candidates targeted to treat infertility include purified entity ( " vitropin ( tm ) " ) for injection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients density atpase mω|densities gata4 density gradients motors|urofollitropin|in addition , at its facility outside of turin , sicor is developing a glycoprotein , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients density atpase mω|gradients densities dens density gata4|urofollitropin|sicor is developing a process for the isolation of entity from the urine of post- menopausal women .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients density atpase mω|gata4 gradients smad1 chimeras chaperones|urofollitropin|entity is involved in the stimulation of ovulation and is used in the treatment of certain types of infertility .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients density atpase mω|gradients densities dens density gata4|urofollitropin|sicor is developing a process for the isolation of entity from the urine of post-menopausal women .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients density atpase mω|densities gata4 density gradients motors|urofollitropin|in addition , at its santhia facility outside of turin , sicor is developing a glycoprotein , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities gradients density atpase mω|gradients gata4 densities smad1 existence|urofollitropin|the company  s present products envisioned to treat infertility include purified entity ( " vitropin ( tm ) " ) for injection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|mω gata4 densities density smad1|eravacycline|we may be unable to develop and commercialize entity or any other product candidate and , even if we do , may never achieve profitability .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|gata4 mω kv densities density|eravacycline|our operations to date have been limited to financing and staffing our company , developing our technology and developing entity and other product candidates .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|atpases densities autoreg retarded dens|autoreg densities cytoskeleton gata4 integrins|eravacycline|the companys commercial product , xerava ( entity ) , a fully synthetic fluorocycline , is an intravenous ( iv ) antibiotic that is approved for use as a first-line empiric monotherapy for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|densities density gata4 smad1 mω|eravacycline|our current plan is to commercialize entity outside the united states with collaborators .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|atpases gradients chimeras densities density|eravacycline|xerava was investigated for the treatment of ciai as part of the companys ignite ( investigating gram-negative infections treated with entity )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|gata4 densities gradients motors autoreg|eravacycline|the companys lead product candidate , entity , is a fully synthetic tetracycline derivative that the company is developing as a broad-spectrum intravenous and oral antibiotic for use
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|gata4 smad1 mω imm damp|eravacycline|tetraphase pharmaceuticals is developing entity for complicated urinary and intra-abdominal infections , as well as pneumonia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|densities gata4 smad1 cd69 density|eravacycline|for example , although entity achieved favorable results in the lead-in part of our phase 3 clinical trial in cuti , the pivotal portion of the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|densities gata4 mω smad1 autoreg|eravacycline|this may make it difficult for entity to compete with these products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|densities gata4 density atpases autoreg|eravacycline|its phase 3 clinical trials ( ignite1 and ignite4 ) would be sufficient to support submission of a new drug application for entity for the treatment of ciai .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|atpases gata4 densities negativity motors|eravacycline|approval of xerava was based on our ignite ( investigating gram-negative infections treated with entity ) phase 3 program .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|atpases densities autoreg retarded dens|mω autoreg binders cholerae densities|eravacycline|moreover , the company does not believe that the statement indicates in any respect that entity covers any or all of these infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|densities gata4 density mω chimeras|eravacycline|if clinical trials of entity or of any other product candidate that we advance to clinical trials fail to demonstrate safety and efficacy to the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|gata4 autoin autoreg mω densities|eravacycline|if entity is approved , it may be priced at a significant premium over other competitive products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|mω smad1 kv chimeras gata4|eravacycline|prior written notice if any governmental agency takes any action that prevents the company from importing , exporting , purchasing or selling entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|gata4 densities gradients mω density|eravacycline|tetraphase is currently selling xeravatm ( entity ) in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|gata4 smad1 smad2 autoin atpases|eravacycline|however , we do not believe these limitations would apply to entity or any of our other investigational antibiotics .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|nedd4 gata4 densities gradients density|eravacycline|entity , along with the companys proprietary drug discovery platform technology , make tetraphase an exceptional opportunity that i look forward to being
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases densities autoreg retarded dens|densities atpases gradients gata4 density|eravacycline|case based on our achievement of company goals with respect to the development of the intravenous and oral formulations of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg gradients motors dens atpases|atpases cyclins motors autoreg atpase|dyclonine|a bema ( tm ) product containing entity as a local anesthetic prior to dental procedures and for the treatment of canker sores has been consumer tested .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg gradients motors dens atpases|motors gradients density atpases gata4|dyclonine|mucosal surfaces single claim  layered bioerodable pharmaceutical ( entity only ) carrier device .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase atpases gradients cush adherens|gata4 smad4 either atpase mω|atosiban|the safety and pharmacokinetics of obe022 administered to pregnant women , who are receiving standard of care therapy for preterm labor , entity infusion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase atpases gradients cush adherens|autoreg mω spher normality cd69|atosiban|these effects were blocked by the oxytocin receptor antagonist , entity , indicating the effects of intranasal oxytocin were mediated by oxytocin receptors .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase atpases gradients cush adherens|autoreg cd69 atpases smad2 gata4|atosiban|in singleton pregnancies , 12 . 5% of women receiving ebopiprant plus entity delivered within 48 hours compared to 26 . 8% receiving entity only ( or 90% ci : 0 . 39 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|atpase atpases gradients cush adherens|damp gata4 gradients mω integrins|atosiban|ferring pharmaceuticals entity , an oxytocin receptor antagonist , has been used in investigator initiated trials in connection with ivf outside the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase atpases gradients cush adherens|gata4 density cd69 gradients densities|atosiban|with respect to obe022 , tractocile ( entity ) is approved to delay preterm birth outside of the united states , and we anticipate potential competition as a single agent ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase atpases gradients cush adherens|mω autoreg cd69 gata4 smad2|atosiban|entity , an oxytocin antagonist , is available in europe , but was denied regulatory approval in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase atpases gradients cush adherens|autoreg either mω cd69 gata4|atosiban|to exacerbate behavioral changes , entity , an oxytocin antagonist , was administered to the pups by slow intravenous push .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase atpases gradients cush adherens|densities gata4 chimeras autoin autoreg|atosiban|two groups were given placebo in place of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|atpase atpases gradients cush adherens|gata4 smad4 cholerae mω atpase|atosiban|the safety and pharmacokinetics of obe022 in pregnant women , who were already receiving standard of care therapy for preterm labor , entity infusion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase atpases gradients cush adherens|autoreg mω cd69 spher gradients|atosiban|entity , an oxytocin antagonist , is available in europe , but was denied regulatory approval in the u . s . the usefulness of these ß2-adrenergic
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities atpase atpases density boltzmann|cholerae atpase veloc biphasic biased|suvorexant|franchises grew · fda approved grastek and ragwitek sublingual allergen extract immunotherapy tablets and accepted filings for v503 and entity
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|autoreg atpase normality gata4 spher|suvorexant|these may include the following :  entity , an orexin receptor antagonist , is being developed by merck & co . , inc . for the treatment of insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|autoreg atpases gata4 autoin atpase|suvorexant|three of these medicines were filed in the u . s . ( entity for insomnia ; sugammadex for neuromuscular blockade and a combination of ezetimibe and atorvastatin for atherosclerosis ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|mω gata4 densities smad1 cd44|suvorexant|the company is continuing with plans to seek approval for entity in other countries around the world .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|densities density gata4 chimeras localization|suvorexant|· received a complete response letter from the fda regarding the new drug application for entity , mercks investigational medicine for the treatment of insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|gata4 binders densities cd69 smad1|suvorexant|if approved , entity would be the first in a new class of medicines , called orexin receptor antagonists , for use in patients with insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities atpase atpases density boltzmann|normality autoreg divertic gata4 densities|suvorexant|in august 2014 , merck & co . s dual orexin receptor antagonist , entity , was approved by the fda and is currently marketed under the name belsomra® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|gata4 autoreg negativity damp smad1|suvorexant|the effects produced by doras on rem sleep explain the motor effects and other side effects seen with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|densities autoreg autoin gradients imm|suvorexant|entity will be evaluated by the controlled substance staff of the fda during nda review .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|mω densities gata4 density gradients|suvorexant|for the treatment of advanced melanoma and metastatic nsclc in patients whose disease has progressed after other therapies , and belsomra ( entity ) for the treatment of insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|mω densities gata4 kv density|suvorexant|merck has announced that it plans to file regulatory applications for entity in 2012 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|gata4 densities localization normality gradients|suvorexant|merck is marketing belsomra® ( entity ) , which is a dual orexin receptor anatomist indicated for insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|densities atpase gata4 atpases gradients|suvorexant|in august 2014 , merck announced that the fda approved belsomra ( entity ) for the treatment of adults with insomnia who have difficulty falling asleep and / or staying asleep .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|atpases autoin gata4 autoreg densities|suvorexant|seeing significant progress in the pipeline this year , and we expect six major filings over the next 18 months , including entity for insomnia and odanacatib for osteoporosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|gata4 densities normality cd69 autoreg|suvorexant|neurosciencebelsomra ( entity ) , an orexin receptor antagonist indicated for the treatment of insomnia , characterized by difficulties with sleep onset and / or sleep maintenance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|mω smad1 gata4 autoreg densities|suvorexant|both fda approval and a separate scheduling determination by the u . s . drug enforcement administration are required before merck can introduce entity in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|densities gata4 density atpase atpases|suvorexant|on may 22 , 2013 , the fdas peripheral and central nervous system drugs advisory committee will meet to discuss the nda for entity ( mk-4305 ) tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpase atpases density boltzmann|gata4 densities density gradients motors|suvorexant|mk-4305 , entity , is an investigational insomnia medicine in a new class of medicines called orexin receptor antagonists for use in patients with
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|gata4 gradients smad1 cd44 densities|guselkumab|entity is currently being investigated in clinical studies in several indications , including plaque psoriasis , pediatric psoriasis , psoriatic arthritis , crohns disease , hidradenitis
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities dens atpases density dwell|gradients density densities integrins cd69|guselkumab|entity ( tremfya® ) is the first approved antibody binding the p19 subunit of il-23 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|gata4 densities gradients mω density|guselkumab|in july , subsequent to the quarter , the fda approved tremfya™ ( entity ) for the treatment of adults living with moderate to severe plaque psoriasis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities dens atpases density dwell|localisation gradients localization densities density|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il-23 ligand and are specific to the il-23 pathway , which is believed to be
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|densities gata4 density gradients chimeras|guselkumab|of morphosys ag , said : we are very pleased that our licensee janssen has further expanded the clinical development program of entity by initiating a clinical study in ulcerative colitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|density densities mω gata4 cd44|guselkumab|in 2017 , tremfya® ( entity ) , marketed by janssen , became the first therapeutic antibody based on morphosyss proprietary technology to receive marketing approval for the treatment
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|gradients mω gata4 densities density|guselkumab|to the same period a year ago driven by strong uptake of stelara® ( ustekinumab ) and the u . s . launch of tremfya® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|mω densities gata4 smad4 spher|guselkumab|more information about entity clinical studies is available on clinicaltrials . gov .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|gata4 densities smad1 gradients autoin|guselkumab|moreover , entity is currently being investigated in two phase 3 trials in psoriatic arthritis and also in a phase 2 / 3 clinical study program in crohns disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|densities density gradients mω ctla|guselkumab|entity ( tremfya ® ) overview guselkumab ( tremfya ® ) is a human hucal antibody targeting the p 19 subunit of il - 23 that is being
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|densities gata4 density mω gradients|guselkumab|in july 2018 , morphosys announced that its licensee , janssen , initiated a clinical development program with tremfya® ( entity ) in crohns disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities dens atpases density dwell|gradients localisation localization densities density|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il‑23 ligand and are specific to the il‑23 pathway , which is believed to be
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|gata4 densities mω density cush|guselkumab|the european commission approved tremfya® ( entity ) for the treatment of adults with moderate to severe plaque psoriasis and granted approval to broaden the existing marketing authorization
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|gata4 atpase dipole gradients cd44|guselkumab|entity is currently approved in the eu for the treatment of moderate to severe plaque psoriasis in adults who are candidates
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|gata4 atpases atpase densities dipole|guselkumab|in november 2017 , the eu commission granted european approval of entity ( tremfya® ) for the treatment of patients with moderate-to-severe plaque psoriasis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|density densities mω cd44 gata4|guselkumab|in 2017 , tremfya® ( entity ) , marketed by janssen , became the first therapeutic antibody based on morphosys  s proprietary technology to receive marketing approval for the treatment
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases density dwell|gata4 gradients densities smad1 cd44|guselkumab|entity is currently being investigated in clinical studies in several indications , including additional studies in plaque psoriasis , pediatric psoriasis , psoriatic arthritis ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|densities dens atpases density dwell|localisation gradients lgr5 densities integrins|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il-23 ligand to confer specificity for the il-23 pathway that is believed to be
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients atpases densities atpase motors|densities mω gradients autoin gata4|triptorelin|entity is in pre-registration in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|gradients atpases densities atpase motors|mω cholerae cd44 dens normality|triptorelin|two additional agents are also currently marketed , trelstar by watson , delivers entity , and zoladex marketed by astrazeneca , a biodegradable rod , that contains goserelin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients atpases densities atpase motors|atpases gata4 atpase ctla autoin|triptorelin|in addition , in europe or certain other parts of the world , entity ( debiopharm s . a . ) and buserelin ( hoechst marion roussel , inc . ) are also approved and being marketed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients atpases densities atpase motors|densities autoreg either gata4 density|triptorelin|women were randomized to one of four mvt-602 dose groups ( 0 . 1 µg , 0 . 3 µg , 1 µg or 3 µg ) , to entity , 0 . 2 mg , or to placebo .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients atpases densities atpase motors|gata4 densities chimeras gradients clarity|triptorelin|entity marketed as trelstar® ( watson pharmaceuticals ) and marketed as decapeptyl® ( ipsen ) is also a lhrh agonist .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|gradients densities cholerae gradient dens|densities gata4 atpases atpase motors|rasburicase|in that role , he had key product sales responsibility for eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) , anzemet® ( dolasetron mesylate ) , and elitek® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|gradients densities cholerae gradient dens|densities atpase autoin atpases dystrophin|rasburicase|dr . bizzari was the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of oxaliplatin , docetaxel and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|gradients densities cholerae gradient dens|densities gata4 density nanog negativity|rasburicase|a specific r&d effort has already culminated in the launch of fasturtec® ( entity ) in 2001 , for prevention of the increase in blood uric acid levels during chemotherapy of acute leukemia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|gradients densities cholerae gradient dens|densities atpases atpase gata4 mω|rasburicase|the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of eloxatin ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|gradients densities cholerae gradient dens|densities atpases motors gata4 atpase|rasburicase|for sanofi-aventis ( formerly rhône-poulenc , rhône-poulenc rorer and aventis ) where he oversaw the approval of eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|gradients densities cholerae gradient dens|densities atpases atpase gata4 motors|rasburicase|the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|gradients densities cholerae gradient dens|densities gata4 atpases atpase motors|rasburicase|in that role , he had key product sales responsibility for eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) , anzemet® ( dolasetron mesylate ) , and elitek® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|autoreg cyclins densities atpase damp|clopidogrel|to $5 . 3 billion in 2007 compared to 2006 due to loss of exclusivity of pravachol and the impact of generic entity bisulfate , partially offset by growth in other key products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|densities segregation mω defec spher|clopidogrel|filed a revocation action before the scottish court of session seeking to invalidate the sanofi-aventis patent in the uk claiming entity bisulfate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|densities autoin atpases dens chimeras|clopidogrel|apotex filed a notice of appeal appealing the holding of validity of the entity bisulfate , hydrochloride , hydrobromide , and taurocholate claims .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|densities density autoreg chimeras gata4|clopidogrel|growth in total prescriptions ( trx ) of entity 82 table of contents bisulfate remained strong , at 11 . 8% ( ims npa 3 channels  q4 2006 ) in the fourth
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|autoreg imm gradients dwell spher|clopidogrel|however , the presence of less common cyp2c10 non-functional alleles or variation in other genes may negatively impact the efficacy of entity therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|certain mω kv chimeras motors|clopidogrel|drug interactions medco health solutions inc . robert epstein , said it is an example of the " law of unintended consequences " entity ( plavix ( r ) )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|density localization autoreg densities chimeras|clopidogrel|medco outcomes study entity alone 0 . 18 entity+ppi 0 . 25 relative risk 1 . 50 ( 1 . 39-1 . 62 ) podium-presented at american heart association 11 / 11 / 08 *
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg densities ante normality sinus|atpases smad1 atpase gata4 dystrophin|clopidogrel|however , this is confounded by the fda warning against the use of certain ppis , such as omeprazole , with entity ( plavix ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|autoreg densities autoin gradients gata4|clopidogrel|o comment : entity is expected to be converted efficiently to its active metabolite in patients with this genotype .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|densities chimeras autoin atpases density|clopidogrel|on august 12 , 2008 , the federal court of australia held that claims of patent no . 597784 covering entity bisulfate , hydrochloride , hydrobromide , and taurocholate salts were valid .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|sinus densities atpases atpase normality|clopidogrel|captisol-enabled intravenous entity is an intravenous formulation of the anti-platelet medication designed for situations where the administration of oral platelet inhibitors is not
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|autoreg densities ante normality sinus|gradients dystrophin mω integrins densities|clopidogrel|plavix® / iscover® plavix® ( entity ) , a platelet adenosine diphosphate ( adp ) receptor antagonist with a rapid onset of action that selectively inhibits platelet aggregation induced by
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|densities autoin atpases chimeras dens|clopidogrel|genrx-apotex appealed the holding of validity of the entity bisulfate , hydrochloride , hydrobromide , and taurocholate claims .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|autoreg imm gradients atpases autoin|clopidogrel|the presence of less common cyp2c19 alleles or variations in other genes may additionally enhance or reduce the efficacy of entity therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg densities ante normality sinus|autoreg adherens cd69 cholerae atpases|clopidogrel|stent thrombosis at 48 hours had been met , as cangrelor demonstrated statistically significant improvement for this endpoint as compared to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|gata4 smad1 densities autoreg autoin|clopidogrel|the federal court also held that the process claims , pharmaceutical composition claims , and claim directed to entity and its pharmaceutically acceptable salts were invalid .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|atpases densities gata4 autoreg chimeras|clopidogrel|when pa32540 and entity were dosed 10 hours apart , data from the study indicate no ex-vivo drug-drug interaction based on the study  s pre-specified primary analysis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities ante normality sinus|densities spher autoreg dens density|clopidogrel|and the minister of health in response to a notice of allegation from apotex directed against canadian patent 1 , 336 , 777 covering entity bisulfate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|autoreg densities ante normality sinus|atpases atpase autoreg gata4 desmin|clopidogrel|us launch of tacrolimus ( prograf® ) ; and the launches in various european countries of pantoprazole ( marketed in the us as protonix® ) , entity ( plavix® ) , and esomeprazole ( nexium® ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|autoreg densities ante normality sinus|atpase atpases autoin integrins dystrophin|clopidogrel|according to present plans , all patients will receive background treatment including heparin , aspirin and entity ( plavix® ) , if not contraindicated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens smad1 uncoupling autoreg decou|gata4 cholerae motors chimeras atpases|cefadroxil|crude bulk drugs of the cephalosporin division and cefalexin and entity of the penicillin division were new products the company introduced during the six-month period of 2008 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens smad1 uncoupling autoreg decou|gata4 motors flagella ante mω|cefadroxil|cefalexin and entity are penicillin g downstream products that are widely used to treat urinary tract infections , respiratory tract , skin and soft tissue
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens smad1 uncoupling autoreg decou|gata4 densities chimeras smad1 gradients|cefadroxil|the increase was lead by increases in market share for medroxyprogesterone , naltrexone , danazol and sales of entity , which the company launched in june 1999 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens smad1 uncoupling autoreg decou|chimeras autoin gata4 densities atpases|cefadroxil|the increase was led by higher sales of warfarin sodium , naltrexone , medroxyprogesterone , danazol , entity and hydroxyurea .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens smad1 uncoupling autoreg decou|gata4 densities smad1 motors traps|cefadroxil|for sake of clarity and avoidance of doubt , " product " does not include any non-oral suspension forms or formulations of duricef ( r ) ( entity monohydrate ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens smad1 uncoupling autoreg decou|gata4 motors autoreg densities mω|cefadroxil|cefzil* cefprozil , an oral cephalosporin used in the treatment of respiratory infections and sinusitis duricef* entity , an oral cephalosporin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|dens smad1 uncoupling autoreg decou|gata4 densities chimeras dystrophin cholerae|cefadroxil|offset by the decrease in gross margins in cephalosporin crude bulk drugs , cephalosporin formulation drugs as well as cefalexin and entity divisional revenues and gross margin analysis
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens smad1 uncoupling autoreg decou|gradients gata4 atpases smad1 motors|cefadroxil|entity is for use to treat strep throat , skin and urinaru tract infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens smad1 uncoupling autoreg decou|gata4 cyclins atpases motors densities|cefadroxil|% 9 . 94 % cefalexin / entity sterilized bulk drug / bulk cephalexin is used in treating urinary tract infections , repiratory tract infections , skin and soft tissue infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens smad1 uncoupling autoreg decou|gradients gata4 atpases smad1 motors|cefadroxil|entity is for use to treat strep throat , skin and urinaru tract infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens smad1 uncoupling autoreg decou|gata4 gradients densities chimeras atpases|cefadroxil|although ivax remains the only fda approved generic manufacturer of entity , the company marketing the brand name version of this drug is marketing its own generic form of this product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens smad1 uncoupling autoreg decou|densities autoreg gata4 autoin atpases|cefadroxil|net revenues attributable to sales of entity , approved in march 1996 , were $17 . 1 million in the 1996 second quarter .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens smad1 uncoupling autoreg decou|gata4 cyclins atpases motors densities|cefadroxil|% 9 . 94% cefalexin / entity sterilized bulk drug / bulk cephalexin is used in treating urinary tract infections , repiratory tract infections , skin and soft tissue infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens smad1 uncoupling autoreg decou|gata4 cholerae chimeras gradients troponin|cefadroxil|sales for the cefalexin and entity for the first quarter of 2010 were approximately 3% lower than the same period in 2009 , because of a 4%
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens smad1 uncoupling autoreg decou|gata4 motors cd90 mω atpases|cefadroxil|the penicillin division currently operates the production and sales of clavulanic acid , cefalexin and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens smad1 uncoupling autoreg decou|gata4 cholerae gradients motors mω|cefadroxil|cefalexin and entity were launched and included in the companys product portfolio only at the beginning of 2008 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|mω autoin smad1 gata4 chimeras|alpelisib|qd : once daily 111 table of contents we also assessed the anti-tumor activity of zn-c5 , alongside fulvestrant and entity , in each case as monotherapy , in preclinical models .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|autoreg motors gata4 spher mω|alpelisib|• byl719 ( entity , approved in the us as piqray ) is an orally bioavailable , alpha-specific pi3k inhibitor approved in combination with fulvestrant for the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|densities density gata4 mω nanog|alpelisib|· byl719 ( entity ) phase iii solar-1 trial data presented at esmo showed byl719 plus fulvestrant nearly doubles median progression free survival in patients with
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|densities spher density mω cush|alpelisib|· byl719 ( entity ) solar-1 trial of the investigational alpha-specific inhibitor byl719 in combination with fulvestrant met its primary endpoint showing an improvement in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities atpases dens clarity autoreg|divertic densities ctla gata4 spher|alpelisib| byl719 ( entity ) is an orally bioavailable , alpha isoform-specific pi3k inhibitor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities atpases dens clarity autoreg|mω imm cholerae veloc cd44|alpelisib|·entity ( byl719 ) is on track for a us submission in pik3ca-related overgrowth spectrum ( pros ) in 2021 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|mω autoreg gata4 autoin adherens|alpelisib|% of pi3k mutated late stage breast cancer patients achieved an objective response in a phase iii clinical trial with entity , a recently approved pi3k inhibitor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|densities density gata4 atpases gradients|alpelisib|therapy in this population , including ibrance , kisqali , afinitor , verzenio , and other therapies currently in phase 3 clinical development such as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|mω gata4 autoreg spher atpases|alpelisib|biomedical research , inc . , or novartis , to evaluate the combination of op-1250 and novartis ribociclib , a cdk4 / 6 inhibitor , as well as entity , their pi3kα inhibitor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities atpases dens clarity autoreg|gata4 dystrophin autoin atpases mω|alpelisib|we also observed that the combination of zn-c5 and entity had more potent anti-tumor activity than the combination therapy using 3 mg / dose of fulvestrant and 50 mg / kg of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|mω gradients autoin gata4 intram|alpelisib|zn-c5 and fulvestrant were also assessed in combination with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|densities density spher gata4 mω|alpelisib|more recently piqray® ( entity ) , an inhibitor of the alpha isoform phosphatidylinositol-3-kinase , became the first agent approved for use in a specific subpopulation of hr+
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|densities gata4 density gradients mω|alpelisib|about piqray® ( entity ) piqray is a kinase inhibitor approved in combination with fulvestrant for the treatment of postmenopausal women , and men , with hr+ / her2- ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|densities either atpases chimeras autoin|alpelisib|even greater anti-tumor activity was observed with the combination of 1 mg / kg of zn-c5 and 50 mg / kg of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|mω autoin autoreg adherens atpases|alpelisib|fulvestrant used in combination with entity , an oral pi3k inhibitor marketed as piqray® by novartis approved by the fda in may 2019 , has demonstrated improved clinical
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|densities density negativity gradients gata4|alpelisib|approved may 2019 ( breast cancer ) [ accelerated approval ] limited toxicities to date does not cross blood-brain barrier ü û ü piqray ( entity )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities atpases dens clarity autoreg|mω gata4 autoreg divertic autoin|alpelisib|entity , marketed as piqray® by novartis , is the only fda-approved inhibitor for cancers with mutated pi3kα .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|autoin atpases densities adherens localization|alpelisib|the study showed that entity added toxicity with only marginal additional activity , therefore the beacon crc trial will replace it with binimetinib in the triplet
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|autoreg gata4 autoin cd69 densities|alpelisib|in contrast , entity and gdc-0077 ( an orthosteric pi3kα inhibitor currently in development ) biochemically inhibited the mutant and wild-type proteins with approximately equivalent potency .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities atpases dens clarity autoreg|autoreg densities mω autoin spher|alpelisib|while these factors limit the clinical utility of entity , these data nonetheless establish mutant pi3kα as a clinically validated target in breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|densities gata4 density autoreg smad1|omadacycline|to depend on independent clinical investigators and cros to conduct our clinical trials , including our planned phase 3 trials of entity in absssi .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|mω densities autoin density imm|omadacycline|entity is ready to advance into phase 3 , the final stage of clinical development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|atpases autoin gradients cd69 chimeras|omadacycline|entity ( paratek pharmaceuticals ) and lefamulin ( nabriva therapeutics ) , and dalafloxcacin ( melinta ) all are expected to be pursued as a possible treatment for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|gata4 gradients atpases densities autoreg|omadacycline|in hong kong and three pending patent applications in taiwan , respectively that relate to different methods of treatment related to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|densities gata4 atpases density mω|omadacycline|under the novartis agreement , novartis was to have led development activities for entity , and the company was to have co-developed and contributed a share of the development expense .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|gata4 densities atpases autoreg autoin|omadacycline|if approved by the fda , entity will also compete with other antibiotics in the community-acquired pneumonia market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|gata4 densities atpases density mω|omadacycline|payment of $50 , 000 to tufts for achieving the first milestone following commencement of the phase 3 non-registration clinical trial for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|densities mω density gata4 negativity|omadacycline|this prsu was awarded under the 2015 plan and vests upon fda approval of entity , and shall , upon achievement of the milestone , be eligible to vest as to 100% of the prsus subject to the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens autoreg gradients motors uncoupling|gata4 integrins motors densities autoreg|omadacycline|our success is currently dependent on the successful development and commercialization of our most advanced product candidates , entity and sarecycline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|densities damp negativity density autoreg|omadacycline|to working with the fda as it considers the comments from the committee members and completes its review of the entity new drug applications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|autoreg autoin densities gata4 gradients|omadacycline|in all three studies , entity met all primary and secondary efficacy outcomes designated by the fda and was generally safe and well-tolerated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|gata4 densities atpases density mω|omadacycline|in addition , achaogen , inc . developed and gained approval for plazomicin and paratek pharmaceuticals , inc . developed and gained approval for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|densities density veloc gata4 atpases|omadacycline|to obtain a return on the investments we have made in our or any of our partners product candidates , including entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|autoreg gradients imm densities normality|omadacycline|“crude entity” has the meaning set forth in the recitals hereto .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|autoreg gata4 imm damp autoin|omadacycline|we believe entity , if approved , will be used in the emergency room , hospital and community care settings .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens autoreg gradients motors uncoupling|gata4 integrins autoreg motors atpases|omadacycline|if entity and sarecycline are not successfully developed and commercialized , we will not have any product candidates under development from which we
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|densities atpases gata4 autoreg density|omadacycline|under our spa agreement , we plan to commence a pivotal registration program including two phase 3 registration trials of entity for the treatment of absssi in the second half of 2012 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|densities gata4 density gradients imm|omadacycline|substantial additional funding in connection with the companys continuing operations to support commercial activities associated with its lead product candidate , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens autoreg gradients motors uncoupling|gata4 autoreg integrins autoin smad1|omadacycline|our two lead antibacterial product candidates are entity and sarecycline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg gradients motors uncoupling|autoreg densities density either gata4|omadacycline|for oral therapy , patients randomized to entity received 200 mg of entity ( dosed as two 100 mg capsules ) every 24 hours .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|gata4 densities dens density chimeras|tamoxifen|increased product sales were due mainly to the introduction of fluoxetine in august 2001 , as well as , increased sales of entity and other products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|atpases clock gata4 damp atpase|tamoxifen|soltamox ( entity citrate ) oral solution , our first proprietary , fda approved product , is a drug primarily used to treat breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|either signals αvβ3 pva differential|tamoxifen|external beam radiation and entity are both used to treat gynecomastia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|gata4 clock uncoupling densities motors|tamoxifen|the company acquired exclusive u . s . marketing rights to its &#160 ; first commercial , fda-approved proprietary product license &#160 ; soltamox&#174 ; ( entity citrate ) oral solution .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|autoreg autoin atpases densities gata4|tamoxifen|femara is generally well tolerated and adverse reactions rates in the first-line study in which femara was compared to entity were similar with those seen in second-line studies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|gata4 densities atpases cyclins clock|tamoxifen|the alamo sales team , in addition to promoting our products soltamox ( entity citrate ) and gelclair , also promotes two mission products : ferralet® 90 , and aquoral® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|autoreg gradients damp densities atpase|tamoxifen|entity therapy is currently indicated by the fda for breast cancer patients for five years .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|gata4 gradients densities atpases density|tamoxifen|nevertheless , we believe that soltamox being the first and only liquid form of entity to successfully make some in roads in to that market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|gata4 gradients smad1 damp atpases|tamoxifen|during 2001 , we announced the issuance of an u . s . patent on the use of our anti-estrogen compound in combination with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities autoreg decou density dens|autoreg atpases autoin signals integrins|tamoxifen|a dcis score result , to help guide treatment decision-making in women with dcis treated by local excision , with or without entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|density densities autoreg cd69 negativity|tamoxifen|we maintain $20 million of product liability insurance and have an indemnification provision in our entity agreement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities autoreg decou density dens|densities cholerae density kv damp|tamoxifen|us revenues for nolvadex fell 27% to $337 million , as sales of our entity products fell as a result of the expiry of our distribution agreement with barr laboratories .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|autoin gradients densities chimeras dens|tamoxifen|however , a number of medical therapies have been used to treat peyronies including vitamin e , colchicine , potassium aminobenzoate ( potaba ) , entity , interferon a2a and corticosteroids .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|autoreg densities trap damp density|tamoxifen|women were assessed for risk of developing breast cancer using the brevagen test to determine eligibility for five years of entity therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities autoreg decou density dens|densities gata4 autoreg cholerae density|tamoxifen|entity sales increased 56% from $145 , 161 to $226 , 749 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|gata4 atpases smad1 atpase adherens|tamoxifen|due to its proven superiority over entity , it has won category leadership in france , spain , belgium , mexico , switzerland and australia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|either densities cd69 atpases atpase|tamoxifen|treatment was stopped due to toxicities in three patients in the everolimus plus entity arm and in four patients in the entity-only arm .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|autoreg densities kolmogorov negativity density|tamoxifen|oncotype dx predicts likelihood of recurrence because it predicts both prognosis and entity benefit .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|densities autoreg density dens mω|tamoxifen|the plaintiff in this action , however , asserts that the companys alleged misclassification of entity improperly denied plan benefits and breached an alleged fiduciary duty under erisa .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities autoreg decou density dens|autoin mω gata4 damp chimeras|tamoxifen|entity , the most commonly used serm treatment for breast cancer , also inhibits this action by estradiol , but with less affinity for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|atpases atpase autoreg densities dens|autoin autoreg spher chimeras divertic|lesinurad|entity is a selective inhibitor of urat1 , a transporter in the proximal tubule cells of the kidney that regulates uric acid
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|densities gata4 density atpase cush|lesinurad|about zurampic ( entity ) 200mg tablets zurampic ( entity ) works in combination with xanthine oxidase inhibitors ( xois ) to treat hyperuricemia associated with uncontrolled gout .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|autoreg densities density nanog negativity|lesinurad|closing of the entity transaction is subject to the expiration or termination of the waiting period under the hart-scott-rodino antitrust improvements act of 1976 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|densities autoreg density chimeras mω|lesinurad|the write-down was recorded as write-down of entity commercial supply to net realizable value in the companys condensed consolidated statement of operations .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|densities lgr5 autoreg ankyrin density|lesinurad|to $140 million ) , and · amortization of intangible assets to be $8 million ( not applicable prior to the u . s . entity license ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|densities autoin atpases autoreg chimeras|lesinurad|astrazeneca entered into a licensing agreement with ironwood pharmaceuticals for the exclusive us rights to zurampic and the fixed-dose combination of entity and allopurinol .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|gradients autoin autoreg smad1 gata4|lesinurad|however , entity , like all other ults , has been shown to increase flares upon initiation of treatment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|atpases atpase autoreg densities dens|autoin autoreg densities spher divertic|lesinurad|entity is an oral inhibitor of urat1 , which is the transporter that mediates reuptake of uric acid from the proximal tubules of the kidney and drives renal elimination of uric acid .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|gradients gata4 densities autoin atpases|lesinurad|entity is a drug in phase 3 development by astrazeneca plc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|gata4 damp densities adherens autoreg|lesinurad|we are developing entity to be used as both monotherapy and in combination with drugs like allopurinol and febuxostat to treat the large number
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|autoin autoreg spher atpases densities|lesinurad|for patients who require more control or who are contraindicated , the uricosuric agent , entity , may be prescribed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|spher densities certain negativity density|lesinurad|entity entity , our most advanced product candidate , previously called rdea594 , is an inhibitor of urat1 , a transporter in the kidney that regulates uric acid excretion from the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|atpases atpase autoreg densities dens|densities density kv dens cholerae|lesinurad|we calculated gross product revenue based on the wholesale acquisition cost that we charged our distributors for the entity products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|autoin gata4 gradients densities atpases|lesinurad|entity has been shown to normalize the amount of uric acid excreted by gout patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|densities atpases mω autoin density|lesinurad|these drugs are entity , sifalimumab , anifrolumab , mavrilimumab and brodalumab .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|autoin mω autoreg gradients gata4|lesinurad|entity carries a black box warning associated with renal toxicity and is contraindicated in patients with renal impairment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|atpases atpase autoreg densities dens|densities density gata4 cholerae smad4|lesinurad|january 2007 , as amended , for our cambridge , massachusetts corporate headquarters and a reduction in reimbursement obligations to astrazeneca under the entity license .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|autoin gradients densities gata4 atpases|lesinurad|entity normalizes the amount of uric acid excreted by gout patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|autoin gradients atpases autoreg smad1|lesinurad|entity is being studied as an add-on treatment to allopurinol patients not reaching target sua levels , as an add-on to febuxostat
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg densities dens|autoreg densities gradients atpases autoin|lesinurad|the combination of entity and allopurinol has been generally well tolerated in the ongoing extension portion of study 203 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|autoin gata4 atpase degenerate cd69|prucalopride|compared to the group receiving entity ( an fda approved drug for the treatment of chronic idiopathic constipation ) , the pcs12852 dose groups showed higher stool frequency for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|gata4 autoin cd69 mendelian atpase|prucalopride|entity has been approved for commercialization in certain european countries for the treatment of chronic constipation in women but has not yet been launched .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|gata4 densities mω autoreg atpases|prucalopride|shire has discussed with the fda the requirements for filing an nda for entity and is currently working towards fulfilling those requirements in anticipation of an nda submission .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities dens autoreg gradients dispersion|gata4 densities mω dystrophin gradients|prucalopride|entity was launched in several european markets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|densities density gata4 imm gradients|prucalopride|phase 3 globally global ( excluding italy and latin america ) resolor ( entity ) chronic constipation ( males ) phase 3 in eu europe spd 556 ( m0002 )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|autoreg gata4 mω smad1 densities|prucalopride|shire intends to develop entity in the united states for cc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|densities dens autoreg gradients dispersion|gata4 dystrophin densities cholerae density|prucalopride|alan has played a major role in development of gastroenterology products such as motilium® and entity and has considerable experience and knowledge of the gastrointestinal ( gi ) space .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|mω smad1 gata4 nedd4 chimeras|prucalopride|johnson & johnson has rights to entity in north american and certain european countries and we expect entity to provide competition in markets around the world .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|gata4 density densities cush damp|prucalopride|shire plc obtained approval of motegrity™ ( entity ) in the u . s . for the treatment of cic in adults in december 2018 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|atpases density densities atpase autoreg|prucalopride|sloots ej , et al . efficacy and safety of entity in patients with chronic non-cancer pain suffering from oic .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|mω smad1 gata4 densities autoreg|prucalopride|movetis was acquired by shire in september 2010 , which intends to develop entity in the u . s . for cc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities dens autoreg gradients dispersion|gata4 nanog polymorph autoin dystrophin|prucalopride|another prokinetic compound in development in europe , with the potential for commercialization in the united states and asia , is entity from movetis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|gata4 smad1 mω densities autoreg|prucalopride|shire has recently announced it acquired rights to develop and commercialize entity in the u . s . for the cc indication .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|densities gata4 autoreg density atpases|prucalopride|entity was launched in germany in january 2010 , in the u . k . in march 2010 and in belgium in september 2010 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|gata4 autoin ≥4 atpase cd69|prucalopride|pcs12852 increased stool frequency with faster onset when compared to entity , an fda approved drug for the treatment of chronic idiopathic constipation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|gata4 densities mω imm density|prucalopride|a number of leadership positions within johnson & johnson focusing on development of gastroenterology products including propulsid® , motilium® , aciphex® and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|gata4 mω densities density imm|prucalopride|held a number of leadership positions within johnson & johnson focusing on development of gastroenterology products including propulsid® , motilium® , aciphex® and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|gata4 densities atpases density cd69|prucalopride|janssen belgium exclusive license agreement to develop and market entity as a treatment for chronic constipation in the u . s . motegrity , approved in december 2018 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|gata4 densities atpases smad1 atpase|prucalopride|trials are on-going in europe testing entity in the treatment of chronic constipation in men .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens autoreg gradients dispersion|densities autoreg gradients mω density|prucalopride|the most recent entrant to the cc marketplace , solely in europe , is resolor ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities dens atpases gradients retarded|densities density mω gata4 cholerae|polidocanol|additional manufacturing information and documentation is also being prepared by kreussler for submission to the fda to support the entity nda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases gradients retarded|autoreg gradients autoin motors chimeras|polidocanol|in contrast , aethoxysklerol contains entity , a chemical with anesthetic properties , which we believe may be one of the key advantages of aethoxysklerol .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases gradients retarded|densities mω density spher negativity|polidocanol|entity nda submission and review  in july 2009 , bioform medicals partner , chemische fabrik kreussler & co . gmbh ( kreussler ) , submitted
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities dens atpases gradients retarded|densities density mω cholerae gata4|polidocanol|the $0 . 7 million milestone payment pursuant to our agreement with kreussler for exclusive united states licensing and distribution rights of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities dens atpases gradients retarded|densities density cholerae dens kv|polidocanol|the definition of product ( s ) may be amended from time to time to include additional entity product ( s ) in accordance with article ii ( b ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens atpases gradients retarded|densities atpases gata4 adherens cd69|polidocanol|our partner , kreussler , is also making good progress in the nda review of entity , our future sclerotherapy product .  31 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg cush ante adherens gradients|cyclins chaperones gata4 densities ≥4|nedocromil|brannan jd , anderson sd , freed r , leuppi jd , koskela h , chan h-k . entity sodium inhibits responsiveness to inhaled mannitol in asthmatic subjects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg cush ante adherens gradients|gata4 cyclins clock cholerae densities|nedocromil|the basic chemical patents for sodium cromoglycate have already expired , and such patents for entity sodium expire principally between 1998 and 2006 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg cush ante adherens gradients|gata4 densities chimeras atpases chaperones|nedocromil|“bulk form” means cromolyn sodium micronized stage 9 ( the “intal bulk form” ) and entity sodium dried stage 11 ( the “tilade bulk form” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens decou densities uncoupling atpases|autoreg gata4 mω integrins cd44|etravirine|during 2008 , the company received regulatory approval in the u . s . , canada and european union for intelencetm ( entity ) for hiv combination therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou densities uncoupling atpases|densities gata4 smad1 atpases mω|etravirine|while at johnson & johnson , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou densities uncoupling atpases|gata4 adherens dens cd44 mω|etravirine|tibotecs drug , entity , received fda marketing approval in early 2008 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens decou densities uncoupling atpases|gata4 densities density cd44 integrins|etravirine|in january 2008 , the company received accelerated approval from the u . s . food and drug administration ( fda ) for intelence ( entity ) tablets , an anti-hiv medication .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou densities uncoupling atpases|densities gata4 density mω smad1|etravirine|in this role , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou densities uncoupling atpases|densities gata4 atpases smad1 density|etravirine|while at j&j , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens decou densities uncoupling atpases|gata4 smad1 atpases integrins densities|etravirine|two new drugs , intelence ( entity ) and prezista ( darunavir ) from tibotec therapeutics , a division of ortho biotech products , l . p . , are included in the revised drug resistance
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou densities uncoupling atpases|densities gata4 density mω smad1|etravirine|in this role , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens decou densities uncoupling atpases|densities gata4 mω density smad1|etravirine|the development and launches of several products , including page 1 of 3 remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens decou densities uncoupling atpases|gata4 mω atpases densities integrins|etravirine|company group chairman for johnson & johnsons worldwide virology business unit , where she oversaw the launches of prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients densities atpases atpase motors|autoreg chimeras damp densities jam|dimercaprol|bal in oil is a therapeutic entity injection used to treat arsenic , gold and mercury poisoning .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|chimeras autoin gradients densities otherwise|galantamine|reminyl was launched using natural entity extracted from daffodil bulbs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|autoreg gata4 mω atpases damp|galantamine|related to ad , patients with ad are prescribed drugs for enhancing their cognition , and include acetylcholinesterase inhibitors such as , donepezil , entity , rivastigmine and memantine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|densities gata4 atpases density gradients|galantamine|entity ir tablets are the ab-rated generic versions of ortho-mcneil and janssen&#8217 ; s razadyne &#174 ; , which had annual sales of approximately
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|atpase gata4 mω densities dens|galantamine|successful in their allegations of patent infringement , barr could be required to pay damages relating to the sale of its entity ir tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|densities gata4 smad4 density autoreg|galantamine|he contributed to the clinical development of currently marketed drugs in epilepsy ( topiramate and levetiracetam ) and entity in alzheimers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|gata4 atpases densities autoreg density|galantamine|seeking a declaration to nullify the supplementary protection certificate ( " spc " ) for ep 236684 ( the patent that claims the use of entity for the treatment of alzheimer  s disease ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|gata4 densities atpases cd69 atpase|galantamine|the new drugs were new drug types such as the antimalarial arteether , echinocandin- derived antifungal caspofungin and the anti-alzheimers drug entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|autoreg densities gata4 density dens|galantamine|deemed to include all parents licensed to shire or its affiliates in the territory in respect of the use of entity for cfs ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|densities gata4 atpase smad4 mω|galantamine|in october 2008 , barr commenced sales of its 8 mg , 16 mg and 24 mg entity extended release ( er ) capsules .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|autoreg benjamini gata4 ante atpases|galantamine|other drugs commonly used to treat ad , such as donepezil and entity , inhibit acetylcholinesterase but not butyrylcholinesterase .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|autoreg benjamini gata4 atpase atpases|galantamine|treatments for ad patients are only indicated for enhancing cognition in ad patients , and include acetylcholinesterase inhibitors such as donepezil , entity , rivastigmine and memantine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens sinus biased normality autoreg|densities gata4 atpases gradients integrins|galantamine|the first european application for marketing of entity was submitted in march 1999 ; subsequently , various other applications have been made .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|gata4 densities atpases cd69 atpase|galantamine|the new drugs were new drug types such as the antimalarial arteether , echinocandin- derived antifungal caspofungin and the anti-alzheimer  s drug entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|densities autoreg atpases motors ctla|galantamine|infringed u . s . patent no . 4 , 663 , 318 ( the 318 patent ) by submitting a paragraph iv certification to the fda for approval of tablets containing entity hydrobromide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|densities density damp gradients gata4|galantamine|entity er capsules are the ab-rated generic versions of ortho-mcneil and janssens razadyne er® , which had annual sales of approximately $110
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|autoreg atpases densities pva smad4|galantamine|in a pre-clinical animal model of cognition , prx-03140 demonstrated synergistic activity when combined with the acetylcholinesterase inhibitor entity ( razadyne ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|autoreg gata4 atpase benjamini atpases|galantamine|namzaricin the market for alzheimers disease treatments , namzaric competes or will compete with branded and generic products such as entity , rivastigmine , memantine , and donepezil .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|densities autoreg atpases motors ctla|galantamine|infringed u . s . patent no . 4 , 663 , 318 ( the 318 patent ) by submitting a paragraph iv certification to the fda for approval of tablets containing entity hydrobromide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens sinus biased normality autoreg|atpase gata4 densities damp mω|galantamine|in august 2008 , barr commenced sales of its 4 mg , 8 mg and 12 mg entity immediate release ( ir ) tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|atpases atpase densities motors autoreg|autoin integrins atpases gradients biphasic|protamine|entity , a drug that reverses the anticoagulant effect of heparin , is rarely used in pci due to its unpredictable effect and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|autoreg gata4 smad1 chaperones atpases|protamine|in medical studies , entity has been associated with adverse side effects , such as abnormal changes in blood pressure , depression of heart function and acute
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|gata4 settle autoin loose chimeras|protamine|phase ii clinical trials indicate that neutralase can reverse heparin anticoagulation without the adverse changes in blood pressure associated with entity usage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|atpases densities atpase junction saturation|protamine|our preclinical data demonstrated improved antigen expression at the site of injection if the entity formulated vaccine was injected via a needle free jet device .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|chimeras gata4 motors cd44 gradients|protamine|one patient that died was found to have used entity and not neutralase .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|gradients csc autoin gata4 motors|protamine|although entity is available as an antidote for heparin , it does not work with lmwh and there currently are no antidotes for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|gata4 gradients atpases chimeras densities|protamine|arc183 has shown potential in preclinical studies to be equally effective , with fewer side effects than heparin and entity in combination .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|densities atpases density gata4 mω|protamine|bi1361849 was administered via conventional needle based intradermal injection , later shown to be a suboptimal mode of injection for the entity formulated rabies vaccine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|gradients gata4 autoin csc cd69|protamine|in the ufh antagonist market , entity is the only available antidote for and antagonist to ufh and , as such , entity currently dominates this market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|gata4 autoreg amphip p63 cush|protamine|because of entitys virtual monopoly of the ufh antidote / antagonist market , we believe that it may be
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|gradients motors densities gata4 atpases|protamine|be safely used in the general cardiac surgery patient population by demonstrating similar results to a regimen of heparin plus entity reversal .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|gata4 smad1 chimeras localization mω|protamine|because of entitys potentially problematic side effect profile , we believe that our heptagonist products may penetrate into
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|gradients gata4 csc chimeras motors|protamine|in addition , the effects of heparin are routinely reversed with entity , the use of which has been associated with an allergic reaction and a subsequent increase in the risk of death
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|atpases atpase densities motors autoreg|gata4 chimeras gradients cholerae smad1|protamine|reversed at the end of the procedure and which does not have the significant side effects associated with heparin and entity would result in improved outcomes for patients undergoing ohs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|autoin gradients either gata4 autoreg|protamine|that directly or indirectly support clotting , such as vitamin k ; fresh frozen plasma , or ffp ; prothrombin complex concentrates , or pccs ; entity ; and recombinant factor viia , or rfviia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|gradients autoin gata4 ankyrin adherens|protamine|currently , entity is the only product commercially available for the reversal of heparin anticoagulation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|atpases atpase densities motors autoreg|atpases dystrophin autoreg gata4 autoin|protamine|the efficacy of rpf4 for the reversal of the anticoagulant effects of heparin in cardiac catheterization patients in comparison to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|autoreg autoin gradients mω gata4|protamine|market opportunity unfractionated heparin ( ufh ) entity is the only available reversing agent for ufh .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|atpases atpase densities motors autoreg|densities density gradients smad1 dystrophin|protamine|an antigenic protein that is expressible in human cells as well as the same mrna formed as a complex with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase densities motors autoreg|autoreg gata4 atpases gradients autoin|protamine|k , ffp and , more recently , pccs , while low molecular weight heparin patients needing reversal are often managed with ffp or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|autoreg densities atpases autoin density|escitalopram|( n=301 ) for the first eight weeks , followed by a two-week period in which patients discontinued study drug but continued receiving entity and placebo .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|autoreg atpase mω atpases gata4|escitalopram|major marketed brands include lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertraline ) , effexor xr ( venlafaxine ) and wellbutrin® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|autoreg junction chimeras autoin homeostasis|escitalopram|these results showed an increase of serotonin and dopamine after a single dose of min-117 , unlike the reference antidepressant entity which only induced a modest and transient increase .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|gata4 atpases atpase localization densities|escitalopram|to approximately 195 legal actions asserting product liability claims relating to the use of celexa® ( citalopram hbr ) ( celexa ) or lexapro® ( entity oxalate ) ( lexapro ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity dens normality smad2 papill|boltzmann atpase autoreg localization divertic|escitalopram|sales of lexapro® ( entity oxalate ) , an ssri indicated for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder in adults ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|autoreg atpases autoin clarity dens|escitalopram|is a significant predictor of patient response and remission from depression when utilized one week following initiation of treatment with entity , an anti-depressant drug .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|smad4 cd69 gata4 smad1 motors|escitalopram|our entity thin film is currently in pre-clinical development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|densities density mω gradients gata4|escitalopram|cns clinical research division ; and forest laboratories , as director , cns clinical development , where he was involved in the development of entity ( lexapro ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|densities boltzmann negativity atpases imm|escitalopram|ranitidine 170 152 gemcitabine 153 143 entity oxalate 128 227 others 2 , 246 3 , 105
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|smad4 gata4 cd69 densities density|escitalopram|our entity thin film is currently in pre-clinical development and we expect to conduct pilot bioavailability / bioequivalence clinical trials during the first half
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|autoreg pyroph chimeras clarity atpase|escitalopram|that affect the serotonin system , as 176 table of contents shown recently in generalized anxiety disorder trials with the ssris entity and paroxetine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|atpase gata4 autoreg mω atpases|escitalopram|major brands include prozac ( fluoxetine ) , lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertraline ) and effexor xr ( venlafaxine ) and wellbutrin® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|clarity dens normality smad2 papill|autoreg cholerae inactivation hypo adherens|escitalopram|patent infringement based on tevas filing of an abbreviated new drug application for a generic equivalent to our lexapro brand entity oxalate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|gata4 densities atpases atpase density|escitalopram|this reduction was principally due to the launch of entity in the first quarter of 2012 , our most significant product launch with shared exclusivity in the prior year .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|densities autoreg gata4 atpases density|escitalopram|excluding the impact of entity in both periods , third party net revenues in north america were essentially flat on a year-over-year basis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|localization boltzmann atpase imm autoreg|escitalopram|· lexapro® ( entity oxalate ) , an ssri for the initial and maintenance treatment of mdd in adults and adolescents and generalized anxiety disorder in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|gradients mω densities gata4 autoin|escitalopram|entity is marketed by forest laboratories , inc . under the brand name lexapro® and generated sales of $2 . 0 billion in 2006 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|gata4 densities mω density smad1|escitalopram|entity oxalate entity is in a class of drugs called selective serotonin reuptake inhibitors .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|localization damp atpase imm atpases|escitalopram|lexapro® : lexapro ( entity oxalate ) , our single isomer version of citalopram hbr , for the treatment of mdd in adults and adolescents and generalized anxiety
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|clarity dens normality smad2 papill|autoreg atpase mω atpases gata4|escitalopram|major marketed brands include lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertaline ) and effexor xr ( venlafaxine ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|gradients atpases cyclins gata4 autoreg|tiotropium|boehringer-ingelheim is developing a combination product with entity and the long-acting beta agonist bi-1744 for the treatment of copd .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|atpases densities cyclins autoreg clarity|tiotropium|explore efficacy and safety at doses of 15 . 6 to 125mcg od and 15 . 6mcg and 31 . 25mcg twice daily ( bid ) compared with entity od or placebo in subjects with copd .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|atpases cyclins autoreg ante gata4|tiotropium|significantly greater than placebo and similar in magnitude to a combination therapy active control of salmeterol dosed twice daily plus entity dosed once daily .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|clarity autoreg adherens cyclins gata4|tiotropium|separately , a phase iii study showed that once-daily nva237 is superior to placebo and similar to entity in improving lung function in patients with moderate-to-severe copd .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|atpases autoreg gata4 autoin either|tiotropium|% of the patients in the study , yupelri demonstrated nominally statistically significant and clinically relevant improvements in trough fev1 versus entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|autoreg cyclins gradients atpases junction|tiotropium|the studies showed that when used in conjunction with entity , indacaterol produces a significantly greater improvement in lung function than entity alone .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|cyclins autoreg gata4 junction cd44|tiotropium|this trial is evaluating rpl554 as an add-on therapy to entity , a commonly used long-acting bronchodilator , in approximately 30 patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|autoreg densities atpases gradients either|tiotropium|this trial is evaluating rpl554 as an add-on therapy to entity in approximately 30 patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|autoreg cyclins mimics ≥1 smad1|tiotropium|phase 2a clinical trial in the united kingdom evaluating rpl554 in approximately 30 patients with copd as an add-on therapy to entity , a commonly used bronchodilator .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|autoreg localization cyclins gata4 atpases|tiotropium|no : p27 ( a6797 ) umec / vi as step-up therapy from entity in moderate symptomatic copd : a randomized , 12-week study exhibit 99 . 4 press release issued : wednesday 18th may 2016
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|gata4 gradients smad1 ≥4 motors|tiotropium|early post-dose spirometry data suggested a more rapid onset of action than entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|autoreg cyclins smad1 spher atpases|tiotropium|mg and 6 mg , or placebo , dosed twice-daily for three days , in addition to a dual bronchodilator therapy comprising entity and olodaterol , a commonly used lama / laba , dosed once daily .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|atpases autoreg gata4 atpase smad1|tiotropium|the primary analysis was to determine non-inferiority ( based on a margin of -50ml ) or superiority of umeclidinium to entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|densities density autoreg mω either|tiotropium|showed that nva237 was well-tolerated with a similar incidence of adverse events for patients treated with nva237 , placebo and open-label entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|densities polymorph atpases chimeras atpase|tiotropium|· in both studies , placebo and open-label od entity 18mcg were comparators .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|autoreg cyclins sinus localization atpases|tiotropium|•verona pharma announced positive data in a 4-week phase 2b copd trial with nebulized ensifentrine on top of entity therapy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|motors atpases cyclins clock gata4|tiotropium|table of contents  braltus® ( entity bromide ) , a long-acting muscarinic antagonist , indicated for adult patients with copd , delivered via the zonda® inhaler , was launched in europe
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|clarity mω cyclins cd69 transients|tiotropium|when compared to placebo , glycopyrronium 50 mcg was also numerically higher than ol entity 18 mcg versus placebo at all-time points for trough fev1 ( day 1 and weeks 12 , 26 and 52 ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|cyclins clock motors cros ≥4|tiotropium|been playing a central role in the management of copd , and are currently the most common therapy in copd ( e . g . , entity bromide ; a long-acting bronchodilator ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|dens densities retarded cholerae gradients|atpase autoreg cyclins gata4 atpases|tiotropium|patients were randomised 1 : 1 to umeclidinium 62 . 5mcg inhalation powder or entity 18mcg .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens clarity cush decou cavities|densities autoreg gata4 atpases atpase|flutemetamol|in october 2013 , the fda approved entity , under the name vizamyltm , for adults being evaluated for ad and dementia with pet brain imaging .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens clarity cush decou cavities|smad4 gata4 densities density dystrophin|flutemetamol|in addition to fluorbetapir , there are two other beta-amyloid imaging agents available : florbetaben from piramal enterprises , imaging division , and entity from ge healthcare .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens clarity cush decou cavities|autoreg inactivation normality densities negativity|flutemetamol|the filing also includes data from a recently completed [ 18f ] entity pet image reader training validation study , results of which will be presented at a scientific forum in coming months .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens clarity cush decou cavities|densities gata4 benjamini atpase autoreg|flutemetamol|as an aid to the evaluation of patients with signs of alzheimers disease : amyvid® ( florbetapir ) , marketed by lilly , and vizamyl® ( entity ) , marketed by ge healthcare .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens clarity cush decou cavities|smad4 gata4 dystrophin npc1 densities|flutemetamol|in addition to fluorbetipir , there are two other beta-amyloid imaging agents in late stage development : florbetaben from bayer schering and entity from general electric .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities cush dens retarded gradients|mω ctla gradients gata4 dipole|goserelin|among the different classes of peptides , gnrh / lhrh agonists ( leuprorelin , entity ) account for almost 50 percent of the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities cush dens retarded gradients|mω gata4 smad1 integrins ctla|goserelin|formulations such as lupron and eligard , which deliver leuprolide , trelstar , which delivers triptorelin , and zoladex , a biodegradable rod , which delivers entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities cush dens retarded gradients|dipole either localization densities density|goserelin|patients in the second arm will receive bnt112 combined with entity acetate and cemiplimab , and patients in the third arm will receive bnt112 combined with entity acetate alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities cush dens retarded gradients|either dipole densities chimeras density|goserelin|primary objective of this study will be to establish the safety and tolerability of bnt112 alone , or in combination with entity acetate with or without cemiplimab .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities cush dens retarded gradients|mω catenin normality damp negativity|goserelin|zoladex ( entity acetate implant ) is a lhrh agonist for treating prostate and breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities cush dens retarded gradients|catenin normality mω negativity existence|goserelin|for all classes , the only astrazeneca drug at issue is zoladex™ ( entity acetate implant ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities cush dens retarded gradients|normality mω catenin localization cadherin|goserelin|astrazeneca announced that it had entered into an agreement with tersera therapeutics llc ( tersera ) for the commercial rights to zoladex ( entity acetate implant ) in the u . s . and canada .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities cush dens retarded gradients|gata4 gradients mω polymorph smad1|goserelin|launches of generic entity ( the active ingredient in zoladex ) are expected in europe during 2012 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|densities cush dens retarded gradients|mω catenin normality integrins ctla|goserelin|zoladex ( entity acetate implant ) , available in one month and three month depots , is the worlds second largest lhrh agonist by value .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities cush dens retarded gradients|catenin mω polymorph negativity normality|goserelin|in the us , the us department of justice has been conducting an investigation into the sales and marketing of zoladex ( entity acetate implant ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities cush dens retarded gradients|gata4 clarity gradients mω polymorph|goserelin|competition in the lhrh agonist market is expected to increase in europe during 2011 , with further launches of generic entity ( the active ingredient in zoladex ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities cush dens retarded gradients|mω gata4 chimeras catenin polymorph|goserelin|examples of commercially marketed lhrh agonists are lupron® ( leuprolide acetate ) , zoladex® ( entity acetate ) , viadur® ( leuprolide acetate ) and eligard® ( leuprolide acetate ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities cush dens retarded gradients|atpases densities atpase cyclins autoin|goserelin|lee011 + tamoxifen + entity or nsai + entity hr+ / her2- premenopausal abc 1st line 2018 iii - fully enrolled lee011 + fulvestrant hr+ / her2- postmenopausal abc 1st / 2nd line 2018 iii
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities cush dens retarded gradients|catenin normality mω polymorph negativity|goserelin|for all classes , the only astrazeneca drug at issue is zoladex ( entity acetate implant ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities autoreg atpases motors gradients|gata4 chimeras densities coexist atpases|biperiden|increases over the same quarter in the prior year in certain molecules including cyclizine hydrochloride , codeine phosphate + paracetomol and entity hydrochloride .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities clarity notation dens gradients|gata4 disintegr density densities cholerae|lanreotide|we do not have patent composition coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® depot ) alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities clarity notation dens gradients|mω boltzmann divertic autoin gradients|lanreotide|somatuline entity ( " somatuline " ) is another long- acting somatostatin analog .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity notation dens gradients|densities density settle polymorph chimeras|lanreotide|we look forward to advancing mycapssa as a preferred treatment option for patients with acromegaly treated with octreotide and entity injectables ,  mr . kannan concluded .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity notation dens gradients|either benjamini dipole extremes cd69|lanreotide|on june 26 , 2020 , chiasma received fda approval of mycapssa for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities clarity notation dens gradients|gata4 disintegr densities density cholerae|lanreotide|we do not have composition of matter patent coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® depot ) alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity notation dens gradients|either densities cd69 adherens notation|lanreotide|receptor type 2 ( sst2 ) biased agonist , in patients with acromegaly whose disease is not biochemically controlled by octreotide lar or entity depot alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities clarity notation dens gradients|gata4 disintegr density densities cholerae|lanreotide|we do not have patent composition coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® autogel® ) alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities clarity notation dens gradients|densities cd44 localization dystrophin adherens|lanreotide|hormone levels used to measure disease at 24 weeks versus continued treatment with the long acting release form of octreotide , or entity autogel , meeting the primary endpoint .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities clarity notation dens gradients|either densities dipole adherens divertic|lanreotide|week 13 in acromegaly patients who were switched from an injected somatostatin receptor ligand ( srl ) depot of either octreotide or entity monotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity notation dens gradients|mω adherens smad1 chimeras gradients|lanreotide|the somatuline® autogel® formulation requires no excipient other than water and releases entity over a period of at least 28 days and up to 56 days .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity notation dens gradients|either dipole benjamini cd69 densities|lanreotide|approval of mycapssa for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity notation dens gradients|densities cd69 cd44 spher motors|lanreotide|a pilot trial involving six children with neuroblastoma cancer and seven adults with neuroendocrine cancer has been completed using entity as the targeting agent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity notation dens gradients|densities either chimeras loose normality|lanreotide|these products include sandostatin lar depot ( octreotide / im injection ) by novartis a . g . , and somatuline depot ( entity acetate ) by tercica inc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity notation dens gradients|gradients gata4 chimeras autoreg densities|lanreotide|active substance the active substance in somatuline® depot is entity , which inhibits the growth and secretion of several endocrine , exocrine and paracrine functions .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities clarity notation dens gradients|either mω autoreg dipole divertic|lanreotide|somatuline® depot is an injectable sustained-release formulation containing entity , a somatostatin analogue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity notation dens gradients|either benjamini dipole mω dispersion|lanreotide|surgical removal of the pituitary tumor consists of lifelong , once-monthly injections of an extended release somatostatin analog , primarily octreotide or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity notation dens gradients|dipole either benjamini mω ctla|lanreotide|care for patients diagnosed with acromegaly consists of lifelong , once-monthly injections of an extended release somatostatin analog , primarily octreotide or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|densities clarity notation dens gradients|dipole mω vw either perforation|lanreotide|long-acting analogues of the hormone somatostatin , such as octreotide and entity have established themselves as a primary treatment of neuroendocrine tumors , although with limited efficacy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity notation dens gradients|dipole either benjamini ctla mω|lanreotide|somatostatin analogs octreotide ( marketed as sandostatin ) and entity ( marketed as somatuline ) are selective for sst2 receptors and are the preferred first-line pharmacologic treatments .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities clarity notation dens gradients|densities either ctla cd69 benjamini|lanreotide|acromegaly in the united states : sandostatin lar ( octreotide ) marketed by novartis ; signifor lar ( pasireotide ) marketed by novartis ; and somatuline depot ( entity ) marketed by ipsen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens inner cracks outer autoreg|densities gradients gata4 cush atpases|cefotetan|entity disodium injectable ( vial ) 1gr , 2gr , 10gr vials entity ® nda / anda indicated for the treatment of various bacterial infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens inner cracks outer autoreg|integrins gata4 motors gradients mω|cefotetan|entity is a second-generation cephalosporin with a broad range of anti-microbial activity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens inner cracks outer autoreg|gradients densities gata4 chimeras integrins|cefotetan|entity disodium 20mg / ml injectable ( bag ) 50ml bags entity ® nda indicated for the treatment of various bacterial infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens inner cracks outer autoreg|motors densities gata4 density atpases|cefotetan|we received fda approval for and launched our first injectable product , cefotan® ( entity for injection ) , in the first quarter of 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens inner cracks outer autoreg|gata4 mω densities density damp|cefotetan|we launched entity in september 2007 and are currently the only company to market entity in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens inner cracks outer autoreg|gata4 densities cholerae density kv|cefotetan|march 31 , 2007 were $23 . 6 million of paclitaxel ( whole plant ) , $3 . 9 million in other abraxane® related materials and $3 . 0 million of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens inner cracks outer autoreg|gata4 densities motors density adherens|cefotetan|and ·in december 2015 , the company received approval of its supplemental new drug application from the fda for cefotan® ( entity for injection ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens inner cracks outer autoreg|densities gata4 density motors adherens|cefotetan|received approval of the company  s supplemental new drug application ( snda ) from the u . s . food and drug administration ( fda ) for cefotan® ( entity for injection ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens inner cracks outer autoreg|gata4 damp mω densities density|cefotetan|we launched entity in september 2007 and are currently the only company to market entity vials in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens inner cracks outer autoreg|motors densities gata4 density atpases|cefotetan|we have received fda approval for our first product in this portfolio , cefotan® ( entity for injection ) , which we launched in the first quarter of 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens inner cracks outer autoreg|motors gata4 chimeras densities mω|cefotetan|·the company launched cefotan® ( entity disodium for injection ) and lidocaine 5% ointment in march of 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens inner cracks outer autoreg|gata4 gradients cd44 autoin smad1|cefotetan|entity is often used for surgical prophylaxis and offers the longest half-life of any cephalopsorin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens inner cracks outer autoreg|densities gata4 atpases chimeras dipole|cefotetan|in the third quarter , app launched entity disodium for injection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|autoreg gata4 chimeras autoin densities|topiramate|an overactive thyroid ; by patients taking a type of anti-depressant called maoi ; or by patients who are allergic to phentermine , entity , or any of the ingredients in qsymia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|atpase atpases autoreg gradients ante|topiramate|controlled-release phentermine / entity therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|gradients autoreg dens clarity densities|gata4 cholerae autoreg ante atpase|topiramate|we anticipate that the label for qnexa , if approved , will contain the similar suicidality warnings to those contained in the entity label .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|autoreg densities smad1 gradients gata4|topiramate|the exercise primarily includes identifying these mother-infant pairs exposed to entity at the doses that the fda has recommended .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|gata4 autoreg atpases atpase densities|topiramate|marketed in the united states under the name belviq and in september 2012 , vivus , inc . commercially launched its combination product , phentermine / entity , under the trade name qsymia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|autoreg atpase atpases gata4 gradients|topiramate|immediate release formulations of entity and oxcarbazepine are available in generic form and are marketed under the brand names of topamax and trileptal , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|densities gata4 atpases density atpase|topiramate|et-104 is one of etons three neurology-focused liquid product candidates , along with et-105 ( lamotrigine oral suspension ) and et-101 ( entity oral solution ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|atpase gata4 atpases densities autoreg|topiramate|the company has two marketed products for epilepsy , oxtellar xr ( extended-release oxcarbazepine ) and trokendi xr ( extended-release entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|gata4 autoreg atpases smad1 mω|topiramate|in the qnexa studies , which included 15 offspring from women exposed to qnexa or entity , there were no reports of congenital malformations .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|atpase atpases autoreg ante normality|topiramate|controlled-release phentermine / entity therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus : authors : w . timothy garvey , md ( a ) ; craig a .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|autoreg gata4 densities gradients negativity|topiramate|entity is believed to work in epilepsy through various mechanisms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|autoreg gradients densities ducts autoin|topiramate|in addition , we currently do not have manufacturing agreements in place for entity or phentermine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|autoreg atpases gata4 atpase gradients|topiramate|in july 2012 , vivus , inc . obtained fda approval for its combination product , phentermine / entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|atpase gata4 atpases densities autoreg|topiramate|the company has two marketed products for epilepsy , oxtellar xr® ( extended-release oxcarbazepine ) and trokendi xr® ( extended-release entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|autoreg notation atpase gradients atpases|topiramate|and patient market research to assess potential growth of the obesity therapeutics market as well as preference shares between nb32 , phentermine / entity and lorcaserin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|gata4 densities density gradients atpases|topiramate|the pharmaceutical company performing research of entity alone announced they had discontinued development of a time-release formulation due to side effects at high doses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|autoreg atpases gata4 gradients densities|topiramate|<a  leland wilson> : we typically characterize our product as the low-dose combination of phentermine and entity , so thats what thats referring to , yes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|mω gradients density densities autoreg|topiramate|u . s . attorneys office in boston , massachusetts seeking documents relating to the marketing , including alleged off-label marketing , of the drug topamax® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|atpases autoreg damp adherens diap|topiramate|qsymia® ( phentermine and entity extended release ) is approved by fda for chronic weight management .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients autoreg dens clarity densities|atpases atpase gata4 autoin mω|topiramate|or aeds , available in the united states and worldwide , including the generic products levetiracetam , lamotrigine , carbamazepine , oxcarbazepine , valproic acid and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|motors either gradients densities atpases|theophylline|fully funds a 36 patient phase 1 / 2 investigator-sponsored phase 1 / 2 study for use of hs-110 as a combination therapy with entity and oxygen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|autoin chimeras atpases gata4 motors|theophylline|therapeutic monitoring of cyp1a2 substrates with a narrow therapeutic index ( e . g . entity and tizanidine ) is recommended when coadministered with ocaliva .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|densities density mω gradients smad1|theophylline|monitor entity levels if concurrent administration cannot be avoided .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|autoreg ≥4 gauge motors gradients|theophylline|entity relaxes the smooth muscle of the bronchial airways and thus acts mainly as a bronchodilator .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|autoreg chimeras gata4 densities smad1|theophylline|when taking zyflo , entity dose should be reduced by 50% and appropriately monitored ; patients taking propranolol or warfarin should be monitored and doses adjusted
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg densities uncoupling decou biased|autoreg cholerae gata4 smad1 chimeras|theophylline|respiratory sales growth was moderated in 1995 by lower sales of theo-dur , a sustained-action entity , due to increased generic competition .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg densities uncoupling decou biased|gata4 cholerae densities damp veloc|theophylline|the company noted that it discontinued marketing its u . s . entity products in june 2001 and that proventil repetabs have not been available since july 2001 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|autoreg spher cyclins motors tetras|theophylline|the most commonly used oral bronchodilator is entity , a drug with good efficacy but which is capable of producing certain undesirable side effects such as disturbances in heart
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|gradients spher atpases cyclins chaperones|theophylline|the bronchodilator agents most often used are ß2 agonists , anticholinergics , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|gata4 atpases motors gradients chimeras|theophylline|euphyllin , a drug based on a substance called entity , is used for the treatment of asthma and copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|densities kv density spher mω|theophylline|[ * * * ] entity ( including product sold under the theochron ( r ) trademark )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|cyclins chaperones junction autoreg atpases|theophylline|entity and albuterol are frequently prescribed to produce dilation of bronchioles for both emphysema and chronic bronchitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|autoreg atpases densities gata4 atpase|theophylline|patients taking zyflo cr and entity should reduce the entity dose by 50% .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|gata4 cush autoreg densities smad4|theophylline|decree also includes a recall , initiated in early may 2002 and directed to u . s . trade accounts , of all lots of entity , usp tablets and proventil ( albuterol sulfate , usp ) repetabs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|autoreg atpases motors chimeras smad1|theophylline|antihistamines , antiemetics , histamine h-2 receptor antagonists , barbiturates , prostoglandins , and bronchial dilators selected from the group consisting of terbutaline , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|gradients densities smad1 autoreg gata4|theophylline|other products choledyl ( r ) choledyl ( r ) ( oxtriphylline ) is the choline salt of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|cush densities vag kv density|theophylline|[ * * * ] entity in elixir form sold under the elixophyllin ( r ) trademark [
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|gata4 chaperones atpases gradients smad1|theophylline|offices and central labs to measure patient blood drug levels for the most commonly prescribed therapeutic drugs to control asthma ( entity ) and epilepsy ( carbamazepine , and phenytoin ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|autoin gata4 ≥1 smad1 ≥4|theophylline|bronchodilators dilate the airways and include beta agonists ( such as albuterol and bitolterol ) , xanthines ( such as entity ) and anticholinergics ( such as ipratropium ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities uncoupling decou biased|gata4 chimeras atpases cyclins smad1|theophylline|serious and fatal reactions have been reported in patients receiving concur-rent administration of ciprofloxacin and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|cush gradients autoreg localization cdh1|gata4 mω adherens nanog troponin|inotersen|the company holds the rights for the commercialization of tegsedi™ ( entity ) and waylivra™ ( volanesorsen ) for the treatment of rare diseases in countries in latin america and the caribbean .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|cush gradients autoreg localization cdh1|gata4 cholerae chimeras mω densities|inotersen|slower rate than revenue with the increase primarily due to higher sg&a expenses as ionis prepares to commercialize volanesorsen and entity this year .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|cush gradients autoreg localization cdh1|densities kv density dens mω|inotersen|commercial entity inventory acquired from ionis commercial inventory acquired clinical material acquired from ionis clinical material acquired liability for costs incurred and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|cush gradients autoreg localization cdh1|autoreg mω gradients imm densities|inotersen|that the defendants breached their fiduciary duties in connection with the licensing transaction that we and ionis entered into regarding entity and akcea-ttr-lrx .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|cush gradients autoreg localization cdh1|densities density gata4 gradients motors|inotersen|akcea has received marketing approval for an antisense drug , entity that was developed by ionis , in the u . s . , the eu and canada , for the treatment of hattr amyloidosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|cush gradients autoreg localization cdh1|densities gata4 autoreg chimeras density|inotersen|the parties agree to maintain books and records for entity and ionis-ttr-lrx that will allow each party to provide the other party with net revenues , expenses ( including each cost category
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|cush gradients autoreg localization cdh1|atpases densities benjamini atpase veloc|inotersen|tafamidis , patisiran and entity are currently marketed for attr-pn in various geographies our product concept  potentially best-in-class oral small molecule ttr stabilizer
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|cush gradients autoreg localization cdh1|gata4 mω densities troponin motors|inotersen|today announced a collaboration under which ptc will commercialize two of akceas rare disease drugs in latin america ( latam ) : tegsedi™ ( entity ) and waylivra™ ( volanesorsen ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|cush gradients autoreg localization cdh1|gata4 mω densities cd69 gradients|inotersen|both entity and volanesorsen are progressing toward regulatory filings for marketing authorization .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|cush gradients autoreg localization cdh1|densities density gata4 atpases gradients|inotersen|icon clinical research limited , inc research toronto , inc . and medpace for the clinical studies for our drugs , including volanesorsen and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|cush gradients autoreg localization cdh1|atpases gata4 atpase densities autoin|inotersen|ag10 also will not be the first treatment on the market for attr-pn as tafamidis , patisiran , and entity are approved for the treatment of attr-pn in a variety of countries globally .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|cush gradients autoreg localization cdh1|certain densities density integrins gata4|inotersen|we created tegsedi™ ( entity ) the worlds first rna-targeted therapeutic approved for the treatment of polyneuropathy of hereditary transthyretin ( ttr ) amyloidosis ( attr ) in adult patients
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|cush gradients autoreg localization cdh1|atpases densities atpase benjamini veloc|inotersen|tafamidis , patisiran and entity are currently marketed for attr-pn in various geographies our product concept  oral small molecule ttr stabilizer
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|cush gradients autoreg localization cdh1|densities cd69 autoreg density gata4|inotersen|for ionis , this transaction achieves all the goals we laid out at the outset of our entity process .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase autoreg dens densities atpases|densities motors atpases adherens density|nepafenac|ilevro ( entity ophthalmic suspension ) , 0 . 3%fda approval received for the treatment of pain and inflammation associated with cataract surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase autoreg dens densities atpases|atpases densities smad4 atpase adherens|nepafenac|ilevro ( entity ophthalmic suspension ) , 0 . 3%launched in the us , received ema approval and launched in europe , and received health canada approval for the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase autoreg dens densities atpases|densities autoreg motors smad4 veloc|nepafenac|entity , new formulation anti-inflammatory us 2011 eu 2012 approved approved - ilevro approved in q4 2012 - ilevro approved q2 2013
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|atpase autoreg dens densities atpases|atpases cd44 gata4 integrins dystrophin|nepafenac|· alcon received approval to market ilevro , a new formulation of entity ophthalmic suspension ( 0 . 3% ) , in the us .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpase autoreg dens densities atpases|atpase atpases adherens motors densities|nepafenac|in august 2005 , the fda approved nevanac ( entity ophthalmic suspension ) 0 . 1% for the treatment of pain and inflammation associated with cataract surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|autoreg cd69 gata4 damp smad4|phentermine|sus has been named as a defendant in a total of 4 , 196 such entity lawsuits , in respect of which sus has been dismissed as a defendant in 3 , 936 cases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|atpases autoreg gata4 atpase densities|phentermine|marketed in the united states under the name belviq and in september 2012 , vivus , inc . commercially launched its combination product , entity / topiramate , under the trade name qsymia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|autoreg atpases gata4 densities atpase|phentermine|qnexa is our investigational drug candidate involving low doses of entity and topiramate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|autoreg autoin gata4 atpases chimeras|phentermine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including entity , phendimetrazine , mazindol , benzphetamine and diethylpropion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|densities motors autoreg gradients atpases|phentermine|entity hcl , usp sales in the year ended december 31 , 2001 reflected an increase in unit volume from the refilling of distribution
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|atpases autoreg gata4 atpase chimeras|phentermine|in particular , it is possible that patients will seek to acquire entity and topiramate , the generic components of qsymia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg densities clarity dens notation|autoreg mω gata4 homeostasis coexist|phentermine|a defendant in more than two thousand five hundred multi-defendant lawsuits involving the manufacture and sale of dexfenfluramine , fenfluramine , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|gata4 densities atpases chimeras autoreg|phentermine|the lawsuits allege that the manufacturers of entity knew that its use could cause serious side effects , but failed to warn against those dangers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|autoreg spher atpases autoin damp|phentermine|to fisons ) and 585 ( as to rugby ) personal injury lawsuits in the u . s . ( including class actions ) concerning the weight-loss drug entity ( fisons brand name ionamin ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|autoreg gata4 atpases atpase gradients|phentermine|the equate study also contained a mid-dose of qnexa containing 46 mg of topiramate cr and 7 . 5 mg of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|gata4 autoreg atpases atpase densities|phentermine|drug candidate for the treatment of obesity , incorporating low doses of active ingredients from two previously approved products , topiramate and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg densities clarity dens notation|autoreg atpases coexist resonance mω|phentermine|contrary to the approved labelling of these products , physicians in the us co-prescribed entity with fenfluramine or dexfenfluramine for management of obesity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|autoreg atpases vag atpase adherens|phentermine|qsymia ( entity and topiramate extended release ) is approved by the u . s . food and drug administration ( &#x201c ; fda&#x201d ; ) for chronic weight management .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|autoreg autoin gata4 spher damp|phentermine|entity is the largest selling antiobesity therapeutic and is available in several generic forms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|atpases densities gata4 atpase autoreg|phentermine|&#160 ; the company had one approved and marketed product , suprenza ( entity hydrochloride ) , which it had out licensed for promotion in the united states , canada and mexico .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg densities clarity dens notation|coexist gata4 chimeras atpase damp|phentermine|to a decline in both unit volume and selling prices of fluvoxamine maleate and a decline in unit volume of entity hcl , usp .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|gata4 autoreg atpases adherens densities|phentermine|as expected , the chmp recommended against approval of the marketing authorization application ( maa ) for qsiva ( entity / topiramate er ) for the treatment of obesity in the european union .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg densities clarity dens notation|gata4 cholerae gradients autoin smad1|phentermine|entity is sold at much lower prices than we charge for qsymia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|autoreg dens normality gata4 spher|phentermine|there are a number of generic pharmaceutical drugs that are prescribed for obesity , predominantly entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg densities clarity dens notation|autoreg atpases atpase vag adherens|phentermine|qsymia ( entity and topiramate extended release ) is approved by the u . s . food and drug administration ( “fda” ) for chronic weight management .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|gata4 atpases densities gradients autoin|carvedilol|which is available as both an oral and an iv formulation , and querto® , a therapeutic based on a substance called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|atpase gata4 atpases autoreg smad1|carvedilol|toprol-xl and coreg have generic equivalents commercially available in the u . s . ( metoprolol succinate and entity , respectively ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|autoreg cd69 spher smad2 gata4|carvedilol|coreg ( entity ) is a beta-blocker indicated for the treatment of congestive heart failure and flomax ( tamsulosin ) is indicated for the treatment of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|cush gata4 densities motors spher|carvedilol|flamel technologies has collaborations with a number of leading pharmaceutical and biotechnology companies , including glaxosmithkline ( coreg cr® , entity phosphate ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|clock autoin gradients traps cyclins|carvedilol|entity phosphate is indicated for the treatment of hypertension and heart failure .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens autoreg clarity densities decou|gata4 densities density atpase cholerae|carvedilol|teva and numerous other generic producers began selling their entity tablets ( the generic version of coreg® ) in september of 2007 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|densities chimeras gradients gata4 atpases|carvedilol|european marketing application submitted in october 2014 ; and ( ix ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens autoreg clarity densities decou|gata4 densities density atpase cholerae|carvedilol|teva and eight other generic producers began selling their entity tablets ( the generic version of gsks coreg® ) in september 2007 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|clock gata4 dipole densities atpases|carvedilol|this technology has successfully transitioned to commercial stage with coreg cr® , a micropump-based controlled-release formulation of entity phosphate , sold in the us since 2007 by gsk .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|gata4 gradients atpases densities atpase|carvedilol|first part of the market includes generic drugs based on the immediate release of the generic active ingredient known as entity ( such as coreg® produced by glaxosmithkline ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|clock gata4 dipole atpases gradients|carvedilol|when we entered into a license agreement for use of our micropump platform for an extended release formulation of entity phosphate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|densities chimeras atpases gradients gata4|carvedilol|planned for the third quarter of 2014 ; and ( viii ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|densities chimeras gradients atpases gata4|carvedilol|european marketing application submitted in october 2014 ; and ( viii ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens autoreg clarity densities decou|gata4 chimeras coexist atpases damp|carvedilol|during fiscal 2008 , we launched entity tablets , meprobamate tablets , omeprazole , finasteride , ceterizine otc , ranitidine otc , zolpidem tablets , terbinafine and ciprofloxacin er tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens autoreg clarity densities decou|densities gata4 density cholerae kv|carvedilol|teva would be permitted to continue selling its entity products , given that gsk  s patent has expired .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|autoreg atpases autoin densities gata4|carvedilol|since 1991 , entity has been approved as a treatment for hypertension in several european countries , and in september 1995 , it was approved by
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|autoreg smad1 autoin fdr motors|carvedilol|bucindolol in sort of all comers , what you see is a data set that compares favorably to metoprolol or a entity , at least on the data that are available .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens autoreg clarity densities decou|densities cholerae kv density gata4|carvedilol|successful in its allegations of patent infringement , teva could be required to pay damages relating to past sales of its entity products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dens autoreg clarity densities decou|gata4 densities density atpase cholerae|carvedilol|teva and eight other generic producers began selling their entity tablets ( the generic version of gsks coreg® ) in september 2007 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens autoreg clarity densities decou|atpase gata4 atpases autoreg smad1|carvedilol|toprol-xl and coreg have generic equivalents commercially available in the u . s . ( metoprolol succinate and entity , respectively ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients atpases atpase dens autoreg|gata4 atpase autoreg normality clarity|lemborexant|merck is marketing belsomra® ( suvorexant ) and eisai is marketing dayvigo® ( entity ) which are dual orexin receptor antagonists indicated for insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients atpases atpase dens autoreg|gata4 densities density gradients spher|lemborexant|in december 2019 , eisai announced u . s . fda approval of dayvigo™ ( entity ) , a dual orexin receptor antagonist for the treatment of insomnia in adult patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients atpases atpase dens autoreg|gata4 density densities mω normality|lemborexant|purdue and eisai are developing entity and glaxosmithkline is developing sb-649868 which are also dual orexin receptor antagonists .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|skewed colocalized sinus dens avidin|gata4 cholerae gradients csc kv|lansoprazole|volume was flat as a result of competition on us sales of enoxaparin , lost us authorized generics of gemcitabine and entity in the prior year , and lower sales in germany .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|skewed colocalized sinus dens avidin|autoreg spher gata4 cd69 desmin|lansoprazole|the principal indications for prevacid ( entity ) , a proton pump inhibitor , are for short-term treatment of duodenal ulcers , gastric ulcers and erosive esophagitis .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|gata4 densities gradients damp motors|lansoprazole|in september 2008 , abbott and takeda settled that patent infringement lawsuit against apotex and apotex was allowed to begin selling generic entity capsules in canada on may 1 , 2009 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|densities gata4 motors gradients density|lansoprazole|the original united states compound patent covering entity is licensed by tap from takeda and will expire in 2009 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|mω dens densities density atpases|lansoprazole|with tap pharmaceutical products inc . , or tap , granting tap the right to develop one or more products based on its entity ppi product and derivatives of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|gata4 atpases atpase cyclins autoin|lansoprazole|in the treatment of reflux oesophagitis , it provides healing and symptom relief in more patients than losec / prilosec , entity or pantoprazole .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|mω chimeras autoreg smad1 gata4|lansoprazole|to tap the north american rights to develop , manufacture and sell products resulting from the use of our technology with entity and derivatives of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|gata4 gradients densities atpases smad1|lansoprazole|our ongoing work with tap pharmaceuticals on an improved formulation of entity continues to progress smoothly .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|skewed colocalized sinus dens avidin|densities gata4 density dystrophin certain|lansoprazole|million ) , which caused pricing to decline , as well as nearly usd 100 million of prior-year sales of sandozs gemcitabine and entity authorized generics .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|gata4 atpase atpases motors densities|lansoprazole|dosage forms of acetaminophen , and an improved method of manufacturing for drugs requiring protection from stomach acid , such omeprazole and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|skewed colocalized sinus dens avidin|gata4 desmin atpases atpase dystrophin|lansoprazole|with respect to omeprazole and entity , we believe that we have created an improved method of manufacture , requiring less time and producing higher purity amid better
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|gata4 smad1 mω dens densities|lansoprazole|the north american rights to develop , manufacture and sell products resulting from the use of our immediate-release ppi technology with entity and derivatives of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|gata4 atpase spher atpases ante|lansoprazole|nexium ( esomeprazole ) is the first proton pump inhibitor ( ppi ) to offer significant clinical improvements over losec / prilosec and its main competitors , entity and pantoprazole .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|gata4 motors densities mω atm|lansoprazole|tap also markets prevacid-registered trademark- ( entity ) , a proton pump inhibitor , and has a co-promotion arrangement with the company for prevacid-registered trademark- .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|atpases atpase gata4 autoin motors|lansoprazole|prevonco™ for the treatment of solid tumors , contains a currently third-party marketed anti-ulcer compound , entity , for the treatment of solid tumors .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|gata4 densities atpases autoreg autoin|lansoprazole|sales of entity , which was launched in december 2004 , accounted for 8% of our branded pharmaceutical revenues during the six months ended june 30 , 2005
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|gata4 atpase damp adherens autoreg|lansoprazole|pantoprazole faces competition from various other branded ppis , including takedas entity and astrazenecas esomeprazole .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|autoin atpases gata4 motors atpase|lansoprazole|prevonco™ for the treatment of solid tumors , contains a marketed anti-ulcer compound , entity , that could be used alone or in combination with other chemotherapeutic agents .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|skewed colocalized sinus dens avidin|gata4 autoreg cytoskeleton localization desmin|lansoprazole|tap also markets prevacid® ( entity ) , a proton pump inhibitor .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|skewed colocalized sinus dens avidin|binders mω localization gata4 autoin|lansoprazole|preceding these notable launches , takeda pioneered gastroenterological breakthroughs in proton pump inhibitors beginning in the 1990s with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg smad1|gata4 autoin cyclins autoreg mω|terconazole|prescription drugs in the antifungal field include nizoral ( ketoconazole ) , sporanox ( itraconazole ) , terazol ( entity ) and daktarin ( miconazole nitrate ) antifungal products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg smad1|gata4 autoin nedd4 smad1 chimeras|terconazole|product in this category which does not contain a fungicide such as 95 table of contents clotrimazole , miconazole , entity or nystatin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg smad1|gradients gata4 chimeras smad1 mω|terconazole|the approved prescription therapies for vvc are diflucan ( fluconazole ) and terazol ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens gradients densities autoreg smad1|autoin gata4 nedd4 chimeras smad1|terconazole|a probiotic , purfem is the only product in this category which does not contain a fungicide such as clotrimazole , miconazole , entity or nystatin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg gradients density|gata4 densities density gradients cush|azelastine|the astelin ( entity ) tablet nda for asthma will be withdrawn as soon as it is no longer needed to support the other two
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg gradients density|gata4 densities density gradients cush|azelastine|the astelin ( entity ) tablet nda for rhinitis is pending at the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg gradients density|gata4 cush nanog cd44 densities|azelastine|division the division had a successful year highlighted by the first full year of marketing a new antihistamine , 2 astelin ( entity ) nasal spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg gradients density|gata4 cd44 traps motors dens|azelastine|in august 2002 , we entered into an agreement with medpointe inc . to co-promote medpointe  s nasal-spray antihistamine , astelin® ( entity hcl ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens densities autoreg gradients density|gata4 motors cd44 traps atpases|azelastine|in august 2002 , we signed an agreement with medpointe , inc . for the co-promotion of astelin® ( entity hcl ) , a nasal-spray antihistamine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dens densities autoreg gradients density|atpase atpases integrins ctla cyclins|azelastine|on october 1 , 2004 , we terminated our co-promotion agreement with medpointe , inc . , or medpointe , for the co-promotion of astelin brand entity hcl for the treatment of allergic rhinitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|gata4 densities density gradients nanog|patiromer|new patient starts , outpatient prescriptions and units sold to hospitals / other institutions for the full month of april 2016 for veltassa® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|gradients densities gata4 density motors|patiromer|on october 21 , 2015 , the u . s . food and drug administration , or fda , approved our first drug , veltassa® ( entity ) for oral suspension , or veltassa , for the treatment of hyperkalemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|atpases densities atpase spher gata4|patiromer|relypsas lead product candidate is entity , which is also known as rly5016 , is a non-absorbed potassium binder that is currently being evaluated for the treatment of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|densities atpases gata4 autoreg density|patiromer|also aware of two products for which regulatory approval in the united states has been sought for treatment of hyperkalemia , entity from relypsa and zs-9 from zs pharma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|mω densities gata4 density gradients|patiromer|veitinger , a member of our board of directors , under which dr . veitinger provides certain consulting services to us in connection with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|gata4 densities gradients density adherens|patiromer|to hospitals / other institutions for the full month of march and the three month period ended march 31 , 2016 for veltassa ® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|gata4 densities mω smad1 density|patiromer|the agreement , dsm fine chemicals has agreed to manufacture and supply for commercial sale the active pharmaceutical ingredient ( api ) for entity , the companys lead product candidate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|densities density atpases gradients autoreg|patiromer|drug discovery technology or by selectively pursuing the in-licensing or acquisition of additional compounds that would be commercially synergistic with entity fos .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|densities gata4 mω chimeras autoreg|patiromer|if the companys new drug application for entity is not accepted by the fda on or before december 31 , 2013 , 25% of the shares subject to the option shall
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|gata4 gradients densities nanog density|patiromer|we are substantially dependent on the success of our first and only drug , veltassa® ( entity ) for oral suspension , or veltassa .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|gata4 mω chimeras cush autoreg|patiromer|relypsa has global royalty-free commercialization rights to entity for oral suspension , which has intellectual property protection in the u . s . until at least 2030 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|damp density localization densities smad1|patiromer|we are not permitted to market entity fos in the u . s . until we receive approval of our nda from the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|densities density gata4 damp gradients|patiromer|in this offer to purchase ) with vifor fresenius medical care renal pharma ltd . ( vfmcrp ) , an affiliate of galenica , to commercialize entity fos outside of the united states and japan .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|gata4 densities density gradients nanog|patiromer|new patient starts , outpatient prescriptions and units sold to hospitals / other institutions for the full month of february 2016 for veltassa® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|gata4 mω chimeras density autoreg|patiromer|relypsa has global royalty-free commercialization rights to entity for oral suspension , which has intellectual property protection in the united states until at least 2030 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|densities density damp clock autoreg|patiromer|relypsa intends to commercialize entity fos , if approved , with its own dedicated u . s . -based commercial team and specialty sales force of approximately 120 sales representatives .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|densities gradients gata4 autoin degenerate|patiromer|the challenge all potassium binders ( e . g . entity ) have limited efficacy on per gram basis therapeutic dose for kayexelate , entity or zs-9 substantially the same ( 15-30 g / day )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|densities density kv mω dens|patiromer|business entity clinical development program—pivotal phase 3 trial , page 101 please expand your discussion of your results to identify the serious adverse
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|atpases atpase gradients autoreg motors|gata4 autoin gradients dystrophin atpases|patiromer|entity is a non-absorbed , potassium binding polymer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase gradients autoreg motors|atpase atpases damp densities localizes|patiromer|veltassa ( entity fos ) , an oral , polymer-based potassium binder , was approved for marketing by the fda in october 2015 and was commercially launched
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens grades normality densities likelihood|autoreg autoin mω gata4 smad1|benzphetamine|several older agents , indicated for short-term administration , are amphetamine-like compounds including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens grades normality densities likelihood|autoin autoreg mω chimeras damp|benzphetamine|in the united states for the treatment of obesity , and several older agents , indicated for short-term administration , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens grades normality densities likelihood|autoin autoreg gata4 mω chimeras|benzphetamine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens grades normality densities likelihood|autoin autoreg mω gata4 chimeras|benzphetamine|several older drugs , indicated for short-term administration , include phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens grades normality densities likelihood|chimeras autoreg gradients atpases autoin|benzphetamine|the treatment of obesity , and several older agents , indicated for short-term administration , including phentermine , phendimetrazine , 33 table of contents entity and diethylpropion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens grades normality densities likelihood|autoin autoreg chimeras mω damp|benzphetamine|products in the united states for the treatment of obesity , and several older agents , indicated for short-term administration , phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens grades normality densities likelihood|autoreg autoin gata4 mω smad1|benzphetamine|several older drugs , indicated for short-term administration , have an amphetamine-like profile , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens grades normality densities likelihood|chimeras autoreg autoin densities atpases|benzphetamine|mg tab mysoline® promethazine 12 . 5 , 25 , 50mg tab ( 2 separate andas ) phenergan® fenofibrate 54 , 160mg tab lofibra® entity 50mg tab didrex® not currently marketed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|dens grades normality densities likelihood|autoin autoreg gata4 mω chimeras|benzphetamine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including phentermine , phendimetrazine , mazindol , entity and diethylpropion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|autoreg differential decou ante dens|ante gata4 integrins autoreg motors|ciprofloxacin|infecton® is the proprietary combination of the widely used antibiotic , entity , with technetium ( 99mtc ) , the most commonly used radioisotope in nuclear medical imaging .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|densities gata4 density atpases atpase|ciprofloxacin|should inform their physician if they are taking , or planning to take , any prescription or over-the-counter drugs , especially antidepressants and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|smad4 motors atpases densities atpase|ciprofloxacin|about otiprio® otiprio ( entity otic suspension ) is a fluoroquinolone antibacterial indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|kv atpase gata4 damp densities|ciprofloxacin|bayer corporation has developed a once-daily entity product for the treatment of urinary tract infections , which is currently marketed by schering-plough corporation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg differential decou ante dens|coexist gata4 autoreg atpase atpases|ciprofloxacin|and we agreed to settle the then pending litigation regarding bayer  s patent protecting entity hydrochloride .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|densities density gata4 mω nanog|ciprofloxacin|carlsbad has withdrawn all other defenses it had originally raised challenging the validity and enforceability of bayer ag  s entity patent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|gata4 densities gradients atpases damp|ciprofloxacin|we intend to begin marketing and selling the tablet dosage form of entity through our alliance with lannett if and when anda approval is given by the fda and following the expiration of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|densities atpase atpases smad4 density|ciprofloxacin|otiprio ( entity otic suspension ) is the first drug approved in the united states for use during tympanostomy tube placement ( ttp ) surgery and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|gata4 smad1 gradients degenerate autoreg|ciprofloxacin|entity is approved as therapy for infectious diarrhea with a dosing regimen of twice daily administrations for five to seven days .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|mω gata4 autoreg smad1 kv|ciprofloxacin|if we lost our patent protection for entity , or if the expiration of the patent were accelerated to october 2002 , we believe that we would forego significant revenue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|gata4 damp kv smad4 densities|ciprofloxacin|if we are not already distributing the product , we , along with our partner , will have the right to begin distributing entity product manufactured by bayer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg differential decou ante dens|cholerae gata4 kv densities imm|ciprofloxacin|the decrease in the quarter reflects the launch of the company  s entity product on june 9 , 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|chimeras autoreg gata4 densities fdr|ciprofloxacin|limitations of entity , rifaximin and tmp / smx , three of the most commonly prescribed treatments for infectious diarrhea , include one or more of the following :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|gata4 densities autoreg smad1 chimeras|ciprofloxacin|based on the plaintiffs expert testimony in the california case , estimated sales of entity in california were approximately $500 million during the alleged damages period .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|densities autoreg damp density gauge|ciprofloxacin|pursuant to the terms of the agreement , we began distributing entity on june 9 , 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|densities autoreg gradients density autoin|ciprofloxacin|year ended march 31 , 2002 2003 entity hcl rs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|autoreg mω gata4 motors smad1|ciprofloxacin|gyra and parc are the targets of the fluoroquinolone class of antibacterial agents , such as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg differential decou ante dens|densities gata4 density dystrophin negativity|ciprofloxacin|the fda placed the valortim® / entity study on partial clinical hold pending the outcome of the investigation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg differential decou ante dens|atpases densities atpase gata4 motors|ciprofloxacin|proquin® xr ( entity hydrochloride ) is a once-daily treatment for uncomplicated urinary tract infections that the company no longer manufactures or markets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg differential decou ante dens|densities density mω autoreg cholerae|ciprofloxacin|we intend to continue taking vigorous action to maintain our entity patent rights in the united states through their normal expiry in december 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|clock motors normality autoreg autoin|sulfadiazine|the most common topical antimicrobial agent used is silver entity cream .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|clock motors normality atpase mω|sulfadiazine|wound epithelialization was 11 days for patients treated with transcyte as compared to 18 days for patients treated with silver entity cream .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|clock mω autoin gradients cyclins|sulfadiazine|as compared to silver entity , dermagraft-tc may reduce the pain , time and cost associated with once or twice daily dressing changes and excision .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|clock autoin mω gradients autoreg|sulfadiazine|a number of studies have been conducted which compared the efficacy of collagenase santyl ( r ) to standard treatment ( silver entity ) for deep second degree burns .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|mω gradients ante normality autoin|sulfadiazine|intended for delivery through the skin ) for the treatment of burns that is expected to not only reduce infection ( silver entity ) , but also enhance tissue growth .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|densities density imm negativity mω|sulfadiazine|in this same model , d2a21 demonstrated significant improvement in percent survival ( 85% versus 0% in the control group , p entity ( ssd ) and sulfamylon .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|clock autoin autoreg mω gradients|sulfadiazine|in a clinical trial under a physician  s ide , transcyte was evaluated as an alternative to silver entity in the treatment of patients with limited to moderate partial-thickness burns .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|autoreg dens densities normality gradients|autoin clock mω cholerae gradients|sulfadiazine|transcyte was compared to silver entity which had twice daily dressing changes and wound debridement as per the burn center  s standard practice .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|autoreg autoin mω rectif gradients|sulfadiazine|sildaflo is a dressing that incorporates silver 6 entity , the most widely-used topical antimicrobial for the treatment of burns .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|clock mω autoin autoreg cyclins|sulfadiazine|in partial-thickness burns , dermagraft-tc , as compared to silver entity , has been shown to significantly reduce pain and to heal burns faster and with less scarring .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|spher autoin gradients veloc cd69|sulfadiazine|entity silver ointment health product designed to assist in the prevention of infections related to burns .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|clock autoin autoreg gradients mω|sulfadiazine|transcyte , as compared to silver entity in treating second degree burns , has been shown to heal burns faster .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|autoin clock autoreg gradients mω|sulfadiazine|sildaflo is a dressing that incorporates silver entity , the most widely-used topical antimicrobial for the treatment of burns .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|gradients mω cd44 motors clock|sulfadiazine|entity silver ointment designed to the treatment or the prevention of infections related to burns .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|clock autoin cyclins motors gata4|sulfadiazine|banlangen tablets , dansheng tablets and entity silver ointment remain listed in the updated state insurance catalogue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|autoreg dens densities normality gradients|clock gata4 motors smad4 cyclins|sulfadiazine|at present , xuesaitong soft capsules and entity silver ointment have already been listed in the insurance catalogue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg motors mω|densities autoreg atpases chimeras ducts|conivaptan|the study evaluated both 20 and 40 mg / day doses of entity in hyponatremic patients and was conducted at 26 u . s . and 2 international centers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg motors mω|gradients autoreg gata4 atpases cd44|conivaptan|of an open label multicenter study adding to the growing body of literature supporting the efficacy and use of vaprisol ( entity ) injection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg motors mω|densities autoreg atpases chimeras gata4|conivaptan|about vaprisol® ( entity hydrochloride ) injectionvaprisol an intravenous treatment for hyponatremia used in the critical care setting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atpases atpase autoreg motors mω|densities autoreg atpases chimeras gata4|conivaptan|about vaprisol® ( entity hydrochloride ) injectionvaprisol is an intravenous treatment for hyponatremia used in the critical care setting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|atpase atpases gata4 adherens motors|roflumilast|two of our newest products , daliresp ( entity ) and viibryd ( vilazodone hcl ) became available to patients during the june 2011 quarter and were formally launched in late august
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|autoreg gata4 cd69 smad1 motors|roflumilast|and these products were nebivolol , milnacipran , ceftaroline , entity , aclidinium , linaclotide , levomilnacipran and cariprazine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|smad4 gata4 cd44 atpases atpase|roflumilast|pending of which we are unaware and which may later result in issued patents that we may infringe by commercializing entity cream , entity foam , arq-252 or arq-255 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|spher gradients restorations autoreg mendelian|roflumilast|one such treatment is an oral formulation of a pde4 inhibitor ( entity ) with anti-inflammatory properties , although frequency of adverse events has limited its use in copd patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|gata4 cytoskeleton mω densities gradients|roflumilast|this year in addition to teflaro . in addition , we are hopeful to obtain fda approval later this quarter for daxas ( entity ) , for the treatment of copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|densities dens gata4 density cytoskeleton|roflumilast|q31 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|gata4 densities cyclins adherens gradients|roflumilast|* forced expiratory volume in 1 second , primary endpoint of the ratio trial table of contents pharmaceuticals 9 entity , administered at a daily dose of 500 µg , is an effective product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sinus densities retarded gradients dens|cd69 cd44 autoreg integrins adherens|roflumilast|daliresp ( entity ) , our selective phosphodiesterase 4 ( pde4 ) enzyme inhibitor indicated for the treatment to reduce risk of exacerbations in patients with severe
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|densities mω gata4 veloc imm|roflumilast|as oral administration ariflo® ( cilomilast ) of glaxosmithkline pharmaceuticals , recently found approvable for maintenance of lung function in certain patients , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|sinus densities retarded gradients dens|densities mω density dystrophin gradients|roflumilast|daliresp ( entity ) us patent proceedings in 2015 and subsequently , in response to paragraph iv notices from multiple anda filers , astrazeneca filed patent
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|gradients autoreg mω sensitivities atpase|roflumilast|each of these areas present a variety of treatment challenges which may be well suited to treatment with topical entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|mendelian autoreg adherens autoin spher|roflumilast|in addition , we did not observe the gastrointestinal or other side effects associated with entity , the only pde4 inhibitor currently on the market approved for the treatment of copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|autoreg autoin atpases chaperones gradients|roflumilast|entity was generally well tolerated in the treatment of patients with copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|densities density mω gata4 nanog|roflumilast|daliresp ( entity ) patent proceedings in the us in april 2015 , astrazeneca received several paragraph iv notices challenging certain patents listed in the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|densities dens gata4 density cytoskeleton|roflumilast|q34 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|sinus densities retarded gradients dens|adherens autoin smad2 divertic mendelian|roflumilast|our clinical trials , and has not been observed to result in the gastrointestinal or other side effects commonly associated with entity , the only pde4 inhibitor currently on the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|densities dens density gata4 cytoskeleton|roflumilast|q33 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|autoreg densities gata4 motors density|roflumilast|daliresp / daxas ( entity ) copd $215m , up 14% ( 15% at cer ) growth driven by favourable affordability-programme changes and inventory movements in the us .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|densities gradients autoreg atpases autoin|roflumilast|we therefore elected to reduce the maximum concentration from 0 . 5% entity to 0 . 3% entity for subsequent development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|sinus densities retarded gradients dens|mω kv junction motors uncoupling|roflumilast|page 4 investment projects 2003 altana pharma will establish an ultra-modern entity tablet-producing factory in cork , ireland .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|densities dens clarity gradients retarded|autoreg chimeras atpases atpase autoin|levamlodipine|simceres strategic cardiovascular portfolio also continues to grow with our recently launched cholesterol lowering drug rosuvastatin and hypertension drug entity both performing well .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients atpases atpase dens autoreg|autoin atpases motors gata4 densities|butoconazole|the caption immediately below the picture of gynazole-1 ( r ) reads : " gynazole-1 ( r ) ( entity nitrate ) vaginal cream 2% only one dose .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients atpases atpase dens autoreg|densities dens damp density motors|butoconazole|the product combines roche  s proprietary entity nitrate with kv  s proprietary site release ( r ) drug delivery technology .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients atpases atpase dens autoreg|atpases autoin chimeras densities mω|butoconazole|its licensing partner , ferring , inc . of canada has received approval from the canadian regulatory agency , hpb to market kv  s gynazole-1 ( r ) ( entity nitrate 2% vaginal cream ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients atpases atpase dens autoreg|atpases densities autoin ctla clock|butoconazole|important safety information for gynazole-1 ( entity nitrate vaginal cream usp , 2% ) 5 . 7% of patients enrolled in the gynazole●1 clinical trials reported complaints such as vulvar / vaginal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|gradients atpases atpase dens autoreg|atpases autoin cush autoreg motors|butoconazole|gynazole-1 ( r ) ( entity nitrate 2% ) is a rapidly growing branded prescription vaginal antifungal product indicated for the local treatment of vulvovaginal candidiasis in butoconazole 
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini spher null|gata4 dystrophin smad1 densities either|achondroplasia|january 2014 , we announced the initiation of a phase 2 clinical trial for vosoritide for the treatment of children with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher null|either chimeras mω chimera densities|achondroplasia|the phase 3 study is a randomized , placebo-controlled study of vosoritide in approximately 110 children with entity ages 5-14 for 52 weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher null|gata4 gradients autoreg smad1 atpases|achondroplasia|currently , there are no medical therapies for entity approved by the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher null|gradients gata4 spher signals mω|achondroplasia|in animal models of entity , administration of synthetic cnp and cnp analogues rescued the impaired bone growth phenotype without significant adverse effects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|mendelian normality benjamini spher null|gata4 autoreg integrins atpases motors|achondroplasia|we announced the initiation of a phase 2 clinical trial for bmn 111 for the treatment of children with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher null|gradients atpases densities gata4 motors|achondroplasia|this is approximately 25 percent of people with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher null|gradients atpases densities gata4 motors|achondroplasia|this is approximately 25% of people with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher null|densities mω density gata4 spher|achondroplasia| bmn-111 for entity : the company expects to initiate a phase 2 trial in patients in mid 2013 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|mendelian normality benjamini spher null|gata4 smad1 integrins autoreg dystrophin|achondroplasia|on july 23 , 2020 , the company announced that it had submitted the maa for vosoritide for the treatment of children with entity to the ema .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher null|gata4 gradients negativity autoreg smad1|achondroplasia|the goal is to provide a safer and more efficacious therapy for entity , than daily administration of short-acting cnp analogues .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|mendelian normality benjamini spher null|gata4 dystrophin smad1 either integrins|achondroplasia|global phase 2 multiple dose , randomized study to assess the safety , tolerability , pharmacokinetics and efficacy of recifercept in children with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher null|gata4 smad1 densities atpases autoreg|achondroplasia|continuing studies include our phase 3 study of vosoritide in approximately 110 children with entity for 52 weeks and a long-term open-label phase 2 study of approximately 23 children .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|mendelian normality benjamini spher null|spher motors autoreg gradients integrins|achondroplasia|transcon cnp is being developed for the treatment of entity , the most common form of dwarfism .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini spher null|gata4 dystrophin smad1 mω densities|achondroplasia|genetically-defined cancers , and bmn-111 , a modified c-natriuretic peptide , which is currently in phase i clinical development for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini spher null|motors autoreg dystrophin densities gata4|achondroplasia|natriuretic peptide , or cnp , is a regulator of bone growth and can rescue defects in fibroblast growth factor 3 that cause entity resulting in dwarfism .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini spher null|gata4 smad1 dystrophin smad4 gradients|achondroplasia|rapid clinical development and ( iv ) the possible approval and commercialization of biomarins product candidates , including vosoritide for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini spher null|mω densities autoreg density dystrophin|achondroplasia|the phase 2 study is a randomized , placebo-controlled study of vosoritide in approximately 70 infants and young children with entity ages zero to less than 60 months for 52 weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality mendelian speeds spher|gata4 mω kv density densities|adrenoleukodystrophy|we will also regain control of the preclinical programs in entity ( ald ) and two ophthalmic programs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality mendelian speeds spher|gata4 dystrophin negativity mω otherwise|adrenoleukodystrophy|european medicines agency ( ema ) granted an accelerated assessment to elivaldogene autotemcel ( eli-cel , lenti-d gene therapy ) for the treatment of cerebral entity ( cald ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality mendelian speeds spher|mω ante otherwise defec kv|adrenoleukodystrophy|trb : x-linked entity , plans current status evaluation of vk0214 ongoing , encouraging in vitro results in vivo model in progress poc results expected 2016
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality mendelian speeds spher|gata4 imm negativity ante cholerae|adrenoleukodystrophy|cerebral entity ( cald ) the cald platform includes three patent portfolios , described below .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality mendelian speeds spher|gata4 dystrophin smad1 negativity mω|adrenoleukodystrophy|our lenti-d product candidate has been granted orphan drug status by the fda and the ema for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality mendelian speeds spher|mω otherwise dens gata4 smad4|adrenoleukodystrophy|our second trß agonist is vk0214 , which we are evaluating in the orphan disease known as x-linked entity , or x-ald .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality mendelian speeds spher|gata4 dystrophin negativity smad1 dipole|adrenoleukodystrophy|our lenti-d product candidate to treat cerebral entity ( cald ) •
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality mendelian speeds spher|gata4 cholerae density densities tags|adrenoleukodystrophy|on our two most advanced programs in tdt and cerebral entity , these data will dictate the timing and path for future regulatory submissions in the us and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality mendelian speeds spher|mω otherwise normality cd11 smad4|adrenoleukodystrophy|vk0214 is being evaluated as a potential treatment for x-linked entity ( x-ald ) , a devastating disease caused by a defect in a peroxisomal transporter called abcd1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality mendelian speeds spher|gata4 negativity densities chimeras smad1|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the three discovery programs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality mendelian speeds spher|gata4 densities saturation density mω|adrenoleukodystrophy|clinical study of our bb2121 product candidate in relapsed / refractory multiple myeloma and updates on our lenti-d program in cerebral entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality mendelian speeds spher|mω gata4 densities αvβ3 dystrophin|adrenoleukodystrophy|diseases treatable with hematopoietic stem cell transplants include inherited metabolic diseases , such as krabbe syndrome , metachromatic leukodystrophy , hurler syndrome and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality mendelian speeds spher|gata4 negativity densities chimeras smad1|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the three discovery programs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality mendelian speeds spher|gata4 dystrophin trpv nemat mω|adrenoleukodystrophy|bio intends to use the net proceeds of this offering primarily to advance its clinical studies in ccald ( childhood cerebral entity ) , beta-thalassemia major and sickle cell disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality mendelian speeds spher|spher mω kolmogorov benjamini autoreg|adrenoleukodystrophy|the worldwide incidence rate for entity , or ald , the superset of ccald , is approximately one in 20 , 000 newborn males .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|benjamini normality mendelian speeds spher|mω spher spd integrins αvβ3|adrenoleukodystrophy|entity , or ald , is a genetically determined neurological disorder that affects 1 in every 17 , 900 boys worldwide or 1 in 50 , 000
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality mendelian speeds spher|gata4 negativity chimeras densities smad1|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the discovery programs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|benjamini normality mendelian speeds spher|gata4 mω integrins dystrophin αvβ3|adrenoleukodystrophy|entity is a rare , often fatal condition believed to occur with an incidence of approximately one in 17 , 000 births .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality mendelian speeds spher|mω otherwise gata4 normality αvβ3|adrenoleukodystrophy|▪ evaluation of vk0214 in an in vivo model of x-linked entity ( x-ald ) recently completed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini normality mendelian speeds spher|mω otherwise normality negativity spd|adrenoleukodystrophy|▪ advancing ind-enabling work for vk0214 in x-linked entity ( x-ald ) ; ind filing planned in 2h19 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini telangiect spher ante|gata4 mω motors smad1 dystrophin|anencephaly|ntds include often devastating abnormalities such as spina bifida and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities normality dens retarded autoreg|gata4 densities density smad4 certain|argininemia|own decreased spasticity adapted from sakiyama et al “a successful trial of enzyme replacement therapy in a case of entity” j exp med .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|densities normality dens retarded autoreg|gata4 autoreg densities dystrophin αvβ3|argininemia|enzyme activity adapted from sakiyama et al “a successful trial of enzyme replacement therapy in a case of entity” j exp med .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|uncoupling gradients decou uncou dens|gata4 dystrophin gradients integrins troponin|asthma|acute inflammatory disease , as well as an oral anti-cytokine therapy that could be directed at chronic inflammatory diseases such as entity , rheumatoid arthritis and crohns disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|gata4 troponin density densities dens|asthma|we currently have programs in entity / allergy , autoimmunity , transplant rejection , rheumatoid arthritis / inflammatory bowel disease , and tumor growth .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|densities gata4 smad1 mω density|asthma|we remain on track to initiate a phase 1a single ascending dose clinical trial for entity in the second quarter with preliminary data anticipated by the end of 2014 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|gata4 atpase jam gradients smad1|asthma|•we reported positive , pivotal , phase 2b data for dupilumab in the entity indication and completed enrollment of three phase 3 studies of dupilumab in atopic dermatitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|gata4 smad1 mω negativity cd44|asthma|acuspheres three initial product candidates are designed to address large unmet clinical needs within cardiology , oncology and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|smad1 gata4 mω negativity cd69|asthma|vla-4 antagonists represent a new class of compounds that has shown promise in multiple preclinical animal models of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|gata4 smad1 autoreg negativity mω|asthma|the primary focus of the collaboration will be to discover orally available vla-4 antagonists as treatments for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncoupling gradients decou uncou dens|gradients traps gata4 ≥4 cholerae|asthma|cromolyn is considered first line therapy in mild persistent entity and is frequently prescribed for children .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|matric mω traps dens gradients|asthma|is designed to mediate the suppression of ige and ige-producing cells and originally was developed for the treatment of allergic entity and other ige-mediated diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|gata4 imm autoreg smad1 gradients|asthma|development program to date for prv-300 included studies in healthy adult volunteers and adult patients with stable ( mild to moderate ) entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|troponin tags gata4 negativity dens|asthma|are engaged in the discovery , development and commercialization of novel therapeutics based on synthetic dna for the treatment of cancer , entity / allergies and infectious diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|agon gata4 mω synapt kurt|asthma|glaxosmithklines , or gsk  s , mepolizumab ( nucala ) which targets il-5 was approved for severe eosinophilic entity in adults and children older than 12 in 2015 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|gradients autoreg gata4 smad1 lattice|asthma|beclomethasone is a steroid used to treat the inflammatory component of entity and certain symptoms of copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|gata4 damp saturation densities atpases|asthma|receptor subtypes , it can cause unwanted side effects including flushing , dyspnea and headache , and it should not be used in entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|gata4 mω oscillatory autoreg gradients|asthma|the first human proof-of-concept data being obtained in a phase 2 study of genentechs anti-il-13 antibody lebrikizumab for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncoupling gradients decou uncou dens|gata4 dystrophin densities density negativity|asthma|however , in certain instances , the process may be overly active , such as during an acute entity attack where an immediate inflammatory reaction occurs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|gata4 densities gradients density troponin|asthma|xmab7195 were developing for entity and allergic disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|matric junction traps tags densities|asthma|it is a prophylactic agent indicated for the management of bronchial entity and exercise-induced bronchospasm .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncoupling gradients decou uncou dens|gata4 smad1 dystrophin either autoreg|asthma|clinical development program for zyflo consisted of 21 safety and efficacy trials in an aggregate of approximately 3 , 000 patients with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncoupling gradients decou uncou dens|gata4 autoreg smad1 kv negativity|asthma|and sales infrastructure to promote zyflo and the controlled-release formulation of zileuton that we are developing for the treatment of entity upon regulatory approval from the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini otherwise autoreg gata4 densities|mω dystrophin densities gata4 saturation|chordoma|we are conducting a multi-cohort , global phase 2 trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini otherwise autoreg gata4 densities|densities autoreg density dystrophin smad4|chordoma|the other three entity subjects in the study have been diagnosed with progressive disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini otherwise autoreg gata4 densities|traps gata4 mω autoin densities|chordoma|the trial was an open-label , phase 1 trial and enrolled 38 patients with metastatic cancer or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini otherwise autoreg gata4 densities|smad1 gata4 mω densities spher|chordoma| a phase 2 study in entity is being prepared for initiation at the nci .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|benjamini otherwise autoreg gata4 densities|mω autoreg motors integrins dystrophin|chordoma|clinical trial designed to investigate the safety and efficacy of evaluating gi-6301 in combination with radiation therapy in patients with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini otherwise autoreg gata4 densities|negativity densities autoreg autoin damp|chordoma|the company believes that the summary results from the 11 entity patients enrolled in this trial compare favorably with historically published data .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini otherwise autoreg gata4 densities|gata4 mω densities dystrophin density|chordoma|additional phase ib / ii clinical trials in various indications are newly opened , including for colorectal and hepatocellular cancers and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini otherwise autoreg gata4 densities|densities mω density imm gata4|chordoma|trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma , malignant rhabdoid tumors , or mrt , other ini1-negative tumors , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini otherwise autoreg gata4 densities|gradients gata4 autoreg densities mω|chordoma|we are excited about the recent initiation of the phase 2 trial of gi-6301 at the nci for patients with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini otherwise autoreg gata4 densities|densities density mω gata4 cyclins|chordoma|mva-bn brachyury for the treatment of metastatic cancer and entity mva-bn brachyury is a cancer immunotherapy developed using our proprietary validated mva-bn platform .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini otherwise autoreg gata4 densities|otherwise autoreg mω kolmogorov motors|chordoma|we have obtained orphan drug designations for tazemetostat for the treatment of patients with fl , entity , malignant rhabdoid tumors , or mrt , soft tissue sarcoma , or sts , and mesothelioma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini otherwise autoreg gata4 densities|mω autoreg dystrophin motors gata4|chordoma|clinical trial designed to investigate the safety and efficacy of evaluating gi-6301 in combination with radiation therapy in patients with entity is still enrolling patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini otherwise autoreg gata4 densities|gata4 densities density αvβ3 autoreg|chordoma|we added the entity cohort due to the high rate of enrollment of these patients in the other ini1-negative cohort and the observed clinical
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini otherwise autoreg gata4 densities|densities dystrophin mω gata4 density|chordoma|the clinical and commercial landscape for pancreas cancer , non-small cell lung cancer , colorectal cancer , mtc , entity and chronic hepatitis b infection is rapidly changing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini otherwise autoreg gata4 densities|mω densities imm density veloc|chordoma|which we collectively refer to as ini1-negative tumors , including epithelioid sarcoma , malignant rhabdoid tumors , or mrt , other ini1-negative tumors , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini otherwise autoreg gata4 densities|densities gata4 density nanog gradients|chordoma|dr . mahony also serves on the board of entity foundation , a nonprofit organization dedicated to improving the lives of those affected by chordoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini otherwise autoreg gata4 densities|mω densities density dystrophin traps|chordoma|are conducting a multi-cohort global phase 2 trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma or metastatic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini otherwise autoreg gata4 densities|negativity mω damp densities dystrophin|chordoma|it is believed that radiation therapy can reduce the risk of recurrence after surgery and prolong survival for entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini otherwise autoreg gata4 densities|densities negativity dystrophin peaked gata4|chordoma|the company believes that the gi-6301 tarmogen® , exclusively licensed to celgene corporation , has demonstrated promising initial results in entity patients evaluated in a recent phase 1 study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini otherwise autoreg gata4 densities|densities density gata4 negativity dystrophin|chordoma|the cohort of patients in the phase 2 study of entity patients is ongoing , and we are evaluating tazemetostat in the dose-expansion portion of a phase 1 study in pediatric patients
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality cholerae otherwise mendelian spher|gata4 gradients smad1 autoreg dystrophin|choroideremia|the company&#8217 ; s lead product candidate , nsr-rep1 , for the treatment of entity is in phase 3 clinical development .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae otherwise mendelian spher|gata4 densities mω αvβ3 kv|choroideremia|products for the treatment of the indications for which we have product candidates , including fabry disease , cystic fibrosis , xlrp and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality cholerae otherwise mendelian spher|gata4 smad1 mω dystrophin autoreg|choroideremia|we are aware that biogen inc . , or biogen , is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae otherwise mendelian spher|densities gata4 density dens motors|choroideremia|the designation of the first [ *** ] such roche product classes under section 2 . 2 ( including entity ) is included in the initiation payment set forth in section 12 . 1 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality cholerae otherwise mendelian spher|gata4 smad1 densities mω dystrophin|choroideremia|the pipeline also includes spk-7001 in an ongoing phase 1 / 2 clinical trial for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality cholerae otherwise mendelian spher|gata4 dystrophin smad1 cd69 motors|choroideremia|spk-rpe65 to address a broad spectrum of blinding conditions , starting with the development of spk-chm for the potential treatment of entity , currently in a phase 1 / 2 clinical trial .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality cholerae otherwise mendelian spher|cd69 gata4 dystrophin motors mω|choroideremia|these diseases include entity , diabetic retinopathy , glaucoma , lebers congenital amaurosis ( lca ) , macular telangiectasia , retinitis pigmentosa , wet amd and xlrs , among others .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae otherwise mendelian spher|gata4 negativity smad1 densities autoreg|choroideremia|spk-7001 has been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae otherwise mendelian spher|gata4 autoreg smad1 negativity mω|choroideremia|has been granted orphan product designation by the european commission and fda for its product candidate for the treatment of entity that is in a phase 1 / 2 clinical trial .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae otherwise mendelian spher|gata4 densities gradients density cd44|choroideremia|our pipeline includes : a product candidate targeting entity , or chm , currently in a phase 1 / 2 clinical trial ; a product candidate for hemophilia a , currently in a phase 1 / 2
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|normality cholerae otherwise mendelian spher|normality spher otherwise spd cd69|choroideremia|some irds , such as retinitis pigmentosa ( rp ) , usher syndrome , or entity ( chm ) are associated with a gradual loss of vision , eventually leading to complete blindness .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae otherwise mendelian spher|mω kv gata4 spher smad1|choroideremia|in addition , roche currently holds a license to 4d-110 in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality cholerae otherwise mendelian spher|gata4 smad1 dystrophin mω autoreg|choroideremia|we are aware that nightstarx is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality cholerae otherwise mendelian spher|gata4 negativity smad1 dystrophin mω|choroideremia|spk-chm has also been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae otherwise mendelian spher|densities localization density dens pul|choroideremia|entity : spark therapeutics is enrolling patients in its first phase 1 / 2 clinical trial of spk-chm , an aav-based gene therapy for the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality cholerae otherwise mendelian spher|gata4 dystrophin gradients atpases chimeras|choroideremia|our first such follow-on product candidate is spk-chm for the treatment of entity , or chm .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality cholerae otherwise mendelian spher|gata4 gradients dystrophin densities atpases|choroideremia|our lead product candidate , nsr-rep1 , for the treatment of entity , or chm , is entering phase 3 clinical development in the first half of 2018 and represents the most clinically advanced
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae otherwise mendelian spher|gata4 negativity smad1 autoreg densities|choroideremia|spk-chm has been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae otherwise mendelian spher|gata4 autoreg mω smad1 atpases|choroideremia|as a result , we have not sought , and may be unable to seek , patent protection for spk-chm to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality cholerae otherwise mendelian spher|gata4 smad1 dystrophin mω autoreg|choroideremia|we are aware that nightstar therapeutics plc , or nightstar , is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality densities dystrophin outer cracks|mω kv dystrophin spher otherwise|citrullinemia|current therapy for entity type 1 is considered difficult for patients and generally ineffective , including diet restriction and nitrogen scavengers , and the only curative
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality densities dystrophin outer cracks|mω otherwise ect unless dystrophin|citrullinemia|individuals with entity type i can build-up excessive levels of ammonia and citrulline in their blood , potentially resulting in neurological deficits and other toxicities .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality densities dystrophin outer cracks|cholerae spher autoreg atpases mω|citrullinemia|*** revision to work plans for pku and entity
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality densities dystrophin outer cracks|mω chimeras gata4 ect kv|citrullinemia|to evaluate the therapeutic response to dtx601 , we plan to measure ammonia levels , which is a well-established measure of entity type i disease status .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|normality densities dystrophin outer cracks|gata4 certain ect spd kv|citrullinemia|you know , wilson , or pku or entity?
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|normality densities dystrophin outer cracks|mω dystrophin otherwise densities microtubules|citrullinemia|the incidence of entity type 1 is estimated at approximately 1 per 250 , 000 live births , affecting more than 2 , 000 individuals worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini telangiect cracks outer dens|spher gata4 smad1 mω gradients|afibrinogenemia|entity , the condition where the factor i is completely absent , is estimated to afflict one in one million , or 300 patients
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|gata4 gradients smad1 autoreg atpases|homocystinuria|the company is orphan medical  s exclusive direct-to-patient distributor for cystadane ( tm ) , indicated for patients with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|density otherwise gata4 densities damp|homocystinuria|acn00177 in entity in the second quarter of 2020 , we announced the approval of our clinical trial application , or cta , by the united
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|gata4 gradients atpases motors densities|homocystinuria|there are approximately 1 , 000 patients with entity in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|normality mendelian benjamini hydroph gradients|gata4 mω densities spd sedimentation|homocystinuria|humans and an antidote for methanol or suspected methanol ingestion in humans ; and cystadane® ( betaine anhydrous for oral solution ) , for entity , a genetic disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|gata4 gradients smad1 mω chaperones|homocystinuria|cystadane is a known compound which has already been used to treat entity and is , therefore , not patentable for this indication .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|gata4 gradients smad1 mω kv|homocystinuria|the company has obtained orphan drug status for cystadane for the treatment of entity , which provides marketing exclusivity to the company through october 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|chimeras gata4 mω certain gradients|homocystinuria|elevated blood levels of this amino acid arise in the rare genetic disease of classical entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality mendelian benjamini hydroph gradients|smad1 gata4 mω densities dystrophin|homocystinuria|for aeb4104 demonstrating decreases in plasma homocysteine levels that improved important disease-related abnormalities and survival in a preclinical model of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|mω negativity autoreg gradients densities|homocystinuria|( “orphan” ) , a privately held , clinical-stage biopharmaceutical company focused on the development of product candidate ot-58 for the treatment of classical entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|gata4 smad1 mω αvβ3 motors|homocystinuria|it has been estimated that entity occurs about once in every 200 , 000 live births worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|normality mendelian benjamini hydroph gradients|normality gata4 densities spd spher|homocystinuria|understanding entity entity is an inherited disorder of methionine metabolism that results in elevated homocysteine and homocystine , or thcy , in plasma and urine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|gata4 gradients mω smad1 densities|homocystinuria|the company obtained orphan drug status for cystadane for the treatment of entity , which provided marketing exclusivity to the company through october 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|densities density kv dwell certain|homocystinuria|acn00177 in entity overview : our product candidate , acn00177 , is a novel pegylated , or polyethylene glycol modified , human enzyme engineered to degrade free homocysteine and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|cd69 gata4 densities autoreg mω|homocystinuria|we believe classical entity represents a viable market opportunity with significant unmet medical need , which we plan to address by continuing our preclinical development
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|normality mendelian benjamini hydroph gradients|spher gata4 mω integrins densities|homocystinuria|it is the first agent approved by the fda for the treatment of entity , an inherited metabolic disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|mω densities chimeras certain gata4|homocystinuria|the board of hcu network america , a non-profit which provides advocacy and support for patients affected by the rare disease entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|gata4 gradients smad1 mω kv|homocystinuria|the company has obtained orphan drug status for cystadane for the treatment of entity , which provides marketing exclusivity to the company through october 24 , 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|normality mendelian benjamini hydroph gradients|gata4 mω spher spd densities|homocystinuria|cystadane is approved by the fda for the treatment of entity , an inherited metabolic disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality mendelian benjamini hydroph gradients|autoreg gata4 gradients dystrophin peaked|homocystinuria|the majority of entity patients suffer mutations of a gene that regulates the production of the enzyme known as cystathionine beta-synthase , or cbs , which
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality mendelian benjamini hydroph gradients|densities gata4 density mω kv|homocystinuria|trial in patients with arginase 1 deficiency and closing cancer trials ; offset by a ramp-up in manufacturing for acn00177 in entity and higher personnel-related expenses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|mω ante gradients dystrophin sensitivities|cystinuria|tablets ) is approved in the united states for the prevention of cystine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini cush kolmogorov dens unless|densities gata4 atpases smad1 mω|cystinuria|aeglea has an active discovery platform , with the most advanced program for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|mω dystrophin myod unless gata4|cystinuria|entity is an inherited disease that causes stones made of the amino acid cystine to form in the kidneys , bladder and / or
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|smad1 gata4 negativity dystrophin atpases|cystinuria|our patent-pending customizable delayed-release tiopronin medications that may be prescribed by physicians as a lower-cost alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini cush kolmogorov dens unless|densities motors gradients autoin mω|cystinuria|aeglea has two programs in ind-enabling studies for homoentity and cystinuria and an active discovery pipeline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini cush kolmogorov dens unless|gata4 autoreg gradients mω smad1|cystinuria|additionally , we have commenced ind-enabling studies for our aeb5100 program for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|mω gradients dystrophin ante kolmogorov|cystinuria|( tiopronin ) is approved in the united states for the prevention of cystine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|gata4 smad1 dystrophin gradients chimeras|cystinuria|evaluating sparsentan for fsgs and iga nephropathy , and the recent approval and launch of thiola ec for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini cush kolmogorov dens unless|gradients autoreg gata4 imm atpases|cystinuria|captopril is not fda approved for the treatment of entity but has been prescribed for patients with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|densities gata4 mω density dystrophin|cystinuria|evaluating the suitability of our ersg library for development in additional renal disorders , including autosomal dominant polycystic kidney disease , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|dystrophin gata4 mω smad1 either|cystinuria|and cysteine , decreased the amount of cystine in the urine and reduced kidney stone formation in a preclinical model of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|gradients dystrophin integrins motors gata4|cystinuria|aeb5100 in patients with entity aeb5100 is a novel recombinant human enzyme that degrades plasma cystine and cysteine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|smad1 gata4 negativity dystrophin atpases|cystinuria|our patent-pending tiopronin delayed-release compounded formulations that may be prescribed by physicians as a lower-cost alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|mω gata4 unless dystrophin gradients|cystinuria|entity occurs due to genetic mutations in amino acid transporters that lead to increased amounts of cystine in the urine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|gata4 smad1 dystrophin autoreg gradients|cystinuria|thiola•in 2018 , the company expects an nda to be filed for its new formulation of thiola for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|mω dystrophin unless gata4 myod|cystinuria|entity is a chronic genetic disease that causes stones made of the amino acid cystine to form in the kidneys , bladder
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|mω gradients dystrophin ante gata4|cystinuria|( tiopronin ) is approved in the united states for the prevention of cysteine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|gata4 dystrophin nanog mω myod|cystinuria|clinical development programs and evaluating the suitability of our ersg library for development in additional renal disorders , including adpkd and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cush kolmogorov dens unless|negativity gata4 atpases smad1 dystrophin|cystinuria|citrate delayed release compounded formulations that may be prescribed by physicians as a lower-cost therapeutic alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini cush kolmogorov dens unless|autoreg gata4 gradients atpases motors|cystinuria|the company believes there are 10 , 000-12 , 000 patients with entity in the united states , of which 4 , 000-5 , 000 patients may be appropriate candidates for treatment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality lob ante benjamini close|densities either veloc density biased|galactosemia|entity patients will be eligible for treatment up to 28 days total ( single dose followed by 27 consecutive days of dosing ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality lob ante benjamini close|densities spher mω gata4 gradients|galactosemia|therapeutics plans to leverage recent fda guidance permitting biomarker-based development in low prevalence , slowly progressing rare metabolic diseases , such as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality lob ante benjamini close|gata4 mω motors dystrophin gradients|galactosemia|in particular , the company is currently targeting treatments for cardiovascular disease , entity and diabetic complications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality lob ante benjamini close|densities density gata4 signals gradients|galactosemia|we also hosted an educational symposium featuring a panel of entity experts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality lob ante benjamini close|densities autoreg gata4 smad1 negativity|galactosemia|we will continue to characterize at-007 long-term safety in adult entity patients and intend to initiate a pediatric study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality lob ante benjamini close|dystrophin biased densities negativity smad1|galactosemia|the key biomarker outcome of the study was reduction in galactitol , an aberrant toxic metabolite of galactose , formed by ar in entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality lob ante benjamini close|smad1 dystrophin gata4 either densities|galactosemia|at-007 treatment resulted in a statistically significant and robust reduction in plasma galactitol versus placebo in adult entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality lob ante benjamini close|gata4 autoreg gradients densities smad1|galactosemia|” recent highlights ·presented data on at-007 for treatment of entity at the entity foundation 2020 virtual conference .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality lob ante benjamini close|dystrophin peaked densities saturation junction|galactosemia|at-007 was well tolerated , with no drug-related adverse events noted to date in entity patients or in the 72 healthy volunteers treated in part 1 of the trial .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality lob ante benjamini close|mω gata4 densities spher density|galactosemia|· received fda orphan drug designation for at-007 in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality lob ante benjamini close|gata4 autoreg gradients densities atpases|galactosemia|· presented data highlighting at-007 for the treatment of entity at the ashg annual meeting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality lob ante benjamini close|mω densities gata4 density dystrophin|galactosemia|·announced start of at-007 pediatric entity study ; released additional 40mg / kg data from adult entity study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality lob ante benjamini close|smad1 densities gata4 mω autoreg|galactosemia|june 2020 , we announced additional supportive biomarker efficacy and safety data for at-007 in entity at 40 mg / kg .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality lob ante benjamini close|gata4 densities smad1 density mω|galactosemia|in may 2019 , we received orphan drug designation for at-007 in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality lob ante benjamini close|gata4 smad1 dystrophin either densities|galactosemia|in june 2019 we initiated a pivotal phase 1 / 2 study in healthy volunteers and adults with entity to evaluate safety , pharmacokinetics , and biomarker endpoints in adults with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality lob ante benjamini close|gata4 smad1 cd44 mω densities|galactosemia|we initiated a phase 1 / 2 study of at-007 in entity in june 2019 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients benjamini ante differential sinus|smad1 gata4 otherwise cd69 negativity|galactosialidosis|in entity , the missing protease , cathepsin a , is a lysosomal stabilizing agent for the two other enzymes : sialidase and beta-galactosidase .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|gradients benjamini ante differential sinus|mω gata4 spher integrins microtubules|galactosialidosis|rhppca is in preclinical development as an enzyme replacement therapy for entity , a rare lysosomal storage disease for which there are no currently approved drug therapies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients benjamini ante differential sinus|mω cholerae damp inactivation imm|galactosialidosis|emil : well entity is another small enzyme therapy program like our mps7 program .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients benjamini ante differential sinus|densities density gata4 motors autoreg|galactosialidosis|how the opportunities at dimension compared to those in your own pipeline at a similar stage such as arcturus and entity?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients benjamini ante differential sinus|gata4 mω smad1 dystrophin negativity|galactosialidosis|currently no issued patents that cover the rhppca composition of matter or the use of rhppca for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg atpase atpases gradients densities|gata4 gradients smad1 densities autoreg|glioma|in january 2013 , the ema also granted orphan drug protection to val-083 for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|mω kv negativity dystrophin densities|glioma|in february 2018 , an investigator-sponsored trial was initiated evaluating day101 in pediatric low-grade entity ( plgg ) , for which sunesis believes the scientific rationale is compelling .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|gata4 smad1 kv autoreg dystrophin|glioma|california , san francisco , which is conducting phase 2 clinical trials of prophage series g-100 and g-200 for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|gata4 mω gradients autoin dystrophin|glioma|research our primary business focus is the clinical development of litx for the treatment of hepatoma , metastatic colorectal cancer , entity and one or more possible follow-on indications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|densities dystrophin density gata4 mω|glioma|rcc tumors received and approximately 85% of the tumors received from patients in our ongoing phase 2 clinical trials in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|dystrophin gata4 mω kv gradients|glioma|by nih , a third party might be able to develop a cintredekin besudotox based drug for the treatment of malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg atpase atpases gradients densities|gradients negativity gata4 mω dens|glioma|the company has completed a phase ii clinical trial for use of su101 as a treatment for refractory malignant entity and has recently initiated a phase iii clinical trial in first relapse entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|gata4 mω densities smad1 dystrophin|glioma|investigator sponsored trials include a phase 2 clinical trial in colorectal cancer and a phase 1 clinical trial in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|dystrophin negativity gradients mω densities|glioma|the median survival time was over 609 days ( approximately 21 months ) , which compares favorably to the survival historically recorded for malignant entity patients ( approximately 12 months ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg atpase atpases gradients densities|mω integrins negativity gata4 kv|glioma|in vivo studies that cannabinoids have a synergistic effect with temozolomide , the standard chemotherapeutic agent used in the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg atpase atpases gradients densities|gata4 autoreg gradients smad1 densities|glioma|sl-701 was awarded orphan drug designation from the fda for the treatment of entity in january 2015 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|gata4 negativity densities density dystrophin|glioma|hypericin compounds to inactivate viruses and retroviruses , as a therapeutic or preventative for viral or retroviral diseases , and for anti- entity ( brain tumor ) indications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg atpase atpases gradients densities|gata4 smad1 gradients autoreg motors|glioma|ca4p has been granted orphan drug designation for the treatment of entity in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|negativity densities mω gata4 dystrophin|glioma|orphan drug act , gliadel® wafer became entitled to seven years of market exclusivity for the treatment of patients with malignant entity undergoing primary surgical resection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg atpase atpases gradients densities|densities mω negativity density gata4|glioma|phase 2 clinical trials in a range of indications and is currently in a phase 2 clinical trial in recurrent entity , a type of brain cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|dystrophin negativity mω gradients gata4|glioma|the first of these trials was a phase i / ii recurrent malignant entity clinical trial .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|mω ante densities dystrophin gradients|glioma|is overexpressed in numerous difficult to treat tumors including lung , breast , bladder , gastric , ovarian , endometrial , cervical , melanoma , esophageal , pancreatic , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|gata4 αvβ3 mω dystrophin smad1|glioma|our product pipeline also includes compounds in phase 1 and 2 clinical development for entity , ulcerative colitis type 2 diabetes and schizophrenia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg atpase atpases gradients densities|densities dystrophin gata4 negativity mω|glioma|the crada also covers research to determine whether expression of a component of this pathway correlates with prognosis in entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg atpase atpases gradients densities|negativity mω gata4 kv otherwise|glioma|granted protection under the orphan drug act by the united states food and drug administration ( “fda” ) for the treatment of entity , including gbm .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian cholerae cush benjamini gata4|densities gata4 dystrophin mω spher|progeria|we are also developing lonafarnib monotherapy for treatment of entity and progeroid laminopathies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mendelian cholerae cush benjamini gata4|densities density mω autoreg nanog|progeria|( a ) the parties acknowledge that a priority review voucher may be available and awarded to eiger as the sponsor of the entity nda ( “entity prv” ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mendelian cholerae cush benjamini gata4|normality awa somat mω spher|progeria|eiger has initiated a rolling new drug application ( nda ) submission process for lonafarnib to treat hutchinson-gilford entity syndrome ( hgps or entity ) and progeroid laminopathies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mendelian cholerae cush benjamini gata4|ante normality amorph crim dul|progeria|licensed field of use under the merck agreement to include all uses of lonafarnib related to the treatment of hutchinson-gilford entity syndrome ( entity ) in humans .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mendelian cholerae cush benjamini gata4|gradients autoreg mω negativity densities|progeria|eiger agrees not to retain the entity prv for itself or any of its affiliates .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian cholerae cush benjamini gata4|densities gata4 dystrophin spher gradients|progeria|with prf any proceeds from the monetization of any prv that we may receive for lonafarnib for the treatment of entity and progeroid laminopathies to support future entity research .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mendelian cholerae cush benjamini gata4|normality somat mω awa ante|progeria|eiger is preparing an nda and maa for lonafarnib to treat hutchinson-gilford entity syndrome ( hgps or entity ) and progeroid laminopathies with plans to file in q4 2019 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|mendelian cholerae cush benjamini gata4|gata4 densities spher dystrophin microtubules|progeria|the u . s . food and drug administration ( fda ) accepted the new drug application ( nda ) for accelerated review of zokinvytm ( lonafarnib ) for treatment of entity and progeroid laminopathies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian cholerae cush benjamini gata4|densities gata4 spher gradients dystrophin|progeria|and data controlled by prf to prepare and file any new drug application ( “nda” ) for a product containing lonafarnib for entity and progeroid laminopathies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mendelian cholerae cush benjamini gata4|smad1 gata4 gradients densities density|progeria|that progerin may make the nucleus unstable , and that cellular instability may lead to the process of premature aging in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mendelian cholerae cush benjamini gata4|micrometer crim dul normality densities|progeria|hutchinson-gilford entity syndrome ( entity ) overview ultra-rare , fatal , premature aging pediatric disease point mutation in the lamin a gene results in a farnesylated aberrant protein ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|mendelian cholerae cush benjamini gata4|atpases gata4 integrins dystrophin motors|progeria|children with entity die of the same heart disease that affects millions of normally aging adults ( arteriosclerosis ) , but at an average age of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mendelian cholerae cush benjamini gata4|autoreg gata4 smad1 atpases mω|progeria|as a result we may not successfully obtain approval by the fda of an nda for lonafarnib for entity in the near term , or at all .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpases densities gradients atpase cholerae|gradients gata4 atpases densities dens|hydrocephalus|two events occurred in one patient , these were headache and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|atpases densities gradients atpase cholerae|gata4 integrins vinculin densities nanog|hydrocephalus|prevents obstruction in the cerebrospinal fluid ( csf ) catheters implanted in the ventricle of the brain of patients who suffer from entity or normal pressure hydrocephalus ( nph ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpases densities gradients atpase cholerae|gata4 cd69 densities localization nanog|hydrocephalus|we believe that our cerebral spinal fluid ( csf ) pressure management product line , including the advanced orbis sigma ii entity shunt , is unsurpassed in the industry .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|atpases densities gradients atpase cholerae|negativity cholerae motors localization gata4|hydrocephalus|entity shunt designs have changed little since their introduction in the 1950s .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpases densities gradients atpase cholerae|gata4 mω tags αvβ3 densities|hydrocephalus|bone sclerosis impinges cranial nerve and spinal foramina with resulting neurologic abnormalities , including entity , progressive blindness and auditory impairment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|atpases densities gradients atpase cholerae|gata4 motors smad1 dystrophin cd44|hydrocephalus|entity has also been reported in children with severe hypoplasminogenemia , apparently related to the deposition of fibrin in the cerebral ventricular
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpases densities gradients atpase cholerae|normality atpases spher unless azide|hydrocephalus|the same condition , known as normal pressure entity ( nph ) , presented mostly in the elderly population , causing thinking and reasoning problems , difficulty walking , etc .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|atpases densities gradients atpase cholerae|gata4 negativity dystrophin heterochromatin cd69|hydrocephalus|implantable drainage valve for treatment of entity - french patent application no . 9306356 filed june 27 , 1993 ( docket 91087 ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpases densities gradients atpase cholerae|gata4 cd69 mω densities autoreg|hydrocephalus|this slow accumulation means that the fluid pressure may not be as high as in other types of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|atpases densities gradients atpase cholerae|gata4 smad1 autoreg negativity dystrophin|hydrocephalus|wayne state university , which supports the scstms potential as a viable technology for preventing occlusion in shunts used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpases densities gradients atpase cholerae|gata4 gradients negativity cd69 smad1|hydrocephalus|shunts in the brain to help drain excess csf either externally or into the body for reabsorption to help treat entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpases densities gradients atpase cholerae|gata4 gradients motors αvβ3 atpases|hydrocephalus|entity occurs in about 1 in every 500 births in the u . s . alone1 , 2 over 1 , 000 , 000 people in the united states currently
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|atpases densities gradients atpase cholerae|gata4 dystrophin cd69 densities αvβ3|hydrocephalus|microbot is developing scs as a device for the treatment of entity and nph and is developing tipcat as an endoscopic tool , with colonoscopy as the most immediate application of the tipcat
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpases densities gradients atpase cholerae|densities gata4 vinculin density negativity|hydrocephalus|virob platform , microbot is currently developing its first product candidate : the self cleaning shunt , or scstm , for the treatment of entity and normal pressure hydrocephalus , or nph .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|atpases densities gradients atpase cholerae|gata4 spher mω integrins motors|hydrocephalus|tuberous sclerosis complex is also associated with a variety of resulting disorders including seizures , swelling in the brain ( entity ) , developmental delays and skin lesions , , .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpases densities gradients atpase cholerae|gradients gata4 autoreg smad1 cd69|hydrocephalus|entity is most often treated by the surgical insertion of a shunt system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpases densities gradients atpase cholerae|motors gradients autoreg gata4 xyle|hydrocephalus|mannitol injection entity , glaucoma , edema caused by deep burning or scald , acute renal failure and ascites .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|atpases densities gradients atpase cholerae|gata4 smad1 dystrophin gradients smad4|hydrocephalus|silicone products , state of the art implanted application systems for spinal opiates and market leading valve systems for treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpases densities gradients atpase cholerae|gata4 densities vinculin density negativity|hydrocephalus|using the virob platform , microbot is currently developing the self cleaning shunt , or scstm , for the treatment of entity and normal pressure hydrocephalus , or nph .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpases densities gradients atpase cholerae|gata4 negativity gradients autoreg smad1|hydrocephalus|the proposed indication for use of the scs device would be for the treatment of entity as a component of a shunt system when draining or shunting of csf is indicated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|gradients gata4 autoreg imm spher|hyperprolactinemia|both sgas and fgas can cause entity , a hormonal imbalance resulting from d2 receptor blockade , which can lead to enlargement of breast tissue in males and infertility .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|gata4 dens negativity smad1 chimeras|hyperprolactinemia|x213 could be developed to treat entity in prolactinomas , a condition of benign tumors on the pituitary gland that leads to sexual dysfunction , infertility , and osteoporosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|densities mω density gata4 atpases|hyperprolactinemia|treated for potential oncology indications for up to 48 weeks ; doses up to 20x higher than expected clinical dose for entity 1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini gradients telangiect likelihood|gata4 mω dystrophin kv αvβ3|hyperprolactinemia|by fda for use in humans for more than 15 years for several indications , including treating parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|gata4 densities negativity chimeras ubiquitin|hyperprolactinemia|corporation ) , and we exercised our right to bring the product back into our portfolio to develop it for diseases of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini gradients telangiect likelihood|gata4 mω dystrophin αvβ3 traps|hyperprolactinemia|respect to the other approved indications , and bromocriptine remains on the market for the treatment of parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|gata4 gradients mω densities autoreg|hyperprolactinemia|finalized the design of a proof-of-concept study for xoma 213 , which may offer a new therapeutic option for patients with entity , and anticipate initiating the study midyear .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|densities gata4 mω gradients smad1|hyperprolactinemia|upjohn announced nda submissions to the fda for pramipexole for parkinson  s disease , remisar ( r ) for bladder cancer and dostinex ( r ) ( cabergoline ) for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|gradients dens densities mω autoreg|hyperprolactinemia|this mechanism likely contributes to the favorable safety profile of iti-007 , with reduced risk for entity , akathisia , extrapyramidal symptoms , and other motoric side effects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|gradients densities dens mω atpases|hyperprolactinemia|the favorable safety profile of iti-007 with reduced risk for akathisia , extrapyramidal side effects and other motoric side effects , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|gata4 gradients normality negativity autoreg|hyperprolactinemia|cabergoline was recently launched in certain european countries for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|densities autoin cush binders ≥4|hyperprolactinemia|iti- 2 007 likely contributes to its favorable clinical profile with motoric tolerability similar to placebo and without entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini gradients telangiect likelihood|gata4 mω αvβ3 dystrophin kv|hyperprolactinemia|approved by fda for use in humans for approximately 20 years for several indications , including treating parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|densities gata4 density mω gradients|hyperprolactinemia|our endocrine portfolio also includes a phase 2-ready product candidate , xoma 213 , targeting the prolactin receptor , and entity , and multiple research-stage programs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|autoreg gata4 damp negativity gradients|hyperprolactinemia|inhibit prolactin secretion with no reported effect on other pituitary hormones and are therefore generally the drugs of choice for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini gradients telangiect likelihood|densities dens density localization imm|hyperprolactinemia|entity : as with other drugs that antagonize dopamine d2 receptors , fanapttm elevates prolactin levels .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian ante sinus gradients|gata4 autoreg mω hysteresis motors|hypophosphatasia|asfotase alfa has shown very compelling phase ii clinical data in infants and juveniles with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante sinus gradients|dystrophin gata4 densities mω signals|hypophosphatasia|we note that other examples of animal models of bone disease such as osteoporosis and entity have previously translated in vivo findings into the clinic .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante sinus gradients|gata4 dystrophin mω negativity cytoskeleton|hypophosphatasia|time investing in preparations for the anticipated 2015 launch of our second commercial product , asfotase alfa for the treatment of entity ( hpp ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg atpase atpases gradients dystrophin|densities autoreg gata4 junction density|kuru|and related stockholder matters market information our common stock is traded on the nasd  s over-the-counter bulletin board under the symbol " entity ob " since november 6 , 2008 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|atpase ante otherwise cholerae benjamini|spher motors mω dystrophin gata4|leprechaunism| type a and type b syndrome  rabson-mendenhall syndrome  entity type a syndrome patients have high circulating concentrations of insulin with impaired glucose tolerance or diabetes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|atpase ante otherwise cholerae benjamini|mω spher densities gata4 αvβ3|leprechaunism|defects in the insulin receptor or insulin signaling pathways and include type a and type b syndromes , rabson-mendenhall syndrome and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|atpase ante otherwise cholerae benjamini|mω gata4 densities αvβ3 dystrophin|leprechaunism|these conditions include :  type a and type b syndrome ,  rabson-mendenhall syndrome , and  entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|pull differential benjamini normality cracks|mω densities gradients density ante|lymphangioleiomyomatosis|the exist-2 study will evaluate everolimus in patients with angiomyolipoma associated with either ts or sporadic entity ( lam ) 9 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients densities cholerae density atpases|densities density mω gata4 integrins|medulloblastoma|the following tumor types were treated thus far : high-grade glioma , entity , neuroblastoma , and ependymoma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities cholerae density atpases|αvβ3 densities mω dystrophin density|medulloblastoma|of five childhood cancers typically treated with intensive cisplatin therapy , including newly diagnosed hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients densities cholerae density atpases|integrins densities gata4 αvβ3 mω|medulloblastoma|the work at nih has now extended to the most common brain tumor of children , entity , and to the most common cancer of children , neuroblastoma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients densities cholerae density atpases|integrins mω densities αvβ3 gata4|medulloblastoma|the work at nih was then extended to the most common brain tumor of children , entity , and to the most common extracranial solid tumor of children , neuroblastoma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|gradients densities cholerae density atpases|mω dystrophin gata4 smad1 integrins|medulloblastoma|in addition , compounds from both series have anti-cancer activity in animal models of glioblastoma multiforme , neuroblastoma , and entity , all cancers of neural tissue .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients densities cholerae density atpases|densities integrins dystrophin dens motors|medulloblastoma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , oligodendroglioma , mixed glioma , entity , and malignant meningioma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients densities cholerae density atpases|mω gata4 integrins dystrophin densities|medulloblastoma|joint patent applications with nih have been filed for the treatment of glioblastoma multiforme , entity , and neuroblastoma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients densities cholerae density atpases|αvβ3 mω densities dystrophin integrins|medulloblastoma|of one of five childhood cancers typically treated with intensive cisplatin therapy , including hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities cholerae density atpases|gata4 gradients densities mω dystrophin|medulloblastoma|in 2016 , the fda also granted orphan drug protection to val-083 for the treatment of entity and ovarian cancer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities cholerae density atpases|densities negativity mω density imm|medulloblastoma|ii - paragon-hf to start aug . 2014 29 lde225 solid tumors ≥ 2018 i entity ≥ 2018 iii lee011 breast cancer 2016 iii - phase iii registration study enrolling solid tumors ≥
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities cholerae density atpases|dystrophin gata4 densities density mω|medulloblastoma|sl-301 has demonstrated activity against brain and pancreatic cscs and tumor bulk in vitro , and against glioblastoma and entity cscs in in vivo animal models .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities cholerae density atpases|mω densities dystrophin autoreg density|medulloblastoma|have presented data indicating that val-083 offers potential therapeutic alternatives for the treatment of pediatric brain tumors including shh-p53 mutated entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities cholerae density atpases|gata4 autoreg mω negativity smad1|medulloblastoma|phase i clinical trials that are designed to evaluate dose and safety of gdc-0449 in pediatric and adult patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities cholerae density atpases|gata4 gradients autoreg imm densities|medulloblastoma|emory studies so far have indicated that entity may be particularly vulnerable to the ability of wp1066 to block the activated form of stat3 , a key signaling protein
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities cholerae density atpases|mω densities αvβ3 dystrophin gata4|medulloblastoma|treated with intensive cisplatin therapy for localized and disseminated disease , including newly diagnosed hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients densities cholerae density atpases|densities αvβ3 density integrins gata4|medulloblastoma|no conventional therapy exists , or a relapsed brain tumor with a predilection for lm dissemination ( primitive neuroectodermal tumor , rhabdoid tumor , entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities cholerae density atpases|gata4 gradients densities mω dens|medulloblastoma|the fda has also granted orphan drug protection to val-083 for the treatment of entity and ovarian cancer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients densities cholerae density atpases|integrins dystrophin densities gata4 mω|medulloblastoma|pre-clinical studies of lb-100 that showed anti-cancer activity in models of a variety of human brain tumors , including glioblastomamultiforme ( gbm ) , entity and malignant meningioma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients densities cholerae density atpases|gata4 dystrophin densities mω integrins|medulloblastoma|we have been granted orphan drug designation in the united states for gbm , ovarian cancer , and entity , and in europe for gbm .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities atpases cholerae autoreg|dens densities gradients dystrophin density|meningioma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , oligodendroglioma , mixed glioma , medulloblastoma , and malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities atpases cholerae autoreg|gata4 autoreg mω gradients dystrophin|meningioma|in february 2012 , the fda granted two orphan drug designations for ar-42 for the treatment of entity and the treatment of schwannoma of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities atpases cholerae autoreg|gata4 mω autoreg gradients densities|meningioma|the fda has granted two orphan drug designations for ar-42 for the treatment of entity and the treatment of schwannoma of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities atpases cholerae autoreg|mω αvβ3 gata4 dystrophin densities|meningioma|in addition , preclinical models have demonstrated anti-tumor activity in tumor types ( schwannoma and entity ) that are associated with the genetic illness , neurofibromatosis type 2 ( nf2 ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities atpases cholerae autoreg|mω αvβ3 gata4 dystrophin densities|meningioma|in addition , pre-clinical models have demonstrated anti-tumor activity in tumor types ( schwannoma and entity ) that are associated with the genetic illness neurofibromatosis type 2 ( nf2 ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients densities atpases cholerae autoreg|integrins αvβ3 gata4 dystrophin mω|meningioma|entity and schwannoma are rare , benign tumors that can present in different locations within the brain and the spinal cord and
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities atpases cholerae autoreg|densities gata4 mω dystrophin αvβ3|meningioma|intend to collaborate with ohio state to conduct a phase 0 investigator-initiated study of ar-42 in patients with schwannoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities atpases cholerae autoreg|gata4 mω autoreg gradients dystrophin|meningioma|this patient was a 61-year-old female that was subsequently diagnosed with a non-treatment related entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities atpases cholerae autoreg|dystrophin densities dens mω gradients|meningioma|lb-100 that showed anti-cancer activity in models of a variety of human brain tumors , including glioblastomamultiforme ( gbm ) , medulloblastoma and malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities atpases cholerae autoreg|mω densities gata4 dystrophin negativity|meningioma|in preclinical studies , ar-42 has demonstrated anti-tumor activity in both entity and schwannoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|mω gradients uncoupling hysteresis densities|obesity|in the majority of these men , often with co-morbid entity , t replacement is not optimal and indeed may be counterproductive .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|dens normality resonance decou compensated|autoreg densities density cholerae gata4|obesity|eps growth  restating 2012 to exclude the 2012 entity impact of $0 . 10 and including the 2012 r&d tax credit impact of $0 . 06 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|gata4 kv negativity smad4 defective|obesity|development of the pyy compound and has recently announced that it expects to file an ind on pyy for an entity indication in 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|mω densities density autoreg cd69|obesity|exhibit 99 . 01 regeneron initiate phase ii entity clinical trial tarrytown , new york ( march 28 , 2000 ) - regeneron pharmaceuticals , inc . ( nasdaq : regn ) announced that it has initiated a
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|mω autoreg motors densities negativity|obesity|with open-label one year extensions , and was planned to include approximately four to six patients with genetically confirmed pomc deficiency entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|gradients gata4 mω saturation autoreg|obesity|-k . about vivus vivus , inc . is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing entity and sexual health .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|gata4 mω chimeras kv gradients|obesity|the company also has drug candidates or development programs for entity , erectile dysfunction , cardiovascular diseases , pulmonary diseases , inflammatory diseases and dermatologic diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|dens normality resonance decou compensated|dystrophin densities gata4 smad4 adherens|obesity|strong business momentum continues to accelerate sales & eps growth * sales growth in local currency retrospectively adjusted to exclude entity intervention business .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|dens normality resonance decou compensated|imm kv gata4 mω cholerae|obesity|in addition , outsourced clinical expenses in the companys entity program increased by $0 . 3 million in 2007 for phase 1 clinical trials on the companys lead compound , ngd-4715 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|gradients gata4 densities mω atpases|obesity|tolerability of topiramate , which was the scientific rationale for combining these two agents at low doses for the treatment of entity and related co-morbidities .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|dens normality resonance decou compensated|gata4 dens mω cholerae troponin|obesity|dr . amatruda was the senior vice president and franchise head , diabetes and entity at merck research laboratories .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|dens normality resonance decou compensated|autoreg densities density cholerae gata4|obesity|* 2012 eps growth includes the 2012 entity impact of $0 . 10 and the 2012 r&d tax credit impact of $0 . 06 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|mω gata4 gradients negativity smad1|obesity|axokine is being developed for the treatment of entity and complications of entity such as type ii diabetes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|negativity autoin density gata4 densities|obesity|incontinence may be caused by a wide range of factors , including childbirth , menopause , surgery , entity , drugs and neurological damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|densities density dens imm autoreg|obesity|academic researchers have increasingly linked chronic entity induced inflammation with type 2 diabetes and the potential role of inflammation in promoting insulin resistance in type 2 diabetes
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|densities spher density dens normality|obesity|● increased waist circumference ( central or apple-shaped entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|gata4 gradients traps densities dens|obesity|about orexigen therapeutics orexigen therapeutics , inc . is a biopharmaceutical company focused on the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|gata4 smad1 mω motors gradients|obesity|we believe that this discovery indicates that overactivity of this gpcr may be associated with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|densities gata4 gradients atpases density|obesity|the companys lead combination product candidates targeted for entity are contrave , which is in phase 3 clinical trials , and empatic , which is in the later stages of phase 2
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|dens normality resonance decou compensated|mω autoreg motors gradients ∗∗|obesity|conversely , transgenic mice that overexpress dgat-1 in adipose tissue are predisposed to entity when fed a high-fat diet and have elevated levels of circulating free fatty acids .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|gata4 gradients smad1 atpases autoreg|osteoporosis|the revenue decline in the second quarter largely reflects lower sales of fosamax for the treatment and prevention of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mω cholerae uncoupling clock decou|dystrophin certain chimeras disintegr damp|osteoporosis|ystps trademarks xiangbala jidan and zangyu in particular are well recognized in china among physicians and hospital administrators , pharmacists and entity patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|dens autoreg densities inactivation density|osteoporosis|other entity therapies include estrogen replacement therapy , selective estrogen receptor modulators , bisphosphonates and several new biologics that are under development .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mω cholerae uncoupling clock decou|gata4 motors dystrophin smad1 αvβ3|osteoporosis|and outcomes management programs targeted at major categories of disease commonly found in the elderly , such as congestive heart failure , entity and atrial fibrillation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|negativity mω autoreg gata4 densities|osteoporosis|a key set of parameters in the monitoring of entity , both before and after therapy , are biochemical markers of bone metabolism .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|gata4 mω motors ubiquitin smad1|osteoporosis|under the asset purchase agreement , par acquired certain assets pertaining to calcitonin nasal spray for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|mω gradients gata4 traps chimeras|osteoporosis|and estraderm mx ( estradiol ) transdermal patches are treatments for symptoms of estrogen deficiency in post-menopausal women , and prevention of post-menopausal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|otherwise densities mω gata4 either|osteoporosis|▪ approved for treatment of adult entity ▪ synthetic analogues of pyrophosphate ▪ inhibit bone resorption ▪ can be given orally or intravenously , depending on compound ▪
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mω cholerae uncoupling clock decou|gata4 dens mω autoreg dystrophin|osteoporosis|portfolio will include two drug candidates in advanced clinical trials for the treatment of types 1 and 2 diabetes , severe entity and polycystic ovary syndrome .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mω cholerae uncoupling clock decou|mω gata4 dystrophin densities either|osteoporosis|currently in preclinical development as a potential treatment for age-related muscle loss , frailty , weight loss associated with cancer cachexia and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|mω gata4 kv dens spher|osteoporosis|since 1990 , he has been the organizer and chairman of the international symposia on nutrition and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|gata4 mω gradients negativity chimeras|osteoporosis|he is treasurer of the international foundation of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mω cholerae uncoupling clock decou|densities density dens cholerae autoreg|osteoporosis|also organize free community healthcare activities , such as arranging for bone density tests and organizing seminars on our products and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|gata4 heterochromatin autoreg gradients densities|osteoporosis|we believe this study population contains a patient population reflective of the type of severe entity patients that specialists will treat in their practices .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|gata4 traps mω dens motors|osteoporosis|we also anticipate using our sales force to promote pharmaceutical products that address other midlife conditions such as hypertension , entity , depression and incontinence .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mω cholerae uncoupling clock decou|mω gradients gata4 dystrophin αvβ3|osteoporosis|is also associated with a wide range of adverse events , including high blood pressure , weight gain , diabetes , serious infections and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|gata4 smad1 gradients dens autoreg|osteoporosis|company and sb will continue to work together to develop one or more novel therapeutic approaches to the treatment of entity utilizing the company  s calcium receptor technology .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mω cholerae uncoupling clock decou|gata4 spher negativity dystrophin gradients|osteoporosis|we have licensed worldwide rights to our manufacturing and delivery technologies for pth for the treatment of entity to gsk .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|gata4 kv gradients atpases autoreg|osteoporosis|pursuant to a tenth amendment , we have been granted the exclusive right to negotiate an expansion of the field of use to include treatment of entity ( the &#8220 ; option&#8221 ; ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mω cholerae uncoupling clock decou|densities chimeras gata4 density kv|osteoporosis|hepatitis c , and multiple sclerosis business categories , as well as other lower margin business categories , including human immunodeficiency virus and entity , versus the prior year .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante cholerae gradients densities benjamini|densities αvβ3 dystrophin gata4 either|paraganglioma|we will make a difference in how patients with prostate cancer , pheochromocytoma , and entity are diagnosed and treated .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante cholerae gradients densities benjamini|densities mω αvβ3 either dystrophin|paraganglioma|administration ( fda ) has designated azedra as a breakthrough therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante cholerae gradients densities benjamini|densities density dystrophin mω αvβ3|paraganglioma|agent for prostate cancer phase 2 testing completed azedra™ treatment of pheochromocytoma and entity phase 2b registrational trial under special protocol assessment ( spa ) relistor®
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|ante cholerae gradients densities benjamini|densities mω density either αvβ3|paraganglioma|study of azedra demonstrating a positive safety profile and durable objective tumor responses in patients with neuroendocrine cancers , pheochromocytoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|ante cholerae gradients densities benjamini|densities either autoreg mω density|paraganglioma|first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant pheochromocytoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante cholerae gradients densities benjamini|densities dystrophin αvβ3 mω either|paraganglioma|a preeminent , patient-centric oncology company and we intend to make a difference in how patients with prostate cancer , pheochromocytoma , and entity are diagnosed and treated .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|ante cholerae gradients densities benjamini|either densities mω ante integrins|paraganglioma|to evaluate the efficacy and safety of the administration of two therapeutic doses of azedra in patients with pheochromocytoma / entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante cholerae gradients densities benjamini|densities density mω dystrophin gata4|paraganglioma|twenty-four subjects were enrolled ( 11 female , 13 male ) , and seven subjects experienced stable disease in breast , neuroendocrine , entity , head / neck or colorectal cancer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante cholerae gradients densities benjamini|densities density benjamini cholerae troponin|paraganglioma|about pheochromocytoma and entity pheochromocytomas and paragangliomas are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|ante cholerae gradients densities benjamini|autoreg densities mω either gata4|paraganglioma|first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant pheochromocytoma and entity , an ultra-orphan indication .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|ante cholerae gradients densities benjamini|densities mω either αvβ3 density|paraganglioma|under compassionate use and named patient programs in 10 european countries in almost 1 , 300 patients , including those with pheochromocytoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante cholerae gradients densities benjamini|densities dystrophin mω gradients density|paraganglioma|or disease stabilization was observed in several cancer types , including parotid gland adenocarcinoma , colon , kaposi  s sarcoma , melanoma , ovarian , pancreatic and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante cholerae gradients densities benjamini|mω gata4 autoreg spher dystrophin|paraganglioma|dysregulation of hif-2α under pseudohypoxia is thought to contribute to pah and entity , a neuroendocrine tumor .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante cholerae gradients densities benjamini|mω αvβ3 densities density dystrophin|paraganglioma|in addition to potentially treating pheochromocytoma and entity , azedra may also have utility in treating neuroblastoma and other neuroendocrine tumors .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante cholerae gradients densities benjamini|mω αvβ3 densities dystrophin density|paraganglioma|in addition to potentially treating pheochromocytoma and entity , azedra may also have utility in treating neuroblastoma and other neuroendocrine diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante cholerae gradients densities benjamini|densities density dystrophin mω αvβ3|paraganglioma|candidates for prostate cancer , and resumed a pivotal phase 2 trial of an ultra-orphan radiotherapy candidate for malignant pheochromocytoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|ante cholerae gradients densities benjamini|mω αvβ3 integrins densities cd47|paraganglioma|we are developing azedra as a treatment for patients with malignant , recurrent , and / or unresectable pheochromocytoma and entity , which are rare neuroendocrine tumors .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|ante cholerae gradients densities benjamini|mω densities integrins αvβ3 ante|paraganglioma|other than azedra , there are currently no approved anticancer treatments in the u . s . for malignant , recurrent , and / or unresectable pheochromocytoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante cholerae gradients densities benjamini|densities density dystrophin gradients mω|paraganglioma|stable disease was observed in several cancer types , including melanoma , ovarian , kaposi  s sarcoma , angiosarcoma , parotid gland adenocarcinoma , colorectal , pancreatic and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|mω densities density spher gata4|phenylketonuria|camp km , et al . entity scientific review conference : state of the science and future research needs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|gata4 densities atpases kv autoreg|phenylketonuria|table of contents until march 2020 , we had been developing rtx-134 for the treatment of entity , or pku .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|spher mω negativity kv densities|phenylketonuria|page 2 of 3 about entity ( pku ) pku , a genetic disorder affecting at least 50 , 000 diagnosed patients under the age of 40 in the developed
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|atpases mω spher otherwise motors|phenylketonuria|kuvan is a commercialized product for the treatment of patients with entity ( pku ) and / or for primary bh4 deficiency in certain countries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|densities mω spher kv atpases|phenylketonuria|privately held biotechnology company focused on developing therapies for orphan metabolic diseases , to evaluate sepiapterin ( " cnsa-001 " ) for the treatment of entity ( " pku " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|mω kv atpases atpase spher|phenylketonuria|company will use intrexons technology relating to the development and commercialization of novel biotherapeutics for the treatment of patients with entity ( pku ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality dots cush gradients mendelian|gata4 smad1 autoreg dystrophin atpases|phenylketonuria|or in-license are currently pending patent applications except that we own one issued u . s . patent directed to methods of treating entity with rtx-134 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|densities mω spher kv atpases|phenylketonuria|privately held biotechnology company focused on developing therapies for the orphan metabolic diseases , is developing cnsa-001 for the treatment of entity ( " pku " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|mω densities biphasic kv atpases|phenylketonuria|· october 1 , 2015 , biomarin to acquire rights to entity ( pku ) franchise from merck serono : the company announced that it has entered into a definitive agreement to acquire all
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|atpases atpase mω kv negativity|phenylketonuria|• pegvaliase for entity ( pku ) : pivotal results for the phase 3 prism-2 study ( formerly referred to as 165-302 ) that pegvaliase met the primary endpoint
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|spher mω atpase kv atpases|phenylketonuria|investigational product candidates include phenoptin ( sapropterin hydrochloride ) , a phase 3 product candidate for the treatment of entity ( pku ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|densities gata4 kv atpases inactivation|phenylketonuria|and in the third quarter of 2017 , both france and germany had their first commercial sales . • kuvan® for entity :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality dots cush gradients mendelian|mω spher densities cholerae kv|phenylketonuria|about entity ( pku ) pku , a genetic disorder affecting at least 50 , 000 diagnosed patients under the age of 40 in the developed
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|mω ante gata4 kolmogorov leakage|phenylketonuria|mucopolysaccharidosis iv type a , or mps iva mucopolysaccharidosis vi , or mps vi entity , or pku 6 kuvan has been granted orphan drug status in the eu , which together with pediatric
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|motors gata4 autoreg atpases chaperones|phenylketonuria|substantial progress has been made over the past six decades , beginning with the first report of dietary control of entity in the early 1950s .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|normality dots cush gradients mendelian|spd densities atpases spher mω|phenylketonuria|nutritional management of individuals with rare , inborn errors of metabolism such as maple syrup urine disease ( mead johnson bcad ) and entity ( mead johnson phenyl-free ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|normality dots cush gradients mendelian|densities mω spd gradients atpases|phenylketonuria|nutritional management of individuals with rare , inborn errors of metabolism such as maple syrup urine disease ( mead johnson bcad® ) and entity ( mead johnson phenyl-free® ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality dots cush gradients mendelian|spher mω dwell denitr negativity|phenylketonuria|about entity ( pku ) pku is caused by a defect in the gene encoding phenylalanine hydroxylase ( pah ) , a liver enzyme that metabolizes phe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini ante densities autoreg|densities density dystrophin mω gata4|pheochromocytoma|we will make a difference in how patients with prostate cancer , entity , and paraganglioma are diagnosed and treated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini ante densities autoreg|dystrophin densities mω gradients gata4|pheochromocytoma|azedra program " means the company  s therapeutic program for the treatment of malignant entity , pediatric neuroblastoma and carcinoid cancers with ultratrace iobenguane i 131 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini ante densities autoreg|densities mω density dystrophin either|pheochromocytoma|trial to evaluate the efficacy and safety of the administration of two therapeutic doses of azedra in patients with entity / paraganglioma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini ante densities autoreg|densities existence mω density αvβ3|pheochromocytoma|although the majority of entity and paragangliomas are benign , approximately 10-25% of these tumors present with metastasis , and up to 35% of these cases are
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|normality benjamini ante densities autoreg|mω densities gata4 integrins autoreg|pheochromocytoma|we are currently pursuing adult clinical trials for entity and pediatric clinical trials for neuroblastoma , which are detailed below .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini ante densities autoreg|densities mω density gata4 autoreg|pheochromocytoma|the company is conducting azedra pivotal trials for both adult entity and pediatric neuroblastoma neuroendocrine tumor indications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|normality benjamini ante densities autoreg|mω densities integrins density cd11|pheochromocytoma|azedra clinical development plan azedra is under development for the systemic treatment of the metastatic neuroendocrine cancers entity and neuroblastoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini ante densities autoreg|densities density mω dystrophin gata4|pheochromocytoma|to become a preeminent , patient-centric oncology company and we intend to make a difference in how patients with prostate cancer , entity , and paraganglioma are diagnosed and treated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini ante densities autoreg|densities mω dystrophin density negativity|pheochromocytoma|that the first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant entity and paraganglioma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini ante densities autoreg|densities dystrophin mω density gradients|pheochromocytoma|two product candidates for prostate cancer , and resumed a pivotal phase 2 trial of an ultra-orphan radiotherapy candidate for malignant entity and paraganglioma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini ante densities autoreg|densities mω density gradients gata4|pheochromocytoma|azedra is currently in a phase 1 trial for entity or carcinoid tumors , and has received orphan drug status and a fast track designation by the united states food and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini ante densities autoreg|densities mω gradients density dystrophin|pheochromocytoma|we are developing azedra as a treatment for patients with malignant , recurrent , and / or unresectable entity and paraganglioma , which are rare neuroendocrine tumors .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini ante densities autoreg|densities mω negativity αvβ3 gradients|pheochromocytoma|about entity and paragangliomas entitys and paragangliomas are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini ante densities autoreg|densities mω density settle either|pheochromocytoma|perelman school of medicine presented preliminary dosimetry data from the phase 2 study in patients with iobenguane-avid metastatic and / or recurrent entity / paraganglioma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality benjamini ante densities autoreg|densities density gradients normality either|pheochromocytoma|pharmacology 2005 ; 74 : 65-78 . " local anesthetic procaine protects rat entity pc12 cells against beta-amyloid-induced neurotoxicity " .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini ante densities autoreg|mω αvβ3 densities dystrophin density|pheochromocytoma|in addition to potentially treating entity and paraganglioma , azedra may also have utility in treating neuroblastoma and other neuroendocrine diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality benjamini ante densities autoreg|densities dystrophin mω spher saturation|pheochromocytoma|patients harboring a rare head and neck cancer , known as paraganglioma , and a rare adrenal or extra-adrenal cancer , known as entity , and rare subset clear cell rcc .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae benjamini gradients densities|spher mω vv gata4 gradients|prolactinoma|entity is a condition in which a non-cancerous tumor of the pituitary gland overproduces prolactin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae benjamini gradients densities|gata4 densities density smad1 negativity|prolactinoma|study for xoma 213 , which , if successful , will allow us to advance the compound into a phase 2 study for entity and potentially into anti-psychotic medication-induced hyperprolactinemia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae benjamini gradients densities|negativity autoreg gata4 damp kv|prolactinoma|for ten percent of the 140 , 000 entity patients in the united states , existing therapies are poorly tolerated or not effective .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality cholerae benjamini gradients densities|gata4 mω spher dystrophin gradients|prolactinoma|entity is a condition of benign tumors on the pituitary gland .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|normality cholerae benjamini gradients densities|densities gradients autoreg dens negativity|prolactinoma|we intend to move xoma 213 into clinical development , initially for symptomatic entity potentially followed by medication-induced hyperprolactinemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities inner papill dens|gata4 dystrophin densities density cd69|sitosterolemia|treatment experience with zetia in the pediatric population is limited to 4 patients ( 9 to 17 years ) in the entity study and 5 patients ( 11 to 17 years ) in the hofh study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities inner papill dens|gata4 autoreg chimeras densities motors|sitosterolemia|doctors ruled out a diagnosis of a disease called entity , based on certain blood test results .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities inner papill dens|smad1 atpases gradients gata4 autoreg|sitosterolemia|this finding indicated that the infant definitely has entity , despite the prior contradictory test results .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities inner papill dens|autoreg gata4 chimeras densities density|sitosterolemia|doctors ruled out a diagnosis of a disease called entity , based on certain test results .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities inner papill dens|autoreg dens mω otherwise gradients|sitosterolemia|treatment experience with ezetimibe in the pediatric population is limited to 4 patients ( 9 to 17 years ) with homozygous entity and 5 patients ( 11 to 17 years ) with hofh .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini gradients ante autoreg gata4|autoreg gata4 kv dens gradients|trichotillomania|patent claims the use of opioid antagonists , including nalmefene , for the treatment of impulse control disorders with the exception of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini gradients ante autoreg gata4|densities gata4 dens density gradients|trichotillomania|dr . blochs research interests focus on studying tourette syndrome , ocd , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini gradients ante autoreg gata4|chimeras mω gata4 junction dystrophin|trichotillomania|yale school of medicine - n oted researcher on the study of tourette syndrome , obsessive - compulsive disorder and entity prof . daniele piomelli
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini gradients ante autoreg gata4|densities gata4 density dens gradients|trichotillomania|dr . blochs research interests focus on studying ts , ocd , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|gata4 gradients chimeras traps density|vitiligo|has registered a variety of domain names and established an initial website to include in depth information regarding psoriasis , eczema , entity , and the psoria-light device .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini normality hydroph ante cholerae|gradients gata4 mω integrins motors|vitiligo|two prior clinical trials of immunotherapies conducted by others suggest that the development of entity was correlated with a favorable response to therapy in melanoma patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|gata4 mω cd44 myod ≥4|vitiligo|the enrollment and / or results for a number of phase 2 studies with ati-502 for the topical treatment of aa and entity , including results from its auatb-201 study .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|mω motors gradients autoin nedd4|vitiligo|specified dermatological conditions , including alopecia areata , or aa , androgenetic alopecia , or aga , also known as male or female pattern baldness , entity and atopic dermatitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality hydroph ante cholerae|mω gata4 motors troponin dystrophin|vitiligo|raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts , alopecia areata , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|gradients chimeras mω gata4 traps|vitiligo|psoriasis , eczema , and entity , are common skin conditions that can be challenging to treat , and often cause the patient significant psychosocial stress .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|gradients mω chimeras traps gata4|vitiligo|psoriasis , eczema , and entity , are common skin conditions that can be challenging to treat , and often cause the client significant psychosocial stress .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|gradients mω cd44 csc gata4|vitiligo|to date , some patients have experienced entity and uveitis , but there has been no other evidence of off-target effects associated with til therapy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality hydroph ante cholerae|mω gata4 motors chimeras dystrophin|vitiligo|pharos 2 excimer laser system is fda-cleared and is used as a tool in the treatment of psoriasis , entity , atopic dermatitis , and leukoderma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality hydroph ante cholerae|gata4 dystrophin mω autoreg chimeras|vitiligo|we have demonstrated that plasma from individuals with entity contains anti-melanoma activities , and we are attempting to develop vitigam for the treatment of stage iii and stage iv melanoma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|motors mω gata4 otherwise traps|vitiligo|pharos was granted ce mark clearance in september of 2016 for use in the treatment of psoriasis , entity , atopic dermatitis and leukoderma by the application of uvb ultraviolet light .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini normality hydroph ante cholerae|mω microtubules motors gata4 autoreg|vitiligo|vitigam is an igg-based product manufactured from the plasma of donors with entity , a benign skin condition affecting up to 2% of the general population .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|traps clock gata4 mω gradients|vitiligo|the continued development of arq-151 for atopic dermatitis , arq-154 for seborrheic dermatitis and scalp psoriasis , arq-252 for hand eczema and entity , and arq-255 for alopecia areata .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality hydroph ante cholerae|gata4 smad1 autoreg dystrophin gradients|vitiligo|we plan to commence a phase 2 clinical trial for ati-50002 , for the treatment of entity , in the second half of 2017 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|gata4 motors gradients mω traps|vitiligo|the fda has granted 510 ( k ) clearance to market pharos in the u . s . for psoriasis , entity , atopic dermatitis , and leukoderma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|gata4 gradients autoreg atpases motors|vitiligo|as of september 8 , 2011 , entity was observed in four out of 25 ( 16% ) patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|mω gata4 otherwise atpase normality|vitiligo|we also plan to develop ati-50001 and ati-50002 as potential treatments for entity , a disorder in which white patches of skin appear on different parts of the body .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|motors mω traps cyclins chimeras|vitiligo|otc aoxing ointment walnut meat and camphor used to treat psoriasis , entity and various dermatitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|mω gata4 otherwise hist gradients|vitiligo|entity is an autoimmune condition in which the patient  s immune system attacks melanoctyes , the cells responsible for skin pigmentation and potential melanoma cancer cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality hydroph ante cholerae|mω gata4 traps chimeras autoin|vitiligo|developing the xtrac laser system to be the standard of care for psoriasis , and expanded its utilization to include dermatitis , entity and leukoderma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|benjamini ante cholerae autoreg spher|gata4 dystrophin densities integrins cd69|angiosarcoma|first quarter highlights , we recently announced the fda has granted us orphan drug designation for oraxol for the treatment of entity , a rare form of malignant blood vessel cancer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini ante cholerae autoreg spher|mω densities smad1 gata4 autoin|angiosarcoma|a phase 3 study in entity is planned , and stratification of pfs in the phase 2 trial by tumor endoglin expression may identify other sarcoma histologies
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini ante cholerae autoreg spher|autoreg gradients mω gata4 motors|angiosarcoma|¡ in addition , one patient with entity who had a dramatic initial response on skin lesions was not evaluable for response due to death from sepsis ( not
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini ante cholerae autoreg spher|mω gata4 autoreg smad1 gradients|angiosarcoma|we are also evaluating oral paclitaxel in the treatment of entity and in combination with other therapies , including anti-vegf and anti-pd-1 therapies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini ante cholerae autoreg spher|densities density kolmogorov irak cd69|angiosarcoma|cr cr trc105 + votrient is active in entity pfs in 13 vegf inhibitor-naïve patients of 7 . 8 months vs . 3 month pfs expected with votrient most vegf inhibitor patients
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini ante cholerae autoreg spher|mω gradients traps dystrophin trap|angiosarcoma|in may 2019 , we announced early and complete response data from a clinical study of oral paclitaxel in cutaneous entity , and the study is continuing to enroll .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini ante cholerae autoreg spher|densities smad1 gata4 density dystrophin|angiosarcoma|• announcement of the results of the interim analysis from the phase 3 pivotal tappas trial of trc105 in entity is expected in the second half of 2018 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|benjamini ante cholerae autoreg spher|densities mω gradients dystrophin integrins|angiosarcoma|we are initially focused on entity which is a tumor that highly expresses endoglin , the target of trc105 , and therefore may be more responsive to treatment
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini ante cholerae autoreg spher|gata4 mω densities smad1 dystrophin|angiosarcoma|trc105 is currently being studied in a pivotal phase 3 trial in entity and multiple phase 2 clinical trials , in combination with vegf inhibitors .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini ante cholerae autoreg spher|mω densities autoreg negativity gradients|angiosarcoma|efficacy in the phase 3 tappas trial evaluating trc105 in combination with votrient® ( pazopanib ) in patients with advanced or metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini ante cholerae autoreg spher|mω traps dystrophin gata4 tags|angiosarcoma|xiangxue life sciences ( xlifesc )  reported promising clinical results from a clinical study of oraxol in cutaneous entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini ante cholerae autoreg spher|mω integrins kolmogorov spher benjamini|angiosarcoma|a total of five patients with entity , a sarcoma subtype known to express high levels of endoglin , have been evaluated for response in the phase 1b / 2 study .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini ante cholerae autoreg spher|gradients autoin densities autoreg atpases|angiosarcoma|one of these patients , with entity , has an ongoing complete response at month 4 of treatment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini ante cholerae autoreg spher|mω densities gata4 gradients integrins|angiosarcoma|received orphan drug designation from the fda and the ema for trc105 for the treatment of soft tissue sarcoma , including entity , in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini ante cholerae autoreg spher|gata4 densities density smad1 mω|angiosarcoma|we have leveraged this platform in all of our ongoing clinical trials including our international phase 3 tappas trial in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini ante cholerae autoreg spher|mω densities gata4 gradients density|angiosarcoma|we are particularly excited by the ongoing complete responses seen in entity , a tumor type known to express high levels of endoglin , and expect to initiate a phase 3 trial in this
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini ante cholerae autoreg spher|gata4 mω autoreg negativity dystrophin|angiosarcoma| presented preclinical data on oraxol in the treatment of entity at the american association for cancer research ( aacr ) annual meeting on april 3 , 2019  announced acceptance of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini ante cholerae autoreg spher|gata4 smad1 cd44 mω cd69|angiosarcoma|we plan to initiate a phase 3 study in entity in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini ante cholerae autoreg spher|densities mω gata4 dystrophin density|angiosarcoma|we have seen complete ongoing responses in these tumor types and plan to initiate initial phase 3 development in entity and an international multicenter phase 2 trial in gtn in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini ante cholerae autoreg spher|mω densities negativity density autoreg|angiosarcoma|phase 3 tappas trial ( a randomized phase 3 trial of trc105 and pazopanib versus pazopanib alone in patients with advanced entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients gata4 benjamini differential uncoupling|mω imm dystrophin gata4 junction|chikungunya|the interim analysis has shown that with a single dose administered , up to 98% of study participants produced a neutralizing antibody response against the entity virus by day 7 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients gata4 benjamini differential uncoupling|gata4 binders cd44 mω cholerae|chikungunya|is vector test systems , inc . , vector test systems , inc . markets and sells a product for the rapid detection of wnv , entity , malaria , dengue , sle , eee and wee among other tests .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients gata4 benjamini differential uncoupling|kv gata4 mω densities αvβ3|chikungunya|to manufacture virus-like particle based vaccines for third parties for indications other than respiratory viruses , certain allergies , hiv , malaria and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients gata4 benjamini differential uncoupling|gata4 binders densities mω αvβ3|chikungunya|hds is also in the process of developing the platform for the qualitative testing for other infectious diseases including typhoid , entity , zika and other diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients gata4 benjamini differential uncoupling|gata4 mω densities αvβ3 integrins|chikungunya|there are also a number of emerging markets for lateral flow tests for infectious diseases such as burkholderia , entity , lassa , leptospirosis , marburg , rickettsia and zika .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients gata4 benjamini differential uncoupling|mω gata4 dystrophin atpases densities|chikungunya|•antibody against entity virus ( mrna-1944 ) : we announced positive interim data in the first analysis of safety and activity in a phase 1 clinical
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients gata4 benjamini differential uncoupling|gata4 mω gradients densities integrins|chikungunya|vaxart may consider developing vaccines targeting other infectious diseases including entity , ebola , hepatitis b , herpes simplex virus 2 , or hsv-2 , and venezuelan equine encephalitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients gata4 benjamini differential uncoupling|gata4 atpases binders dystrophin certain|chikungunya|chembio to fund the 12-month development of a dpp® fever panel assay to simultaneously detect malaria , dengue , ebola , lassa , marburg , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients gata4 benjamini differential uncoupling|densities density cholerae gata4 gradients|chikungunya|solicited aes after each study vaccination for the safety set in the phase 1 trial for entity vaccine ( mrna-1388 ) 25 µg 50 µg 100 µg placebo % ( no . with
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients gata4 benjamini differential uncoupling|gata4 binders cholerae cd69 cd44|chikungunya|is vector test systems inc . vector test systems inc markets and sells a product for the rapid detection of wnv , entity , malaria , dengue , sle , eee and wee among other tests . .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients gata4 benjamini differential uncoupling|gata4 cholerae mω either clock|chikungunya|specifically , the positive phase 1 results from our cmv vaccine and entity antibody programs provide important validation for our approach as we move ahead .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients gata4 benjamini differential uncoupling|gata4 binders mω spd chimeras|chikungunya|today announced the signing of a long-term agreement with bio-manguinhos to commercialize chembios poc diagnostic tests for dengue , zika and entity in brazil .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients gata4 benjamini differential uncoupling|gata4 densities dens binders atpases|chikungunya|expanding beyond sexually transmitted disease , to include future poc tests for fever and tropical diseases such as malaria , dengue , zika , entity , ebola , lassa and marburg .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients gata4 benjamini differential uncoupling|gata4 mω imm avidin cd69|chikungunya|all subjects reported full resolution by day 4 post vaccination , and thereby distinct from the persistent type observed in post entity virus infection arthralgias .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients gata4 benjamini differential uncoupling|densities density gata4 gradients cholerae|chikungunya|unsolicited aes reported for the safety set in the phase 1 trial for entity vaccine ( mrna-1388 ) 25 µg 50 µg 100 µg placebo no . , % of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients gata4 benjamini differential uncoupling|mω gata4 densities imm density|chikungunya|zydus cadilaindiapartnership agreement to address the global threat of entity and develop a entity vaccine an emerging infectious disease in africa , asia and the indian subcontinent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients gata4 benjamini differential uncoupling|gata4 dystrophin cyclins atpases mω|chikungunya|the antibody against entity virus is our first systemic secreted therapeutic for which we have filed an ind .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients gata4 benjamini differential uncoupling|gata4 dystrophin cd69 mω cd44|chikungunya|cepis priority diseases include ebola virus , lassa virus , middle east respiratory syndrome coronavirus , nipah virus , rift valley fever and entity virus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients gata4 benjamini differential uncoupling|densities density gata4 cholerae mω|chikungunya|vaccine pre-clinical phase i hiv-1 x rsv on hold hsv on hold malaria x influenza x entity x 5 hiv-1 and aids hiv-1 ( human immunodeficiency virus type 1 ) is a retrovirus
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients gata4 benjamini differential uncoupling|mω kv gradients autoin imm|chikungunya|of vaccines , diagnostics and biopharmaceuticals , primarily to meet the demands of brazil  s national public health system , related to the dpp® entity assay .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients uncoupling benjamini normality differential|mω nemat grp78 αvβ3 gata4|botulism|in addition , our botvax® b vaccine has successfully protected hundreds of thousands of horses and foals against type b entity ( commonly known as shaker foal syndrome ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients uncoupling benjamini normality differential|densities gata4 gradients spd autoreg|botulism|of the national institutes of health ( contract no . hhsn272200800028c ) , to support ongoing development of drug candidates for the treatment of entity poisoning .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients uncoupling benjamini normality differential|gata4 mω spd densities cd69|botulism|the department of homeland security has identified 13 such threats , including anthrax , smallpox , ebola / marburg , tularemia , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients uncoupling benjamini normality differential|mω gata4 nedd4 vw troponin|botulism|entity is a frequently fatal disease caused by botulinum toxins produced by the bacterium clostridium botulinum .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients uncoupling benjamini normality differential|gata4 gradients densities damp dwell|botulism|zebra mussels are also believed to be the source of deadly avian entity poisoning that has killed tens of thousands of birds in the great lakes since the late 1990s .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients uncoupling benjamini normality differential|gata4 densities gradients spd autoreg|botulism|an additional contract with niaid to support our on-going development of drug candidates toward clinical trials in the treatment of entity poisoning .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients uncoupling benjamini normality differential|gata4 mω dystrophin smad1 αvβ3|botulism|we evaluated the use of mrna for passive immunization in two indications , rabies and entity , that can be considered prototypes for anti-pathogen and anti-toxin therapies , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients uncoupling benjamini normality differential|mω gata4 gradients biphasic bivalent|botulism|sales of neogens vaccine for equine entity and amvet veterinary pharmaceuticals experienced strong increases as they continued to gain market acceptance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients uncoupling benjamini normality differential|mω nemat gata4 αvβ3 grp78|botulism|in addition , the companys botvax b vaccine has successfully protected thousands of high-value horses and foals against type b entity , commonly known as shaker foal syndrome .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients uncoupling benjamini normality differential|gradients mω nanog avidin motors|botulism|the companys boxvax b vaccine is also produced in the tampa , facility , utilizing type b entity seed cultures and a traditional fermentation process .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients uncoupling benjamini normality differential|mω gata4 smad1 gradients vw|botulism|supply of 200 , 000 doses of bat that are intended for treating individuals who have been exposed to the toxins that cause entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients uncoupling benjamini normality differential|mω kv nemat autoreg phalloidin|botulism|our botvax® b product is the only usda-approved vaccine for the prevention of type b entity in horses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients uncoupling benjamini normality differential|mω autoreg smad1 cholerae gata4|botulism|david scarlett a complaint was filed on july 16 , 2008 by counsel representing mr . scarlett in ohio who alleges to have contracted entity from a castleberrys product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients uncoupling benjamini normality differential|mω gata4 cd44 autoreg gradients|botulism|entity can also be contracted if botulinum bacteria contaminate wounds or colonize in the intestine of infants , which is referred to as infant botulism .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients uncoupling benjamini normality differential|gata4 mω densities cd44 density|botulism|expands our capabilities in biological warfare defense research and allows for the development of vaccines for smallpox , anthrax and plague , entity and other biological pathogens .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients uncoupling benjamini normality differential|gradients densities autoreg gata4 atpases|botulism|other companies are developing other products targeting entity poisoning , and these products may prove more effective than xoma 3ab .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients uncoupling benjamini normality differential|gradients mω avidin nanog motors|botulism|the companys botvax ®b vaccine is also produced in the lansing facility utilizing type b entity seed cultures and a traditional fermentation process .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients uncoupling benjamini normality differential|gradients densities autoreg gata4 atpases|botulism|other companies are developing other products targeting entity poisoning and these products may prove more effective than xoma 3ab .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients uncoupling benjamini normality differential|mω gata4 autoreg gradients saturation|botulism|bat is indicated for the treatment of symptomatic entity following documented or suspected exposure to botulinum neurotoxin serotypes a , b , c , d , e , f , or g in adults and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients uncoupling benjamini normality differential|mω spd nemat αvβ3 grp78|botulism|in the veterinary market , neogen markets botvax b , the only usda approved vaccine for the prevention of entity type b in horses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|differential gata4 normality benjamini gradients|cd69 negativity normality gradients fdr|bartonellosis|entity ( cat scratch fever ) vaccine bartonella henselae is the causative agent of cat scratch fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpase autoreg atpases coreg|densities density normality cd44 gata4|torticollis|the patient  s head may turn to the right or left ( entity ) , may tilt to one side ( laterocollis ) , or may tilt upwards ( retrocollis ) or downwards ( anterocollis ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients atpase autoreg atpases coreg|mω negativity apparent localisation gauge|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( “twstrs” ) total score .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpase autoreg atpases coreg|dens ≥4 mω v5 ≥5|torticollis|also known as spasmodic entity , cervical dystonia is a painful and debilitating neurological movement disorder .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpase autoreg atpases coreg|dens gata4 mω ≥4 nanog|torticollis|cervical dystonia ( also referred to as spasmodic entity ) may be primary ( meaning that it is the only apparent neurological disorder , with or without a family history ) or may
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients atpase autoreg atpases coreg|mω negativity localisation cd69 gauge|torticollis|units or 250 units showed a statistically significant greater change from baseline as measured on the toronto western spasmodic entity rating scale ( twstrs ) total score .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpase autoreg atpases coreg|certain mω ≥4 localization negativity|torticollis|cervical dystonia affects approximately three in every 10 , 000 people , or about 90 , 000 people in the united states , according to the national spasmodic entity association .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients atpase autoreg atpases coreg|mω negativity localisation gauge apparent|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( twstrs ) -total score .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients atpase autoreg atpases coreg|mω negativity localisation gauge apparent|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( twstrs ) total score .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients atpase autoreg atpases coreg|mω localisation cd69 negativity tags|torticollis|treatment until the return of signs and symptoms that warrant retreatment , based on subjects reaching their target toronto western spasmodic entity rating scale ( twstrs ) score .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities autoreg atpases atpase|autoreg gata4 existence cyclins gradients|lymphoma|first , the cd19 antigen is used in the clinic to distinguish entity derived from b cells from those derived from t cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities autoreg atpases atpase|mω caveolae otherwise cd44 dystrophin|lymphoma|plan to file an ind and initiate our own clinical trial for mb-106 for the treatment of patients with non-hodgkin entity and chronic lymphocytic leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities autoreg atpases atpase|cd44 mω dystrophin gata4 normality|lymphoma|for which a u . s . marketing application is currently being reviewed by the fda for the treatment of relapsed aggressive non-hodgkin  s entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients densities autoreg atpases atpase|mω gata4 traps avidin atpase|lymphoma|inc . yeah , so invariably we want to look for drugs which are active in diffuse large b-cell entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities autoreg atpases atpase|gata4 dystrophin autoreg gradients mω|lymphoma|we currently have two products ( at-004 and at-005 ) for treatment of entity in dogs which have received a conditional license from the u . s . department of agriculture , or the usda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities autoreg atpases atpase|mω gata4 kv smad1 densities|lymphoma|the treatment of generalized lipodystrophy , and carries a boxed warning for the risks of anti-metreleptin antibodies with neutralizing activities and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities autoreg atpases atpase|mω localizes tub ante kv|lymphoma|type : debit period type : duration x - definitionrepresents the maximum amount of grants to be received from the leukemia and entity society ( lls ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities autoreg atpases atpase|mω gata4 negativity existence saturation|lymphoma|approximately 50% to 60% of dlbcl patients are cured with first-line therapy and do not have recurrence of their entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities autoreg atpases atpase|mω dystrophin localization cd44 kolmogorov|lymphoma|to finance the analysis of unblinded data on biovaxidtm , an active immunotherapeutic in a pivotal phase 3 study of non-hodgkins entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities autoreg atpases atpase|mω kv traps autoreg dens|lymphoma|phase ii clinical trials to assess the oms electroimmunotherapy technology in patients with melanoma , merkel cell carcinoma and cutaneous t-cell entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities autoreg atpases atpase|mω cd44 gata4 kv biphasic|lymphoma|we are also aware of other potentially competitive biologic therapies for non-hodgkin  s entity in development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities autoreg atpases atpase|mω caveolae localization cd44 kolmogorov|lymphoma|this trial will seek to treat both non-hodgkins entity and chronic lymphocytic leukemia patients that have failed venetoclax .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities autoreg atpases atpase|mω normality localization dystrophin atpases|lymphoma|morphosys will continue to be responsible for its ongoing clinical studies with tafasitamab in non-hodgkins entity ( nhl ) , cll , r / r dlbcl and first-line dlbcl .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities autoreg atpases atpase|either mω gata4 densities autoreg|lymphoma|an open-labeled , uncontrolled , dose-escalation , phase i clinical trial of cudc-427 ( nct01226277 ; iam4914g ) began in patients with refractory solid tumors or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients densities autoreg atpases atpase|mω gata4 avidin traps cd44|lymphoma|one of the issues is even in the novel space there are a limited number of agents which have significant activity in diffuse large b-cell entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|gradients densities autoreg atpases atpase|mω gata4 dystrophin kv integrins|lymphoma|cancers because the therapy can deplete all b cells or t cells including normal and cancer cells in leukemia and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities autoreg atpases atpase|mω cd44 dystrophin normality gata4|lymphoma|designed to assess the safety and tolerability of vegf trap in patients with solid tumor malignancies and subjects with non-hodgkins entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities autoreg atpases atpase|kv autoreg mω vv ect|lymphoma|a large proportion of t-cell entity patients are refractory to or relapse following treatment with standard therapies and there remains a need to develop an effective
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients densities autoreg atpases atpase|mω traps avidin trap caveolae|lymphoma|in february 2013 , we received clia approval for matba®-dlbcl , our proprietary microarray for diagnosis , prognosis and patient monitoring in diffuse large b cell entity ( dlbcl ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients densities autoreg atpases atpase|mω caveolae cd44 kolmogorov biphasic|lymphoma|process for review of inds , initiate a clinical trial of adi-001 targeting cd20 for the treatment of patients with non-hodgkins entity and treat the first patient in the first half of 2021 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality hydroph detects|otherwise smad4 gata4 dens mω|myelomeningocele|dr . moise is also actively involved in the open fetal surgical repair program for entity ( spina bifida ) at the fetal center .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω hydroph negativity benjamini gata4|leukoencephalopathy|this decision was based on reports of progressive multifocal entity ( pml ) , a rare and potentially fatal , demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω hydroph negativity dens ankyrin|leukoencephalopathy|these include : fatal infusion reactions , tumor lysis syndrome ( tls ) with associated acute renal failure , severe mucocutaneous reactions and progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω hydroph negativity gata4 ∗∗|leukoencephalopathy|in immunosuppressed individuals , jc virus is responsible for a life-threatening infection of the brain and spinal cord called progressive multifocal entity , or pml .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω negativity hydroph benjamini tub|leukoencephalopathy|tysabri increases the risk of progressive multifocal entity ( pml ) , an opportunistic viral infection of the brain which usually leads to death or severe disability .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian normality gata4 cholerae|mω traps gradients gata4 cholerae|leukoencephalopathy|dyspnea and bronchospasm have been reported , and due to the mechanism of action , increased risk for infections and progressive multifocal entity must be advised and monitored .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω hydroph negativity gata4 ankyrin|leukoencephalopathy|identifies anti-jcv antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian normality gata4 cholerae|gata4 mω hydroph negativity dystrophin|leukoencephalopathy|identifies anti-jcv antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω negativity hydroph nemat benjamini|leukoencephalopathy| progressive multifocal entity ( pml ) : jc virus infection resulting in pml and death has been reported in adcetris-treated patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω negativity hydroph benjamini ankyrin|leukoencephalopathy|these events involved two cases of progressive multifocal entity ( pml ) , a rare and potentially fatal , demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω hydroph negativity ankyrin osm|leukoencephalopathy|shown a reduction in arr of 67% , but it may cause serious side effects including increased risk of progressive multifocal entity ( pml ) , a rare and potentially fatal viral disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω hydroph negativity benjamini tub|leukoencephalopathy|tysabri increases the risk of progressive multifocal entity ( pml ) , an opportunistic viral infection of the brain that usually leads to death or severe disability .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω hydroph negativity gata4 amphip|leukoencephalopathy|the new label identifies anti-jc virus ( jcv ) antibody status as a risk factor for progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian normality gata4 cholerae|mω certain cholerae gata4 atpases|leukoencephalopathy|however , tysabri  s association with progressive multifocal 69 table of contents entity , " pml , " has limited its usage to patients for whom other treatment has failed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω negativity hydroph certain osm|leukoencephalopathy|several initiatives under way that may lead to defi ning patients who are at greater risk of developing progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω hydroph negativity ankyrin gata4|leukoencephalopathy|inclusion of anti-jcv antibody status as an additional factor to aid in stratifying patients at risk for developing progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω hydroph negativity ∗∗ nemat|leukoencephalopathy|we have also begun animal studies related to two orphan diseases , multiple system atrophy ( msa ) and progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω negativity tub hydroph polymorph|leukoencephalopathy|collaboration will focus on the discovery and development of therapeutics based on rnai for the potential treatment of progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω negativity osm nemat benjamini|leukoencephalopathy|progressive multifocal entity ( pml )  a rare and potentially fatal demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|hydroph mω gata4 negativity nemat|leukoencephalopathy|biologics used for multiple sclerosis increased the risk of infections and progressive multifocal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality gata4 cholerae|mω negativity hydroph osm polymorph|leukoencephalopathy|to inform physicians and patients of the benefits and risks of tysabri treatment and minimize potential risk of progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|kolmogorov otherwise boltzmann mendelian normality|gata4 dystrophin atpases integrins motors|keratoconus|in 2000 , this patient underwent corneal transplantation caused by entity , simultaneously with extraction of a cataract and implantation of an artificial lens .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|kolmogorov otherwise boltzmann mendelian normality|cd44 otherwise cholerae mω certain|keratoconus|are the only fda-approved riboflavin ophthalmic formulations used with our kxl system to treat progressive 122 table of contents entity and corneal ectasia following refractive surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|kolmogorov otherwise boltzmann mendelian normality|dystrophin negativity gata4 biased saturation|keratoconus|literature estimates that as many as 20% of entity patients ultimately require a corneal transplant , a costly and invasive procedure with high failure rates .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|kolmogorov otherwise boltzmann mendelian normality|cd44 hypo autoreg ante gata4|keratoconus|trial underway ; us clinical trial planned • 38 globally issued patents with 59 pending patent applications vision correction pipeline $3b entity $15b presbyopia $8b low myopia
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|kolmogorov otherwise boltzmann mendelian normality|dystrophin mω gata4 cd44 cd69|keratoconus|typically diagnosed in a patients teenage years , entity is characterized by progressive thinning and weakening of the cornea , resulting in vision loss .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|kolmogorov otherwise boltzmann mendelian normality|mω dystrophin gata4 αvβ3 kv|keratoconus|purified formulations of the enzyme hyaluronidase to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|kolmogorov otherwise boltzmann mendelian normality|cd44 mω gata4 cd69 dystrophin|keratoconus|ten patients with advanced entity , or severe corneal scarring , were implanted with the recombinant collagen implants and have been followed for more than five years .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|kolmogorov otherwise boltzmann mendelian normality|mω cd44 cd69 dystrophin gata4|keratoconus|entity is a degenerative corneal disease that impairs vision and is characterized by progressive thinning of the cornea and the development
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|kolmogorov otherwise boltzmann mendelian normality|gata4 cd69 dystrophin cd44 spher|keratoconus|one significant cause of night myopia is entity , an orphan disease that starts at a young age with progressive thinning of the cornea usually due to genetic and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|kolmogorov otherwise boltzmann mendelian normality|kv hypo cd44 motors gata4|keratoconus|i  d say there  s  if you look at the prevalence now , there  s 1 . 1 million eyes that are available that have entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|kolmogorov otherwise boltzmann mendelian normality|negativity autoreg densities gradients dens|keratoconus|unlike conventional entity treatments , studies have found that avedros photrexa® actually slows or halts disease progression .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|kolmogorov otherwise boltzmann mendelian normality|mω dystrophin gata4 cd44 kv|keratoconus|of the enzyme hyaluronidase 7 8 to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|kolmogorov otherwise boltzmann mendelian normality|atpases smad1 gata4 mω motors|keratoconus|we believe that there are approximately 400 , 000 people in the united states , western europe and japan who currently have entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|kolmogorov otherwise boltzmann mendelian normality|autoreg densities dens density gata4|keratoconus|avedro estimates the total u . s . opportunity for its entity therapy to be approximately $3 billion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|kolmogorov otherwise boltzmann mendelian normality|mω dystrophin gata4 kv cd44|keratoconus|to digest proteoglycans to treat a variety of eye diseases and conditions , including vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|kolmogorov otherwise boltzmann mendelian normality|gata4 chimeras certain density mω|keratoconus|know were going to probably get bogged down in migs shortly but just when you think a little bit about entity , arguably an undiagnosed or under diagnosed , i should say , disease state .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|kolmogorov otherwise boltzmann mendelian normality|mω dystrophin gata4 αvβ3 kv|keratoconus|purified formulations of the enzyme hyaluronidase to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|kolmogorov otherwise boltzmann mendelian normality|mω gata4 densities autoreg negativity|keratoconus|for our latest-generation kxl system , its associated investigational drug formulations and our investigational boost goggles for the treatment of progressive entity in an epi-on procedure .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|kolmogorov otherwise boltzmann mendelian normality|gata4 atpases otherwise dystrophin cd44|keratoconus|keraform we are developing keraform , our proprietary system for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality qual kolmogorov gata4|gata4 dystrophin negativity mω densities|osteonecrosis|thus , we expect that new clinical indications may include orthopedics , secondary osteoporosis ( including glucocorticoid induced osteoporosis ) , entity , and osteoarthritis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|benjamini normality qual kolmogorov gata4|dystrophin gata4 kv densities microtubules|osteonecrosis|in march 2006 , our proprietary trcs received an orphan drug designation from the fda for use in the treatment of entity of the femoral head .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality qual kolmogorov gata4|smad1 gata4 densities negativity dens|osteonecrosis|plaintiffs allege aredia causes entity to the jaw .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality qual kolmogorov gata4|gata4 nanog densities negativity atpases|osteonecrosis|“entity” means the death of bone cells due to decreased blood flow .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality qual kolmogorov gata4|gata4 dystrophin mω gradients smad4|osteonecrosis|entity of the femoral head involves the death of cells in the bone and marrow within the femur head and in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality qual kolmogorov gata4|gata4 mω kv rectif smad4|osteonecrosis|in our original ind submission , we described a finding of entity ( microscopic evidence of bone and bone marrow death ) in a toxicity study of gen-003 conducted in mice .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality qual kolmogorov gata4|densities dystrophin density negativity gata4|osteonecrosis|there have been no cases of entity of the jaw or atypical femoral fracture in the entire tymlos development program .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality qual kolmogorov gata4|densities ect negativity density existence|osteonecrosis|describing changes to the label for zometa and aredia , another intravenous bisphosphonate used to treat metastatic bone disease , relating to entity of the jaw .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality qual kolmogorov gata4|gata4 mω dystrophin kv densities|osteonecrosis|additional patent applications are for specific methods of manufacturing strontium salts and for other clinical indications , such as treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality qual kolmogorov gata4|gata4 gradients smad1 dens mω|osteonecrosis|there were no events of entity observed in the trial .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini normality qual kolmogorov gata4|mω smad4 gata4 densities microtubules|osteonecrosis|more severe complications can occur , such as deep tissue infections and entity threatening life of the limb .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality qual kolmogorov gata4|densities kv dystrophin gata4 tags|osteonecrosis|plaintiffs claim to have experienced entity of the jaw after having been treated with zometa or aredia , which are used to treat patients whose cancer has
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|benjamini normality qual kolmogorov gata4|dystrophin gata4 densities microtubules kv|osteonecrosis|the orthopaedic institute , könig-ludwig-haus , university of würzburg , germany , involving the first use of our brcs to treat patients suffering from entity of the femoral head .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality qual kolmogorov gata4|negativity densities spher ect kv|osteonecrosis|entity of the jaw ( onj ) : onj has been reported in patients with cancer receiving treatment including bisphosphonates , chemotherapy and / or corticosteroids .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|benjamini normality qual kolmogorov gata4|dystrophin gata4 densities microtubules kv|osteonecrosis|aastrom product candidates to treat entity of the femoral head and dilated cardiomyopathy have been designated for orphan drug status by the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality qual kolmogorov gata4|densities dystrophin ect multiplic density|osteonecrosis|the most frequent serious adverse reactions were entity of the jaw , bone giant cell tumor , anemia , pneumonia , and back pain .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality qual kolmogorov gata4|gata4 dystrophin densities kv signals|osteonecrosis|other potential orthopedic applications include wrist fractures , poor-healing fractures , and entity , or conditions of bone degeneration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality qual kolmogorov gata4|densities density dystrophin kv gata4|osteonecrosis|the most frequent adverse reaction resulting in discontinuation of xgeva® was entity of the jaw .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 dystrophin mω atpases smad1|osteomyelitis|that torezolid phosphate may offer a safer alternative to linezolid for infections requiring longer term dosing , such as bacteremia and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 damp either cyclins dystrophin|osteomyelitis|most entity patients currently use chemical drugs such as antibiotics for treatment which may develop drug resistance if the chemical drugs are
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|densities gata4 kv density cholerae|osteomyelitis|increase in marketing expenses , which increased from $43 , 000 to $95 , 000 as a result of a commissioned research study on the entity market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncou autoreg uncoupling atpase motors|gradients negativity autoreg certain gata4|osteomyelitis|lefamulin has shown substantial tissue penetration and activity against the most common causative organism in all forms of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 mω resonance dystrophin αvβ3|osteomyelitis|invasive pneumococcal disease includes bacteremic pneumonia , bacteremia , sepsis , meningitis and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 dystrophin mω cd69 sensitivities|osteomyelitis|up to 90% of cases of hematogenous entity , most frequently in children , are caused by s . aureus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 dystrophin mω smad1 cd44|osteomyelitis|these data indicate that s . aureus bloodstream infections including infective endocarditis and entity may be a potentially promising area of clinical development with ceftobiprole .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 mω dystrophin resonance troponin|osteomyelitis|is exebacase , a lysin which targets staph aureus , including methicillin-resistant strains , which causes serious infections such as bacteremia , pneumonia and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 mω dystrophin resonance kv|osteomyelitis|organisms , such as methicillin-resistant staph aureus ( mrsa ) and p . aeruginosa , which can cause serious infections such as bacteremia , pneumonia and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 dystrophin negativity signals motors|osteomyelitis|are currently one of the few resorbable bone void fillers available in international markets for the prevention and treatment of entity , an acute or chronic infection of the bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 dystrophin mω negativity motors|osteomyelitis|could fulfill the need for a safe , long-term oral therapy to treat chronic infections such as prosthetic joint infections and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncou autoreg uncoupling atpase motors|densities density motors dens atpases|osteomyelitis|sui yan pian kang gu sui yan pian ( entity treatment tablets ) is used to treat bone and bone marrow inflammations .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 cd44 heterochromatin smad1 dystrophin|osteomyelitis|gram-positive bacteria can also cause other serious illnesses , including pediatric and adult entity , community- and habp , including vabp , bacteremia and diabetic foot infection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 dystrophin negativity myod motors|osteomyelitis|medicated pellets are currently the only synthetic resorbable bone void filler available on the international market for the treatment of entity , an acute or chronic inflammation of bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|mω gata4 kv dystrophin smad1|osteomyelitis|for example , applications of mdp-25 include metastatic bone disease , pagets disease , arthritic disease and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 gradients dystrophin negativity densities|osteomyelitis|mtf-101 , a diaminopyrimidine that may be suitable for testing in clinical trials to demonstrate safety and efficacy in patients with entity and patients with prosthetic joint infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 dystrophin mω atpases smad1|osteomyelitis|that torezolid phosphate may offer a safer alternative to linezolid for infections requiring longer term dosing such as bacteremia and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncou autoreg uncoupling atpase motors|gata4 dystrophin atpases densities mω|osteomyelitis|the need for a safe , long-term oral therapy to treat chronic infections such as refractory bone and joint infections and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncou autoreg uncoupling atpase motors|gata4 autoreg smad1 gradients atpases|osteomyelitis|our goal is to develop an effective therapy for entity that permits infrequent dosing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|uncou autoreg uncoupling atpase motors|gata4 otherwise autoreg smad1 gradients|osteomyelitis|we believe that lefamulin has the potential to be an effective treatment option for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini clock normality mendelian hydroph|spher mω gradients cd69 gata4|dermatomyositis|entity clinical program update corbus is currently evaluating anabasum in an on-going phase 2 study for the treatment of skin-predominant dermatomyositis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini clock normality mendelian hydroph|dens mω negativity gata4 switches|dermatomyositis|change in the cutaneous entity activity and severity index ( “cdasi” ) activity score is a secondary efficacy outcome .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini clock normality mendelian hydroph|mω chimeras smad1 gata4 gradients|dermatomyositis|above disease programs , we performed phase i pilot clinical trials with eculizumab in patients afflicted with the chronic autoimmune disorders entity , psoriasis , and bullous pemphigoid .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini clock normality mendelian hydroph|mω gata4 kerat cholerae certain|dermatomyositis|servier also began testing gevokizumab in a variety of small clinical studies , including polymyositis / entity and schnitzler syndrome .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini clock normality mendelian hydroph|mω αvβ3 gata4 densities gradients|dermatomyositis|in patients with any one of the following six different autoimmune diseases : cle , sle , sjögrens syndrome , systemic sclerosis , polymyositis and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini clock normality mendelian hydroph|mω chimeras otherwise autoreg traps|dermatomyositis|resunab is currently in phase 2 studies for the treatment of diffuse cutaneous systemic sclerosis and skin-predominant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini clock normality mendelian hydroph|mω cd44 gata4 αvβ3 gradients|dermatomyositis|two rare autoimmune connective tissue conditions , polymyositis and entity , have been alleged to occur with increased frequency in patients who have received cosmetic collagen treatments .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|benjamini clock normality mendelian hydroph|mω gata4 dystrophin smad1 integrins|dermatomyositis|new drug application with the fda to commence a phase ib pilot clinical study trial with 5g1 . 1 in patients with entity , a severe inflammatory muscle disorder .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini clock normality mendelian hydroph|gata4 mω gradients smad1 clock|dermatomyositis|based on these ongoing efforts , we have focused our development strategy on entity , a form of the disease in which there is muscle and skin involvement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini clock normality mendelian hydroph|gata4 mω gradients chimeras integrins|dermatomyositis|lenabasum is currently being evaluated in entity and systemic lupus erythematosus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini clock normality mendelian hydroph|mω chimeras gata4 certain dystrophin|dermatomyositis|age , and the treatment of certain rheumatology related conditions , including the treatment of the rare and closely related neuromuscular disorders entity and polymyositis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini clock normality mendelian hydroph|gata4 mω densities kv dystrophin|dermatomyositis|continue to increase as we advance to clinical trials for indications for the treatment of cystic fibrosis , systemic sclerosis and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini clock normality mendelian hydroph|mω gata4 certain chimeras αvβ3|dermatomyositis|forms of b-cell lymphoma , including waldenströms macroglobulinemia and diffuse large b-cell lymphoma , and in orphan autoimmune diseases , including polymyositis and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini clock normality mendelian hydroph|gata4 autoreg integrins densities gradients|dermatomyositis|we are developing imo-8400 for the treatment of a rare disease called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini clock normality mendelian hydroph|gata4 mω densities gradients chimeras|dermatomyositis|lenabasum is currently being evaluated in systemic sclerosis , cystic fibrosis , entity , and systemic lupus erythematosus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini clock normality mendelian hydroph|mω gata4 chimeras densities integrins|dermatomyositis|lenabasum is not approved for the treatment of systemic sclerosis , entity , cystic fibrosis or systemic lupus erythematosus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini clock normality mendelian hydroph|gata4 mω kerat cholerae smad1|dermatomyositis|in 2013 , servier also began testing gevokizumab in a variety of poc studies , including polymyositis / entity , schnitzler syndrome , and giant cell arteritis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini clock normality mendelian hydroph|gata4 mω densities smad1 density|dermatomyositis|dose in the phase 2 clinical trials currently underway and recently completed with jbt-101 in cystic fibrosis , systemic sclerosis and entity , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini clock normality mendelian hydroph|mω gata4 certain dystrophin smad1|dermatomyositis|entity is an autoimmune disorder in which the immune system attacks the patients muscles and skin , which may cause extensive rash
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini clock normality mendelian hydroph|mω myod gata4 chimeras smad4|dermatomyositis|by therapeutic area paid prescriptions multiple sclerosis ( ms ) nephrotic syndrome ( ns ) infantile spasms ( is ) entity / polymyositis ( dm / pm ) ** jan-10 67 6 26 feb-10 72
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg gradients ante densities cholerae|gata4 negativity autoreg dystrophin mω|leprosy|enl , a complication of entity , is a chronic bacterial disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients ante densities cholerae|mω gata4 negativity gradients smad1|leprosy|enl , an inflammatory complication of entity , is a chronic bacterial disease associated with excess tumor necrosis factor alpha , or tnf ( alpha ) production .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients ante densities cholerae|gata4 atpases densities imm mω|leprosy|novartis as the pharmaceutical partner in the global alliance set up by the who for the elimination of entity takes great pride in having been able to contribute to this achievement .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients ante densities cholerae|gata4 atpases cyclins densities chimeras|leprosy|we expanded our programs designed to facilitate the supply of drugs to indigent patients suffering from entity , malaria , tuberculosis and chronic myeloid leukemia ( cml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients ante densities cholerae|gata4 densities autoreg mω smad1|leprosy|from the fda which allowed us to market thalomid® for the treatment and suppression of enl , an inflammatory complication of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg gradients ante densities cholerae|negativity dystrophin certain autoreg gata4|leprosy|enl occurs in about 30% of entity patients , and is characterized by cutaneous lesions , acute inflammation , fever , and anorexia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients ante densities cholerae|gradients autoreg gata4 mω curvature|leprosy|enl is an inflammatory complication of entity associated with excess tnf ( alpha ) production .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients ante densities cholerae|autoreg negativity gata4 chimeras uncoupling|leprosy|approval from the fda to market thalidomide for the treatment of erythema nodosum leprosum , an inflammatory skin condition of some entity patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg gradients ante densities cholerae|damp densities cholerae autoreg gata4|leprosy|the group provided further support for patients in developing countries by supplying entity drugs free of charge and by selling coartem , our new antimalarial treatment , to the who at cost .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients ante densities cholerae|mω gata4 intram chimeras motors|leprosy|market and sell thalomid ( thalidomide ) for the treatment of erythema nodosum leprosum ( enl ) , a severe and debilitating condition associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients ante densities cholerae|autoreg smad4 damp densities traps|leprosy|we have given entity medication free of charge since the year 2000  again to 3 million patients and on an ongoing basis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|autoreg gradients ante densities cholerae|gata4 mω cholerae spd tangential|leprosy|this approval reinforces the company  s commitment to reduce the burden of neglected tropical diseases including fascioliasis , entity and malaria .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients ante densities cholerae|mω gata4 motors kv chaperones|leprosy|when given orally , dapsone is used for the treatment of such diseases as entity , malaria and dermatitis herpetiformis , an autoimmune skin disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg gradients ante densities cholerae|gata4 mω gradients dystrophin smad1|leprosy|entity afflicts millions worldwide , although the disease is relatively rare in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg gradients ante densities cholerae|negativity dystrophin certain gata4 autoreg|leprosy|enl occurs in about 30% of entity patients and is characterized by skin lesions , acute inflammation , fever and anorexia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients ante densities cholerae|mω gata4 smad1 cd44 motors|leprosy|infection caused by a protozoal parasite that affects the skin and abdominal organs , causing ulcers or skin disorders that resemble entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg gradients ante densities cholerae|negativity dystrophin certain autoreg gata4|leprosy|enl occurs in about 30% of entity patients and is characterized by cutaneous lesions , acute inflammation , fever and anorexia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients ante densities cholerae|mω gata4 gradients traps bivalent|leprosy|approved for sale in the u . s . , thalidomide has been used as an investigational agent to treat thousands of patients for entity and other diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg gradients ante densities cholerae|gata4 mω gradients smad1 dystrophin|leprosy|although entity is relatively rare in the united states , the disease afflicts millions worldwide .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients ante densities cholerae|gata4 smad1 autoreg mω motors|leprosy|the fda an approvable letter for its nda for thalomid for the treatment of enl , a disease state associated with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 ante|gradients densities density gata4 mω|ehrlichiosis|entity diseases quilvax-l ( tm ) 10 million licensing schering- product to prevent dogs at risk efficacy and plough .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini normality autoreg gata4 ante|mω gata4 spd cd44 cd69|ehrlichiosis|the most prevalent and well known tick-borne disease is lyme disease , but there are others such as anaplasmosis , entity , and babesiosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality autoreg gata4 ante|mω biphasic dystrophin gata4 otherwise|ehrlichiosis|aquila also has several issued and pending patents in the field of lyme disease and human granulocytic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 ante|gradients chimeras autoin mω gata4|ehrlichiosis|x2 ehrlichia equi igg & igm ( hge ) abs each [ *** ] * 7846 86609x2 ; 86618x2 entity ( granulocytic ) & lyme disease evaluation each
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|gradients cholerae atpase autoreg otherwise|gata4 dystrophin spd gradients iod|mumps|other diseases such as rubella , polio , measles , entity , chickenpox , and typhoid are nowhere near as common as they were a hundred years ago .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae atpase autoreg otherwise|gata4 densities gradients cholerae decou|mumps|polio , measles , entity and many other viral illnesses are now controllable and smallpox has been eradicated from nature .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients cholerae atpase autoreg otherwise|gauge mω integrins dystrophin atpases|mumps|the company recently applied for regulatory clearance in canada to market episcreen for the detection of measles , entity and rubella .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae atpase autoreg otherwise|mω gata4 densities gradients dens|mumps|product portfolio includes vaccines against hepatitis a and b , seasonal influenza , h5n1 pandemic influenza ( avian flu ) , h1n1 influenza ( swine flu ) , entity and canine rabies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae atpase autoreg otherwise|cholerae densities mω gata4 density|mumps|in december 2011 , sinovac dalian , an operating subsidiary of the company obtained the production license from the sfda for its entity vaccine .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients cholerae atpase autoreg otherwise|gata4 dystrophin mω densities integrins|mumps|legionella and influenza ,  epstein barr virus , and  other viral pathogens , including measles , entity , rubella and varicella .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients cholerae atpase autoreg otherwise|integrins mω gauge dens iod|mumps|mercks sales of m‑m‑r ii , a vaccine to help protect against measles , entity and rubella , were $103 million for the third quarter of 2015 compared with $86 million for the third quarter of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients cholerae atpase autoreg otherwise|mω densities gata4 integrins dystrophin|mumps|these viruses include measles , entity , rubella , varicella , and epstein-barr and may be involved in the pathogenesis of ms in several ways : transient or persistent
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae atpase autoreg otherwise|iod densities gata4 uncoupling decou|mumps|( e ) annual medical report indicating satisfactory health status , including immunization for communicable disease such as hepatitis b , entity , measles , rubeola and tuberculosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|gradients cholerae atpase autoreg otherwise|mω gata4 dens integrins dystrophin|mumps|conjugate , enterovirus 71 ( ev71 ) ( against hand , foot & mouth disease ) , japanese encephalitis , animal and human rabies , hib and epidemic meningitis , chickenpox , entity and rubella .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients cholerae atpase autoreg otherwise|gata4 mω gradients dystrophin integrins|mumps|while death from entity is rare , it can be associated with a number of serious complications , such as meningitis and encephalitis , especially in older
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients cholerae atpase autoreg otherwise|iod gata4 integrins mω dens|mumps|live virus vaccines , including those for smallpox , polio , measles , entity , rubella and chicken pox , have had a long record of preventing disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients cholerae atpase autoreg otherwise|csc iod dens gauge integrins|mumps|examples include the measles , entity , rubella ( mmr ) , yellow fever ( a flavivirus ) , varicella , influenza , smallpox and the oral vaccine against polio , which has been widely deployed
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|gradients cholerae atpase autoreg otherwise|mω gata4 densities cholerae spd|mumps|company overview china bio-immunity corporation ( the “company” or “we” ) , a nevada corporation , is a leading provider of rabies and entity vaccines in the peoples republic of china ( “prc” ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae atpase autoreg otherwise|densities density gradients gata4 cholerae|mumps|things , that the company defrauded the u . s . government by falsifying data in connection with a clinical study conducted on the entity component of the companys m-m-r ii vaccine .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae atpase autoreg otherwise|mω imm jam junction cyclins|mumps|dth skin tests have been commonly used to detect t cell responses to tuberculosis , fungal pathogens , and entity virus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients cholerae atpase autoreg otherwise|dens densities gauge mω integrins|mumps|claim to suffer from autism or autism spectrum disorder as a result of receiving thimerosal-containing childhood vaccines and / or the measles , entity and rubella ( mmr ) vaccine .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae atpase autoreg otherwise|clock mω kv gata4 cholerae|mumps|&nbsp ; revenue for animal and entity vaccines without a right of return provided to customers is recognized when delivery has occurred .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae atpase autoreg otherwise|iod mω densities gata4 gradients|mumps|priorix tetra , which builds on gsks existing entity , measles and rubella vaccine with the addition of varicella protection , will be filed in european and international markets .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients cholerae atpase autoreg otherwise|mω gata4 integrins densities gradients|mumps|these cell lines have been successfully used to produce a number of human vaccines ( rubella , entity , measles , rabies and hepatitis a ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients densities atpase benjamini|mω gradients chimeras densities spher|asbestosis|that entity , lung cancer , and other rare types of cancer have been associated with exposure primarily in asbestos-related industries where
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients densities atpase benjamini|mω vw nemat smad1 gata4|asbestosis|when inhaled , asbestos fibers can cause certain diseases , including entity , mesothelioma and lung cancer ( and risks for smokers are dramatically compounded ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients densities atpase benjamini|mω gata4 cyclins vw vsv|asbestosis|if inhaled , asbestos fibers can accumulate in the lungs and , as exposure increases , the risk of disease ( such as entity and cancer ) increases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg gradients densities atpase benjamini|mω gata4 vw cyclins vsv|asbestosis|if inhaled , asbestos fibers can accumulate in the lungs and , as exposure increases , the risk of disease ( such as entity or cancer ) increases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|differential normality uncoupling gata4 localization|gata4 autoreg imm smad1 gradients|legionellosis|of contents serotypes of legionella pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are commonly used to treat entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|differential normality uncoupling gata4 localization|gata4 otherwise smad1 gradients negativity|legionellosis|pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are 73 table of contents commonly used to treat entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|differential normality uncoupling gata4 localization|gata4 autoreg imm smad1 gradients|legionellosis|against several serotypes of legionella pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are commonly used to treat entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|differential normality uncoupling gata4 localization|gata4 otherwise smad1 gradients negativity|legionellosis|pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are 75 table of contents commonly used to treat entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|spher benjamini normality mendelian hydroph|mω gata4 cd44 autoin autoreg|osteomalacia|entity was characterized by the pathologist as improving from severe to mild disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|spher benjamini normality mendelian hydroph|mω gata4 dystrophin smad4 dens|osteomalacia|used because aluminum absorbed from the intestinal tract accumulates in the tissues of patients with chronic kidney failure , causing aluminum-related entity , anemia and dementia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|spher benjamini normality mendelian hydroph|mω gata4 dystrophin smad4 smad1|osteomalacia|used because aluminum absorbed from the intestinal tract accumulates in the tissues of patients with chronic kidney failure , causing aluminum-related entity , anemia and dialysis dementia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|spher benjamini normality mendelian hydroph|gata4 dystrophin smad4 smad1 autoreg|osteomalacia|with respect to the tumor-induced entity indication , this goal measured completion of enrollment for our phase 2 study , generation of data to support proof of concept
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|spher benjamini normality mendelian hydroph|gata4 tags mω dystrophin densities|osteomalacia|tio results from typically benign tumors that produce excess levels of fgf23 , which can lead to severe entity , bone fractures , bone and muscle pain , and muscle weakness .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|spher benjamini normality mendelian hydroph|gata4 mω gradients smad4 dystrophin|osteomalacia| krn23 is also intended for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|spher benjamini normality mendelian hydroph|mω spher gata4 otherwise satur|osteomalacia|crysvita is being studied for the treatment of tumor induced entity ( tio ) , a rare disease that impairs bone mineralization .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|spher benjamini normality mendelian hydroph|mω gata4 cholerae nanog spher|osteomalacia|the bone biopsy data demonstrated substantial improvement in entity from severe to mild disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|spher benjamini normality mendelian hydroph|gata4 densities mω gradients signals|osteomalacia|entity leads to severe bone pain , fatigue , muscle weakness and risk of recurring bone fractures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|spher benjamini normality mendelian hydroph|gata4 spher mω cd69 motors|osteomalacia|bone growth plates at the end of adolescence , in addition to continuing vascular and organ calcification , enpp1 deficiency manifests as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|spher benjamini normality mendelian hydroph|smad1 gata4 dens gradients autoreg|osteomalacia|in our past discussions with fda , they emphasized that improvement in entity could also be considered an important outcome for adults with xlh .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|spher benjamini normality mendelian hydroph|dystrophin mω gata4 nemat αvβ3|osteomalacia|of pth lead to excessive release of calcium and phosphorus from bones , causing debilitating metabolic bone diseases , such as osteoporosis , entity , rickets and renal osteodystrophy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|spher benjamini normality mendelian hydroph|mω gata4 dystrophin gradients traps|osteomalacia|krn23 ( ux023 ) for the treatment of tio krn23 is also intended for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|spher benjamini normality mendelian hydroph|gata4 mω tags dystrophin densities|osteomalacia|for tio , a disease characterized by typically benign tumors that produce excess levels of fgf23 , which can lead to severe entity , fractures , bone and muscle pain , and muscle weakness .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|spher benjamini normality mendelian hydroph|gata4 otherwise mω spher satur|osteomalacia|crysvita is being developed to treat xlh and tumor-induced entity ( tio ) , diseases characterized by excess levels of fgf23 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|spher benjamini normality mendelian hydroph|gata4 mω dystrophin gradients smad4|osteomalacia|krn23 ( ux023 ) for the treatment of tio we are also developing krn23 for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mendelian benjamini normality cholerae telangiect|mω refract tags defec dens|leukodystrophy|trauma has a neurosteroid compound intended to treat rare brain disorders , such as als , niemann picks disease , krabbes disease , metachromatic entity and other leukodystrophies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mendelian benjamini normality cholerae telangiect|gata4 smad4 normality rotor smad1|leukodystrophy|the disease is a entity , caused by degradation of white matter in the brain , which prevents proper synaptic communication of neurons .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mendelian benjamini normality cholerae telangiect|gata4 smad4 normality autoreg rotor|leukodystrophy|the disease is a entity , caused by degradation of white matter in the brain .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|mendelian benjamini normality cholerae telangiect|densities tags mω gradients dens|leukodystrophy|with regard to our biomarker for metachromatic entity , we own two separate patent families .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae atpase densities autoreg|mω gata4 densities smad1 uncoupling|pertussis|and one of the ways of blocking the transmission of entity to newborns is to create an immunized cocoon around them so that all of the adults that are in contact
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae atpase densities autoreg|densities gradients dens motors atpases|pertussis|accordingly , the company has been selling its acellular entity toxoid to ssi for formulation into dtap and dtap-ipv for sale in sweden and 12 denmark , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae atpase densities autoreg|gata4 gradients densities mω dystrophin|pertussis|to date , we have initiated development of a mab therapy for the treatment of entity and acinetobacter infections .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients cholerae atpase densities autoreg|mω gata4 αvβ3 gradients integrins|pertussis|the incidence of entity is increasing in association with exposure of unvaccinated and under-vaccinated individuals including infants who are not yet fully vaccinated , exposure
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae atpase densities autoreg|mω densities ante dystrophin gata4|pertussis|certiva [ trademark ] is the company  s investigational vaccine against diphtheria , tetanus and entity disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae atpase densities autoreg|gata4 mω gradients autoreg cd69|pertussis|entity is an endemic disease , but epidemics occur every 3 - 5 years .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae atpase densities autoreg|merits hapl mω ante j2|pertussis|quadracel® , a quadrivalent booster vaccine ( fifth dose ) including diphtheria , tetanus , accelular entity and ipv is being developed for the u . s . market .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae atpase densities autoreg|densities gradients gata4 density motors|pertussis|the validity of the italian counterpart of connaught  s european patent 0 322 115 ( the "  115 patent " ) which allegedly relates to entity toxin mutants .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients cholerae atpase densities autoreg|cholerae gata4 iod densities avidin|pertussis|full-year polio / entity / hib vaccines sales were down 0 . 7% to 1 , 749 million .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae atpase densities autoreg|motors gata4 atpases dystrophin gradients|pertussis|infants with entity often require hospitalization in pediatric intensive care units , frequently requiring mechanical ventilation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae atpase densities autoreg|iod densities mω cholerae localization|pertussis|reported 2013 reported change on a reported basis change at constantexchange rates polio / entity / hib vaccines ( including pentacel® and pentaxim® ) 1 , 154 1 , 148 +0 . 5% +1 . 9%
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae atpase densities autoreg|densities density cholerae gradients mω|pertussis|the company  s manufacturing operations for neisvac-c ( tm ) , certiva ( r ) and its acellular entity vaccine are located principally in one facility .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients cholerae atpase densities autoreg|gata4 mω integrins gradients dystrophin|pertussis|worldwide , nearly 50 million cases of entity are diagnosed annually and about 350 , 000 people die of the disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae atpase densities autoreg|motors cholerae imm densities gata4|pertussis|illumigene® bordetella entity ( whooping cough )  commercialized in march 2014 6 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients cholerae atpase densities autoreg|iod densities cholerae avidin mω|pertussis|+33 . 3 % total vaccines 1 , 800 1 , 422 +26 . 6 % +24 . 5 % polio / entity / hib vaccines posted 2017 first-half net sales of 901 million , up 41 . 3% cer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality null telangiect benjamini hydroph|mω gata4 clock gradients dystrophin|syndactyly|however , the severity of the condition does increase with age due to scarring , entity and generalized skin atrophy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality null telangiect benjamini hydroph|mω gata4 clock gradients chimeras|syndactyly|however , the severity of the condition does increase with age due to scarring , entity and generalized skin 82 table of contents atrophy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini kolmogorov normality hydroph mendelian|gradients signals mω either gata4|hypoparathyroidism|we believe transcon pth may provide patients suffering from entity with a pth replacement therapy that is designed to fully address all aspects of the disease more than standard of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini kolmogorov normality hydroph mendelian|gata4 smad1 densities kv dystrophin|hypoparathyroidism|we now have the financial resources to fund the continued u . s . development of preos in a variety of indications , including entity and osteoporosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini kolmogorov normality hydroph mendelian|mω gradients gata4 autoreg traps|hypoparathyroidism|treatment , even with the less frequent regimens , may be an effective treatment option for those patients suffering from less severe entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini kolmogorov normality hydroph mendelian|gradients gata4 autoreg dystrophin atpases|hypoparathyroidism|eb612 for the treatment of entity we believe eb612 may offer several advantages over natpara for the following reasons : • eb612 is designed to be dosed
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini kolmogorov normality hydroph mendelian|gata4 smad1 gradients autoreg negativity|hypoparathyroidism|would enable us to seek u . s . marketing approval of npsp558 as a new standard of care for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini kolmogorov normality hydroph mendelian|spher gata4 otherwise mω csc|hypoparathyroidism|our lead oral pth product candidate , eb612 , has successfully completed a phase 2a trial for entity , a rare condition in which the body fails to produce sufficient amounts of pth .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini kolmogorov normality hydroph mendelian|gata4 dystrophin atpases αvβ3 smad1|hypoparathyroidism|we believe positive results from steps and replace will enable us to seek u . s . marketing approval of gattex for sbs and npsp558 for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini kolmogorov normality hydroph mendelian|mω gata4 autoreg smad1 gradients|hypoparathyroidism|origin ] injection ) is being evaluated in a phase 3 registration study known as replace as a hormone replacement therapy for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini kolmogorov normality hydroph mendelian|spher gata4 otherwise mω csc|hypoparathyroidism|our lead oral pth product candidate , eb612 , has successfully completed a phase 2a trial for entity , a rare condition in which the body fails to produce sufficient amounts of pth .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini kolmogorov normality hydroph mendelian|gradients either dystrophin gata4 densities|hypoparathyroidism|showed the predicted pharmacokinetic and pharmacodynamic response , suggesting the ability to normalize serum and urinary calcium levels in patients with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini kolmogorov normality hydroph mendelian|gata4 densities dystrophin either αvβ3|hypoparathyroidism|candidate we chose to pursue was pth , which has the potential for therapeutic use in a number of indications including entity , osteoporosis and non-union fractures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini kolmogorov normality hydroph mendelian|mω either gata4 densities autoreg|hypoparathyroidism|( sbs ) and a phase 3 registration study has been completed for natpara ( recombinant human parathyroid hormone ( rhpth [ 1-84 ] ) in adult entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini kolmogorov normality hydroph mendelian|gata4 dystrophin atpases smad1 troponin|hypoparathyroidism|while sbs and entity are relatively rare disorders , we believe they represent a substantial commercial opportunity to us due to the significant unmet need
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini kolmogorov normality hydroph mendelian|either dystrophin densities gata4 smad1|hypoparathyroidism|replace , a phase 3 registration study of npsp558 , the companys bioengineered replica of human parathyroid hormone ( rhpth 1-84 ) , in adult entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini kolmogorov normality hydroph mendelian|gradients gata4 dystrophin mω spher|hypoparathyroidism|the symptoms of entity are typically managed with large doses of oral calcium supplementation and active vitamin d therapy to reduce the severity of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini kolmogorov normality hydroph mendelian|gata4 dystrophin gradients mω densities|hypoparathyroidism|short bowel syndrome ) and our study of npsp558 is known as replace ( recombinant parathyroid hormone to normalize calcium and treat entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini kolmogorov normality hydroph mendelian|gata4 smad1 gradients dystrophin atpases|hypoparathyroidism|criteria for 20 , 250 of these options was satisfied when the fda accepted the bla for natpara for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini kolmogorov normality hydroph mendelian|gata4 densities density smad1 mω|hypoparathyroidism|we are committed to advancing the development of preos in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini kolmogorov normality hydroph mendelian|mω autoreg gradients gata4 dystrophin|hypoparathyroidism|we are also developing natpara® ( rhpth [ 1-84 ] ) for the treatment of adult entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini kolmogorov normality hydroph mendelian|either gradients gata4 dystrophin densities|hypoparathyroidism|reported the fdas approval of natpara as an adjunct to calcium and vitamin d to control hypocalcemia in patients with entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini autoreg spd otherwise gradients|gata4 otherwise atpases gradients motors|typhus|doxycycline is an antibiotic used to treat anthrax , rocky mountain spotted fever , entity and mycoplasma pneumonia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini autoreg spd otherwise gradients|gata4 densities binders mω dystrophin|typhus|diseases that can be acquired from such accidents include hiv / aids , hbv , hcv , diphtheria , gonorrhea , entity , herpes simplex virus , malaria , syphilis and tuberculosis .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini autoreg spd otherwise gradients|gata4 otherwise motors gradients atpases|typhus|doxycycline is an antibiotic used to treat rocky mountain spotted fever , entity and mycoplasma pneumonia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities ante autoreg cholerae|gata4 densities mω smad1 density|rabies|these efforts , we will continue the development of these drugs , as well as our other drug development endeavors that include entity , dengue viruses , and ebola / marburg viruses .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities ante autoreg cholerae|gata4 mω αvβ3 dystrophin chimeras|rabies|talecris also has a line of hyperimmune therapies that provide treatment for tetanus , entity , hepatitis b , hepatitis a and rh factor control during pregnancy and at birth .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities ante autoreg cholerae|imm mω dystrophin gata4 junction|rabies|the candidate ligands for this nanoviricide were designed by the company using publicly available information regarding the interaction of the entity virus with cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities ante autoreg cholerae|imm densities cholerae density mω|rabies| an additional phase ii study in healthy adults evaluating crucells monoclonal antibody in combination with a entity vaccine is scheduled to start in india in the second quarter of 2009 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities ante autoreg cholerae|gata4 mω dystrophin chimeras densities|rabies|seasonal influenza , hiv , oral and genital herpes ( hsv ) , viral diseases of the eye including ekc and herpes keratitis , hepatitis c , entity , dengue fever , and ebola virus , among others .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities ante autoreg cholerae|gata4 dystrophin mω vw jam|rabies|cv7202 is an mrna that encodes the entity virus glycoprotein , rabv-g , formulated with lnps .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities ante autoreg cholerae|nanog gata4 densities junction dens|rabies|sales volume for human albumin and human immunoglobulin for intravenous decreased by 19 . 4% and 24 . 3% , respectively , while human entity immunoglobulin recorded an increase of 94 . 9% .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities ante autoreg cholerae|gata4 smad1 densities atpases chaperones|rabies|nihe thereafter requested that we develop a drug for entity , a request to which we agreed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities ante autoreg cholerae|gata4 densities density mω atpases|rabies|types i , ii , iii , & iv ; · hepatitis b virus ( hbv ) ; · hepatitis c virus ( hcv ) ; · entity ; · ebola and marburg viruses ; · japanese encephalitis ; and · west nile virus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities ante autoreg cholerae|gata4 mω gradients smad1 imm|rabies|our lead vaccine program , cv7202 , is being developed for prophylactic vaccination against entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities ante autoreg cholerae|gata4 mω gradients otherwise dystrophin|rabies|rabicide , a nanoviricide against entity finished its first set of animal studies in the first quarter of 2007 in vietnam .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities ante autoreg cholerae|gata4 cyclins cholerae densities binders|rabies|[ **** ] against rsv , para influenza , cmv pneumo ( including s . pneumoniae , branhamalla , non-typable haemophilus influenza and otitis media ) and entity in the field in the territory .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities ante autoreg cholerae|gata4 mω dystrophin αvβ3 troponin|rabies|we evaluated the use of mrna for passive immunization in two indications , entity and botulism , that can be considered prototypes for anti-pathogen and anti-toxin therapies , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities ante autoreg cholerae|mω gata4 either deleted normality|rabies|anti-entity immune globulin therapy is prescribed for individuals suspected of recent exposure to the entity virus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities ante autoreg cholerae|gradients mω gata4 vw imm|rabies|entity is commonly transmitted by infectious saliva from the bite of a rabid animal .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients densities ante autoreg cholerae|densities density mω cholerae gradients|rabies|since 2010 , isconova and vetbiochem have collaborated on the development of entity vaccines for dogs and cats .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities ante autoreg cholerae|gata4 smad1 densities autoreg mω|rabies|in january 2020 , we reported preliminary data from our phase 1 trial of cv7202 in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities ante autoreg cholerae|gata4 cd69 dens mω cd44|rabies|have entered into work orders for the preclinical development of a lassa virus vaccine , a yellow fever vaccine and our entity virus vaccine .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities ante autoreg cholerae|densities gata4 density atpases mω|rabies|licenses in perpetuity for technologies developed by theracour for the virus types : hiv , hcv , herpes , asian ( bird ) flu , influenza and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients densities ante autoreg cholerae|gata4 smad1 mω cd44 gradients|rabies|further , the company has identified highly active nanoviricide drug candidates against ebola / marburg , and against entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpases atpase densities|gata4 densities mω αvβ3 density|psittacosis|dr . moore has conducted clinical research on infectious diseases such as venezuelan equine encephalitis , tuberculosis , listeriosis , entity , human orf , malaria , and hiv / aids .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg cholerae atpase normality gata4|gradients ante biphasic imm boltzmann|trachoma|chlamydia entitytis also causes the ocular disease entity , which is a form of vesicular conjunctivitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg cholerae atpase normality gata4|gata4 autoreg mω gradients smad4|trachoma|through the iti , we donate the antibiotic zithromax to combat blinding entity in developing countries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg cholerae atpase normality gata4|mω autoreg imm negativity gradients|trachoma|we intend to help the world health organization achieve its goal of eliminating blinding entity by the year 2020 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg cholerae atpase normality gata4|gata4 otherwise autoreg motors ubiquitin|trachoma|increase in annual dividends to $1 . 36 from $0 . 80•since 2010 , donated more than 580 million doses of zithromax ( azithromycin ) to treat entity , the leading cause of infectious blindness .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg cholerae atpase normality gata4|kv sense diagn gata4 nav|trachoma|internationally , we have two innovative access programs : the international entity initiative ( iti ) and the diflucan partnership program ( dpp ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg cholerae atpase normality gata4|densities pkd density gradients gata4|trachoma|dr . feczko is a member of the technical expert committee for the international entity initiative of the task force for global health .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg cholerae atpase normality gata4|retrograde ante clock gradients forth|trachoma|because c . entitytis also causes entity , the world  s most common form of preventable blindness , the who estimates chlamydia is responsible for at least 15 percent of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg cholerae atpase normality gata4|otherwise motors cholerae cd69 void|trachoma|in response , the number of people at risk of entity blindness worldwide has been reduced to 158 million from more than 300 million in 2010 . shantanu narayen , lead independent director of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg cholerae atpase normality gata4|osm retrograde conditional hist gradients|trachoma|because c . entitytis also causes entity , the worlds most common form of preventable blindness , the who estimates c . entitytis is responsible for at least 15 percent of the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg cholerae atpase normality gata4|gata4 cd69 otherwise mω motors|trachoma|entity is the leading cause of preventable blindness worldwide .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg cholerae atpase normality gata4|dystrophin gata4 mω αvβ3 kv|trachoma|medicine for human diseases to treat a host of bacterial infections , including acute otitis media infection , pharyngitis , pneumonia , skin infection , entity , and etc .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg cholerae atpase normality gata4|densities density gata4 imm mω|trachoma|the iti , in which pfizer is a partner , has initiated entity programs in nine developing countries to date and plans to launch programs in an additional 10 countries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|autoreg cholerae atpase normality gata4|retrograde forth clock ante gradients|trachoma|because c . entitytis also causes entity , the worlds most common form of 4 preventable blindness , the who estimates chlamydia is responsible for at least 15 percent
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients benjamini autoreg densities atpases|gata4 cd44 dystrophin ≥4 autoin|erysipelas|in this trial , patients with wound infections , major abscesses , and entity / cellulitis were enrolled in equal numbers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients benjamini autoreg densities atpases|gata4 cd44 dystrophin ≥4 mω|erysipelas|a lesion size of at least 75 cm2 ( lesion size measured by the area of redness , edema or induration ) , and includes cellulitis / entity , wound infections and major cutaneous abscesses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients benjamini autoreg densities atpases|gata4 cd44 dystrophin clock mω|erysipelas|is defined as a bacterial infection of the skin with a lesion size area of at least 75 cm and includes cellulitis / entity , wound infections , and major cutanenous abscesses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients benjamini autoreg densities atpases|dystrophin gata4 cd44 autoin motors|erysipelas|were more than 4 . 8 million hospital admissions of adults with absssi from 2005 through 2011 , which included patients with cellulitis , entity , wound infection and major cutaneous abscess .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients benjamini autoreg densities atpases|gata4 cd44 dystrophin mω ≥4|erysipelas|lesion size of at least 75 cm2 ( lesion size measured by the area of redness , edema or induration ) , and includes cellulitis / entity , wound infections and major cutaneous abscesses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients benjamini autoreg densities atpases|gata4 densities atpases density gradients|erysipelas|reported for at least 0 . 1% of subjects and for which p<0 . 01 included concussion ( denosumab <0 . 1% , n=1 ; placebo 0 . 3% , n=11 ) and entity ( denosumab 0 . 2% , n=7 ; placebo 0% , n=0 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients benjamini autoreg densities atpases|gata4 dystrophin cd44 clock mω|erysipelas|examples of absssi are cellulitis / entity , wound infection , major cutaneous abscess and burn infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients benjamini autoreg densities atpases|gata4 dystrophin αvβ3 integrins cd44|erysipelas|in pairs or chains , many species of which destroy red blood cells and cause various diseases in human beings , including entity , scarlet fever , and septic sore throat .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients benjamini autoreg densities atpases|dystrophin gata4 cd44 autoin motors|erysipelas|were more than 4 . 8 million hospital admissions of adults with absssi from 2005 through 2011 , which included patients with cellulitis , entity , wound infection , and major cutaneous abscess .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|gradients cd44 gata4 curvature autoreg|sarcoidosis|the primary treatment for entity is corticosteroids ; however , the outcome of this treatment on the ph is unclear .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|gata4 smad1 motors gradients densities|sarcoidosis|there are a number of different mechanisms linking ph with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|smad1 gata4 mω merits dens|sarcoidosis|we selected pulmonary entity as our first ild indication and we are currently enrolling a proof-of-concept phase 1b / 2a clinical trial .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|densities density gata4 either gradients|sarcoidosis|in 2018 , we also initiated development of inopulse for the treatment of ph associated with entity ( ph-sarc ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|densities gradients ante autoreg uncou|gata4 spher cholerae cd69 densities|sarcoidosis|entity initial phase ii trial completed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|densities gradients ante autoreg uncou|gata4 dystrophin αvβ3 densities atpases|sarcoidosis|that we are exploring in multiple rare diseases of unmet medical need , including methicillin-resistant staph aureus ( mrsa ) , ntm , pah , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|autoreg mω densities gata4 inactivation|sarcoidosis|phase 1b / 2a clinical trial and , if that trial is successful , we believe we can expedite development of atyr1923 for pulmonary entity towards regulatory approval .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|smad1 mω gata4 dens autoreg|sarcoidosis|we selected pulmonary entity as our first ild indication and initiated a phase 1b / 2a proof-of-concept clinical trial in december 2018 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|mω autoreg gata4 vv ante|sarcoidosis|entity is a multi-system disease which is characterized by the growth of granulomas ( inflammatory cells ) in one or more organs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|densities gradients ante autoreg uncou|gata4 dystrophin mω αvβ3 microtubules|sarcoidosis|by mondobiotech and the ema has designated aviptadil an orphan medicinal product for the treatment of acute lung injury and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|autoreg gradients gata4 junction densities|sarcoidosis|for example , we are just now beginning to explore the potential for acthar in symptomatic entity with a small pilot selling effort to pulmonologists .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|densities gradients ante autoreg uncou|gata4 dystrophin densities αvβ3 atpases|sarcoidosis|that we are evaluating in multiple rare diseases of unmet medical need , including methicillin-resistant staph aureus ( mrsa ) , ntm , pah and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|smad1 densities gata4 autoreg density|sarcoidosis|the presence of ph in entity is associated with a poor prognosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|densities gata4 gradients density traps|sarcoidosis|inopulse for ph-sarc we are also developing inopulse for the treatment of ph associated with entity , or ph-sarc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|densities gata4 autoreg density gradients|sarcoidosis|there is no approved therapy for ph associated with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|autoreg gata4 densities smad1 gradients|sarcoidosis|who group v consists of ph with multifactorial mechanisms , of which we are focusing on a subset of patients with entity that has caused ild .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|densities gradients ante autoreg uncou|densities gata4 density either autoreg|sarcoidosis|in 2018 , we initiated development of inopulse for the treatment of ph associated with entity ( “ph-sarc” ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients cholerae densities autoreg atpases|dens ante gradients densities integrins|tetanus|the same participants when stimulated with 85 table of contents cytomegalovirus ( cmv ) , epstein barr virus ( ebv ) , influenza virus and entity toxoid-derived immuno- dominant peptide panels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients cholerae densities autoreg atpases|ante mω gradients avidin kv|tetanus|and is manufacturing and marketing , a line of vaccines including whole virus and split virus influenza vaccines , a combined diphtheria entity vaccine and a vaccine to prevent tuberculosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae densities autoreg atpases|densities density gradients junction gata4|tetanus|particularly applied to patients who have allergic reactions to entity antitoxin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients cholerae densities autoreg atpases|gata4 densities mω density integrins|tetanus|response facilitates the use of preventative vaccines that protect against viral and bacterial infections such as measles , polio , diphtheria and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae densities autoreg atpases|mω gradients gata4 densities motors|tetanus|hyperimmune products currently available include hepatitis b , entity , rabies cytomegalovirus and rhod immune globulins .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae densities autoreg atpases|densities cholerae mω gata4 density|tetanus|during 2000 , we anticipate that innovaccines will begin to scale up an oral entity vaccine to take into human clinical trials .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae densities autoreg atpases|gata4 densities cholerae curvature cd44|tetanus|human entity immunoglobulin – 250iu mainly used for the prevention and therapy of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae densities autoreg atpases|ante gradients motors atpases densities|tetanus|if ssi fails to continue to supply the company with these components , the company has a royalty-bearing license to produce diphtheria and entity toxoids for this purpose .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae densities autoreg atpases|dens gradients desp motors densities|tetanus|then the antigenic proteins , entity toxoid and candida albicans were applied topically to the treated skin sites .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae densities autoreg atpases|densities density gradients junction gata4|tetanus|particularly applied to patients who have allergic reactions to entity antitoxin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae densities autoreg atpases|junction gata4 nanog gradients cd44|tetanus|for our plasma products , entity immunoglobulin , factor viii and pcc are included on the life-saving essential drug list in most chinese provinces , for which drug
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae densities autoreg atpases|gata4 densities nanog dens cholerae|tetanus|three of our approved products , human albumin , human rabies immunoglobulin and human entity immunoglobulin are affected by the 2013 adjustments .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients cholerae densities autoreg atpases|integrins gata4 αvβ3 mω cd47|tetanus|vaccines against two life-threatening bacterial diseases , diphtheria and entity , came into use early in this century .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae densities autoreg atpases|either densities gata4 junction density|tetanus|xmab5871 inhibited anti-entity antibody responses in mice engrafted with human b cells and immunized with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients cholerae densities autoreg atpases|gata4 cholerae cyclins bifurcation cd44|tetanus|human entity immunoglobulin  250iu mainly used for the prevention and therapy of tetanus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae densities autoreg atpases|gata4 mω densities atpases density|tetanus|ivig product enriched with naturally occurring polyclonal anti-pathogen antibodies , such as streptococcus pneumonia , h . influenza type b , cytomegalovirus , measles and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients cholerae densities autoreg atpases|densities avidin gata4 endos nemat|tetanus|sales of adacel ( adult entity / diphtheria / whooping cough booster ) , launched in the united states in july 2005 , reached 154 million in 2006 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae densities autoreg atpases|densities motors ante crow grp78|tetanus|sp0173 : the current adacel® ( tdap booster vaccine containing entity toxoid , diphtheria toxoid , and 5-component acellular pertussis ) is not indicated in the us for persons aged over 64 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae densities autoreg atpases|gata4 junction atpases binders mω|tetanus|streptococcus pneumoniae , h . influenza type b , cmv , measles , entity etc . ) as well as high levels of antibodies targeted to respiratory syncytial virus , or rsv .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients cholerae densities autoreg atpases|merits densities cd47 mω grp78|tetanus|food and drug administration ( " fda " ) to market its dtap vaccine ( certiva ( registered ) ) in the united states for the prevention of diphtheria , entity , and pertussis ( whooping cough ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg gata4 atpase uncoupling|mω ante kv cholerae grade|diphtheria|vaccines business segment :  march 27 , 2007 : akorn announced the signing of a three-year exclusive distribution agreement for tetanus entity vaccine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg gata4 atpase uncoupling|gata4 densities mω dystrophin iod|diphtheria|they have eradicated smallpox and dramatically reduced the mortality and morbidity associated with many other infectious diseases , such as entity , measles , polio and tetanus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg gata4 atpase uncoupling|mω densities gata4 dystrophin density|diphtheria|adaptive immune response is the basis for preventative vaccines that protect against viral and bacterial infections such as measles , polio , entity and tetanus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg gata4 atpase uncoupling|densities gata4 mω iod density|diphtheria|adaptive immune response facilitates the use of preventative vaccines that protect against viral and bacterial infections such as measles , polio , entity , and tetanus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients autoreg gata4 atpase uncoupling|gata4 mω αvβ3 dystrophin integrins|diphtheria|vaccines against two life-threatening bacterial diseases , entity and tetanus , came into use early in this century .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg gata4 atpase uncoupling|mω csc gata4 densities smad1|diphtheria|under supply agreements , the company manufactures the acellular pertussis component , and ssi manufactures the entity , tetanus and ipv components for the dtap and dtap-ipv vaccines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg gata4 atpase uncoupling|densities gata4 iod dystrophin mω|diphtheria|total sales of rotarix , for rotavirus , boostrix , for prevention of entity , tetanus and whooping cough , and influenza vaccines , fluarix / flulaval , reached £274 million , up 91% .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients autoreg gata4 atpase uncoupling|gata4 gradients densities ante integrins|diphtheria|according to the world health organization , the majority of the western world  s population is immunized to entity toxin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg gata4 atpase uncoupling|densities mω density gata4 cd44|diphtheria|the company produces the monocomponent acellular pertussis toxoid and formulates the final product with entity and tetanus toxoids manufactured and supplied by ssi .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg gata4 atpase uncoupling|dens motors atpases densities gradients|diphtheria|the peptide is joined to a carrier , entity toxoid , to enhance the immune response .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg gata4 atpase uncoupling|densities mω gata4 density smad1|diphtheria|vaccination against entity , tetanus and pertussis is mandated by most states for all children with a total of five doses administered at two ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg gata4 atpase uncoupling|gradients gata4 autoreg dens densities|diphtheria|using a plasmid with an expression cassette of the entity toxin , no immune response will be encountered as happens when using a virus ; moreover , people born in western countries are routinely
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg gata4 atpase uncoupling|ante gradients desp gata4 densities|diphtheria| crm197  we have several development and commercial partnerships in place for crm197 , which is a non-toxic mutant of entity toxin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg gata4 atpase uncoupling|ante mω drain rab5 grp78|diphtheria|we obtain some of the key components , including entity toxoid ( dt ) and tetanus toxoid ( tt ) , through a supply contract with aventis pasteur , one of our strategic collaborators .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg gata4 atpase uncoupling|motors gradients nanog dystrophin ante|diphtheria|gtb-1550 binds to cancer cells , the cancer cells internalize gtb-1550 , and are killed due to the action of drugs cytotoxic entity toxin payload .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg gata4 atpase uncoupling|gata4 smad1 mω cyclins densities|diphtheria|expanded its internal research and development efforts with emphasis on a mucosal vaccine against chlamydia and a mucosal vaccine against entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg gata4 atpase uncoupling|ante gata4 diagn mω dens|diphtheria|biocancell  s leading drug , bc-819 , is a double stranded dna plasmid construct that incorporates the gene for entity toxin ( dta ) under the regulation of the promoter sequence for h19 gene .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg gata4 atpase uncoupling|mω gata4 smad1 densities dystrophin|diphtheria|daptacel® , a trivalent vaccine against pertussis , entity and tetanus , was launched in the united states in 2002 and has become a strong sales contributor due to its
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg gata4 atpase uncoupling|densities desp motors dens mω|diphtheria|the supply commitment of materials suitable for human use consists of entity toxoid and / or tetanus toxoid .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg gata4 atpase uncoupling|mω densities smad1 density gata4|diphtheria|also launched in 1995 was infanrix , the combined acellular vaccine for entity , tetanus and pertussis ( whooping cough ) in switzerland .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini cholerae pull gata4 normality|gata4 certain motors cd44 autoreg|choroiditis|as a student during the 1950s he had lost much of the sight in his right eye to entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cholerae pull gata4 normality|mω cd44 gradients dystrophin gata4|choroiditis|no vasculitis , retinitis , or entity were observed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini cholerae pull gata4 normality|gata4 cd44 dystrophin normality imm|choroiditis|this type of uveitis is called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality null telangiect mendelian hydroph|mω motors gata4 dystrophin dens|polydactyly|early onset obesity and hyperphagia often associated with bbs , a rare genetic disorder that is also characterized by vision loss , entity , kidney abnormalities , and other symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality null telangiect mendelian hydroph|mω motors gradients gata4 ante|polydactyly|it is a rare monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality null telangiect mendelian hydroph|mω motors spher gata4 dystrophin|polydactyly|bardet-biedl syndrome is a monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality null telangiect mendelian hydroph|spher mω kv gata4 gradients|polydactyly|acrania / turner syndrome / prader willi syndrom / left ventricular hypoplasia entity 112 table of contents in the trial , ongoing pregnancies were followed up to 28 days post-delivery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|normality null telangiect mendelian hydroph|mω motors spher dens gata4|polydactyly|bardet‑biedl syndrome is a monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg benjamini gata4 differential mendelian|gradients gata4 mω smad1 autoreg|listeriosis|entity has also been reported as a grade 3 ae .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg benjamini gata4 differential mendelian|gata4 mω gradients densities atpases|listeriosis|examples of the aes experienced include , fevers , chills , nausea , vomiting , fatigue , headaches , hypotension and entity among others .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg benjamini gata4 differential mendelian|gata4 mω densities gradients atpases|listeriosis|examples of the aes experienced include among others , fevers , chills , nausea , vomiting , fatigue , headaches , hypotension and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg benjamini gata4 differential mendelian|gata4 autoreg gradients atpases densities|listeriosis|the event was diagnosed by the treating investigator as being a case of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg benjamini gata4 differential mendelian|mω gata4 smad1 dystrophin imm|listeriosis|when ingested , some strains of listeria can cause entity , which affects primarily the elderly , pregnant women , newborns and adults with weakened immune systems .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg benjamini gata4 differential mendelian|gradients gata4 densities mω smad1|listeriosis|one grade 3 serious ae of entity was reported .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg benjamini gata4 differential mendelian|densities mω gata4 cholerae motors|listeriosis|the overhalla facility was purchased by the aahd in november 1994 and presently manufactures ringworm vaccines for cattle and entity vaccines for sheep and goats .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg benjamini gata4 differential mendelian|otherwise gata4 cholerae damp densities|listeriosis|dr . lorbers major interest in infectious diseases is in human entity , an area in which he is regarded as an international authority .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg benjamini gata4 differential mendelian|smad1 mω notation ≥4 cholerae|listeriosis|the attenuation of the listeria strains used in advaxis immunotherapies , these listeria are nonpathogenic and therefore limit the potential for entity from our immunotherapies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg benjamini gata4 differential mendelian|smad1 mω notation cd44 nedd4|listeriosis|advaxis immunotherapies , the listeria do not replicate and spread from cell to cell at this point , limiting the potential for entity from our immunotherapies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|autoreg pull cush hydroph gradients|gata4 cholerae densities spd iod|onchocerciasis|apply outside the disease endemic countries , or in relation to sales of the product for purposes other than filariasis or entity control .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|normality suggestive benjamini smad2 mendelian|densities gata4 density dens dystrophin|clubfoot|hips at birth , prominent chin and forehead , flat feet , soft skin , floppy heart valve ( mitral valve prolapse ) , curved spine and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|ante benjamini cracks negativity outer|densities dens autoreg density ect|gastroparesis|dr . aurora reported that this entity can result in up to an 80% slower rate of digestion , or gastric motility , in migraineurs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante benjamini cracks negativity outer|mω gata4 smad1 ∗∗ dystrophin|gastroparesis|this protein may have utility in the treatment of post-operative ileus and gastrointestinal motility disorders , such as diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante benjamini cracks negativity outer|mω gata4 dystrophin smad1 spher|gastroparesis|agonist of the motilin receptor that enhances esophageal motility in gerd patients and accelerates gastric emptying in patients with diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|ante benjamini cracks negativity outer|gata4 gradients αvβ3 density smad1|gastroparesis| the results of the recent atopic dermatitis ( epione ) , entity ( vly686-2301 ) and motion sickness ( motion sifnos ) studies have all been submitted to peer-review publications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante benjamini cracks negativity outer|mω gata4 αvβ3 dystrophin trpv|gastroparesis|post-surgical entity is often associated with peptic ulcer surgery , bariatric procedures or esophageal procedures and is thought to result from damage / desensitization of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|ante benjamini cracks negativity outer|gata4 gradients mω smad1 dens|gastroparesis|results from a phase 3 clinical trial of gimoti in female patients with symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|ante benjamini cracks negativity outer|gata4 gradients junction traps atpases|gastroparesis|we believe our novel intranasal delivery formulation will address a significant unmet market need for patients with the symptoms of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|ante benjamini cracks negativity outer|gata4 dystrophin mω kv integrins|gastroparesis|in march 2015 , we initiated a phase 2b study of velusetrag for the treatment of patients with entity and other gastrointestinal motility disorders .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|ante benjamini cracks negativity outer|gata4 gradients tags mω smad1|gastroparesis|are the only products currently approved in the united states to treat the symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante benjamini cracks negativity outer|gata4 dystrophin smad1 myod binders|gastroparesis|ati-7505 has potential use in five indications : chronic constipation , functional dyspepsia , gerd , entity and ibs with constipation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|ante benjamini cracks negativity outer|gata4 gradients cd44 traps resonance|gastroparesis|spray , the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|ante benjamini cracks negativity outer|traps gata4 mω imm smad1|gastroparesis|neurokinin-1 receptor ( nk-1r ) antagonist , which is presently in clinical development for the treatment of chronic pruritus in atopic dermatitis and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|ante benjamini cracks negativity outer|mω gata4 smad1 dens gradients|gastroparesis|the results of these clinical trials support our belief that relamorelin has the potential to be a safe and effective treatment for diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante benjamini cracks negativity outer|gata4 gradients smad1 mω dystrophin|gastroparesis|in april 2014 , we commenced a phase 3 clinical trial of evk-001 in female patients with symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|ante benjamini cracks negativity outer|certain gata4 mω motors troponin|gastroparesis|subjects with no history of migraine , migraineurs experienced , to varying degrees , paralysis of the muscles of the stomach , or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante benjamini cracks negativity outer|mω gata4 dystrophin dens smad1|gastroparesis|motus has the worldwide rights to rm-131 ( relamorelin ) , a peptide ghrelin agonist being developed for the treatment of diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|ante benjamini cracks negativity outer|gata4 mω gradients smad1 traps|gastroparesis|the company believes that emitasol ( r ) , when given intranasally , may be effective in treating diabetic entity and in preventing delayed onset emesis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|ante benjamini cracks negativity outer|gata4 smad1 gata3 saturation negativity|gastroparesis|metoclopramide is the only product currently approved in the united states to treat entity , and is currently available only in oral and intravenous forms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ante benjamini cracks negativity outer|gradients traps gata4 junction dystrophin|gastroparesis|the primary endpoint will be the effect of velusetrag on symptoms in subjects with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|ante benjamini cracks negativity outer|gata4 gradients mω chimeras smad1|gastroparesis|emitasol ( r ) is proposed as a method to control diabetic entity and to prevent delayed emesis associated with cancer chemotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|differential benjamini gata4 normality mendelian|gata4 gradients smad1 densities mω|cryptococcosis|in addition , the fda has granted orphan drug designation to mat2203 for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|differential benjamini gata4 normality mendelian|densities density gata4 cholerae nedd4|cryptococcosis|according to entity statistics maintained on the centers for disease control and preventions website from february 2014 , the greatest burden of this disease
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|differential benjamini gata4 normality mendelian|gata4 nedd4 mω binders smad1|cryptococcosis|cryptococcal meningitis has become the most common cause of adult meningitis in many parts of africa , where entity now rivals tuberculosis in all-case mortality .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|differential benjamini gata4 normality mendelian|gata4 gradients smad1 atpases otherwise|cryptococcosis|●as previously reported , during the fourth quarter of 2019 , fda granted mat2203 orphan drug designation for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|differential benjamini gata4 normality mendelian|mω cyclic gata4 cd69 gradients|cryptococcosis|the three major types of these infections are candidiasis , aspergillosis and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|differential benjamini gata4 normality mendelian|mω gata4 sarc biased otherwise|cryptococcosis|entity is an infectious disease of the lungs caused by the fungus cryptococcus neoformans and is one of the most common
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|differential benjamini gata4 normality mendelian|mω gata4 gradients dystrophin cd44|cryptococcosis|examples of such infections include aspergillosis , blastomycosis , candidiasis , coccidioidomycosis , entity and zycomycosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|differential benjamini gata4 normality mendelian|mω gata4 sarc biased merits|cryptococcosis|entity is an infectious disease of the lungs caused by the fungus cryptococcus neoformans and is one of the most common life-threatening fungal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|differential benjamini gata4 normality mendelian|gata4 integrins mω otherwise gradients|cryptococcosis|in april 2015 , the ema granted two orphan drug designations for ar-12 for the treatment of entity and tularaemia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini gata4 cholerae ante telangiect|mω gradients dens imm autoreg|arachnoiditis|if left untreated , chemical entity may be fatal .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini gata4 cholerae ante telangiect|dens gradients imm densities gata4|arachnoiditis|the incidence and severity of chemical entity can be reduced by coadministration of dexamethasone .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini gata4 cholerae ante telangiect|gradients dens gata4 densities imm|arachnoiditis|patients receiving depocyt should be treated concurrently with dexamethasone to mitigate the symptoms of chemical entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini gata4 cholerae ante telangiect|mω gradients gata4 dens spher|arachnoiditis|in all clinical studies , chemical entity , a syndrome manifested primarily by nausea , vomiting , headache and fever , was a common adverse event .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients benjamini uncoupling uncou decou|densities density dens smad4 gradients|aniridia|entity therapeutic interventions , such as artificial iris implantation , are being developed by humanoptics ag . •emflaza for dmd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients benjamini uncoupling uncou decou|autoreg gata4 densities gradients integrins|aniridia|we estimate that approximately one-third of all entity cases are due to a nonsense mutation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients benjamini uncoupling uncou decou|spher otherwise hist cd69 mω|aniridia|entity is a genetic disorder due to mutations in the pax6 gene associated with loss of eyesight and other symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients benjamini uncoupling uncou decou|gata4 smad1 densities dystrophin mω|aniridia|· translarna pipeline will expand with a proof of concept study in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients benjamini uncoupling uncou decou|spher cd69 mω otherwise gata4|aniridia|entity is a rare genetic disorder that results in disruption in the development of the eye .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients benjamini uncoupling uncou decou|spher otherwise cd69 hist normality|aniridia|for example , investigators studying entity , a genetic disorder due to mutations in the pax6 gene associated with loss of eyesight and other symptoms in which
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients benjamini uncoupling uncou decou|autoreg mω agon certain densities|aniridia|ptc plans to initiate a phase 2 proof of concept study in nonsense mutation entity by year end 2015 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients benjamini uncoupling uncou decou|mω smad1 gata4 dystrophin cd69|aniridia|in addition to its advanced dmd and cf programs , ptc is now pursuing two additional indications , mps i and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase atpases dens|mω gata4 gradients cholerae smad1|malaria|other pox virus vectors are being evaluated in experimental models of human entity and , in a hybrid regimen combining doses of a modified live virus , with a subunit hiv vaccine to protect high
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase atpases dens|densities gradients density mω cholerae|malaria|ema regulatory decision on glaxosmithklines entity vaccine candidate rts , s , which contains agenuss qs-21 stimulon® adjuvant .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase atpases dens|cholerae mω gradients imm densities|malaria| entity vaccine based on advac® / per . c6® technologies : crucell and its collaborator , the us national institute of allergy and infectious diseases ( niaid ) , part
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|densities gradients density signals dens|malaria|the global plan for insecticide resistance management in entity vectors , released in 2012 , contains a five-pillar strategy on managing the threat of insecticide resistance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|gata4 gradients nanog chimeras pkd|malaria|as per the entity foundation international , malaria now kills more people than it did 3 decades ago .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|gata4 motors cyclins chaperones atpases|malaria|quinine , a natural product from the bark of the cinchona tree , was one of the first treatments for entity and appeared in the 17 ( th ) century .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|autoreg densities gata4 damp nedd4|malaria|in 2004 , the entity program revenue was limited to breeding activities to create a new founder line .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|gata4 gradients densities atpases otherwise|malaria|currently pursuing our negotiation with several countries in africa to introduce our larvicide product , greenex™ as a prevention agent for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|imm dens autoreg endos meristem|malaria|dr . rosenberg also serves on the boards of directors of lovelace respiratory research institute , karo bio ab , and medicines for entity venture .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|gata4 mω smad1 cyclins densities|malaria|we expect similarly to advance our novel non-clinical prophylactic vaccine and immunotherapy programs against chlamydia , hsv-2 and entity through human 3 table of contents proof of concept .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|gata4 densities iod signals kinases|malaria|mosquito resistance to at least one insecticide used for entity control has been identified in 64 countries around the world .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase atpases dens|autoreg cholerae densities nanog gata4|malaria|currently , both our cassette entity pf and entity pf / pv have been listed under the who procurement process .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|mω kv gata4 imm densities|malaria|we are collaborating with the bill & melinda gates foundation on entity vaccine research .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase atpases dens|imm autoreg densities atpases cholerae|malaria|the who has made the roll back of entity , by 50% during the decade ending 2011 , one of its 4 major objectives of the current decade .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|densities gata4 density inactivation damp|malaria|in the case of our entity product candidate , we may encounter difficulties in finding potential patients because our initial regimen requires patients to first fail other
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase atpases dens|mω gata4 smad1 dystrophin gradients|malaria|as well as an extended spectrum of activity against ca-mrsa , streptococci , haemophilus , enterococci , mycobacterium avium and in animal models of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|autoreg gata4 rectif imm downregulated|malaria|who currently recommends chloroquine for the treatment of p . vivax entity where the drug remains effective .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|gata4 imm densities kv mω|malaria|the kemri / cdc research and public health collaboration has well-developed entity , hiv , microbiology , and tuberculosis laboratories that perform a range of standard diagnostic procedures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase atpases dens|imm autoreg gradients retrograde downregulated|malaria|who recommends acts for the treatment of chloroquine-resistant p . vivax entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase atpases dens|gata4 mω cd44 cd69 dystrophin|malaria|u . s . naval medical research center ( nmrc ) allowing them to use our proprietary adenovector technology for the development of vaccines against entity and dengue virus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini gata4 differential autoreg gradients|mω gata4 lgr5 cyclic phalloidin|blastomycosis|endemic mycoses are caused by coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) found in the soil of certain regions of the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini gata4 differential autoreg gradients|mω gata4 cd44 cyclic myod|blastomycosis|there are three basic forms of endemic mycoses : coccidioidomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini gata4 differential autoreg gradients|mω gata4 cyclic cd69 gradients|blastomycosis|examples of such infections include aspergillosis , entity , candidiasis , coccidioidomycosis , cryptococcosis and zycomycosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini gata4 differential autoreg gradients|mω gata4 cd44 myod cyclic|blastomycosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto , " respectively ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini gata4 differential autoreg gradients|mω gata4 cd44 cyclic myod|blastomycosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian cholerae normality spher|spher mω dystrophin tail cd11|mucopolysaccharidosis|if approved , this would be the first human enzyme replacement therapy for the treatment of hunter syndrome , also known as entity ii ( mps ii ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian cholerae normality spher|ect mω junction dystrophin gata4|mucopolysaccharidosis|entity i , or mps i lambert eaton myasthenic syndrome , or lems firdapse has not received
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian cholerae normality spher|otherwise mω densities dystrophin density|mucopolysaccharidosis|the u . s . patent and trademark office issued to us the u . s . patent no . 6 , 426 , 208 covering aldurazyme for the treatment of entity i ( or mps i ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian cholerae normality spher|mω dystrophin spher dens tail|mucopolysaccharidosis|alpha-n-acetylglucosaminidase ( naglu ) with a peptide derived from insulin-like growth factor 2 ( igf2 ) for the treatment of sanfilippo b syndrome or entity iiib ( mps iiib ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian cholerae normality spher|densities density mω imm dystrophin|mucopolysaccharidosis|hgt- 1410 for sanfilippo a syndrome ( entity iiia ) hgt- 1410 is in development as an ert delivered intrathecally for the treatment of sanfilippo a syndrome ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian cholerae normality spher|density densities mω imm dystrophin|mucopolysaccharidosis|shp610 for sanfilippo a syndrome ( entity iiia ) shp610 is in development as an ert delivered intrathecally for the treatment of sanfilippo a syndrome , a lysosomal
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian cholerae normality spher|mω spher settle otherwise carries|mucopolysaccharidosis|our most advanced programs are for the treatment of two severe genetic diseases , homozygous familial hypercholesterolemia ( hofh ) and entity type i ( mps i ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian cholerae normality spher|spher mω dystrophin ect otherwise|mucopolysaccharidosis|entity i , or mps i , is a rare genetic disorder that affects many body systems and that leads to organ damage .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian cholerae normality spher|mω otherwise spher settle tail|mucopolysaccharidosis|elaprase elaprase is a treatment for hunter syndrome ( also known as entity type ii or mps ii ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian cholerae normality spher|dystrophin mω otherwise densities density|mucopolysaccharidosis|alexion decided to reduce its investment in sbc-103 , a recombinant form of the naglu enzyme being evaluated in patients with entity iiib , or mps iiib .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian cholerae normality spher|mω spher settle otherwise dystrophin|mucopolysaccharidosis|naglazyme is a recombinant form of n-acetylgalactosamine 4-sulfatase ( arylsulfatase b ) indicated for patients with entity vi ( mps vi ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian cholerae normality spher|mω otherwise spher cd11 dystrophin|mucopolysaccharidosis|agreement with genzyme to establish a joint venture ( biomarin / genzyme llc ) for the worldwide development and commercialization of aldurazyme to treat entity i ( mps i ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian cholerae normality spher|mω tail spher cd11 cbm|mucopolysaccharidosis|our initial programs are focused on lsds such as entity ( mps ) iiia and iiib .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian cholerae normality spher|mω dystrophin spher otherwise chimeras|mucopolysaccharidosis|this model , initially focused on gaucher disease , has extended to fabry disease , entity type i , and pompe disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian cholerae normality spher|mω dystrophin dens spher otherwise|mucopolysaccharidosis|decreased levels of the alpha-l-iduronidase enzyme result in -------------- individuals having entity i ( " mps i " ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients normality cholerae negativity benjamini|dens negativity cd69 gradients cd44|uveitis|we believe that reproxalap and certain of our other product candidates may qualify as an orphan drug for noninfectious anterior entity , and possibly other diseases that we may test .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients normality cholerae negativity benjamini|dens negativity cd44 cd69 defec|uveitis|patients with noninfectious anterior entity generally experience severe pain , sensitivity to light , and vision loss .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients normality cholerae negativity benjamini|negativity dens cd69 gata4 gradients|uveitis| clinical trials in 2015 , pending successful ind submissions , we intend to initiate clinical trials in sls and noninfectious anterior entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients normality cholerae negativity benjamini|gata4 dystrophin negativity atpases cd69|uveitis|in december 2018 for xipere , and , if approved , xipere will be the first therapy indicated for macular edema associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients normality cholerae negativity benjamini|mω gata4 dystrophin αvβ3 smad1|uveitis|we have conducted with our mc1r peptide drug candidates have shown positive results in experimental models of inflammatory bowel disease , entity and nephritis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients normality cholerae negativity benjamini|dystrophin gata4 αvβ3 cd69 normality|uveitis|the company is planning phase ii studies for age-related macular degeneration ( later diabetic macular edema , proliferative vitreoretinopathy and entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients normality cholerae negativity benjamini|gata4 dystrophin smad1 certain smad4|uveitis|value . ”about ebi-031 eleven biotherapeutics  most advanced preclinical product candidate is ebi-031 for treatment of diabetic macular edema , or dme , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|gradients normality cholerae negativity benjamini|mω dystrophin gata4 cholerae smad1|uveitis|and drug administration ( fda ) to review the phase 3 eyeguard-b data together with the data from the two behçets disease entity phase 2 studies conducted independently by xoma and servier .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients normality cholerae negativity benjamini|gata4 dystrophin negativity gata3 chimeras|uveitis|also demonstrate comparability of the proposed drug , which we believe may require a clinical trial in macular edema associated with entity , against our product , unless a biowaiver is obtained .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients normality cholerae negativity benjamini|dens cd69 negativity gata4 cd44|uveitis|both the sjögren-larsson syndrome ( sls ) trial and noninfectious anterior entity trial have begun enrollment and we expect to begin to provide preliminary data for these indications by the end of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients normality cholerae negativity benjamini|dens negativity otherwise gata4 csc|uveitis|lombs ) product retisert ( a surgically implanted intravitreal drug delivery device containing fa approved for the treatment of chronic non-infectious posterior entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients normality cholerae negativity benjamini|mω dens gata4 densities negativity|uveitis|due to its th17 activity , we believe vtp-43742 will be most effective in psoriasis , ms , behcet  s disease and autoimmune entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients normality cholerae negativity benjamini|gata4 mω smad1 kv dystrophin|uveitis|develop and sell psividas proprietary delivery device for indications for diseases outside of the eye or for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients normality cholerae negativity benjamini|gata4 autoreg smad1 dystrophin gradients|uveitis|the second quarter of 2016 ; and ( ii ) planning on initiating a phase ii study of cf101 for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients normality cholerae negativity benjamini|gata4 otherwise dystrophin negativity smad4|uveitis|bausch + lomb markets retisert , an intravitreal implant of the corticosteroid fluocinolone acetonide , for the treatment of non-infectious entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients normality cholerae negativity benjamini|cd44 dystrophin csc gata4 vw|uveitis|diseases , including inflammatory bowel disease , nephritis , which is inflammation of the kidneys , and rheumatoid arthritis , and ocular indications such as entity and dry eye .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients normality cholerae negativity benjamini|dens negativity otherwise cd44 segregation|uveitis|trial of the ns2 eye drop formulation in a serious and , we believe , poorly treated ocular disease called noninfectious anterior entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients normality cholerae negativity benjamini|negativity cd44 dens cd69 ect|uveitis|in noninfectious anterior entity , aldehydes may mediate , at least in part , inflammation , pain , fibrotic changes , and lipid destruction leading to dryness and surface irritation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients normality cholerae negativity benjamini|otherwise saturation cd69 cd44 mω|uveitis|novartis ( esba105 ) and eyegate pharmaceuticals , inc . ( egp-437 ) have conducted or are conducting clinical trials in anterior entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients normality cholerae negativity benjamini|cd69 cd44 dystrophin gata4 csc|uveitis|in addition to entity , rvo and wet amd , there are a number of ophthalmic conditions affecting the retina and choroid with unmet medical need
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|ante icd down differential ubiquitin|typhoid|these vaccines , which currently include vaccines to prevent urinary tract infections and entity fever , are all in basic research or preclinical stage of development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|gata4 mω densities density kv|typhoid|company also anticipates continued investment in its advanced product development pipeline , including an anthrax ig therapeutic , hepatitis b therapeutic and entity vaccine , among others .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|ante iod vw otherwise gata4|typhoid|innovative vector vaccine delivery , manufacturing and preservation technologiesthe technology behind our single dose , oral , rapidly protecting vaccines for cholera and entity fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients otherwise ante gata4 differential|mω gata4 densities cholerae integrins|typhoid|establishing a travel vaccines franchise through its us-based subsidiary berna products corporation , which markets vivotif® , the worlds only licensed oral entity vaccine , in north america .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|densities density motors mω kv|typhoid|a two-year extension of the development program with brookwood pharmaceuticals and a commercial evaluation license with nih for developing a entity vaccine with gelsiteò polymer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|iod ante otherwise gradients motors|typhoid|avant is also developing an oral entity fever vaccine , ty800 , for global health needs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|densities mω density gata4 cyclins|typhoid|one oral entity vaccine and one injectable entity vaccine are currently approved and administered in the united states and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|autoreg motors otherwise ante oscillatory|typhoid|of health ( nih ) initiated a phase 1 / 2 in-patient dose-ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients otherwise ante gata4 differential|mω gata4 densities gradients cholerae|typhoid|acambis  us-based subsidiary berna products corporation markets vivotif ( r ) , the world  s only licensed oral entity vaccine , in north america .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|ante gata4 forth autoreg flo|typhoid|status bacterial vaccines global health choleragarde® ty800 cholera entity fever ivi nih phase 2b phase 2 travelers  etec enterotoxigenic e coli infection  pre-clinical
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients otherwise ante gata4 differential|gata4 mω cholerae cd69 densities|typhoid|patents for the technology used in the cholera and entity vaccines expire between 2013 and 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients otherwise ante gata4 differential|densities spher density mω cholerae|typhoid|entity phase 2 medeva tolerising peptide ( rye grass ) . . . . .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|densities gata4 density cd69 mω|typhoid|emergent biosolutions program pipeline currently includes programs focused on anthrax , tuberculosis , entity , influenza and chlamydia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|iod either down ubiquitin motors|typhoid|a broad portfolio of vaccines against viral and bacterial diseases , including single-dose oral vaccines aimed at protecting travelers from cholera , entity fever and other illnesses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|ante gata4 autoreg forth flo|typhoid|pre-clinical infectious disease choleragarde® ty800 cholera entity fever ivi nih phase 2b phase 2 etec enterotoxigenic e coli infection nih pre-clinical
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients otherwise ante gata4 differential|gata4 densities mω density spd|typhoid|emergents clinical pipeline includes programs focused on anthrax , botulism , entity , tuberculosis , hepatitis b and chlamydia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|autoreg motors otherwise ante oscillatory|typhoid|to conduct a phase i in-patient dose ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients otherwise ante gata4 differential|autoreg otherwise ante motors oscillatory|typhoid|niaid to conduct a phase i in-patient dose-ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients otherwise ante gata4 differential|otherwise integrins motors pull unless|typhoid|thus immunity to an intestinal disease such as entity fever , is best induced by giving the vaccine orally , so that the antigens are presented directly to the lining of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients otherwise ante gata4 differential|densities gata4 density dystrophin binders|typhoid|including rheumatoid arthritis , or ra , and systemic lupus erythematosus , or sle ; and other infectious diseases such as tuberculosis , influenza and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian ante mω gata4|atpases gradients gata4 autoreg motors|porphyria|people with entity should not be treated with visudyne .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante mω gata4|dystrophin traps densities gradients autoreg|porphyria|the most advanced of these programs are the following : amt-021 for acute intermittent entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian ante mω gata4|atpases gradients gata4 mω densities|porphyria|people with entity should not be treated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante mω gata4|dystrophin mω densities motors gata4|porphyria|doses of aln-as1 resulted in lowering of aminolevulinic acid ( ala ) and porphobilinogen ( pbg ) , the toxic heme synthesis intermediates that mediate entity attacks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante mω gata4|dystrophin gradients gata4 mω negativity|porphyria|or pnh ;  filed a cta to initiate a phase 1 trial with aln-as1 in acute intermittent entity , or aip patients ;  initiated a phase 1 trial with aln-pcssc in normal human volunteers with elevated
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante mω gata4|gradients dystrophin gata4 mω cd44|porphyria|this trial are encouraging , the data are preliminary in nature , based on a limited number of patients with acute intermittent entity , or aip .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante mω gata4|mω ante dystrophin negativity normality|porphyria|we and our collaborator digna biotech are developing amt-021 as a gene therapy for acute intermittent entity , or aip , a severe liver disorder .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante mω gata4|gata4 densities gradients dystrophin density|porphyria|excluding entity attacks , three patients had four saes , including one previously reported fatal episode of hemorrhagic pancreatitis ; none of these saes were
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante mω gata4|gata4 dystrophin densities gradients dens|porphyria| present data from the ongoing phase 1 study  including initial data in patients that experience recurring entity attacks  in late 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante mω gata4|benjamini dystrophin densities kolmogorov mω|porphyria|acute intermittent entity aip disease and market background aip is a rare metabolic liver disorder resulting from mutations in the pbgd gene .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante mω gata4|mω dystrophin gata4 normality negativity|porphyria|advanced investigational rnai therapeutic , givosiran , targets aminolevulinic acid synthase 1 , or alas1 , for the treatment of patients with acute hepatic entity , or ahp .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante mω gata4|negativity mω normality ante dystrophin|porphyria|food and drug administration ( fda ) approved givlaari ( givosiran ) injection for subcutaneous use for the treatment of adults with acute hepatic entity ( ahp ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante mω gata4|gata4 dystrophin mω saturation autoreg|porphyria|defined mutation in the pbgd gene and elevated urinary levels of ala and pbg , but no current entity attacks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian ante mω gata4|mω dystrophin gradients ante benjamini|porphyria|amt-021 for acute intermittent entity we are developing amt-021 as a gene therapy for acute intermittent porphyria , or aip , a severe liver disorder .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini differential gata4 mendelian hydroph|gata4 otherwise atpases mω integrins|coccidioidomycosis|status in the united states for vt-1129 for the treatment of cryptococcal meningitis and for vt-1598 for the treatment of entity , also known as valley fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini differential gata4 mendelian hydroph|gata4 otherwise troponin gradients certain|coccidioidomycosis|our third program , vt-1598 for the treatment of entity , a fungal infection in the southwestern united states also known as valley fever , is in ind-enabling studies targeting an ind
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini differential gata4 mendelian hydroph|gata4 otherwise atpases mω αvβ3|coccidioidomycosis|these diseases include entity , commonly known as valley fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini differential gata4 mendelian hydroph|mω gata4 cyclic gradients cd69|coccidioidomycosis|examples of such infections include aspergillosis , blastomycosis , candidiasis , entity , cryptococcosis and zycomycosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini differential gata4 mendelian hydroph|gata4 gradients densities atpases negativity|coccidioidomycosis|vt-1598 for entity ( valley fever ) vt-1598 is an orally available inhibitor of fungal cyp51 that has shown high potency and selectivity in in vitro studies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher sinus|spher mω negativity otherwise benjamini|osteopetrosis|infantile malignant entity ( imo ) : imo is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini spher sinus|gata4 mω dystrophin otherwise chimeras|osteopetrosis|imo is a severe form of entity that typically presents in the first year of life and is associated with severe manifestations leading to death within the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini spher sinus|mω gata4 dystrophin lgr5 kv|osteopetrosis|hcv collaboration with roche and sales of actimmune® , which is approved for two indications , chronic granulomatous disease ( cgd ) and severe , malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher sinus|gata4 mω ante lgr5 otherwise|osteopetrosis|actimmune is currently approved in the united states for the treatment of chronic granulomatous disease ( cgd ) and severe , malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher sinus|spher otherwise negativity mω dens|osteopetrosis|infantile malignant entity ( “imo” ) imo is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mendelian normality benjamini spher sinus|mω gata4 dystrophin cholerae traps|osteopetrosis|is approved in the united states and numerous other countries for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mendelian normality benjamini spher sinus|gata4 mω dystrophin lgr5 cholerae|osteopetrosis|actimmune has been approved by the fda f16 for use in the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher sinus|mω sinus dens traps hydroph|osteopetrosis|frequency and severity of serious infections associated with chronic granulomatous disease ( cgd ) and to slow the worsening of severe malignant entity ( smo ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher sinus|mω gata4 negativity traps densities|osteopetrosis|the fda approved actimmune as a treatment to delay the time to disease progression in patients with severe , malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher sinus|mω gata4 ante kv lgr5|osteopetrosis|in the united states , the company estimates that there are approximately 1 , 200 patients with cgd and less than 500 patients with severe , malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini spher sinus|dystrophin mω otherwise funnel gata4|osteopetrosis|is also targeting research in other diseases such as pyruvate kinase deficiency ( pkd ) , leukocyte adhesion deficiency-i ( lad-i ) , and infantile malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mendelian normality benjamini spher sinus|gata4 mω dystrophin lgr5 cholerae|osteopetrosis|actimmune we currently market our lead product , actimmune , for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher sinus|mω gata4 lgr5 agon traps|osteopetrosis|actimmune is approved by the fda for use in children and adults with chronic granulomatous disease ( cgd ) and severe , malignant entity ( smo ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher sinus|gata4 smad1 cd69 mω traps|osteopetrosis|in entity , the cells that break down bone ( osteoclasts ) do not work properly , which leads to the bones becoming thicker and not as healthy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher sinus|gata4 smad1 autoreg gradients kv|osteopetrosis|for example , we have ongoing phase 4 post-marketing commitments to the fda relating to actimmune for the treatment of entity , including a registry and drug interaction study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|mendelian normality benjamini spher sinus|mω gata4 dystrophin kv cholerae|osteopetrosis|we currently market actimmune in the united states for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini spher sinus|gata4 spher mω cd69 dystrophin|osteopetrosis|entity is a disorder of bone development in which the bones become thickened .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini spher sinus|gata4 signals either gradients minima|osteopetrosis|in people with entity , this balance is not maintained and the resorption of old bone material decreases while the formation of new bone continues .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|mendelian normality benjamini spher sinus|gata4 otherwise mω ante integrins|osteopetrosis|severe , malignant entity is a life-threatening , congenital disorder that primarily affects children .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini spher sinus|gata4 mω dystrophin dens lgr5|osteopetrosis|actimmune has been approved by the fda for use in the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian differential gata4 clock|gata4 mω cd44 myod cd69|aspergillosis|entity , a fungal infection caused by aspergillus , begins as an upper airway infection and can become a systemic fungal infection in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian differential gata4 clock|mω densities gradients dystrophin differential|aspergillosis|astellas commercially launched isavuconazole in the united states in april 2015 for the treatment of invasive entity and invasive mucormycosis in adults .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian differential gata4 clock|mω negativity densities dystrophin gata4|aspergillosis|overview until recently , we were focused on developing our novel antifungal vl-2397 , for the treatment of patients with invasive entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian differential gata4 clock|densities mω gata4 imm density|aspergillosis|the fda has also granted vical qualified infectious disease product ( qidp ) , orphan drug and fast track designations for vl‑2397 for the treatment of invasive entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian differential gata4 clock|gata4 negativity mω smad1 autoreg|aspergillosis|compound , cancidastm ( caspofungintm ) or mk-0991 , in the same class as our v-echinocandin , recently received fda approval for salvage therapy in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian differential gata4 clock|mω gata4 kv densities gradients|aspergillosis|indications currently being explored for mat2203 include resistant candidiasis , cryptococcal meningoencephalitis , entity and leishmaniasis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian differential gata4 clock|mω gata4 dystrophin gradients negativity|aspergillosis|it is indicated for primary treatment of acute invasive entity and salvage therapy for rare but serious fungal infections caused by the pathogens scedosporium apiospermum and fusarium spp .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian differential gata4 clock|densities density autoreg dens dystrophin|aspergillosis|fda has advised that vl‑2397 would be eligible for a limited use indication ( lui ) approval for the treatment of invasive entity for patients with limited treatment options .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian differential gata4 clock|mω densities gradients imm dystrophin|aspergillosis|with soc vs . aspergillus spp . , we plan to initiate a phase 2 study of oral scy-078 in patients with invasive entity in the third quarter of 2018 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian differential gata4 clock|gata4 dystrophin mω differential negativity|aspergillosis|we market amphotec® worldwide for the treatment of invasive entity , a life-threatening systemic fungal infection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian differential gata4 clock|densities gata4 mω dens autoreg|aspergillosis|although we market amphotec for invasive entity , we do not believe that it will provide sufficient revenue to us in the near future , if ever , and , consequently ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian differential gata4 clock|mω gata4 dystrophin gradients cd69|aspergillosis|development history of mat2203 mat2203 was extensively studied in animal model studies of various fungal infections including invasive candidiasis , entity , and visceral leichmaniasis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian differential gata4 clock|mω differential gata4 dystrophin negativity|aspergillosis|amphotec is an fda-approved lipid-complexed form of amphotericin b indicated for the treatment of invasive entity , a life-threatening systemic fungal infection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian differential gata4 clock|mω densities gata4 negativity gradients|aspergillosis|an estimated 200 , 000 cases of invasive entity are diagnosed annually worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian differential gata4 clock|gata4 negativity gradients densities mω|aspergillosis|sequus is conducting a phase iii double-blind , randomized study comparing amphotec with amphotericin b in treating patients with first-line entity infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian differential gata4 clock|mω ante nemat gata4 biased|aspergillosis|the amphotericin b cochleate demonstrated reasonable activity against at least one strain of entity fumigatus and one strain of candida albicans in vitro .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian differential gata4 clock|traps negativity dystrophin matric merits|aspergillosis| received a second qidp status for pulmazole to treat fungal infections in the airways of allergic bronchopulmonary entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian differential gata4 clock|densities gata4 gradients dens imm|aspergillosis|cancidas  has not been studied as an initial therapy for invasive entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian differential gata4 clock|densities gata4 dens density dystrophin|aspergillosis|hepatitis c virus ( hcv ) , infections , and amphotec® ( amphotericin b cholesteryl sulfate complex for injection ) , approved for the treatment of invasive entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian differential gata4 clock|densities density dens gata4 gradients|aspergillosis|we have world-wide marketing rights to amphotec for the treatment of invasive entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|gata4 autoreg autoin otherwise mω|schistosomiasis|three months ended march 31 , 2012 , approximately 60% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients autoreg densities spher spd|mω gata4 otherwise spd negativity|schistosomiasis|deuterated praziquantel in collaboration with the therapeutics for rare and neglected diseases division of the nih for the treatment of entity and other parasitic diseases .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|autoreg gata4 autoin otherwise atpases|schistosomiasis|three months ended june 30 , 2009 , approximately $943 , 137 or 15 . 52% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|gata4 autoreg autoin cyclins gradients|schistosomiasis|lucanthone was originally used as an antiparasitic agent for the treatment of entity in the 1950s and 1960s , and has a demonstrated safety profile .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|autoreg gata4 autoin otherwise mω|schistosomiasis|three months ended june 30 , 2011 , approximately 22% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|autoreg autoin gata4 otherwise atpases|schistosomiasis|the three months march 31 , 2010 , approximately $830 , 600 , or 17% of total revenues , resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|autoreg gata4 autoin otherwise atpases|schistosomiasis|ended december 31 , 2010 , approximately $12 , 198 , 522 or 25 . 7% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|autoreg gata4 autoin otherwise atpases|schistosomiasis|three months ended september 30 , 2009 , approximately $3 , 330 , 000 or 26% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|gata4 gradients smad1 mω imm|schistosomiasis|it is an anthelmintic effective against entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients autoreg densities spher spd|mω gata4 vw gradients spd|schistosomiasis|entity is a parasitic disease that affects both animals and humans .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|autoreg autoin gata4 otherwise atpases|schistosomiasis|during the three months ended june 30 , 2010 , approximately $1 , 864 , 203 or 33 . 7% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|gata4 mω smad1 otherwise autoreg|schistosomiasis|entity is prevalent in southern china where there are a lot of fresh water lakes and rivers .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|autoreg gata4 autoin otherwise mω|schistosomiasis|nine months ended september 30 , 2012 , approximately 44% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|autoreg autoin gata4 otherwise atpases|schistosomiasis|during the three months ended september 30 , 2010 , approximately $5 , 104 , 961 or 41% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|gata4 autoin autoreg cyclins gradients|schistosomiasis|table of contents lucanthone was originally used as an antiparasitic agent for the treatment of entity in the 1950s and 1960s , and has a demonstrated safety profile .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|gata4 autoreg autoin otherwise mω|schistosomiasis|during year ended december 31 , 2011 , approximately 36% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|autoreg gata4 autoin mω otherwise|schistosomiasis|during the three months ended march 31 , 2011 , approximately 1 , 058 , 132 or 15% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|gata4 mω vw vv autoreg|schistosomiasis|praziquantel is a compound of pyrazine and isoquinolin designed to treat and prevent entity in livestock .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg densities spher spd|autoreg gata4 autoin otherwise mω|schistosomiasis|three months ended september 30 , 2011 , approximately 26% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg densities spher spd|mω gata4 densities dystrophin chimeras|schistosomiasis|examples of analytes in this field are : aspergillus , candida , markers or antibodies associated with entity , giardia lamblia , leishmaniasis , lyme disease , chagas , toxoplasmosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|atpase ante gata4 benjamini autoreg|saturation mω dystrophin αvβ3 densities|lymphangioma|aortic body and other paraganglia coccygeal body glomus jugulare para-aortic body 227 . 8 other 227 . 9 endocrine gland , site unspecified 228 hemangioma and entity , any site includes :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|atpase ante gata4 benjamini autoreg|saturation mω dystrophin αvβ3 densities|lymphangioma|paraganglia coccygeal body glomus jugulare para-aortic body 227 . 8 other 227 . 9 endocrine gland , site unspecified 228 hemangioma and entity , any site includes :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients autoreg atpase densities ante|gata4 densities density imm integrins|cholera|during the entity outbreak we responded to a further specific request for antibiotics and donated £250 , 000 to the british red cross to support
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase densities ante|mω gradients dystrophin imm cd44|cholera|quarter of 2000 , will test the safety , immunogenecity and protective capacity of the vaccine against a challenge with live virulent entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase densities ante|mω gata4 dystrophin smad4 imm|cholera|qilian shan® oxytetracycline api used for treating following diseases : rickettsia , mycoplasma infection , chlamydia infection , regression fever , brucellosis entity , rabbit fever and plague .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase densities ante|gata4 gradients binders mω αvβ3|cholera|( the causative agent of entity ) are often confused with travelers diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase densities ante|gata4 dystrophin mω αvβ3 cd69|cholera|in human patients with various types of watery diarrhea , including traveler  s diarrhea , hiv-related diarrhea and other acute infectious diarrheas , including entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase densities ante|gata4 αvβ3 smad1 dystrophin mω|cholera|in addition , an early stage cftr inhibitor program is planned for the treatment of secretory diarrhea disorders , including entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients autoreg atpase densities ante|gata4 mω integrins cd69 imm|cholera|entity is an acute diarrheal illness that kills thousands of people worldwide each year due to rapid dehydration in the first 2 -18 hours after infection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients autoreg atpase densities ante|gata4 mω imm integrins smad1|cholera|and supported the start of phase ii trials in december 2002 with the international vaccine institute ( ivi ) in bangladesh where entity is endemic .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase densities ante|gata4 mω gradients smad1 atpases|cholera|investigation , peru-15 may be an excellent candidate as a potential single dose , oral vaccine for travelers going to areas where entity is endemic .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|gradients autoreg atpase densities ante|gata4 αvβ3 smad1 dystrophin avidin|cholera|entity / general watery diarrhea we are investigating lechlemer for the indication of cholera / general watery diarrhea in adults and children .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase densities ante|gradients nedd4 cholerae densities gata4|cholera|development of a safe , effective entity vaccine is the first step in establishing avants single-dose , oral bacterial vaccine franchise .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase densities ante|cholerae mω densities iod density|cholera|ctb has already been administered to hundreds of thousands of patients worldwide and is a major component of an existing oral entity vaccine and traveler  s diarrhea vaccine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase densities ante|dystrophin mω gata4 imm density|cholera|published results have shown the vaccine to be well tolerated and immunogenic against the entity organism in the adult portion of this trial .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase densities ante|dens ante pull microns bival|cholera|maxvax mucosal vaccine carrier / adjuvant platform maxvax is a mucosal vaccine carrier / adjuvant platform based on the entity toxin b subunit ( ctb ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase densities ante|mω gata4 densities cholerae density|cholera|crucell also markets travel vaccines , such as the only oral anti-typhoid vaccine , an oral entity vaccine and the only aluminium-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients autoreg atpase densities ante|mω gata4 densities iod density|cholera|crucell also markets travel vaccines , such as an oral anti-typhoid vaccine , an oral entity vaccine and the only aluminum-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gradients autoreg atpase densities ante|gata4 mω integrins imm smad1|cholera|this vaccine and supported the start of phase 2 trials in december 2002 with the international vaccine institute ( ivi ) in bangladesh where entity is endemic .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase densities ante|densities density imm gata4 cholerae|cholera|we will then determine our commercialization strategy with respect to the entity vaccine based on clinical data from the trial .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase densities ante|gata4 mω densities cholerae density|cholera|crucell also markets travel vaccines , such as the only oral anti-typhoid vaccine , an oral entity vaccine and the only aluminum-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gradients autoreg atpase densities ante|gata4 smad1 dystrophin cd44 ubiquitin|cholera|in addition , a second-generation proprietary anti-secretory agent is in development for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|mω ante spher merits mendelian|ichthyosis|the loss of tgm-1-activity results in the severe genetic skin disease autosomal recessive congenital entity ( arci ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|gradients mω smad1 ante densities|ichthyosis|there is no prescription drug currently approved in the united states that is indicated for the treatment of congenital entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|mω densities gradients otherwise gata4|ichthyosis|announced that the united states food and drug administration ( fda ) granted adx-102 orphan drug designation for the treatment of congenital entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|mω vesicles papill vesicle cd10|ichthyosis|entity vulgaris is the most common form of ichthyosis affecting around one in 250 people worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|gradients traps mω chimeras otherwise|ichthyosis|moisturizers that are used for the treatment of dry skin or certain inflammatory skin conditions , such as psoriasis , eczema or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|mω gata4 gradients hydroph otherwise|ichthyosis| liarozolean oral therapeutic for the treatment of congenital entity , a rare genetic disease characterized by dryness and scaling of the skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian normality telangiect mω|mω dystrophin ante gata4 smad4|ichthyosis|kb105 , delivers functional human transglutaminase-1 , or tgm1 genes using our gene therapy platform to patients with tgm1-deficient autosomal recessive congenital entity , or arci .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|autoreg otherwise mω ≥4 gata4|ichthyosis|a dermatologic form of adx-102 is in late-stage clinical development for the treatment of entity due to sjögren-larsson syndrome , an inborn error of aldehyde metabolism .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|gradients mω gata4 traps junction|ichthyosis|thus , ns2 may be partially or wholly effective in preventing and treating entity or other dermal symptoms , signs , or pathologies in sls .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian normality telangiect mω|gata4 mω ≥4 cholerae nedd4|ichthyosis|sls patients are generally diagnosed as neonates given the severe entity that presents at birth .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian normality telangiect mω|mω ante dystrophin spher smad4|ichthyosis|- dosing of the 4th patient in the phase 1 / 2 study of kb105 in patients with tgm1 deficient autosomal recessive congenital entity ( arci ) has completed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|gradients mω autoreg gata4 negativity|ichthyosis|compared to the same periods 2006 due to the completion of our phase 2 / 3 trial for the treatment of lamellar entity in april 2007 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|mω gradients dens densities smad1|ichthyosis|in june , barrier therapeutics announced that liarozole was granted orphan drug status from the fda for the treatment of congenital entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|benjamini mendelian normality telangiect mω|mω dystrophin ubiquitin microtubules traps|ichthyosis|frequently results in lethargy and reduced libido in men above the age of 40 , and glylorin ( tm ) , a novel treatment for entity vulgaris , a debilitating skin disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian normality telangiect mω|mω papill dystrophin nedd4 spher|ichthyosis|“primary indication” means the netherton syndrome , also known as comel-netherton syndrome , ns , bamboo hair syndrome , and entity linearis cirumflexa .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|mω negativity gradients imm cd44|ichthyosis|barrier has other product candidates in various stages of clinical development for the treatment of onychomycosis , lamellar entity , acne , psoriasis and fungal infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|mω gata4 dens gradients αvβ3|ichthyosis|of fatty aldehydes in sjögren-larsson syndrome , an orphan disease caused by mutations in fatty acid aldehyde dehydrogenase , lead to severe entity , retinal disease and neurological disorders .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian normality telangiect mω|mω vesicles ubiquitin dystrophin traps|ichthyosis|table of contents was licensed to ohr cosmetics for dermatological uses was evaluated in a moisturizer formulation in subjects with entity vulgaris at a non-us testing site .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini mendelian normality telangiect mω|mω hydroph otherwise ≥4 gata4|ichthyosis|in april 2017 , we announced that the fda granted reproxalap orphan drug designation for the treatment of congenital entity , a severe skin disease characteristic of sls .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini mendelian normality telangiect mω|mω hydroph dystrophin smad1 gradients|ichthyosis|in or entering phase 3 clinical trials for the treatment of seborrheic dermatitis , fungal infections , including vaginal candidiasis , and congenital entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 differential|mω gata4 cyclic gradients cd44|histoplasmosis|among the most common systemic fungal infections that may infect these patients include candidiasis , aspergillosis , entity , and cryptococcal meningitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality autoreg gata4 differential|dens normality dystrophin tags cd44|histoplasmosis|visudyne is also used for the treatment of subfoveal cnv due to pathologic myopia , or severe near-sightedness , and presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 differential|mω gata4 gradients cd44 spher|histoplasmosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto , " respectively ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality autoreg gata4 differential|gata4 cyclins gradients mω dystrophin|histoplasmosis|in conjunction with fujisawa , is conducting two phase iii clinical trials of ambisome in the u . s . for the treatment of entity and for the treatment of cryptococcus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality autoreg gata4 differential|gata4 dens normality cd44 dystrophin|histoplasmosis|other macular neovascular conditions such as minimally classic and occult with no classic amd lesions , pathologic myopia and presumed ocular entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality autoreg gata4 differential|dens normality gata4 tags dystrophin|histoplasmosis|in some countries , including the u . s . and canada , visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 differential|mω gata4 cyclic gradients cd44|histoplasmosis|among the most common 5 8 systemic fungal infections that may infect these patients include candidiasis , aspergillosis , entity , and cryptococcal meningitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 differential|mω gata4 gradients lgr5 cd44|histoplasmosis|endemic mycoses are caused by coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) found in the soil of certain regions of the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 differential|gata4 smad1 densities mω negativity|histoplasmosis|the trial for entity is being monitored and analyzed by the mycology study group of the national institutes of health .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|benjamini normality autoreg gata4 differential|mω gata4 chimeras densities integrins|histoplasmosis|many antibody drugs are immunosuppressive , which may lead to increased risk of serious or opportunistic infection , such as tuberculosis , entity and hepatitis b , or malignancy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 differential|mω gata4 gradients cd44 lgr5|histoplasmosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 differential|dens tags normality cd44 densities|histoplasmosis|visudyne has recently been launched for two new indications , pathologic myopia ( in the united states and europe ) and ocular entity syndrome ( in the united states ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality autoreg gata4 differential|dens normality gata4 tags dystrophin|histoplasmosis|in some countries ( including the u . s . and canada ) visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 differential|gata4 mω gradients cd44 cyclic|histoplasmosis|there are three basic forms of endemic mycoses : coccidioidomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 differential|benjamini normality calm traps negativity|histoplasmosis|presumed ocular entity syndrome ( ohs ) is a condition caused by a fungal infection endemic to certain areas in the central and eastern u . s .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality autoreg gata4 differential|dens gata4 normality dystrophin cd44|histoplasmosis|in some countries visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 differential|densities density negativity mω kv|histoplasmosis|entity phase iii cryptococcal meningitis phase iii daunoxome advanced kaposi  s sarcoma approved for marketing in the u . s . , canada and 12 western
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 differential|mω densities gata4 dens gradients|histoplasmosis|in the us , visudyne has received an additional approval for cnv due to presumed ocular entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality autoreg gata4 differential|normality dens ante biolabs tags|histoplasmosis|due to pathologic myopia in the united states , canada and the european union and for cnv due to presumed ocular entity syndrome ( " ohs " ) in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|chimeras atpases mω densities sensed|epilepsy|mothers exposed to other antiepileptic drugs , or aeds , and a purported prevalence of 0 . 07% in infants born to mothers without entity or treatment with other aeds .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|gata4 smad1 gradients kv density|epilepsy|the company has clinical stage programs in entity and asthma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|gata4 kv gradients mω smad1|epilepsy|the company is conducting research and development activities in a number of disease areas , including entity , pain and inflammation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|smad1 either densities autoreg curvature|epilepsy|we are also preparing for the potential commercial launch of diazepam nasal spray , a treatment for people with entity who experience cluster seizures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|localization densities gradients atpase autoreg|gata4 mω traps dens dystrophin|epilepsy|the products are intended to treat a variety of disorders including the following : hypertension , arthritis , seizures , entity , diabetes and pain management .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|localization densities gradients atpase autoreg|densities density cholerae autoreg certain|epilepsy|continue making payments to parteq of c$108 , 000 each quarter as a result of the renewal of the alzheimers agreement and entity agreement with parteq .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|densities density damp dens negativity|epilepsy|in 2005 , the fda requested that all makers of entity drugs analyze their clinical trial data to determine whether these drugs increase the risk of suicide in patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|≥4 refract gata4 cing cd44|epilepsy|myoclonic entity 0 1 ( 3 . 4% ) 2 ( 6 . 9% ) serious aes , or saes , of seizure were reported
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|smad1 gata4 densities mω density|epilepsy|to evaluate cbd and cbdvhs ( and possibly additional cbd-derivatives ) in a human in vitro neural model with an application to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|localization densities gradients atpase autoreg|autoreg gata4 dens kv cholerae|epilepsy|the uk entity and pregnancy register reported a similarly increased prevalence of oral clefts ( 3 . 2% ) among infants born to mothers exposed to topiramate
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|gata4 smad1 density negativity densities|epilepsy|amarins cns development pipeline includes two programs in parkinsons disease , one in entity and one in memory and cognition .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|mω gradients densities autoreg gata4|epilepsy|a patent application relating to the epm1 entity gene is pending in the uspto .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|negativity mω autoreg dens densities|epilepsy|patients with refractory focal seizures , which we refer to as the star 1 ( synthetic transdermal cannabidiol for the treatment of entity ) trial .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|gata4 autoreg negativity atpases smad1|epilepsy|in chronic use for the treatment of entity , vigabatrin has been generally well tolerated with lower than average neurological side effects compared to other approved entity therapies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|gata4 autoreg gradients atpases smad1|epilepsy|sales of drugs for the treatment of entity decreased by approximately $967 , 000 in the second quarter of fiscal 2008 compared to the second quarter of fiscal 2007 because
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|gata4 density densities kv either|epilepsy|electrical neurostimulation technology has seen growing use in recent years for numerous applications– such as chronic pain , parkinsons , essential tremor , entity , and others .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|nanog gata4 mω density gradients|epilepsy|this study was sponsored by the entity foundation , and conducted in 2013 in the laboratory of dr . annamaria vezzani at the mario negri institute for pharmacological research
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|autoreg densities gata4 chimeras smad1|epilepsy|we are developing sage-217 so that it will have what we believe is an optimal profile as a monotherapy for entity in many forms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|gata4 gradients autoreg smad1 densities|epilepsy|with janssen pharmaceuticals , inc . , is scheduled to enter a phase 2a proof of concept clinical study for the treatment of entity in h1 2021 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|localization densities gradients atpase autoreg|density densities damp dwell atpase|epilepsy|our two entity product candidates are spn-538 ( extended release topiramate ) , for which we submitted a new drug application , or nda , that was accepted
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality differential ante cracks|gata4 dystrophin gradients mω atpases|cholecystitis|these include entity ( gallbladder inflammation ) , seizure , palpitations , paresthesia and vertigo .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality differential ante cracks|mω gradients atpases gata4 autoreg|cholecystitis|there was one report of entity in a phase 1 clinical trial of lum001 and one report of elevated levels of alanine aminotransferase and aspartate aminotransferase ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality differential ante cracks|dystrophin gata4 mω αvβ3 ante|cholecystitis|ciai diagnoses include intra-abdominal abscess , stomach or intestinal perforation , peritonitis , appendicitis , entity , or diverticulitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality differential ante cracks|gata4 ante cd44 αvβ3 dystrophin|cholecystitis|a single patient during the extension study developed acute entity and cholelithiasis later treated with cholecystectomy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality differential ante cracks|gata4 gradients mω ante αvβ3|cholecystitis|one subject had a baseline pro-c3 of 9 . 9 ng / ml , experienced a serious ae of acute entity , stopped taking axa1125 at the end of week 1 and then discontinued from the study on week 5 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality differential ante cracks|autoin gata4 gradients smad1 mω|cholecystitis|serious adverse events reported in the trial included disease progression , pyrexia , mastitis , pneumonia , nausea , entity and pain in extremity , each of which was reported only once .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality differential ante cracks|gata4 gradients dens mω motors|cholecystitis|a single patient during the extension study experienced acute entity classified as a serious adverse event but deemed unlikely related to sbc-102 by the investigator .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality differential ante cracks|gata4 chimeras densities negativity dens|cholecystitis|the one subject who received akr-001 70mg iv had a serious adverse event of entity initially reported as abdominal pain beginning on day 11 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality differential ante cracks|mω gata4 gradients cd44 ante|cholecystitis|two study group subjects experienced saes , severe acute entity and moderate cellulitis , with the latter subject discontinuing treatment prior to end of treatment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality differential ante cracks|gata4 motors smad1 nanog αvβ3|cholecystitis|serious adverse events included skin infection ( cellulitis , two cases ) , abdominal pain and inflammation of the gall bladder ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality differential ante cracks|dystrophin gata4 mω ante cd69|cholecystitis|findings from a subsequent cholecystectomy were consistent with chronic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality differential ante cracks|gata4 dystrophin mω atpases csc|cholecystitis|with respect to hepatobiliary events , more patients ( 3% ) on oca 25 mg experienced gallstones or entity compared to <1% on placebo and 1% on oca 10 mg .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality differential ante cracks|mω gata4 kv αvβ3 densities|cholecystitis|the biliary system is a significant target for many conditions , including drug toxicities , entity , and liver-related abnormal function associated with the cystic fibrosis mutation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality differential ante cracks|dystrophin gata4 αvβ3 smad1 chimeras|cholecystitis|this potentially represents a previously unrecognized factor in the development of entity and cholelithiasis disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality differential ante cracks|dystrophin mω gata4 spher smad1|cholecystitis|the project seeks to determine if human cell derived nanoparticles are pathogenic and induce inflammatory ( entity ) and calcific pathologic ( cholelithiasis ) disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality differential ante cracks|gradients gata4 mω cd44 αvβ3|cholecystitis|there were two serious aes reported , acute entity and right toe infection , which were deemed not reasonably associated with the study product , and more likely due to subject  s
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality differential ante cracks|gata4 dystrophin gradients density densities|cholecystitis|the subject  s end-of-study pro-c3 level was 31 . 9 ng / ml , reflecting both the acute inflammatory state ( i . e . , acute entity ) and also likely a washout effect of axa1125 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|benjamini normality differential ante cracks|gata4 atpases gradients csc autoreg|cholecystitis|one patient was hospitalized for entity , a serious ae , two days after receiving seven days of treatment with torezolid phosphate , which the clinical investigator determined to
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality differential ante cracks|dystrophin gata4 gradients atpases motors|cholecystitis|both consisted of entity , or gall bladder inflammation , which is common in people who experience rapid or significant weight loss .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|benjamini normality differential ante cracks|mω dystrophin gata4 αvβ3 kv|cholecystitis|lidan paishi pian clear heat and promote diuresis , cholagogue and remove calculi , biliary tract infection , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|densities gata4 mω spd dens|tularemia|category is category a . the six agents that the cdc has classified as category a are anthrax , botulism , plague , smallpox , entity and viral hemorrhagic fevers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 cd44 mω spd cd69|tularemia|barda is funding studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 mω cd69 cd44 spd|tularemia|equally compelling , restanza has shown effectiveness against several lethal pathogens , including anthrax , plague , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 mω spd cd44 dystrophin|tularemia|cethromycin is also being developed as a biodefense agent for use in the treatment of anthrax , plague and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|mω gata4 cd69 spd cd44|tularemia|these two bacteria species are considered potential bioweapons and are the causative agents for plague and entity , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg benjamini normality differential gata4|densities mω gradients density motors|tularemia|the company has been in contractual negotiations for the first two products , entity and vaccinia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 cd44 mω cd69 spd|tularemia|preliminary data from our preclinical experiments indicates that our product candidates have potent activity against biowarfare agents that cause anthrax , entity and plague .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg benjamini normality differential gata4|gata4 smad1 dystrophin cd44 cyclins|tularemia|these tests have been completed in non-human primates and have shown that solithromycin is effective in treating anthrax and entity when the infection was initiated by the pulmonary route .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 densities mω spd cd69|tularemia|the department of homeland security has identified 13 such threats , including anthrax , smallpox , ebola / marburg , entity , and botulism .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 mω cd69 cd44 spd|tularemia|the bicyclolides are to be used as medical countermeasures against multiple biodefense bacteria found in anthrax , plague and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 mω spd cd44 cd69|tularemia|the fda has granted cethromycin an orphan drug designation for the prophylactic treatment of inhalation anthrax , plague and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 mω spd dystrophin cd44|tularemia|other tick-borne diseases include rocky mountain spotted fever , babesiosis , erlichiosis , anaplasmosis , powassan disease , tick-borne relapsing fever and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 mω spd troponin cd69|tularemia|· received fda orphan drug designation for restanza in plague and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg benjamini normality differential gata4|gata4 mω dystrophin chimeras αvβ3|tularemia|a non-exclusive , royalty-bearing license to use certain of our patents and related know how for the prevention or treatment of entity and viral hemorrhagic fever indications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 cd44 mω spd cd69|tularemia|barda funded studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|spd gata4 mω cd44 cd69|tularemia|for the treatment of serious hospital infections as well as the treatment of bioterror pathogens , such as anthrax , plague and entity after signs and symptoms are present .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 cd44 mω cd69 spd|tularemia|is focused on the development of antibiotic compounds to treat biowarfare agents , including the highly infectious bacteria that cause anthrax , entity and plague .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 cd44 spd nemat grp78|tularemia|solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens , specifically anthrax and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|autoreg benjamini normality differential gata4|gata4 cd44 mω spd cd69|tularemia|barda also is funding studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg benjamini normality differential gata4|dystrophin gata4 mω otherwise smad1|tularemia|after symptoms developed ; · pivotal primate study showing protective efficacy in plague ; · pivotal animal study showing 100% survival in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gata4 biased autoreg nanog benjamini|gata4 otherwise integrins mω αvβ3|hemophilia|used in the trial consistently led to long-term expression of the hfix transgene at therapeutic levels in patients with severe entity b , without acute or long-lasting toxicity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gata4 biased autoreg nanog benjamini|integrins gata4 αvβ3 otherwise mω|hemophilia|we further note that you cite uniqure and spark therapeutics as competitors with treatments for entity b in phase 3 clinical trials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gata4 biased autoreg nanog benjamini|gata4 notch integrins mω dystrophin|hemophilia|human coagulation factor ix prevention and control of bleeding in patients who suffer from entity b . completed the clinical trial and preparing documentation for the registration purpose .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gata4 biased autoreg nanog benjamini|gata4 mω αvβ3 kv motors|hemophilia|kedrion markets therapies globally for entity , hemolytic disease of the newborn , immune and neurological disorders .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gata4 biased autoreg nanog benjamini|mω gata4 densities atpases cd44|hemophilia|he has served as baxters global franchise head for entity since june 2012 and is expected to continue in that role until the separation is completed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gata4 biased autoreg nanog benjamini|gata4 cholerae mω densities atpases|hemophilia|he served as baxters global franchise head for entity from 2012 until the separation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gata4 biased autoreg nanog benjamini|gata4 mω dystrophin autoreg vw|hemophilia|for example : · porcine spleen tissue was successfully implanted into a mouse , effectively treating entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gata4 biased autoreg nanog benjamini|gata4 mω autoreg kv atpases|hemophilia| continue to build a liver-directed gene therapy platform , with an initial focus on the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gata4 biased autoreg nanog benjamini|gata4 nedd4 mω densities smad4|hemophilia|spark hereby grants pfizer the exclusive right to negotiate an agreement with spark with respect to the entity a program subject to the terms of this section 2 . 9 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gata4 biased autoreg nanog benjamini|autoreg gata4 certain ≥1 detected|hemophilia|the treatment concept is similar to entity , in which a patient is treated regularly with the particular clotting factor in which he is deficient .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|gata4 biased autoreg nanog benjamini|gata4 integrins smad1 kv microtubules|hemophilia|vwd may experience mild symptoms , but some patients can experience severe bleeding events similar to bleeding experienced by patients with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gata4 biased autoreg nanog benjamini|gata4 dystrophin cd44 integrins notch|hemophilia|an improved next-generation coagulation factor viia variant , cb 813d , that has successfully completed a phase 1 clinical trial in severe entity a and b patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gata4 biased autoreg nanog benjamini|gata4 cdh dystrophin syntaxin cd44|hemophilia|therapeutic proteins are increasingly used to treat diseases , including interferon beta for multiple sclerosis , factor viii for entity a , and monoclonal antibodies for various disorders .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|gata4 biased autoreg nanog benjamini|mω gata4 cdh integrins dystrophin|hemophilia|of our collaboration agreement for the development of coagulin-b , our product candidate that we were developing for the treatment of entity b , involving administration to the liver .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gata4 biased autoreg nanog benjamini|mω gradients αvβ3 trpv pull|hemophilia| entity b . entity b patients typically are treated by a variety of plasma-derived , recombinant or long-acting products that are produced by a number of companies , including pfizer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gata4 biased autoreg nanog benjamini|gradients gata4 mω densities density|hemophilia|in june 2014 , we acquired medpro , a specialty pharmacy focused on specialty infusion including entity and immune globulin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|gata4 biased autoreg nanog benjamini|integrins gata4 mω otherwise αvβ3|hemophilia|many other companies are developing gene therapies to treat entity b , including baxter , uniqure and dimension .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gata4 biased autoreg nanog benjamini|dystrophin gata4 normality cd44 mω|hemophilia|preliminary data in entity b mice indicate that treatment with amt-060 induces normalization of fix levels as well as clotting time .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gata4 biased autoreg nanog benjamini|gata4 chimeras damp atpases gradients|hemophilia|in december 2013 , we acquired ahf , which provides specialty drugs and infusion services for bleeding disorders , principally entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gata4 biased autoreg nanog benjamini|kv imm junction densities density|hemophilia|outlook 2017 in 2017 we plan to : · drive our entity b program towards late stage clinical development ; · continue non-clinical and preclinical studies that are expected to support an ind
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg normality benjamini gata4 differential|kv gata4 densities density cholerae|leptospirosis|we are completing the manufacture of the entity product so that we can provide evaluation lots and documentation to fiocruz for their regulatory approval submission of this product
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg normality benjamini gata4 differential|gata4 dystrophin smad1 cytoskeleton nedd4|leptospirosis|similar increases in both clinical and analytical sensitivity were observed for our human tb and entity assays .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|densities gata4 kv ubiquitin density|leptospirosis|agreements are for the following rapid test products : i ) dpp® hiv 1 / 2 screen , ii ) dpp® hiv 1 / 2 confirmatory , iii ) dpp® entity and iv ) dpp® leishmaniasis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|binders mω densities gata4 autoin|leptospirosis|we also have licensed the antigens used in other tests including our syphilis , tuberculosis , entity , leishmaniasis and chagas tests , and we may enter other license agreements .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|autoreg densities dens density negativity|leptospirosis|dpp® entity – in june 2009 , as we previously reported , we were awarded a three-year $3 million small business innovative research ( sbir )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|gradients densities spher dens cd69|leptospirosis|entity [ member ] refers to agreements relates to research and development arrangements .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg normality benjamini gata4 differential|gata4 mω dystrophin gradients imm|leptospirosis|in addition to viral vaccines , diamond also manufactures vaccines against bacterial infections , such as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|gata4 mω binders autoin densities|leptospirosis|the five products under agreement with fiocruz are for dpp® products for hiv screening , hiv confirmatory , leishmaniasis , entity and syphilis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|gata4 mω densities nedd4 ante|leptospirosis|believe fiocruz will receive during 2011 the required approvals from anvisa for the second dpp® syphilis test and the dpp® entity test , although there can be no assurance of this .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|kv autoin adherens densities mω|leptospirosis|with respect to chembio  s dpp® entity test , bio-manguinhos had not qualified to request the technology transfer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|densities autoreg dens density imm|leptospirosis|dpp® entity – we have approximately nine months left of the three-year $3 million small business innovative research ( sbir ) phase ii grant
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|gata4 mω autoin binders densities|leptospirosis|separate right to request a technology transfer for that product only are : dpp® products for hiv screening , hiv confirmatory , leishmaniasis , entity and syphilis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|autoreg normality benjamini gata4 differential|gata4 dystrophin mω αvβ3 desmin|leptospirosis|bacterial vaccines are bacterial products that are used on a routine basis to prevent diseases such as black leg , entity , red water and shipping fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|gata4 autoreg mω motors gradients|leptospirosis|from the united states national institutes of health ( nih ) to fully develop , validate , and commercialize a rapid diagnostic test for entity for general use worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|density densities mω cd69 gata4|leptospirosis|· dpp® entity phase ii grant – in 2009 we were awarded a three year , $1 . 9 million small business innovative research ( sbir ) phase
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|kv gata4 nedd4 gradients smad4|leptospirosis|three of these products ( leishmaniasis and the hiv screening and confirmation tests ) , and we have substantially completed development of the entity test .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg normality benjamini gata4 differential|gata4 smad1 densities density dystrophin|leptospirosis|this new patent-pending platform , including the testing of our current hiv test strip ( as well as our human tb and entity assays ) that was recently approved in this new platform .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|autoreg normality benjamini gata4 differential|densities mω gata4 smad1 density|leptospirosis|to be completed three-year grant from the united states national institutes of health to complete development of a test for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg normality benjamini gata4 differential|densities mω kv cholerae density|leptospirosis|a press release entitled “chembio awarded three year $3mm nih sbir phase ii grant to complete dpp® test for human entity ” .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|autoreg normality benjamini gata4 differential|densities gata4 density mω cholerae|leptospirosis|three year , $3mm phase ii nih grant for entity awarded june 2009 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian benjamini normality pull detectable|spher densities dystrophin normality pul|craniosynostosis|of limb and lungs and unregulated fgf signaling leads to a variety of human bone morphogenic disorders , including dwarfism and entity syndromes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian benjamini normality pull detectable|gata4 dystrophin otherwise densities motors|craniosynostosis|his research interests include the molecular mechanism of entity , which is the premature fusion of calvarial suture line in infants and tissue engineering of bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|mendelian normality benjamini cush autoin|gata4 gradients mω integrins autoreg|hemochromatosis|u . s . safety information for auryxia® ( ferric citrate ) contraindication auryxia® ( ferric citrate ) is contraindicated in patients with iron overload syndromes , e . g . , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini cush autoin|gata4 nanog densities autoreg density|hemochromatosis|prontotm prothrombin ( factor ii ) approved f9923 prontotm thromborisktm approved f9949 prontotm entity approved f9904 prontotm fmf basic approved f9946 prontotm cf euro i
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini cush autoin|mω chimeras gata4 restorations densities|hemochromatosis|beta thalassemia patients suffering from iron overload and the initiation of a phase 2 study for ljpc-401in patients with hereditary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini cush autoin|mω gata4 kv densities dystrophin|hemochromatosis|it is also estimated that one million americans are afflicted with hereditary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|mendelian normality benjamini cush autoin|gata4 gradients spher dens integrins|hemochromatosis|we are developing ljpc-401 for the treatment of conditions characterized by iron overload , such as entity and beta thalassemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini cush autoin|mω spher ante kv chimeras|hemochromatosis|hereditary entity hereditary hemochromatosis is an iron overload disease that can lead to life-threatening conditions such as cirrhosis , liver cancer , diabetes , heart failure and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini cush autoin|mω gata4 densities autoreg chimeras|hemochromatosis|treatment of patients with polycythemia vera , myelodysplastic syndromes and hereditary entity may represent additional opportunities for future development of ptg-300 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini cush autoin|gata4 mω smad1 dystrophin αvβ3|hemochromatosis|in addition , savyon  s products are used in clinical laboratories performing pre-disposition testing ( thrombosis , entity , certain cancers and several other diseases and conditions ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini cush autoin|gata4 kv smad1 otherwise chimeras|hemochromatosis|and chief executive officer of bond biosciences , inc . , a private start-up biotechnology company focused on addressing the iron overload in entity , from july 2016 to may 2018 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini cush autoin|mω gata4 kv vw gradients|hemochromatosis|ferisk ( tm ) is intended to become a standard in the screening , diagnosis and follow-up of hereditary entity patients , as well as others who suffer from iron overload .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|mendelian normality benjamini cush autoin|gata4 gradients autoreg autoin integrins|hemochromatosis|important safety information contraindication : patients with iron overload syndrome , e . g . entity , should not take auryxia ( ferric citrate ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini cush autoin|mω gradients spher chimeras otherwise|hemochromatosis|in addition , hereditary entity and the more severe form , juvenile hemochromatosis , are both inherited disorders of reduced hepcidin production and consequently iron overload .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini cush autoin|gata4 mω kv dystrophin motors|hemochromatosis|iron levels can be found in disorders such as cooley  s anemia , sickle cell anemia and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|mendelian normality benjamini cush autoin|mω dystrophin existence kv ante|hemochromatosis|iron overload is also associated with hereditary entity where a genetic defect in a protein involved in iron absorption leads to excess absorption of iron and iron overload
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|mendelian normality benjamini cush autoin|fals normality spher vw mω|hemochromatosis|evaluate the safety and efficacy of ljpc-401 , la jollas proprietary formulation of synthetic human hepcidin , as a treatment for hereditary entity ( hh ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients atpases otherwise atpase nanog|gata4 integrins αvβ3 atpases dystrophin|kernicterus|in june 2001 , the center for disease control  s morbidity and mortality weekly report published four case studies of entity , a form of hyperbilirubinemia which is preventable .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpases otherwise atpase nanog|autoreg gata4 smad1 motors atpases|kernicterus|the national quality forum has in the past described entity as a “never event , ” one which physicians should ensure never occurs in their practice .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpases otherwise atpase nanog|mω motors autoreg αvβ3 chimeras|kernicterus|however , phototherapy rapidly becomes less effective following puberty , increasing the risk for entity , resulting in the need for liver transplantation to control the disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpases otherwise atpase nanog|gradients mω atpases ante gata4|kernicterus|use : atazanavir is not recommended for use in pediatric patients below the age of 3 months due to the risk of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpases otherwise atpase nanog|imm densities mω negativity certain|kernicterus|the center for disease controls morbidity and mortality weekly report published four case studies of 7 table of contents entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients atpases otherwise atpase nanog|mω gata4 gradients dystrophin integrins|kernicterus|entity is a completely preventable condition that often results in permanent neurological damage brought on by the known toxic effects of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpases otherwise atpase nanog|mω negativity smad1 autoreg gata4|kernicterus|the center for disease controls report stated that early detection of hyperbilirubinemia is critical to prevent the irreversible effects of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|gradients atpases otherwise atpase nanog|gata4 integrins αvβ3 dystrophin atpases|kernicterus|in june 2001 , the center for disease controls morbidity and mortality weekly report published four case studies of entity , a form of hyperbilirubinemia which is preventable .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|gradients atpases otherwise atpase nanog|mω gata4 integrins autoreg dystrophin|kernicterus|bilirubin toxicity can ultimately result in a chronic , severe , and disabling condition called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpases otherwise atpase nanog|motors gata4 nedd4 gradients mω|kernicterus|the total loss of ugt1a1 activity and the resulting severe jaundice and risk of neurological sequelae ( entity ) are associated with cn type 1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpases otherwise atpase nanog|mω motors gata4 αvβ3 gradients|kernicterus|its effects on the fetus or newborn include hemolytic anemia , hyperbilrubinemia , entity , or intrauterine deaths due to hydrous fetalis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpases otherwise atpase nanog|mω negativity smad1 gata4 autoreg|kernicterus|the center for disease control  s report stated that early detection of hyperbilirubinemia is critical to prevent the irreversible effects of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gradients atpases otherwise atpase nanog|gata4 mω smad4 certain gradients|kernicterus|entity is a cerebral palsy-like condition in which the patient lacks muscle tone and motor control , cannot operate self-sufficiently , and typically requires long-term care .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality null cholerae dens kolmogorov|motors mω gata4 gradients densities|cytotrophoblasts|high complexity probes according to claim 28 wherein said fetal cells are leukocytes and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|mω smad1 density autoreg densities|oligodendrocytes|the pathology of spinal cord injury involves extensive loss of the myelin sheath produced by entity at the site of injury .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|densities density imm mω saturation|oligodendrocytes|was studied in rat brain 3d microtissues , a 3d cell model containing a mix of neurons , astrocytes , microglial cells and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|densities density mω traps hypo|oligodendrocytes|occurs in a diffuse fashion throughout the adult brain and appears to reflect a loss of axonal support by local entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|densities gata4 density mω gradients|oligodendrocytes|in our preclinical research , we have shown that hucns-sc cells differentiate into entity , the myelin producing cells , and produce myelin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|densities gata4 dens density saturation|oligodendrocytes|mechanism of action underlying the enhanced remyelination in vivo and shown that multistem cells and secreted factors increase differentiation of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|gata4 autoreg uncou atpases smad1|oligodendrocytes|remyelination remyelination is the process propagating oligodendrocyte precursor cells to form entity to create new myelin sheaths on demyelinated axons in the cns .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|gradients gata4 density gradient densities|oligodendrocytes|entity are natures neuronal insulating cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|gata4 densities ≥4 autoreg mω|oligodendrocytes|deficient in myelin production , transplantation of hcns-sc into the brain resulted in widespread engraftment of human cells that matured into entity , the myelin producing cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|gata4 namely densities autoreg gradients|oligodendrocytes|q-cells produce astrocytes and entity , the support cells that enable the normal function of neurons .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|gradients gata4 gradient density densities|oligodendrocytes|entity are natures neural insulating cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|dens densities negativity boltzmann density|oligodendrocytes|japan patent 2011-047716 – entity derived from human embryonic stem cells for remyelination and treatment of spinal cord injury are described .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|gradients saturation gata4 gradient densities|oligodendrocytes|myelin sheath that insulates nerve fibres , or axons , in the central nervous system and the cells that make myelin , the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|gata4 smad1 gradients atpases autoreg|oligodendrocytes|like the insulation covering an electrical wire , entity enable the conduction of electrical impulses along nerve fibers throughout the central and peripheral nervous system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|densities density gradients mω negativity|oligodendrocytes|$ 4 , 000 tissue culture - culture of primary entity derived from mixed glial cultures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|densities mω dens gata4 sensitivities|oligodendrocytes|financial statements gpc program our gpc program aims to deliver healthy allogeneic gpcs , the precursors to both astroglia and myelin-producing entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|densities atpases autoreg dens chimeras|oligodendrocytes|the patent relates to methods of making entity from human embryonic stem cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density dens uncoupling|densities gata4 density namely sensitivities|oligodendrocytes|the resulting differentiated cells ( astrocytes and entity , shown in figure 2 ) then can perform the support functions of these glial cells in vivo as described above .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae atpases|densities gradients density either gata4|osteocytes|sclerostin is produced in entity , which are mature bone cells that are thought to be the mechanoreceptor cells that regulate the activity of bone-building osteoblasts
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae atpases|mω motors gradients resides exists|osteocytes|the presence and absence of particular biological markers , and the ability of the cell to differentiate into at least adipocytes , entity , endothelial cells and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients density cholerae atpases|gata4 dystrophin mω resonance namely|osteocytes|merits bone formation involves the migration of undifferentiated mesenchymal cells , differentiation into cartilage , and subsequent bone replacement by osteoblasts and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|densities gradients gata4 density signals|osteoclasts|in addition , unlike currently marketed ra 1 table of contents drugs , fpa008 directly inhibits bone-destroying cells called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities cytoskeleton motors nanog null|gata4 dystrophin mω cd69 densities|osteoclasts|gallium acts upon bone by enhancing the formation of osteoblasts and inhibiting entity , thereby increasing bone deposition and reducing bone turnover .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|densities density gradients existence negativity|osteoclasts|up to now , bisphosphonates have been most effective in tumors where bone destruction is caused primarily by overstimulation of entity , which abnormally accelerate the breakdown of bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities cytoskeleton motors nanog null|gata4 dystrophin densities peaked cd69|osteoclasts|two main types of cells are responsible for this process : entity , which break down bone tissue , and osteoblasts , which secrete new bone tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|densities gradients peaked namely gata4|osteoclasts|bisphosphonates are compounds that bind with high affinity to bone mineral and inhibit the bone‑resorbing cells called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|negativity trap densities gata4 existence|osteoclasts|entity resorb bone by secreting protons and generating an acidic extracellular microenvironment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|gata4 densities gradients signals minima|osteoclasts|sct is a hormone that inhibits the bone-tissue resorbing activity of specialized bone cells called entity , enabling the bone to retain more of its mass and functionality .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|gata4 optimum namely existence mω|osteoclasts|bone health is maintained through regulation of the competing activities of bone forming cells ( osteoblasts ) and bone resorbing cells ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|densities gradients density junction gata4|osteoclasts|treatment of ra in which it reversibly blocks signaling in multiple cell types involved in inflammation and tissue degradation ( e . g . macrophages , entity , mast cells and b cells ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|densities cytoskeleton motors nanog null|gata4 integrins densities microtubules csc|osteoclasts|( osteopenia ) • ( a ) when bone marrow derived macrophages ( bmdm ) from nomid mice are stimulated with rankl ( rank ligand ) , they differentiate into entity • : 1315-1325 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|densities smad4 junctions junction density|osteoclasts|rankl stimulation macrophages entity nomid bmdm nomid bmdm plus ati-450 ( a ) ( b ) bone marrow derived macrophages ( bmdm ) from nomid mice 19© copyright 2020 aclaris
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|peaked densities gradients existence density|osteoclasts|zoledronic acid is the most potent bisphosphonate , a class of drugs known to inhibit entity , which are key cells involved in the maintenance , repair and remodeling of bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|gata4 mω densities existence junction|osteoclasts|cells called osteoblasts cause new bone formation while other cells called entity remove old bone through a process called resorption .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|densities gata4 peaked signals gradients|osteoclasts|axs‑02 is a potent inhibitor of entity , which are bone remodeling cells that break down bone tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|densities existence gradients namely signals|osteoclasts|bisphosphonate drugs slow down the rate at which entity , which are cells which resorb or take away bone , reduce the bones mass .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|densities gradients density gata4 tight|osteoclasts|in people with osteopetrosis , this balance is not maintained because their entity do not function properly .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|densities gradients peaked namely sensitivities|osteoclasts|bisphosphonates are compounds that bind with high affinity to bone mineral and inhibit the bone-resorbing cells called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|densities gata4 density mω smad1|osteoclasts|calcitonin , a peptide , inhibits bone resorption by acting on specific receptors on entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|adherens motors gata4 junction nedd4|osteoclasts|ntx serum became the first and only commercially available test in the united states that measures specific bone breakdown by entity using a blood sample .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities cytoskeleton motors nanog null|mω densities gradients dens saturation|osteoclasts|the drug appears to be selectively toxic for activated entity , displaying a negligible effect on bone marrow stromal cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|densities atpases gradients gata4 density|monocytes|csf-1r is expressed on the surface of specific immune cells known as macrophages and their precursor cells known as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|density densities junction atpases autoreg|monocytes|this is an exclusive license to a stem cell technology in which adult pluripotent stem cells are derived from entity obtained from the patient  s own blood .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|autoreg densities certain saturation nanog|monocytes|these mdsc can be derived from a patients entity , expanded ex vivo , and then administered to the same patient .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|densities density gradients gata4 namely|monocytes|targets the colony stimulating factor-1 receptor , or csf-1r , a cell surface protein thought to control the survival and function of entity and macrophages .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|densities mω density gradients autoreg|monocytes|researchers have been able to turn these dedifferentiated entity into several different types of cells including islet cells , nerve cells , liver cells , blood vessel cells and skin cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities dens gradients junction density|density densities gata4 negativity dystrophin|monocytes|in january 2017 , we reported that targeting of mospd2 inhibits chemotaxis of entity and neuropils , and that unpublished vbl data also show mospd2 expression on certain tumor cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|densities density gradients gata4 saturation|monocytes|fpa008 ( cabiralizumab ) : an investigational antibody that inhibits csf1r and has been shown to block the activation and survival of entity and macrophages .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities dens gradients junction density|gradients saturation mω dystrophin gata4|monocytes|cells ; and  these proteins secondarily activate other innate immune cells such as natural killer cells and entity , which become able to recognize and kill some tumor cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|motors junction densities mω atpases|monocytes|eascs exhibit broad immunomodulatory properties , including the regulation of immune cells such as b lymphocytes , t lymphocytes , natural killer cells , entity or macrophages and neutrophils .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|densities dens gradients junction density|gradients densities density gradient integrins|monocytes|when applied to human immune cells such as entity , selective immunoproteasome inhibitors , like kzr-616 and onx 0914 , blocked the release of inflammatory cytokines following cell stimulation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|uncoupling densities density nanog leak|monocytes|the companys stem cell technology isolates novel multipotent stem cells derived from peripheral blood entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|densities density mω gradients saturation|monocytes|patients with various diseases , as well as established cell lines from immune and non-immune cell lineages , including t cell subsets , entity , macrophage subpopulations and cancer cell lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|gradients junction densities gauge density|monocytes|fcgri is expressed in certain human immune cells including entity , macrophages and dendritic cells and may function to activate these immune cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|density uncoupling densities nanog leak|monocytes|our stem cell technology isolates novel multipotent stem cells derived from peripheral blood entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|densities saturation junction gata4 density|monocytes|immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , granulocytes , mast cells and entity / macrophages .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|autoreg densities certain saturation nanog|monocytes|these mdsc can be derived from a patients entity , expanded ex vivo , and then administered to the same patient .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|densities dens gradients junction density|gradients mω motors uncoupling microtubules|monocytes|cells with the cd4 receptor are critical components of the immune system and include t lymphocytes , entity , macrophages and dendritic cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|densities density gradients gata4 saturation|monocytes|developments clinical pipeline : cabiralizumab ( fpa008 ) : an antibody that inhibits csf1r and has been shown to block the activation and survival of entity and macrophages .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|junction uncoupling density densities gradients|monocytes|our novel multi-potent stem cell is derived from peripheral blood entity which when cultured under defined conditions are able to further differentiate into several cellular lineages .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens gradients junction density|density junction uncoupling densities gradients|monocytes|our multi-potent stem cell is derived from peripheral blood entity which when cultured under defined conditions are able to further differentiate into several cellular lineages .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|densities autoin autoreg mω gata4|fibroblasts|the entity are then harvested , tested by quality control and released by quality assurance prior to shipment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|banding dens gradients cholerae junction|dystrophin sensitivities resonance signals autoin|fibroblasts|of disease causing ability , was accomplished by making over 500 passages of the virus in chicken embryos or chick embryo entity which resulted in large genomic deletions .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|banding dens gradients cholerae junction|dystrophin resonance junction sensitivities signals|fibroblasts|products and reagents like avian cell substrates have rt activity that does not represent adventitious infectious retroviruses ( e . g . chicken embryo entity , dermal cells and eggs ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|saturation gradients smad1 gata4 motors|fibroblasts|method of enhancing wound healing by stimulating entity and keratinocyte growth in vivo , utilizing amphipathic peptides .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|gradients densities density mω saturation|fibroblasts|the company has produced clonal populations of human entity which have been transfected to express factor viii in vitro , demonstrated that the protein is properly processed and achieved protein
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|mω gradients autoin chimeras junction|fibroblasts|hses are composed of both a dermal layer containing entity and an epidermal layer containing keratinocytes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|densities density gradients either gata4|fibroblasts|cold selectively inhibits akt activation in human cancer cells compared to normal proliferating cells ( e . g . , human entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|mω chimeras atpases autoreg certain|fibroblasts|used are fat injections and cell injections , which are mainly based on enriching the damaged tissue with external source of entity cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|saturation either junction mω gradients|fibroblasts|furthermore , ccl24 is constitutively expressed by skin and dermal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|junction mω gradients densities junctions|fibroblasts|pierer m , brentano f , rethage j , et al . the tnf superfamily member light contributes to survival and activation of synovial entity in rheumatoid arthritis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|mω gradients kerat densities optimum|fibroblasts|● increase in apoptosis of inflammatory cells , including neutrophil and pro-fibrotic cells , including entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|gradients otherwise saturation density densities|fibroblasts|product consisting of a cream vehicle blended with the conditioned media extract from the cell culture of a customers own entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|densities density gradients gata4 saturation|fibroblasts|we isolated and cultured entity from lhon-nd4 patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|banding dens gradients cholerae junction|junction mω junctions gap dystrophin|fibroblasts|the rheumatic diseases 72 adenosine a2a receptor activation stimulates collagen production in sclerodermic dermal entity either directly and through a cross-talk with the cannabinoid system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|banding dens gradients cholerae junction|tight density divertic autoreg smad4|fibroblasts|in these entity , we demonstrated that gs010 restores mitochondrial function , including complex i activity and atp production , to the level of normal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|banding dens gradients cholerae junction|gradients motors imm junction microtubules|fibroblasts|in ssc patients , increased production of no is suggested by increased expression of inos in endothelial cells , entity , mononuclear cells infiltrating ssc skin and alveolar macrophages .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|gradients saturation density densities mω|fibroblasts|much of tkt  s work has focused on gene therapy using entity , a cell type present in the skin ( and throughout the body ) that is readily obtained from patients and propagated in
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|gradients gata4 densities mω atpases|fibroblasts|entity are also found in the dermis and are responsible for creating collagen and elastin that provide strength and flexibility to
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|banding dens gradients cholerae junction|junction junctions sensitivities tags adherens|fibroblasts|dermagraft dermagraft is a dermal substitute grown from human dermal entity and has received pma approval for the treatment of dfus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|banding dens gradients cholerae junction|densities dystrophin density atpases gata4|fibroblasts|von zglinicki t , saretzki g , docke w , lotze c . mild hyperoxia shortens telomeres and inhibits proliferation of entity : a model for senescence? .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens atpases|mω either gata4 smad1 nanog|thymocytes|description thymoglobulin* [ anti-thymocyte globulin ( rabbit ) ] is a purified , pasteurized , gamma immune globulin , obtained by immunization of rabbits with human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|densities gradients density dens atpases|gradients autoreg microtubules gata4 densities|thymocytes|under control conditions , lps kills entity , which are important immune system precursor cells , known as t cells , created in the thymus to fend off infection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|densities gradients density dens atpases|gradients microtubules densities autoreg boltzmann|thymocytes|under control conditions , lps kills entity , which are important immune system precursor cells created in the thymus to fend off infection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens atpases|mω gradients saturation densities dens|thymocytes|implants in the haart and nanoviricide treatment groups exhibited 80-85% cd4+ , cd8+ dp cells while the vehicle control groups had only approximately 30% cd4+cd8+ entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens atpases|mω either gata4 nanog cd44|thymocytes|description thymoglobulin® [ anti-thymocyte globulin ( rabbit ) ] is a purified , pasteurized , gamma immune globulin , obtained by immunization of rabbits with human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens atpases|mω gradients either densities density|thymocytes|its cognate receptor , pd-1 , is a co-inhibitory transmembrane protein expressed on t cells , b cells , natural killer cells and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients density dens atpases|gradients uncoupling gata4 dystrophin densities|thymocytes|senescos technology allowed for approximately 90% greater survival of these entity in the presence of lps .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|gradients mω traps saturation gata4|neutrophils|the effect of the drug on the recovery of entity is slow .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cell|gradients densities density uncoupling cholerae|gata4 gradients integrins dystrophin motors|neutrophils|in preclinical studies , plinabulin increased the survival of entity , a type of white blood cell important in the prevention of bacterial infections .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|gradients densities density uncoupling cholerae|gata4 smad1 microtubules either imm|neutrophils|factor in promoting bacterial invasion as well as rendering the bacteria resistant to attack from reactive oxygen species ( ros ) and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|gata4 uncoupling gradients smad1 nanog|neutrophils|neulasta selectively stimulates the production of entity that are depleted by cytotoxic chemotherapy , a condition called neutropenia that makes it more difficult for the body to fight
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|negativity imm smad1 mω gradients|neutrophils|role of c5a and c5ar in hs entity are believed to play an important disease-promoting role , as well as certain cytokines and mediators commonly found in autoimmune diseases ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|saturation gata4 gradients mω densities|neutrophils|patients treated with omidubicel recovered their entity ( 500 cells per microliter ) with a median recovery of 11 . 5 days after transplantation , which is significantly shorter than the 21
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|gradients saturation junction pits sensitivities|neutrophils|in addition , 10150 decreased sm-induced increase in the numbers of bal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|gradients densities saturation mω gata4|neutrophils|immunomodulatory properties , including the regulation of immune cells such as b lymphocytes , t lymphocytes , natural killer cells , monocytes or macrophages and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|gradients densities junction density mω|neutrophils|addition to its expression on b cells , cd32b is also expressed on other immune cells such as dendritic cells , macrophages , entity , and mast cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|gata4 motors mω either cyclins|neutrophils|these cells are programmed to end up as blood cells of a specific type , such as entity , red blood cells and platelets .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|densities density autoin mω motors|neutrophils|blood versus the lymphoid tissues , you have a preferential depletion of cd4 , cd8 and b cells , much greater than nk , entity and plasma cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|gata4 mω benjamini kolmogorov ante|neutrophils|in addition , the treatment is associated with considerable adverse events like neutropenia ( low entity ) and neuropathy ( damage to the peripheral nervous system ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|saturation gata4 smad1 mω gauge|neutrophils|although these conditions have multiple causes , each involves neutrophil adhesion to the blood vessel wall and the subsequent migration of entity into the tissue .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|gradients densities density uncoupling cholerae|gradients microtubules gata4 motors junction|neutrophils|also treated with viprovex , did not develop the clinical symptoms of viral infection , which included increases in alveolar macrophages and entity in broncho-alveolar lavage fluid .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|gata4 gradients outer autoin densities|neutrophils|the studys primary endpoint was time to neutrophil engraftment , and was met based on recovery of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|saturation gata4 gradients mω densities|neutrophils|patients treated with nicord recovered their entity ( 500 cells per microliter ) with a median recovery of 11 . 5 days after transplantation , which is significantly shorter than the 21
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|mω dens gata4 gradients kh|neutrophils|animal studies to allow manipulation and control of oxidative biomarkers of protein and dna , nitric oxide , antioxidant enzymes and inflammatory entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities density uncoupling cholerae|gata4 dystrophin saturation gradients mω|neutrophils|second , pep005 activates the bodys immune system , causing entity , a type of white blood cell , to infiltrate the treated site .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|gradients smad1 autoreg atpases mω|neutrophils|companies such as amgen inc . have developed or are developing products to boost entity after chemotherapy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density uncoupling cholerae|gradients saturation densities mω imm|neutrophils|once in the tissue , entity release toxins which attack normal cells as well as the antigen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|mω dens traps uncoupling autoreg|lymphocytes|approximately 80% of all all cases involve lineage entity in the bone marrow .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|gradients clock nanog atpases autoreg|lymphocytes|were generated in the t cell transfer model which utilizes immunodeficient mice which are deficient in functional b and t entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|gradients densities dens mω density|lymphocytes|there are two main categories of entity : b-entity , or b-cells , and t-entity , or t-cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|densities gradients dens density motors|gradients junction mω intraepithelial dens|lymphocytes|the immune system is composed of a network of immune cells that include t entity ( t cells ) and b entity ( b cells ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|gradients densities saturation density imm|lymphocytes|the most crucial types of cells are antigen-presenting cells , or apcs , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|gata4 gradients either densities unless|lymphocytes|to the occurrence and severity of these adverse events due to its role in inducing lymphopenia , or low levels of entity in the blood , and enhanced car t cell activity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|mω gradients gata4 motors atpases|lymphocytes|or more diagnostic antigens for detection of tuberculosis infection by measuring g-ifn ( gamma-interferon ) ( or , in field b , other cytokine- ) secreting entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|saturation mω motors cyclins densities|lymphocytes|allogeneic bone marrow transplant in which tissues of the host , most frequently the gut , liver , and skin , are attacked by entity in the donor ( graft ) marrow .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|mω gap junction uncoupling gata4|lymphocytes|abnormally large numbers of immature , abnormal entity called lymphoblasts are produced and released into the bloodstream .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|lamina discrimination atpase gradients clock|lymphocytes|as shown below , following gp2 immunotherapy , cd8+ cytotoxic t entity recognize and destroy her2 / neu-expressing cancer cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|gradients discrimination curvature autoreg mω|lymphocytes|lymphokine any of a number of soluble physiologically active factors produced by t entity in response to specific antigens .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|autoreg densities density gradients dens|lymphocytes|ceplene is designed to protect entity responsible for immune-mediated destruction of residual leukemic cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|densities gradients dens density motors|gradients avidin uncoupling nanog motors|lymphocytes|white blood cells that have differentiated to produce a specific antibody are called b entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|gradients saturation atpases gata4 densities|lymphocytes|the type of immune response is characterized by the way the response was initiated through specialized cells known as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|mω restorations ante dens grades|lymphocytes|as predefined in the clinical protocol , patient subgroups were evaluated for levels of tumor infiltrating entity ( til ) and for pd-l1 checkpoint protein expression on tumor cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|saturation gradients mω autoreg gata4|lymphocytes|consequently , in each persons bloodstream , only a relatively few entity will recognize the same antigen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|junction junctions saturation mω dens|lymphocytes|til means tumor infiltrating entity that are collected from a tumor cell , including naturally-occurring t cells with specificity against such tumor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|nanog mω autoreg saturation dens|lymphocytes|itk , an enzyme that functions in t‑cell signaling and differentiation , is expressed predominantly in t‑cells , which are entity that play a vital role in immune responses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients dens density motors|restorations mω dystrophin dens junctions|lymphocytes|) – lion biotechnologies , inc . ( otcqb : lbio ) , a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating entity ( til )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|uncoupling gradients clock nanog cracks|lymphocytes|although the exact mechanism of action for alemtuzumab is unknown , it is presumed to deplete circulating t and b entity after each treatment course .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|gradients density densities gata4 smad1|platelets|genetically linked by an amino acid linker , targeting the a1 domain of vwf and inhibiting the interaction between ulvwf and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities junction cholerae density|motors dystrophin gradients gata4 densities|platelets|the ellipse in the upper left- hand corner contains the phrase " virally inactivated red blood cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|smad1 gata4 kv densities motors|platelets|against acutect® because fibrimage® binds to fibrin , which comprises 75-80% of an actively forming blood clot , whereas acutect® binds to entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities junction cholerae density|gradients saturation motors dystrophin gata4|platelets|blood and immune systems , including : t cells and b cells to fight infections ; red blood cells to carry oxygen and entity to control bleeding .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|gata4 gradients uncoupling mω optimum|platelets|immune thrombocytopenia ( itp ) - itp is an uncommon autoimmune bleeding disorder characterized by insufficient entity in the blood .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|densities density gradients gata4 smad1|platelets|these agents work by preventing the ability of entity to aggregate together .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|nanog gata4 atpases gata3 localizes|platelets|we have contributed novel research and technologies for approved medicines that treat cancer , osteoporosis , fungal infections and low blood entity , among others .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|gata4 motors gradients kv mω|platelets|are overproduced in the bone marrow affecting the synthesis of normal blood cells , causing a decrease in red blood cells , entity and normal white blood cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|saturation gata4 density uncoupling existence|platelets|glutamate release by a platelet acts to stimulate release of glutamate from other entity , potentially leading to aggregation and the formation of the thrombus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|gata4 nanog saturation gradients mω|platelets|banks or transfusion centers because the main objective of these banks and centers is to obtain the blood cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|density densities trap junction gradients|platelets|released glutamate acts by binding cell surface glutamate receptors expressed on entity themselves .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|nanog gradients gata4 existence densities|platelets|the affected individuals make antibodies against their own entity leading to the entity  destruction , which in turn leads to the abnormal bleeding .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|smad1 autoreg gata4 gradients densities|platelets|the effects of integrilin are specific to entity , avoiding interference with other normal cardiovascular processes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|gradients densities junction cholerae density|mω motors integrins autoin gata4|platelets|in many hematological disorders , there is abnormal proliferation and differentiation of the progenitor cells for red blood cells , entity and neutrophils .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|dens gradients nanog gata4 either|platelets|in addition to anemia , fatigue , hair-loss , reduction in blood entity and white and red blood cells , and bone pain , one of the most common side effects of chemotherapy is nausea
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|gradients imm saturation gata4 densities|platelets|our laboratory personnel had previously developed a pre-clinical itp model with data showing that prtx-100 inhibits the phagocytosis ( ingestion ) of entity in vitro .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities junction cholerae density|smad1 gata4 gradients dystrophin motors|platelets|integrilin is a small synthetic peptide administered by injection that prevents the aggregation of entity by blocking the platelet receptor glycoprotein , or gp , iib-iiia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|gata4 autoreg density densities ubiquitin|platelets|a2 ( blocked by aspirin ) and adenosine diphosphate ( blocked by plavix® ) , researchers have recently demonstrated the release of glutamate by entity during platelet activation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities junction cholerae density|motors junction nanog gradients atpases|platelets|plasma donation means that donors give only plasma but not the other blood components such as entity , red cells and infection-fighting white cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities junction cholerae density|gata4 densities gradients dystrophin density|platelets|training he performed basic research at the royal prince of wales hospital to develop a new monoclonal antibody to inhibit entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|smad1 either density densities gata4|leukocytes|integrins are subdivided into those on entity , and those that recognize rgd‑peptide , collagen and laminin ligands .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|autoreg gata4 chimeras densities mω|leukocytes|the costs and availability of entity are subject to fluctuation depending on a variety of factors beyond our control , including competitive factors , changes in technology , and
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|either uncoupling gata4 cd44 gradients|leukocytes|human entity produce millions of different types of antibodies , all with varying shapes that allow them to attach to and , as a
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|smad1 either density gata4 densities|leukocytes|integrins are subdivided into those on entity , and those that recognize rgd-peptide , collagen and laminin ligands .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|densities gradients cholerae junction cracks|gradients gata4 phalloidin cytoskeleton leak|leukocytes|manufacture of interferon human white blood cells , also known as entity , and a stimulating agent are needed to produce human leukocyte derived interferon .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|autoin autoreg mω densities gradients|leukocytes|if we are unable to obtain the necessary entity , we may be required to scale back our operations or stop manufacturing multiferon® .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|cytoskeleton normality vul gata4 cd69|leukocytes|in inflammation , white blood cells ( entity ) move out of the bloodstream into the inflamed tissue , for example , the cns in ms , and the lung airways in
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|chimeras gata4 smad1 densities dens|leukocytes|comprising phosphosugar residues , that play a central role in the entry of is , sugar residues bearing at least one entity into inflammatory sites .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|smad1 gata4 densities density imm|leukocytes|the next stage of development of integrins as drug targets has focused on integrin receptors on entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients cholerae junction cracks|densities gata4 density cholerae either|leukocytes|edinburgh , scotland , and has the physical and , with the company  s proprietary technology , the technical capacity to manufacture omniferon ( tm ) from human entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|saturation gradients dens junction pits|leukocytes|in addition , the bronchoalveolar lavage of anti-siglec-8 treated mice displayed reduced levels of infiltrating entity that were similar to sham treated animals .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|motors atpases mω outer nanog|leukocytes|revenue was derived from the commercial sales of its leukonet system , a medical device designed for the removal of contaminating entity from donated blood .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|saturation gradients dens junction pits|leukocytes|in addition , the bronchoalveolar lavage ( bal ) of anti-siglec-8 treated mice displayed reduced levels of infiltrating entity that were similar to sham treated animals .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|gradients saturation mω resonance gradient|leukocytes|chemokines are cytokines which regulate the trafficking patterns of entity , the effector cells of the human immune system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|gradients mω uncoupling cytoskeleton gata4|leukocytes|antibodies are made in the immune system by human white blood cells , called entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|leak atpases leakage nanog gata4|leukocytes|by the first quarter 2007 , we anticipate preparing new alferon n injection ( r ) lots from blood entity at our new jersey facility .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|atpases mω dens pull gata4|leukocytes|typically by extraction with vegetable oil and hydrophobic chromatography , and sterile filtering to remove bacteria , parasites and all undesirable blood entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|uncoupling saturation nanog gata4 leak|leukocytes|monocytes phagocytic blood entity , originating from the bone marrow .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|either saturation resonance smad1 density|leukocytes|addition of sialyl lewis x ( " slex " ) carbohydrate side chains yielding scr1sle x . slex is a carbohydrate which mediates binding of entity including neutrophils to selectin proteins .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction cracks|gata4 densities density gradients ante|leukocytes|risk of poorer clinical outcomes as measured by atlas score , a tool for evaluating cdi in patients by age , temperature , entity and albumin levels , and use of systemic antibiotics .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|mω uncoupling saturation densities either|macrophages|abx-cbl the cbl antigen is selectively over-expressed on activated immune cells including t-cells , b-cells and certain entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|gradients gata4 density uncoupling densities|macrophages|activated entity release a variety of mediators of inflammation that contribute to a broad range of diseases , such as rheumatoid arthritis , osteoarthritis ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|cholerae junction gradients telangiect junctional|gata4 gradients autoreg microtubules motors|macrophages|the targeting of cd47 to make cancer cells susceptible to entity , a component of the innate immune system , is analogous to the approach that has been applied with checkpoint inhibitors and
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|saturation gradients mω sensitivities gata4|macrophages|beyond cancer , we have discovered that activated entity , a type of white blood cell found at sites of acute and chronic inflammation , also over-express the folate receptor .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|gradients densities density gata4 motors|macrophages|this is carried out primarily by some specialized cells in the blood ( e . g . , monocytes and entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|gradients motors autoreg densities atpases|macrophages|these compounds , intended for use as immuno- pharmaceutical agents , activate entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cholerae junction gradients telangiect junctional|densities density gata4 dystrophin motors|macrophages|immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , granulocytes , mast cells and monocytes / entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|motors densities mω unless gradients|macrophages|in patients with cancer , immuno-evasion occurs as a result of suppressor entity ( m2 ) and inhibitory myeloid suppressive cells and treg cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|gradients gata4 motors mω gauge|macrophages|entity are cells found in the blood which recognize and destroy malignant cells and invading microbes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|densities gradients saturation dens otherwise|macrophages|the mt-2000 series is designed to modulate activated entity from a classically activated phenotype to the alternatively activated phenotype .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|saturation mω gradients smad1 motors|macrophages|recent experiments have shown that complex polynucleotides administered topically are absorbed by cells such as keratinocytes and entity within the superficial skin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|densities gradients autoreg gata4 atpases|macrophages|the mt-1000 series is designed to deplete activated entity via apoptosis and / or alter the phenotype of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cholerae junction gradients telangiect junctional|saturation gradients gata4 dystrophin densities|macrophages|expressed by tumor cells and have been modified to more efficiently attract immune effector cells , such as nk cells and entity , to effectively kill tumor cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|cholerae junction gradients telangiect junctional|autoin motors integrins densities autoreg|macrophages|phagocytes are a class of white blood cells , which include monocytes , entity and neutrophils , found in abundant quantities in and around tumors and areas of infection .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|gata4 densities density saturation gradients|macrophages|we believe that by inhibiting csf-1r activation on monocytes and entity , that axatilimab has the potential to be used to treat cgvhd .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|peaked gradients saturation gata4 existence|macrophages|entity affected by the disease become highly enlarged due to the accumulation of glccer and are referred to as “gaucher cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|densities gata4 autoreg smad1 sensitivities|macrophages|our anti-mirs promotes reverse cholesterol transport , or rct , which is the efflux of cholesterol from specific cholesterol-laden inflammatory cells called entity in atherosclerotic plaques .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|gata4 gradients autoreg normality otherwise|macrophages|absence of an active gcd enzyme leads to the accumulation of glccer in lysosomes of certain white blood cells called entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|gradients mω junction saturation densities|macrophages|the surface of almost all nucleated cells , and mhc class ii , expressed constitutively on professional antigen presenting cells ( apc ) , including entity and dendritic cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae junction gradients telangiect junctional|gradients densities saturation gata4 density|macrophages|growth factor receptors known as her2 and her3 , as well as recruit immune killer cells , such as nk cells and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|densities uncoupling cyclins autoin mω|plasmablasts|promising approach for the treatment of rrmm patients due to the restriction of bcmas expression solely on the surface of entity and differentiated plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients normality uncoupling kolmogorov cracks|gradients gata4 autoreg cholerae densities|plasmablasts|entity are highly enriched for vaccine-specific b cells and , therefore , negligible in pre-vaccination , day 0 samples .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|mω motors otherwise uncoupling junction|plasmablasts|disease , and other conditions such as kidney transplant , are associated with autoantibodies secreted by a subset of b cells known as entity and plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|mω gradients junction dens refractory|plasmablasts|cd19 is a cell surface molecule broadly expressed on b cells , including some antibody-secreting entity and plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|dens gradients gata4 densities autoreg|plasmablasts|we presented data from the study demonstrating that our vaccine elicited a significant expansion of mucosal homing receptor entity to approximately 60% of all activated b cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|gata4 gradients atpases veloc densities|plasmablasts|if entity are elevated in a particular sample , we then employ a multi-step process to generate a potential product candidate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|mω motors junction otherwise gradients|plasmablasts|other conditions such as kidney transplant desensitization , are associated with autoantibodies secreted by a subset of immune b cells known as entity and plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|mω motors otherwise gradients autoin|plasmablasts|in the autoantibody pathway , autoantibodies are secreted by a subset of immune system b cells known as entity and plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|gradients cd44 junction gata4 dens|plasmablasts|we believe these mucosal entity are a key indicator of a protective mucosal immune response and a unique feature of our vaccines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|mω gap gata4 junction gradients|plasmablasts|in in vitro studies using human immune cells , cpi-006 led to activation of b cells and differentiation into antibody producing entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|mω gradients junction refractory dens|plasmablasts|cd19 is a molecule broadly expressed on b cells , including some antibody-secreting entity and plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|mω densities density gradients motors|plasmablasts|mechanism of action a number of autoimmune diseases , including nmosd , are associated with autoantibodies secreted by entity and some plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|gata4 gradients pkcα smad1 cd44|plasmablasts|we believe entity are a key indicator of a protective mucosal immune response and a unique feature of our vaccines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|gradients normality uncoupling kolmogorov cracks|gata4 autoreg gradients motors microtubules|plasmablasts|pbmcs were collected at day 0 and day 7 , enriched for entity and analyzed in elisas against either the prefusion or the postfusion version of the f protein antigen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|gata4 gradients autoreg motors atpases|plasmablasts|for those patients , we then examine their samples for rare antibody-producing b cells called entity that are elevated during an active immune response .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality uncoupling kolmogorov cracks|gradients densities saturation autoreg gata4|plasmablasts|we start by isolating single entity and determining the sequences of the co-expressed antibody genes using our proprietary immune repertoire capture® technology .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|motors dens cholerae gradients densities|junction atpases motors densities microtubules|pericytes|in contrast , svf is merely a heterogeneous fraction including preadipocytes , endothelial cells , smooth muscle cells , entity , macrophages , fibroblasts and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|motors dens cholerae gradients densities|mω dystrophin gata4 peaked gradients|pericytes|in wet amd abnormal new blood vessels are predominantly made up of two cell types , endothelial cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|gradients resonance saturation either mω|pericytes|entity then intimately cover the outside of these blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|gradients junction localizes motors autoin|pericytes|these normal , blood vessel endothelial cells have matured , and have much greater supporting structures such as entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|gradients gata4 smad1 autoreg motors|pericytes|entity locally supply the endothelial cells with growth and survival factors , including vegf , and play a major role in endothelial cell survival .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|gradients gata4 densities gata3 density|pericytes|entity are not targeted by vegf inhibitor therapies , but because they express endoglin , they are an additional target for anti-endoglin antibodies
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|junction autoin density densities negativity|pericytes|after the entity are stripped from the new blood vessels , endothelial cells located inside the newly formed blood vessels are left unprotected and
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|gradients densities density gata4 autoreg|pericytes|the binding of pdgf provides an important cell survival signal to entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|gradients densities density mω motors|pericytes|function of multiple growth factors involved in blood vessel formation and angiogenesis in the retina while sparing key retinal cells ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|gradients density densities gata4 autoreg|pericytes|entity also physically support and stabilize the abnormal new blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|gradients density densities motors gata4|pericytes|of multiple growth factors involved in blood vessel formation and angiogenesis in the retina while sparing key retinal -21- cells ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|motors dens cholerae gradients densities|gata4 gradients motors dystrophin smad1|pericytes|this increased resistance to vegf inhibitors is thought to be related to the presence of entity as a result of cancers up-regulating other angiogenesis pathways including those involving pdgfrβ .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|junction mω gradients peaked gata4|pericytes|( va ) from baseline over time abnormal new blood vessels are predominantly made up of two cell types , endothelial cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|gata4 atpases densities junction cd69|pericytes|pdgfrβ signaling is responsible for recruiting cells called entity which play a key role in the development and stabilization of blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|saturation gata4 resonance peaked gradients|pericytes|pdgf also recruits entity to the abnormal new blood vessel , where they mature and cover the endothelial cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|gradients gata4 densities gata3 density|pericytes|entity are not targeted by vegf inhibitor therapies , but because they express endoglin , they are an additional target for endoglin 13
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|autoin junction densities density saturation|pericytes|after the entity are stripped from the new blood vessels , endothelial cells lining the inside of the newly formed blood vessels are left
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|motors dens cholerae gradients densities|junction atpases motors dystrophin densities|pericytes|in contrast , svf is merely a heterogeneous fraction including preadipocytes , endothelial cells , smooth muscle cells , entity , macrophages , fibroblasts , and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|motors dens cholerae gradients densities|gata4 gradients junction mω saturation|pericytes|in addition , the impact of vegf inhibitors may be limited by the activity of entity , which are the cells that cover the outside of blood vessels and support and stabilize newly formed vessels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|gata4 autoreg densities motors nanog|granulocytes|the enzyme tyrosine kinase in the bone marrow , which causes too many stem cells to develop into white blood cells ( entity or blasts ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|gradients densities density atpases cholerae|gata4 mω junction cyclins integrins|granulocytes| enables aml blast cells to differentiate into entity and may be applicable in a broad range of aml patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|gata4 gradients uncoupling motors csc|granulocytes|oncology biosimilar udenyca™ stimulates production of entity ( a type of white blood cell ) in order to promote the bodys ability to fight infections .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|smad1 autoin densities otherwise density|granulocytes|for up to two years after treatment , as well as preliminary efficacy as measured by changes in cystine levels in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|gradients densities mω density motors|granulocytes|of naive and activated immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , entity , mast cells and monocytes / macrophages .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|gradients saturation uncoupling gata4 motors|granulocytes|responses detected in treated pts  klh carrier as immune stimulant  gm-csf stimulates entity and macrophages antigen binding site = idiotype ( id ) biovaxld : id-klh + gm-csf  first in a
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|uncoupling gap gradients mω gata4|granulocytes|in apl , there is an abnormal accumulation of immature entity called promyelocytes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities density atpases cholerae|gata4 saturation dystrophin motors smad1|granulocytes|soluble fibrin and formed elements in the blood , maintains the deformability of red blood cells , non-adhesiveness of unactiviated platelets and entity and the normal viscosity of blood .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|gradients densities saturation junction motors|granulocytes|immune cells recruited by the antibody to kill the cancer include entity , macrophages and nk cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|uncoupling gradients junction gata4 saturation|granulocytes|cml is a clonal bone marrow stem cell disorder in which proliferation of mature entity ( neutrophils , eosinophils , and basophils ) and their precursors is the main finding .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|smad1 gata4 atpases gradients densities|granulocytes|in an animal model of infection , the antibacterial activity of sivextro was reduced in the absence of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|mω gata4 gradients saturation motors|granulocytes|mg / kg alx377 in mouse models and measured red blood cell , or rbc , platelet and white blood cell ( lymphocyte , monocytes and entity ) counts .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|gradients densities gata4 density junction|granulocytes|gm-csf stimulates the growth and differentiation of entity and macrophages .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|densities density gradients motors mω|granulocytes|however , cll-1 is also expressed on normal hematopoietic cells such as entity and monocytes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|gradients densities density atpases cholerae|gata4 junction cyclins microtubules integrins|granulocytes|aslan003 has demonstrated the ability to differentiate aml blast cells into entity in a variety of aml cell lines that do not respond to atra .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities density atpases cholerae|gata4 lgr5 dystrophin mω autoin|granulocytes|evidence that normal cell maturation is returning , as noted by the increase in normal maturing cells ( promyeocytes , myeocytes , metamyelocytes and entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|gata4 nanog uncoupling autoreg saturation|granulocytes|in aml , blast cells are unable to differentiate and form entity , such as neutrophils and eosinophils , causing depletion of white blood cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|mω densities autoin density motors|granulocytes|lymphocytes : the white blood cells ( leukocytes ) that include the b cells and t cells , but not the others ( such as entity and eosinophils ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|gradients densities density atpases cholerae|gata4 integrins cyclins otherwise biphasic|granulocytes|the lead compound , lg7455 , activates the gcsf-gcsfr signaling pathway and induces the differentiation of human bone marrow cells into entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density atpases cholerae|motors mω densities junction otherwise|granulocytes|clone 818-18 produces a murine igg1 monoclonal antibody which recognizes a nuclear antigen expressed in human entity and myeloid precursors and acute and chronic myeloid leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|gradients saturation parametric gata4 densities|eosinophils|it has also been shown to impact some diseases , such as asthma , that are driven by entity , another important class of immune cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|densities gata4 gradients autoreg density|eosinophils|despite the knowledge that entity and mast cells drive many pathological conditions , there are no approved therapies that selectively target both entity and mast cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|gradients densities density mω gata4|eosinophils|believes that it is helpful to provide investors with an overview of the types of diseases that are affected by entity and / or mast cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|densities gradients density junction gata4|eosinophils|ak002 binds to siglec-8 , an inhibitory receptor found on entity and mast cells , which represents a novel way to selectively deplete or inhibit these important immune cells and thereby resolve
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|mω chimeras saturation smad1 gata4|eosinophils|eg is a rare disease that is characterized by chronic inflammation due to patchy or diffuse infiltration of entity into layers of the stomach .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|gradients junction dwell densities dispens|autoin integrins motors gauge mω|eosinophils|cml is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes ( neutrophils , entity , and basophils ) and their precursors is the main finding .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|gradients densities density gradient gata4|eosinophils|in ad , entity are important effector cells that promote inflammation and tissue damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|mω gata4 cyclins saturation gradients|eosinophils|eotaxin-1 is expressed on type 2 t helper ( “th2” ) cells and entity in bp lesions and an increasing body of data documents the role of these cells in both the innate and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|junction gradients densities mω chimeras|eosinophils|** ** prs-060 48-hr 1 1006 ** * 0 total macrophages entity lymphocytes 48hr timepoint anticaln control *p 34 . 5 µm 60?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|gradients gata4 gradient atpases motors|eosinophils|entity are a type of white blood cell .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|gata4 gradients density saturation junction|eosinophils|bertilimumab may prevent eotaxin-1-induced chemotaxis of entity and neutralize eotaxin-1 in the circulation , preventing eosinophil migration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|gradients ≥5 gata4 ≥4 densities|eosinophils|cardiac screening should be considered in patients with hes / cel , and patients with mds / mpd with high level of entity ( echocardiogram , serum troponin level ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|saturation pits gauge gata4 smad1|eosinophils|background on eoe and current treatments eoe results from a dysregulation of th2-mediated immunity that drives recruitment of entity to the esophagus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|gradients mω densities uncoupling motors|eosinophils|provided data on the mechanism of anticancer activity for il-17e , showing that il-17e activated the immune system , specifically acting on entity and b cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|gradients junction dwell densities dispens|autoin gata4 mω motors integrins|eosinophils|in aml , blast cells are unable to differentiate and form granulocytes , such as neutrophils and entity , causing depletion of white blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|densities gradients density gata4 autoreg|eosinophils|importantly , and in contrast to other agents , hgen005 appears to have an effect solely on entity , without impacting other populations , such as mast cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|dens either atpases density uncoupling|eosinophils|outcomes associated with asthma symptoms , as measured using the asthma control questionnaire 5 and biomarker levels as measured using blood entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|saturation gata4 mω density gradients|eosinophils|eotaxin  a protein that attracts entity into tissues , where they degranulate and cause tissue damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|gradients junction densities motors atpases|eosinophils|in addition to the effects on neutrophils and cytokines , a trend towards reduction in other immune cells in sputum , namely entity and macrophages , was also observed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dwell densities dispens|saturation smad1 gata4 cyclins gradients|eosinophils|wo 97 / 00960 also discloses methods of use of the eotaxin proteins in the recruitment of entity to a particular site or in the treatment of allergic conditions .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities uncoupling gradients atpases dens|densities density cholerae dens autoreg|erythrocytes|we are aware of an issued patent outside the united states that is directed to entity that comprise exogeneous polypeptides .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|gata4 mω cyclins nanog junction|erythrocytes|shown that our imids ( r ) can interact with stem cells and modulate them in such a way that they differentiate into entity , or red blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|mω uncoupling lattice gradients gata4|erythrocytes|dna , genes , and transcription factors dna is present in all cells , except mature entity , and encodes the inherited characteristics of all living organisms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities uncoupling gradients atpases dens|cd69 atpases polymorph colocalized smad4|erythrocytes|ra101495 protects against complement-mediated hemolysis of type dose response iii pnh entity drug concentration no drug ra101495
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|gradients mω uncoupling nanog otherwise|erythrocytes|bilirubin entity ( red blood cells ) circulating in the blood stream have a life expectancy of 120 days .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|motors mω junction autoin gata4|erythrocytes|these cells have a limited life span ; neutrophils live a few hours and entity or red blood cells survive for a few weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|densities density gradients mω motors|erythrocytes|with an increased likelihood of sle . test method description results were obtained using flow cytometry for complement c4d fragment bound to entity ( ec4d ) and b-lymphocytes ( bc4d ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|gata4 nanog motors saturation degenerate|erythrocytes|and inflammations ( leukocytes ) and form the basis of the immune system ( lymphocytes ) ; red cells that carry oxygen through our bodies ( entity ) ; and platelets that help blood to clot .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|nanog gata4 atpases gradients smad1|erythrocytes|the entity are then separated from the other blood compounds and opened by osmotic hemolysis , thus releasing the hemoglobin molecules .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|densities mω gradients density saturation|erythrocytes|drugs like ribavirin to infected liver cells while reducing the amount of drug going to other cells and tissues , including entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|gata4 densities density smad1 nanog|erythrocytes|up to 20 percent of the eculizumab-treated population , is most commonly attributable to extravascular hemolysis driven by intense c3 deposition on entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|gata4 nanog motors atpases mω|erythrocytes|inflammations ( leukocytes ) and form the basis of the immune system ( lymphocytes ) ;  red cells that carry oxygen through our bodies ( entity ) ; and  platelets that help blood to clot .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|densities density nanog kolmogorov cyclins|erythrocytes|the nine month post-infusion data point , with total hemoglobin levels of 11 . 9 g / dl , 10 . 1 g / dl fetal hemoglobin and 99 . 8 percent f-cells ( entity expressing fetal hemoglobin ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities uncoupling gradients atpases dens|mω dystrophin densities motors gradients|erythrocytes|( hsa ) , a glycoprotein expressed on the surface of many human cell types , including immature human hematopoietic cells , peripheral blood lymphocytes , entity , and many human carcinomas .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities uncoupling gradients atpases dens|dystrophin gata4 gradients densities mω|erythrocytes|strong cell mediated immunity ( e . g . th1 biased cd4+ ad cd8+ ) to reduce parasitemia by clearing infected cells ( liver cells or entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|chimeras autoin motors gata4 atpases|erythrocytes|blood : this test is based on the pseudo peroxidase action of hemoglobin and entity which catalyzes the reaction of 3 , 3 , 5 , 5-tetramethyl-benzidine and buffered organic peroxide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|mω atpases gata3 gata4 densities|erythrocytes|it provides vital oxygen supplies to places in the human body entity cannot reach for instance due to arterial sclerosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities uncoupling gradients atpases dens|gata4 mω degenerate nanog saturation|erythrocytes|( leukocytes ) and form the basis of the immune system ( lymphocytes ) ;  red cells that carry oxygen through our bodies ( entity ) ; and  platelets that help blood to clot .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities uncoupling gradients atpases dens|gata4 densities gradients density dystrophin|erythrocytes|for example , the deposition of the c4d fragment to entity forms erythrocyte c4d , or ec4d .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities uncoupling gradients atpases dens|gata4 gradients dystrophin saturation smad1|erythrocytes|unlike cd47-blocking antibodies , tti-622 bound minimally to human entity and did not induce hemagglutination in vitro .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities otherwise cytoskeleton sensitivities normality|mω normality certain dystrophin junction|hepatocytes|target of 10% enzyme replacement at all doses in otc-deficient mouse model lunar-otc treatment increases otc expression in mouse periportal entity ( main site of ureagenesis )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|densities density gradients saturation resonance|hepatocytes|in the companys preclinical studies , transduction of primary human entity with aavs3 pseudotyped vectors was significantly higher as compared with the other vectors listed above .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|densities density smad1 localizes autoreg|hepatocytes|our initial focus is on monogenic diseases with clear biology linking the missing activity of a gene in entity to a disease outcome .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|nanog saturation deteriorated sensitivities leak|hepatocytes|the polymer is targeted to the asialoglycoprotein receptor on liver entity by the inclusion of a galnac moiety to one end of the polymer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|densities gradients density autoreg mω|hepatocytes|improvements in the function of our immortalized entity will open more markets and expand the usage in the current markets for our cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|gata4 densities autoreg density saturation|hepatocytes|mrt5201 , is designed to address the underlying cause of otc deficiency by delivering mrna encoding fully functional otc enzyme to entity through intravenous administration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|mω imm autoin saturation densities|hepatocytes|have shown that the rap receptor , lrp1 , is well expressed on human hcc and under-expressed on non-cancerous , but otherwise diseased , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|saturation either imm dens densities|hepatocytes|we recently demonstrated that liver entity show a rapid , primary nf-kb activation response following in vivo administration of cblb502 in mice and nhps .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|imm otherwise either autoreg mω|hepatocytes|however , combining multiple interventions , particularly multiple small molecules , places an additional burden of drug metabolism and clearance upon already stressed entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities otherwise cytoskeleton sensitivities normality|densities mω gradients otherwise coexist|hepatocytes|these cells have been shown to retain many key synthetic and metabolic processes of normal human entity , the primary functional cell of the liver .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|settle sensitivities gradients chimeras mω|hepatocytes|pmx-30063 has been tested for stability in the presence of mouse and human liver entity to investigate the extent to which liver metabolism could be a factor upon compound administration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|otherwise autoin mω atpases superposition|hepatocytes|pmx-30063 demonstrated high stability in the presence of liver entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|densities density spher saturation chimeras|hepatocytes|percentage of entity showing steatosis , or fatty change , mean ± sd ( n ) 54 . 8 ± 21 . 2 49 . 9 ± 24 . 3
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|negativity gradients gata4 saturation smad1|hepatocytes|it has been previously demonstrated that impairment of entity by ethanol is associated with the production of free radical and oxidative stress .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|mω densities autoreg gradients density|hepatocytes|these efforts have been towards improving the functionality of our immortalized entity , introducing products utilizing these cells and expanding our intellectual property base .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|densities density gradients saturation junction|hepatocytes|our liversafe 3d™bioassay system uses our stem cell-derived entity , or liver cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|otherwise density gata4 gradients densities|hepatocytes|for example , the asg receptor exists primarily in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|gata4 density saturation densities nanog|hepatocytes|patient has a mutation in both copies of the serpina1 gene , which causes aat to aggregate inside liver cells , or entity , rather than being secreted from the liver .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|gradients densities junction gradient density|hepatocytes|entity are the most biochemically complex cells in the human body and play an important role in the synthesis and metabolism
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities otherwise cytoskeleton sensitivities normality|mω densities imm saturation gradients|hepatocytes|apoptosis of entity manifests as ballooning of the cells , a characteristic microscopic feature of nash liver tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|gata4 gradients densities motors otherwise|megakaryocytes|lx-5431 has been demonstrated in ex vivo bone marrow culture to stimulate production of platelet forming cells called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|normality otherwise gradients autoreg grades|gata4 densities junction cyclins dystrophin|megakaryocytes|we have developed a manufacturing process for generating entity , proplatelet forming cells and ultimately platelets using either hescs or ipscs as the starting materials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|normality otherwise gradients autoreg grades|gata4 microtubules autoreg cyclins ≥4|megakaryocytes|in addition , bet proteins promote the generation of entity from hematopoietic stem cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|gata4 cyclins densities junction autoreg|megakaryocytes|we have developed a manufacturing process for generating entity , proplatelet forming cells and ultimately platelets using either hes or ips cells as the starting materials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|gradients gata4 saturation autoreg motors|megakaryocytes|tpo-ras , like tpo , stimulate the activation , proliferation and maturation of entity , resulting in an increase in circulating platelet counts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|gradients uncoupling densities saturation density|megakaryocytes|we believe that the blood cells most responsible for bone marrow scarring in mf are dysfunctional entity , which produce inflammatory molecules in part through elevated nf-kb signaling .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|gata4 saturation autoreg dens certain|megakaryocytes|the angiopoietins are in preclinical studies for their abilities to promote growth and mobilization of hemopoietic stem cells and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|densities gata4 dens density autoreg|megakaryocytes|an editorial entitled , myelodysplasia , entity , and methylation was also published in the same issue of leukemia research ( steensma , leuk .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|normality otherwise gradients autoreg grades|gata4 motors dystrophin gradients biphasic|megakaryocytes|precursors of the red blood cells or of the granulocytes and macrophages , which are also of the immune system , and entity , which produces platelets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|gradients gata4 saturation autoreg densities|megakaryocytes|tpo-ras , like tpo , stimulate the activation , proliferation and maturation of entity , resulting in an increase in circulating platelets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|gradients gata4 densities motors autoreg|megakaryocytes|entity normally function to produce platelets , which are small blood cells involved in blood clotting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|gata4 gradients atpases densities biphasic|megakaryocytes|entity , which are large cells found in the bone marrow , are the source of platelets that are released into the bloodstream .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|gata4 gradients atpases densities motors|megakaryocytes|these cells , known as entity , are found in the bone marrow and are the precursor cells to platelets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|normality otherwise gradients autoreg grades|gata4 microtubules motors nanog autoreg|megakaryocytes|specifically , jak2 activation leads to proliferation of red blood cell progenitors and platelet progenitors , or entity , that fail to mature to platelets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|densities gradients density gata4 saturation|megakaryocytes|the inability of entity to fully differentiate leads to the release of pro-inflammatory and pro-fibrotic factors that results in scarring of the bone marrow ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|gradients gata4 uncoupling atpases densities|megakaryocytes|entity are the bone marrow cells that give rise to blood platelets . 13 about eltrombopag eltrombopag was given accelerated approval by the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|gradients gata4 mω density densities|megakaryocytes|itp can also result in damage to entity , leading to impaired platelet production .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|densities gradients dens density smad1|megakaryocytes|we could not readily identify entity in our conditions on morphological grounds despite some effort with mgdf and therefore do not know which of our sampled
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise gradients autoreg grades|densities gradients density gata4 saturation|megakaryocytes|the inability of entity to fully differentiate leads to the release of pro-inflammatory and pro-fibrotic factors that results in scarring of the bone marrow , which further exacerbates the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|densities saturation density gata4 imm|podocytes|inhibition of calcineurin within the entity can prevent the dephosphorylation of synaptopodin which in turn inhibits the degradation of the actin cytoskeletion within the podocyte .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|densities density gradients saturation gata4|podocytes|these immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity of the entity : 931-8 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|saturation densities density imm dens|podocytes|additionally , recent evidence suggests that inhibition of calcineurin has direct physical impacts on the entity within the kidney .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|gradients dens densities certain smad1|podocytes|voclosporin also potentially stabilizes disease modifying entity , which protects against proteinuria .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients cholerae junction density|gata4 smad1 dystrophin settle densities|podocytes|( a and b ) gl-3 reduction in entity was closely paralleled by a reduction in podocyte volume .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|density densities saturation imm gradients|podocytes|immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity 8 of the entity : 931-8 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|gradients densities otherwise gata4 density|podocytes|voclosporin also potentially stabilizes entity , which can protect against proteinuria .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|otherwise chimeras gradients densities cush|podocytes|voclosporin also potentially stabilizes entity , s-12 table of contents which can protect against proteinuria .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients cholerae junction density|densities density gradients spher dystrophin|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 29 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients cholerae junction density|densities density spher dystrophin gradients|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 30 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|densities chimeras autoin gradients autoreg|podocytes|there were statistical trends towards associations between 24-hr urine protein and % change in gl-3 inclusion content of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|gradients motors gata4 junction certain|podocytes|entity form part of the barrier that enable the glomerulus to filter the blood in a manner that retains large molecules
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|densities density gata4 traps autoin|podocytes|curr pharm des 21 overactive cannabinoid 1 receptor in entity drives type 2 diabetic nephropathy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|gata4 junction autoreg gradients imm|podocytes|gas6 is upregulated in either endothelial / mesangial cells or entity in igan dual involvement of growth arrest-specific
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|gata4 smad1 junction mω optimum|podocytes|combined with reduction of local hypoxia , plxdc2 can improve the health and homeostasis of renal epithelial cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients cholerae junction density|densities density gradients spher dystrophin|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 32 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients cholerae junction density|densities autoreg density dystrophin gata4|podocytes|( c ) volume fraction of gl-3 inclusions in entity did not change during the 6 months migalastat treatment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|gradients mω densities saturation density|podocytes|endothelial cells , tubular epithelial cells , cns mc5r cns , exocrine glands , lymphocytes , entity adapted from gong 2011 , catania 2004 , schioth 1997
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|gradients densities density smad1 saturation|podocytes|these immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity of the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae junction density|gradients densities imm optimum gap|podocytes|fsgs is understood to start with damage to entity , cells that wrap around capillaries of the glomerulus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients junction dispens motors densities|mω autoin dystrophin pkcα arrived|basophils|neutrophils , eosinophils and entity , which are types of mature leukocytes , are normally formed only in the bone marrow and are stored there until they
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients junction dispens motors densities|cholerae densities veloc gradients dens|basophils|high affinity anti-human ige- 12 / 31 / 87 s / n 140 , 036 u . s . monoclonal antibody which bind to igge-bearing b cells and not entity tnx87-12a change et al .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|mω autoin arrived motors pkcα|basophils|cml is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes ( neutrophils , eosinophils , and entity ) and their precursors is the main finding .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|junction gradients densities junctions gap|basophils|vista is an immunoregulatory receptor and is highly expressed on various immune system cells including neutrophils , monocytes , macrophages , entity and dcs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients mω gradient density densities|basophils|anb020 inhibits secretion of il-5 from primary entity purified from peripheral blood of healthy subjects with an ic 50 of approximately 1 . 5 nm , which is approximately 15-fold greater
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients junction dispens motors densities|cholerae densities junction veloc gata4|basophils|high affinity anti-human ige- 7 / 29 / 88 s / n 226 , 421 u . s . monoclonal antibody which binds to ige-bearing b cells and not entity tnx87-12aa chang et al .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients saturation densities density gata4|basophils|e25 blocks ige from binding to mast cells and entity , thereby inhibiting the allergic response .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients mω gradient density uncoupling|basophils|anb020 inhibits secretion of il-5 from primary entity purified from peripheral blood of healthy subjects with an ic50 of approximately 1 . 5 nm , which is approximately 15-fold greater than
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients mω motors densities gata4|basophils|mast cells , entity , goblet cells and other cells also play a role .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients saturation densities density junction|basophils|these ige molecules circulate in the blood stream and find their way to attach to the mast cells or entity through specific ige receptors on the cell surface .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients saturation gata4 densities mω|basophils|pci-32765 is a potent inhibitor of histamine release ( also known as degranulation ) from mast cells and entity , which are specific immune cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients saturation mω gata4 curvature|basophils|to the antigen , or allergen in this case , by producing ige . ige binds to the surface of mast cells and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients junction saturation densities density|basophils|these ige molecules attach to the surfaces of mast cells or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients saturation densities mω density|basophils|and masking the binding site for the ige receptor which prevents ige from binding to and arming mast cells and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|saturation gradients imm mω namely|basophils|similarly , calcium ions also play a central role in the activation and degranulation of tissue mast cells and circulating counterpart entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients junction saturation densities density|basophils|these ige molecules circulate in the blood stream and find their way to attach to the mast cells or entity , thereby arming these cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients saturation densities gata4 density|basophils|in animal models that ccr2 is important for host defense , inflammation and immunity mediated through hematopoietic cells including monocytes and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gata4 densities mω gradients imm|basophils|siglec-8 is an inhibitory receptor located selectively on eosinophils , mast cells and , to a lesser extent , on entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients mω saturation gata4 densities|basophils|omalizumab works by binding to the immune mediator immunoglobulin e , or ige , and inhibiting ige-mediated activation of mast cells and entity , types of white blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction dispens motors densities|gradients densities motors density either|basophils|cd123 is also expressed by plasmacytoid dendritic cells , or pdcs , entity , endothelial cells and , to a lesser extent , monocytes and eosinophils .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|junction heterochromatin either damp cd44|neurons|in parallel , electrophysiology recordings of single ganglion entity that innervate the craniofacial muscles were performed ( 33 masticatory muscle mechanoreceptors ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|density smad1 gradients mω gata4|neurons|amyloid fibrils are believed to be neurotoxic and interfere with the normal communication between entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|dens autoreg density densities saturation|neurons|these entity are responsible for producing dopamine , an essential brain signaling chemical , or neurotransmitter , that enables smooth , coordinated movements of both voluntary
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|junction dens densities chimeras density|neurons|these results suggest that the photoreceptor entity and pigmented retinal epithelial cells  cell types that are both lost in ga  are sandwiched between deposits of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|gradients densities mω density autoreg|neurons|as a result , entity are unable to respond to normal stimuli and can become over-stimulated by a neurotransmitter or be unable to respond to
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|≥1 certain smad1 autoreg mω|neurons|in ad , tau protein is misfolded , becomes hyperphosphorylated and aggregates into neurotoxic oligomers that ultimately form neurofibrillary tangles within entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|dens junction restorations typesetting clarity|neurons|these symptoms are caused by the degeneration of dopaminergic entity in the substantia nigra and depletion of dopamine in the striatum .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|localizes gata4 saturation dens mω|neurons|can transition into mild , moderate and , finally , severe stages of alzheimers disease that are characterized by greater systemic loss of entity and synapses in the brain tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|dens otherwise autoreg traps normality|neurons|parkinsons disease ( the “mptp model” ) showed that when administered orally , aeol 11207 crosses the blood brain barrier and protected dopamine entity in a dose-dependent manner .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|saturation gradients junction either mω|neurons|the dendrites and axons , or nerve endings , of the entity contain an elaborate series of thin tubes , or microtubules , which serve to support them and transport nutrients down to the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|dens mω localizes junction lattice|neurons|sma is caused by a genetic defect in the smn1 gene that codes smn , a protein necessary for survival of motor entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|dens density densities otherwise gata4|neurons|accumulation of mhtt protein causes progressive loss of entity in the brain .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|otherwise junction dens mω densities|neurons|cord in commercial quantities , and the ability to control the differentiation of these cells constitutively into mature , physiologically relevant human entity and glia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|smad1 gata4 mω gradients saturation|neurons|neurotoxic peptiderefers to a small protein ( called a peptide ) that can be toxic to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|autoreg densities gata4 atpases density|neurons|· ep1937352 sub-threshold stimulation to precondition entity for supra-threshold stimulation – opposition hearing is scheduled for january 21 , 2015 in munich , germany .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|dens junction uncoupling autoreg gradients|neurons|limitations of current therapies als is a neurodegenerative disorder that involves gradual breakdown of motor entity leading to muscle weakness , disability , and ultimately death .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|gata4 smad1 gradients density otherwise|neurons|which leads to production of a mutant huntingtin protein that is thought to be neurotoxic and promote the degeneration of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|saturation gata4 density smad1 either|neurons|to further demonstrate this , we utilized in vivo electrophysiology where cbn blocked the pain signals in the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|saturation nanog density damp dens|neurons|loss of dopamine causes critical nerve cells , or entity , in the brain , to fire out of control , leaving patients unable to direct or control their movement in a normal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities density gradients dens localizes|dens junction uncoupling gradients lattice|neurons|about sma sma is a severe neuromuscular disease characterized by the loss of motor entity leading to progressive muscle weakness and paralysis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|cyclins gata4 ante densities smad1|cardiomyocytes|we have derived human entity ( grncm1 ) from hescs for the potential treatment of heart disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients junction uncoupling dens densities|cholerae gata4 clock kolmogorov benjamini|cardiomyocytes|cm1 – entity heart failure 6 million total patients in u . s . cells derived and characterization studies performed ( parameters analyzed showed normal cell functions
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients junction uncoupling dens densities|autoreg densities cholerae dens nedd4|cardiomyocytes|product sales for both 2012 and 2013 is primarily attributable to an increase in unit volume sales of our icell entity and , in 2012 , to our icell neurons .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients junction uncoupling dens densities|cholerae gata4 kolmogorov autoreg negativity|cardiomyocytes|cm1 - entity heart failure 6 million total patients in u . s . cells derived and fully characterized ( all normal cell functions verified in vitro ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|gradients saturation autoreg smad1 densities|cardiomyocytes|gerons grncm1 program is developing hesc-derived entity for the treatment of heart failure .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|saturation trap dots junction gauge|cardiomyocytes|in human entity isolated from the left ventricle of patients with end-stage heart failure , serca2a levels were correlated with improved diastolic function .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients junction uncoupling dens densities|saturation smad1 gata4 cholerae junction|cardiomyocytes|isolated entity from aav-s100a1 treated pig heart showed superior systolic and diastolic performance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|smad1 smad2 autoreg gata4 traps|cardiomyocytes|moreover , old g5terc-null mice exhibited shorter telomeres in entity than did younger counterparts , and this led to ventricular dilation , page .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients junction uncoupling dens densities|gata4 densities dens existence cholerae|cardiomyocytes|the targeted entity are expected to produce sustained therapeutic protein levels in the myocardium where it is needed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|nanog smad1 either mω gata4|cardiomyocytes|such cells include entity or heart muscle cells , neural cells , hepatic cells and pancreatic ( logo ) islet cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|densities density otherwise gata4 cyclins|cardiomyocytes|the first product developed under the alliance , human entity derived from hescs , was launched in october 2010 by gehc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|smad1 gata4 junction cd44 myo|cardiomyocytes|specific precursor cells which , together with a specific combination of growth factors , develop full culture wells of functional , beating human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients junction uncoupling dens densities|junction cholerae gauge gata4 outer|cardiomyocytes|the product is predominantly composed of ventricular entity which have been shown to electrically and mechanically couple to the animal myocardium in which they are injected and contract
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|autoreg dens mω densities gata4|cardiomyocytes|u . s . patent no . 7 , 425 , 448 was issued to geron with broad claims to entity derived from hescs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|mω densities density gata4 smad1|cardiomyocytes|that asterias will reach an agreement for support in the manufacture of vac2 or the development of hes cell derived entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|gradients otherwise localizes gata4 limit|cardiomyocytes|heart muscle cells ( entity ) do not regenerate during adult life .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|autoreg densities smad1 mω imm|cardiomyocytes|dbcm is caused by metabolic derangements in entity that result in cell death and fibrosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|densities density gradients cyclins gata4|cardiomyocytes|cm1 , hes cell-derived entity , have been extensively characterized in vitro and in vivo .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|gradients density densities dens junction|cardiomyocytes|we used our hpsc-derived entity ( human heart cells ) in cardiosafe 3d™ , our novel , customized in vitro bioassay system for predicting potential cardiotoxicity of drug rescue
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients junction uncoupling dens densities|densities density sensitivities gradients dens|cardiomyocytes|today we have entity , two types of neural cells -- dopaminergic neurons and oligodendrocytes -- and hematopoietic cells in animal models , and we hope
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|dens densities gradients motors cholerae|densities junction integrins density gata4|keratinocytes|these supported isolation , expansion and long-term culture of entity , fibroblasts , smooth muscle cells and mesenchymal stem cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|gradients smad1 density curvature saturation|keratinocytes|il-17 binding to il-17ra on entity stimulates and perpetuates the inflammation cascade of psoriasis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|gradients mω atpases uncoupling densities|keratinocytes|believes that the therapeutic utility of 2-cdap in psoriasis would result from its ability to gain direct access to hyperproliferating entity in a form that would be rapidly effective .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|junction motors cyclins mω densities|keratinocytes|apligraf contains living human skin cells , entity and fibroblasts , organized in an epidermal and dermal layer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|gradients saturation smad1 gata4 gradient|keratinocytes|hyperproliferation of entity contributes to psoriasis , and work by sugen and others has demonstrated that egf tk signalling is required for the growth of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|vesicles cyclins gradients junction traps|keratinocytes|hemidesmosome formation also occurs during normal differentiation of entity as they mature from the basal layer , not only in a wound-healing situation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|nanog uncoupling cyclins density densities|keratinocytes|etiology – entity infected by human papillomavirus ( hpv ) ; manifests as common warts , plantar warts or genital warts virus spreads via direct contact or
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|junction junctions sinus mω either|keratinocytes|revitix provides a more complete array of growth factors than those produced by dermal fibroblasts or epidermal entity alone , which helps to speed the healing process of skin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|saturation gradients degenerate junction either|keratinocytes|tanning is mediated by melanocytes producing melanin , which is subsequently transferred to the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|dens densities gradients motors cholerae|mω smad1 gata4 autoreg microtubules|keratinocytes|in in vitro skin models , p529 was shown to inhibit keratinocyte proliferation ( growth of entity ) and induce apoptosis ( cause death of hyperproliferating entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|junction notation saturation smad1 junctional|keratinocytes|in preclinical studies , xcur17 inhibited il-17ra in the entity of the skin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|gradients gradient junction coupled cyclins|keratinocytes|entity are the most abundant cells in the epidermis and account for 80 to 90% of the total epidermal cellular population .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|dens densities gradients motors cholerae|densities density dystrophin junction gradients|keratinocytes|kx-01 inhibits the proliferation of entity and up-regulates p53 so its utility in clinically treating ak was of interest .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|gradients coupled cyclins trap cytoskeleton|keratinocytes|the epidermis is comprised mainly of cells known as entity that are continually regenerated and move toward the skin surface where they flatten , lose their nucleus , and become the outermost
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|gradients densities uncoupling imm mω|keratinocytes|this exposure can lead to oncogenic changes , such as inactivation of p53 , and consequential hyper-proliferation of mutated entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|gradients gradient coupled junction pyroph|keratinocytes|entity are the predominant cell type in the epidermis , the outermost layer of the skin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|dens densities gradients motors cholerae|gradients gata4 motors mω dystrophin|keratinocytes|first , il-8 is produced by a type of skin cell called entity , and is a potent growth factor for these skin cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|gradients smad1 gata4 saturation otherwise|keratinocytes|as p529 has been shown to inhibit neovascularization , together with its effect on entity , p529 is expected to show activity in psoriasis and atopic dermatitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|gradients curvature motors cytoskeleton cyclins|keratinocytes|barrier function and inflammation in atopic dermatitis the most abundant cells in the epidermis are entity , shown in figure 16 below .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|dens densities gradients motors cholerae|gradients coupled junction cyclins cytoskeleton|keratinocytes|the epidermis is comprised mainly of cells known as entity which are continually regenerated and move toward the skin surface where they flatten , loose their nucleus and become the outermost
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|gata4 smad1 densities mω density|astrocytes|the chronic activation of microglia and entity has been implicated as an important disease mechanism in huntingtons disease , progressive ms , and other neurodegenerative disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|gata4 density gradients densities saturation|astrocytes|when innate immune dysfunction causes chronic inflammation , activated microglial cells produce soluble tnf that activates entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|densities density mω junction nanog|astrocytes|in addition , the target cells , motor neurons and entity , or cells supporting the neurons , reside within and surrounding the spinal cord and brain stem , which we believe can be
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|cholerae densities normality density biolabs|integrins gata4 cd69 densities junction|astrocytes|when ipsc-derived hgpcs were transplanted into these mice , the cells spread widely throughout the brain , developing as entity and oligodendrocytes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|mω gradients gata4 densities density|astrocytes|cells that repair damage to myelin and neurons and prevent chronic activation of inflammatory cells of the brain , microglia and entity , which is implicated in neurodegenerative diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|gata4 density saturation densities smad1|astrocytes|jun ; 71 : 1500-4 ; modulation of interleukin-1beta mediated inflammatory response in human entity by flavonoids : implications in neuroprotection . brain res bull .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|cholerae densities normality density biolabs|integrins cd69 gata4 dens gradients|astrocytes|entity and oligodendrocytes , the other two principle types of central nervous system cells , are also generated from the human neural stem
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|density densities gata4 motors autoreg|astrocytes|av-101s ability to activate entity for focal delivery of an anti-epileptic principle , and its dual action as a nmdar glyb antagonist and quinolinic acid synthesis
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|densities density gata4 imm signals|astrocytes|together , these activities lead to a cascade of enhanced disease responses in neurons , oligodendrocytes , and entity , cell types that are most vulnerable to energetic deficiencies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|densities density mω gradients gata4|astrocytes|spinal cord are damaged , guanosine , which is present normally in every cell , can be released in high concentrations to stimulate entity to produce these protective factors .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|densities density gradients gata4 dens|astrocytes|conditions anavex®3-71 demonstrated the formation of new synapses between neurons ( synaptogenesis ) without causing an abnormal increase in the number of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|density gradients densities imm junction|astrocytes|pre-clinical data suggest that ccr2 , and mcp-1 , are upregulated in cells , such as macrophages , microglial cells and entity which play a central role in the origination of pain signals .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|autoreg densities atpases gradients density|astrocytes|customers frequently request entity to build a more complete human neurological model .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|densities gradients density dens traps|astrocytes|anavex 3-71 demonstrated the formation of new synapses between neurons ( synaptogenesis ) without causing an abnormal increase in the number of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|density densities imm junction signals|astrocytes|the effect of iw-6463 was studied in rat brain 3d microtissues , a 3d cell model containing a mix of neurons , entity , microglial cells and oligodendrocytes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cholerae densities normality density biolabs|localization smad1 cholerae gata4 density|astrocytes|clr1501 uptake was visualized with confocal microscopy and compared to matched sergbm , normal human entity , and human nscs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|cholerae densities normality density biolabs|negativity gata4 integrins gradients atpases|astrocytes|glioblastoma are tumors that arise from entity , which are star-shaped cells making up the supportive tissue of the brain .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|cholerae densities normality density biolabs|otherwise gata4 gradients chimeras integrins|astrocytes|q-cells produce entity and oligodendrocytes , the support cells that enable the normal function of neurons .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cholerae densities normality density biolabs|densities density gradients cholerae motors|astrocytes|entity cells found in the brain that support neuronal function these cells are synergistic with icell neurons .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|cholerae densities normality density biolabs|gata4 density either certain imm|astrocytes|aß peptides are derived from the amyloid precursor protein , or app , an integral membrane protein , in neurons and entity in the brain .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens autoreg normality null banding|junction motors exists atpases gata4|preadipocytes|in contrast , svf is merely a heterogeneous fraction including entity , endothelial cells , smooth muscle cells , pericytes , macrophages , fibroblasts , and adipose-derived stem cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens autoreg normality null banding|junction motors exists atpases gata4|preadipocytes|in contrast , svf is merely a heterogeneous fraction including entity , endothelial cells , smooth muscle cells , pericytes , macrophages , fibroblasts and adipose-derived stem cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens autoreg normality null banding|gradients junction mω junctions boundaries|preadipocytes|a paper entitled “chromium picolinate depressed proliferation and differentiation of 3t3-l1 entity” was published in nutrition research .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gata4 densities unstable namely signals|osteoblasts|only a portion of the bone remodeling process : they either block bone breakdown by osteoclasts or stimulate bone formation by entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gata4 namely densities coupled gradients|osteoblasts|small areas of bone are constantly being broken down by special cells called osteoclasts , then made again by cells called entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|mω densities negativity resonance density|osteoblasts|entity for osteoporosis and non-union bone fractures we have made osteoblasts from hescs and are now conducting preclinical tests in animals .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|densities gata4 mω namely gradients|osteoblasts|n / a ( generic ) ​ in osteoporosis patients , who have normal basal levels of pth , therapeutic administration of pth activates osteoclasts and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gata4 densities dens junction restorations|osteoblasts|it has a potent anabolic effect on bone tissues , stimulating the formation and maturation of bone-forming entity which in turn causes significant increases in new bone formation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|densities gata4 namely sensitivities motors|osteoblasts|k , arris and its partner believe that a new drug may be able to re-balance the activity of osteoclasts and entity and arrest the bone-destroying effects of osteoporosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gata4 gradients signals densities otherwise|osteoblasts|intravenously administered antibody that is designed to inhibit sclerostin , a protein that inhibits the activity of bone-forming cells , known as entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gradients densities gata4 density gata3|osteoblasts|while both types of cells are activated when pth is administered , entity are activated to a greater extent , increasing net bone formation and bone mass .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gradients leak densities gata4 density|osteoblasts|current work focuses on confirming their characteristics as entity , improving cell yields , testing function in vitro and then testing the cells in animals .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|densities density gata4 gradients atpases|osteoblasts|we intend to infuse entity derived from hescs to treat osteoporosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gata4 peaked densities unstable minima|osteoblasts|bone loss ( mediated by osteoclasts  cells which resorb bone ) that is incompletely compensated by new bone formation ( mediated by entity  cells which form new bone ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gata4 densities sensitivities benjamini mω|osteoblasts|because osteosarcoma usually develops from entity , it most commonly affects children and young adults experiencing their adolescent growth spurt .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gradients gata4 density localization densities|osteoblasts|while both types of cells are activated when pth is administered , entity 92 table of contents are activated for a longer period , increasing bone formation and bone mass .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|densities gata4 refract negativity density|osteoblasts|cells called entity cause new bone formation while other cells called osteoclasts remove old bone through a process called resorption .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gata4 densities gradients sensitivities namely|osteoblasts|the condition is the stimulation of a population of normal bone cells ( osteoclasts ) relative to another population of bone cells ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gata4 densities sensitivities mω chimeras|osteoblasts|because osteosarcoma usually develops from entity , it most commonly develops in teenagers who are experiencing their adolescent growth spurt .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gata4 densities signals minima gradients|osteoblasts|forteo ( marketed as forsteo in europe ) builds bone primarily by increasing the activity of entity ( cells that deposit bone ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|autoreg densities negativity storm mω|osteoblasts|osteoclasts mediate destruction of bone and entity are responsible for bone growth and mineral production .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|gata4 densities negativity exists namely|osteoblasts|bone loss ( mediated by osteoclasts -- cells which resorb bone ) that is incompletely compensated by new bone formation ( mediated by entity -- cells which form new bone ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients cholerae density dens|namely densities gata4 gradients motors|osteoblasts|normal functioning of bone depends on osteoclasts and entity acting in concert .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|normality autoreg banding gradients cyclins|mω gradients densities spd vsv|erythroblasts|b , which are more immature entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|normality autoreg banding gradients cyclins|mω motors gradients microtubules chimeras|erythroblasts|it is well-known that fetal cells , including trophoblasts , lymphocytes and entity , circulate in the peripheral blood of pregnant women , in some cases as early as five weeks gestation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality autoreg banding gradients cyclins|gradients densities dens gata4 mω|erythroblasts|c , which is the population of mature entity , in comparison to ery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|normality autoreg banding gradients cyclins|gata4 integrins motors clock gradients|erythroblasts|reactivation of hbf occurs in immature rbcs , known as entity and reticulocytes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|normality autoreg banding gradients cyclins|mω motors gradients microtubules chimeras|erythroblasts|it is well-known that fetal cells , including trophoblasts , lymphocytes , and entity , circulate in the peripheral blood of pregnant women , in some cases as early as five weeks gestation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|damp autoreg densities density saturation|transitional|the initial application of ifrs 9 at january 1 , 2018 has resulted in no significant entity effects for immunic .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|autoreg cush nedd4 autoin mω|transitional|after the expiry of any applicable entity period , only ivds that have been ce marked under the ivd regulation may be placed on the market in the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|autoreg densities nedd4 density mω|transitional|as per the benefit arrangement contemplated by the entity services agreement , the existing stock shall be delivered to purchaser exw - incoterms 2010 , delivery in monheim or other sellers
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|densities density smad1 autoreg negativity|transitional|the provisions of sfas 142 require that a entity impairment test be performed as of the beginning of the year the statement is adopted .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|autoreg gradients densities atpase cholerae|microtubules spher δψ mω linearity|transitional|entity cell carcinoma of the bladder frequently occurs in adolescents with costello syndrome , a presentation that is rare in the general
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|densities dens autoreg density smad4|transitional|“entity costs” shall mean all costs incurred by seller that are identified in exhibit “j” .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|densities cush density spher gradients|transitional|entity small business disclosure format ( check one ) :
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|densities damp density autoreg smad4|transitional|will also pay bms for any required product supply at a price approximating the product cost as well as negotiated entity service fees .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|atpases endos densities nedd4 motors|transitional|( ii ) and section 2 . 2 , in no event shall aetna use or permit any affiliate to use any mark or the entity mark
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|nedd4 dens densities cush gata4|transitional|we elected to use the entity practical expedient allowing the standard to be applied only to contracts that were previously identified as leases under ias 17
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|densities dens density autoreg imm|transitional|retrospectively from january 1 , 2019 , but has not restated comparatives for the 2018 reporting period , as permitted under the specific entity provisions in the standard .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|autoreg densities density nedd4 inactivation|transitional|and the buyer are expected to enter into related transaction agreements at the closing of the proposed transaction , including a entity services agreement .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|mω autoreg lgr5 densities dwell|transitional|respect to any grant ( including the grant made on the effective date ) a-3 to secure the benefit of any applicable entity rule promulgated under section 409a of the code .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|autoreg imm mω densities nedd4|transitional|internal costs and out-of-pocket expenses shall not exceed the corresponding agreed to budget for such services set forth in the entity service plan .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|autoreg nedd4 densities negativity dens|transitional|the entity requirements of sfas 148 are effective for all financial statements for fiscal years ending after december 15 , 2002 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|autoreg gradients densities atpase cholerae|autoreg densities nedd4 cd69 cholerae|transitional|we elected the optional entity guidance under asc 842 that allowed the initial recognition of the operating right-of-use assets and the corresponding lease liabilities as
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|densities autoreg density negativity damp|transitional|the entity impact was finalized during the fiscal year ended june 30 , 2019 , with no significant impact on income tax expense .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|densities density dens mω gata4|transitional|acquisition by cytyc corporation , a diagnostic and medical device company , he served as a consultant to cytyc to assist with entity matters from 2001 to 2002 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|densities cush density spher gradients|transitional|entity small business disclosure format ( check one ) :
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients densities atpase cholerae|autoreg densities certain adherens tight|transitional|we adopted these changes using the prospective application entity alternative in accordance with the entity provisions of cica handbook section 3870 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|gradients gata4 densities density motors|oocytes|we anticipate that in the unites states cryopreservation of entity will be regulated similarly to viacords family umbilical cord blood cryopreservation product .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|chimeras junction junctional gata4 gradients|oocytes|if successful , the ovature treatment could reduce , or possibly eliminate , the need for hormonal hyperstimulation for the maturation of multiple entity prior to egg retrieval in the ivf process .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|mω nanog density densities localization|oocytes|with a number of in vitro fertility clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|gradients densities mω gata4 density|oocytes|media supplier will be required to obtain 510 ( k ) clearance for the technology we have licensed for use in the cryopreservation of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|gradients densities nanog autoreg density|oocytes|“raw material” means conforming rana pipiens entity to be supplied to spl by alfacell .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|junction mω either gradients uncoupling|oocytes|cancer research technology limited rnai uses in mammalian entity , preimplantation embryos and somatic cells ( ep only : wherein the rnai compound is at least 25 base pairs ) 11 / 19 / 1999
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|densities junction dens density sinus|oocytes|which includes the production of human differentiated cells from stem cells and involves the use of nuclear transfer technology , human entity , and embryonic material .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|mω nanog density chimeras smad1|oocytes|a number of in vitro fertility ( “ivf” ) clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|intram autoreg junction otherwise gradients|oocytes|the first patent covers the use of fertilized human entity for the creation of human embryonic stem cell lines , and was issued in great britain .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|chimeras junction autoin gradients null|oocytes|another opportunity in the use of cells for therapy relates to entity , which are female egg cells essential to reproduction .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|density densities either resonance nanog|oocytes|of health information we obtain from research collaborators or from providers who enroll patients and collect cord blood or human entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|nanog mω density chimeras motors|oocytes|a number of in vitro fertility ( ivf ) clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|junction intram nanog junctions chimeras|oocytes|iscos core technology , parthenogenesis , results in the creation of pluripotent human stem cells from unfertilized entity ( eggs ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|either densities density saturation dens|oocytes|is focused on human cell therapy , which includes the production of human differentiated cells from stem cells and involves human entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|nanog junction gradients csc densities|oocytes|viacyte , a product expected to offer women the ability to preserve or extend their fertility through the cryopreservation of their entity ( eggs ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|either densities density saturation dens|oocytes|are focused on human cell therapy , which includes the production of human differentiated cells from stem cells and involves human entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|gradients otherwise densities gata4 dens|oocytes|the second and third patents , both covering parthenogenetic activation of human entity , were 47 table of contents issued in japan and korea .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|gradients densities dens cholerae atpases|densities gradients density microtubules gata4|oocytes|for ovature , ovascience was exploring different subculture systems that allow for even further maturation of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|autoin intram autoreg densities sensitivities|oocytes|although our focus is on stem cells derived from unfertilized entity , certain aspects of that work may involve the use of nuclear transfer technology or material deemed to be embryonic material .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities dens cholerae atpases|autoin junction intram autoreg chimeras|oocytes|although our focus is on parthenogenetic stem cells derived from unfertilized entity , certain aspects of that work may involve the use of embryonic stem cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|densities gradients density saturation mω|chondrocytes|autologous cultured entity ( " carticel ( tm ) aucc " ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients density cholerae uncoupling|gata4 densities density negativity cholerae|chondrocytes|chnd1 : entity for cartilage disorders and degenerative disc disease articular cartilage is the shock absorber for joints .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|gradients sensitivities densities resonance density|chondrocytes|maci® ( autologous cultured entity on porcine collagen membrane ) is an autologous cellularized scaffold product indicated for the repair of symptomatic , single or multiple full-thickness
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|gata4 densities gradients sensitivities density|chondrocytes|use of hystem® hydrogels with purestem™ progenitors resulting in a combined product that produces cartilage- producing cell masses known as entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|autoreg densities mω imm autoin|chondrocytes|some third party payers , however , do not cover carticel entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients density cholerae uncoupling|gata4 densities cholerae cytoskeleton autoreg|chondrocytes|the commercial success of carticel-registered trademark- entity will depend on many factors , including the following : - positive results from post-marketing studies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|damp autoreg saturation nanog densities|chondrocytes|compared to the same period a year ago due primarily to decreased shipments of both epicel skin grafts and carticel entity during the three months ended march 31 , 2002 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|autoreg cytoskeleton mω atpases gata4|chondrocytes|some third-party payers , however , do not cover carticel-registered trademark- entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|densities density peaked resonance gradients|chondrocytes|preclinical studies have shown that entity embedded in bst-gel ( tm ) produce a matrix having the characteristics of normal cartilage tissue .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients density cholerae uncoupling|mω densities atpases gata4 cholerae|chondrocytes|genzyme biosurgery has developed a device to improve the procedure for implanting carticel-registered trademark- entity and has filed for marketing approval with the fda .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|gradients sensitivities densities saturation density|chondrocytes|as reported in this article , 19 of 23 patients had restored or improved joint function after treatment with cultured autologous entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|mω densities gradients autoin biased|chondrocytes|since the fda approved carticel entity , genzyme has seen a substantial increase in the number of third party payers who cover it .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|sensitivities gradients densities density gata4|chondrocytes|gtr is aware of at least one other company that is culturing autologous entity for cartilage repair in europe .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|gata4 densities density gradients nanog|chondrocytes|there are two type of entity , “articular” and “growth plate” .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|negativity tags uncoupling gata4 junction|chondrocytes|articular entity are responsible for cartilage that lines our joints , whereas growth plate entity are involved with new bone formation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|gata4 autoreg atpases densities chimeras|chondrocytes|the increase in sales of carticel-registered trademark- entity was a result of continued increases in the numbers of patients treated and surgeons trained as well as an increase
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|gradients sensitivities mω gata4 densities|chondrocytes|the process used by gtr to grow autologous entity is not patentable , and gtr does not yet have significant patent protection covering the other methodologies used in providing carticel ( tm )
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients density cholerae uncoupling|densities mω adherens gata4 cholerae|chondrocytes|since the fda approved carticel-registered trademark- entity , genzyme has seen a substantial increase in the number of third-party payers who cover it .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|sinus gradients densities mω gata4|chondrocytes|solid tissue cell therapies one of the newest areas of cell therapy involves the production of entity for the restoration of cartilage .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density cholerae uncoupling|gradients chimeras densities density saturation|chondrocytes|chondrocyte therapy involves the surgical removal of a small amount of tissue from the patient  s knee and a therapeutic quantity of entity is produced from this surgical biopsy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|gata4 notation refractory mω motors|myofibroblasts|tgf-b is a cytokine that is a key driver of fibrosis and acts by activating fibroblasts into entity , which in turn drives the production of fibrotic tissues .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities cholerae motors junction|mω dystrophin densities gata4 cd69|myofibroblasts|in a sampling of approximately 200 tumors , epha2 was found to be expressed in tumor cells , entity and / or tumor-associated blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities cholerae motors junction|junction densities mω cholerae junctions|myofibroblasts|fezagepras has been observed to regulate several cell types involved in the fibrotic pathway : macrophages , fibroblasts / entity and epithelial cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|gradients dens mω densities chimeras|myofibroblasts|the number of entity and hydroxyproline ( i . e . , collagen ) content was also significantly reduced in both organs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|densities gradients mω gata4 arrived|myofibroblasts|moreover , ehp-101 has been shown to inhibit the tgfβ-associated differentiation of cells ( called entity ) that are responsible for fibrosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|densities mω gradients junction motors|myofibroblasts|vla-1 is found on a variety of cells associated with tissue inflammation and fibrosis , including activated t-cells , macrophages and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|gradients gata4 signals mω transients|myofibroblasts|ctgf increases the abundance of entity , a cell type that drives wound healing , and stimulates them to deposit ecm proteins such as collagen at the site of tissue injury .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|saturation mω chimeras smad1 pits|myofibroblasts|in the skin , it has been shown to reduce scar formation by reduction of infiltration of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|gradients mω smad1 densities gata4|myofibroblasts| anti-fibrosiscysteamine blocks tgf-ß signaling and thereby inhibits the production and proliferation of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|mω gradients notation saturation vv|myofibroblasts|constant myofiber breakdown results in persistent activation of entity and altered production of ecm resulting in extensive fibrosis in skeletal muscles of dmd patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|gradients gata4 motors notation vv|myofibroblasts|in fibrotic conditions , excess ctgf results in chronic activation of entity , which leads to chronic ecm deposition and fibrosis ( see figure above ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities cholerae motors junction|densities mω dystrophin junction motors|myofibroblasts|anti-tshr antibodies also increase the proliferation of adipose or fat cells as well as entity , smooth muscle-like cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|gata4 refractory mω notation motors|myofibroblasts|tgf-b is a cytokine that is a key driver of fibrosis and acts by activating fibroblasts into entity , which in turn drives the production of fibrotic connecting tissues .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|densities autoreg density outer smad1|myofibroblasts|research programs involving cell-based approaches to restoring cardiac function and a research program involving a gene therapy approach to converting entity into cardiac muscle .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|mω autoreg gradients nanog junction|myofibroblasts|in the case of normal healing of a limited tissue injury , entity eventually die by programmed cell death , or apoptosis , and the fibrous scarring process recedes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|mω chimeras exists autoin gradients|myofibroblasts|fibrosis is the formation of excess connective tissue ( collagen and other proteins plus cellular elements such as entity ) in response to damage , inflammation or repair .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae motors junction|mω saturation gradients imm gata4|myofibroblasts|additionally supported by the anti-inflammatory effects , including downregulation of tnf and il-6 , that can reduce the proliferation and activation of entity in the liver .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|junction densities gradients density dens|gradients mω densities density dystrophin|adipocytes|the ultrashape system targets and selectively destroys fat cells ( entity ) , leaving critical surrounding structures such as blood vessels , nerves and connective tissue unharmed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|negativity densities mω saturation gata4|adipocytes|in addition , the fraction also contains blood cells from the capillaries supplying the entity and the extracellular matrix .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|mω densities junction gata4 density|adipocytes|in non-cancerous tissues , it is predominantly found at low levels on entity , or fat cells , and briefly on precursors to b-cells , or pre-b-cells , during normal b-cell maturation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|junction densities gradients density dens|densities mω dystrophin chimeras density|adipocytes|vitro studies have shown that activation of the beta-3 adrenergic receptor in the colon causes the release of somatostatin from entity , or fat cells , which causes pain relief .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|mω densities gradients density motors|adipocytes|antibodies form against the thyroid-stimulating hormone receptor , or tshr , which is present in the thyroid and other cells such as entity and fibroblasts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|junction densities gradients density dens|smad1 densities gata4 gradients dystrophin|adipocytes|this attenuation by protein-rich tissue results in the preferential destruction of entity by atx-101 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|densities density mω gradients gata4|adipocytes|mechanism of action atx-101 is designed to be a locally-injected drug that causes proximal , preferential destruction of entity , or fat cells , with minimal effect on surrounding tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|gata4 smad1 densities mω uncoupling|adipocytes|believe that rnai could potentially be a reliable method to selectively inhibit certain genes and their corresponding protein expression in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|gradients densities density junction dens|adipocytes|the research is focused on using cultured entity ( fat cells ) as a model system for studying the regulation of gene expression involved in adipocyte differentiation and function .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|gata4 smad1 traps either density|adipocytes|rnai delivery for therapeutic gene silencing in cells and animals ; and  inhibition of gene expression in entity using rnai .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cell|junction densities gradients density dens|mω normality phalloidin gradients dystrophin|adipocytes|initial product development plans include : pluripotent stem cell-derived brown entity ( agex-bat1 ) ; vascular progenitors ( agex-vasc1 ) ; and induced tissue regeneration ( itr ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|mω gradients smad1 junction gata4|adipocytes|the destruction of entity , or adipocytolysis , elicits a natural response in which macrophages are attracted to remove cellular debris and fat particles through the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|densities autoreg gradients dens gata4|adipocytes|in addition , msi-1436 was shown to reduce the size of entity , reduce body fat with no reduction of lean mass , and improve glucose tolerance via inhibition of a unique combination of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|gradients density densities leak localizes|adipocytes|cells obtained from the blood vessels in the lipoaspirate from the small volume of fat harvested , minus the fat cells ( entity ) and non-cellular material .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|mω densities junction exists gradients|adipocytes|by the presence and absence of particular biological markers , and the ability of the cell to differentiate into at least entity , osteocytes , endothelial cells and smooth muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|junction densities gradients density dens|densities gradients dystrophin mω junction|adipocytes|these antibodies activate certain cell types , such as fibroblasts and entity , present in the extraocular space , which are known to highly express tshr .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|densities gradients density gata4 atpases|adipocytes|namodenoson was also shown to inhibit the proliferation of entity , further hampering the expansion of fat producing cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|mω normality gradients densities junction|adipocytes|metabolic benefits of the lancl2 signaling axis are observed in hepatocytes , entity and myocytes through uptake and oxidation of glucose to improve the systemic glucose homeostasis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|densities gata4 atpases density gradients|adipocytes|pending delivery of sirna into entity for treatment of diabetes and obesity michael p . czech qiong l . zhou zhen y . jiang 12 / 11 / 2002 exclusive
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|junction densities gradients density dens|mω gradients chimeras densities density|adipocytes|liposarcomas arise by malignant transformation of entity , not necessarily entity from within a lipoma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases cholerae autoreg gradients|densities atpases gata4 gradients density|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic , meaning blood cell-forming , and angiogenic , meaning blood vessel endothelium-forming ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases cholerae autoreg gradients|densities atpases gata4 gradients density|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic ( blood cell forming ) and angiogenic ( blood vessel endothelium forming )
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases cholerae autoreg gradients|chimeras junction atpases gradients mω|hemangioblasts|no . 6 , 338 , 942 selective expansion of target cell populations 5 / 19 / 2015 us patent no . 6 , 429 , 012 cell population containing non-fetal entity and method for producing same
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases cholerae autoreg gradients|densities atpases gradients density gata4|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic , meaning blood cell forming , and angiogenic , meaning blood vessel
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases cholerae autoreg gradients|chimeras junction atpases gradients mω|hemangioblasts|no . 6 , 338 , 942 selective expansion of target cell populations 10 / 7 / 2014 us patent no . 6 , 429 , 012 cell population containing non-fetal entity and method for producing same
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases cholerae autoreg gradients|saturation gradients mω density chimeras|hemangioblasts|development of its rpe cells for conditions involving retinal degeneration · act is evaluating research and development programs for esc-derived entity and dermal regeneration .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|atpase atpases cholerae autoreg gradients|gradients densities otherwise integrins gata4|hemangioblasts|this patent broadly covers the derivation and growth of human entity from a non-fetal source .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality banding junction kolmogorov autoreg|gata4 atpases motors densities dens|myeloblasts|acute myeloid leukemia aml is a type of cancer in which the bone marrow makes abnormal entity ( a type of white blood cell ) , red blood cells or platelets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|normality banding junction kolmogorov autoreg|gata4 densities kv microtubules motors|myeloblasts|comprises normalizing peripheral blood counts , resolution of bone marrow dysplasia and reduction in the percentage of immature blood cells , or entity , to less than 5% .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality banding junction kolmogorov autoreg|gata4 uncoupling autoreg certain gap|myeloblasts|leukemia aml is a rapidly progressing cancer of the blood and bone marrow characterized by the uncontrolled proliferation of dysfunctional entity that do not mature into healthy blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|normality banding junction kolmogorov autoreg|gata4 mω densities microtubules autoreg|myeloblasts|which both failure to differentiate and excessive proliferation in the stem cell compartment result in accumulation of non-functional cells termed entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality banding junction kolmogorov autoreg|gata4 gradients motors junction densities|myeloblasts|the myeloid cells are predominantly immature platelet cells called entity , or blasts , which are the leukemia cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality banding junction kolmogorov autoreg|densities gradients gata4 density dens|myeloblasts|this suggests that differentiation of entity  made possible by inhibition of mutated idh2  may drive the clinical efficacy of enasidenib .  targeting idh mutations is
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality banding junction kolmogorov autoreg|densities gradients density mω gata4|myeloblasts|the gm-csf receptor is expressed on entity and other progenitor cells , and binding results in differentiation and maturation into monocytes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality banding junction kolmogorov autoreg|uncoupling gata4 autoreg gap nanog|myeloblasts|aml is a rapidly progressing cancer of the blood and bone marrow characterized by the uncontrolled proliferation of dysfunctional entity that do not mature into healthy blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality banding junction kolmogorov autoreg|gata4 motors densities gradients nanog|myeloblasts|immature white blood cells known as entity , or blasts proliferate in the bone marrow rather than mature into normal blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality banding junction kolmogorov autoreg|gata4 atpases mω motors densities|myeloblasts|acute myeloid leukemia market • bone marrow makes abnormal entity ( a type of white blood cell ) , red blood cells , or platelets • if left untreated , aml progresses rapidly to death
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|normality banding junction kolmogorov autoreg|gata4 kv motors microtubules ≥4|myeloblasts|acute leukemia or blood cancer that results from the improper maturation of myeloid stem cells leading to the production of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality banding junction kolmogorov autoreg|gradients dwell dens resides localizes|myeloblasts|blast ( % ) refers to the percentage of leukemic entity , or blood cells affected by disease , compared to all blood cells in the sample .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality banding junction kolmogorov autoreg|dens gradients gata4 ideally densities|myeloblasts|from this trial show that patients with relapsed , refractory acute myeloid leukemia , or aml , experienced a decrease in peripheral blood entity , a measure of clinical activity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality banding junction kolmogorov autoreg|gata4 atpases motors localizes chimeras|myeloblasts|aml is a type of cancer in which the bone marrow makes abnormal entity , a type of white blood cell , red blood cells or platelets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients autoreg cracks atpases clock|gradients gata4 densities mω imm|proerythroblasts|on stained slides the cells had the features of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients autoreg cracks atpases clock|gata4 gradients cyclins densities junction|proerythroblasts|increase in overall numbers of entity in mice the rapid expansion of the pro-e population also coincided with decreased numbers of erythroid burst-forming units and erythroid
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|curvature densities dens junction boltzmann|dens settle junction clock dispersion|interneurons|specifically , inhibitory gabaergic entity are susceptible to excessive excitatory amino acid release .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|curvature densities dens junction boltzmann|densities density curvature peaked plastic|interneurons|this loss of nav1 . 1 channels in inhibitory entity and other nerve cells results in dravet syndrome .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|densities density peaked mω sensitivities|myotubes|in non-clinical studies with human entity grown from 35 different nmdmd patients , ataluren also exhibited a bell-shaped dose-response curve with maximal dystrophin staining observed at 10
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities density cholerae atpases|gradients cholerae nanog certain smad4|myotubes|force increased exon skipping in human dmd entity with exon 51 mutation *** p < 0 . 001 in studies in the mdx mouse dmd model , a validated and
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|densities autoreg density gradients saturation|myotubes|we used rna-sequence ( rna-seq ) analysis of the entity from dm1 patients to create a splice score for control human subjects cells treated with sidmpk . 19 or the inactive sirna , sidmpk . 29 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities density cholerae atpases|cholerae gradients autoreg veloc densities|myotubes|mock treated dm1 entity ( open black diamonds ) show the full splice derangement .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|gradients gata4 nedd4 densities smad1|myotubes|when patient entity were analyzed , there was a marked improvement in the splice score of the entity treated with the sidmpk . 19 compared to the inactive sidmpk . 29 ( see figure 11 below ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|autoreg densities gata4 gradients cd69|myotubes|as shown in the figure on the right below , we also observed reduced cell death , or apoptosis , in fshd entity , as measured by active caspase-3 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|densities density chimeras junction grades|myotubes|effect of ataluren on dystrophin staining scores in entity isolated from nmdmd mice myotubes from nmdmd patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|densities density either gata4 localization|myotubes|able to sustain utrophin protein expression based on in vitro data generated in myoblast cells from dmd patients and human entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|densities traps gradients smad1 mω|myotubes|the proprietary compounds bio101 and bio103 on muscle cells in particular regarding protein syntheses and growth in the diameter of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|gata4 gradients densities otherwise cyclins|myotubes|as depicted below , results from an in vitro study demonstrate that human entity are larger in muscle cells treated with sarconeos ( bio101 ) as compared to untreated control cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|densities localization autoreg mω smad1|myotubes|the splice signature approached that of control entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|densities density gradients saturation autoreg|myotubes|the studies used gymnotic uptake , or no transfection reagents , in patient-derived entity ( in vitro ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|autoreg gata4 densities gradients cd69|myotubes|as shown in the figure on the right below , also observed reduced cell death , or apoptosis , in fshd entity , as measured by active caspase-3 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|gradients densities density cholerae atpases|junction mω smad1 junctions integrins|myotubes|fgfs can also induce or inhibit differentiation in a variety of cell types ( e . g . of myoblasts into entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|densities smad1 gata4 density gradients|myotubes|in the study , we demonstrated that mbd3l2 was representative of broader dux4-driven gene expression changes in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|either smad1 densities gata4 ≥4|myotubes|administration of our proprietary aso conjugated to a fab targeting tfr1 reduced expression of key dux4 biomarkers in fshd patient entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|gradients densities density cholerae atpases|densities density cholerae adherens dystrophin|myotubes|and 50% , respectively , based on our in vitro studies that were undertaken in myoblast cells from patients with dmd and entity from healthy individuals .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|mω gata4 traps smad1 densities|myotubes|we used active caspase-3 to quantify cell death because it is a protein that has been shown to be an important regulator of the apoptosis pathway in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|either densities density saturation gata4|myotubes|human entity when dosed with smt c1100 for 7 days demonstrated and increase of utrophin protein of around 50% when compared to
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|gradients densities density cholerae atpases|dystrophin saturation densities cholerae normality|myotubes|the four hearts and in one heart diacrin noticed an increase in small vessel formation at the site of surviving entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|densities chimeras density autoreg gradients|myoblasts|we use a number of proprietary processes to create therapeutic quantities of entity from a patients thigh muscle biopsy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|gradients densities chimeras junction gata4|myoblasts|entity are precursors to muscle cells that have the capacity to fuse with other myoblasts or with damaged muscle fibers to regenerate skeletal muscle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|junction nemat gauge restorations densities|myoblasts|genvec , genzyme , and bioheart are all developing products consisting of skeletal entity isolated from muscle , expanded in culture , and injected into a patients heart to repair dead tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|gradients densities density mω uncoupling|myoblasts|bv , was previously awarded a manufacturing permit from the netherlands ministry of health for the in vitro culture of autologous entity for use as human medications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|densities density junction atpases chimeras|myoblasts|by using entity obtained from a patients own body , we believe myocell is able to avoid certain challenges currently faced by other types
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|autoreg outer mω smad1 localizes|myoblasts|in the capacity that we have at diacrin without stressing the facilities and continuing to also be able to produce entity for cardiac repair .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|densities chimeras density autoreg gradients|myoblasts|we use a number of proprietary processes to create therapeutic quantities of entity from a patients thigh muscle biopsy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|mω densities chimeras density junction|myoblasts|at the cell culturing site , our proprietary techniques are used to isolate and remove entity from the muscle tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|density densities autoreg decay cd69|myoblasts|histopathology confirmed that entity expressing sdf-1a resulted in increased muscle and blood vessel formation in the damaged areas of the hearts , which was not
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|densities density saturation atpases kolmogorov|myoblasts|when injected into scar tissue within the heart wall , entity have been shown to be capable of engrafting in the damaged tissue and differentiating into mature skeletal muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|junction imm saturation gata4 atpases|myoblasts|after expansion , the entity are packaged and delivered to the clinical site for implantation into the injured heart tissue by a surgeon or interventional
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients dens density motors|cholerae junction sensitivities mω dens|myoblasts|intellectual property in connection with products , processes or services developed or provided by genvec other than autologous and allogenic skeletal entity for cardiac therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|densities density gradients smad1 junction|myoblasts|similarly , the fusion of entity with other entity is essential for the formation , growth , and regeneration of skeletal muscle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients dens density motors|densities density atpases cholerae gata4|myoblasts|for example , some of our competitors are exploring whether the use of cells , other than entity , is safer or more effective than myocell .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|atpases gauge adherens outer autoreg|myoblasts|implantation during coronary artery bypass graft ( cabg ) surgery may lead to similar effects , as do recent studies using percutaneous delivery of entity as a stand-alone procedure .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|densities density gata4 signals autoreg|myoblasts|ctgf treatment of entity induced their de-differentiation , or failure to become mature muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|densities density junction atpases chimeras|myoblasts|by using entity obtained from a patients own body , we believe myocell is able to avoid certain challenges currently faced by other types
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|density mω densities autoreg otherwise|myoblasts| wve-n531 induced a dose-dependent increase in dystrophin production ( up to 71% ) in vitro in dmd patient-derived entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|dens junction densities density mω|myoblasts|cellular based therapies such as skeletal entity and embryonic stem cells are being pursued by companies such as bioheart , mg biotherapeutics , a joint venture created by medtronic
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients dens density motors|atpases chimeras densities saturation density|myoblasts|clinical therapy designed to improve cardiac function by populating regions of scar tissue within a 8 patients heart with entity derived from a biopsy of a patients thigh muscle .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω gradients matric dens gata4|lymphoblastic|we are developing marqibo for the treatment of acute entity leukemia and other blood cancers including lymphoma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω gates otherwise densities localizes|lymphoblastic|exclusive license agreement pursuant to which we licensed the patent rights to a specific gene mutation with respect to chronic entity leukemia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω gradients exists densities otherwise|lymphoblastic|achieve the primary endpoint of efficacy in the phase 2 clinical trial of blinatumomab in patients with acute entity leukemia 10 % 12 . 5 % 6 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω gradients gata4 localizes densities|lymphoblastic|in the second quarter , we initiated a pharmacokinetic study in phase 2 for erwinaze for the treatment of acute entity leukemia in the young adult population .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω dens gata4 matric hysteresis|lymphoblastic|all patients receiving autologous sb-modified t cells had non-hodgkin lymphoma , and most patients receiving allogeneic car+ t cells had acute entity leukemia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω restorations localizes dispens negativity|lymphoblastic|of the most important potential uses of annamycin is in the treatment of children with either aml or all ( acute entity leukemia , which is more common in children ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω restorations dispens gradients hysteresis|lymphoblastic|nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute entity leukemia after at least two prior regimens .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω trpv gradients biphasic oscillatory|lymphoblastic|candidate blinatumomab ( mt103 ) is currently the subject of a european pivotal trial in patients with minimal residual disease positive acute entity leukemia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω matric dispens localizes restorations|lymphoblastic|erwinaze , a biologic product , is used in conjunction with chemotherapy to treat patients with acute entity leukemia , or all , with hypersensitivity to e . coli-derived asparaginase .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|dispens mω negativity restorations bimodal|lymphoblastic|pbcar0191 , is an allogeneic car t cell therapy targeting the well-validated tumor target cd19 and is being developed for acute entity leukemia , or all , and non-hodgkin lymphoma , or nhl .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω gata4 localizes otherwise restorations|lymphoblastic|oncaspar is a first-line biologic used as part of a chemotherapy regimen to treat patients with acute entity leukemia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω restorations localizes trpv phal|lymphoblastic|for iclusig is bcr-abl , an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia ( cml ) and philadelphia-chromosome positive acute entity leukemia ( ph+ all ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω restorations kolmogorov kerat trpv|lymphoblastic|sar3419 targets cd19 and is a potential new treatment for cd19-expressing b-cell malignancies including nhl and b-cell acute entity leukemia , or b-all .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω restorations dispens localizes negativity|lymphoblastic|the fda approved kymriah ( tisagenlecleucel ) for the treatment of certain pediatric and young adult patients with a form of acute entity leukemia ( all ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω gradients dens gata4 otherwise|lymphoblastic|it is in a phase 2 clinical trial for the treatment of patients with acute entity leukemia and a phase 1 clinical trial for the treatment of patients with non-hodgkin  s lymphoma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω gradients hysteresis densities dens|lymphoblastic|patients , in august 2011 , we initiated a phase 1 clinical trial of quizartinib in pediatric patients with either relapsed acute entity leukemia , or all , or relapsed aml .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|otherwise dens hysteresis gradients mω|lymphoblastic|may 2005 , we commenced an open-label , multicenter phase i and ii study of talotrexin in the treatment of refractory adult entity leukemia or “all .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω gradients otherwise localizes densities|lymphoblastic|the company also acquired the u . s . and canadian marketing rights to oncaspar ( tm ) for use in the treatment of acute entity leukemia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω dispens restorations localizes trpv|lymphoblastic|u . s . for advanced non-hodgkins lymphoma , and vincristine sulfate liposome injection ( marqibo® ) approved in the u . s . for advanced adult ph- acute entity leukemia ( all ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities autoreg cholerae atpases|mω dens matric otherwise kolmogorov|lymphoblastic|two other sar3419 phase ii trials are ongoing in relapsed / refractory dlbcl and in acute entity leukemia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities cholerae gradients atpases atpase|limit junction saturation tags gata4|enterocytes|fxr activation in intestinal entity results in the secretion of fibroblast growth factor 19 , or fgf19 , which has been associated with increased serum low-density lipoprotein ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities cholerae gradients atpases atpase|saturation junction gata4 otherwise curvature|enterocytes|by inhibiting nhe3 on the apical surface of the entity , tenapanor reduces absorption of sodium from the small intestine and colon , resulting in an increase in water secretion into the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities cholerae gradients atpases atpase|otherwise densities density grades grade|enterocytes|we believe that kp201 is then completely hydrolyzed down to hydrocodone and the ligand in the entity , which then release the hydrocodone directly into the blood stream .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities cholerae gradients atpases atpase|junction mω restorations dystrophin tags|enterocytes|it can thus inhibit iron absorption from the gi tract by interacting with duodenal entity and limit the release of iron in the bone marrow by interacting with macrophages .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities cholerae gradients atpases atpase|limit junction saturation tags dystrophin|enterocytes|fxr activation in intestinal entity results in the secretion of fibroblast growth factor 19 , or fgf19 , which has been associated with increased serum ldl cholesterol
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities cholerae gradients atpases atpase|junction junctions degenerate existence junctional|enterocytes|believe that due to kp201s low binding affinity to the µ-opioid receptors it is absorbed largely intact into the intestinal entity , which are the cells lining the small intestine .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities cholerae gradients atpases atpase|mω junction dystrophin normality either|enterocytes|the cellular trans-membrane protein ferroportin , which functions as an export channel for intracellular iron in macrophages , liver hepatocytes , and duodenal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities cholerae gradients atpases atpase|chimeras autoreg densities gata4 smad1|enterocytes|this was observed in a preclinical study in mice in which kd026 caused fat accumulation in entity and prevented fat accumulation in the liver tissues .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|densities cholerae gradients atpases atpase|junction gradients density saturation densities|enterocytes|lomitapide also blocks mtp in entity ( cells lining the gastrointestinal tract ) , leading to an accumulation of fat in the intestinal mucosa .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities constitutive null density|gata4 gradients chimeras csc gata3|spermatids|hormone ) drives synthesis of testosterone in the leydig cells of the testes and fsh ( follicle stimulating hormone ) drives production of entity in the sertoli cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|gradients densities constitutive null density|gradients mω densities microtubules chimeras|spermatids|clinical dose on a mg / m2 basis ) in a 6-month iv study had bilateral degeneration of the seminiferous epithelium with retained entity and atrophy of interstitial cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities constitutive null density|gradients mω densities autoreg chimeras|spermatids|entity mature over a 72 day cycle in the seminiferous tubules in the testes under the influence of endogenous testosterone produced
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities constitutive null density|mω autoin either dystrophin smad1|spermatids|to be mutagenic in the in vivo mouse micronucleus assay and positive for the induction of chromosomal aberrations in mouse entity and murine lymphocytes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|nanog chimeras densities junction smad1|sperm|taken from the womans ovarian follicles and fertilized in vitro with either standard insemination , or icsi , in which a single entity is injected by needle into the egg .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|gradients densities autoreg density inactivation|sperm|the decrease is due to a smaller demand for the entity bank services .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|chimeras dens spher junction gradients|sperm|each parent , including recombination , or the exchange of dna within the parent chromosomes that occurs during the formation of the entity and the egg that become the fetus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|density autoreg nanog densities inactivation|sperm|the company operates in two distinct reporting segments , one for the entity bank division and one for its stem-cell and skin care divisions as of december 31 , 2009 and 2008 and for
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|gradients saturation densities dens loose|sperm|this trial showed that androxal® was able to maintain entity counts in men being treated for their low testosterone levels , whereas testim® resulted in suppressed entity levels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|fdr dens dipolar densities dispens|sperm|the latter include , among other technologies , in vitro fertilization , or ivf , and intracytoplasmic entity injection , or icsi .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|null nanog mω gradients gata4|sperm|lastly , semen samples that had fewer normal entity had slightly , but not significantly , higher sorp values .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities cholerae atpases dens|atpases autoreg dystrophin densities chimeras|sperm|of the protocol or for other unanticipated reasons , and we may be unable to achieve the same results with the entity of infertile donors that have been achieved with entity of fertile donors .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|gradients densities gata4 density motors|sperm|those with an abnormally low entity concentration or overall total number , have significantly higher sorp values than those in the normal range .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|nanog gata4 smad1 densities gradients|sperm|o application as an enhancement in human intercourse - for couples prone to male factor infertility from immotile or poorly motile entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|either junction smad1 densities gata4|sperm|the university of pennsylvania safety and efficacy laboratory studies with atp ( the active ingredient in atpotent ) using human and animal entity as well as animal eggs and animal embryos .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|damp mω densities nedd4 dens|sperm|the contractor must provide full service cryobiology program to include storage of embryos and entity all laboratory equipment and staffing as work load requires .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|smad1 gradients chimeras densities density|sperm|conducted in 20 women and published in the journal of reproductive medicine® in 2009 , ovaprene demonstrated the ability to immobilize entity and prevent their progression into the cervical mucus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|junction dens gata4 nanog smad1|sperm|abnormally few motile entity or few entity with a progressive motility were also associated with significantly higher sorp values than those in the normal range .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities cholerae atpases dens|dystrophin chimeras autoin spher refractory|sperm|transgenic animal  shall mean a non-human animal , or an egg , entity or embryo of such animal , which bears in its germline a foreign gene derived from another animal species .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|density densities kv inactivation nanog|sperm|continued to develop its pre-clinical-stage therapeutic agents and various treatments utilizing stem cell treatments while generating revenues and operating its entity bank division .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|smad1 mω gradients vv chimeras|sperm|that plays a key role in masculine growth and development during puberty — or has an impaired ability to produce entity or both .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|junction autoreg refractory autoin dens|sperm|not viable , the work prompted calls for a moratorium or other types of restrictions on gene editing of human eggs , entity , and embryos .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|mω densities gradients smad1 nanog|sperm|program with androxal as a treatment for men being treated for low testosterone that want to maintain or improve their entity function during treatment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities cholerae atpases dens|smad1 chimeras gradients densities density|sperm|conducted in 21 women and published in the journal of reproductive medicine in 2009 , ovaprene® demonstrated the ability to immobilize entity and prevent their progression into the cervical mucus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|autoreg densities autoin leak mω|gametes|( b ) donors of entity , embryos , somatic cells or human tissue did not receive valuable consideration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|nanog dens junction gradients densities|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology , or " art " , services .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|autoin autoreg densities mω density|gametes|( e ) individuals who consented to donate stored entity , embryos , somatic cells , or human tissue were not reimbursed for the cost of storage prior to the decision to donate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|autoreg mω densities smad1 motors|gametes|( c ) a person may not knowingly , for valuable consideration , purchase or sell entity , embryos , somatic cells , or human tissue for research purposes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|nanog dens junction gradients densities|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology , or art , services .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|autoreg autoin junction gauge nanog|gametes|ivf treatment while the procurement , processing and distribution of entity and embryos for use in ivf and other assisted reproduction treatments falls within the scope of the eu rules governing
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|leak autoreg mω autoin motors|gametes|national stem cell oversight committee , or · been derived under the following conditions : ( a ) donors of entity , embryos , somatic cells , or human tissue gave voluntary and informed consent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|uncoupling junction dens nanog chimeras|gametes|enactment of this act , that is derived by fertilization , parthenogenesis , cloning , or any other means from one or more human entity or human diploid cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|nanog dens junction gradients densities|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as art services .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|autoreg autoin mω densities leak|gametes|( b ) donors of entity , embryos , somatic cells , or human tissue did not receive valuable consideration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|nanog dens junction gradients density|gametes|procedures that require entity ( sperm and eggs ) to be handled in 3 vitro ( outside the body ) are classified as assisted reproductive technology , or " art " ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|leak autoreg autoin mω motors|gametes|national stem cell oversight committee , or ● been derived under the following conditions : ( a ) donors of entity , embryos , somatic cells or human tissue gave voluntary and informed consent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|mω nanog leak autoreg motors|gametes|of a duly authorized institutional review board ( irb ) ; and prohibits the knowing purchase , sale or transfer of human embryos or entity for valuable consideration for research purposes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|nanog dens junction gradients densities|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology ( " art " ) services .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|dens normality autoreg junction saturation|autoin autoreg mω leak endos|gametes|( d ) donation of entity , embryos , somatic cells , or human tissue was overseen by an irb ( or , in the case of foreign sources , an irb-equivalent ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality spher gradients motors densities|either traps mω pde altered|somatotrophs|gh is an anabolic hormone synthesized , stored in , and secreted from entity of the anterior pituitary gland in response to chemical modulators from the hypothalamus and stomach .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality spher otherwise clarity mendelian|gradients densities density imm boundary|corticotrophs|similarly , dipyridamole did not amplify prednisolone effects in entity , cells that mediate the hpa axis suppression of high-dose glucocorticoid treatment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality gradients otherwise cyclins cytoskeleton|gradients saturation junction gradient densities|sebocytes|because there are no preclinical models of acne , human entity , which are the cells that make up the sebaceous glands and secrete sebum , are a useful research tool for a
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality gradients otherwise cyclins cytoskeleton|saturation gradients densities density saturated|sebocytes|it has also been shown in a laboratory study that a chemical that blocks acetylcholine from reaching the entity reduces sebum production .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality gradients otherwise cyclins cytoskeleton|gradients mω coupled restorations vesicles|sebocytes|acetylcholine has been shown in laboratory studies to increase activity in the sebum-producing skin cells called entity , which form sebaceous glands .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|otherwise sinus cytoskeleton junction cholerae|densities density mω gradients saturation|synoviocytes|synoviocyte inhibitory moa : pro-inflammatory entity in the ra joint proliferate highly and secrete multiple cytokines involved in ra disease pathogenesis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|otherwise sinus cytoskeleton junction cholerae|gradients mω junction densities saturation|synoviocytes|rheumatoid arthritis results from interactions between immune cells and entity that leads to joint swelling , pannus formation and bone loss .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|otherwise sinus cytoskeleton junction cholerae|gradients gata4 junction junctions nanog|synoviocytes|the synovium is lined by cells , or entity , which produce a small amount of liquid called synovial fluid that nourishes and lubricates the joint .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|otherwise sinus cytoskeleton junction cholerae|gradients negativity mω saturation junction|synoviocytes|the entity , in turn , secrete a variety of chemicals that contribute to inflammation , tissue degradation and harmful new blood vessel formation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|otherwise sinus cytoskeleton junction cholerae|gata4 gradients mω densities motors|synoviocytes|of articular joints and joint surfaces , characterized by the rapid , uncontrolled growth of the cells that line the joints , called entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|otherwise sinus cytoskeleton junction cholerae|nanog gata4 densities mω density|synoviocytes|of most individuals with rheumatoid arthritis , which drive the production of tnf and the recruitment of neutrophils and fibroblast like entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|otherwise sinus cytoskeleton junction cholerae|mω gradients densities density uncoupling|synoviocytes|synoviocyte inhibition : pro-inflammatory entity in the ra joint proliferate highly and secrete multiple cytokines involved in ra disease pathogenesis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|otherwise sinus cytoskeleton junction cholerae|densities density gradients nanog mω|synoviocytes|data published today demonstrate that ppi-2458 potently inhibits the growth of both human fibroblast-like entity derived from rheumatoid arthritis patients and human endothelial cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|nanog dens normality autoreg densities|heterochromatin cd44 nanog dens nedd4|mechanoreceptors|in parallel , electrophysiology recordings of single ganglion neurons that innervate the craniofacial muscles were performed ( 33 masticatory muscle entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cyclins atpases otherwise normality atpase|gata4 dystrophin saturation mω autoreg|angioblasts|the young entity will be tested in preclinical mouse models of accelerated aging to assess the safety and efficacy of the cells in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|cyclins atpases otherwise normality atpase|junction cyclins atpases autoreg sensitivities|angioblasts|recyte will also develop ips cells into primitive entity , which are cells believed to be capable of reconstituting and repairing age-related changes in the vascular system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cyclins atpases otherwise normality atpase|gata4 dystrophin saturation mω autoreg|angioblasts|the young entity will be tested in preclinical mouse models of accelerated aging to test the safety and efficacy of the cells in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|gradients either motors saturation resonance|phagocytes|binding of ar-101 to p . aeruginosa bacteria facilitates human complement binding and improves immune recognition and destruction by circulating human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|clock uncoupling gradients normality mω|phagocytes|important entity include macrophages , that rid the body of dead cells and other debris , and granulocytes , including neutrophils , that contain granules filled
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|autoreg smad1 densities motors either|phagocytes|t cells have been shown to be sensitive to oxygen free radical-induced apoptosis when these immune cells were exposed to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|autoreg densities either motors imm|phagocytes|nk / t cells have been shown to be sensitive to oxygen free radical-induced apoptosis when these immune cells were exposed to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|gata4 autoreg imm uncoupling gradients|phagocytes|these defective entity cannot generate superoxide , leading to an inability to kill harmful microorganisms such as bacteria and fungi .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|gata4 mω gauge normality motors|phagocytes|one part of the innate immune system involves large white blood cells called entity ( literally , " cell-eaters " ) that can engulf and digest foreign microorganisms and other antigens .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|gradients namely uncoupling either gata4|phagocytes|have been shown to induce antibodies that are protective in animal models and that facilitate killing of bacteria by human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|densities imm density autoreg smad1|phagocytes|laboratory research has demonstrated that ceplene reduces formation of oxygen radicals from entity , inhibiting nadph oxidase and protecting il-2-activated nk-cells and t-cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients density dens saturation|gata4 saturation gradients densities dystrophin|phagocytes|entity were depleted using clodronate loaded liposomes through day 21 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients density dens saturation|gata4 gradients dystrophin saturation atpases|phagocytes|and increasing anti-inflammatory mediators , the production of antimicrobial effectors and increased absorption of pathogens by specially adapted cells known as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|saturation gata4 gradients densities density|phagocytes|we observed that depletion of entity , including myeloid apcs , significantly reduced our bdc-1001 surrogate-mediated anti-tumor activity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients density dens saturation|gata4 gradients densities dens dystrophin|phagocytes|furthermore , significant increases in entity and cd8 t cells were measured in tumors following bdc-1001 surrogate treatment , further supporting a mechanism that bridges the innate
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities gradients density dens saturation|dystrophin densities density either atpases|phagocytes|figure 4 : bdc-1001 surrogate activity dependent on presence of entity scid / beige were dosed systemically with 5 mg / kg on day 0 , 5 and 10 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|saturation imm gata4 smad1 density|phagocytes|or other molecules in the class known as histamine type-2 ( h ) receptor agonists bind to the h receptor on the entity , the production and release of free radicals is temporarily prevented .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|autoreg densities density imm gata4|phagocytes|the release of free radicals by entity results in apoptosis , or programmed cell death , of nk , t and nk / t cells , thereby destroying their cytotoxic capability and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|autoreg imm densities gata4 density|phagocytes|the release of free radicals by entity results in apoptosis ( programmed cell death ) of nk cells and t cells , thereby destroying their cytotoxic capability and rendering the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|autoreg densities density imm gata4|phagocytes|the release of free radicals by entity results in apoptosis , or programmed cell death , of nk , t and nk / t cells , thereby destroying their cytotoxic capability and rendering
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|gradients gata4 atpases gradient motors|phagocytes|entity are a class of white blood cells found in abundant quantities at the site of tumors and viral infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|densities gradients density dens saturation|motors gradients atpases microtubules either|phagocytes|maxim  s researchers have shown , however , that nk cells and t cells are suppressed by entity , another component of the body  s immune system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities gradients density dens saturation|saturation mω smad1 gata4 resonance|phagocytes|table of contents results in a dramatic increase in the production of cytokines that orchestrate the proliferation and recruitment of entity to the site of damage , resulting in inflammation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|gradients junction autoreg densities gata4|splenocytes|entity were analyzed by flow cytometry to confirm effector / memory phenotype , and cultured with anti-human cd3 antibodies at 2 . 5 mg / ml and anti-human
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|densities gradients density saturation grades|splenocytes|entity were lysed and assayed for phospho- nuclear factor kappa b ( nfb ) p65 using an enzyme-linked immunosorbent assay .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|saturation densities autoreg density gradients|splenocytes|figure 11 : entity from eae mice treated with edp1815 produced an anti-inflammatory cytokine profile .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|kolmogorov densities adherens smad4 loose|splenocytes|svp 1 3 week week naïve recipient lmb-100 transfer entity lmb-100 + / -lmb-100 + / -
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|rho ubiquitin junction cytoskeleton gradients|splenocytes|cell responses will be assessed by in vivo cd4 and cd8 cell depletion and measure cytotoxicity and gamma-ifn release by entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|saturation gradients density densities either|splenocytes|administration for 14 days ( 10 mg / kg , sid , ip ) : no effect on blood count , blood chemistry and cytokine secretion by isolated entity no herg inhibition observed ( in vitro )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities kerat gradients neurovascular density|kolmogorov refract adherens nedd4 dystrophin|splenocytes|svp prime challenge donor transfer entity day 0 14 aav8-hfix day 0 19 20 21 32 recipient anti-cd25 treg depletion day 0 1 28 anti-aav8 igg
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|gradients saturation density densities imm|splenocytes|in vitro studies demonstrated that treatment of isolated entity with virulizin ( r ) result in increased il-17e mrna expression .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|saturation densities gradients junction chimeras|splenocytes|entity from either young or older atherosclerotic apoe ko mice were isolated from the spleen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities kerat gradients neurovascular density|dystrophin autoreg densities nanog mω|splenocytes|to explore further the mechanisms of cns remyelination , we made a panel of monoclonal antibodies ( mabs ) derived from entity of sjl / j mice injected with homogenized spinal cord .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|saturation junction gradients certain chimeras|splenocytes|stimulation of entity harvested 7 days post last vaccination with respective peptides demonstrated strong induction of antigen specific t cells in elispot ( depicted in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities kerat gradients neurovascular density|junction saturation chimeras gradients dystrophin|splenocytes|stimulation of entity harvested 7 days post last vaccination with respective peptides demonstrated strong induction of antigen specific t cells in enzyme-linked immune absorbent
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|gradients autoreg saturation smad1 densities|splenocytes|t cell responses were measured on day 15 by re-stimulating entity with either control ( medium ) or peptides corresponding to each antigen ( 1 , 2 , 6 , 9 , and 12 ) in the mrna vaccine
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|gradients densities gata4 junction either|splenocytes|before transfer , immunized entity were separated or fractionated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities kerat gradients neurovascular density|autoreg smad1 dystrophin ubiquitin autoin|splenocytes|robust and specific antigen specific cd8+ifng+ t cell responses were detected in entity after re-stimulation with kras mutation 1 peptide and kras mutation 2 peptide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities kerat gradients neurovascular density|saturation dystrophin either imm gradients|splenocytes|cgen-25007 exhibited anti-inflammatory activity in both human pbmcs and murine entity challenged with various inflammatory stimuli as well as in an animal model of endotoxemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|imm adherens traps gradients either|splenocytes|enumeral platform used for antibody discovery • mice were immunized with pd - 1 - his • entity activated with lps for 3 days •
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|either densities damp mω gradients|splenocytes|these methods were applied to analyze gene expression data from mouse entity exposed to either copaxone® or the purported generic ga .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|junction densities autoreg saturation density|splenocytes|cd4+ and cd8+ t cells from entity isolated from bnt162b2-immunized mice were strongly positive for ifn-ɣ and il-2 , producing high levels of the th1 cytokines but minute
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities kerat gradients neurovascular density|saturation densities density imm gradients|splenocytes|preincubation of the endothelial cells with blocking antibodies to eotaxin-2 was found to attenuate the adhesion of the entity to these cells ( fig . 15a ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality sinus otherwise cyclins|gradients nanog gata4 mω autoreg|corneocytes|in addition , to providing most of the mechanical strength of the tissue , these entity provide a stabilizing scaffold for the mortar .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality sinus otherwise cyclins|gata4 autoreg junction smad1 density|corneocytes|the bricks ,  or entity , provide a durable defense against the ordinary frictional wear and tear of life .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality sinus otherwise cyclins|junction mω chimeras smad1 nanog|corneocytes|the stratum corneum , consisting of flattened and hardened non-living entity held together by a lipid matrix , acts as the main barrier to drug delivery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality sinus otherwise cyclins|mω smad1 densities density nanog|corneocytes|the mortar is primarily made up of fats or lipids that are organized into broad sheets or membranes .  stacks of these membranes fill the spaces between the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients normality sinus otherwise cyclins|gradients chimeras gata4 densities smad1|corneocytes|keratinocytes , the most common cell type in the outer layer of skin , has been shown to increase the formation of entity and the production of lamellar lipids .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients grades normality densities curvature|densities dystrophin density smad1 autoin|heterokaryons|elegans to isolate innate immunity mutations , and implementing species specific primers to distinguish rat transcipts from mouse transcripts in rat-mouse entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|otherwise normality cholerae cytoskeleton kolmogorov|densities gradients mω junction dystrophin|cholangiocytes|the licensed technology describes advanced methods for the production of mature hepatocytes and entity , the primary cell types of the liver .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|otherwise normality cholerae cytoskeleton kolmogorov|gradients keap1 junction functionality gata4|cholangiocytes|specific and robust ccl24 staining was also shown in entity , the epithelial cells of the bile ducts .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|biolabs gradients cholerae telangiect junction|gradients outer gauge junction mω|pneumocytes|sars - cov - 2 infects type ii entity in lung alveoli 1 these cells also serve as progenitor cells for repairing damaged alveoli .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|biolabs gradients cholerae telangiect junction|gradients densities mω imm gata4|pneumocytes|type it entity , known to be primary targets / reservoirs for flu , are plated in a transwell system , which essentially suspends the polarized cell monolayer
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|biolabs gradients cholerae telangiect junction|imm gradients autoreg grades inner|pneumocytes|in covid - 19 , infection of type ii entity results in impaired gas exchange and fluid leakage into alveoli .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase gradients resonance mω saturation|gata4 densities cd44 autoreg density|oncocyte|as of december 31 , 2017 , entity had $2 . 1 million outstanding and payable to biotime and affiliates in connection with the costs incurred under the shared facilities
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|atpase gradients resonance mω saturation|densities density mω cholerae autoin|oncocyte|entity incurred no royalty expenses to date as of december 31 , 2014 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase gradients resonance mω saturation|autoreg densities clock gradients cd69|oncocyte|importantly , entitys methods appear to be compliant with commercial manufacturing processes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|atpase gradients resonance mω saturation|gata4 densities density autoreg integrins|oncocyte|the fact that certain of our executive officers and directors own shares of entity common stock should not be considered to mean that they constitute or are acting in concert as a “group” with
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase gradients resonance mω saturation|mω damp densities dens density|oncocyte|the patent is useful for biotimes subsidiary entity corporation for its cancer diagnostic product development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|atpase gradients resonance mω saturation|autoreg gata4 densities gradients dystrophin|oncocyte|on july 2 , 2018 , entity entered into a lease schedule under the lease agreement no . 2 for certain equipment costing approximately $209 , 000 , requiring payments of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase gradients resonance mω saturation|gata4 atpases density mω atpase|oncocyte|another subsidiary , entity corporation , focuses on the therapeutic applications of stem cell technology in cancer , including using vascular progenitor cells engineered to destroy
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase gradients resonance mω saturation|gata4 cracks mω adherens atpases|oncocyte|additional information about biotime , recyte therapeutics , cell cure , orthocyte , entity , biotime asia , lifemap sciences , and esi can be found on the web at www . biotimeinc . com .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|atpase gradients resonance mω saturation|gata4 gradients density cholerae dystrophin|oncocyte|in concert with the protocol development , entity has established a broad range of support assays to monitor and measure vascular progenitor cell differentiation processes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|atpase gradients resonance mω saturation|autoreg densities autoin gata4 cholerae|oncocyte|on may 11 , 2017 , entity entered into another master lease line agreement ( “lease agreement no . 2” ) with the same finance company on terms similar to lease agreement no . 1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|atpase gradients resonance mω saturation|gata4 dystrophin nedd4 atpases densities|oncocyte|to beneficially own the shares owned by broadwood , in the aggregate beneficially own approximately 18 . 9% of the outstanding shares of entity common stock as of april 22 , 2019 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|atpase gradients resonance mω saturation|autoreg gradients imm whatever cholerae|oncocyte|under the provisions of the contracts , entity may be required to incur severance obligations for matters relating to changes in control , as defined , and involuntary terminations .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase gradients resonance mω saturation|mω atpases gata4 autoreg gradients|oncocyte|you should direct any requests to : entity corporation 15 cushing irvine , california 92618 409-7600 s-11 3 , 523 , 776 shares common stock january
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|atpase gradients resonance mω saturation|mω autoreg gata4 densities cholerae|oncocyte|entity will reimburse sbmri for 25% of the costs incurred in filing , prosecuting , and maintaining patent protection , subject to entity&#8217 ; s approval of the costs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase gradients resonance mω saturation|mω autoin gata4 densities spher|oncocyte|entity has entered into employment contracts with certain executive officers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase gradients resonance mω saturation|gata4 autoreg gradients smad4 nanog|oncocyte|references to “entity , ” “we , ” “us , ” and “our” are references to entity corporation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|atpase gradients resonance mω saturation|mω dystrophin densities density cush|oncocyte|of royalty bearing products commence , the annual fee will be credited towards entity  s royalty payment obligations for the applicable year .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase gradients resonance mω saturation|densities density gata4 nedd4 coreg|oncocyte|in note 3 , the asterias shares of common stock lineage held generated similar deferred tax liabilities to lineage as the entity shares discussed above .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase gradients resonance mω saturation|gata4 mω cd44 gradients damp|oncocyte|entity has expanded and banked large numbers of vascular progenitor cells derived from multiple hes cell lines , including clinical-grade stem cells provided by us and our subsidiary esi .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase gradients resonance mω saturation|gradients autoreg mω imm cd69|oncocyte|except as required by law , entity disclaims any intent or obligation to update these forward-looking statements .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality cracks gradients cholerae uncoupling|densities autoreg density autoin gata4|amniocytes|fluorescence images demonstrating hybridization of the cep x / y and lsi 21 probes on uncultured entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|density densities cholerae cytoskeleton junction|gata4 densities motors gradients atpases|promonocytes|two leukine treated patients had progressive increase in circulating monocytes and entity and blasts in the marrow which reversed when leukine was discontinued .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gradients gata4 mω motors chimeras|reticulocytes|to six months have shown a profound and durable reduction in hemolysis ( red blood cell destruction ) as assessed by hemoglobin , entity and / or bilirubin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gata4 atpases kv densities autoin|reticulocytes|the streck patents relate to the addition of entity to hematology controls .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|autoreg autoin gata4 imm kv|reticulocytes|is successful , after cancellation of the streck patents , the company may be issued a patent covering integrated hematology controls containing entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|kv cush gradients biased clock|gata4 gradients chimeras nanog dystrophin|reticulocytes|ldh and bilirubin are released when rbcs undergo hemolysis , and entity are young rbcs that are released by the bone marrow in response to the ongoing hemolysis ; thus we believe that
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|kv cush gradients biased clock|otherwise gata4 dystrophin smad1 autoreg|reticulocytes|mg / kg , *** ) , elevated hemoglobin concentrations in entity ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gata4 autoreg dens intram gradients|reticulocytes|we observed an 18% reduction in entity in the 10 mg treatment arm relative to the placebo arm .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|densities junction chimeras cd44 dens|reticulocytes|then exposed to a defined media formulation to promote further expansion and differentiation until they differentiate and mature into enucleated entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gata4 gradients smad1 autoreg αvβ3|reticulocytes|improvement in the hemolytic anemia would be expected to result in a decrease in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gata4 autoin motors kv resides|reticulocytes|products provide a means of assessing the linearity of hematology analyzers for white blood cells , red blood cells , platelets and entity ( immature red blood cells ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|kv cush gradients biased clock|gata4 gradients chimeras nanog dystrophin|reticulocytes|bilirubin and ldh are released when rbcs undergo hemolysis , and entity are young rbcs that are released by the bone marrow in response to the ongoing hemolysis ; thus we believe that
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gata4 ≥4 gradients densities autoin|reticulocytes|these controls are designed for manual and automated counting of entity ( immature red blood cells ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gata4 gradients motors ≥4 adherens|reticulocytes|the increase in hemoglobin levels was preceded by an increase in entity showing that an increase in hemoglobin levels is a result of a physiologic increase in rbc production .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gata4 motors mω intram outer|reticulocytes|dose ( mg / kg / day ) average bodyweight at end ofstudy hematology results at end of study entity ( x 103 / µl ) neutrophils ( x 103 / µl ) control - 603 m / 324 f
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gradients junction chimeras densities uncoupling|reticulocytes|at this stage , the enucleated entity are rcts that express one or more biotherapeutic proteins in the cytosol or on the cell surface .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gradients gata4 autoin nanog dens|reticulocytes|while gbt4 showed improvement in hemoglobin , entity and ldh levels in the first 15 days , these values worsened after day 15 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gradients gata4 kv chimeras dens|reticulocytes|levels and improved clinical measures of hemolysis at 16 weeks , as evaluated by changes from baseline in hemoglobin , percent of entity , and percent of unconjugated bilirubin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gata4 gradients saturation dens nanog|reticulocytes|robust and sustained increase in red blood cells , hemoglobin and entity , supporting monthly or less frequent dosing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gata4 dens mω gradients saturation|reticulocytes|receiving the 300 mg dose , measuring changes in parameters over the 14-day treatment and 7-day follow-up period including hemoglobin and entity , as well as tolerability and safety .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|mω traps dens junction cracks|reticulocytes|standard in vivo genotoxicity studies in rodents , including a 2-day comet assay and a 28-day evaluation of micronucleated entity , revealed no test-article effects on genotoxicity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kv cush gradients biased clock|gradients dens gata4 mω densities|reticulocytes|( 700 mg ) 8 ( 900 mg ) 9 ( 3 per cohort ) akb-6548 was well tolerated , and dose responsive increases in entity and hemoglobin levels were demonstrated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality cytoskeleton banding linearity sinus|gata4 gradients motors autoreg sensitivities|promyelocytes|in apl , there is an abnormal accumulation of immature granulocytes called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality cytoskeleton banding linearity sinus|gata4 gradients motors autoreg sensitivities|promyelocytes|in apl , immature white blood cells called entity accumulate in the bone marrow .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|normality cytoskeleton banding linearity sinus|gata4 gradients dystrophin smad1 nedd4|promyelocytes|in addition , the data showed that plinabulin has a superior immune profile compared to neulasta based on entity and immature neutrophil data from the clinical study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|normality cytoskeleton banding linearity sinus|gata4 gradients densities atpases microtubules|promyelocytes|the overgrowth of entity leads to a shortage of normal white and red blood cells and platelets in the body , which causes many of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality cytoskeleton banding linearity sinus|gradients autoreg densities gap dens|promyelocytes|differentiation therapy causes leukemic entity to mature and undergo cell death .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality cytoskeleton banding linearity sinus|gata4 densities gradients saturation kv|promyelocytes|the accumulation of entity in the bone marrow results in a reduction in the production of normal red blood cells and platelets resulting in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality cytoskeleton banding linearity sinus|gata4 motors atpases nanog gradients|promyelocytes|this fusion gene leads to the overproduction of immature white blood cells called entity and the underproduction of healthy blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|normality otherwise cytoskeleton cracks gradients|mω autoin motors lgr5 junction|metamyelocytes|associated with evidence that normal cell maturation is returning , as noted by the increase in normal maturing cells ( promyeocytes , myeocytes , entity and granulocytes ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients normality otherwise densities cholerae|either densities saturation any density|pituicytes|mechanism of action of lum-201 ghsr1a activation via lum-201 binding induces gh release , as demonstrated in vitro in rat entity ( lum-201 ec50 1 . 3 nm ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients normality otherwise densities cholerae|autoreg either densities gradients settle|pituicytes|in addition , the treatment of entity with lum-201 augments the effect of ghrh on gh secretion , as the two compounds synergistically stimulated gh release from rat
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|otherwise junctional normality sinus dens|gradients saturation gata4 motors mω|keratocytes|activated entity have been associated with increased collagen deposition and collagen disorganization which correlate with corneal haze and regression of the correction
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|otherwise junctional normality sinus dens|mω junction gradients cracks imm|keratocytes|the superficial entity initially undergo apoptosis , followed by proliferation and activation of the remaining entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|otherwise junctional normality sinus dens|mω junction gata4 microtubules imm|keratocytes|treatment resulted in a reduction of pro-fibrotic gene expression from day 7-14 post-injury , indicating that target engagement was achieved in entity and myofibroblasts in the corneal stroma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|cracks junction uncoupling biphasic densities|densities mω density boltzmann gata4|fibrocytes|igf-1r , the receptor for igf-1 , is highly expressed in entity , cells that are derived from the bone marrow and that have the potential to differentiate into either myofibroblasts or fat
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|cracks junction uncoupling biphasic densities|densities density gata4 dens saturation|fibrocytes|inflammation and when chronically activated , drives the development of fibrosis via several pathways and several cell inflammatory cell types and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|gradients trap mω gata4 chaperones|melanocytes|entity produce melanin , the pigment that determines skin color and protects the body from ultraviolet radiation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|chimeras autoreg gradients densities gata4|melanocytes|tanning is mediated by entity producing melanin , which is subsequently transferred to the keratinocytes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|mω chimeras gradients restorations uncoupling|melanocytes|vitiligo is an autoimmune condition in which the skin turns white due to the loss of entity , cells that produce the pigment melanin , which gives skin color .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|gradients saturation mω otherwise chimeras|melanocytes|melanoma melanoma is a type of cancer which originates in the entity , the cells responsible for pigmentation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|otherwise mω autoreg chaperones gradients|melanocytes|melanin is produced by entity and is the pigment that gives human skin , hair and eyes their color .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|gradients gata4 cyclins uncoupling coupled|melanocytes|the skin cells that produce the melanins are called entity and comprise 5 to 10% of the total cellular population in the epidermis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|mω gata4 negativity otherwise chimeras|melanocytes|melanoma is a malignant tumor of entity , a potentially dangerous form of skin cancer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|mω dens restorations densities junction|melanocytes|cutaneous melanomamelanoma tumors originate in the pigment-producing entity in the basal layer of the epidermis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|mω gradients uncoupling motors autoreg|melanocytes|· melanoma : melanoma is a cancer that begins in specific skin cells called entity , and exposure to ultraviolet rays is a major risk factor for most melanomas .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|gradients mω motors optimum cyclins|melanocytes|the epidermis is comprised of specialized cells such as keratinocytes and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|uncoupling peaked gradients densities mω|melanocytes|melanoma begins in entity cells that make a pigment called melanin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|gradients saturation mω chimeras uncoupling|melanocytes|melanoma melanoma is a type of cancer which originates in the entity , the cells responsible for pigmentation of the skin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|mω uncoupling cyclins otherwise gradients|melanocytes|melanoma is a disease in which pigmented cells in the skin , called entity , turn into cancer cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|gradients mω uncoupling chimeras atpases|melanocytes|melanoma occurs when entity ( pigment cells ) become malignant .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|mω density densities gradients outer|melanocytes|normal entity do not express mcam , but expression is turned on and continues to increase as the cells become more malignant .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|saturation mω otherwise chimeras gata4|melanocytes|malignant melanoma - predominantly a skin cancer , malignant melanoma can also occur in entity found in the bowel and the eye .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|gradients gradient junction saturation otherwise|melanocytes|melanoma is a cancer of the entity , the cells that produce pigment in the skin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|gradients mω gata4 uncoupling atpases|melanocytes|melanoma melanoma is a cancer that begins in specific skin cells called entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|junction cd44 saturation notation negativity|melanocytes|melanoma is primarily a skin tumor , although it may also occur less frequently in the entity of the eye .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities density cholerae atpases|negativity saturation otherwise gradients mω|melanocytes|melanoma is a malignant tumor of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients densities differential density gradient|gata4 gradients mω nanog density|endospores|proteins and cross-linking of unprotonated proteins thereby denaturing the proteins to corrupt and penetrate the bacterial walls to kill the entity and other microorganisms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens banding density normality|autoreg densities mω normality negativity|neuroblasts|a neuroblastoma tumor develops from immature nerve cells called entity and arises predominantly in the adrenal glands and abdomen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens banding density normality|gata4 densities gradients smad1 mω|neuroblasts|the license also covers methods for the production and screening of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities dens density gradients atpases|gradients uncoupling autoreg chimeras motors|protoplasts|electroporation is a method for increasing dna uptake by entity through prior exposure to a high voltage , which results in the temporary formation of small pores in the cell membrane .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients normality densities otherwise|gradients densities density gata4 spher|melanophores|entity are pigment-bearing cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients normality densities otherwise|gradients spher motors gata4 chaperones|melanophores|for most types of lower animals , entity are the primary chromatophores responsible for skin color control .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients normality densities otherwise|gradients traps chimeras autoreg gata4|melanophores|receptor targets melanophore technology melanophore technology is a unique screening technique based upon the use of pigment bearing cells called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients normality densities otherwise|gradients mω gata4 gradient motors|melanophores|entity are amphibian cells that are responsible for skin color .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients normality densities otherwise|gradients traps chimeras autoreg gata4|melanophores|receptor targets melanophore technology melanophore technology is a unique screening technique based upon the use of pigment bearing cells called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients normality densities otherwise|gradients cyclins gata4 autoin densities|melanophores|entity undergo a color change in response to light or stimulation by chemicals .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients gata4 normality otherwise cytoskeleton|motors gata4 kv gradients αvβ3|spherocytes|the laboratory evaluation of waiha begins with a peripheral blood analysis revealing evidence of extravascular hemolysis ( entity , low haptoglobin , elevated bilirubin and elevated ldh ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|autoreg gradients traps ante ≥4|sideroblasts|treatment of anemia failing an erythropoiesis stimulating agent in adult patients with very low- to intermediate-risk mds who have ring entity and require rbc transfusions .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|gradients autoreg traps mω ante|sideroblasts|patients to evaluate the efficacy and safety of luspatercept in patients with anemia due to lower-risk mds with ring entity who require regular rbc transfusions .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|gradients autoreg gata4 mω traps|sideroblasts|the medalist trial , a global phase 3 study in patients with very low , low , or intermediate risk , mds with ring entity who require red blood cell transfusions , is currently enrolling .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|autoreg mω motors ante kv|sideroblasts|when at least 15% of the cells in an mds patients bone marrow are ring entity , this patient is considered rs positive .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|gradients autoreg gata4 nanog mω|sideroblasts|new class of therapy , for the treatment of adult patients with very low- to intermediate-risk mds-associated anemia who have ring entity and require red blood cell ( rbc ) transfusions .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|gradients autoreg traps ante dens|sideroblasts|the phase 3 mds medalist trial targets patients with very low , low or intermediate risk mds with ring entity who require rbc transfusions .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|normality traps autoreg heatmap ante|sideroblasts|patients with mf that has transformed into aml , known as blast-phase mf , and in patients with refractory anemia with ringed entity , or rars , a subpopulation of mds .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|autoreg gradients traps dens mω|sideroblasts|the majority of patients with mds that develop cytopenias lack ring entity or a single , defining splicing factor mutation and are termed non-rs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|normality traps autoreg heatmap benjamini|sideroblasts|clinical safety and efficacy data on imetelstat from patients with a form of mds known as refractory anemia with ringed entity ( mds-rars ) enrolled as part of the mayo clinic pilot study .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|mω imm autoreg cytoskeleton ante|sideroblasts|of contents subgroup of patients with mds that show the presence of iron deposits around the mitochondria , known as ring entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|gata4 nedd4 gradients autoreg certain|sideroblasts|all patients presented with ring entity were rbc transfusion dependent and were either refractory or intolerant to prior erythropoiesis-stimulating agent ( esa ) therapy , or were esa naïve
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|≥4 ≥5 gradients dens normality|sideroblasts|and safety of luspatercept versus placebo in patients with anemia due to very low , low , or intermediate-risk mds with ring entity ( ≥ 15% ) who require red blood cell transfusions .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|autoreg cytoskeleton traps mω gradients|sideroblasts|these ring entity are associated with ineffective erythropoiesis and anemia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|normality spher benjamini cholerae motors|autoreg densities dens gradients imm|sideroblasts|in the overall trial population , the rate of ≥8-week rbc ti did not differ based on the presence of ringed entity , indicating activity of imetelstat across different subtypes of mds .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities atpases cholerae autoreg|gata4 gradients densities saturation motors|retic|g / dl . this was thought to be not clinically possible for a hgb at this level in conjunction with markedly elevated entity and low rbc counts .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities atpases cholerae autoreg|autoin dystrophin atpases saturation gata4|retic|mg / kg , *** ) , elevated hemoglobin concentrations in entityulocytes ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities atpases cholerae autoreg|autoin atpases dystrophin saturation autoreg|retic|mg / kg ) , elevated hemoglobin concentrations in entityulocytes ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|gradients densities atpases cholerae autoreg|gata4 kv nedd4 atpases autoin|retic|the entity procedure , which is now implemented , measures the number of entityulocytes ( immature red blood cells produced in the bone marrow ) and
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities atpases cholerae autoreg|autoin dystrophin atpases saturation autoreg|retic|elevated hemoglobulin concentrations in entityulocytes ( retic ch ) as determined on day 30 ( ** : p < 0 . 005 , *
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities atpases cholerae autoreg|autoin dystrophin atpases saturation autoreg|retic|elevated hemoglobulin concentrations in entityulocytes ( retic ch ) as determined on day 30 ( ** : p 2 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients densities atpases cholerae autoreg|saturation vag ranks dystrophin autoin|retic|in may 1996 , the company received fda 510 ( k ) clearances for two additional commonly performed microscope procedures : entityulocyte count ( entity ) and anti-nuclear antibodies ( anas ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities motors density autoreg atpase|densities autoreg gata4 dens imm|subclones|progressive disease to elucidate whether these alterations were newly acquired following ibrutinib exposure or represent selective expansions of pre-existing small entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|densities motors density autoreg atpase|densities autoreg density damp microtubules|subclones|evidence against the existence of mammalian tpe comes from a comparison of mrna levels for a telomeric neo gene in entity of sv40-transformed human fibroblasts with varying telomere lengths .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities motors density autoreg atpase|densities density mω nedd4 nanog|subclones|such non-limiting examples include : entity of unmodified cell lines , purified or fractionated subsets of materials provided by atcc , proteins expressed by dna / rna supplied by atcc ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities motors density autoreg atpase|densities density mω nanog motors|subclones|some examples include : entity of unmodified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by university , monoclonal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities motors density autoreg atpase|densities mω density nanog dystrophin|subclones|some examples include : entity of unmodified or modified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities motors density autoreg atpase|gata4 dens cholerae densities dwell|subclones|the term " moab 7e11 " includes all entity claimed in such patent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cell|densities motors density autoreg atpase|mω densities density microtubules dystrophin|subclones|some examples include : entity of cell lines ; purified or fractionated subsets of the original materials or progeny ; dna or rna ; genetic material ; secreted or
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|densities motors density autoreg atpase|densities density mω microtubules nanog|subclones|some examples include : entity of unmodified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by genencor or
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities motors density autoreg atpase|densities density autoreg autoin spher|subclones|with information concerning the enzymes being used for ongoing subcloning to determine -9- 11 the absolute orientation and position of entity and deletions with respect to the original clone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities motors density autoreg atpase|autoreg densities atpases motors cyclins|subclones|( i ) licensed products means materials and all progeny , entity , and unmodified derivatives of the cell clones .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|densities motors density autoreg atpase|densities nanog spd localization sensitivities|subclones|concentrate samples and load curagen  s dna sequencing gels , allowing the integrated system to generate base called sequences directly from dna entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|densities motors density autoreg atpase|densities density mω nanog dystrophin|subclones|some examples include : entity of unmodified cell lines , purified or fractionated subsets of the material , proteins expressed by dna / rna supplied by m . i . t . , or monoclonal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities motors density autoreg atpase|densities gata4 density dens mω|subclones|with any refills of the material and any progeny and unmodified derivatives of the material ( including , without limitation , expression products , entity , sub-units or fractionations ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|densities motors density autoreg atpase|microtubules spd autoreg densities autoin|subclones|biological materials means the materials identified in appendix a together with any progeny , entity , or derivatives thereof provided by the foundation or created by licensee .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities motors density autoreg atpase|autoreg densities imm gradients gata4|subclones|in the face of immune pressure , entity susceptible to t cell killing are eliminated , leaving behind resistant tumor clones that are mhc deficient , and hence no longer
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities motors density autoreg atpase|densities gata4 density dens mω|subclones|with any refills of the material and any progeny and unmodified derivatives of the material ( including , without limitation , expression products , entity , sub-units or fractionations ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|densities motors density autoreg atpase|dens densities autoreg density kv|subclones|materials shall mean the tangible material specifically described in exhibit a and physically transferred to licensee and any unmodified copies , progeny and entity made therefrom .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg dens gradients cush density|atpases densities gata4 atpase cd69|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( “licensed products” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg dens gradients cush density|atpases densities atpase gata4 cd69|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( &#147 ; licensed products&#148 ; ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg dens gradients cush density|atpases atpase densities gata4 cd69|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( &#8220 ; licensed products&#8221 ; ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg dens gradients cush density|atpases densities gata4 atpase motors|allostim|the license granted covered two experimental products for the treatment of cancer in clinical development called entity tm and allo vax tm ( &#147 ; licensed products&#148 ; ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg dens gradients cush density|atpases densities gata4 atpase density|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vax tm ( “licensed products” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients atpases atpase motors|densities autoreg mω gata4 atpases|carticel|the improvement in gross margin is primarily the result of an increase in entity [ r ] aucc sales and a reduction in labor and manufacturing expenses and decreased material expenses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients atpases atpase motors|dens amorph clock gata4 mω|carticel|through june 30 , 1997 , gtr had received approximately $5 . 1 million in revenues from u . s . sales of entity ( tm ) acc since its market introduction in march 1995 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|autoreg gradients atpases atpase motors|smad1 nedd4 mω autoreg cholerae|carticel|efficacy data demonstrating durability of repair is now out to 20 years for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients atpases atpase motors|atpases atpase gata4 gradients densities|carticel|the following table summarizes the early results of the commercialization of entity ( tm ) acc in the u . s . :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|autoreg gradients atpases atpase motors|atpases mω cholerae boltzmann gata4|carticel|if gtr were prohibited from marketing entity ( tm ) aucc in the u . s . , its results of operations would be materially adversely affected .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients atpases atpase motors|densities certain imm density damp|carticel|the company recognizes maci ( or entity ) kit revenue upon delivery of the biopsy kit at which time the customer ( the doctor ) is in control of the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients atpases atpase motors|atpases densities mω gradients atpase|carticel|in august 1997 , the fda approved gtr  s bla for entity ( tm ) aucc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|autoreg gradients atpases atpase motors|gata4 densities cholerae density autoreg|carticel|for the first half of 2015 , total entity and epicel net product revenues increased approximately 17% over pro-forma net product revenues for the same period in 2014 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|autoreg gradients atpases atpase motors|autoreg imm kv mω spd|carticel|the blue cross blue shield association has determined that its technology assessment committee does not believe that entity chondrocytes meets all of its published criteria for new treatments .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|autoreg gradients atpases atpase motors|gata4 densities cholerae density autoin|carticel|the cambridge facility has been used for u . s . manufacturing and distribution of entity , worldwide manufacturing and distribution of epicel and production of maci for clinical testing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients atpases atpase motors|smad4 chimeras nanog gradients cytoskeleton|carticel|orthopaedics gabi*  sepra  synvisc®  provisc® ( alcon )  entity  hylaform® ( inamed ) focused on treating disease and restoring health through local effects on biology
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|autoreg gradients atpases atpase motors|gata4 densities cholerae density autoreg|carticel|total entity and epicel net product revenues in the second quarter increased approximately 31% over pro-forma second-quarter net product revenues in 2014 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|autoreg gradients atpases atpase motors|mω dystrophin atpases gata4 cyclins|carticel|the commercial success of entity ( tm ) aucc will also depend materially on the ability of gtr to increase the approval rate for reimbursement of the product
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients atpases atpase motors|density densities inactivation defective damp|carticel|total revenues for the quarter ended june 30 , 2015 were $13 . 6 million and included $9 . 1 million in net sales of entity implants and surgical kits and $4 . 3 million in net sales of epicel .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients atpases atpase motors|densities gata4 density autoin chimeras|carticel|the increase is primarily due to higher demand for entity , offset , in part , by a decline in sales of epicel due to a decrease in patients requesting this service .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|autoreg gradients atpases atpase motors|densities imm divertic localization autoreg|carticel|genzyme believes that entity chondrocytes does in fact meet all of these criteria and are discussing the evaluation with the blue cross blue shield
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients atpases atpase motors|densities atpases dens atpase gradients|carticel|( 5% ) 16 ( 76% ) 1 ( 5% ) 4 ( 19% ) gtr has compiled safety data on 460 patients who have undergone treatment with entity ( tm ) acc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|autoreg gradients atpases atpase motors|gata4 cd69 mendelian dystrophin signals|carticel|entity is indicated for the repair of symptomatic cartilage defects of the femoral condyle ( medial , lateral or trochlea ) caused by acute
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients atpases atpase motors|gata4 negativity densities smad1 inactivation|carticel|market opportunity for entity in the u . s . annually , there are approximately 1 million arthroscopic procedures and more than 250 , 000 cartilage surgical procedures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|autoreg gradients atpases atpase motors|densities junction gradients dens mω|carticel|gtr is conducting additional research relating to entity ( tm ) aucc pursuant to a sponsored research agreement with the university of gotenburg in sweden and certain physicians , including the two
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase densities autoreg ante atpases|density mω densities gata4 endos|rivogenlecleucel|about rivo-cel ( bpx-501 ) rivo-celtm ( entity ) is an allogeneic polyclonal t-cell product designed to accelerate immune recovery after hsct and to reduce relapse of leukemia following
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase densities autoreg ante atpases|gata4 autoreg saturation mω imm|rivogenlecleucel|rimiducid will be administered to inactivate entity ( rivo-cel ) in the event of gvhd not responsive to standard of care treatment updated 8 nov 2018 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase densities autoreg ante atpases|gata4 densities autoreg boltzmann binders|rivogenlecleucel| rivo-cel ( entity , formerly known as bpx-501 ) is a product candidate intended to improve hsct outcomes in the treatment of hematologic malignancies , including
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase densities autoreg ante atpases|density mω densities gata4 binders|rivogenlecleucel|about rivo-cel ( bpx-501 ) rivo-celtm ( entity ) is an allogeneic polyclonal t cell product designed to reduce the rate of relapse of leukemia following a stem cell
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|densities density kv mω loose|kymriah|– conserving the clinically validated cd19 car cell manufacturing process minimizes confounding risks penn process , not novartis process ; avoids entity release
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|nanog damp chimeras nedd4 motors|kymriah|the fda has also approved two non-aav gene therapy products , entity by novartis international ag , for pediatric and young adult patients with a form of acute lymphoblastic leukemia and yescarta by
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|motors endos gata4 mω localization|kymriah|two such companies , novartis international ag ( entity® ) and kite pharma inc . / gilead sciences , inc . ( yescarta® ) , have now commercialized autologous car+ t cells against cd19 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|gata4 densities mω smad1 autoreg|kymriah|the company did not recognize royalty revenue in the comparative periods in the prior year given that entity was first approved for commercial sale in the second half of 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cell|gradients atpases disintegr autoreg atpase|gata4 gradients cd44 dystrophin integrins|kymriah|only 20% of entity or yescarta patients treated with tocilizumab had resolution of signs and symptoms 6 days after onset of crs and ~50%
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|imm mω densities gradients localization|kymriah|nomenclature ‘zuma-19 , may be the basis for the registration of lenzilumab , given the similar trial design to yescartas and novartiss entity® ( “entity” or “entity®” ) registration trials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients atpases disintegr autoreg atpase|gata4 densities atpases cholerae autoreg|kymriah|both entity and yescarta carry “black box” warnings in their labels for nt and crs and are subject to a rems program ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|densities gradients autoreg heterochromatin motors|kymriah|maintaining clear leadership in share of voice entity polivy xpovio yescarta share of voice aug sep oct monjuvi compared to >50% monjuvi monjuvi 50% 30% 0% hcp engagement
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|mω density gata4 densities cd44|kymriah|the fda approved entity ( tisagenlecleucel ) for the treatment of certain pediatric and young adult patients with a form of acute lymphoblastic leukemia ( all ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|densities gata4 gradients density cd44|kymriah|because of the risk of cytokine release syndrome and neurological events , entity is being approved with a rems .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|mω densities localization imm adherens|kymriah|september 2018 , we entered into a license and collaboration agreement with novartis to manufacture and supply their car-t cell therapy entity® in china .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|gata4 dysfunctions densities atpases chimeras|kymriah|no head to head trials have been conducted that would enable a direct safety and efficacy comparison to yescarta or entity source : uspi unless otherwise noted a aacr , 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|gradients atpases disintegr autoreg atpase|densities density gata4 atpases cholerae|kymriah|in 2017 , three gene therapies were approved for the first time in the united states , namely , entity , yescarta , and luxturna .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|density densities gata4 motors autoreg|kymriah|in 2017 , three gene therapies were approved for the first time in the united states , entity , yescarta , and luxturna .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|gata4 densities mω chaperones atpases|kymriah|in august 2017 , novartis received fda approval for entity and paid the company $2 . 5 million as a result of the achievement of a related milestone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|mω gradients densities density gata4|kymriah|entity is a genetically-modified autologous t-cell immunotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|mω cd44 junction damp existence|kymriah|there are currently two car-t therapies approved in the u . s . and eu , novartis entity ( tisagenlecleucel ) and gilead / kites yescarta ( axicabtagene ciloleucel ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|density gata4 motors densities certain|kymriah|commenting on the results , joseph jimenez , ceo of novartis , said : “novartis became the first company to commercialize a car-t therapy , entity , in q3 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|gradients atpases disintegr autoreg atpase|mω densities integrins ctla cd44|kymriah|• entity ( tisagenlecleucel ) is a cd19-directed genetically modified autologous chimeric antigen receptor t-cell ( car-t ) therapy delivered as an intravenous infusion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients atpases disintegr autoreg atpase|mω gata4 autoreg benjamini densities|kymriah|yescarta has been approved for the treatment of relapsed or refractory large b-cell lymphoma and entity for the treatment of relapsed or refractory b-cell precursor acute lymphoblastic leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|densities density gata4 binders cd44|yescarta|in 2017 , the fda approved the first two car-t cell therapies , kymriah and entity , after these products demonstrated strong efficacy in select relapsed or refractory b cell malignancies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|endos mω motors densities benjamini|yescarta|one of these therapies , entity® obtained accelerated approval for treatment of refractory non-transplant-eligible dlbcl patients in october 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|densities gata4 density mω endos|yescarta|finally , two car-t cell therapies were just approved for the treatment of all – kymriah™ ( novartis ) and entity™ ( gilead ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|imm pyroph mω localization vv|yescarta|novartis kymriah™ and gileads entity™ , two gene-modified cell-based therapies , are approved in both the united states and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|autoreg densities smad1 gata4 density|yescarta|further , if contaminants are discovered in our supply of entity or in the manufacturing facilities , such manufacturing facilities may need to be closed for an extended period of time to
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|mω gata4 densities autoreg atpases|yescarta|in october 2017 , kite obtained fda approval to commercialize entity for the treatment of adults with relapsed / refractory diffuse large b-cell lymphoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|gradients smad1 autoreg atpases densities|yescarta|the primary objective of the study is to determine the effect of lenzilumab on the safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|atpase atpases autoreg gradients benjamini|gata4 densities atpases cholerae density|yescarta|no head to head trials have been conducted that would enable a direct safety and efficacy comparison to entity or kymriah source : uspi unless otherwise noted a aacr , 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|gradients smad1 densities autoreg mω|yescarta|the objective of the phase 2 trial is to determine the effect of mavrilimumab on the safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|gata4 densities atpases smad1 mω|yescarta|kite has published data on entity in all as well .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|gata4 densities atpases gradients cush|yescarta|arcalyst® is a registered trademark of regeneron pharmaceuticals , inc . and entity® is a registered trademark of gilead sciences , inc . , or its related companies . ​5 table of contentspart 
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|gata4 densities atpases atpase gradients|yescarta|the royalties stem from sales and milestones related to the entity® product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|mω densities gata4 density atpases|yescarta|additionally , in october 2017 , kite received approval from the fda for entity ( axicabtagene ciloleucel ) , formerly known as kte-c19 , for treatment of patients with r / r nhl .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|gata4 densities atpases density atpase|yescarta|both kymriah® and entity® were approved with a rems .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|gata4 densities density mω nanog|yescarta|two car-t therapies have been approved to treat large b-cell lymphoma , kymriah® and entity® , and others are being tested in clinical trials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|gata4 endos densities mω atpases|yescarta|pipeline , building on current marketed products and late-stage clinical candidates for patients with hematological malignancies at kite and gilead , including entity® , tecartus® and magrolimab .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|gradients smad1 autoreg atpases densities|yescarta|the primary objective of the study is to determine the effect of lenzilumab on the safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|endos cush mω gradients gata4|yescarta|the initial results of axicabtagene ciloleucel ( entity ) , the prognosis of high-grade chemo refractory nhl , is dismal with a medium survival time of a few weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|autoreg gradients autoin densities spher|yescarta|entity is a therapy for patients who have not responded to or who have relapsed after at least two other kinds
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|atpase atpases autoreg gradients benjamini|atpase atpases gradients endos densities|yescarta|this was notable given the patient had relapsed following treatment with entity® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients cush adherens densities atpase|densities density mω gata4 kv|tabelecleucel|recent highlights and anticipated upcoming milestones tab-cel® ( entity ) • two phase 3 clinical studies are ongoing ( match and allele ) to evaluate tab-cel® for patients with ebv+ ptld
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients cush adherens densities atpase|mω densities cd44 cd69 gata4|tabelecleucel|we believe that entity has the potential to be the first commercially available off-the-shelf t-cell immunotherapy and the first fda- and ema-approved therapy for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients cush adherens densities atpase|mω densities cd69 cd44 density|tabelecleucel|we believe that entity has the potential to be the first commercially available off-the-shelf t-cell immunotherapy and the first fda and ema approved therapy
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gradients cush adherens densities atpase|densities density binders cd44 mω|tabelecleucel|with entity poised to potentially become the first approved off-the-shelf t-cell therapy and a robust pipeline of high potential candidates , our ambition
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|negativity dens densities mω either|tendon|and adcon-t / n to be marketed in the 19 european union countries which recognize ce marking for lumbar disc surgery and entity and peripheral nerve surgeries , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|nanog gata4 smad1 biased disturbed|tendon|warnings and precautions risk of tendinitis , entity rupture , peripheral neuropathy and central nervous system effects is increased with use of fluoroquinolones .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg suggestive gradients cholerae sensitivities|dystrophin nanog gata4 certain saturation|tendon|and / or product development for various treatments for or involving fracture repair , spine fusion surgery , cartilage defect repair and ligament and entity repair .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg suggestive gradients cholerae sensitivities|dens ranks dystrophin gata4 tags|tendon|graftjacket® maxforce extreme is a high strength form of graftjacket® matrix which provides maximum suture holding power for the most challenging of entity and ligament repairs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|negativity gata4 density densities either|tendon|now being sold in all major countries in the eu , as well as australia and new zealand for use in entity and peripheral nerve surgeries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|gata4 either density saturation nanog|tendon|therapeutic devices utilizing its nonthermal ultrasound technology ( " orthosound " ) for use in medical applications that relate to bone , cartilage , ligament or entity diagnostics and healing .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|either resonance mω kinases exists|tendon|extent the gingiva functions as part of the apparatus holding the tooth to the jaw ) , ligament ( including the periodontal ligament ) , entity and / or cartilage .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|densities damp density gradients smad1|tendon|quinsair is contraindicated in patients with hypersensitivity to levofloxacin , a history of entity disorders related to fluoroquinolones , epilepsy , or who may be pregnant or breast feeding .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|densities density gata4 nanog negativity|tendon|bone & entity pill it consists of extracts of a variety of chinese medicinal herbs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|densities damp density gradients smad1|tendon|quinsair is contraindicated in patients with hypersensitivity to levofloxacin , a history of entity disorders related to fluoroquinolones , epilepsy , or who may be pregnant or breast feeding .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|gata4 smad1 density mω densities|tendon|the medicinal product is to be taken orally for the purpose of curing bone and entity disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|densities density imm negativity damp|tendon|warnings regarding the risk of entity related adverse events were already included in the prescribing information , as part of a class labeling , for all fluoroquinolones .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|smad1 gata4 nanog tags restorations|tendon|graftjacket® is a human-derived soft tissue graft designed for augmentation of entity and ligament repairs such as those of the rotator cuff in the shoulder and achilles entity in the ankle .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg suggestive gradients cholerae sensitivities|nanog smad1 gata4 autoreg dystrophin|tendon|by augmenting the strength of the entity repair and incorporating biologically , graftjacket® regenerative tissue matrix increases surgeons confidence in the surgical outcome .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg suggestive gradients cholerae sensitivities|smad1 gata4 nanog restorations dystrophin|tendon|graftjacket® matrix is a human-derived soft tissue graft designed for augmentation of entity and ligament repairs such as those of the rotator cuff in the shoulder and achilles entity in the ankle .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|gata4 grp78 grade boltzmann gradients|tendon|fluoroquinolones are 26 known for several undesirable effects such as entityitis , achilles entity rupture , c . difficile colitis , and hepatotoxicity and central nervous system side effects .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|negativity densities dens gata4 mω|tendon|adcon-l and adcon-t / n to be marketed in the 19 european countries which recognize ce marking for lumbar disc surgery and entity and peripheral nerve surgeries , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|densities negativity density imm smad1|tendon|currently , warnings regarding the risk of entity related adverse events are included in the prescribing information , as part of a class labeling , for all fluoroquinolones .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|nanog certain gata4 biased negativity|tendon|ligament and entity repair ligaments are the soft tissues that connect bone to bone .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg suggestive gradients cholerae sensitivities|densities density smad1 gata4 gradients|tendon|further , in july 2008 , the fda requested manufacturers of fluoroquinolones to include a black box warning for entity damage .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpase gradients cholerae atpases|gata4 smad4 clock j2 negativity|macula|optina for diabetic entity edema on october 7 , 2013 , we received positive results from the interim analysis of optina trial for diabetic macular edema .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|autoreg atpase gradients cholerae atpases|gata4 mω dystrophin normality cholerae|macula|company presented preclinical data at the association for research and vision in opthalmology conference in may 2012 , and at the entity society meeting in june 2012 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpase gradients cholerae atpases|smad1 gata4 nanog saturation mω|macula|the leakage of fluid , solutes , proteins and immune cells cause the entity to swell and thicken .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpase gradients cholerae atpases|csc gradients saturation junction mω|macula|described as a partial or total loss of visual field resulting from certain progressive disease or degeneration of the retina , entity or nerve fiber bundle .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|autoreg atpase gradients cholerae atpases|gata4 dystrophin saturation microtubules otherwise|macula|in patients with dme , leakage from these abnormal blood vessels occurs in the central portion of the retina , called the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpase gradients cholerae atpases|otherwise gata4 negativity smad4 gradients|macula|introduction to amd amd is a progressive and irreversible disorder of the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpase gradients cholerae atpases|otherwise gradients cd44 saturation gata4|macula|the entity is the central portion of the retina in the eye and is responsible for both high acuity vision and color
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpase gradients cholerae atpases|peaked biased nanog gata3 gata4|macula|according to the entity vision research foundation , as many as 15 million people in the united states suffer from some form of amd , with more
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpase gradients cholerae atpases|saturation nanog gata4 gradients otherwise|macula|these vessels can leak fluid and blood , which may lead to swelling and damage of the entity causing vision loss .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpase gradients cholerae atpases|gata4 otherwise cd44 gradients saturation|macula|implies , usually affects older adults and results in a loss of vision in the center of the visual field ( the entity ) because of damage to the retina .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg atpase gradients cholerae atpases|dystrophin otherwise mω negativity vsv|macula|for age-related entityr degeneration , or amd , which is a disorder of the central portion of the retina , known as the entity , that may result in blindness .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpase gradients cholerae atpases|gata4 saturation gradients smad4 nanog|macula|or neovascularization , causes vision loss due to blood and protein - 94 - table of contents leakage below the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg atpase gradients cholerae atpases|gata4 mω densities density dystrophin|macula|the principal investigator of study 003 presented a case report from the first patient to complete the protocol at the entity society meeting on february 19 , 2014 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg atpase gradients cholerae atpases|gata4 certain saturation dystrophin otherwise|macula|in the dry form , there is a breakdown of retinal pigment epithelial cells in the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpase gradients cholerae atpases|gata4 cd44 gradients ploidy nanog|macula|the wet form is caused by growth of abnormal blood vessels ( cnv ) under the central part of the retina or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg atpase gradients cholerae atpases|gata4 dystrophin normality spher otherwise|macula|an eye disease characterized by the growth of abnormal blood vessels under the central part of the retina , called the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg atpase gradients cholerae atpases|unless negativity gata4 dystrophin clock|macula|entityr edema is the build-up of fluid that can cause abnormal swelling of the macula , the portion of the retina responsible for central vision and color perception .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpase gradients cholerae atpases|otherwise gradients cd44 saturation gata4|macula|the central portion of the retina is the entity , which is the region responsible for seeing color and the acute central vision necessary for activities such as reading , face
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpase gradients cholerae atpases|normality otherwise gata4 gradients negativity|macula|that usually affects older adults and results in a loss of vision in the center of the visual field ( the entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|autoreg atpase gradients cholerae atpases|gata4 microtubules dystrophin cd44 saturation|macula|this process , known as angiogenesis or neovascularization , results in fragile blood vessels that leak fluid and blood into the entity , the center portion of the retina .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases atpase densities gradients motors|gradients nanog mω smad1 imm|perineurium|the lamellar structure of the entity and a deficiency in collagen packing in the endoneurium was observed more frequently and to a larger extent in fibromyalgia
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|benjamini sensitivities cracks normality autoreg|gata4 nanog smad1 mω junction|endoneurium|the lamellar structure of the perineurium and a deficiency in collagen packing in the entity was observed more frequently and to a larger extent in fibromyalgia patients than in controls .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs autoreg telangiect normality cyclins|junction microtubules mω smad1 junctions|urothelium| by three months post-implantation , the scaffold is replaced by native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|tissue|biolabs autoreg telangiect normality cyclins|junction mω microtubules smad1 integrins|urothelium|months post-implantation , the bioabsorbable scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|tissue|biolabs autoreg telangiect normality cyclins|microtubules phalloidin cyclins atpase motors|urothelium|bladder carcinoma is a specific form of bladder cancer resulting from the development and progression of cancerous tumors within the entity layer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs autoreg telangiect normality cyclins|negativity gradients poor density junction|urothelium|eligible patients included those with transitional cell carcinoma of the entity , including renal pelvis , ureters , urinary bladder , and urethra .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|biolabs autoreg telangiect normality cyclins|mω atpases densities dystrophin gradients|urothelium|not effectively permeating the entity  rtgel delivered treatment to the bladder as expected with dwell time of up to 10 hours
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs autoreg telangiect normality cyclins|gradients gata4 imm saturation microtubules|urothelium|one theory of cpps pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|biolabs autoreg telangiect normality cyclins|junction microtubules mω smad1 dystrophin|urothelium|three months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs autoreg telangiect normality cyclins|junction gradients densities density microtubules|urothelium|upper tract urothelial carcinoma ( utuc ) utuc refers to malignant changes of the entity ( the epithelial lining ) of the upper urinary tract of the calyces , renal pelvis and ureter .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs autoreg telangiect normality cyclins|junction smad1 mω microtubules atpases|urothelium|three months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like urinary tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs autoreg telangiect normality cyclins|mω junction gradients densities smad1|urothelium|beneath the entity , there is a layer called the lamina propria .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs autoreg telangiect normality cyclins|saturation negativity gradients densities smad1|urothelium|apollo trial did not meet the primary endpoint , believed to be the result of botox not effectively permeating the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs autoreg telangiect normality cyclins|gradients gata4 imm microtubules saturation|urothelium|one theory of pbss pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs autoreg telangiect normality cyclins|nanog junction smad1 saturation gradients|urothelium|normally , the entity is covered with a mucus layer , the glycosaminoglycan , or gag , layer , which is thought to protect the bladder from urinary
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs autoreg telangiect normality cyclins|gradients gata4 imm saturation microtubules|urothelium|one theory of cpps pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs autoreg telangiect normality cyclins|smad1 gradients negativity mω density|urothelium|implantation of stray " floating " tumor cells in areas in which the entity has been disrupted may be followed by the growth of the implanted cells to form a new tumor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs autoreg telangiect normality cyclins|gradients gata4 imm microtubules saturation|urothelium|one theory of bpss pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs autoreg telangiect normality cyclins|junction gata4 microtubules mω cyclins|urothelium|the innermost lining is comprised of cells called urothelial or transitional cells , and this inner layer is called the entity or transitional epithelium .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs autoreg telangiect normality cyclins|junction nanog smad1 saturation gradients|urothelium|normally , the entity is covered with a mucus layer , the glycosaminoglycan , or gag layer , which is thought to protect the bladder from urinary
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs autoreg telangiect normality cyclins|densities density nanog gradients notation|urothelium|be well positioned , as it will address both the acute pain the patient experiences and the dysfunctional aspect of the entity of the bladder wall .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|tissue|atpase atpases autoreg biolabs pka|junction mω microtubules dystrophin cyclins|epithelium|overview of ibd ulcerative colitis ( uc ) description uc is a chronic gi inflammatory disorder which involves the surface mucosa , the entity and the submucosa of the colon .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|otherwise cytoskeleton spher ∗∗ mω|epithelium|key portions of the eye that were evaluated for levels of drug remaining were the sclera-choroid-retinal pigmented entity , or scr , the neural retina and the vitreous .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|otherwise mω gradients cytoskeleton ∗∗|epithelium|in occult lesions , all of the blood vessels are below the retinal pigment entity , or rpe , and the areas on angiograms have a stippled appearance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|mω junction notation saturation nanog|epithelium|this includes injuries to the hematopoietic and immune systems , the entity of the digestive tract and hair follicles .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|junction saturation either mω gradients|epithelium|tamibarotene does not bind the rar-g receptor , the major retinoic acid receptor in the dermal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|junction either saturation mω gradients|epithelium|tamibarotene does not bind the rar-g receptor , the major retinoic acid receptor in the dermal entity , which should lessen the occurrence of ras .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|otherwise mω cytoskeleton grade spher|epithelium|by the much greater amount of the fluorescent protein expressed ) with aav8 as compared to aav2 in the retinal pigment entity ( rpe ) and to the photoreceptor ( pr ) layer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|junction nanog saturation smad1 mω|epithelium|of calcium and phosphate ions , which are hypothesized to exert their beneficial effects by diffusing into intracellular spaces in the entity and permeating the mucosal lesion in mucositis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg biolabs pka|junction dystrophin chimeras negativity boltzmann|epithelium|these events are commonly observed following removal of the corneal entity and in the treatment group of our trials , occurred at a higher incidence than observed in control patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|mω junction dens nedd4 smad1|epithelium|pathologic analysis showed marked effects on breast duct entity in ducts treated with either drug compared with untreated ducts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|junction negativity mω nanog traps|epithelium|blood causes a prolonged period of low blood flow to the intestines that can lead to damage to the intestinal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|junction junctional junctions notation limit|epithelium|the expression of il-15 in the intestinal entity is necessary for villous atrophy in animal models of celiac disease and circumstantial evidence suggests this to be the case
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg biolabs pka|junction specified dystrophin 1r boundary|epithelium|the procedure involves the removal of " bowman  s layer , " an intermediate layer between the entity ( outer corneal layer ) and the stroma ( middle corneal layer ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|gradients mω pull settle smad4|epithelium|the hair matrix entity is one of the fastest growing cell populations in the human body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|gata4 mω uncoupling cyclins either|epithelium|the gi tract is highly sensitive due to the continuous need for crypt stem cells and production of mucosal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|otherwise gradients cytoskeleton mω junction|epithelium|loss of the functional oca2 protein results in a lack of pigment in the retinal pigment entity and the underlying choroid layers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|otherwise cytoskeleton dispersion mω grade|epithelium|for lca2 , retinal function was restored by reconstituting gene function in the retinal pigment entity ( rpe ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|junction kerat hist saturation junctions|epithelium|the nasal administration is intended to determine if physiologic measurement of cftr function can be obtained in the nasal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|junction junctions degenerate notation junctional|epithelium|our vaginal products adhere to the vaginal entity until discharged upon normal cell turnover , a physiological process that can take 72 hours , or longer , and provide sustained and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg biolabs pka|junction mendelian maxima kerat transients|epithelium|however , the nasal entity is the most accessible site for measuring cftr function in humans and provides a human model of epithelial cell uptake
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases density atpase|spher resonance suggestive kinases negativity|ectoderm|and the capability to differentiate into cells representing the three germ layers - endoderm ( gut epithelium ) , mesoderm ( striated muscle ) and entity ( neural epithelium ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients atpase atpases saturation|cyclins densities gata4 atpases gradients|endoderm|the third patent , granted in the united states , covers the method for deriving entity cells using stem cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg gradients atpase atpases saturation|chimeras junction mω dystrophin autoreg|endoderm|territory patent no . general subject matter expiration us 7 , 763 , 466 method to produce entity cells may 2025 us 7 , 955 , 849 method of enriching population of mesoderm cells may 2023 us
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients atpase atpases saturation|densities gradients density either atpases|endoderm|in particular , entity cells make cells of internal organs such as the lung , pancreas , and liver as well as other internal cell types .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients atpase atpases saturation|cyclins densities mω autoreg either|endoderm|by way of example , we are currently a party to an interference proceeding that involves patent filings for making entity cells from hescs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients atpase atpases saturation|densities density dwell gata4 parametric|endoderm|that the derivation of any of the entityal lineage cells from embryonic stem cells would necessarily pass through the definitive entity stage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients atpase atpases saturation|autoreg gradients densities imm mω|endoderm|if we are not successful in the viacyte appeal , viacyte would retain its patent claims directed to definitive entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients atpase atpases saturation|gradients autoreg spher imm densities|endoderm|definitive entity is an early pre-cursor of numerous cell types including liver and β-cells of the pancreas that could potentially treat diabetes ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients atpase atpases saturation|densities peaked mω either saturation|endoderm|entity cells develop into the internal organs such as the heart , liver , pancreas and intestines , among other cell types .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients atpase atpases saturation|densities mω autoreg density motors|endoderm|australia patent 2010200610 – the claims in this patent relate to cell cultures comprising entity cells , one of the three major lineages of cells that make up the human body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients atpase atpases saturation|junction mω either localizes nanog|endoderm|stem cells and pluripotency stem cell primative and thus unspecialized self-renewing can differentiate into cells with specific functions ectoderm mesoderm entity skin hair brain nerves etc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients atpase atpases saturation|junction atpases mω autoreg smad1|endoderm|mesentity cells are precursor cells that differentiate into mesoderm and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients atpase atpases saturation|autoreg densities gradients mω density|endoderm|these rulings related to interference proceedings involving patent filings relating to definitive entity cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|gradients densities atpases atpase motors|integrins either otherwise dwell gata4|mesoderm|emt is essential for numerous developmental processes including entity formation and neural tube formation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|densities atpases signals autoreg mω|mesoderm|entity cells develop into muscle , bone and blood , among other cell types .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|densities dens dwell segregation chimeras|mesoderm|developing a drug-targeting platform based on the proprietary use of the human protein called receptor-associated protein , or rap , and the entity development protein , or mesd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|gata4 otherwise mω motors smad1|mesoderm|the libraries and screens will focus on genes important to entity and early hematopoietic development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|gradients densities atpases atpase motors|kinases either spher mω microtubules|mesoderm|produce such cells , and applications of such cells for es cell-derived immature pluripotent precursors of all the cells of the entity and endoderm lineages .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|segregation densities adherens density chimeras|mesoderm|table of contents raptors entity development protein , or mesd , platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|adherens dens densities segregation cd69|mesoderm|our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|gradients densities atpases atpase motors|atpases densities gata4 motors microtubules|mesoderm|in the early embryo , the middle layer of cells ( known as the entity ) and certain portions of the outer cell layers give rise to groups of cells that differentiate into bone marrow stroma ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases atpase motors|segregation cholerae densities cdh adherens|mesoderm|promising novel drug-targeting platform , based on the proprietary use of a human protein called receptor-associated-protein , or rap and the protein entity development , or mesd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|adherens dens densities segregation limit|mesoderm|- 38 - table of contents our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|densities dens dwell segregation desp|mesoderm|are developing drug-targeting platforms based on the proprietary use of the human protein called receptor-associated protein , or rap , and the entity development protein , or mesd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|tissue|gradients densities atpases atpase motors|spher junction microtubules either integrins|mesoderm|mesendoderm cells are precursor cells that differentiate into entity and endoderm .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases atpase motors|segregation cdh cholerae densities adherens|mesoderm|and drug delivery platform , based on the proprietary use of a human protein called receptor-associated-protein , or rap and the protein entity development , or mesd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|dens densities negativity mω density|mesoderm|the seven new cell lines have markers of diverse entity and neural crest cell types and are designated w11 , z2 , sk31 , sm35 , t36 , en51 , and en55 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|densities chimeras dwell spher segregation|mesoderm|is a promising novel drug-targeting platform , based on the proprietary use of a human protein called receptor-associated protein ( rap ) and entity development protein ( mesd ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases atpase motors|adherens dens densities density cholerae|mesoderm|· our entity development protein , or mesd , platform consists of wnttide™ for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|adherens dens densities segregation cd69|mesoderm|our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|adherens dens densities density cd69|mesoderm|• our entity development protein , or mesd , platform consists of wnttide™ for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|dens adherens densities density cd69|mesoderm| our entity development protein , or mesd , platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase motors|nanog certain smad1 smad4 refractory|mesoderm|mesenchymal stem cells ( mscs ) : embryonic-like cell capable of differentiating into multiple tissues of the entity , including cartilage , bone , tendon , ligament , muscle , stroma and fat .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|densities gradients atpases autoreg density|dystrophin dens densities gata4 density|lamina|in-vitro experiments have shown that sirnas against factor 5a protected human entity cribrosa ( optic nerve ) and colon epithelial ( ht-29 ) cells from tnf alpha induced apoptosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|atpases mω cyclins junction exists|lamina|beneath the urothelium , there is a layer called the entity propria .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|atpases exists mω localizes kerat|lamina|the adaptive response is mediated by gluten-reactive cd4+ t cells in the entity propria that recognize gluten-derived peptides when presented by the hla class ii molecules dq2 or dq8 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|mω junction atpases cyclins localizes|lamina|gliadin fragments in celiac disease , they are able to pass thru the leaky paracellular pathway from the lumen to the entity propria , where the immune cells reside and are then activated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|junction atpases adherens mω junctions|lamina|targeted localization of amt-101 to the gi tissue entity propria is expected to translate into clinically meaningful reductions in inflammation and disease activity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|mω atpases junction nanog exists|lamina|gi tissue or entering into systemic circulation : when designing our product candidates , we can target the therapeutic payload to the entity propria of the local gi tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|junction mω cyclins atpases caveolae|lamina|in healthy bowel wall , bacteria cannot pass from the lumen to the entity propria because tight junctions are maintained between the epithelial cells ( intact barrier function of the bowel wall ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|mω gata4 densities localization density|lamina|on february 25 , 2015 , the company entered into the license agreement with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|atpases junction mω cyclins exists|lamina|at any given time , over 70% of an individuals immune system resides in the entity propria , which is the target-rich tissue of the intestinal tract .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|densities gradients atpases autoreg density|gata4 dystrophin nanog densities autoin|lamina|in a decompressive laminectomy , the surgeon removes bone , known as the entity , from the back part of the symptomatic vertebrae over the spinal canal to create more space for , and relieve pressure
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|tissue|densities gradients atpases autoreg density|motors mω atpases microtubules dystrophin|lamina|cell-secreted gp96-ig-peptide complexes induce entity propria and intraepithelial cd8+ cytotoxic t lymphocytes in the intestinal mucosa .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|gata4 gradients damp mω cd44|lamina|entity is a private corporation over which dr . raouf guirguis has sole control .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|autoreg nanog gata4 densities smad4|lamina|&#160 ; on february 25 , 2015 , the company entered into a license agreement with entity equities corporation ( &#8220 ; entity&#8221 ; ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|densities gradients atpases autoreg density|dystrophin benjamini dens normality microtubules|lamina|these data were collected in tests in human entity cribrosa cells grown from human optic nerve heads and from human intestinal epithelial cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|nanog gata4 density dens densities|lamina|of all or part of a damaged disc , and laminectomy , which is the removal of all or part of a entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|caveolae atpases junction cyclins localizes|lamina|in the gut antigens such as gluten are processed by resident dendritic cells in the entity propria which then migrate to the local mesenteric 31 lymph nodes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|junction mω junctions motors catenin|lamina|disease activity index , colonic leukocytic infiltration , entity propria neutrophils and colonic tnf expression were used as endpoints .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|densities gradients atpases autoreg density|dystrophin dens densities otherwise density|lamina|in-vitro experiments have shown that sirnas against factor 5a protected human entity cribrosa ( optic nerve ) and colon epithelial cells from tnf alpha induced apoptosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients atpases autoreg density|atpases mω exists cyclins arp2|lamina|ta and cis are limited to the urothelial layer , and t1 is limited to the layer below , which is the entity propria .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|densities gradients atpases autoreg density|dystrophin mω densities atpases resonance|lamina|by inhibiting factor 5a , we were able to reduce tnf-a induced apoptosis by 80% in entity cribrosa cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|smad1 gata4 inactivation density nanog|myocardium|finally , the cells could promote regeneration of viable new tissue , improving the functional capacity of the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|smad1 autoreg negativity downregulation gata4|myocardium|thus such a molecule should have desirable properties in experiments aimed at inducing collateral circulation in the entity of patients with coronary stenosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|saturation mω smad1 gradients dens|myocardium|may also provide information on cardiac mitochondrial membrane potential , enabling global and regional assessment of the electro-physiologic integrity of the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|gradients saturation nanog densities density|myocardium|characterized by thoracic pain and a feeling of suffocation , most often due to anoxia ( lack of oxygen supply ) to the entity precipitated by physical exertion or excitement .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae otherwise autoreg junction atpases|smad1 existence dystrophin gata4 cd69|myocardium|the primary objectives of this trial are to evaluate the safety and efficacy of injecting 150 million mpcs into the native entity of lvad recipients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|gradients smad1 nanog gata4 chimeras|myocardium|cm1 has been shown to couple electrically and mechanically with the host entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|gata4 mω densities tags smad1|myocardium|the death of myocardial cells first occurs in the area of entity that is most distal to the arterial blood supply , the endocardium .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae otherwise autoreg junction atpases|junction dispersion moves otherwise cholerae|myocardium|potassium channels that control normal functioning of the middle layer of heart wall composed of cardiac muscle , or the ventricular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|ante saturation densities ploidy adherens|myocardium|the hesc-cm treated heart ( right ) shows a large graft of human heart muscle ( green ) replacing the entity lost to infarction .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|junction dispersion segregation moves myo|myocardium|appear to target these channels which mediate atrial arrhythmia without disrupting potassium channels that control normal functioning of the ventricular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|saturation density densities ante ploidy|myocardium|the heart of an nhp by hesc-cm transplantation the saline-treated heart ( left ) shows infarct scar tissue ( blue ) replacing the entity lost to infarction .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae otherwise autoreg junction atpases|cholerae gata4 cd69 smad1 autoreg|myocardium|responsive relationship , with higher doses of bone marrow mononuclear cells resulting in reduced fibrosis and increased microvascular change in infarcted entity 60 days after treatment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|either smad1 saturation certain smad4|myocardium|the targeted 24 table of contents cardiomyocytes are expected to produce sustained therapeutic protein levels in the entity where it is needed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae otherwise autoreg junction atpases|autoreg dystrophin gata4 normality sensitivities|myocardium|when injected into ischemic entity , mlcs are very potent inducers of large caliber arteriogenesis compared to 104 table of contents index to financial statements
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|negativity smad1 gata4 density smad4|myocardium|bfpet has been designed to effectively differentiate among those cells of the entity that are ischemic , infarcted and those that are healthy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|smad1 outer densities dens gata4|myocardium|physicians to screen for coronary artery disease , to assess flow rates and flow reserve , and to distinguish viable from nonviable entity for bypass and transplant candidates .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|gata4 autoreg normality smad1 dens|myocardium|if blood flow can be restored to at-risk entity , more heart muscle can be saved from irreversible damage or death .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae otherwise autoreg junction atpases|junction gata4 dystrophin smad1 motors|myocardium|as the duration of the occlusion increases , the area of myocardial cell death enlarges , extending from the endocardium to the entity and ultimately to the epicardium .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae otherwise autoreg junction atpases|saturation certain junction gradients smad1|myocardium|this results in the solution entering the entity via post capillary venules .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae otherwise autoreg junction atpases|smad1 cd44 dystrophin gradients saturation|myocardium|we believe that ik-5001 will work as a temporary structural support while the damaged entity heals by replacing the dead tissue that would normally support the wall of the heart .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs smad1 normality tubulin autoreg|mω densities kv damp motors|mesothelium|the company will license entity mab from the nih and in return the agreement , requires the company to make a $75 , 000 non-refundable license issue payment
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs smad1 normality tubulin autoreg|junction atpases mω gradients existence|mesothelium|mesothelioma mesothelioma is a rare form of cancer in which malignant cells develop in the entity , a protective lining that covers most of the bodys internal organs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs smad1 normality tubulin autoreg|densities mω motors density inactivation|mesothelium|of march 22 , 1999 , the company and nih entered into an exclusive worldwide licensing agreement to develop and commercialize a entity antigen therapy ( mesothelin mab ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs smad1 normality tubulin autoreg|mω densities damp dwell kv|mesothelium|the company will license entity mab from the nih and in return , the agreement requires the company to make a $75 , 000 non-refundable license issue payment
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs smad1 normality tubulin autoreg|junction either csc gap saturation|mesothelium|malignant pleural mesothelioma is an aggressive form of cancer that occurs in the entity , the thin layer of tissue that covers the lungs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|biolabs smad1 normality tubulin autoreg|gradients negativity otherwise dystrophin saturation|mesothelium|differentiating mesothelioma from adenocarcinoma mesothelioma is a cancer that develops in the entity - a protective sac that covers most of the bodys internal organs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs smad1 normality tubulin autoreg|saturation densities density damp microtubules|mesothelium|when ovarian cancer spreads to the entity of the organs within the peritoneal cavity , it can result in encasement of these organs with significant pain and eventual
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs smad1 normality tubulin autoreg|mω saturation ≥1 negativity existence|mesothelium|about malignant mesothelioma malignant mesothelioma is a cancer that originates in the entity – the tissue that surrounds different organs in the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|smad1 outer cyclins leak biolabs|mω smad1 gata4 microtubules resonance|dentine|the lactic acid erodes the mineral in enamel and entity , weakening the tooth and ultimately resulting in decay .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg gradients cholerae|cholerae gradients smad1 mω degenerate|enamel|ongoing dental projects include : o an entity matrix protein-based product for endodontic therapy ( treatment of dental pulp ) - a phase i trial is underway .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg gradients cholerae|tags decay storm junction signals|enamel|fluorinex has developed a unique device that delivers fluoride ions directly to the tooth entity via a sophisticated electro-chemical technique .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg gradients cholerae|smad1 cholerae degenerate mω kv|enamel|o an entity matrix protein-based product to reduce pain and discomfort following scaling and root planing of periodontal pockets - a phase ii
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg gradients cholerae|otherwise cholerae autoreg gata4 nedd4|enamel|in nail entity , sally hansen® , the number one brand , increased its market share to 27 . 4% .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg gradients cholerae|motors smad1 smad4 cholerae damp|enamel|toilet core walls shall receive 2 coats latex entity paint .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg gradients cholerae|smad1 motors pkd1 autoin dystrophin|enamel|d . exposed columns and ironwork at open ceiling areas shall be cleaned , primed painted with semi-gloss entity paint to cover .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg gradients cholerae|smad4 autoin gata4 motors gradients|enamel|entity care is the first toothpaste to combine the cleaning and whitening properties of baking soda with fluoride and patented liquid calcium to fill tooth surfaces and restore enamel luster .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg gradients cholerae|nanog smad1 gradients mω otherwise|enamel|the active ingredient is the entity matrix protein amelogenin and the product has been launched in north america , europe and japan for treatment of patients who
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg gradients cholerae|smad1 mω refractory nanog smad4|enamel|derives its energy from carbohydrate metabolism as it converts dietary sugar to lactic acid which , in turn , erodes the tooth entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg gradients cholerae|nanog smad4 ubiquitin smad1 motors|enamel|- more - early in the quarter , the company launched arm & hammer entity care toothpaste , its most important oral care initiative in several years .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg gradients cholerae|density kv gata4 cholerae densities|enamel|wash and polish all mirrors , powder shelves , bright work and entity surfaces , including flushometers , piping , toilet set hinges , and all metal .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg gradients cholerae|junction cholerae mω dens nedd4|enamel|will continue to market multiple nat robbins color cosmetics items including lipliner pencils , lipsticks , eyeliner pencils , eye shadow , mascara , nail entity and assorted accessories .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg gradients cholerae|nedd4 αvβ3 kv densities autoreg|enamel|simply wow™ was compared to orange clean , fantastik and formula 409 for the ability to remove cooked-on grease from an entity stovetop .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg gradients cholerae|dens mω smad1 cholerae gata4|enamel|number of its principal product categories in the u . s . mass-market distribution channel , including the lip , eye , face makeup and nail entity categories .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg gradients cholerae|tags signals mω degenerate storm|enamel|hap is naturally found in bone and tooth entity and is rapidly integrated into the human body .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg gradients cholerae|mω gata4 smad4 autoin cholerae|enamel|remover and nail care products in certain countries outside the u . s . in 2003 , the company launched colorstay always on nail entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg gradients cholerae|smad4 gata4 smad1 csc autoin|enamel|on net sales of a hair-off mitten that is a depilatory-product accessory , and nutra nail 60 , a fast- acting nail entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg gradients cholerae|smad1 mω nanog gata4 smad4|enamel|as a person ages the adult teeth often become darker due to changes in the mineral structure of the tooth , as the entity becomes less porous and phosphate-deficient .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg gradients cholerae|density densities csc imm smad4|enamel|floors , hand brush corners and hand brush toilet edges with approved germicidal detergent solution . 2 . wash completely all partitions , tile walls and entity surfaces .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg gradients cholerae|smad1 sin negativity autoin degenerate|enamel|tooth decay is characterized by the dissolution of entity and dentin , eventually resulting in the destruction of the entire tooth .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|smad1 gata4 smad2 kolmogorov benjamini|autoin dystrophin degenerate smad1 damp|cementum|dental field  means the field of treatment , repair or replacement of the tooth , dentin , alveolar bone , tooth-root entity , gingiva and / or periodontal ligament .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|smad1 gata4 smad2 kolmogorov benjamini|traps smad1 mω damp tags|cementum|by coating the surface of the exposed dental root with emdogaingel during periodontal surgery , new root entity , periodontal ligament fibers , and surrounding bone tissue can be formed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|smad1 gata4 smad2 kolmogorov benjamini|mω rho nanog biased tags|cementum|a healthy tooth attachment apparatus is made up of the root entity , the outer layer of the root ; the periodontal ligament , which both anchors the root to the jawbone and cushions the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|smad1 gata4 smad2 kolmogorov benjamini|mω rho biased tags nanog|cementum|a healthy tooth attachment apparatus is made up of the root entity , the outer layer of the root ; the periodontal ligament , which both anchors the root to the jaw bone and cushions
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|smad1 gata4 smad2 kolmogorov benjamini|either mω resonance exists smad1|cementum|the extent , the gingiva functions as 6 7 part of the apparatus holding the tooth to the jaw ) , alveolar bone , entity , enamel and periodontal ligament .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|smad1 gata4 smad2 kolmogorov benjamini|mω exists resonance smad1 junction|cementum|the periodontal setting , these agents do not directly stimulate the repair of other important tissues such as periodontal ligaments or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|smad1 gata4 smad2 kolmogorov benjamini|mω either resonance exists smad1|cementum|only to the extent , the gingiva functions as part of the apparatus holding the tooth to the jaw ) , alveolar bone , entity , enamel and periodontal ligament .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|smad1 gata4 smad2 kolmogorov benjamini|mω nanog smad1 autoin either|cementum|are utilized even though these methods do not have the same capability as emdogain of regenerating the tissues - bone , entity and ligament - that make up the tooth-supporting structures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|sinus stabilizes mω gata4 normality|density degenerate nanog negativity smad1|periodontium|data indicate that the presence of streptococcus oralis and streptococcus uberis provide a good indication of the health of the entity ( gums ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|sinus stabilizes mω gata4 normality|density degenerate nanog negativity smad1|periodontium|data indicate that the presence of streptococcus oralis and streptococcus uberis provides a good indication of the health of the entity ( gums ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|sinus stabilizes mω gata4 normality|smad1 mω gradients negativity gata4|periodontium|these patents relate to the biodegradable in situ forming implants and the biodegradable system for regenerating the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|sinus stabilizes mω gata4 normality|negativity gata4 saturation gradients otherwise|periodontium|dr . caton has conducted many studies evaluating various treatment modalities for periodontitis and other diseases involving the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|junction cholerae dens autoreg gradients|cholerae densities junction saturation ≥1|endothelium|drug candidate indicates that consistent increases in gb3 levels were measured in cardiomyocytes ( as opposed to decreases measured in vascular entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|junction cholerae dens autoreg gradients|cholerae localizes dystrophin chimeras motors|endothelium|research articles , serves as an editorial board member to several biomedical journals and is the founder of the biomedical journal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|saturation junction gata4 either gradients|endothelium|in the inflammatory component , white blood cells begin to roll along and then adhere to the entity , the thin layer of cells that lines the interior surface of blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|junction saturation gata4 gradients smad1|endothelium|that the company believes may be important in identifying unique sites on the lining of the blood vessels or the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|junction cholerae dens autoreg gradients|smad1 negativity saturation mω microtubules|endothelium|atherosclerotic plaque to 732 nanometer light delivered through a catheter resulted in elimination of the lesions without damage to the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|densities junction saturation gata4 smad1|endothelium|atherosclerotic apoe ko mice corresponding to initial steps of atherosclerosis that comprise cell to cell adhesion of monocytes / macrophages to the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|gradients saturation densities nanog density|endothelium|the interaction between certain cell adhesion molecules on the surface of both the leukocyte and the entity facilitates these contacts .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|saturation gata4 resonance smad1 density|endothelium|into inflamed areas because sle ( x ) present on the surface of white blood cells binds to selectin molecules present on activated entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|junction cholerae dens autoreg gradients|saturation densities otherwise autoreg dystrophin|endothelium|nitric oxide produced by the entity also inhibits the clumping of platelets , which are cells in the blood that promote clotting , and the adhesion of platelets
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|junction cholerae dens autoreg gradients|gradients densities density mω dystrophin|endothelium|initially , this new tissue consists of healthy cells from the lining of the arterial wall ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|autoreg chimeras densities saturation gata4|endothelium|large caliber arteriogenesis compared to only small vessel angiogenesis obtained with hematopoietic stem cells which only give rise to the entity of capillaries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|gata4 nanog certain cd69 gradients|endothelium|clot is most often triggered when there is damage or disruption to the lining of the blood vessel wall , or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|gata4 certain nanog densities cd69|endothelium|cascade is most often triggered when there is damage or disruption to the lining of the blood vessel wall , or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|junction cholerae dens autoreg gradients|junction densities junctions cholerae junctional|endothelium|these experiments used cells important in human disease and aging--retinal pigment epithelium , fibroblasts , and vascular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|junction gata4 smad1 junctional notation|endothelium|white blood cells express carbohydrates on their surfaces that bind to e-selectin that is present on inflamed vascular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|junction cholerae dens autoreg gradients|gata4 smad1 saturation dystrophin densities|endothelium|specifically , we believe that by inhibiting selectin-mediated adhesion of white blood cells to the entity , rivipansel prevents propagation of voc and promotes early resolution .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|gradients cd69 junction atpases gata4|endothelium|the entity , a single-cell lining of the arteries that acts as an interface between the blood and arterial wall , is impaired in
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|saturation nanog junction densities density|endothelium|protein markers , unique to the surface of the entity in specific organs and those markers that distinguish tumor blood vessels from those vessels in healthy tissue , are thought to
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|saturation gata4 chimeras smad1 densities|endothelium|an overgrowth of the entity that forms capillaries and lines blood vessel interiors contributes to atherosclerosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|junction cholerae dens autoreg gradients|gata4 saturation smad1 either density|endothelium|binding of all three types of selectins and inhibit the selectin-mediated recognition and binding of white blood cells to the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|kolmogorov benjamini null cholerae mendelian|gata4 smad1 gradients dystrophin lgr5|fibrocartilage|another type of cartilage ( entity ) serves a shock-absorbing function in the knee and in the spine between the vertebrae .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|kolmogorov benjamini null cholerae mendelian|nanog mω cd44 gata4 junction|fibrocartilage|biopsies from 135 of 141 of these re-looks showed the development of meniscus-like entity , confirming the devices effectiveness as a surgical mesh .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|benjamini kolmogorov autoreg densities gradients|gata4 densities gradients microtubules veloc|perichondrium|model was completed and bmp signaling was shown to be enhanced in the outermost cells of the growth plate , or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|benjamini kolmogorov autoreg densities gradients|gradients gata4 densities microtubules noise|perichondrium|by dr . yu yamaguchi , bmp signaling was shown to be enhanced in the outermost cells of the growth plate , or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae benjamini kolmogorov gata4 cracks|certain junction either cholerae gap|mesangium|igan is a nonsystemic renal disease that is characterized by predominant iga deposition in the glomerular entity , causing mesangial proliferation and fibrosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae benjamini kolmogorov gata4 cracks|certain junction junctional either imm|mesangium|iga nephropathy igan is a common glomerulopathy diagnosed by the predominant histologic presence of galactose-deficient iga1 deposits in the glomerular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|cholerae benjamini kolmogorov gata4 cracks|junction gap imm transportation microtubules|mesangium|these iga containing immune complexes deposit in the entity of glomeruli in the kidney and are proinflammatory .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae benjamini kolmogorov gata4 cracks|nanog imm junction saturation mω|mesangium|chronic activation of inflammatory pathways also leads to long-term structural alterations in the entity , which results in reduced glomerular surface area and gfr .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg normality boltzmann signals benjamini|atpases veloc densities autoreg uncoupling|neuroectoderm|entity cells are committed to developing into cells of the skin and nervous systems .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|autoreg normality boltzmann signals benjamini|junction atpases microtubules chimeras spher|neuroectoderm|with the differentiation signals resulting from the physical attributes of the cell culture techniques , induce the epiblasts to differentiate into entity or mesendoderm cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg normality boltzmann signals benjamini|atpases veloc densities autoreg uncoupling|neuroectoderm|entity cells are committed to developing into cells of the skin and cells of the nervous system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg normality boltzmann signals benjamini|junction either gata4 autoreg junctions|neuroectoderm|van rooijen m , xu x , zweigerdt r , mummery c , passier r . insulin redirects differentiation from cardiogenic mesoderm and endoderm to entity in differentiating human embryonic stem cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|autoreg normality boltzmann signals benjamini|junction microtubules atpases spher mω|neuroectoderm|together with the differentiation signals resulting from the physical attributes of the culture techniques , induce the epiblasts to differentiate into entity or mesendoderm cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase ante boltzmann autoreg gata4|gata4 csc dystrophin densities density|tonsil|the company introduced during fiscal 1995 a line of specialty sponges , including eye spears , dissecting , stick and entity sponges , all of which are
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase ante boltzmann autoreg gata4|densities density cd69 gata4 csc|tonsil|( b ) entity sponges - a round , fiber filled gauze constructed with a strong abdominal tape string sewn into the sponge to anchor
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase ante boltzmann autoreg gata4|densities density saturation negativity gradients|tonsil|tumor shrinkage was also seen in patients with renal cell cancer , liver cancer , sarcoma , and cancer of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase ante boltzmann autoreg gata4|either gata4 densities density biphasic|tonsil|tjx7 has been shown to completely inhibit the migration of primary human entity b cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase ante boltzmann autoreg gata4|dystrophin csc density densities gata4|tonsil|the company has also introduced a line of specialty sponges , including eye spears , dissecting , stick and entity sponges , all of which are used in a variety of surgical procedures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase ante boltzmann autoreg gata4|densities density saturation negativity gradients|tonsil|tumor shrinkage also was seen in patients with renal cell cancer , liver cancer , sarcoma , and cancer of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase ante boltzmann autoreg gata4|density densities csc nanog gata4|tonsil|products used primarily in the operating room environment ; medical action introduces a line of specialty sponges , which include dissecting sponges , entity sponges , stick sponges and eye spears .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|smad1 mω gata4 nanog gradients|cartilage|it has a dual method of action that could provide the unique benefit of protecting bones and preserving entity in patients with osteoarthritis and osteoporosis , all in one medication .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|smad1 cd69 density densities mω|cartilage|in comparison with tissue stiffness , streaming potentials measured showed almost identical behavior for the normal and degraded entity explant .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|nanog densities density gata4 negativity|cartilage|developed and commercialized chondrocelect , the first cell-based medicinal product to receive marketing authorization from the ema , which was indicated for entity repair in the knee .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|nanog gata4 smad1 cd69 autoreg|cartilage|the secondary endpoints were entity repair at 12 months by assessment of changes of the knee joint entitys volume measured with 3d spgr quantitative mri ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|gata4 smad1 chimeras minima densities|cartilage|these compounds induce the formation of entity and regenerates new bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|dens localizes gradients nanog adherens|cartilage|the handle ; o software for the acquisition of electrical signals and for the analysis and interpretation of data to quantify entity quality ; and o a computer system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|densities gradients density gata4 autoreg|cartilage|the simplicity of the technique for the assessment of entity quality was demonstrated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|gata4 densities density dens mω|cartilage|in both of these prior positions dr . christgau worked in the area of bone and entity research .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|nanog notation density smad1 junction|cartilage|disease that affects almost 1% of the adult population worldwide and it ultimately results in irreversible damage of the joint entity and bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|junction junctions gata4 nanog mω|cartilage|oa background oa is a joint disorder involving the degeneration of the articular entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|junction junctions sinus gata4 negativity|cartilage|treatment of various injuries and degeneration of other tissue structures such as the intervertebral disc of the spine and articular entity of degenerated joints .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|mω autoin grade smad1 gata4|cartilage|sarcomas are cancers of the bone , entity , fat , muscle , blood vessels , or other connective or supportive tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|smad1 nanog gata4 mω gradients|cartilage|entity on any of these surfaces can be damaged due to disease or injury , leading to pain and inflammation requiring knee
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|smad1 mω nanog gata4 densities|cartilage|it assists in regained mobility as it refurbishes entity in the bone end of joints , consisting of the same cellular structure , collagen type ii .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|ante mω negativity benjamini stratification|cartilage|a fully functional clinical version of the arthro-bst ( tm ) was presented at the third meeting of the international entity repair society ( icrs ) in sweden in april 2000 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|gata4 smad1 nanog mω grade|cartilage|from a mouse with cia with no treatment showing severe inflammation in the joint with sever damage to bone and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|junction junctions gradients sinus gata4|cartilage|major teaching hospital and other institutions have demonstrated that the use of the company  s compounds inhibit the loss of synovial entity in the joint .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|gata4 nanog junction tags junctions|cartilage|this condition grows more severe over time and leads to progressive thinning of articular entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|mω either density densities junction|cartilage|product development programs utilize adult bone marrow stem and progenitor cells for forming solid tissues such as bone , vascular tissue , entity , and blood and immune system cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|uncoupling uncou gradients sensitivities decou|mω densities negativity smad1 gata4|cartilage|additional studies are being carried out to confirm the entity regrowth .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|dens junction gradients densities autoreg|negativity junction dens saturation sensitivities|mesenchyme|the scientific publication demonstrates that 4d20 . 8 cells possess site-specific markers of craniofacial entity , in particular , markers of proximal mandibular entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase benjamini ante otherwise sensitivities|densities negativity density dystrophin nanog|ependyma|filters toxins 1 cerebrospinal fluid ( csf ) – brain barrier / glymphatic system : extracts toxins from the brain 2 ventricle brain entity ( glial cells ) astrocytes ( glial cells )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|otherwise gata4 cush boltzmann densities|mω either damp gata4 cd44|umbilicus|it usually involves the face , digits , arms , inguinal area , anogenital area , entity and nipples , and can also affect the hair .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|otherwise gata4 cush boltzmann densities|gata4 atpases densities αvβ3 ctla|umbilicus|reductions observed in the circumference at the entity and treatment area volume were the same in both the placebo and lipo-202 treatment groups .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|otherwise gata4 cush boltzmann densities|atpases dens gata4 autoreg jam|umbilicus|manual tape measure procedure , the 0 . 4 µg total weekly dose of lipo-202 produced significant reductions in abdominal circumference at the entity compared to placebo .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|junction gradients mω saturation imm|epidermis|most common form of skin cancer , is an uncontrolled growth of abnormal cells arising from the squamous cells in the entity , the skins outermost layer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|nanog mω negativity gradients smad1|epidermis|skin in order to achieve enough heating at the required depth significantly increases the risk of damaging or burning the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|mω gradients saturation junction autoreg|epidermis|bcc develops in the basal , or lower , layer of the entity , and accounts for approximately 80% of all new cases of skin cancer annually .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|mω smad1 gradients tea saturation|epidermis|psoriasis , for example , which is characterized by inflammation and accelerated growth of the entity , can sometimes be triggered by a simple cut or abrasion to the skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|gradients mω saturation negativity degenerate|epidermis|removal is based upon the selective heating of hair follicles while cooling the surface of the skin to protect the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|saturation mω gradients imm autoreg|epidermis|scc usually develops in the entity , the upper layer of the skin , and accounts for approximately 16% of all new cases of skin cancer annually .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|mω junction junctions saturation restorations|epidermis|autologous skin regeneration construct of its kind , which can regrow full-thickness and functional polarized skin , including all layers ( dermis & entity ) , hair , and skin appendages .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|mω saturation junction smad1 nanog|epidermis|by precisely focusing ultrasound energy to cause permanent disruption , or ablation , of fat cells , or adipocytes , without damage to the entity , dermis or underlying tissues and organs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|mω smad1 gradients restorations saturation|epidermis|to effectively penetrate the skin barrier , reducing their ability to improve the health of the skin at the stratum corneum , entity and dermis level .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|chimeras nanog gradients gata4 dens|epidermis|the cold sapphire tip protects the entity while allowing the laser light to efficiently destroy the target follicles .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|gradients saturation mω junction dispersion|epidermis|plaque psoriasis is a disease marked by hyperproliferation of the entity , resulting in inflamed and scaly skin plaques .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|mω junction restorations gradients junctions|epidermis|designed to penetrate below the skin  s surface to correct damage in all layers of the skin ( the stratum corneum , the entity and the dermis ) and accelerate cellular turnover .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|saturation gradients junction certain junctional|epidermis|topical interferon alpha-2b is intended to deliver interferon alpha-2b therapy to the viable entity , combating hpv infections where they would otherwise cause abnormal cellular proliferation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|mω saturation smad1 gradients gata4|epidermis|the ability to effectively penetrate the skin barrier , reducing their ability to improve the health of the skin at the entity and dermis level .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|junction mω nanog saturation densities|epidermis|these changes can visibly affect the shape of the entity and resemble an orange peel-like dimpling of the skin . 1 in the normal subcutaneous fat layer directly under the skin , there
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|gradients junction hist saturation mω|epidermis|keratinocytes are the predominant cell type in the entity , the outermost layer of the skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|mω saturation junction either gmp|epidermis|our products will be naturally infused into hair follicles , dermis and entity layers of the scalp through the direct application and use of all-natural products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|mω junction junctions restorations smad1|epidermis|vii collagen , or col7 , that forms anchoring fibrils that bind the dermis , or inner layer of the skin , to the entity , or outer layer of the skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients atpase autoreg spin dens|otherwise saturation chimeras smad1 gata4|epidermis|concentration of hydroquinone , which is designed to correct skin pigmentation problems by normalizing the production of new melanin in the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|gradients atpase autoreg spin dens|smad1 kolmogorov merits cholerae dystrophin|epidermis|azitra inc . is developing azt-02 , a staphylococcus entity strain engineered to express lekti in preclinical development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases autoreg densities otherwise atpase|densities gradients cdh1 inactivation atpases|anlage|thereof ; 4 . 1 . 3 all running expenses as defined in appendix 3 to section 27 , subsection 1 , of the second computation order ( entity 3 zu section 27 abs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases autoreg densities otherwise atpase|autoreg either downregulated mω resonance|anlage|the business address for each of the persons listed below other than christopher k . norton is messeturm , friedrich-ebert- entity 49 , 60308 frankfurt am main , germany .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|atpases autoreg densities otherwise atpase|autoreg dens nanog spd exists|anlage|l . der verkaufer verkauft und ubertragt hiermit samtliche vertrags-erfindungen und vertrags-schutzrechte , die in den in entity 1 und entity 2 beigefugten schutzrechtskaufvertragen definiert sind .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases autoreg densities otherwise atpase|autoreg localization densities inactivation either|anlage|des verschmelzungsplans ) wird die übernehmende gesellschaft die neue satzung , wie sie als entity 2 dem verschmelzungsplan beigefügt ist , beschließen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases autoreg densities otherwise atpase|autoreg spher inactivation motors negativity|anlage|zeitpunkt dieser lizenzerklärung im eigentum der sag stehen , darin insbesondere eingeschlossen die patente und patentanmeldungen gemäss entity 2 , die sich auf die substanz prostone
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases autoreg densities otherwise atpase|autoreg localization cd69 dens inactivation|anlage|verkauft und ubertragen werden daher insbesondere die in der entity 3 aufgefuhrten vermogensgegenstande und rechte ( insgesamt der , , kaufgegenstand " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases autoreg densities otherwise atpase|autoreg vul epha2 coreg motors|anlage|schutzrechtsanmeldungen , die vom dkfz parallel dazu gemäß entity 2 vorgenommen worden sind .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases autoreg densities otherwise atpase|autoreg either mω grp78 confused|anlage|the principal business address of each of gscp ii germany and gs ohg is messeturm friedrich-ebert- entity 49 , 60308 frankfurt am main , germany .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases autoreg densities otherwise atpase|autoreg densities spher density papill|anlage|belastungen des in entity 1 . 1 beschriebenen grundbesitzes in abteilung iii des grundbuchs werden vom käufer nicht übernommen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases autoreg densities otherwise atpase|autoreg localization cdh1 coreg cd69|anlage|schutzrechtsanmeldungen gemäß entity 2 zugrundeliegenden erfindungen zu zahlen ist , steht den erfindern von asta pharma ein anteil von 20% zu .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases autoreg densities otherwise atpase|autoreg cdh1 localization grp78 vul|anlage|​ die satzung der übernehmenden gesellschaft , als aus der gesellschaft hervorgehende gesellschaft , ist als entity 1 zu diesem verschmelzungsplan beigefügt .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases autoreg densities otherwise atpase|spher cd69 localization imm decou|anlage|dr . thomas drosdeck beiten burkhardt rechtsanwaltsgesellschaft mbh bockenheimer entity 15 mozartplatz 60322 frankfurt am main germany 30 . 13 execution by counterpart .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpases autoreg densities otherwise atpase|cd69 mω localization ctla autoreg|anlage|rechten und ansprüchen gegen sie an pcof 1 llc ( der zessionar ) im wege der sicherungsabtretung abgetreten haben , einschließlich der in entity 1 genannten forderungen .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|dystrophin benjamini otherwise gata4 densities|densities gata4 density smad1 autoreg|osteoid|the six patients had mean entity volume / bone volume decreases from 24 . 3 percent to 7 . 0 percent , representing a 71 percent improvement .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|dystrophin benjamini otherwise gata4 densities|densities density existence gata4 dens|osteoid|at 48 weeks , all ten patients with evaluable paired bone biopsies demonstrated meaningful improvements from baseline in mean entity volume / bone volume .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|dystrophin benjamini otherwise gata4 densities|densities gata4 smad1 chimeras mω|osteoid|the patients also demonstrated mean improvements of 32% and 26% in entity thickness and entity surface / bone surface parameters respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|densities negativity density junction nanog|fascia|this procedure may be done without disrupting the endopelvic entity and is especially valuable for women who have scarring from previous abdominal surgery and are not good candidates for a
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|either gata4 tags myo smad1|fascia|background dupuytrens disease is a slowly progressive fibroproliferative disease of the palmar entity in the hand .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|negativity nedd4 autoreg damp cush|fascia|any changes or additions to the entity sign shall be subject to landlords prior written approval , in landlords sole discretion , and shall be made at tenant  s sole cost and expense .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|nanog gata4 chimeras mω smad1|fascia|plantar fibromatosis is a non-malignant thickening of the feets deep connective tissue or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|nedd4 smad4 densities density gata4|fascia|for all purposes under the lease , the entity sign shall be deemed to be tenant  s off-premises equipment . 7 . brokerage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|smad4 smad1 sensed autoreg damp|fascia|tenant shall repair , paint , and / or replace the building entity surface to which its signs are attached upon vacation of the premises , or the removal or alteration of its signage ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|densities density gata4 autoin localizes|fascia|no alteration shall ( i ) affect the exterior walls , entity or fenestration of the building or the demising walls of the premises , ( ii ) affect any part of the project other than
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients autoreg atpases densities atpase|mω saturation junction dystrophin gradients|fascia|are you going to start accepting dermis , entity and pericardium recoveries?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|autoreg smad1 localization smad4 cyclins|fascia|the revenue increase was primarily due to an increase in the demand for our entity lata products to treat incontinence and urologic and gynecologic defects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|mω either autoin exists gata4|fascia|muscoloskeletal conditions  means conditions of the muscles , bones , joints ( including the intervertebral discs ) , ligaments , tendons , cartilage and entity of the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|densities negativity nanog junction density|fascia|this procedure may be done without disrupting the endopelvic entity and is especially valuable for women who have scarring from previous abdominal surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients autoreg atpases densities atpase|density densities gradients autoreg cholerae|fascia|green  s dairy road a . all entity signs to be single faced cabinets , and shall be constructed of 100% aluminum with stencil cut aluminum backgrounds with white
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|saturation mω junction gradients imm|fascia|cutaneous eosinophilias are inflammatory diseases that manifest in dermal and subcutaneous layers including the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|cush adherens autoreg cdh1 cd44|fascia|signage no entity , sign , name plate , bill , notice , placard , advertisement or similar device shall be affixed to or displayed in or on any
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients autoreg atpases densities atpase|dystrophin ante benjamini npc1 segregating|fascia|meanwhile , the company is offering alternative tissues such as entity lata and bovine pericardium to the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|density densities autoin gata4 nanog|fascia|kind and quality and having made good any material physical damage resulting from the removal of any tenant  s fixtures , fittings , entity or signs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|smad1 gata4 nanog either chimeras|fascia|the plantar entity is the foots shock absorber .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|mω gradients junction smad1 otherwise|fascia|a therapeutic protein and / or bioactive rna for the treatment of autoimmune and non-infectious inflammatory disorders that manifest in cutaneous tissues , entity and / or muscle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients autoreg atpases densities atpase|densities autoreg gata4 cholerae density|fascia|entity inventories are higher than normal by $720 due to reduced demand and the anticipation of the launch of a new
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients autoreg atpases densities atpase|mω gradients junction smad1 otherwise|fascia|therapeutic protein and / or bioactive ribonucleic acid for the treatment of autoimmune and non-infectious inflammatory disorders that manifest in cutaneous tissues , entity and / or muscle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients benjamini ante gata4|mω nanog gradients smad1 gata4|endomysium|- 5 - in muscle tissue , collagen serves as a major component of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients benjamini ante gata4|mω nanog gradients chimeras smad1|endomysium|in muscle tissue , collagen serves as a major component of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|normality autoreg linearity null telangiect|saturation gradients nanog junction smad1|neuroepithelium|the entity is the tissue by which man detects the presence of odor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|normality autoreg linearity null telangiect|junction nanog dens cd44 otherwise|neuroepithelium|smell ) can result from a number of causes , including mechanical obstruction of the nasal cavity and damage to the olfactory entity , the olfactory bulb , or the nerves between them .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg gradients mω spher atpase|αvβ3 mω dens cholerae cd44|mole|the major histologic entities for this disease include complete molar pregnancy , partial molar pregnancy , invasive entity , and choriocarcinoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|spher normality smad1 autoin densities|mole|mm  shall mean one-thousandth of a entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|tissue|autoreg gradients mω spher atpase|mω αvβ3 dens cholerae integrins|mole|the term gestational trophoblastic neoplasia ( gtn ) is used when molar and non-molar pregnancies become malignant , and comprise the morphologic entities of invasive entity and choriocarcinoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|mω autoreg vsv gata4 normality|mole|to 12-month period in order to detect new or changing entitys through total body photography , by monitoring a specific entity or entitys .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|densities mω gata4 gradients autoin|mole|cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|mω autoreg vsv gata4 normality|mole|to 12 month period in order to detect new or changing entitys through total body photography , by monitoring a specific entity or entitys .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|densities mω gata4 gradients autoin|mole|american cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|autoin biased mω saturation normality|mole|present in two forms , nodular bcc , which appears as a shiny bump or nodule that may be confused with a entity , and superficial bcc , which has a slightly raised , ulcerated or crusted surface .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|densities autoreg density autoin smad1|mole|we believe that their software , at present , cannot define whether a entity is a new one or not .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg gradients mω spher atpase|atpases motors dystrophin gradients mω|mole|referred to antibodies excluded from the licence 1all antibodies to alpha tumour necrosis factor having an association constant greater than 106l / entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|autoreg disintegr amorph cd69 motors|mole|tks , tps , stks and related downstream signalling entitycules ( target identification ) and vali- dation of the role , if any , of those entity- cules in a given disease ( target valida- tion ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|mω nanog negativity xyle smad4|mole|the abcd rule is defined as follows : a ● asymmetry , a benign entity that is not asymmetrical ; b ● border , a benign entity has smooth , even borders , unlike melanomas ; c ● color .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|smad1 normality gradients imm saturation|mole|one of the best early indicators of melanoma is a new or changing entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg gradients mω spher atpase|densities dystrophin density atpases mω|mole|/ s / weisberg , polansky , kulberg , einhorn & entity , llp carle place , new york july 30 , 1996 exhibit 23 . 8 consent of independent certified public accountants we consent to the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|autoreg gradients mω spher atpase|negativity cd44 dystrophin spher differential|mole|choriocarcinoma metastasizes hematogenously and can follow any type of pregnancy , but most commonly develops after complete hydatidiform entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|autoin biased mω saturation normality|mole|itself in two forms , nodular bcc , which appears as a shiny bump or nodule that may be confused with a entity , and superficial bcc , which has a slightly raised , ulcerated or crusted surface .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|densities mω gata4 gradients autoin|mole|american cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients mω spher atpase|saturation mω unstable nanog normality|mole|it may begin in a entity as skin melanoma , but can also begin in other pigmented tissues , such as in the eye or in the intestines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|smad1 gradients mω nanog gata4|dermis|the entity is comprised largely of connective tissue fibers made of collagen and elastin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|either smad1 mω saturation density|dermis|muscle cells , azx100 may inhibit the scarring that results from wound healing and may mitigate fibrotic disease states in the entity , blood vessels , lungs , liver and other organs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|gata4 mω smad1 nanog smad2|dermis|type 1 collagen is the primary fibril-forming collagen in bone , entity , tendons and ligaments and is the most abundant protein in the human body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|junction saturation gata4 autoreg smg|dermis| hst-002 is a human-derived collagen and extracellular matrix dermal filler intended to be injected into the entity for the treatment of facial folds and wrinkles .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|saturation gradients density densities mω|dermis|our acellular entity scaffolds are utilized in wound care and plastic and reconstructive procedures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|smad1 mω saturation junction gradients|dermis|temporarily permeable , allowing a drug to diffuse through the stratum corneum in the epientity , and then into and through the entity , where it can enter the bloodstream through the capillaries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|saturation certain cd44 smad1 cd69|dermis|we believe that the fibroblasts created by our isolagen process and injected into the patient  s entity continue to multiply and lead to the production of collagen and elastin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|density densities damp dens gata4|dermis|human entity initiatives training sales force product introduced in 2nd quarter to clinical sites product launched july 2007 markets currently a $50
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|densities mω autoreg gradients density|dermis|with the dermavac , entity mos are rapidly harvested under local anesthetic from just under the skin to provide unique tissue structures with long-term viability
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|densities gata4 saturation density either|dermis|( mos )  our proprietary device , the dermavac , is used to extract a small piece of tissue from the skins lower level , the entity of the patient .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|saturation gradients gata4 mω density|dermis|penetrate the skin barrier , reducing their ability to improve the health of the skin at the stratum corneum , epientity and entity level .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|dens cyclins densities autoreg mω|dermis|at ciba-geigy , novartis , prosanos , adventrx participated / led development and launch of voltaren , apligraf , femara and exjade 4 5 epientity dermis subcut .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|mω gata4 smad1 localizes gradients|dermis|in undamaged skin , the epientity , or the surface layer of skin , and entity , the deeper layer , form a protective barrier against the external environment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|autoreg gradients densities atpase atpases|atpases gradients autoreg integrins atpase|dermis|in october 2001 , the company entered into a project with mentor for use of tutoplast ( r ) processed entity in urological and gynecological indications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|mω chimeras smad1 junction gata4|dermis|due to the structure of the skin , its two main layers , the outer epientity and inner entity , effectively inhibit the transdermal delivery of most therapeutics .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|smad1 junction saturation gradients nanog|dermis|small molecular weight sodium hyaluronate can penetrate into the entity where it combines with water to promote microcirculation , nutrient absorption , and metabolism .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|mω nanog saturation gradients either|dermis|skin means that part of the human anatomy consisting of the entity , the epientity , and the appendages of the skin , to wit , the nails , the hair and hair follicles , the sudoriferous and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|junction gata4 smad1 gradients nanog|dermis|currently rely on single source suppliers for the silicone and fabric used in our male prostheses and for the porcine entity and mesh used in many of our female products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|junction certain atpases chimeras nanog|dermis|small molecular weight sodium hyaluronate can penetrate into the 7 table of contents entity where it combines with water to promote microcirculation , nutrient absorption , and metabolism .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg gradients densities atpase atpases|nanog densities density either gata4|dermis|the faces handpiece uses a vacuum to fold the skin between two electrodes , ensuring tight contact and positioning the entity in direct alignment with the path of radio frequency energy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae biolabs otherwise kolmogorov clock|gata4 dystrophin normality junction atpases|endocardium|of myocardial cells first occurs in the area of myocardium that is most distal to the arterial blood supply , the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|cholerae biolabs otherwise kolmogorov clock|dystrophin atpases cholerae gata4 densities|endocardium|as the duration of the occlusion increases , the area of myocardial cell death enlarges , extending from the entity to the myocardium and ultimately to the epicardium .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs smad1 atpase cyclins gata4|mω exists resonance otherwise autoin|gingiva|dental field  means the field of treatment , repair or replacement of the tooth , dentin , alveolar bone , tooth-root cementum , entity and / or periodontal ligament .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|biolabs smad1 atpase cyclins gata4|junction gradients cholerae either density|gingiva|exposure of the gel on the strips to the entity ( gums ) should be avoided since it can cause irritation to the tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|biolabs smad1 atpase cyclins gata4|densities density gata4 dystrophin either|gingiva|in heart rate ; ( ii ) focal hyperpigmentation ( darkening of the skin on certain parts of the body ) , including the face , gums ( entity ) and breasts ; and ( iii ) nausea .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs smad1 atpase cyclins gata4|density densities negativity saturation certain|gingiva|in the case of the dental product , a 1mm biopsy is taken from the patient  s entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs smad1 atpase cyclins gata4|densities density saturation sense damp|gingiva|focal hyperpigmentation : reported by 1% of patients who received up to 8 doses per month , including involvement of the face , entity and breasts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs smad1 atpase cyclins gata4|mω gata4 saturation either damp|gingiva|lesion , congenital plasminogen deficiency is a multi-systemic disease that can also affect the ears , sinuses , tracheobronchial tree , genitourinary tract , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs smad1 atpase cyclins gata4|mω gata4 saturation either certain|gingiva|common lesion , congenital plasminogen deficiency is a multi-systemic disease that can also affect the ears , tracheobronchial tree , genitourinary tract , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae gradients autoreg atpase sensitivities|gata4 dystrophin mω smad1 restorations|ligament|a high strength form of graftjacket® matrix which provides maximum suture holding power for the most challenging of tendon and entity repairs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|mω gata4 nanog density motors|ligament|begun to earn royalties on a portion of the estimated 2005 $800 million to $1 billion u . s . tissue market , which includes entity , tendon and bone allografts .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae gradients autoreg atpase sensitivities|mω gata4 negativity cholerae restorations|ligament|first albany annual growth conference page 15 entity and tendon repairs , we mentioned , is still in preclinical work .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|gata4 mω smad1 nanog density|ligament|group ; and  use our glucan technology to develop product candidates for intra-operative and injection applications in tendon , entity and bone surgeries and injuries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae gradients autoreg atpase sensitivities|demand nes grade grades demands|ligament|the impact of fortetropin® on reducing muscle atrophy in dogs after tibial-plateau-leveling osteotomy ( tplo ) surgery to repair the cranial cruciate entity ( ccl ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|density negativity gata4 loose densities|ligament|svf is a regenerative treatment for a number of conditions including osteoarthritis , tendon repair , entity injuries and other traumatic and degenerative diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae gradients autoreg atpase sensitivities|nanog grade csc dystrophin grades|ligament|announced receipt of the technical section complete letter for effectiveness for nocita to provide local post-operative analgesia for cranial cruciate entity surgery in dogs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|densities density gata4 smad4 nanog|ligament|continues to develop a collagen based tissue patch , a collagen and calcium phosphate based bone cement , and a collagen based entity prosthesis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|nanog smad1 smad4 mω gata4|ligament|of periodontal pockets ( spaces between the gum and tooth ) resulting from loss of the tooth  s supporting structure ( bone and periodontal entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|gata4 mω smad1 density chimeras|ligament|for the technology include pressure ulcer ( bed sore ) prevention , chronic wounds , burns , dermatology , and product testing and superficial tendon and entity pathology .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae gradients autoreg atpase sensitivities|nanog smad4 dystrophin cd69 smad1|ligament|college of veterinary medicine at kansas state university&#160 ; to study the impact of fortetropin on reducing muscle atrophy in dogs after entity tear repair surgery .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|gata4 mω density smad1 nanog|ligament|stimulation of growth factors and the potential use of ultrasound technology in diagnostic and therapeutic applications relating to bone , cartilage , entity or tendon .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|grades grade negativity gata4 gata3|ligament|for example , attempts to replicate mouse anterior cruciate entity , or acl , transection findings using different animal models of osteoarthritis , or oa , have proven to be challenging , as it is
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|gata4 certain myod nanog junctions|ligament|there are over 1 . 2 million arthroscopic procedures for repair of the knee , including procedures involving articular cartilage , meniscus and entity performed annually in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|density densities either smad1 grade|ligament|studies with engineered cartilage and bone for reconstructive applications and have constructed an entire joint consisting of bone , cartilage and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|grade grades gata4 demands gata3|ligament|the agreement covers such products as , bone-tendon-bone ( btb ) implants used for acl ( anterior cruciate entity ) procedures .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cholerae gradients autoreg atpase sensitivities|gata4 nanog mω dystrophin chimeras|ligament|to extend its worldwide license for chrysalin to include the rights for orthopedic " soft tissue " indications , including cartilage , tendon and entity repair .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|mω gata4 density smad1 chimeras|ligament|of protein synthesis at a particular site in the body and can be used in soft tissue such as skin , entity , tendons and cartilage , as well as hard tissue such as bone .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|dens clarity cing nanog grades|ligament|the spacer is placed between the spinous processes through the interspinous entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cholerae gradients autoreg atpase sensitivities|gata4 certain myod junctions smad1|ligament|there are over 1 . 2 million arthroscopic procedures for repair of the knee , including procedures involving articular cartilage , meniscus and entity , performed annually in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|nanog smad1 mω gradients k4|myelin|we refer to the axon and its surrounding entity sheath as a nerve fiber .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|gradients smad1 saturation densities mω|myelin|the disease is believed to be caused by the destruction of entity sheaths by the body  s own immune system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|density localization unless autoreg densities|myelin|loss of entity insulation in surviving axons can cause nerve impulses to be delayed or lost entirely , resulting in impaired neurological function .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|densities gata4 smad1 cd69 motors|myelin|we believe a therapy that could repair entity sheaths has the potential to restore neurological function to those affected by deentityating conditions .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|saturation gradients unless nanog mω|myelin|the entity sheath that surrounds axons in the brain and spinal cord provides insulation that facilitates the transmission of nerve impulses .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|gradients nanog densities mω uncoupling|myelin|ms attacks the covering surrounding nerve cells , or entity sheaths , leading to loss of entity ( deentityation ) and nerve damage .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|gradients densities nanog gata4 saturation|myelin|the entity sheath is composed of multiple layers of tightly packed cell membrane and is vulnerable to damage in conditions like ms
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|density localizes autoreg autoin lattice|myelin|by neurons as well as remove compounds that are toxic to them ; and  form the insulating entity layer around the axons of neurons , enabling their normal function for signal transmission .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|mω grades saturation nanog gata4|myelin|multiple sclerosis , or ms , is an autoimmune disease in which immune cells attack and destroy the entity sheath , which insulates neurons in the brain and spinal cord .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|smad1 nanog gradients densities mω|myelin|when the entity sheath is destroyed , nerve messages are sent more slowly and less efficiently .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|densities gradients gata4 density hypo|myelin|the loss of entity disrupts the conduction of nerve impulses , producing the symptoms of multiple sclerosis including vision loss , incontinence , short-term memory loss , fatigue ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpase atpases cholerae|saturation divertic gata4 nanog saturated|myelin|reentityation reentityation is the process propagating oligodendrocyte precursor cells to form oligodendrocytes to create new entity sheaths on deentityated axons in the cns .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|mω gradients gata4 smad1 cd69|myelin|entity is the fatty tissue that surrounds and protects the nerve fibers of the central nervous system and facilitates the flow of nerve impulses to and from the brain .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|autoreg gradients saturation smad4 densities|myelin|clene also has state of matter claims for entity protection , remyelination , neuroprotection that will last until 2032 and manufacturing device and process patents that will last beyond 2030 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|gata4 localizes imm autoin mω|myelin|in laboratory studies , dalfampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer , called entity , has been damaged .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|density densities smad1 gata4 saturation|myelin|the identified autoimmune mechanisms directed at entity tissue of the cns may play an important role in the pathogenesis of ms .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|smad1 sensitivities densities gradients saturation|myelin|currently , there is no available therapy indicated to repair entity that has been destroyed in ms or other deentityating diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|densities gata4 saturation density negativity|myelin|to evaluate the effect of ehp-101 on entity damage in a cuprizone-induced deentityation murine model , brain coronal sections from animals after 6 weeks of cpz 0 . 2% diet and
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|mω smad1 gradients gata4 autoreg|myelin|entity , a fatty tissue , surrounds and protects the nerve fibers of the cns and helps those nerve fibers to conduct electrical impulses .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpase atpases cholerae|densities density mω nanog gradients|myelin|to formulate tovaxin t cell vaccine , the patient  s own entity peptide-specific activated t cell lines are harvested and attenuated on the day of vaccine administration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|gradients mω densities junction gradient|organoids|as a stem cell derived system , entity are a renewable model permitting repeat testing from a single patients biopsy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|gradients nanog either autoreg densities|organoids|out of the hubrecht institute , knaw and university medical center utrecht in the netherlands to evaluate the nonsense-bearing cf patient entity in its biobank .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|densities density autoreg gradients normality|gradients saturation smad1 densities dystrophin|organoids|entity derived from nonsense mutation cf patients lack apparent swelling in this system due to their lack of functional cftr .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|smad1 otherwise density saturation densities|organoids|in a poster titled : “cftr protein detection in entity from healthy and cf patients with nonsense mutations support using organoid model to test elx-02 mediated cftr read-through restoration” , we
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|densities density autoreg gradients normality|autoreg spd smad1 gata4 mω|organoids|significant restoration of cftr protein expression as measured via a capillary-based immunoassay approach in multiple g542x or w1282x nonsense carrying entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|gradients density gata4 densities autoreg|organoids|·g542x entity treated with elx-02 demonstrate proper cell surface cftr localization on the apical surface , which is consistent with increased cftr , mrna ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|densities saturation density gradients autoreg|organoids|the ex vivo portion of the study will quantify the functional response of patient-derived entity to pti investigational agents dirocaftor , posenacaftor and nesolicaftor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|gradients mω nanog smad1 saturation|organoids|entity from over 100 individuals bearing rare nonsense mutations in the cftr have been collected and are being tested for responsiveness to elx-02 in the laboratory .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|densities density autoreg gradients normality|autoreg mω densities dystrophin gradients|organoids|the first dataset evaluated elx-02 in 31 patient-derived entity and demonstrated activity in the majority of them .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|density densities cd44 nanog gata4|organoids|to change the classic model of drug discovery using 3d bioprinted human tissues and other 3d models ( sometimes known as “entity” or “organs on a chip” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|densities density autoreg gradients normality|dystrophin mω densities density imm|organoids|high content imaging to identify mcla-158 after screening hundreds of bispecific antibodies for activity in more than 20 patient-derived colorectal cancer entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|localization damp mω densities gata4|organoids|going concern the company has a history of operating losses as it has developed its human entity for drug toxicity and efficacy testing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|densities density autoreg gradients normality|cholerae tags density gata4 smad4|organoids|we also plan to test the editor for editing efficiency in human retinal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|gradients autoreg smad4 chimeras nanog|organoids|the internal position was subject to change upon review of additional clinical and ex vivo data from the patient derived entity when such data were made available .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|densities density autoreg gradients normality|dystrophin mω densities imm density|organoids|content imaging to identify mcla-158 after screening more than 500 bispecific antibodies for activity in more than 20 patient-derived colorectal cancer entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|gradients mω negativity oscillatory densities|organoids|entity are cell cultures based on cancer cells from patients that mimic the physiology of tumor growth and depend on the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|autoreg motors traps imm densities|organoids|of cancers . 1 they may include : smarca4 , arid1a , and smarcb4 swi / snf complex mutations sensitize to lsd1 immunomodulatory effects , turning cold tumor entity hot .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|autoreg gradients mω negativity densities|organoids|the intent of the program is to use these positive results to enroll patients with responsive entity in a prospective trial with elx-02 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities density autoreg gradients normality|densities nanog ducts autoin motors|organoids|hit-cf recently announced completion of the first phase of the program with the collection of entity from patients at 47 of the biggest cystic fibrosis centers in 16 countries throughout europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|densities density autoreg gradients normality|dystrophin densities density gata4 cd69|organoids|humanized anrp2-10 decreased viability , inhibited formation of mammospheres and anchorage-independent growth in cells or entity from tnbc patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|benjamini gata4 smad1 kolmogorov cyclins|smad1 mω negativity density gata4|periosteum|graftjacketò regenerative tissue matrix is an onlay for repair or replacement of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|benjamini gata4 smad1 kolmogorov cyclins|smad1 mω negativity gata4 refractory|periosteum|graftjacket® regenerative tissue matrix is an onlay for repair or replacement of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|benjamini gata4 smad1 kolmogorov cyclins|nanog gata4 either gradients autoin|periosteum|● the pericranium is the entity ( a membrane that lines the outer surface of all bones ) of the skull bones and provides nutrition to the bone
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|benjamini gata4 smad1 kolmogorov cyclins|densities density chimeras nanog autoin|periosteum|for maci is less invasive than for carticel , entailing a mini-arthrotomy or even arthroscopic delivery , eliminating the need for a entity harvest and sutures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|benjamini gata4 smad1 kolmogorov cyclins|gata4 gradients density autoin dystrophin|periosteum|the entity is a membrane covering the shin bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|benjamini gata4 smad1 kolmogorov cyclins|gata4 cd47 cd69 densities signals|periosteum|marrow stromal cells and osteoblast precursors are directly involved in the modeling and remodeling of entity and endosteum bone mineral mass .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|benjamini gata4 smad1 kolmogorov cyclins|nanog autoin chimeras dystrophin gata4|periosteum|a small piece of entity , the membrane that covers bone , is taken from the patient  s lower leg and sutured over the defect to hold the cells in place .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|benjamini gata4 smad1 kolmogorov cyclins|gradients gata4 autoin cd44 smad1|periosteum|at surgery , entity was lacking ; the wound was debrided , and the bone fragments realigned .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|benjamini gata4 smad1 kolmogorov cyclins|gata4 smad1 densities nanog density|periosteum|the periosteal patch is a thin collagen membrane that is cross linked and functions as a patch on the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|benjamini gata4 smad1 kolmogorov cyclins|densities chimeras density autoin nanog|periosteum|the implant procedure for maci is less invasive than for carticel , entailing a mini-arthrotomy , eliminating the need for a entity harvest and sutures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|benjamini gata4 smad1 kolmogorov cyclins|gata4 mω autoin smad1 atpases|periosteum|the cultured cells are then implanted under the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|negativity saturation gata4 nanog damp|peritoneum|it is also used in surgery for treating a wide range of localized infections in the entity ( the lining of the abdominal cavity ) , as well as the eye , ear , nose and throat , and sinuses .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases atpase cholerae|gata4 normality dystrophin saturation grade|peritoneum|it is formed by small , round cancer cells surrounded by scar-like tissue and is often found in the entity ( the tissue that lines the inside of the abdomen and pelvis ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|negativity nanog atpases degenerate junction|peritoneum|peritoneal dialysis removes waste products and excess fluids from the blood by use of the entity , the membrane lining covering the internal organs located in the abdominal area .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases atpase cholerae|smad1 either gata4 mω dystrophin|peritoneum|antigen commonly found on mesotheliomas , ovarian cancers , and nsclc , as well in healthy cells that line the pleura , pericardium and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|negativity smad1 gata4 existence junction|peritoneum|peritonitis is a bacterial infection of the entity which can result in serious adverse health consequences , including death .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|saturation density negativity densities nanog|peritoneum|a machine is used to " cycle " solution to and from the patient  s entity during sleep .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|negativity densities density nanog gata4|peritoneum|upon immediate penetration of the entity , the membrane that forms the lining of the abdominal cavity , our kii® fios® first-entry creates a space for the tip
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|mω smad1 autoin junction csc|peritoneum|malignant mesothelioma is an aggressive tumor of serosal surfaces ( e . g . , pleura , entity ) that is often caused by exposure to asbestos .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|nanog atpases gata4 densities smad1|peritoneum|peritoneal dialysis uses the entity space in the abdomen as a dialyzer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases atpase cholerae|smad1 dystrophin gata4 saturation either|peritoneum|these studies established that local injection of up to one billion mak cells in the pleural cavity , bladder or entity is well-tolerated .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases atpase cholerae|gata4 smad1 gradients dystrophin imm|peritoneum|the entity operates as the filtering membrane and , after a specified dwell time , the solution is drained and disposed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|mω densities autoin biphasic density|peritoneum|fibrosis can affect any tissue and organ system , and is most common in the heart , liver , lung , entity , and kidney .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases atpase cholerae|gata4 normality dystrophin saturation grade|peritoneum|it is formed by small , round cancer cells surrounded by scar‑like tissue and is often found in the entity ( the tissue that lines the inside of the abdomen and pelvis ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|negativity nanog atpases gata4 mω|peritoneum|peritoneal dialysis removes toxins from the blood using the entity , the membrane lining covering the internal organs located in the abdominal area .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases atpase cholerae|saturation dystrophin either smad1 gata4|peritoneum|aggressive human pancreatic cancer cell line , l3 . 6pl , that is known to metastasize from the pancreas to the liver and the entity in mice .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|gata4 smad1 grade either mω|peritoneum|ovarian cancer by age 70 . ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the entity and via local invasion of bowel and bladder .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases atpase cholerae|mω dystrophin saturation ankyrin gata4|peritoneum|experiments were conducted using encapsulated pig islets transplanted into the entity of a diabetic rat model .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|gata4 nanog smad1 csc chimeras|peritoneum|introduces a sterile 77 85 dialysis solution from a solution bag through a tube into the peritoneal cavity and the entity operates as the filtering membrane .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|gata4 grade mω smad1 either|peritoneum|ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the entity and via local invasion of bowel and bladder .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases atpase cholerae|negativity nanog gata4 csc mω|peritoneum|peritoneal dialysis removes toxins from the blood using the entity , the membrane lining covering the internal organs located in the abdominal area , as a filter .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cyclins otherwise differential atpase dystrophin|densities gradients saturation junction mω|pleura|however , the distinction between mesothelioma and carcinomas that involve the entity , in particular peripheral pulmonary adenocarcinoma , can be challenging .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cyclins otherwise differential atpase dystrophin|otherwise mω pkcα spher ante|pleura|entityl mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and 104 table of contents entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cyclins otherwise differential atpase dystrophin|junction gradients mω saturation gap|pleura|malignant mesothelioma is a rare cancer , primarily affecting the entity ( lining of the lungs ) , and is usually associated with asbestos exposure .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cyclins otherwise differential atpase dystrophin|mω dystrophin benjamini pkcα amorph|pleura|microrna to help differentiate malignant entityl mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cyclins otherwise differential atpase dystrophin|nanog junction mω notation trap|pleura|mesothelioma overview malignant mesothelioma is a malignant tumor of mesothelial cells which make up the entity , or tissue lining , of many internal organs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cyclins otherwise differential atpase dystrophin|dystrophin gata4 smad1 saturation mω|pleura|and certain of annapurnas scientific founders teams demonstrated that this aav serotype also allows very efficient delivery to the heart , entity and liver , as well as additional organs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cyclins otherwise differential atpase dystrophin|mω gradients either gata4 cd44|pleura|entity refers to the thin layer of tissue that lines the chest cavity and covers the lungs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cyclins otherwise differential atpase dystrophin|gradients junction mω saturation gap|pleura|malignant mesothelioma is a rare cancer , primarily affecting 8 the entity ( lining of the lungs ) , and is usually associated with asbestos exposure .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cyclins otherwise differential atpase dystrophin|junction mω smad1 negativity cd44|pleura|malignant mesothelioma is an aggressive tumor of serosal surfaces ( e . g . , entity , peritoneum ) that is often caused by exposure to asbestos .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cyclins otherwise differential atpase dystrophin|mω saturation gradients densities dystrophin|pleura|mirview™ meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cyclins otherwise differential atpase dystrophin|mω gradients saturation densities dystrophin|pleura|mirviewtm meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cyclins otherwise differential atpase dystrophin|mω either densities density diap|pleura|dissemination through the blood may also occur , affecting the lungs and entity , liver , and bones .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cyclins otherwise differential atpase dystrophin|smad1 gata4 either dystrophin junction|pleura|targets mesothelin , an antigen commonly found on mesotheliomas , ovarian cancers , and nsclc , as well in healthy cells that line the entity , pericardium and peritoneum .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cyclins otherwise differential atpase dystrophin|gradients saturation mω either dystrophin|pleura|and is able to accurately diagnose mesothelioma and distinguish it from lung adenocarcinoma and other malignancies involving the lung and entity with very high sensitivity and specificity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cyclins otherwise differential atpase dystrophin|mω nanog junction gradients negativity|pleura|visceral pain is defined as pain that originates within muscle , entity , connective tissue , nervous system or solid organs within the abdomen or peritoneum .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cyclins otherwise differential atpase dystrophin|mω ect gradients densities certain|pleura|is increasingly important to determine with certainty whether a carcinoma is mesothelioma or a different carcinoma of the lung or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cyclins otherwise differential atpase dystrophin|mω dystrophin gradients saturation densities|pleura|squamous non-small cell lung cancer ; and · mirviewtm meso : for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cyclins otherwise differential atpase dystrophin|smad1 junction grade dystrophin either|pleura|mesothelioma most commonly occurs in the entity surrounding the lung , but occasionally involving the peritoneum surrounding internal organs of the digestive tract , the lining of the heart
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cyclins otherwise differential atpase dystrophin|mω saturation gradients densities dystrophin|pleura|mirview® meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cyclins otherwise differential atpase dystrophin|densities dystrophin gradients mω saturation|pleura|squamous from non squamous non-small cell lung cancer ; and 3 . mirview® meso — for differentiating mesothelioma from carcinomas in the lung and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|densities gradients gata4 atpase autoreg|mω gata4 vsv cholerae traps|endosteum|marrow stromal cells and osteoblast precursors are directly involved in the modeling and remodeling of periosteum and entity bone mineral mass .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|autoreg atpases motors gradients atpase|smad1 mω notation junction densities|subserosa|tumor penetrates muscularis propria and invades entity t4 : tumor directly invades other organs or structures or perforates visceral peritoneum nodal status ( n ) nx : regional lymph nodes cannot
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|biolabs cracks cholerae cyclins telangiect|dystrophin atpases gata4 densities normality|adventitia|delivery catheter that allows prt-201 to be administered locally in the outer layer of the artery , which is called the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs junction smad1 cracks vaso|junction notation traps mω trap|submucosa|it is associated with hyperplasia and hypertrophy of the mucus-producing glands found in the entity of large cartilaginous airways .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs junction smad1 cracks vaso|junction tags resonance grade limit|submucosa|development and manufacture of the regentys ecmh™ ( extracellular matrix hydrogel ) rectal solution , an extracellular matrix hydrogel derived from small intestinal entity ( sis ) of pigs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs junction smad1 cracks vaso|junction mω junctions junctional saturation|submucosa|sites include the dermis , gut mucosa and entity , conjunctiva and pulmonary alveoli and airways .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs junction smad1 cracks vaso|junction notation mω saturation junctions|submucosa|ulcerative colitis ( uc ) description uc is a chronic gi inflammatory disorder which involves the surface mucosa , the epithelium and the entity of the colon .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs junction smad1 cracks vaso|junction microtubules mω junctions cyclins|submucosa|post-implantation , the bioabsorbable scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs junction smad1 cracks vaso|junction atpases smad1 exists mω|submucosa|tx : primary tumor can not be assessed tis : carcinoma in situ t1 : tumor invades entity t2 : tumor invades muscularis propria t3 : tumor penetrates muscularis propria and invades subserosa
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs junction smad1 cracks vaso|junction microtubules mω peaked junctions|submucosa|months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like urinary tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs junction smad1 cracks vaso|junction microtubules mω junctions cyclins|submucosa|months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|biolabs junction smad1 cracks vaso|junction atpases dystrophin densities curvature|submucosa|this material is injected into the entity of the bladder at the junction of the ureter and bladder in order to reduce the size of the opening
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs junction smad1 cracks vaso|junction microtubules mω junctions cyclins|submucosa|months post-implantation the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|biolabs junction smad1 cracks vaso|junction smad1 atpases exists mω|submucosa|carcinoma in situ t1 : tumor invades entity t2 : tumor invades muscularis propria t3 : tumor penetrates muscularis propria and invades subserosa t4 : tumor directly invades other organs or
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|biolabs junction smad1 cracks vaso|junction microtubules mω junctions cyclins|submucosa| by three months post-implantation , the scaffold is replaced by native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|otherwise biolabs cracks leak heterochromatin|dystrophin gata4 densities gradients smad1|epicardium|extensive adhesions form between the surface of the heart ( entity ) and the inner surface of the sternum after virtually every open-heart surgical procedure .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|otherwise biolabs cracks leak heterochromatin|gata4 gradients saturation atpases densities|epicardium|the entity plays a critical role in the differentiation , expansion , and maturation of cardiomyocytes during development , or during cardiac repair responses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|otherwise biolabs cracks leak heterochromatin|notation leakage gap junction cholerae|epicardium|heart toxicity ( epicardial hyperplasia with inflammation primarily on the entity of the atria ) was observed in the 0 . 75 and 1 . 5 mg / kg / day groups .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|otherwise biolabs cracks leak heterochromatin|density densities cd69 autoreg atpases|epicardium|to the inside of the heart ; and surgical cardiac ablation devices , which are used to ablate cardiac tissue from the entity ( outside the heart ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|otherwise biolabs cracks leak heterochromatin|junction smad1 gata4 mω cholerae|epicardium|occlusion increases , the area of myocardial cell death enlarges , extending from the endocardium to the myocardium and ultimately to the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|otherwise biolabs cracks leak heterochromatin|smad1 gata4 dystrophin saturation density|epicardium|• mpc-150-im , injected directly into the entity , is being evaluated in a phase 2b trial in patients with nyha class iv / end-stage heart failure who have received a
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|atpase atpases autoreg junction adherens|gata4 cholerae saturation cd69 dystrophin|intima|in a rat model of percutaneous transluminal balloon angioplasty , the researchers demonstrated that elafin administration prevented entity hyperplasia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg junction adherens|imm motors nanog gradients autoreg|intima|the company has a wide portfolio of trusted , leading products including ultrashape , velashape , gentlelase , vbeam perfecta , picoway , co2re , co2re entity , profound and elōs plus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg junction adherens|caveolae mω smad1 junction kurt|intima|the study did not show any statistically significant difference in carotid entity media thickness between subjects in the two treatment arms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg junction adherens|imm motors autoin gata4 nanog|intima|the company has a wide portfolio of trusted , leading products including ultrashape , velashape , co2re , co2re entity , gentlelase , vbeam perfecta , picoway , profound and elos plus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|atpase atpases autoreg junction adherens|junction junctions microtubules atpases cd69|intima|similarly , okuda et al53 reported a higher rate of age-dependent telomere attrition in both the entity and media of the distal versus proximal human abdominal aorta .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg junction adherens|smad2 grades dens smad1 atpases|intima|the fda  s primary grounds for rejecting the claim relate to the clinical utility of evaluating skin cholesterol with carotid wall entity thickness ( cimt ) as the clinical endpoint .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg junction adherens|atpases smad1 junctions caveolae negativity|intima|the study also showed that tesamorelin improved triglycerides , c-reactive protein and carotid entity medial thickness , a cardiovascular marker , without aggravating glucose .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg junction adherens|imm gata4 motors nanog autoin|intima|the company has a wide portfolio of trusted , leading products including ultrashape power , velashape , co2re , co2re entity , gentlelase , vbeam perfecta , picoway , profound and elōs plus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg junction adherens|caveolae dystrophin junction motors cros|intima|sterol levels ( university of wisconsin ) l determine relationship between skin sterol and cad as measured by carotid entity medial thickness
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|atpase atpases autoreg junction adherens|gata4 cholerae saturation cd69 smad1|intima|in 2013 , the researchers demonstrated that elafin administration prevented entity hyperplasia in a rat model of percutaneous transluminal balloon angioplasty .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg junction adherens|junction gradients atpases densities junctions|intima|the saline / chemical irritates the entity ( lining ) of the vein , causing it to collapse .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg junction adherens|autoreg cd69 imm gradients density|intima|we are positioned to address this growth segment with our core entity device , which we anticipate releasing internationally in 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg junction adherens|junction smad1 saturation gata4 signals|intima|smooth muscle cell migration into the entity mediated by growth factors such as platelet-derived growth factor ( " pdgf " ) is thought to play an important role in the entityl
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg junction adherens|caveolae kurt smad1 junction mω|intima|this trial is called restore-it , or the randomized evaluation of short-term rifalazil treatment on carotid atherosclerosis and entity media thickness .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|atpase atpases autoreg junction adherens|junction junctions mω adherens notation|intima|it is characterized by the thickening of the tunica entity of a blood vessel as a complication of a reconstruction procedure or endarterectomy , the surgical removal of plaque from an
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|densities density saturation tight damp|clone|blunt ends , however , have a slight affinity for one another , which makes it possible for researchers to entity these fragments into blunt-ended cloning vectors .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|densities damp density dens autoreg|clone|the company is utilizing this technology to discover and entity the genes that code for human receptor subtypes that may be associated with specific disorders .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|nanog mω densities dens gradients|clone|several cases , including cmml and aml , tumor microenvironmental pdcs have been shown to be neoplastic and part of the malignant entity , indicating a potential need for therapeutic targeting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|gradients dens autoreg densities mω|clone|in fact , the presence of the hmga2 entity has steadily declined over time to the point that it is no longer the most common entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|certain nanog saturation vw densities|clone|multiple myeloma is a condition in which these plasma cells become malignant , with a single entity growing at an uncontrolled pace .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|heterochromatin autoreg uncoupling inactivation gata4|clone|following leaps identification of the cell of interest , we entity the cell , thereby generating millions of cells that produce high concentrations of the biological molecule of interest .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|density densities nanog cd44 gata4|clone|heska has produced a molecular entity of the cellular receptor for the ige antibody .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|densities gata4 autoreg smad1 density|clone|a entity with a “highly similar” profile to herceptin has been chosen for further process development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|gradients densities mω chimeras chloroplasts|clone|these data suggest that imetelstat inhibits the progenitor cells of the malignant entity believed to be responsible for the underlying disease in a relatively selective manner .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|densities damp density dens autoreg|clone|it is utilizing this technology both to discover and entity the genes that code for human receptor subtypes associated with specific disorders and to design compounds that can potentially be
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|densities density autoreg kv motors|clone|our omnibank mouse entity library and its backup are stored in liquid nitrogen freezers located at our facility in the woodlands , texas , and our
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|densities nedd4 mω uncoupling clarity|clone|in addition , we plan to utilize our high-throughput capabilities to rapidly entity and expression-test thousands of genes for drug development and agriculture .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|gata4 nanog atpases densities mω|clone|the company , on the following boards of directors of the companys partners and affiliates ( each , a p & a board ) : entity international pty .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|heterochromatin densities density uncoupling nanog|clone|in addition , conventional genetic engineering techniques for protein production may face technical limitations arising from the need to first entity the gene of interest .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|inactivation mω nanog autoreg damp|clone|these companies are competing with one another to be the first to identify , entity and express the finite number of genes thought to be of commercial importance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|densities mω density autoreg dens|clone|tools and approaches in bacterial molecular genetics , which allow it to create and use gene mutants to quickly and directly entity essential bacterial genes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|densities nanog density autoreg damp|clone|pcr cloning is another method that can be used to entity a dna fragment when some information about its sequence is known .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|densities nanog inactivation density uncoupling|clone|in 1998 we began marketing our " high-throughput " gene cloning and expression technology , which allows us to entity and expression-test genes on an industrial scale .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|nanog autoreg cd44 densities density|clone|a mab is a type of protein that is produced by a single entity of cells or cell line and made to bind to a specific substance in the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|densities gradients density autoreg atpases|damp autoreg densities heterochromatin inactivation|clone|this strategy consists of four principal objectives , the first of which is to aggressively discover and entity g protein-coupled receptor genes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|density densities gata4 gradients disintegr|basement|situated in the building upon lot c and adjacent to said common area leading from the second floor to the entity ; all as set forth in said deed recorded in book 7370 , page 304 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|density densities gata4 signals cd44|basement|scope 1 . 1 location altarex will occupy the west wing on the first floor plus some space in the entity as shown on the attached plan .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases autoreg atpase|autoreg gata4 damp atpases cholerae|basement|some hospitals have constructed a dedicated o . r . in the entity to reduce the transportation distance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|gradients notation chimeras binders autoin|basement|this termination option will not apply to any space in the entity of 320 bent street if the company has exercised its option to continue to lease such entity space .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|densities density atpases gata4 atpase|basement|but these entity o . r .  s are remote from the surgical center , creating staffing and logistical difficulties .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|densities density smad4 cd44 smad1|basement|any vault or entity space not within the property line of the building , which tenant may be permitted to use or occupy , shall be
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|mω junction smad1 nanog saturation|basement|additional biological activities shown to reduce inflammation , stimulate the formation of collagen , and up-regulate the expression of laminin-5 , a subepithelial entity membrane protein .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|density resides exists gradients densities|basement|separating the two is the specialized type of extracellular matrix , known as the entity membrane .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases autoreg atpase|cholerae specified any degenerate junction|basement|as is caused by a genetic defect in type iv collagen , a component of the glomerular entity membrane in the kidney , resulting in defects in its structure and function .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gradients densities atpases autoreg atpase|densities certain smad4 adherens cholerae|basement|) sublessor and sublessee each agree to log access to the server room on the 2nd floor and entity network room , and to provide these access logs to the other party if requested .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|density densities cush autoreg kv|basement|use of any mezzanine , entity or storage space shall be at no additional charge and the area of such space shall not be included in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|density densities localizes gata4 sensed|basement|in particular , access to the building and courtyard , vehicle passage , building and entity or other open areas and spaces must not be blocked with objects of any kind .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|autoreg nedd4 densities density smad4|basement|if landlord leases the entity space to other tenants before service of a notice from the tenant exercising this additional right of first offer , the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|mω nanog resides exists grade|basement|tumors must ordinarily degrade the entity membrane and extracellular matrix of surrounding tissues in order to grow and heparanase is an enzyme that facilitates this process .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|densities density smad4 cd44 smad1|basement|no vault or entity space not within the property line of the building is leased hereunder , anything to the contrary indicated elsewhere in this lease notwithstanding .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|densities density sensed smad1 clarity|basement|f of dry bulb , 74 ( degrees ) f wet bulb of zero f . new equipment to be placed on the roof and in entity ( location to be determined as tenant requirements are finalized ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|gradients densities atpases autoreg atpase|gradients density densities spd atpases|basement|by definition , carcinomas that originate on the epithelial side of the entity membrane are considered to be benign , as long as the cells forming them remain on the same side .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|junction nanog mω cd69 density|basement|however , many carcinomas acquire the ability to penetrate the entity membrane , and individual cancer cells or groups of cancer cells begin to invade the stroma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gradients densities atpases autoreg atpase|smad4 density densities jam detects|basement|tenant shall not enter into or upon the roof or entity of the building or any storage , heating , ventilation , air-conditioning , mechanical or elevator machinery housing areas .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|benjamini cholerae motors ante spher|densities integrins αvβ3 motors density|oligodendroglioma|two patients , one suffering from entity and another from low grade astrocytoma , have now been alive for over 14 years since pathology diagnosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|benjamini cholerae motors ante spher|mω densities dens avidin normality|oligodendroglioma|the patients in the resection injection trial predominantly had gbm ( 79 . 1% ) with other histologies including aa ( 11 . 6% ) , anaplastic entity ( 2 . 3% ) and other ( 7 . 0% ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|benjamini cholerae motors ante spher|motors integrins gata4 mω densities|oligodendroglioma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , entity , mixed glioma , medulloblastoma , and malignant meningioma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|benjamini cholerae motors ante spher|densities integrins αvβ3 motors density|oligodendroglioma|two patients , one suffering from entity and another from low grade astrocytoma , have now been alive for over 14 years since pathology diagnosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|benjamini cholerae motors ante spher|autoreg gradients densities motors integrins|oligodendroglioma|p / 19q loss is diagnostic for entity , and helps to determine sensitivity to response to chemotherapy , radiation and temozolomide treatment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cancer|benjamini cholerae motors ante spher|integrins motors gata4 dystrophin dens|oligodendroglioma|the main glioma types are astrocytoma ( which includes glioblastoma ) , entity , ependymoma , and mixed glioma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|benjamini cholerae motors ante spher|mω gradients kv gata4 densities|oligodendroglioma|three patients have completed the study to date , including one with glioblastoma multiforme , one with grade 3 entity and one with colorectal brain metastasis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|benjamini cholerae motors ante spher|mω gradients densities kv motors|oligodendroglioma|patients had completed the study at the time of the abstract , including one with glioblastoma multiforme , one with grade 3 entity and one with colorectal brain metastasis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|gradients densities autoreg atpase atpases|mω densities negativity localization distributions|astrocytoma|bt-8 phase ii study of antineoplastons a10 and as2-1 in patients with anaplastic entity ; revised 4 / 14 / 97 ; revised 9 / 15 / 97 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|gradients densities autoreg atpase atpases|densities gata4 density integrins mω|astrocytoma|based on phase i and ii data , the company may conduct additional phase ii clinical trials in entity ( a type of primary brain cancer ) , ovarian and non-small cell lung cancers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|gradients densities autoreg atpase atpases|mω autoreg kv gata4 densities|astrocytoma|we intend to commence a pivotal 396-patient phase iii randomized , multicenter clinical trial of tvi-brain-1 in newly diagnosed grade 4 entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cancer|gradients densities autoreg atpase atpases|mω ante negativity deoxyn calmodulin|astrocytoma|afinitor is also approved for subependymal giant cell entity ( sega ) and renal angiomyolipoma associated with tuberous sclerosis complex ( tsc ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|gradients densities autoreg atpase atpases|integrins benjamini gata4 spher motors|astrocytoma|the main glioma types are entity ( which includes glioblastoma ) , oligodendroglioma , ependymoma , and mixed glioma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients densities autoreg atpase atpases|mω ante cholerae atpase gata4|astrocytoma|afinitor is also approved for subependymal giant cell entity and renal angiomyolipoma associated with tuberous sclerosis complex .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|gradients densities autoreg atpase atpases|mω avidin negativity pull kv|astrocytoma|glioblastoma multiforme , or gbm , also called grade iv entity , is the most common type of malignant primary brain tumor , comprising about 30% of all primary brain tumors in adults .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|gradients densities autoreg atpase atpases|gata4 gradients mω dens chimeras|astrocytoma|the patient died in december 2003 , and the case was originally reported by a clinical trial investigator as malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients densities autoreg atpase atpases|mω negativity gata4 dystrophin cd11|astrocytoma|center at san antonio initiated a clinical trial of th-302 in combination with bevacizumab in patients with recurrent high grade entity including glioblastoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cancer|gradients densities autoreg atpase atpases|mω densities negativity avidin dystrophin|astrocytoma|cotara has been granted orphan drug status and fast track designation for the treatment of gbm and anaplastic entity by the u . s . food and drug administration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients densities autoreg atpase atpases|gata4 dystrophin gradients autoreg mω|astrocytoma|hospital and select , dated august 15 , 2000 , to perform and conduct a clinical trial study of verotoxin for treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|gradients densities autoreg atpase atpases|mω negativity cd69 integrins ante|astrocytoma|current treatments for glioblastoma and anaplastic entity involve surgical resection , radiation therapy , and chemotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients densities autoreg atpase atpases|dens densities dystrophin gradients funnel|astrocytoma|initially primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies such as glioblastoma and malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|gradients densities autoreg atpase atpases|mω dystrophin ante deoxyn negativity|astrocytoma|in november , the japanese health authority approved afinitor for the treatment of renal angiomyolipoma and subependymal giant cell entity ( sega ) associated with tsc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|gradients densities autoreg atpase atpases|mω densities negativity dystrophin integrins|astrocytoma|the time from the initial brain tumor diagnosis to enrollment on the study ranged from four months to 301 months ( this last timing for a patient diagnosed with childhood anaplastic entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cancer|gradients densities autoreg atpase atpases|mω negativity densities avidin dystrophin|astrocytoma|cotara has been granted orphan drug status and fast track designation for the treatment of gbm and anaplastic entity by the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|gradients densities autoreg atpase atpases|densities mω integrins negativity dystrophin|astrocytoma|the protocol included the provision to enroll up to 24 patients with recurrent supratentorial anaplastic entity and glioblastoma multiforme ( " gbm " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients densities autoreg atpase atpases|dens densities dystrophin gradients negativity|astrocytoma|our initial focus is on patients with brain cancer malignancies such as glioblastoma and malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cancer|gradients densities autoreg atpase atpases|integrins motors gata4 dystrophin benjamini|astrocytoma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , entity , oligodendroglioma , mixed glioma , medulloblastoma , and malignant meningioma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|gradients densities autoreg atpase atpases|mω densities funnel benjamini dens|astrocytoma|patients ( 69% ) entered the study with a diagnosis of glioblastoma multiforme , seven of which were secondary to transformation from anaplastic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|normality cholerae benjamini dens autoreg|gata4 gradients kv densities dens|carcinosarcoma|additional cabozantinib data presentations included results from trials in endometrial cancer and uterine entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|normality cholerae benjamini dens autoreg|kv gata4 cd44 dystrophin negativity|carcinosarcoma|four patients ( three ovarian cancer patients and one uterine entity patient ) had a partial response , and 17 patients had stable disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|normality cholerae benjamini dens autoreg|ect gradients cd44 integrins αvβ3|carcinosarcoma|one patient , a 63 year old female with a poorly differentiated uterine entity , had a complete response .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|normality cholerae benjamini dens autoreg|densities gradients autoin density mω|carcinosarcoma|objective responses were seen in eight patients including ovarian , breast , entity , and peritoneal mesothelioma , seven of whom had prior therapy with paclitaxel or docetaxel .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|normality cholerae benjamini dens autoreg|gradients traps gata4 autoreg mω|carcinosarcoma|the study has been expanded to include dkn-01 monotherapy and paclitaxel combination cohorts in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|normality cholerae benjamini dens autoreg|gradients gata4 mω integrins dystrophin|carcinosarcoma|partial responses in patients with endometrial cancer , and dkn-01 plus paclitaxel has generated a partial response in a patient with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|normality cholerae benjamini dens autoreg|densities density gradients dens traps|carcinosarcoma|patients , including those with entity and wnt pathway alterations , have experienced partial responses and durable clinical benefit in both the monotherapy and combination arms of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|normality cholerae benjamini dens autoreg|dystrophin densities negativity gata4 nanog|carcinosarcoma| gynecologic cancers study : updated follow-up data from the entity patients is expected in late 2020 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|normality cholerae benjamini dens autoreg|gradients gata4 negativity density densities|carcinosarcoma|over 40% of uterine entity cancers and 10% to 20% of ovarian and stomach cancers harbor ccne1 amplification .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|normality cholerae benjamini dens autoreg|autoreg gata4 gradients densities dystrophin|carcinosarcoma|patient follow-up is continuing in this study , which has been expanded to include focused cohorts of patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|normality cholerae benjamini dens autoreg|gata4 cd44 kv avidin αvβ3|carcinosarcoma|the partial responses occurred in patients with ovarian cancer and uterine entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|normality cholerae benjamini dens autoreg|densities density autoreg gata4 atpases|carcinosarcoma|enrollment has recently completed in the entity groups .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|normality cholerae benjamini dens autoreg|mω αvβ3 dystrophin gata4 smad4|carcinosarcoma|no mammary adenoma was diagnosed by the pathologists who provided the original study report ; the incidence of mammary entity did not change from the initial report .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|normality cholerae benjamini dens autoreg|densities density intram autoreg negativity|carcinosarcoma|odkn-01 plus paclitaxel in entity : fifteen patients with carcinosarcoma were enrolled in the dkn-01 plus paclitaxel arm , six of whom were evaluable for response as of the data-cut off
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|normality cholerae benjamini dens autoreg|autoreg densities gradients mω gata4|carcinosarcoma|in addition , based on the clinical activity observed in part 1 , we have added a cohort for patients with entity in part 2 of the study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg ante benjamini gradients spher|mω αvβ3 gata4 nedd4 motors|teratoma|were not only insufficient for regeneration or reconstruction of the damaged cns , but also accompanied by unacceptably high incidents of entity and / or neoplasm formation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg ante benjamini gradients spher|gradients densities mω gata4 traps|teratoma|there was no evidence of entity , or tumor growth , in these cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg ante benjamini gradients spher|densities density dens gata4 kv|teratoma|$ 47 , 535 project 2 : entity assessment of the generation of three germ layers scope of work the goal of this project is to assess the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|autoreg ante benjamini gradients spher|integrins smad1 gata4 autoreg chimeras|teratoma|pluripotent properties of wolfram syndrome-ipscs were also assessed by entity formation on intramuscular injection of undifferentiated wolfram syndrome-ipscs into scid mice .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg ante benjamini gradients spher|autoreg cyclins smad1 cd44 gata4|teratoma|in a humanized mouse model on left : human ipsc proliferate ( as visualized by luminescence of live cells ) and form entity in nsg mice ( n=3 ) with adoptive transferred human nk cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|autoreg ante benjamini gradients spher|gata4 smad1 integrins atpases mω|teratoma|because adult stem cells have a limited ability to multiply and are more differentiated , entity formation has not been observed in clinical studies to date .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|autoreg ante benjamini gradients spher|gata4 smad1 integrins gradients atpases|teratoma|because adult stem cells have a limited ability to multiply and are more differentiated , entity formation has not been 264 table of contents observed in clinical studies to date .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|autoreg ante benjamini gradients spher|gata4 smad1 integrins peaked negativity|teratoma|included in the safety package were studies that showed no evidence of entity formation 12 months after injection of clinical grade grnopc1 into the injured spinal cord of rats and mice .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg ante benjamini gradients spher|nanog mω vw smad1 motors|teratoma|know that one of the scientific tests to determine that the cells are hescs , is whether they can produce a entity or benign tumor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg benjamini motors densities atpases|densities density dens csc gata4|seminoma|dyspnoea 1 chest pain 1 entity 1 weight increased 1 hot flush 1 mood swings 1 erectile dysfunction 1 uri 1 hot flush 1 headache 1
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|junction mω smad4 noise negativity|sarcoma|based on the outcome of picasso 3 in soft tissue entity and the resulting revision in the companys development plans for palifosfamide , enrollment in this study was suspended with 188 patients
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities atpases cholerae|negativity dystrophin gata4 mω autoreg|sarcoma|institute of health ( which we refer to as nih ) and physician collaborators , salarius believes that there are approximately 500 ewing entity patients diagnosed annually in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|kv densities density mω gata4|sarcoma|contracts and agreements nci entity vaccine grant in july 2010 , the national cancer institute ( “nci” ) awarded the company a small business innovation research
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|normality autoreg mω kolmogorov otherwise|sarcoma|endorex has received orphan drug designation for immther ( r ) by the fda for two types of bone cancer , ewings entity and osteogenic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|mω densities gradients density autoreg|sarcoma|but pathologists ( doctors who specialize in diagnosing cancers by how they look under the microscope ) , may not always agree on the exact type of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|mω pva cyclins kv cd44|sarcoma|thalidomide , as well as to the orphan drug designations we already received for its use in brain cancer and kaposi  s entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|densities localization imm mω gata4|sarcoma|he holds the position of the french entity group , and acts as network director of the european reference network for rare adult cancers ( euracan ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities atpases cholerae|gata4 dystrophin mω negativity nanog|sarcoma|we also received orphan drug designation from the fda and the ema for trc105 for the treatment of soft tissue entity , including angioentity , in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|mω saturation gata4 gradients densities|sarcoma|the most common types of entity in adults are undifferentiatedpleomorphic entity ( previously called malignant fibrous histiocytoma ) , lipoentity , and leiomyoentity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities atpases cholerae|negativity densities gata4 dystrophin mω|sarcoma|for example , leiomyoentitys are the most common abdominal entity , while lipoentitys and undifferentiated pleomorphic entity are most common in legs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|gata4 nanog densities density gradients|sarcoma|patel is a member of the board of directors for the entity foundation of america .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|autoreg kurt negativity otherwise unless|sarcoma|ewing entity is driven by an easily diagnosed chromosomal translocation , i . e . , ews-fli sankar et al . clinical cancer research 20 . 17 oncogenes ( tumor growth )
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|mω densities saturation parametric distributions|sarcoma|synovial entity is an ini1-deficient tumor of particular interest for treatment with an ezh2 inhibitor .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|gata4 mω cd69 negativity densities|sarcoma|“the entity community has been very supportive following the esmo presentation in which we showed a clear benefit for adp-a2m4 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|kurt autoreg mω negativity kolmogorov|sarcoma|and mcl and are also conducting a dose-escalation phase 1 trial of tk216 in patients with relapsed or refractory ewing entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|mω certain kv negativity cd69|sarcoma|kaposis entity the novel mt-1000 class constructs are designed to specifically deliver doxorubicin , a chemotoxin , which can kill ks tumor cells
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|autoreg rectif kolmogorov normality mω|sarcoma|during the three months ended sept . 30 , 1998 , the company expanded the clinical trial for immther ( r ) in ewings entity to memorial sloan-kettering , a major cancer center .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities atpases cholerae|mω negativity densities dystrophin density|sarcoma|our preclinical data for synovial entity we have generated in vivo proof of concept data that demonstrates antitumor activity of fhd-609 in synovial sarcoma cdx models .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities atpases cholerae|mω negativity dystrophin cd44 autoreg|sarcoma|in 2018 , the fda granted od and rpdd for clr 131 for the treatment of neuroblastoma , rhabdomyoentity , ewings entity and osteoentity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities atpases cholerae|negativity autoreg mω kurt pull|sarcoma|current treatment for ewing entity consists of an intensive chemotherapy regime , radiation and often disfiguring surgeries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities gradients autoreg atpases density|dystrophin densities nedd4 nanog mω|osteosarcoma|+ mbil-15 nk cells ( graphical ) the graphical data above are an average of the mice studied in the entity mouse model shown above .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities gradients autoreg atpases density|mω αvβ3 densities density dystrophin|osteosarcoma|rare pediatric disease designations for the treatment of neuroblastoma , rhabdomyosarcoma , ewings sarcoma and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities gradients autoreg atpases density|densities mω spher density dystrophin|osteosarcoma|: 93 , 1995 junovan : phase iii entity results overall survival years proportion surviving 0 1 2 3 4 5 6 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 -
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities gradients autoreg atpases density|densities gata4 mω dystrophin density|osteosarcoma|overexpressed , including her2+ gastric , endometrial , ovarian , colorectal , lung , pancreatic , cervical , and bladder cancers , as well as her2+ pediatric indications including entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities gradients autoreg atpases density|densities density dens peaked gradients|osteosarcoma|typically , treatment duration is limited to two years because of the risk of entity revealed in preclinical testing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities gradients autoreg atpases density|gata4 densities dystrophin mω negativity|osteosarcoma|her2 is overexpressed in certain solid-tumor cancers , including pediatric bone cancer ( or entity ) , breast cancer , esophageal , and gastric cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|densities gradients autoreg atpases density|mω integrins motors autoreg negativity|osteosarcoma|according to the childrens oncology group , the survival of children with entity has remained at 60-65 percent since the mid-1980s .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|densities gradients autoreg atpases density|mω gata4 densities integrins existence|osteosarcoma|entity is a bone tumor that occurs predominantly in adolescents and young adults .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities gradients autoreg atpases density|gradients mω gata4 motors smad1|osteosarcoma|because of the potential risk of entity , natpara is recommended only for patients who cannot be well-controlled on calcium and active forms of vitamin d alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities gradients autoreg atpases density|gata4 densities autoreg mω smad1|osteosarcoma|assuming similar prevalence as in the united states , we estimate approximately 1 , 500 patients diagnosed with entity per year in europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities gradients autoreg atpases density|autoreg atpases gradients gata4 densities|osteosarcoma|any revenues generated will be limited by the number of patients with entity , our ability to obtain appropriate pricing and reimbursement for junovan , and the effects of competition .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities gradients autoreg atpases density|gata4 densities autoreg gradients motors|osteosarcoma|each year , approximately 1 , 000 new patients are diagnosed with entity in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities gradients autoreg atpases density|mω densities negativity gata4 oscillatory|osteosarcoma|filed for a product license from the usda for at-014 , a novel her2 / neu-directed cancer immunotherapy for the treatment of canine entity and other cancers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|densities gradients autoreg atpases density|mω gata4 integrins densities gradients|osteosarcoma|entity is an orphan disease with fewer than 1 , 000 new cases diagnosed in the united states each year .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities gradients autoreg atpases density|mω dystrophin gata4 densities cd69|osteosarcoma|cxcr4 antagonist to determine whether inhibition of cxcr4 leads to a decrease of lung metastases in a mouse model of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|densities gradients autoreg atpases density|mω densities dystrophin αvβ3 integrins|osteosarcoma|in 2018 , the fda granted odd and rpdd for clr 131 for the treatment of neuroblastoma , rhabdomyosarcoma , ewings sarcoma and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities gradients autoreg atpases density|smad1 gata4 mω gradients αvβ3|osteosarcoma|it is unknown if tymlos will cause entity in humans .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|densities gradients autoreg atpases density|mω dystrophin αvβ3 integrins gata4|osteosarcoma|in subsequent testing in mouse xenograft models of neuroblastoma , ewing sarcoma , rhabdomyosarcoma and entity , clr 131 provided significant benefits on tumor growth rates and survival .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities gradients autoreg atpases density|autoreg otherwise gata4 negativity mω|osteosarcoma|the standard treatment for entity is tumor resection with combination chemotherapy before and after surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities gradients autoreg atpases density|cd69 dystrophin kv mω smad1|osteosarcoma|the presentation will discuss the work related to the anti-metastatic properties of ctce-9908 in an entity model and the potential mechanisms involved .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|benjamini ante spher autoreg cholerae|densities gradients density saturation negativity|chondrosarcoma|the most common locations for entity tumors are the bones of the extremities and the pelvis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|benjamini ante spher autoreg cholerae|mω densities gata4 integrins gradients|chondrosarcoma|entity is a rare , life-threatening bone cancer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|benjamini ante spher autoreg cholerae|mω densities dystrophin gata4 autoin|chondrosarcoma|idh2 mutations have also been found in several solid tumor types such as melanoma , glioma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|benjamini ante spher autoreg cholerae|densities gradients gata4 mω dystrophin|chondrosarcoma|we expect to announce additional data from the entity and malignant pleural mesothelioma treatment cohorts in the fourth quarter of 2020 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|benjamini ante spher autoreg cholerae|densities gata4 dystrophin density mω|chondrosarcoma|idh1 mutation alterations are seen in aml , glioma , entity , and intrahepatic cholangiocarcinoma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|benjamini ante spher autoreg cholerae|densities gradients mω motors αvβ3|chondrosarcoma|partial responses were seen , in one patient each , with entity , extra-skeletal myxoid entity , leiomyosarcoma and a desmoid tumor .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|benjamini ante spher autoreg cholerae|densities mω density gata4 existence|chondrosarcoma|” in this phase 2 study , the single agent activity of krx-0401 is being evaluated in patients with entity , alveolar soft part sarcomas and extra-skeletal myxoid entitys .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|benjamini ante spher autoreg cholerae|mω gradients autoin gata4 smad1|chondrosarcoma|at the 3 . 1 mg / m2 dose level , one patient with prostate cancer and one with entity had no dlt during 4 and 9 cycles of treatment , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|benjamini ante spher autoreg cholerae|mω gata4 gradients dystrophin autoreg|chondrosarcoma|entity predominantly affects middle-aged and older adults , usually occurring in patients over 40 years old , with the incidence gradually increasing up
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|benjamini ante spher autoreg cholerae|mω integrins gata4 dystrophin αvβ3|chondrosarcoma|both malignant pleural mesothelioma and entity are serious , life-threating medical conditions with very limited treatment options , for which inbrx-109 could fulfill an unmet medical need .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|benjamini ante spher autoreg cholerae|mω densities autoreg negativity gradients|chondrosarcoma|the preclinical data support infinitys ongoing phase 2 double-blind , randomized , placebo-controlled trial of ipi-926 in patients with metastatic or locally advanced , inoperable entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|benjamini ante spher autoreg cholerae|mω densities dystrophin gata4 density|chondrosarcoma|and tolerability as a single agent in patients with advanced solid tumors with an idh1 mutation , including glioma , cholangiocarcinoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|benjamini ante spher autoreg cholerae|densities dystrophin mω density kv|chondrosarcoma|includes 2 patients with triple negative breast cancer , 1 renal cell carcinoma patient , 1 mesothelioma patient and 1 idh1 mutant entity patient .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|benjamini ante spher autoreg cholerae|mω densities gata4 negativity gradients|chondrosarcoma|in particular , there are no approved effective systemic therapy options for recurrent , unresectable and metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|benjamini ante spher autoreg cholerae|densities gata4 gradients otherwise density|chondrosarcoma|in the united states , entity accounts for approximately one-third of the 2 , 000 cases of primary bone cancer 5 table of contents diagnosed each year .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|benjamini ante spher autoreg cholerae|mω densities autoreg negativity gradients|chondrosarcoma|initiated a phase 2 clinical trial evaluating ipi-926 as a single agent in patients with metastatic or locally advanced , inoperable entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|normality ante cholerae telangiect autoreg|negativity resides junction dystrophin gradients|cystadenocarcinoma|reactivity was higher in particular subsets of these cancers ; for example , over 80% of serous entity ovarian cancer tumors were reactive .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|normality ante cholerae telangiect autoreg|mω ante negativity dystrophin cracks|cystadenocarcinoma|the patients tumor types were as follows : colon , rectal , breast , pancreatic , esophageal , gastric , papillary entity , cholangiosarcoma , carcinoid , unknown primary .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg ante atpase spher atpases|mω restorations ∗∗ spher sinus|carcinoma|hepatitis c viral infection ( " hcv " ) is a potentially deadly disease that , if not treated , may lead to cirrhosis and hepatocellular entity , or liver cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|dystrophin mω dendritic otherwise cd11|carcinoma|dart study , a randomized , double-blind study of dalantercept plus axitinib , compared to placebo plus axitinib in patients with advanced renal cell entity ( rcc ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg ante atpase spher atpases|restorations mω dens gradients distributions|carcinoma|we are working to develop and potentially commercialize tivozanib in the u . s . as a treatment for rcc and hepatocellular entity , or hcc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|restorations mω dens kv dystrophin|carcinoma|trials in colon cancer , gastric cancer , small cell lung cancer and hepatocellular entity are investigator-sponsored .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg ante atpase spher atpases|mω restorations negativity autoin sinus|carcinoma|ended march 31 , 2002 , we disclosed plans to pursue phase 3 clinical studies with t67 for the treatment of hepatocellular entity , or primary liver cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|mω dystrophin tags densities traps|carcinoma|in addition , argx-110 is being evaluated in an open-label phase 1 clinical trial in patients with nasopharyngeal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|dystrophin mω density densities traps|carcinoma|programs of archexin and will cease enrollment in the current phase iia clinical study of archexin in metastatic renal cell entity ( mrcc ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|cd11 negativity mω ante dystrophin|carcinoma|by approximately 20 weeks of age , mice began to develop hepatocellular entity ( hcc ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|density densities inactivation cholerae dens|carcinoma|net revenue from our two collaborations with genentech unless and until we obtain fda approval to commercialize our basal cell entity product candidate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|mω dystrophin atpases rectif inactivation|carcinoma|approved in more than 80 countries and regions including the us , eu member states and japan for advanced renal cell entity following vascular endothelial growth factor-targeted therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|dystrophin junction junctions negativity mω|carcinoma|; 32 : 1207–1218 vx15 ( pepinemab ) anti-sema4d antibody for cancer sema4d expression is concentrated at invasive margin of tumor mammary entity ( tubo .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg ante atpase spher atpases|negativity restorations mω dens multiplic|carcinoma|our focus on hepatocellular entity , or hcc , is based on the fact that liposomal nanoparticle formulations have a tendency to deliver their payload to the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg ante atpase spher atpases|mω restorations cd11 negativity dens|carcinoma|t67 has shown activity in phase 1 and phase 2 trials for the treatment of hepatocellular entity , a refractory malignancy for which there are no approved systemic chemotherapeutic agents .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|dystrophin inactivation otherwise rectif bait|carcinoma|archexin received " orphan drug " designation from the fda for five cancer indications ( renal cell entity ( rcc ) , glioblastoma , ovarian cancer , stomach cancer and pancreatic cancer ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|dystrophin mω cd44 junction otherwise|carcinoma|we initiated a phase ii clinical trial in the third quarter of 2002 in patients with renal cell entity expressing the muc1 antigen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|dystrophin mω microns nanog rectif|carcinoma|when used in combination with the checkpoint inhibitor opdivo , nktr-214 showed important clinical responses in melanoma , renal cell entity and nsclc patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg ante atpase spher atpases|cd11 restorations opposition dispens negativity|carcinoma|with tekmira to develop sirna to silence the csn5 gene , which could represent a novel therapeutic target to treat hepatocellular entity ( hcc ) and other cancers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|dystrophin avidin tags junction merits|carcinoma|lung cancer , including nsclc and small cell lung entity , or sclc , is the most common form of human cancer , and about 80% of diagnosed lung cancer cases are categorized
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg ante atpase spher atpases|mω spher ante normality benjamini|carcinoma|bacillus calmette-guérin ( bcg ) -refractory entity in situ ( cis ) bladder cancer—cis of the urinary bladder is a rare form of bladder cancer , affecting about 7 of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg ante atpase spher atpases|mω dystrophin cd44 nanog microns|carcinoma|renal cell entity doesn  t respond to chemotherapy and 15 to 20% of the patients respond to cytokine ( il2 or ifn-y ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities atpases gradients autoreg atpase|mω dystrophin gata4 densities gradients|cholangiocarcinoma|phase 1 / 2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer ( nsclc ) , ovarian cancer , malignant pleural / peritoneal mesothelioma , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities atpases gradients autoreg atpase|negativity spher mω gata4 densities|cholangiocarcinoma|biliary cancers , including entity , gallbladder and ampullary carcinoma , are cancers originating in the bile duct , a vessel that transports bile from the liver to
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities atpases gradients autoreg atpase|autoreg autoin gata4 gradients densities|cholangiocarcinoma|[ *** ] after a specified period of time following regulatory approval of varlitinib for the treatment of entity in south korea and ( ii ) milestone payments of $
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities atpases gradients autoreg atpase|gata4 atpases negativity densities mω|cholangiocarcinoma|additionally , we made a payment of $325 , 000 to hyundai in order to buy back the rights to commercialize varlitinib in entity ( cca ) and recorded as operating costs in february 2019 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities atpases gradients autoreg atpase|dystrophin gata4 densities chimeras density|cholangiocarcinoma|that ros1 is rearranged in non-small cell lung adenocarcinoma cancer patients , stomach cancer patients , glioblastoma patients , gastric cancer patients and entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities atpases gradients autoreg atpase|densities autoreg mω damp imm|cholangiocarcinoma|in november , the fda accepted the new drug application ( nda ) for pemigatinib in second-line entity for priority review .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities atpases gradients autoreg atpase|gata4 mω dystrophin αvβ3 smad1|cholangiocarcinoma|compared to phenoxodiol , triphendiol has substantially greater activity in laboratory testing against pancreatic cancer and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities atpases gradients autoreg atpase|gata4 mω dystrophin densities smad1|cholangiocarcinoma|dkn-01 is in clinical trials in esophageal cancer and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities atpases gradients autoreg atpase|densities autoreg mω negativity density|cholangiocarcinoma|the fda has also granted fast-track designation to ivosidenib for treatment of patients with previously treated , unresectable or metastatic entity with and idh1 mutation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities atpases gradients autoreg atpase|densities mω gata4 autoin negativity|cholangiocarcinoma|had been granted orphan drug status by the fda for the treatment of pancreatic cancer and for the treatment of entity , or bile duct cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities atpases gradients autoreg atpase|densities dystrophin mω density negativity|cholangiocarcinoma|biliary tract cancer consists of intra-hepatic and extra-hepatic entity ( cancer of the bile duct ) , cancer of the gall bladder and papilla of vater ( the final portion of the bile
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities atpases gradients autoreg atpase|negativity mω spher otherwise autoreg|cholangiocarcinoma|one type of liver cancer ( entity ) that is rare in most parts of the world has high incidence rates in thailand and other parts of asia
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities atpases gradients autoreg atpase|negativity ante stratification cd11 imm|cholangiocarcinoma|the development of rly-4008 will focus on solid tumor patients with fgfr2 alterations , including intrahepatic entity ( icc ) patients harboring fgfr2 gene fusions .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities atpases gradients autoreg atpase|gradients ante normality dens imm|cholangiocarcinoma|“icca” means intrahepatic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities atpases gradients autoreg atpase|gata4 dystrophin mω autoin densities|cholangiocarcinoma|in october 2017 , we initiated a phase 1b / 2 clinical trial to assess tecentriq with pegph20 in patients with entity and gall bladder cancer ( halo 110-101 / matrix ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities atpases gradients autoreg atpase|gata4 gradients densities dystrophin autoreg|cholangiocarcinoma|opaganib received orphan drug designation from the u . s . fda for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities atpases gradients autoreg atpase|gata4 mω dystrophin densities smad1|cholangiocarcinoma|dkn-01 is currently being studied in clinical trials in esophageal cancer and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities atpases gradients autoreg atpase|densities dystrophin density spher gata4|cholangiocarcinoma|breast cancer gastric cancer , nsclc pancreas cancer , gastric cancer gall bladder cancer , entity robust pan-tumor testing of pegph20 17 1 pending continued enrollment rate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|densities atpases gradients autoreg atpase|dystrophin densities gata4 density gradients|cholangiocarcinoma|studies suggest that ros1 is rearranged in non small cell lung adenocarcinoma cancer patients , stomach cancer patients , glioblastoma patients , and entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|densities atpases gradients autoreg atpase|damp negativity autoreg densities gata4|cholangiocarcinoma|the company commenced a second combination trial , examining the combination of prolindac and gemcitabine in entity patients , in the fourth quarter of 2011 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|normality mendelian benjamini hydroph gradients|gata4 atpases dystrophin αvβ3 gradients|keratoacanthoma|in the pooled safety population , cuscc and entity occurred in 7% and 1 . 9% of 351 patients , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|normality mendelian benjamini hydroph gradients|gata4 dens gradients densities mω|keratoacanthoma|the two trsaes included a grade 2 infusion reaction and a grade 1 entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|normality mendelian benjamini hydroph gradients|mω motors gata4 gradients autoreg|keratoacanthoma|tafinlar results in an increased incidence of cutaneous squamous cell carcinoma ( cuscc ) , entity and melanoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|normality mendelian benjamini hydroph gradients|gradients mω clock motors gata4|keratoacanthoma|in the columbus trial , cutaneous squamous cell carcinoma , including entity , occurred in 2 . 6% and basal cell carcinoma occurred in 1 . 6% of patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|normality mendelian benjamini hydroph gradients|gradients mω gata4 motors ≥4|keratoacanthoma|cutaneous squamous cell carcinoma , including entity , occurred in 7% of patients receiving the combination and 19% of patients receiving tafinlar as a single agent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens negativity spher biolabs normality|mω dystrophin junction negativity restorations|adenocarcinoma|treatment of cervical cancer and other solid tumors , including head and neck cancer , squamous non-small-cell lung cancer , or nsclc , pancreatic entity and colorectal cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens negativity spher biolabs normality|mω otherwise negativity dystrophin kv|adenocarcinoma|entity of the pancreas , which accounts for approximately 95% of all cases of pancreatic cancer , has a median overall survival of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens negativity spher biolabs normality|dystrophin negativity gata4 mω densities|adenocarcinoma|o ing-1 is a human engineered ( tm ) monoclonal antibody developed by us to specifically target tumor cells in entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|dens negativity spher biolabs normality|mω negativity gata4 αvβ3 gradients|adenocarcinoma|it is estimated that around 65 , 000 patients were diagnosed with pancreatic cancer ( mainly entity ) in the united states and the top 5 eu countries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens negativity spher biolabs normality|mω dystrophin negativity gata4 either|adenocarcinoma|of medicine , which investigated marker therapeutics , inc . s ( the “company” ) multitaa t cell therapy for the treatment of patients with pancreatic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens negativity spher biolabs normality|mω negativity dystrophin existence gata4|adenocarcinoma|clinical trial led by baylor college of medicine ( bcm ) , evaluating the companys multitaa t cell therapy in patients with pancreatic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cancer|dens negativity spher biolabs normality|mω dystrophin negativity avidin autoreg|adenocarcinoma|am0010 development for the treatment of pancreatic ductal entity in our phase 1 / 1b clinical trial , we treated 22 pdac patients with am0010 monotherapy and 21 patients with am0010 in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens negativity spher biolabs normality|mω dystrophin negativity gata4 kv|adenocarcinoma|trial evaluating keytruda as monotherapy and in combination with chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|dens negativity spher biolabs normality|motors mω spher gradients clock|adenocarcinoma|types of nsclc include squamous cell carcinoma , entity , and large cell carcinoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens negativity spher biolabs normality|junction dystrophin cd44 motors disintegr|adenocarcinoma|studies suggest that ros1 is rearranged in non small cell lung entity cancer patients , stomach cancer patients , glioblastoma patients and cholangiocarcinoma patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|dens negativity spher biolabs normality|mω kv negativity existence densities|adenocarcinoma|the u . s . food and drug administration ( fda ) approved abraxane in combination with gemcitabine as first-line treatment of patients with metastatic entity of the pancreas .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|dens negativity spher biolabs normality|motors mω spher gradients junction|adenocarcinoma|about 85% of lung cancers are nsclc , which has different subtypes , including squamous cell carcinoma , entity , and large cell carcinoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|dens negativity spher biolabs normality|mω densities autoreg junction density|adenocarcinoma|the study will target enrolling 35 patients with histologically or cytologically confirmed diagnosis of invasive entity originating in the breast .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens negativity spher biolabs normality|mω dystrophin cd44 negativity nanog|adenocarcinoma|and multiple myeloma , and expects to commence clinical trials of maxamine for the treatment of additional cancers , such as prostate entity , in 1998 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cancer|dens negativity spher biolabs normality|dystrophin mω negativity junction avidin|adenocarcinoma|high msi is present in about 15% of gastrointestinal tumor cancers , including in approximately 22% of stomach entity and 16% of colorectal cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|dens negativity spher biolabs normality|mω gata4 spher motors autoreg|adenocarcinoma|entity is a general term that refers to a cancer that starts in glandular tissues anywhere in the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|dens negativity spher biolabs normality|cd69 mω vsv motors gata4|adenocarcinoma|· inability to detect entitys — pap tests are unable to detect the presence of the more virulent entity ( clinical laboratory medicine , 20 : 140 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|dens negativity spher biolabs normality|mω negativity densities existence kv|adenocarcinoma|abraxane® was approved for the treatment of metastatic entity of the pancreas in the united states in september 2013 and the european union in december 2013 . net sales of abraxane®
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens negativity spher biolabs normality|mω dystrophin junction negativity kv|adenocarcinoma|our phase 1 clinical trial , which was a safety and tolerability study in patients with previously treated metastatic pancreatic ductal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens negativity spher biolabs normality|mω junction gata4 dystrophin densities|adenocarcinoma|the first target of the collaboration is early stage lung entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|autoreg atpase gata4 atpases benjamini|boltzmann negativity mω kv gata4|blastoma|neuroentity - market insights , epidemiology and market forecast - 2027 the market of neuro entity in 7mm was found to be usd 733 . 58 million in 2016 , and is expected to increase at from 2016 -
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities cholerae atpases|densities density negativity tek mω|melanoma|five patients experienced entity relapses shortly after inclusion in the trial and despite initiation of standard treatment had progressing metastases at start of their
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities cholerae atpases|densities density gata4 kv dystrophin|melanoma|that our cash reserves are sufficient to fund two years of anticipated operating activities , including our recently announced phase ii entity combination trial .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities cholerae atpases|mω dystrophin gata4 gradients densities|melanoma|in preclinical studies conducted by the company  s scientists , tlc ell-12 has been shown to be active in tumor models of entity , lung cancer , leukemia and multiple drug resistant cell lines .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities cholerae atpases|mω densities gradients negativity traps|melanoma|provectus has completed phase 2 trials of pv-10 as a therapy for metastatic entity , and of ph-10 as a topical treatment for atopic dermatitis and psoriasis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities cholerae atpases|dystrophin mω densities gradients spher|melanoma|• data from the nsclc and entity cohorts of the encore 601 trial will each be featured during oral presentations at the american association of cancer research
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities cholerae atpases|gata4 mω autoreg smad1 dystrophin|melanoma|bms / p  s most advanced program involves a vaccine called gmk that incorporates qs-21 with a ganglioside preparation called gm2 to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities cholerae atpases|mω densities negativity traps gradients|melanoma|what im trying to say here is we have completely changed the outcome and treatment of patients with metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities cholerae atpases|mω densities gata4 gradients autoreg|melanoma|we introduced canvaxin that was manufactured using this new process into our two phase 3 clinical trials for advanced-stage entity in 2003 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities cholerae atpases|mω densities gata4 dystrophin density|melanoma|triphendiol has recently been granted orphan drug status by the fda for pancreatic and bile duct cancers , and late stage entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities cholerae atpases|densities gata4 chimeras mω αvβ3|melanoma|the company has received orphan drug designations from the fda for its entity and hepatocellular carcinoma indications .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities cholerae atpases|mω densities negativity binders dystrophin|melanoma|accordingly , a comparable distribution of patients with liver metastases is important in clinical trials of metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities cholerae atpases|mω densities negativity gradients traps|melanoma|it was approved to treat metastatic entity by the fda in 2015 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities cholerae atpases|mω gata4 negativity dystrophin densities|melanoma|the first oncolytic immunotherapy , imlygic , also known as t-vec , which was approved by the fda for the treatment of advanced entity in 2015 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities cholerae atpases|mω densities density gradients traps|melanoma|have completed enrollment in part i of a phase 3 trial for renal cell carcinoma and a phase 3 trial for metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities cholerae atpases|negativity mω densities gradients dystrophin|melanoma|the improvement in two and three year survival remained statistically significant in the subpopulation of advanced malignant entity patients with liver metastases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|gradients autoreg densities cholerae atpases|autoreg densities gradients integrins mω|melanoma|the pivotal phase iii study in high-risk entity patients completed enrollment in 1999 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities cholerae atpases|mω densities dystrophin gradients gata4|melanoma|product has potential utility in adjuvant therapy and for the treatment of advanced cancers that express the gd2 ganglioside , including entity , small cell lung cancer and sarcoma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities cholerae atpases|mω densities gradients traps either|melanoma|we  re recruiting patients with metastatic entity for a phase i safety study in israel .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|gradients autoreg densities cholerae atpases|mω gata4 dystrophin densities gradients|melanoma|and metastatic breast cancer ; and intron a injection , marketed for numerous anticancer indications worldwide , including as adjuvant therapy for malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|gradients autoreg densities cholerae atpases|gata4 imm densities cd69 autoreg|melanoma|the most common adverse events associated with our entity trials have consisted of flu-like symptoms such as fever , chills and nausea .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg cholerae benjamini dens normality|mω αvβ3 densities dystrophin density|leiomyosarcoma|or cbr , rates was achieved in the three most prevalent types of sarcoma , namely bone sarcoma ( cbr rate of 30% ) , entity ( 33% ) and liposarcoma ( 30% ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg cholerae benjamini dens normality|mω densities αvβ3 gata4 dystrophin|leiomyosarcoma|these include patients with osteosarcoma , ewing sarcoma family tumours , malignant fibrous histiocytoma , synovial sarcoma , fibrosarcoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg cholerae benjamini dens normality|densities gata4 density dystrophin autoreg|leiomyosarcoma|the entity study was initiated and screening of patients began in early 2006 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|autoreg cholerae benjamini dens normality|densities density autoreg negativity veloc|leiomyosarcoma|we also enrolled a first entity patient in the phase 2 basket arm evaluating ide196 as monotherapy , expanding the tissue-agnostic approach to additional solid tumors harboring
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg cholerae benjamini dens normality|mω densities gradients autoreg dystrophin|leiomyosarcoma|out of 2 heavily pre-treated stage iv entity patients and 1 heavily pre-treated triple negative breast cancer patient experienced stable disease as best response .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg cholerae benjamini dens normality|dystrophin gata4 mω densities cd69|leiomyosarcoma|developed a fully-human antibody , designated imc-3g3 , that effectively blocks the function of pdgfra and inhibits the growth of glioblastoma and entity tumors in animal models .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg cholerae benjamini dens normality|mω dystrophin gata4 densities density|leiomyosarcoma|elevated cd47 has been reported in solid tumors , including breast , colon , ovarian , brain , liver and prostate cancers and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|autoreg cholerae benjamini dens normality|mω densities gradients density integrins|leiomyosarcoma|doxorubicin has historically been the standard of care for the treatment of entity and other sts .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg cholerae benjamini dens normality|mω dystrophin motors αvβ3 densities|leiomyosarcoma|this multicenter clinical trial is to assess the efficacy of ap23573 in four groups of sarcomas : bone sarcoma , entity , liposarcoma , and other soft tissue sarcomas .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|autoreg cholerae benjamini dens normality|densities density otherwise gata4 integrins|leiomyosarcoma|●results by year end are expected from ongoing clinical trials evaluating ptc596 in entity and diffuse intrinsic pontine glioma ( dipg ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|autoreg cholerae benjamini dens normality|gradients gata4 mω densities density|leiomyosarcoma|on these findings , as well as pre-clinical data , the phase 2 dose employed in the arq 501 monotherapy trials in entity and head and neck cancer is 450 mg / m2 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|autoreg cholerae benjamini dens normality|densities gradients autoreg integrins otherwise|leiomyosarcoma|ptc596 is also being evaluated in entity , or lms , in patients who have relapsed or are refractory to current treatments .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|autoreg cholerae benjamini dens normality|αvβ3 mω dystrophin motors integrins|leiomyosarcoma|the most common types of sarcoma in adults are undifferentiatedpleomorphic sarcoma ( previously called malignant fibrous histiocytoma ) , liposarcoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg cholerae benjamini dens normality|mω αvβ3 densities motors dystrophin|leiomyosarcoma|clinical-benefit responses were demonstrated in 39% of bone sarcoma patients , 50% of entity , 21% of liposarcoma , and 24% of other soft-tissue sarcomas .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|autoreg cholerae benjamini dens normality|mω αvβ3 densities atpases motors|leiomyosarcoma|the 246 patients with entity or liposarcoma comprise 57% of the total trial population .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|autoreg cholerae benjamini dens normality|densities mω gata4 dystrophin density|leiomyosarcoma|interim data from the entity study show a 17 . 5 percent objective response rate among patients to monotherapy treatment with arq 501 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cancer|autoreg cholerae benjamini dens normality|densities density gata4 autoin negativity|leiomyosarcoma|-- the cbr rates were not statistically different among the four sub-groups ( i . e . , bone , 30% ; entity , 33% ; liposarcoma , 30% ; and other , 23% ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|autoreg cholerae benjamini dens normality|mω densities density integrins gata4|leiomyosarcoma|axl is a tyrosine kinase receptor that is highly expressed and activated in numerous human sarcomas , including aggressive subtypes of entity , ewings sarcoma and liposarcoma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|autoreg cholerae benjamini dens normality|mω αvβ3 integrins densities motors|leiomyosarcoma|entity and liposarcoma are the two most common types of sts and accounted for 57% of the patients enrolled in the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|autoreg cholerae benjamini dens normality|mω integrins motors ante trap|leiomyosarcoma|trabectedin ( yondelis® ) was approved in 2015 for patients with entity or liposarcoma that have had prior treatment with an anthracycline such as doxorubicin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|mω gata4 either dystrophin densities|rhabdomyosarcoma|indications for our impact therapeutic vaccines and have developed cell lines for ovarian cancer , triple negative breast cancer and pediatric entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|mω dystrophin motors αvβ3 integrins|rhabdomyosarcoma|vincristine is used to treat hodgkin  s disease , leukemia , entity , neuroblastoma , and wilms  tumor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|dens benjamini spher normality linearity|densities mω density αvβ3 integrins|rhabdomyosarcoma|rare pediatric disease designations and odds were granted for the treatment of , neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|mω densities density dystrophin αvβ3|rhabdomyosarcoma|in 2018 , the fda granted orphan drug and rare pediatric disease designations for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|dens benjamini spher normality linearity|mω gata4 integrins otherwise densities|rhabdomyosarcoma|granted orphan drug designation to clr 131 , the companys lead phospholipid drug conjugate™ ( pdc ) product candidate , for the treatment of entity , a rare pediatric cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|mω αvβ3 dystrophin gata4 integrins|rhabdomyosarcoma|since then the drug has been used to treat various types of cancer , including wilms tumor , entity , ewing  s sarcoma , trophoblastic neoplasm , and testicular cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|mω densities dystrophin density integrins|rhabdomyosarcoma|in 2018 , the fda granted od and rpdd for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|densities density mω dystrophin αvβ3|rhabdomyosarcoma|pv-10 is also undergoing preclinical study for pediatric solid tumor cancers ( including neuroblastoma , ewing sarcoma , entity , and osteosarcoma ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|mω densities dystrophin density integrins|rhabdomyosarcoma|in 2018 , the fda granted odd and rpdd for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|densities mω density existence dystrophin|rhabdomyosarcoma|description / conclusion the poster covered preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|dens benjamini spher normality linearity|densities cd44 smad1 mω density|rhabdomyosarcoma|the nci has initiated a phase i / ii clinical trial in entity of ganitumab with the kinase inhibitor dasatinib based on promising preclinical animal model data with this combination .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|densities mω density dystrophin integrins|rhabdomyosarcoma|multiple myeloma as well as orphan drug and rare pediatric disease designations for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|dens benjamini spher normality linearity|mω gradients αvβ3 negativity gata4|rhabdomyosarcoma|“entity is the most common type of tissue sarcoma in children .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|densities mω density existence dystrophin|rhabdomyosarcoma|the poster covers preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|densities mω density dystrophin existence|rhabdomyosarcoma|the poster covered preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|mω nemat αvβ3 cholerae integrins|rhabdomyosarcoma|entity is a skeletal muscle neoplasm occurring primarily in the first decade of life , while osteosarcoma , a bone neoplasm , occurs primarily
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|dens benjamini spher normality linearity|dystrophin mω gata4 densities spher|rhabdomyosarcoma|is to investigate the gene expression patterns stimulated by sca using two malignant tumor cell lines , saos-2 ( osteosarcoma ) and rd ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|dens benjamini spher normality linearity|mω gata4 smad1 gradients negativity|rhabdomyosarcoma|the nci has conducted pk / pd and dose escalation studies in preclinical models of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|autoimmune_disease|benjamini mendelian normality cholerae null|mω negativity cholerae dystrophin normality|polyradiculoneuropathy|oral 2008 2015 / iii chronic inflammatory demyelinating entity 2012 2016 / iii hsc835 tbd stem cell regeneration stem cell transplantation
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|autoimmune_disease|benjamini mendelian normality cholerae null|mω cholerae dystrophin gata4 smad4|polyradiculoneuropathy|a phase ii / iii study of gilenya in patients with chronic inflammatory demyelinating entity was initiated in 2012 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|autoimmune_disease|benjamini mendelian normality cholerae null|mω smad4 dystrophin gata4 cholerae|polyradiculoneuropathy|development work for a u . s . pediatric indication to treat primary immunodeficiencies and a phase 3 indication in chronic inflammatory demyelinating entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|dystrophin gata4 smad1 kv fibrill|hypertension|addition , matria provides home healthcare services for the management of other complicated obstetrical and gynecological conditions , such as pregnancy induced entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|autoreg gradients gata4 mω dens|hypertension|however , the letter indicated that such a boxed warning could be reconsidered if suitable data demonstrating a lack of severe entity in a fully supine position were provided .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|gata4 mω dystrophin αvβ3 traps|hypertension|aventis claims its therapeutic innovations rank among the leading treatments for lung and breast cancer , thrombosis , seasonal allergies , diabetes and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|amorph dens traps cholerae chimeras|hypertension|pulmonary entity in interstitial lung diseases market there are no therapies currently approved for ph-ild .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|gata4 cholerae smad1 negativity mω|hypertension|dr . oparil has an extensive bibliography in clinical cardiology and entity , including over 350 journal articles , books and book chapters .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|gata4 mω dystrophin gradients kv|hypertension|the subpoena requests documents relating to benicar® , benicar hct® , and azor® , prescription medications approved for the treatment of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|autoreg gata4 chaperones smad1 dens|hypertension|the king board made note of mylans proprietary product nebivolol , a beta blocker for the treatment of entity , the nda for which was accepted for filing in june by the fda .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|traps banding gata4 autoreg αvβ3|hypertension|he was responsible for the clinical trials and subsequent approval of inhaled nitric oxide for the treatment of persistent pulmonary entity of the newborn .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|dens atpases traps dystrophin cholerae|hypertension|release announcing united states food and drug administration approval of intravenous dosing of remodulin for the treatment of pulmonary arterial entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|tags dens cd44 dystrophin gata4|hypertension|rhopressa® , and our product candidate , roclatantm , are designed to lower intraocular pressure ( iop ) in patients with open-angle glaucoma or ocular entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|gradients dens densities atpases gata4|hypertension|most common non-hematologic adverse reactions : ( ≥20% ) were entity , rash , abdominal pain , fatigue , headache , dry skin , constipation , arthralgia , nausea , and pyrexia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|dens motors autoreg spher dystrophin|hypertension|have been found to be an independent predictor of a number of cardiovascular risk factors including obesity , abnormal lipid levels , entity , type 2 diabetes , and systemic inflammation .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|gata4 dens smad1 cd47 troponin|hypertension|about plendil plendil ( felodipine ) is a calcium antagonist for the treatment of entity and angina .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|gata4 gradients smad1 atpases chaperones|hypertension|lotrel ( +11% us ) , the leading us fixed combination treatment for entity , sustained double-digit sales growth well ahead of market ( +6% ytd ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|autoreg gradients negativity autoin mω|hypertension|therapy for depression , is approved in the united states as inversine for the management of moderately severe to severe essential entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|chimeras autoreg gata4 mω chaperones|hypertension|phentolamine has been approved by the fda for the treatment of entity and for use in the diagnosis of certain tumors of the adrenal gland , and has been used " off-label " by urologists ,
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|densities density negativity damp chimeras|hypertension|partner product / candidate application status teva clonidine tds entity marketed par fentanyl tds pain marketed p&g crest whitestrips ( 5 products )
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|dens gata4 traps gradients smad1|hypertension|pulmonary entity may be present in as many as 74% of patients depending on how the pulmonary entity ( “ph” ) is defined .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|autoreg gradients gata4 densities dens|hypertension|we cannot be certain that darusentan for the treatment of resistant entity will be approved in the united states or in countries outside of the united states or whether marketing approvals will
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|dens benjamini normality avidin uncoupling|gata4 gradients dystrophin atpases smad1|hypertension|except for inversine for the management of entity , neither the fda nor any foreign regulatory authority has approved any of our product candidates for marketing .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|gata4 biased mω dens otherwise|vasculitis|dr . jaynes research includes investigator-initiated international trials and the introduction of newer therapies in entity and sle with collaborators on five continents .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω otherwise gata4 refractory cd44|vasculitis|ifx-1 is currently being developed for various inflammatory indications , including hidradenitis suppurativa , anca-associated entity and pyoderma gangraenosum .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω gata4 dens cd44 resonance|vasculitis|rituxan we are currently planning for phase iii clinical trials in systemic lupus eruthematosus , lupus nephritis and anca-associated entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω dens refractory negativity probes|vasculitis|ccx168 for anca-associated entity understanding anca-associated entity ancas are autoantibodies that attack certain type of white blood cells called neutrophils .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω gata4 refractory dens cd44|vasculitis|ifx-1 is currently being developed for various indications , including hidradenitis suppurativa , anca-associated entity , pyoderma gangraenosum and covid-19 induced pneumonia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|gata4 mω dystrophin smad1 cd69|vasculitis|entity is an inflammatory process of blood vessels , histopathologically characterized by vessel wall destruction and occlusion of the vascular lumen .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω gata4 kv chimeras integrins|vasculitis|test could be used by clinicians in the management of several autoimmune diseases , including but not limited to rheumatoid arthritis , entity and irritable bowel disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|autoin gata4 spher cush kolmogorov|vasculitis|in 2012 , we plan to initiate phase 3 trials of benlysta in entity and active lupus nephritis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|gata4 cd44 mω myod otherwise|vasculitis|of those cells to do damage in response to c5a activation , which is known to be the driver of anca-associated entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω cd44 dens merits either|vasculitis|all iga protease-mediated diseases , including iga nephropathy , linear iga bullous dermatitis , iga pemphigus , and henoch-schonlein purpura ( also known as iga entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|gradients densities imm disintegr rotor|vasculitis|the method of claim 1 , wherein the adverse effect is entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω gata4 otherwise dens probes|vasculitis| completed enrollment of the companys pivotal phase iii advocate trial of avacopan for the treatment of anca-associated entity ; top line data expected in the fourth quarter of 2019 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|intram gata4 mω gradients ≥4|vasculitis|toxicological findings included changes in hematologic and chemistry parameters and fibrinoid entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|gata4 otherwise gradients dens mω|vasculitis|actually , my first experience outside of ms was treating a condition called entity and thats another autoimmune disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω gata4 dens refractory cd44|vasculitis|rituxan is also being evaluated in lupus nephritis and anca-associated entity in collaboration with biogen idec .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω gata4 cholerae densities nanog|vasculitis|in egpa , patients usually develop asthma initially , before the entity extends to inflammation in the walls of small blood vessels that supply tissues in the lungs , sinuses , skin , nerves and
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω gata4 dens chimeras traps|vasculitis|as basal cell cancer in the area of laviv® injections and the risk of immune-mediated hypersensitivity reactions such as leukocytoclastic entity ) , which must be completed by 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω cd44 gata4 dystrophin certain|vasculitis|anca-associated entity is a rare autoimmune disease that largely affects the small blood vessels of the kidneys , lungs , sinuses , and a variety
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω gata4 otherwise refractory cd44|vasculitis|vilobelimab is currently being developed for various indications , including hidradenitis suppurativa , anca-associated entity , pyoderma gangraenosum and severe covid‑19 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients cholerae dwell ante benjamini|mω gata4 dens cd44 ≥4|vasculitis|evaluated in phase iii clinical trials for anti-tnf ( tumor necrosis factor ) refractory rheumatoid arthritis , primary progressive multiple sclerosis , and anca-associated entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|mω kurt rectif ante dystrophin|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , a chronic inflammatory disease of the medium-large blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|mω ante kurt rectif ≥1|arteritis|abbvie initiated a phase 3 clinical trial to evaluate the efficacy and safety of upadacitinib in subjects with giant cell entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|dystrophin nemat otherwise mω negativity|arteritis|targeting gm-csfrα ) ·kiniksa recently announced positive data from the global phase 2 clinical trial of mavrilimumab in giant cell entity ( gca ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|negativity dystrophin mω troponin certain|arteritis|background and market opportunity for giant cell entity gca is an inflammatory disease of the medium-to-large arteries that strikes older adults and causes headaches , jaw and other muscle
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|mω agon ante rectif ≥5|arteritis|in 2013 , servier also began testing gevokizumab in a variety of poc studies , including polymyositis / dermatomyositis , schnitzler syndrome , and giant cell entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|dystrophin mω otherwise negativity ante|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , or gca , an inflammatory disease of the blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|kurt gradients dystrophin autoreg biphasic|arteritis|current treatment landscape for giant cell entity glucocorticoids , a type of corticosteroid , are the mainstay for the treatment of gca because they normalize inflammatory markers and resolve
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|mω kurt agon cd44 rectif|arteritis|testing gevokizumab in a variety of small clinical studies , including polymyositis / dermatomyositis and schnitzler syndrome ; a third study in giant cell entity , is expected to open shortly .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|mω agon ante ≥5 rectif|arteritis|in 2013 , servier began testing gevokizumab in a variety of poc studies , including polymyositis / dermatomyositis , schnitzler syndrome , and giant cell entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|gata4 imm negativity mω ankyrin|arteritis|developed to address the accelerated inflammation of grafted blood vessels common in chronic organ transplant rejection and known as transplant entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|mω dystrophin kurt rectif cd44|arteritis|an ongoing phase iii study , announced in november 2015 , is currently investigating sirukumab in giant cell entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|negativity mω dystrophin troponin certain|arteritis|background and market opportunity for giant cell entity gca is an inflammatory disease of the blood vessels that strikes older adults and causes headaches , jaw and other muscle
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|mω dystrophin rectif kv otherwise|arteritis|the focus of these compounds appears to be in chronic autoimmune disorders such as rheumatoid arthritis , ankylosing spondylitis , giant cell entity and related disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|mω dystrophin kurt ≥1 ante|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , a chronic inflammatory disease of the medium-to-large arteries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|mω dystrophin kurt rectif cd44|arteritis|· kiniksa plans to advance to a phase 2 clinical trial of mavrilimumab for the treatment of giant cell entity in the second half of 2018 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality cholerae benjamini gata4 dens|dystrophin otherwise mω negativity ema|arteritis|in november 2015 gsk announced the start of a phase iii study of sirukumab for patients with giant cell entity ( gca ) , and plans to start a study in asthma were disclosed at gsk  s r&d day .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|smad1 gata4 atpases dens gradients|phlebitis|intermune requested this self-imposed clinical hold in part due to the observance of entity at the infusion site judged to be unexpectedly greater in incidence and severity than anticipated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|clock gata4 benjamini merits normality|gata4 atpases dystrophin gradients ≥4|phlebitis|levels were generally well tolerated with one subject at the 5 mg / kg dose level experiencing moderate localized blood vessel inflammation , or entity , that was attributed to the study drug .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|gradients mω smad1 densities atpases|phlebitis|the product may also cause entity ( vein irritation ) in approximately one-third of treated patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|clock gata4 benjamini merits normality|gata4 dystrophin chimeras mω dens|phlebitis|for injection : used for preventing and treating cerebral thrombosis , coronary heart disease , and complication after the surgery - thrombus deep entity , etc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|clock gata4 benjamini merits normality|gata4 dystrophin chimeras mω dens|phlebitis|hepatitis ) propylgallate for injection : used for preventing and treating cerebral thrombosis , coronary heart disease , and complication after the surgery-thrombus deep entity , etc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|clock gata4 benjamini merits normality|mω dystrophin gradients motors cd44|phlebitis|blood collection by venipuncture is associated with mild discomfort , and the possibility of localized bruising , entity , or extravasation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|clock gata4 benjamini merits normality|motors gradients gata4 dystrophin cd69|phlebitis|other events such as entity , mechanical block of the capillaries or arterioles , activation of platelets , or subsequent generation of microthrombi are also possible .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|gata4 atpases motors mω autoreg|phlebitis|peripheral venous catheters have been associated with a 7% to 9% incidence of entity and a 0 . 2% to 0 . 4% incidence of bacteremia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|clock gata4 benjamini merits normality|mω gradients smad1 gata4 dystrophin|phlebitis|sdp-016 is designed to reduce the vein irritation and entity associated with the iv-delivered drug .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|gradients densities dens spher gata4|phlebitis|in terms of entity , which is another thing that the fda mentioned in their complete response , that is something that we feel has been
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|smad1 atpases gata4 dens ≥4|phlebitis|patients who received dyloject ( tm ) also had a lower incidence and severity of entity at the site of intravenous administration compared to those given voltarol ( r ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|mω gata4 motors atpases gradients|phlebitis|peripheral venous catheters have been associated with entity and bacteremia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|autoreg gradients motors atpases gata4|phlebitis|we believe that some clinicians elect to use a central line or a different chemotherapeutic regimen as a means to avoid entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|gradients mω cyclins gata4 smad1|phlebitis|we believe the current formulations of these drugs have limitations , such as entity , erythema and hypersensitivity reactions , that present opportunities for improvement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|gradients mω cd44 dens density|phlebitis|the most common adverse reactions in clinical trials associated with cinryze were rash , headache , nausea , erythema , entity and local reactions at the injection site .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|cd44 autoin chimeras certain negativity|phlebitis|local none pain pain and swelling with inflammation or entity ulceration plastic surgery indicated fever of unknown origin
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|clock gata4 benjamini merits normality|dystrophin gata4 mω αvβ3 atpases|phlebitis|cerebral infarction and thrombosis , brain damages like apoplectic sequela , cerebral trauma , brain surgery sequela , also used for thromboangitis obliterans and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|mω gata4 dens ante αvβ3|phlebitis|clinically significant toxicities observed to date include neutropenia , thrombocytopenia and mild to moderate entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|gradients mω gata4 spher densities|phlebitis|the main side effect at the maximum dose tested was moderate entity ( blood vessel inflammation ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|clock gata4 benjamini merits normality|gradients gata4 mω spher densities|phlebitis|the main side effect at the maximum dose tested has been moderate entity ( blood vessel inflammation ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|benjamini cracks clock kolmogorov ante|gata4 dystrophin smad1 ≥4 mω|thrombophlebitis|eight of the patients had pulmonary embolism and / or deep vein thrombosis with three additional patients reporting an event of superficial entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|benjamini cracks clock kolmogorov ante|gata4 atpases gradients smad1 dystrophin|thrombophlebitis| 1 % elevated lipase   1 % entity ( associated with infusion sites )  1 %  a for the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|benjamini cracks clock kolmogorov ante|dystrophin cd44 chimeras gata4 amphip|thrombophlebitis|events included : deep venous thrombosis , pulmonary embolism , superficial entity , and retinal vein thrombosis with vision loss .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|benjamini cracks clock kolmogorov ante|hydroph gata4 chimeras ≥4 mω|thrombophlebitis|no venous thromboembolism events or occurrences of superficial entity were observed or reported .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|benjamini cracks clock kolmogorov ante|dystrophin dens atpases nemat chur|thrombophlebitis|thalidomide in combination with other agents may have an increased incidence of thromboembolic events such as pulmonary embolism , deep vein entity , entity , or thrombosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|benjamini cracks clock kolmogorov ante|gata4 smad4 density imm cholerae|thrombophlebitis|both saes have subsequently resolved , with the entity sae verbally reported to the company as resolved following the safety data cut-off date .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|benjamini cracks clock kolmogorov ante|gradients smad1 motors spher gata4|thrombophlebitis|entity ( vein irritation ) was significantly less with dyloject than with ketorolac or placebo .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|certain tir motors dystrophin gata4|thromboembolism|pulmonary embolism : a pulmonary embolism , or entity , occurs when a blood clot , generally a venous thrombus , becomes dislodged from its site of formation and embolizes to the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|gata4 gradients motors dystrophin smad1|thromboembolism|poaf is independently associated with an increased risk of morbidity and mortality caused by stroke , heart failure , ventricular arrhythmias , entity and bleeding from anticoagulation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|ankyrin atpases gata4 cholerae resonance|thromboembolism|james d . extended-duration prohylaxis against venous entity after total hip or knee replacement : a meta-analysis of the randomized trials .  the lancet .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|gata4 dystrophin mω motors smad1|thromboembolism|inhibition of intracellular signaling involved in tumor growth and metastases and 2 ) inhibition of early coagulation processes associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|dens negativity biphasic resonance kv|thromboembolism|risk factors for arterial vascular disease and / or venous entity ( vte ) should be managed appropriately .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|gata4 gradients motors smad1 dystrophin|thromboembolism|heparin is also used to prevent the occurrence of entity and to prevent clotting during dialysis and other surgical procedures , particularly vascular surgery .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|mω atpases dystrophin ankyrin nemat|thromboembolism|and states that esas increase the risk of death and major adverse cardiovascular events , such as myocardial infarction , stroke , venous entity and thrombosis of vascular access .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|dens kv mω negativity microns|thromboembolism|a risk associated with hormonal contraceptives is a rare but serious adverse event called venous entity , or vte , which involves the formation of a blood clot in a vein .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|atpases dens biphasic gata4 mω|thromboembolism|fdas approval of annovera™ , the fda has required a post-approval observational study be performed to measure the risk of venous entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|dens kv resonance gata4 negativity|thromboembolism|xa in phase 3 development for extended duration prophylaxis , or preventive treatment , of a form of thrombosis known as venous entity , or vte , in acute medically ill patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|gata4 dystrophin αvβ3 cd44 cd69|thromboembolism|similarly , cerebral entity and cerebral vasculitis would be unexpected ( by virtue of greater specificity ) if the labeling only listed cerebral vascular accidents .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|dens gata4 autoreg gradients αvβ3|thromboembolism|pipeline we aim to broaden our cv portfolio into the areas of entity , dyslipidaemia , type 2 diabetes / metabolic syndrome , atrial fibrillation and vascular disease prevention .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|dystrophin atpases densities resonance dens|thromboembolism|are in danger of forming life-threatening blood clots as a result of atrial fibrillation , prosthetic heart valve replacement or venous entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|gradients mω dens chimeras gata4|thromboembolism|the committees concluded that users of evra have an increased risk of venous entity , or vte compared to users of second generation contraceptives , such as those containing lng .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|gata4 atpases gradients chimeras dystrophin|thromboembolism|patients and physicians are advised to be observant for the signs and symptoms of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|dens negativity microns resonance kv|thromboembolism|of the ag200-15 patch , levonorgestrel ( lng ) , is considered as one of the safest progestins , with the lowest risk for venous entity ( vte ) when combined with ee .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|atpases dens biphasic gata4 densities|thromboembolism|the approval of annovera , the fda has required a post-approval observational study be performed to measure the risk of venous entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|gata4 microtubules gradients motors αvβ3|thromboembolism|in the ats heart valve is intended to lower the likelihood of blood clot formation and the resulting incidence of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|dystrophin gata4 αvβ3 densities gradients|thromboembolism|response clinical tests are commercially available for the aid in early detection of heart attack , congestive heart failure , entity , sepsis , influenza a and b and rsv .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|densities autoreg gradients atpases cholerae|biphasic atpases gata4 densities dystrophin|thromboembolism|there were approximately 510 , 000 patients being treated for venous entity in the united states in 2005 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg atpases atpase densities gradients|gata4 dens autoreg αvβ3 mω|embolism|pulmonary entity is the most common preventable cause of hospital death and a leading cause of increased length of hospital stay .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|gata4 dystrophin cd47 cd69 tags|embolism|to sell abbokinase for the treatment of acute massive pulmonary entity , we are required to continue an ongoing 200-patient immunogenicity clinical trial that commenced in 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|gata4 cd44 dystrophin microtubules mω|embolism|will look natural to blood as it passes through the valve , thus inhibiting platelet aggregation that may later lead to entity or blood clots .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|dystrophin gata4 cd47 ≥4 microtubules|embolism|urokinase is an fda-approved thrombolytic , or clot-dissolving agent , indicated for the treatment of acute massive pulmonary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|smad1 gata4 nemat αvβ3 dystrophin|embolism|the primary efficacy endpoint is the occurrence of venographically-confirmed dvt , pulmonary entity , or death during the treatment phase , when measured at day 30 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|gata4 mω dystrophin keap1 cd47|embolism|allegedly sustained as a result of their product use ; the most common alleged injuries are deep vein thrombosis and pulmonary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|mω αvβ3 dens dystrophin gata4|embolism|used berlex hrt products together with other hrt products and suffered injuries , including breast cancer , ovarian cancer , stroke and pulmonary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|autoreg atpases atpase densities gradients|dystrophin mω cholerae gradients atpases|embolism|one patient in the mst-188 group died due to cardiopulmonary arrest , which was considered secondary to a fat entity based on autopsy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg atpases atpase densities gradients|either traps autoin gata4 densities|embolism|patients were dyspnea ( 7 percent ) , pneumonia ( 5 percent ) , hypoxia ( 4 percent ) , neoplasm progression ( 4 percent ) , pyrexia ( 2 percent ) and pulmonary entity ( 2 percent ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|gata4 dystrophin cd47 chloroplasts ≥4|embolism|abbokinase is fda approved and marketed for the treatment of acute massive pulmonary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|mω αvβ3 dystrophin gata4 smad1|embolism|the blood clots can travel to the lung and cause a pulmonary entity development all activities required to bring a new drug to the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|αvβ3 gata4 dystrophin cd44 mω|embolism|in two cases , the patient developed a pulmonary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|autoreg atpases atpase densities gradients|atpases dystrophin autoreg cholerae gata4|embolism|numerous companies either offer or are developing competing treatments for ischemic stroke , massive pulmonary entity and catheter occlusion , the three indications we are currently targeting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg atpases atpase densities gradients|autoreg gata4 αvβ3 dens nanos|embolism|ivc filters have been shown in several studies to significantly reduce the risk of pulmonary entity and related mortality in certain high risk patient populations .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|dens gata4 densities dystrophin smad1|embolism|triage d-dimer test as an aid in the assessment and evaluation of patients suspected of having thromboembolic events , including pulmonary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|gata4 dystrophin dens cd44 mω|embolism|in some cases , a venous clot can cause lung injury ( pulmonary entity ) by migrating from the veins to the lungs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg atpases atpase densities gradients|αvβ3 dens smad1 gata4 mω|embolism|were a total of 48 serious adverse events , two of which were determined to be related to glybera , a pulmonary entity and fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg atpases atpase densities gradients|dens gata4 αvβ3 atpases cd44|embolism|patients at high risk for pulmonary entity are typically patients undergoing a significant surgical procedure , trauma patients or patients that have experienced a previous embolic event .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|gata4 merits dystrophin densities autoin|embolism|the most frequent ( >1% ) principal diagnoses were als , sepsis , respiratory failure , aspiration pneumonia , pneumonia , pulmonary entity , and urinary-tract infection ( table 2 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpases atpase densities gradients|αvβ3 mω smad1 dystrophin gradients|embolism|in addition , one patient was reported to have a pulmonary entity ( grade 4 ) that was an incidental finding on ct scan .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|gata4 mω gradients motors kv|thrombosis|pnh is a rare chronic blood disease characterized by severe anemia and risk of blood clotting or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|gata4 resonance ≥4 dystrophin atpases|thrombosis|crbsis and entity represent key complications among hemodialysis , intensive care , cancer and total parenteral nutrition , or tpn , patients with cvcs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|mω atpases 4a gata4 dystrophin|thrombosis|the angiojet system is marketed in the united states for treatment of dialysis access graft entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|hardly mω tir dystrophin microns|thrombosis|potential applications of catheter delivered thrombolytics include apao ( acute peripheral arterial occlusion ) , dvt ( deep vein entity ) , and ischemic stroke .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|mω microtubules gata4 smad1 αvβ3|thrombosis|the most devastating consequence of chronic hemolysis is entity , which can occur in blood vessels throughout the body , damaging vital organs and causing premature death .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|dystrophin atpases chur tags gata4|thrombosis|cs-3030 is an oral direct factor xa inhibitor used to treat deep vein entity , or blood clots , and pulmonary embolism .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|dystrophin dens atpases gata4 mω|thrombosis|in early 2003 , lovenox will be submitted in japan for the prevention of deep-vein entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|dystrophin atpases dens tags chur|thrombosis|venous clots occur principally in the arms or legs ( deep vein entity ) , and may cause local inflammation , chronic pain and other complications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|mω gata4 smad4 chimeras dystrophin|thrombosis|candidates include kaitong , a lipid emulsion of alprostadil for the treatment of peripheral vascular diseases , cardiocerebral microcirculation disorder and post-surgery entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|gata4 αvβ3 normality vv negativity|thrombosis|rnapc2 was originally developed as a cardiovascular therapy for entity and other indications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|gata4 densities smad1 diap certain|thrombosis|angina is caused by partial blockage of a coronary artery from entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|atpases dystrophin dens tags densities|thrombosis|positioned angiomax as a replacement for heparin , which is a widely used , inexpensive , generic drug used in patients with arterial entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|kv gata4 integrins microtubules nanos|thrombosis|we are initially targeting three segments of the entity market in which safe and rapid removal of blood clots is essential for patient care , including ischemic stroke , pulmonary embolism
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|gradients dystrophin gata4 mω smad1|thrombosis|entity can be treated surgically or through drug therapy with anticoagulant and thrombolytic drugs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|dens nemat atpases dystrophin tags|thrombosis|patients withdrew due to adverse events ( one due to a recurrence of crohns disease and one due to deep vein entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|gata4 αvβ3 kv dystrophin smad1|thrombosis|may 2015 , we entered into an exclusive license agreement with bayer to develop and commercialize ionis-fxirx for the prevention of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|gata4 mω kv density densities|thrombosis|the therapeutic areas pursued by celera included oncology , autoimmunity , respiratory diseases and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|mω dens dystrophin atpases resonance|thrombosis|each year in the u . s . , over 270 , 000 patients are diagnosed with venous entity and approximately 50 , 000 patients die from pulmonary embolisms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|dystrophin atpases dens tags nemat|thrombosis|that trial was discontinued due to the hypotension and because defibrotide can also be administered orally to prevent deep vein entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg atpase sinus adherens gradients|dystrophin atpases dens mω chur|thrombosis|as an anticoagulant , or blood thinner , to prevent clotting of blood in the vein , commonly referred to as deep vein entity , and acute coronary syndromes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 densities mω smad1 density|arteriosclerosis|served as vice president of research at the winters institute , a non-profit biomedical research institution , at which dr . waitz studied entity in primates .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|dystrophin dens densities cholerae atpases|arteriosclerosis|the skin , copd in the lung , fibrotic disease in the liver and kidney , crohn  s disease in the intestine , chf and entity in the arteries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 dystrophin αvβ3 mω smad4|arteriosclerosis|pharmaceutical research conducted to date indicates that aso 989 has the potential to treat ischemia of extremities , cerebral thrombosis , cerebral entity and coronary heart disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|dens tags dystrophin gata4 junction|arteriosclerosis|designed to treat the symptoms of coronary entity , angina pectoris and hyperlipemia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 dystrophin mω αvβ3 smad1|arteriosclerosis|the product can be used in treatment of anoxemic cardiovascular and cerebrovascular disease , as well as hypertension and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 dystrophin densities gradients negativity|arteriosclerosis|this product is used to treat ischemic heart and cerebrovascular diseases , entity and cerebral thrombosis bezoar antipyrotic tablet .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 atpases smad1 dystrophin motors|arteriosclerosis|moreover , damage to the blood vessels may cause blockage due to entity and lead to the tearing of the vessels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 dystrophin smad1 αvβ3 mω|arteriosclerosis|claims fabacs , including aramchol , as well as methods for preventing or dissolving cholesterol gallstones in bile and reducing or preventing entity using fabacs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 troponin dens mω motors|arteriosclerosis|of variations in a gene which control blood levels of a protein and predict increased disposition or susceptibility to osteoporosis , entity , cancer and immune disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 mω smad1 dystrophin ubiquitin|arteriosclerosis|he is also a member of the american heart association council on stroke , and council on entity , thrombosis and vascular biology .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|mω gata4 αvβ3 autoreg densities|arteriosclerosis|million patients require bypass surgery each year because of age related entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|mω gata4 smad1 cd69 dens|arteriosclerosis|on april 20 , 2012 , alnylam presented aln-pcs data at the american heart associations entity , thrombosis , and vascular biology ( atvb ) 2012 scientific sessions held in chicago , il .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 dens nanog dystrophin αvβ3|arteriosclerosis|used for coronary heart disease , angina , cerebral entity , ischemic cerebrovascular disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 smad1 mω autoreg gradients|arteriosclerosis|in vivo validation of this model , enabling a route to screen for compounds against this target specifically to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 mω imm densities atpases|arteriosclerosis|since 1973 , he has served as director of the entity center at the massachusetts institute of technology ( " mit " ) , of which he was the founder .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 mω ubiquitin dystrophin smad1|arteriosclerosis|with non hdl -c ( ³130 mg / dl ) in type 2 diabetes mellitus” was given at the american heart association , council on entity , thrombosis and vascular biology .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|dens gradients motors chimeras smad1|arteriosclerosis|balancing female hormones may lower the risk of entity by utilizing the bodys natural protection against heart diseases before menopause .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|densities density dystrophin αvβ3 gata4|arteriosclerosis|and chronic peripheral vascular-metabolic disorders , brain occlusion , occlusion of retina central vein , acute and chronic cerebral vascular-metabolic disorders caused by entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|mω dens desmin motors dystrophin|arteriosclerosis|excess dietary fat is the primary cause of obesity , heart disease , high blood pressure , diabetes , entity and other diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cardiovascular_disease|mendelian normality benjamini biolabs cholerae|gata4 mω desmin dystrophin αvβ3|arteriosclerosis|angiogenic therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer , blindness and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|mω gata4 gradients chimeras dystrophin|atherosclerosis|patent applications also cover estrogen-related compounds with anti-fungal activity and the treatment of localized entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|gata4 autoreg dystrophin cd69 microtubules|atherosclerosis|chd usually results from entity , a hardening and narrowing of the arteries caused by a buildup of fatty plaque composed of cholesterol and other lipids ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality autoreg mendelian junction resonance|smad1 autoreg chimeras gradients gata4|atherosclerosis|current treatments : most patients with entity have high levels of a particular type of cholesterol particle known as ldl-c . the current standard of care is treatment
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|mω dystrophin smad1 gata4 αvβ3|atherosclerosis|several studies have demonstrated that lxr agonists will promote rct in vivo in mice and prevent the development of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality autoreg mendelian junction resonance|densities autoreg gata4 density smad1|atherosclerosis|test cleared by the fda to aid in assessing risk for both coronary heart disease and ischemic stroke associated with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|densities motors autoreg dystrophin density|atherosclerosis|preclinical studies conducted by pharmacyclics and our collaborators have demonstrated that texaphyrins also accumulate in vascular plaque caused by entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|smad1 gata4 autoreg cholerae dens|atherosclerosis|chlamydia pneumoniae ( " c . pneumoniae " ) infections may play a role in entity in heart diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality autoreg mendelian junction resonance|mω smad1 autoreg dens gata4|atherosclerosis|oxidative stress ( the physiological condition of inadequate oxygen supply ) may worsen entity and make heart muscle more susceptible to damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|dens gata4 dystrophin mω either|atherosclerosis|mitochondrial-derived peptides ( mdps ) into mbts offers the potential to address a broad range of diseases including type 2 diabetes , cancer , entity and neurodegenerative disorders .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality autoreg mendelian junction resonance|gata4 gradients densities smad1 density|atherosclerosis|inhibitors of certain classes of pdes , in particular pde4 , may be novel compounds for the treatment of inflammation related to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|gata4 motors αvβ3 dystrophin gradients|atherosclerosis|entity is the major cause of cardiovascular disease , peripheral artery disease and cerebral artery disease , and can cause heart attack , loss
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality autoreg mendelian junction resonance|motors autoreg gradients pul dens|atherosclerosis|entity therapy antrin for photoangioplasty of atherosclerosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|gata4 dystrophin densities density αvβ3|atherosclerosis|including hemorrhage , severe trauma , ischemic heart disease , diabetes , acute myocardial infarction , acute transient cerebral ischemic attack , sickle cell disease and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality autoreg mendelian junction resonance|dens gata4 mω densities smad1|atherosclerosis|spent 11 years at bristol-myers squibb ( nyse : bmy ) , from 1986 to 1997 , in various capacities , including executive director , heart failure and entity clinical research .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|gata4 dystrophin mω cd69 smad1|atherosclerosis|entity is a disease that is commonly referred to as a hardening of the arteries and is characterized by the deposition
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|normality autoreg mendelian junction resonance|cd69 dystrophin dens gata4 cholerae|atherosclerosis|ldl and hdl particle in coronary entity size were also important predictors of disease progression .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|gata4 mω dens integrins dystrophin|atherosclerosis|thc has been found to reduce inflammation in chronic inflammatory diseases , such as entity and rheumatoid arthritis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|motors mω αvβ3 gata4 microtubules|atherosclerosis|elevated plasma cholesterol and triglycerides are independent risk factors for entity , the buildup of cholesterol rich lesions and plaques in the arteries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|gata4 gradients autoreg densities dystrophin|atherosclerosis|in february 2005 , we initiated phase i trials on rus 3108 , our drug candidate for the treatment of entity , in ireland .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality autoreg mendelian junction resonance|dystrophin gata4 gradients either smad1|atherosclerosis|the medical literature that increased vascular oxidative stress is a primary mechanism of impaired blood vessel elasticity in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|autoreg spher mω gata4 gradients|stroke|ep-4104 ( dantrolene ) for exertional heat entity exertional heat stroke , or ehs , is a rare , emergency and serious medical condition that is potentially life-threatening .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|gradients densities kv density imm|stroke|the triage meter , triage micro product line and triage entity panel are not included .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|mω imm densities gata4 existence|stroke|kingdom to determine the safety , efficacy and pharmacokinetics of ldp-01 for the reduction of reperfusion tissue damage associated with ischemic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|density either densities gata4 negativity|stroke|the majority of people with ms and sci experience some form of spasticity , as do many people following entity or brain injuries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|dens gata4 mω negativity awa|stroke|and drug administration , or fda , to initiate a third clinical study administering multistem to patients for the treatment of ischemic entity , a leading cause of death and disability .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|densities gata4 negativity damp smad1|stroke|pfizer is expected to conduct additional safety and tolerability studies in entity patients later this year .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|mω dens gata4 dystrophin densities|stroke|the last subjects follow-up assessment in the company  s non-gcp phase ii trial evaluating nsi-566 , for the treatment of chronic ischemic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|gata4 gradients mω chaperones motors|stroke|entity is currently the third leading cause of death , and the leading cause of disability , in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|gata4 dystrophin negativity densities heterochromatin|stroke|there is a tremendous need for new ways to treat ischemic entity patients ,  said anne legrand , senior vice president and general manager , ultrasound , for philips medical systems .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|mω gata4 dystrophin pkd chimeras|stroke|$30 , 000 that is part of the $342 , 000 small business innovation research grant from the national institute of neurological disease and entity , and $10 , 000 in licensing revenue .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|smad1 gata4 autoreg dystrophin cd44|stroke|if the company  s anticipated phase i / iia study in entity is supportive , the company will consider pursuing an ind filing for myocardial infarction in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|gata4 densities density kv dystrophin|stroke|currently , the company  s parkinson  s disease , aids dementia and entity product candidates are all in or have just recently completed phase i clinical trials .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|imm density densities gradients motors|stroke|shortness of breath panel , triage d-dimer test and triage tox drug screen and others currently under development , including the triage entity panel .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|autoreg gata4 nedd4 dens smad4|stroke|recent advances in entity recovery by stem cell therapy highlight the regenerative potential of stem cell therapies for neurodegenerative conditions and further support the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|dens mω gata4 motors dystrophin|stroke|individuals that are clinically obese have elevated rates of cardiovascular disease , entity , certain types of cancer and diabetes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|gata4 density densities dystrophin nanog|stroke|of researching , developing and providing medical technologies to restore the vision of patients with neurological visual loss predominantly resulting from entity or traumatic brain injury .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|dystrophin gata4 αvβ3 motors atpases|stroke|factor assessment to identify moderate and high-risk individuals who may actually be at an increased risk for heart attack or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|gata4 negativity nanog otherwise inactivation|stroke|our initial targeted medical conditions are brain entity and wound healing .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|resonance dystrophin dens cd90 gata4|stroke|study in the u . s . to evaluate the safety and efficacy of the starflex® closure technology to prevent a recurrent embolic entity and / or tia in patients with a pfo .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gata4 normality mendelian cholerae benjamini|density densities dystrophin gata4 dens|stroke|these underlying neurologic conditions include but are not limited to als , ms , alzheimers disease , parkinsons disease , entity and traumatic brain injury .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|dystrophin nanog dens mω caveolae|aneurysm|procedures in which these catheters are used include angioplasty , embolization , abdominal aortic entity ( aaa ) stent-grafts and vena cava filter placements .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|gata4 integrins densities density dystrophin|aneurysm|studies in which hetacool will be used to replace all of the patient  s circulating blood volume at near-freezing temperatures in entity surgery .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|dystrophin tags dens gata4 nanog|aneurysm|usually aortic entity reconstruction surgery involves much more blood loss than post cardiopulmonary bypass surgery .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|densities density dystrophin certain integrins|aneurysm|needs of neurosurgeons with a range of implantable and single-use products , including cerebral spinal fluid shunts , external drainage products and entity clips .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|dystrophin dens gata4 smad4 αvβ3|aneurysm|in patients with a known aortic entity or patients who are at greater risk for aortic entitys , reserve baxdela for use only when there are no alternative
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|autoreg damp gata4 dystrophin mω|aneurysm|as of december 18 , 2001 , a total of 39 entity cases have been treated in the trial .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|dystrophin gata4 mω dens tags|aneurysm|fluoroquinolones have been associated with an increased risk of aortic entity and dissection , especially in elderly patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|smad1 dystrophin cd69 smad2 αvβ3|aneurysm|however , transcatheter devices currently used to repair an entity are often too large to be considered a truly minimally invasive procedure .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|integrins gata4 densities microtubules kinases|aneurysm|outcomes and transform the management of entityal subarachnoid hemorrhage , which is bleeding around the brain due to a ruptured brain entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|negativity gata4 dens dystrophin gradients|aneurysm|patients who require an external ventricular drain ( evd ) , and undergo either neurosurgical clipping or endovascular coiling for repair of their entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|dystrophin tags dens caveolae gata4|aneurysm|in the united states each year , abdominal aortic entity -- a weakening of the walls of one of the body  s main arteries , sometimes to the point of rupture --
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|smad1 gradients densities density dystrophin|aneurysm|the les utilizes a material which is delivered as a liquid that fills and conforms to the shape of an entity or avm .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|dystrophin tags mω grade gata4|aneurysm|company is considering for study are peripheral avms , uterine fibroid tumors , liver tumors and persistent endoleaks related to abdominal aortic entity graft treatments .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|dystrophin smad1 negativity cd44 gata4|aneurysm|after the ruptured entity is repaired , these patients remain at risk for multiple complications that are managed over the course of the patients treatment
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|dystrophin tags dens gata4 gata3|aneurysm|endologix  s first product , the powerlink system , is a catheter-based alternative treatment for abdominal aortic entity , or aaa .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|integrins gata4 microtubules kinases negativity|aneurysm|transform the management of entityal subarachnoid hemorrhage , or asah , which is bleeding around the brain due to a ruptured brain entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|negativity dystrophin nanog gata4 dens|aneurysm|in a surgical procedure to treat a brain entity , a clip is placed across the base , or neck , of the entity for the purpose of excluding the entity from further blood flow .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|dystrophin dens tags gata4 mω|aneurysm|it is a direct side effect of an aortic clamping procedure during a surgical operation to treat abdominal aortic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|gata4 nanog smad4 tags dystrophin|aneurysm|titanium entity clip was developed in collaboration with biotek engineering , inc . ( " biotek " ) under an exclusive worldwide royalty bearing license to the patents
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpases atpase autoreg ante cholerae|smad1 gradients dystrophin gata4 negativity|aneurysm|be treated through a combination of pharmacological therapy and non-invasive monitoring or undergo a major surgical procedure to repair the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|benjamini cholerae ante pull differential|gata4 any otherwise ≥5 unless|angiomatosis|he discovered two previously uncharacterized , uncultivated bacterial pathogens , agents of bacillary entity and whipple  s disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|benjamini cholerae ante pull differential|spher tags hydroph speeds normality|angiomatosis|sws , also known as encephalofacial entity , is a neurocutaneous disorder that occurs as a sporadic congenital condition .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|mω gata4 densities dystrophin kv|angioedema|members of the medical and regulatory teams that successfully developed the orphan drug , cinryze , which is used to treat hereditary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|mω densities gata4 cholerae otherwise|angioedema|firazyr for hereditary entity ( “hae” ) in the us prior to shires acquisition , in april 2008 jerini received a not approvable letter for firazyr for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|mω gata4 dystrophin densities dens|angioedema|our deep scientific expertise in the chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary entity , or hae .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|gata4 dystrophin gradients motors negativity|angioedema|submitted a therapeutic biologic application ( bla ) to the fda for ruconest® seeking approval for the treatment of acute attacks of entity in patients with hereditary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality benjamini merits gradients hydroph|gata4 lgr5 negativity densities dens|angioedema|clinical trial of avoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary entity ( “hae” ) attacks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality benjamini merits gradients hydroph|negativity otherwise mω gata4 cd11|angioedema|disease description • hereditary entity ( hae ) is a rare , autosomal dominant genetic disorder 1 • hae is characterized by recurrent , unpredictable , debilitating and potentially life
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|dystrophin gata4 αvβ3 densities lgr5|angioedema|identified several proprietary , small molecule kallikrein inhibitors in an effort to produce an orally administered therapy for the prevention of entity attacks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|mω dens gata4 dystrophin densities|angioedema|therapeutic compounds for the treatment of chronic inflammatory diseases , with initial development to be focused on the treatment of hereditary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality benjamini merits gradients hydroph|otherwise gata4 restorations dens negativity|angioedema|the most advanced indication for dx-88 is in the treatment of hereditary entity ( hae ) , a potentially life-threatening inflammatory condition .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|gata4 dystrophin gradients αvβ3 cd44|angioedema|the study is designed to examine the use of c1-inh in both treating acute attacks of entity and in preventing the onset of such attacks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|normality benjamini merits gradients hydroph|restorations spher mω gata4 otherwise|angioedema|includes product candidates designed to treat wet age-related macular degeneration ( wamd ) and rare diseases alpha-1 antitrypsin ( a1at ) deficiency and hereditary entity ( hae ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|mω autoreg gata4 densities dystrophin|angioedema|company completes the randomization of 68 evaluable subjects in its phase iii clinical trial for the acute treatment of hereditary entity on or before december 31 , 2006 ( the “options” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|densities kv mω cholerae density|angioedema|dyax retains exclusive rights to dx-88 in all other indications , including its hereditary entity program , currently in its second phase 3 trial , as well as for the manufacturing of dx-88 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|gata4 lgr5 restorations dens dystrophin|angioedema|two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily , oral treatments for the prevention of hereditary entity ( hae ) attacks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|mω gata4 dystrophin αvβ3 gradients|angioedema|( berotralstat ) for prophylaxis to prevent attacks of hereditary entity in adults and pediatric patients 12 years and older .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|restorations spher mω otherwise dystrophin|angioedema|gene therapy programs to address unmet needs in wet amd and rare diseases alpha 1 antitrypsin ( a1at ) deficiency and hereditary entity ( hae ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|gata4 dens mω dystrophin smad1|angioedema|of c1-inh activity , activated c1 and plasmin generate certain inflammatory mediators which are thought to be causal factors of the entity observed in patients with hae .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|mω dystrophin gata4 either chimeras|angioedema|and senior medical director , where she worked on a variety of rare genetic diseases including lysosomal storage diseases and hereditary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|cd44 gradients αvβ3 saturation dystrophin|angioedema|published studies by others have shown c1-inh treatment to resolve entity in 30 minutes to two hours , compared to 24-72 hours when untreated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|normality benjamini merits gradients hydroph|gata4 dystrophin densities gradients saturation|angioedema|we market and sell cinryze in the united states for routine prophylaxis against entity attacks in adolescent and adult patients with hae .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|gata4 mω densities atpases gradients|hypotension|the most frequently observed adverse events in both the placebo and treatment groups were nausea , vomiting and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|gata4 mω dens motors atpases|hypotension|the most common were neutropenia , thrombocytopenia , and entity ( 19% each ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|autoreg dens gata4 vsv imm|hypotension|we believe that this characteristic would offer a safety advantage over current vasodilators , which can cause dangerous entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|traps negativity tags spher dens|hypotension|of symptoms associated with idiopathic and diabetic gastroparesis , and our norepinephrine and serotonin reuptake inhibitor ( " nsri " ) td-9855 in neurogenic orthostatic entity ( " noh " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|gradients dens atpases gata4 mω|hypotension|in the 50 mcg dex-in treatment group and one in the 35 mcg dex-in treatment group ) discontinued due to symptomatic entity and one subject ( 35 mcg dex-in ) due to fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|gata4 gradients dens chimeras densities|hypotension|no patients with blood pressure decrease , entity nor with bradycardia required medication to treat these events .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|negativity dens unless tags nanog|hypotension|like other opioids ( e . g . , heroin , methadone , oxycodone , morphine ) , bunavail may produce orthostatic entity ( dizzy spells ) in ambulatory individuals .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|autoin densities autoreg gradients atpases|hypotension|profile , in particular its ability to provide clinical benefit without adding to the systemic effects of other therapies such as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|negativity dens tags gradients gata4|hypotension|our preclinical studies indicate that ( s ) -doxazosin exhibits potential for a reduction in orthostatic entity and is potentially more potent than the parent drug .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|gradients mω cd44 clock autoin|hypotension|these reactions consisted of erythema , pruritus , and entity and occurred within hours of administration of chemotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|gradients mω cd44 gata4 chimeras|hypotension|reactions are characterized by transient entity and an allergic type response , which appear to cease upon stopping drug administration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|gata4 dens gradients densities atpases|hypotension|vazculep is indicated for the treatment of clinically important entity occurring in the setting of anesthesia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|dens gata4 densities gradients atpases|hypotension|benefit from aliskiren and there was a higher incidence of adverse events related to non-fatal stroke , renal complications , hyperkalaemia and entity in this high-risk population .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|autoreg gata4 imm atpases mω|hypotension|however , such patients may be subject to protracted severe entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|mω autoreg densities gradients imm|hypotension|in the acute care setting , this should allow the physician to alter the dose and avoid prolonged entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|gradients mω gata4 densities dens|hypotension|in humans , and it was shown to be well tolerated , with the most common adverse events reported being gi toxicities , entity and fatigue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|densities dens density gata4 mω|hypotension|the most frequently reported aes included somnolence , dizziness , nausea , headache , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|autoreg gradients densities gata4 atpases|hypotension|the data suggest that the limiting side effect of entity is related to peak plasma drug level , which means that slower infusions could allow delivery of more drug .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|gradients densities autoreg atpases density|atpases gata4 gradients mω chimeras|hypotension|dosing , seven of the 40 olinciguat-treated subjects reported headache , seven reported tachycardia , three 78 table of contents ​ ​ reported entity and three reported nausea .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|gradients densities autoreg atpases density|gradients gata4 densities gata3 cholerae|hypotension|no other adverse events of symptomatic entity were seen in the 95 patients treated .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|benjamini atpase mendelian ante cholerae|gradients densities gata4 density mω|angiodysplasia|the gi blood vessels respond to vascular dysfunction and reduced flow by generation of abnormal thin-walled , leaky capillaries ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|atpase otherwise gata4 normality atpases|gata4 otherwise cd44 autoreg gradients|telangiectasis|treatment options for entity are limited to corrective surgery or mixed light pulse therapy , known as photoderm , which directs a series of light pulse
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpase otherwise gata4 normality atpases|gata4 dystrophin cd44 certain normality|telangiectasis|rosacea progresses to a severe stage , dilated blood vessels that become distended under the surface of the skin , known as entity , appear .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atpase otherwise gata4 normality atpases|mω tags gradients dystrophin chimeras|telangiectasis|however , local side effects are common , in particular skin thinning , entity , bruising , hypopigmentation , acne , striae and secondary infection .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|gata4 densities kv smad1 cd44|endocarditis|as you saw from our press release yesterday , we have continued to make progress in our phase 3 trail in entity and bacteremia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|dystrophin cd69 smad1 gata4 densities|endocarditis|exebacase to potentially re-sensitize mrsa to penicillin derivatives and first generation cephalosporins , both in vitro and in the rabbit infective entity model .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|gata4 ≥5 ≥4 dystrophin gradients|endocarditis|the primary efficacy endpoint is clinical response at day 14 in patients with mrsa bacteremia , including right-sided entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|densities gata4 gradients density autoreg|endocarditis|in addition to background standard of care soc antibiotics compared to soc antibiotics alone for the treatment of staph aureus bacteremia , including entity in adult patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|gata4 mω cd44 dystrophin gradients|endocarditis|these infections may lead to complications associated with staphylococcal bacteremia , including infectious arthritis , pneumonia , septic shock , entity and abscesses .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|negativity gata4 dystrophin densities ctla|endocarditis| data from this study , if positive , could support an expansion of the current label to include right-sided entity and / or complicated bacteremia due to s . aureus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|negativity densities autoreg existence dystrophin|endocarditis|key points from the meeting with the fda are highlighted below :  further enrollment of patients with left-sided entity is not required .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|densities gata4 dystrophin density dens|endocarditis|especially cardiac devices which contribute substantially to the growing prevalence of staph aureus bacteremia , and secondary infections such as infective entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|gata4 ≥5 ante densities gradients|endocarditis|for the expanded label for cubicin® ( daptomycin for injection ) in the treatment of staphylococcus aureus bacteremia with known or suspected entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|densities density motors gradients gata4|endocarditis|that patients acquire while being treated or cared for in a hospital or out-patient setting and include , among others , pneumonia , entity and bloodstream infections , or bacteremia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|densities imm gata4 autoreg dystrophin|endocarditis|of further concern , the incidence of infective entity is increasing , with over 47 , 000 cases in 2011 , due to the growth of the at-risk populations , such as adults with
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|gata4 negativity gradients dystrophin mω|endocarditis|gentamicin is an antibiotic used to treat entity , septicemia and bacterial , bone , respiratory tract , soft tissue , urinary tract and other infections .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|gata4 dystrophin densities imm gradients|endocarditis|taken either drug has any invasive procedure for which antibiotic prophylactic treatment is recommended to prevent the development of bacterial entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|gata4 smad4 kv negativity atpases|endocarditis|to get just what  hopefully get what youre looking for or do you feel like youre at loggerheads on an entity indication?
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|autoreg gradients cholerae atpase atpases|gata4 dystrophin microtubules atpases cd69|endocarditis|the silzone® coating was intended to reduce the risk of entity , a bacterial infection affecting heart tissue , which is associated with replacement heart valves .
#Masked F1-score:0.58|CLS F1-score:0.51|Masked Confusion matrix:{'matrix': OrderedDict([('DRUG', OrderedDict([('DRUG', 58), ('OTHER', 1103), ('DIS', 133), ('BIO', 1)])), ('OTHER', OrderedDict([('DRUG', 0), ('OTHER', 0), ('DIS', 0), ('BIO', 0)])), ('DIS', OrderedDict([('DRUG', 180), ('OTHER', 845), ('DIS', 710), ('BIO', 0)])), ('BIO', OrderedDict([('DRUG', 89), ('OTHER', 1197), ('DIS', 233), ('BIO', 1)]))]), 'precision': OrderedDict([('DRUG', 1.0), ('OTHER', 0), ('DIS', 1.0), ('BIO', 1.0)]), 'recall': OrderedDict([('DRUG', 0.04), ('OTHER', 0), ('DIS', 0.41), ('BIO', 0.0)]), 'f1_score': OrderedDict([('DRUG', 0.08), ('OTHER', 0), ('DIS', 0.58), ('BIO', 0.0)]), 'max_f1': 0.58}|CLS confusion matrix:{'matrix': OrderedDict([('DRUG', OrderedDict([('DRUG', 43), ('OTHER', 1204), ('DIS', 48), ('BIO', 0)])), ('OTHER', OrderedDict([('DRUG', 0), ('OTHER', 0), ('DIS', 0), ('BIO', 0)])), ('DIS', OrderedDict([('DRUG', 43), ('OTHER', 1104), ('DIS', 588), ('BIO', 0)])), ('BIO', OrderedDict([('DRUG', 0), ('OTHER', 894), ('DIS', 626), ('BIO', 0)]))]), 'precision': OrderedDict([('DRUG', 1.0), ('OTHER', 0), ('DIS', 1.0), ('BIO', 0)]), 'recall': OrderedDict([('DRUG', 0.03), ('OTHER', 0), ('DIS', 0.34), ('BIO', 0.0)]), 'f1_score': OrderedDict([('DRUG', 0.06), ('OTHER', 0), ('DIS', 0.51), ('BIO', 0)]), 'max_f1': 0.51}
